PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Klareskog, L; Hamsten, A				Klareskog, L; Hamsten, A			Statins in rheumatoid arthritis - two birds with one stone?	LANCET			English	Editorial Material							MORTALITY; METHOTREXATE; ATORVASTATIN; SIMVASTATIN; PARALYSIS; DISEASE		Karolinska Univ Hosp, Karolinska Inst, Dept Med, Rheumatol Res Unit, S-17176 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Med, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Klareskog, L (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Med, Rheumatol Res Unit, S-17176 Stockholm, Sweden.	lars.klareskog@medks.ki.se		Klareskog, Lars/0000-0001-9601-6186				Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Palinski W, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018400.39687.8C; Symmons DPM, 1998, J RHEUMATOL, V25, P1072; Van Doornum S, 2002, ARTHRITIS RHEUM-US, V46, P862, DOI 10.1002/art.10089; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wallberg-Jonsson S, 1999, J RHEUMATOL, V26, P2562; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	12	17	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2011	2012		10.1016/S0140-6736(04)16485-4	http://dx.doi.org/10.1016/S0140-6736(04)16485-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207947				2022-12-28	WOS:000222159800003
J	Peen, J; Dekker, J				Peen, J; Dekker, J			Is urbanicity an environmental risk-factor for psychiatric disorders?	LANCET			English	Editorial Material							ADMISSION RATES; SCHIZOPHRENIA; URBANIZATION; NETHERLANDS; PSYCHOSIS; PREVALENCE; HISTORY; BIRTH		Vrije Univ Amsterdam, Mentrum Mental Hlth Org Amsterdam, Res Dept, NL-1070 AV Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Clin Psychol, NL-1070 AV Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Peen, J (corresponding author), Vrije Univ Amsterdam, Mentrum Mental Hlth Org Amsterdam, Res Dept, NL-1070 AV Amsterdam, Netherlands.	jaap.peen@mentrum.nl						Allardyce J, 2001, BRIT J PSYCHIAT, V179, P335, DOI 10.1192/bjp.179.4.335; Boydell J, 2001, BMJ-BRIT MED J, V323, P1336, DOI 10.1136/bmj.323.7325.1336; Dekker J, 1997, INT J SOC PSYCHIATR, V43, P235, DOI 10.1177/002076409704300401; FREEMAN H, 1994, BRIT J PSYCHIAT, V164, P39, DOI 10.1192/S0007125000292726; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; Jablensky AV, 2003, AM J PSYCHIAT, V160, P425, DOI 10.1176/appi.ajp.160.3.425; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Marcelis M, 1998, PSYCHOL MED, V28, P871, DOI 10.1017/S0033291798006898; Paykel E, 2003, INT REV PSYCHIATR, V15, P97, DOI 10.1080/0954026021000046001; Pedersen CB, 2001, BRIT J PSYCHIAT, V179, P46, DOI 10.1192/bjp.179.1.46; Pedersen CB, 2001, ARCH GEN PSYCHIAT, V58, P1039, DOI 10.1001/archpsyc.58.11.1039; Peen J, 2003, SOC PSYCH PSYCH EPID, V38, P535, DOI 10.1007/s00127-003-0671-y; Peen J, 1997, ACTA PSYCHIAT SCAND, V96, P301, DOI 10.1111/j.1600-0447.1997.tb10167.x; Sundquist K, 2004, BRIT J PSYCHIAT, V184, P293, DOI 10.1192/bjp.184.4.293; Sytema S, 1996, PSYCHOL MED, V26, P109, DOI 10.1017/S0033291700033754; TORREY EF, 1990, SCHIZOPHRENIA BULL, V16, P591, DOI 10.1093/schbul/16.4.591; van Os J, 2003, AM J PSYCHIAT, V160, P477, DOI 10.1176/appi.ajp.160.3.477; van Os J, 2001, ARCH GEN PSYCHIAT, V58, P663, DOI 10.1001/archpsyc.58.7.663; Van Os J, 2000, BRIT J PSYCHIAT, V176, P243, DOI 10.1192/bjp.176.3.243	19	25	25	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2012	2013		10.1016/S0140-6736(04)16486-6	http://dx.doi.org/10.1016/S0140-6736(04)16486-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	830YJ	15207948				2022-12-28	WOS:000222159800004
J	Barrett, MD; Chiaverini, J; Schaetz, T; Britton, J; Itano, WM; Jost, JD; Knill, E; Langer, C; Leibfried, D; Ozeri, R; Wineland, DJ				Barrett, MD; Chiaverini, J; Schaetz, T; Britton, J; Itano, WM; Jost, JD; Knill, E; Langer, C; Leibfried, D; Ozeri, R; Wineland, DJ			Deterministic quantum teleportation of atomic qubits	NATURE			English	Article							PODOLSKY-ROSEN CHANNELS; TRAPPED IONS; STATE; INFORMATION; OPERATIONS	Quantum teleportation(1) provides a means to transport quantum information efficiently from one location to another, without the physical transfer of the associated quantum-information carrier. This is achieved by using the non-local correlations of previously distributed, entangled quantum bits (qubits). Teleportation is expected to play an integral role in quantum communication(2) and quantum computation(3). Previous experimental demonstrations have been implemented with optical systems that used both discrete and continuous variables(4-9), and with liquid-state nuclear magnetic resonance(10). Here we report unconditional teleportation(5) of massive particle qubits using atomic (Be-9(+)) ions confined in a segmented ion trap, which aids individual qubit addressing. We achieve an average fidelity of 78 per cent, which exceeds the fidelity of any protocol that does not use entanglement(11). This demonstration is also important because it incorporates most of the techniques necessary for scalable quantum information processing in an ion-trap system(12,13).	NIST, Time & Frequency Div, Boulder, CO 80305 USA; NIST, Math & Computat Sci Div, Boulder, CO 80305 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA	Wineland, DJ (corresponding author), NIST, Time & Frequency Div, Boulder, CO 80305 USA.	djw@boulder.nist.gov	Barrett, Murray D/G-2732-2012; Itano, Wayne/AAV-8781-2020; Jost, John D/F-4701-2010	Barrett, Murray D/0000-0002-1483-8029; jost, john/0000-0002-1698-8602; Britton, Joe/0000-0001-8103-7347				BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Boschi D, 1998, PHYS REV LETT, V80, P1121, DOI 10.1103/PhysRevLett.80.1121; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Bowen WP, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032302; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Furusawa A, 1998, SCIENCE, V282, P706, DOI 10.1126/science.282.5389.706; Kielpinski D, 2002, NATURE, V417, P709, DOI 10.1038/nature00784; Kim YH, 2001, PHYS REV LETT, V86, P1370, DOI 10.1103/PhysRevLett.86.1370; King BE, 1998, PHYS REV LETT, V81, P1525, DOI 10.1103/PhysRevLett.81.1525; Leibfried D, 2003, NATURE, V422, P412, DOI 10.1038/nature01492; MASSAR S, 1995, PHYS REV LETT, V74, P1259, DOI 10.1103/PhysRevLett.74.1259; Nielsen MA, 1998, NATURE, V396, P52, DOI 10.1038/23891; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Rowe MA, 2002, QUANTUM INF COMPUT, V2, P257; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; Wineland DJ, 2003, PHILOS T R SOC A, V361, P1349, DOI 10.1098/rsta.2003.1205; Zhang TC, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.033802	20	690	708	6	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					737	739		10.1038/nature02608	http://dx.doi.org/10.1038/nature02608			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201904				2022-12-28	WOS:000222059900032
J	Ebel, C; Mariconti, L; Gruissem, W				Ebel, C; Mariconti, L; Gruissem, W			Plant retinoblastoma homologues control nuclear proliferation in the female gametophyte	NATURE			English	Article							GEMINIVIRUS REPLICATION PROTEIN; SEED DEVELOPMENT; ENDOSPERM DEVELOPMENT; ARABIDOPSIS-THALIANA; GENE; RB; FERTILIZATION; PATHWAY; MEDEA; DIFFERENTIATION	Haploid spores of plants divide mitotically to form multicellular gametophytes. The female spore ( megaspore) of most flowering plants develops by means of a well-defined programme into the mature megagametophyte consisting of the egg apparatus and a central cell(1,2). We investigated the role of the Arabidopsis retino-blastoma(3,4) protein homologue and its function as a negative regulator of cell proliferation during megagametophyte development. Here we show that three mutant alleles of the gene for the Arabidopsis retinoblastoma-related protein, RBR1 (ref. 4), are gametophytic lethal. In heterozygous plants 50% of the ovules are aborted when the mutant allele is maternally inherited. The mature unfertilized mutant megagametophyte fails to arrest mitosis and undergoes excessive nuclear proliferation in the embryo sac. Supernumerary nuclei are present at the micropylar end of the megagametophyte, which develops into the egg apparatus and central cell. The central cell nucleus, which gives rise to the endosperm after fertilization, initiates autonomous endosperm development reminiscent of fertilization-independent seed (fis) mutants(5). Thus, RBR1 has a novel and previously unrecognized function in cell cycle control during gametogenesis and in the repression of autonomous endosperm development.	Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Gruissem, W (corresponding author), Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Plant Sci, Univ Str 2, CH-8092 Zurich, Switzerland.	wilhelm.gruissem@ipw.biol.ethz.ch	Gruissem, Wilhelm/H-1752-2013	Gruissem, Wilhelm/0000-0002-1872-2998				Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Ach RA, 1997, PLANT CELL, V9, P1595, DOI 10.1105/tpc.9.9.1595; ALEXANDER MP, 1969, STAIN TECHNOL, V44, P117, DOI 10.3109/10520296909063335; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; De Veylder L, 2002, EMBO J, V21, P1360, DOI 10.1093/emboj/21.6.1360; Drews GN, 2002, ANNU REV GENET, V36, P99, DOI 10.1146/annurev.genet.36.040102.131941; Du W, 1999, EMBO J, V18, P916, DOI 10.1093/emboj/18.4.916; Durfee T, 2000, PLANT MOL BIOL, V43, P635, DOI 10.1023/A:1006426808185; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; Grossniklaus U, 1998, SEMIN CELL DEV BIOL, V9, P227, DOI 10.1006/scdb.1997.0214; Grossniklaus U, 2001, CURR OPIN PLANT BIOL, V4, P21, DOI 10.1016/S1369-5266(00)00130-8; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Honys D, 2003, PLANT PHYSIOL, V132, P640, DOI 10.1104/pp.103.020925; Howden R, 1998, GENETICS, V149, P621; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kiyosue T, 1999, P NATL ACAD SCI USA, V96, P4186, DOI 10.1073/pnas.96.7.4186; Kohler C, 2003, EMBO J, V22, P4804, DOI 10.1093/emboj/cdg444; Kong LJ, 2000, EMBO J, V19, P3485, DOI 10.1093/emboj/19.13.3485; Kwee HS, 2003, PLANT J, V36, P853, DOI 10.1046/j.1365-313X.2003.01925.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li Y, 2003, BIOINFORMATICS, V19, P1441, DOI 10.1093/bioinformatics/btg170; LIN BY, 1978, CAN J GENET CYTOL, V20, P249, DOI 10.1139/g78-028; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Luo M, 1999, P NATL ACAD SCI USA, V96, P296, DOI 10.1073/pnas.96.1.296; Ohad N, 1996, P NATL ACAD SCI USA, V93, P5319, DOI 10.1073/pnas.93.11.5319; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan W, 2001, ONCOGENE, V20, P1343, DOI 10.1038/sj.onc.1204254	30	195	214	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					776	780		10.1038/nature02637	http://dx.doi.org/10.1038/nature02637			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201912				2022-12-28	WOS:000222059900042
J	Konner, M				Konner, M			The ties that bind - Attachment: the nature of the bonds between humans are becoming accessible to scientific investigation.	NATURE			English	Editorial Material									Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA	Emory University	Konner, M (corresponding author), Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA.							Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003; Bowlby J., 1969, ATTACHMENT AND LOSS; Cassidy J., 1999, HDB ATTACHMENT THEOR; Fisher HE, 2002, ARCH SEX BEHAV, V31, P413, DOI 10.1023/A:1019888024255; KONNER M, 2000, REV GEN PSYCH, V4, P176	5	12	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					705	705		10.1038/429705a	http://dx.doi.org/10.1038/429705a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201891	Bronze			2022-12-28	WOS:000222059900020
J	Schexnayder, SM; Klein, SG				Schexnayder, SM; Klein, SG			Gas gangrene	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Arkansas Med Sci, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Schexnayder, SM (corresponding author), Univ Arkansas Med Sci, Little Rock, AR 72205 USA.								0	0	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2603	2603		10.1056/NEJMicm980151	http://dx.doi.org/10.1056/NEJMicm980151			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201417				2022-12-28	WOS:000222054700011
J	Kaminski, J; Call, J; Fischer, J				Kaminski, J; Call, J; Fischer, J			Word learning in a domestic dog: Evidence for "fast mapping"	SCIENCE			English	Article							CANIS-FAMILIARIS; COMPREHENSION; COGNITION; CHILDREN; LANGUAGE; STIMULI; ABILITY; HUMANS	During speech acquisition, children form quick and rough hypotheses about the meaning of a new word after only a single exposure - a process dubbed "fast mapping." Here we provide evidence that a border collie, Rico, is able to fast map. Rico knew the labels of over 200 different items. He inferred the names of novel items by exclusion learning and correctly retrieved those items right away as well as 4 weeks after the initial exposure. Fast mapping thus appears to be mediated by general learning and memory mechanisms also found in other animals and not by a language acquisition device that is special to humans.	Max Planck Inst Evolutionary Anthropol, Dept Dev & Comparat Psychol, D-04103 Leipzig, Germany	Max Planck Society	Fischer, J (corresponding author), Max Planck Inst Evolutionary Anthropol, Dept Dev & Comparat Psychol, Deutsch Pl 6, D-04103 Leipzig, Germany.	scher@eva.mpg.de	Fischer, Julia/B-6674-2008	Fischer, Julia/0000-0002-5807-0074; Kaminski, Juliane/0000-0002-3437-3484; Call Balaguer, Josep/0000-0002-8597-8336				BALDWIN DA, 1993, DEV PSYCHOL, V29, P832, DOI 10.1037/0012-1649.29.5.832; Bergman TJ, 2003, SCIENCE, V302, P1234, DOI 10.1126/science.1087513; Call J, 2003, J COMP PSYCHOL, V117, P257, DOI 10.1037/0735-7036.117.3.257; CAREY S, 1978, CHILD LANG DEV, V15, P29; Coppinger R, 1995, DOMESTIC DOG ITS EVO; Fischer J, 2004, ANIM BEHAV, V67, P655, DOI 10.1016/j.anbehav.2003.08.006; Hare B, 2002, SCIENCE, V298, P1634, DOI 10.1126/science.1072702; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; HEIBECK TH, 1987, CHILD DEV, V58, P1021, DOI 10.1111/j.1467-8624.1987.tb01438.x; HERMAN LM, 1984, COGNITION, V16, P129, DOI 10.1016/0010-0277(84)90003-9; Markson L, 1997, NATURE, V385, P813, DOI 10.1038/385813a0; MERVIS CB, 1994, CHILD DEV, V65, P1662; Miklosi A, 2003, CURR BIOL, V13, P763, DOI 10.1016/S0960-9822(03)00263-X; Miles HWL, 1994, HOMINID CULTURE PRIM; SCHUSTERMAN RJ, 1984, PSYCHOL REC, V34, P3, DOI 10.1007/BF03394849; Tomasello M., 2003, CONSTRUCTING LANGUAG; Warden CJ, 1928, Q REV BIOL, V3, P1, DOI 10.1086/394292; Wilkinson KM, 1998, PSYCHOL REC, V48, P407, DOI 10.1007/BF03395281; YOUNG CA, 1991, APPL ANIM BEHAV SCI, V32, P75, DOI 10.1016/S0168-1591(05)80165-0	20	371	384	6	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1682	1683		10.1126/science.1097859	http://dx.doi.org/10.1126/science.1097859			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	827WL	15192233				2022-12-28	WOS:000221934300054
J	Shykind, BM; Rohani, SC; O'Donnell, S; Nemes, A; Mendelsohn, M; Sun, YH; Axel, R; Barnea, G				Shykind, BM; Rohani, SC; O'Donnell, S; Nemes, A; Mendelsohn, M; Sun, YH; Axel, R; Barnea, G			Gene switching and the stability of odorant receptor gene choice	CELL			English	Article							MAMMALIAN OLFACTORY-BULB; TOPOGRAPHIC MAP; TRANSGENIC MICE; MOUSE; EXPRESSION; EPITHELIUM; ORGANIZATION; DEFICIENT; GLOMERULI; EXCISION	Individual olfactory sensory neurons express only a single odorant receptor from a large family of genes, and this singularity is an essential feature in models of olfactory perception. We have devised a genetic strategy to examine the stability of receptor choice. We observe that immature olfactory sensory neurons that express a given odorant receptor can switch receptor expression, albeit at low frequency. Neurons that express a mutant receptor gene switch receptor transcription with significantly greater probability, suggesting that the expression of a functional odorant receptor elicits a feedback signal that terminates switching (Lewcock and Reed, 2004; Serizawa et al., 2003). This process of receptor gene switching assures that a neuron will ultimately express a functional receptor and that the choice of this receptor will remain stable for the life of the cell.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Axel, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	ra27@columbia.edu		Axel, Richard/0000-0002-3141-4076	NCI NIH HHS [2P01CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEA G, 2004, IN PRESS SCIENCE; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Eggan E, 2004, NATURE, V428, P44, DOI 10.1038/nature02375; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; HOLCOMB JD, 1995, DEV BIOL, V172, P307, DOI 10.1006/dbio.1995.0025; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Iwema CL, 2003, J COMP NEUROL, V459, P209, DOI 10.1002/cne.10583; Lewcock JW, 2004, P NATL ACAD SCI USA, V101, P1069, DOI 10.1073/pnas.0307986100; Li JS, 2004, NATURE, V428, P393, DOI 10.1038/nature02433; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Poole AM, 2003, BIOSYSTEMS, V69, P163, DOI 10.1016/S0303-2647(02)00131-4; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Royal SJ, 1999, J NEUROSCI, V19, P9856; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; Schwob JE, 1999, J COMP NEUROL, V412, P439, DOI 10.1002/(SICI)1096-9861(19990927)412:3<439::AID-CNE5>3.0.CO;2-H; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; Tsuboi A, 1999, J NEUROSCI, V19, P8409; Uchida N, 2000, NAT NEUROSCI, V3, P1035, DOI 10.1038/79857; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wachowiak M, 2001, NEURON, V32, P723, DOI 10.1016/S0896-6273(01)00506-2; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Young JM, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r71; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	39	180	183	3	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					801	815		10.1016/j.cell.2004.05.015	http://dx.doi.org/10.1016/j.cell.2004.05.015			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186780	Bronze			2022-12-28	WOS:000222048400012
J	Lin, JC; Wang, WY; Chen, KY; Wei, YH; Liang, WM; Jan, JS; Jiang, RS				Lin, JC; Wang, WY; Chen, KY; Wei, YH; Liang, WM; Jan, JS; Jiang, RS			Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIPHERAL-BLOOD CELLS; IN-SITU HYBRIDIZATION; QUANTITATIVE-ANALYSIS; PHASE-III; RADIOTHERAPY; CHEMOTHERAPY; EXPRESSION; MARKER; CANCER; TUMOR	BACKGROUND We investigated the clinical significance of plasma concentrations of Epstein - Barr virus (EBV) DNA in patients with advanced nasopharyngeal carcinoma. METHODS Ninety-nine patients with biopsy-proven stage III or IV nasopharyngeal carcinoma and no evidence of metastasis (M0) received 10 weekly chemotherapy treatments followed by radiotherapy. Plasma samples from the patients were subjected to a real-time quantitative polymerase-chain-reaction assay. EBV genotypes of paired samples from plasma and primary tumor were compared. RESULTS Plasma EBV DNA was detectable before treatment in 94 of the 99 patients, but not in 40 healthy controls or 20 cured patients. The median concentrations of plasma EBV DNA were 681 copies per milliliter among 25 patients with stage III disease, 1703 copies per milliliter among 74 patients with stage IV disease, and 291,940 copies per milliliter among 19 control patients with distant metastasis (P< 0.001). Patients with relapse had a significantly higher plasma EBV DNA concentration before treatment than those who did not have a relapse ( median, 3035 vs. 1202 copies per milliliter; P=0.02). The consistent genotyping of EBV DNA between paired samples of plasma and primary tumor suggested that the circulating cell-free EBV DNA may originate from the primary tumor. Unlike the rebound of plasma EBV DNA concentrations in the patients who had a relapse, the plasma EBV DNA concentration was persistently low or undetectable in patients with a complete clinical remission. Overall survival ( P< 0.001) and relapse-free survival ( P=0.02) were significantly lower among patients with pretreatment plasma EBV DNA concentrations of at least 1500 copies per milliliter than among those with concentrations of less than 1500 copies per milliliter. Patients with persistently detectable plasma EBV DNA had significantly worse overall survival ( P< 0.001) and relapse-free survival ( P< 0.001) than patients with undetectable EBV DNA one week after the completion of radiotherapy. CONCLUSIONS Quantification of plasma EBV DNA is useful for monitoring patients with nasopharyngeal carcinoma and predicting the outcome of treatment.	Taichung Vet Gen Hosp, Dept Radiat Oncol, Taichung 407, Taiwan; Taichung Vet Gen Hosp, Dept Otorhinolaryngol, Taichung 407, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Dept Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Ctr Cellular & Mol Biol, Taipei 112, Taiwan; Natl Cheng Kung Univ Hosp, Dept Radiat Oncol, Tainan 70428, Taiwan; China Med Univ, Sch Med, Dept Med, Taichung, Taiwan; China Med Univ, Dept Publ Hlth, Taichung, Taiwan; Hung Kuang Univ, Dept Basic Med, Taichung, Taiwan; Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan	Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Cheng Kung University; National Cheng Kung University Hospital; China Medical University Taiwan; China Medical University Taiwan; Hungkuang University; Taipei Veterans General Hospital	Lin, JC (corresponding author), Taichung Vet Gen Hosp, Dept Radiat Oncol, Taiwan 160,Sec 3,Taichung Kang Rd, Taichung 407, Taiwan.	jclin@vghtc.gov.tw	Wei, Yau-Huei/ABA-6841-2021	Wei, Yau-Huei/0000-0002-6429-2546; Jiang, Rong-San/0000-0002-8280-6029				Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Chan ATC, 2002, JNCI-J NATL CANCER I, V94, P1614, DOI 10.1093/jnci/94.21.1614; Chan KCA, 2003, CANCER RES, V63, P2028; Chang JTC, 2000, RADIOTHER ONCOL, V54, P135, DOI 10.1016/S0167-8140(99)00177-2; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; Chao TY, 1996, CANCER-AM CANCER SOC, V78, P24, DOI 10.1002/(SICI)1097-0142(19960701)78:1<24::AID-CNCR5>3.0.CO;2-H; CHEN CL, 1993, INTERVIROLOGY, V36, P91, DOI 10.1159/000150327; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Fleming ID, 1997, AJCC CANC STAGING MA, P31; Hsiao JR, 2002, CANCER, V94, P723, DOI 10.1002/cncr.10251; Lee WY, 2000, HEAD NECK-J SCI SPEC, V22, P336, DOI 10.1002/1097-0347(200007)22:4<336::AID-HED4>3.0.CO;2-T; Leung TW, 2000, INT J RADIAT ONCOL, V48, P1331, DOI 10.1016/S0360-3016(00)00776-8; Lin JC, 2003, HEAD NECK-J SCI SPEC, V25, P438, DOI 10.1002/hed.10238; Lin JC, 2003, BRIT J CANCER, V88, P187, DOI 10.1038/sj.bjc.6600716; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Lin JC, 2001, J CLIN ONCOL, V19, P2607, DOI 10.1200/JCO.2001.19.10.2607; Lo YMD, 1999, CANCER RES, V59, P1188; Lo YMD, 1999, CANCER RES, V59, P5452; Lo YMD, 2000, CANCER RES, V60, P6878; Lo YMD, 2000, ANN NY ACAD SCI, V906, P99; MACDONALD MR, 1995, HEAD NECK-J SCI SPEC, V17, P487, DOI 10.1002/hed.2880170606; Mutirangura A, 1998, CLIN CANCER RES, V4, P665; Ngan RKC, 2001, ANN NY ACAD SCI, V945, P73; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Shotelersuk K, 2000, CLIN CANCER RES, V6, P1046; Teo PML, 1998, INT J RADIAT ONCOL, V40, P897, DOI 10.1016/S0360-3016(97)00854-7; Tsai ST, 1996, CANCER, V77, P231, DOI 10.1002/(SICI)1097-0142(19960115)77:2<231::AID-CNCR2>3.0.CO;2-P; Wang WY, 2002, CLIN CANCER RES, V8, P2586; WU TC, 1991, AM J PATHOL, V138, P1461; YEUNG WM, 1993, INT J CANCER, V53, P746, DOI 10.1002/ijc.2910530507	32	613	643	2	44	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2461	2470		10.1056/NEJMoa032260	http://dx.doi.org/10.1056/NEJMoa032260			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190138				2022-12-28	WOS:000221887200005
J	Steiner, MJ; DeWalt, DA; Byerley, JS				Steiner, MJ; DeWalt, DA; Byerley, JS			Is this child dehydrated?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPILLARY REFILL; CLINICAL SIGNS; SKIN TURGOR; ACUTE GASTROENTERITIS; INFANTS; TEMPERATURE; MANAGEMENT; THERAPY; VOLUME; INDEX	Context The ability to assess the degree of dehydration quickly and accurately in infants and young children often determines patient treatment and disposition. Objective To systematically review the precision and accuracy of symptoms, signs, and basic laboratory tests for evaluating dehydration in infants and children. Data Sources We identified 1561 potential articles by multiple search strategies of the MEDLINE database through PubMed. Searches of bibliographies of retrieved articles, the Cochrane Library, textbooks, and private collections of experts in the field yielded an additional 42 articles. Study Selection Twenty-six of 1603 reviewed studies contained original data on the precision or accuracy of findings for the diagnosis of dehydration in young children (1 month to 5 years). Data Extraction Two of the 3 authors independently reviewed and abstracted data for estimating the likelihood ratios (LRs) of diagnostic tests. We eliminated 13 of the 26 studies because of the lack of an accepted diagnostic standard or other limitation in study design. The other 13 studies were included in the review. Data Synthesis The most useful individual signs for predicting 5% dehydration in children are an abnormal capillary refill time (LR, 4.1; 95% confidence interval [CI] 1.7-9.8), abnormal skin turgor (LR, 2.5; 95% Cl, 1.5-4.2), and abnormal respiratory pattern (LR, 2.0; 95% Cl, 1.5-2.7). Combinations of examination signs perform markedly better than any individual sign in predicting dehydration. Historical points and laboratory tests have only modest utility for assessing dehydration. Conclusions The initial assessment of dehydration in young children should focus on estimating capillary refill time, skin turgor, and respiratory pattern and using combinations of other signs. The relative imprecision and inaccuracy of available tests limit the ability of clinicians to estimate the exact degree of dehydration.	Univ N Carolina, Sch Med, Dept Pediat, Internal Med & Pediat Residency Program, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Internal Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Robert Wood Johnson Clin Scholars Program, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	DeWalt, DA (corresponding author), Univ N Carolina, Sch Med, Dept Pediat, Internal Med & Pediat Residency Program, CB 7593, Chapel Hill, NC 27599 USA.	dewaltd@med.unc.edu	Steiner, Mike/AAE-8437-2019	DeWalt, Darren/0000-0003-2270-751X				Amin S S, 1980, Paediatr Indones, V20, P77; Bates B, 1995, GUIDE PHYS EXAMINATI; Behrman R. E., 2000, NELSON TXB PEDIAT; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BROWN LH, 1994, AM J EMERG MED, V12, P46, DOI 10.1016/0735-6757(94)90196-1; BRUCK E, 1968, AM J DIS CHILD, V115, P281, DOI 10.1001/archpedi.1968.02100010283001; CZACZKES JW, 1961, AM J DIS CHILD, V102, P190, DOI 10.1001/archpedi.1961.02080010192006; DARROW DC, 1949, PEDIATRICS, V3, P129; DAWSON KP, 1991, NEW ZEAL MED J, V104, P162; DORRINGTON KL, 1981, LANCET, V1, P264; Duggan C, 1997, J TROP PEDIATRICS, V43, P119, DOI 10.1093/tropej/43.2.119; Duggan C, 1992, MMWR Recomm Rep, V41, P1; Duggan C, 1996, J PEDIATR GASTR NUTR, V22, P56, DOI 10.1097/00005176-199601000-00009; DWGOWIN R, 1994, DEGOWIN DEGOWINS DIA; English M, 1997, TROP DOCT, V27, P235, DOI 10.1177/004947559702700419; GLASS RI, 1991, J PEDIATR-US, V118, pS27, DOI 10.1016/S0022-3476(05)81422-2; Gorelick MH, 1997, PEDIATR EMERG CARE, V13, P305, DOI 10.1097/00006565-199710000-00001; Gorelick MH, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e6; GORELICK MH, 1993, PEDIATRICS, V92, P699; Gove S, 2003, B WORLD HEALTH ORGAN, V75, P7; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; LARON Z, 1957, PEDIATRICS, V19, P816; LEUNG AKC, 1989, LANCET, V2, P1038; MACKENZIE A, 1989, LANCET, V2, P605; Mange K, 1997, ANN INTERN MED, V127, P848, DOI 10.7326/0003-4819-127-9-199711010-00020; Margolis P, 1998, JAMA-J AM MED ASSOC, V279, P308, DOI 10.1001/jama.279.4.308; McConnochie KM, 1999, ARCH PEDIAT ADOL MED, V153, P1233, DOI 10.1001/archpedi.153.12.1233; McGee S, 1999, JAMA-J AM MED ASSOC, V281, P1022, DOI 10.1001/jama.281.11.1022; Nazarian LF, 1996, PEDIATRICS, V97, P424; NECHYBA C, 2002, H LANE PEDIAT HDB; Porter SC, 2003, ANN EMERG MED, V41, P196, DOI 10.1067/mem.2003.5; RUEDA EP, 1974, B MED HOSP INFANT M, V31, P561; SAAVEDRA JM, 1991, AM J DIS CHILD, V145, P296, DOI 10.1001/archpedi.1991.02160030064022; Santosham M, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e10; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCHRIGER DL, 1988, ANN EMERG MED, V17, P932, DOI 10.1016/S0196-0644(88)80675-9; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Teach SJ, 1997, CLIN PEDIATR, V36, P395, DOI 10.1177/000992289703600703; Tibby SM, 1999, ARCH DIS CHILD, V80, P163, DOI 10.1136/adc.80.2.163; Vega RM, 1997, PEDIATR EMERG CARE, V13, P179, DOI 10.1097/00006565-199706000-00001; *WHO PROGR CONTR D, 1990, MAN TREATM DIARRH; Yilmaz K, 2002, J PAEDIATR CHILD H, V38, P226, DOI 10.1046/j.1440-1754.2002.00792.x; ZITELLI B, 2002, ATLAS PEDIAT PHYS DI; 1971, BMJ, V1, P125	45	199	208	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2746	2754		10.1001/jama.291.22.2746	http://dx.doi.org/10.1001/jama.291.22.2746			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826XH	15187057				2022-12-28	WOS:000221862300030
J	Andre, T; Boni, C; Mounedji-Boudiaf, L; Navarro, M; Tabernero, J; Hickish, T; Topham, C; Zaninelli, M; Clingan, P; Bridgewater, J; Tabah-Fisch, I; de Gramont, A				Andre, T; Boni, C; Mounedji-Boudiaf, L; Navarro, M; Tabernero, J; Hickish, T; Topham, C; Zaninelli, M; Clingan, P; Bridgewater, J; Tabah-Fisch, I; de Gramont, A		MOSAIC Investigators	Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC COLORECTAL-CANCER; HIGH-DOSE LEUCOVORIN; RANDOMIZED-TRIAL; FOLINIC ACID; DUKES B; 1ST-LINE TREATMENT; THERAPY; BREAST; CHEMOTHERAPY; CARCINOMA	Background: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. Methods: We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival. Results: A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). Conclusions: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.	Hop St Antoine, F-75012 Paris, France; Hop Tenon, F-75970 Paris, France; GERCOR Oncol Multidisciplinary Grp, Paris, France; Arcisped Santa Maria Nuova, Reggio Emilia, Italy; Sanofi Synthelabo, Paris, France; Hosp Llobregat, Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain; Valle Hebron Univ Hosp, Barcelona, Spain; Royal Bournemouth Hosp, Dorset Canc Ctr, Bournemouth, Dorset, England; Poole Hosp, Dorset Canc Ctr, Bournemouth, Dorset, England; Royal Surrey Cty Hosp, Surrey, England; Osped Borgotrento, Verona, Italy; So Med Day Care Ctr, Wollongong, NSW, Australia; N Middlesex Hosp, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; IRCCS Arcispedale S. Maria Nuova; Sanofi-Aventis; Sanofi France; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Hospital Universitari Vall d'Hebron; Poole Hospital; Royal Surrey County Hospital; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	de Gramont, A (corresponding author), Hop St Antoine, 184 Rue Faubourg St Antoine, F-75012 Paris, France.	aimery.de-gramont@sat.ap-hop-paris.fr	Tabernero, Josep/AAG-5026-2019; André, Thierry P/N-8830-2017; Bridgewater, John/J-5957-2018	Tabernero, Josep/0000-0002-2495-8139; André, Thierry P/0000-0002-5103-7095; Hickish, Tamas/0000-0001-6770-7279				*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN, P83; Andre T, 1999, J CLIN ONCOL, V17, P3560, DOI 10.1200/JCO.1999.17.11.3560; Andre T, 2003, J CLIN ONCOL, V21, P2896, DOI 10.1200/JCO.2003.10.065; Buyse M, 2001, SEMIN ONCOL, V28, P20, DOI 10.1053/sonc.2001.19727; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Elfenbein GJ, 2003, NEW ENGL J MED, V349, P80, DOI 10.1056/NEJMe030087; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; EXTRA JM, 1990, CANCER CHEMOTH PHARM, V25, P299, DOI 10.1007/BF00684890; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Gill S., 2003, PROGRAM P AM SOC CLI, V22; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Haller DG, 1998, P AN M AM SOC CLIN, V17, p256a; LABIANCA R, 1995, LANCET, V345, P939; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; Obrand DI, 1997, DIS COLON RECTUM, V40, P15, DOI 10.1007/BF02055676; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801; SARGENT D, 2003, 3 YEAR DFS VS 5 YEAR; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Wolmark N, 1999, J CLIN ONCOL, V17, P3553, DOI 10.1200/JCO.1999.17.11.3553; Wolmark N, 1998, J NATL CANCER I, V90, P1810, DOI 10.1093/jnci/90.23.1810; Zaniboni A, 1997, J CLIN ONCOL, V15, P2432, DOI 10.1200/JCO.1997.15.6.2432; 2001, IARC CANCERBASE	28	2689	2775	4	154	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2343	2351		10.1056/NEJMoa032709	http://dx.doi.org/10.1056/NEJMoa032709			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175436	Green Published, Bronze			2022-12-28	WOS:000221754200005
J	Hwangbo, DS; Gersham, B; Tu, MP; Palmer, M; Tatar, M				Hwangbo, DS; Gersham, B; Tu, MP; Palmer, M; Tatar, M			Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body	NATURE			English	Article							RECEPTOR; GROWTH; HOMOLOG; MUTANT; DOWNSTREAM; EXPRESSION; LONGEVITY; DAF-16; SYSTEM; GENE	In Drosophila melanogaster, ageing is slowed when insulin-like signalling is reduced: life expectancy is extended by more than 50% when the insulin-like receptor (InR) or its receptor substrate (chico) are mutated, or when insulin-producing cells are ablated(1-3). But we have yet to resolve when insulin affects ageing, or whether insulin signals regulate ageing directly or indirectly through secondary hormones. Caenorhabditis elegans lifespan is also extended when insulin signalling is inhibited in certain tissues, or when repressed in adult worms(4,5), and this requires the forkhead transcription factor (FOXO) encoded by daf-16 (ref. 6). The D. melanogaster insulin-like receptor mediates phosphorylation of dFOXO, the equivalent of nematode daf-16 and mammalian FOXO3a(7,8). We demonstrate here that dFOXO regulates D. melanogaster ageing when activated in the adult pericerebral fat body. We further show that this limited activation of dFOXO reduces expression of the Drosophila insulin-like peptide dilp-2 synthesized in neurons, and represses endogenous insulin-dependent signalling in peripheral fat body. These findings suggest that autonomous and non-autonomous roles of insulin signalling combine to control ageing.	Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Brown University	Tatar, M (corresponding author), Brown Univ, Div Biol & Med, Box G-W, Providence, RI 02912 USA.	Marc_Tatar@brown.edu	Gimenez, Luis E Diaz/D-9291-2011	Tatar, Marc/0000-0003-3232-6884				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Cao C, 2001, CELL TISSUE RES, V304, P317, DOI 10.1007/s004410100367; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Dobens LL, 1997, MECH DEVELOP, V65, P197, DOI 10.1016/S0925-4773(97)00080-4; Garofalo RS, 2002, TRENDS ENDOCRIN MET, V13, P156, DOI 10.1016/S1043-2760(01)00548-3; Gerisch B, 2001, DEV CELL, V1, P841, DOI 10.1016/S1534-5807(01)00085-5; Jia KL, 2002, DEVELOPMENT, V129, P221; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Osterwalder T, 2001, P NATL ACAD SCI USA, V98, P12596, DOI 10.1073/pnas.221303298; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Roman G, 2001, P NATL ACAD SCI USA, V98, P12602, DOI 10.1073/pnas.221303998; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Simon AF, 2003, SCIENCE, V299, P1407, DOI 10.1126/science.1080539; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tu MP, 2002, AGING CELL, V1, P75, DOI 10.1046/j.1474-9728.2002.00010.x; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147	26	702	739	5	119	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					562	566		10.1038/nature02549	http://dx.doi.org/10.1038/nature02549			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175753				2022-12-28	WOS:000221767700040
J	Weiss, R; Dziura, J; Burgert, TS; Tamborlane, WV; Taksali, SE; Yeckel, CW; Allen, K; Lopes, M; Savoye, M; Morrison, J; Sherwin, RS; Caprio, S				Weiss, R; Dziura, J; Burgert, TS; Tamborlane, WV; Taksali, SE; Yeckel, CW; Allen, K; Lopes, M; Savoye, M; Morrison, J; Sherwin, RS; Caprio, S			Obesity and the metabolic syndrome in children and adolescents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR RISK-FACTORS; INSULIN-RESISTANCE; NATIONAL-HEALTH; GLUCOSE; ASSOCIATION; PREVALENCE; PREDICTS	Background: The prevalence and magnitude of childhood obesity are increasing dramatically. We examined the effect of varying degrees of obesity on the prevalence of the metabolic syndrome and its relation to insulin resistance and to C-reactive protein and adiponectin levels in a large, multiethnic, multiracial cohort of children and adolescents. Methods: We administered a standard glucose-tolerance test to 439 obese, 31 overweight, and 20 nonobese children and adolescents. Baseline measurements included blood pressure and plasma lipid, C-reactive protein, and adiponectin levels. Levels of triglycerides, high-density lipoprotein cholesterol, and blood pressure were adjusted for age and sex. Because the body-mass index varies according to age, we standardized the value for age and sex with the use of conversion to a z score. Results: The prevalence of the metabolic syndrome increased with the severity of obesity and reached 50 percent in severely obese youngsters. Each half-unit increase in the body-mass index, converted to a z score, was associated with an increase in the risk of the metabolic syndrome among overweight and obese subjects (odds ratio, 1.55; 95 percent confidence interval, 1.16 to 2.08), as was each unit of increase in insulin resistance as assessed with the homeostatic model (odds ratio, 1.12; 95 percent confidence interval, 1.07 to 1.18 for each additional unit of insulin resistance). The prevalence of the metabolic syndrome increased significantly with increasing insulin resistance (P for trend, <0.001) after adjustment for race or ethnic group and the degree of obesity. C-reactive protein levels increased and adiponectin levels decreased with increasing obesity. Conclusions: The prevalence of the metabolic syndrome is high among obese children and adolescents, and it increases with worsening obesity. Biomarkers of an increased risk of adverse cardiovascular outcomes are already present in these youngsters.	Yale Univ, Sch Med, Dept Pediat, POB 802064, New Haven, CT 06520 USA; Yale Univ, Sch Med, Childrens Gen Clin Res Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA	Yale University; Yale University; Yale University; Cincinnati Children's Hospital Medical Center	Caprio, S (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 802064, New Haven, CT 06520 USA.	sonia.caprio@yale.edu			NCRR NIH HHS [M01-RR00125, M01-RR06022] Funding Source: Medline; NICHD NIH HHS [R01-HD40787, K24-HD01464, R01-HD28016] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040787, R01HD028016] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K24HD001464] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006022, M01RR000125] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abbasi F, 2002, J AM COLL CARDIOL, V40, P937, DOI 10.1016/S0735-1097(02)02051-X; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Altman D.G., 1991, PRACTICAL STAT MED R; Arslanian S, 2002, HORM RES, V57, P19, DOI 10.1159/000053308; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Blake GJ, 2002, J INTERN MED, V252, P283, DOI 10.1046/j.1365-2796.2002.01019.x; Bonora E, 1998, DIABETES, V47, P1643, DOI 10.2337/diabetes.47.10.1643; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Caprio S, 2002, J PEDIATR ENDOCR MET, V15, P487; Cook S, 2003, OBES RES, V11, pA27; Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821; Cureton E.E., 1983, FACTOR ANAL APPL APP; Falkner B, 1996, PEDIATRICS, V98, P649; Ford ES, 2003, CIRCULATION, V108, P1053, DOI 10.1161/01.CIR.0000080913.81393.B8; Gavin JR, 1999, DIABETES CARE, V22, pS5; Goran MI, 1999, AM J HUM BIOL, V11, P201, DOI 10.1002/(SICI)1520-6300(1999)11:2&lt;201::AID-AJHB8&gt;3.0.CO;2-R; Goran MI, 1998, CORONARY ARTERY DIS, V9, P483, DOI 10.1097/00019501-199809080-00003; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HOLM S, 1979, SCAND J STAT, V6, P65; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Levitt Naomi S, 2002, Cardiovasc J S Afr, V13, P179; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; *NAT CHOL ED PROGR, 2001, NIH PUBL; *NAT CHOL ED PROGR, 1991, NIH PUBL; NGHS Coordinating Center, 1998, NHLBI GROWTH HLTH ST; Ozanne SE, 2002, TRENDS ENDOCRIN MET, V13, P368, DOI 10.1016/S1043-2760(02)00666-5; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pepys MB, 2003, J CLIN INVEST, V112, P299, DOI 10.1172/JCI200318921C; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Sinha R, 2002, NEW ENGL J MED, V346, P1756; Steinberger J, 2003, CIRCULATION, V107, P1448, DOI 10.1161/01.CIR.0000060923.07573.F2; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Tan KCB, 2003, DIABETES CARE, V26, P2323, DOI 10.2337/diacare.26.8.2323; Tanner JM, 1962, GROWTH ADOLESCENCE G; Yanovski JA, 1996, AM J CLIN NUTR, V64, P833, DOI 10.1093/ajcn/64.6.833; Zietz B, 2003, FEBS LETT, V545, P103, DOI 10.1016/S0014-5793(03)00568-4	42	2284	2426	7	214	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2362	2374		10.1056/NEJMoa031049	http://dx.doi.org/10.1056/NEJMoa031049			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175438				2022-12-28	WOS:000221754200007
J	Nalin, DR; Hirschhorn, N; Greenough, W; Fuchs, GJ; Cash, RA				Nalin, DR; Hirschhorn, N; Greenough, W; Fuchs, GJ; Cash, RA			Clinical concerns about reduced-osmolarity oral rehydration solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAINTENANCE THERAPY; STOOL OUTPUT; CHOLERA; DIARRHEA; CHILDREN; ELECTROLYTE; DEHYDRATION; EFFICACY; SAFETY; TRIAL		Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Johns Hopkins Sch Med, Baltimore, MD USA; Univ Arkansas, Sch Med, Little Rock, AR 72204 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA	Yale University; Johns Hopkins University; Johns Hopkins Medicine; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Harvard University; Harvard T.H. Chan School of Public Health	Nalin, DR (corresponding author), 100 Lucky Hill Rd, W Chester, PA 19382 USA.	davidnalin@aol.com	Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Alam NH, 2003, J PEDIATR-US, V143, P614, DOI 10.1067/S0022-3476(03)00500-6; Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Alam S, 2000, Indian Pediatr, V37, P952; BLACK RE, 1982, ACUTE DIARRHEA ITS N, P79; CASH RA, 1970, LANCET, V2, P549; CASH RA, 1970, AM J TROP MED HYG, V19, P653, DOI 10.4269/ajtmh.1970.19.653; Dutta D, 2000, ACTA PAEDIATR, V89, P787, DOI 10.1080/080352500750043657; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; FAYAD IM, 1992, LANCET, V339, P389, DOI 10.1016/0140-6736(92)90079-I; Fuchs GJ, 2001, BRIT MED J, V323, P59, DOI 10.1136/bmj.323.7304.59; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; GREENOUGH WB, 1964, LANCET, V1, P355; GUZMAN C, 1988, J PEDIATR GASTR NUTR, V7, P694, DOI 10.1097/00005176-198809000-00013; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; MATA L, 1982, ACUTE DIARRHEA ITS N, P10; NALIN D R, 1970, Bulletin of the World Health Organization, V43, P361; Nalin D.R., 1970, ANN, V72, P288, DOI [10.7326/0003-4819-72-2-288_3, DOI 10.7326/0003-4819-72-2-288_3]; NALIN DR, 1972, J INFECT DIS, V125, P528, DOI 10.1093/infdis/125.5.528; NALIN DR, 1979, B WORLD HEALTH ORGAN, V57, P453; NALIN DR, 1980, J PEDIATR-US, V97, P848, DOI 10.1016/S0022-3476(80)80287-3; NALIN DR, 1970, T ROY SOC TROP MED H, V64, P769, DOI 10.1016/0035-9203(70)90020-9; NALIN DR, 1968, LANCET, V2, P370; NALIN DR, 1973, USES EPIDEMIOLOGY PL, P1048; PARKER RL, 1980, POPULATION REPORTS, V8, pL41; PATRA FC, 1984, ACTA PAEDIATR SCAND, V73, P18, DOI 10.1111/j.1651-2227.1984.tb09891.x; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; RABBANI H, 1992, CHOLERA, P213; Wright EM, 1997, J EXP BIOL, V200, P287	32	10	13	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2632	2635		10.1001/jama.291.21.2632	http://dx.doi.org/10.1001/jama.291.21.2632			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173156				2022-12-28	WOS:000221738800028
J	Rivera, JA; Sotres-Alvarez, D; Habicht, JP; Shamah, T; Villalpando, S				Rivera, JA; Sotres-Alvarez, D; Habicht, JP; Shamah, T; Villalpando, S			Impact of the Mexican Program for Education, Health, and Nutrition (Progresa) on rates of growth and anemia in infants and young children - A randomized effectiveness study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPPLEMENTATION	Context Malnutrition causes death and impaired health in millions of children. Existing interventions are effective under controlled conditions; however, little information is available on their effectiveness in large-scale programs. Objective To document the short-term nutritional impact of a large-scale, incentive-based development program in Mexico (Progress), which included a nutritional component. Design, Setting, and Participants A randomized effectiveness study of 347 communities randomly assigned to immediate incorporation to the program in 1998 (intervention group; n=205) or to incorporation in 1999 (crossover intervention group; n=142). A random sample of children in those communities was surveyed at baseline and at 1 and 2 years afterward. Participants were from low-income households in poor rural communities in 6 central Mexican states. Children (N=650) 12 months of age or younger (n=373 intervention group; n=277 crossover intervention group) were included in the analyses. Intervention Children and pregnant and lactating women in participating households received fortified nutrition supplements; and the families received nutrition education, health care, and cash transfers. Main Outcome Measures Two-year height increments and, anemia rates as measured by blood hemoglobin levels in participating children. Results Progresa was associated with better growth in height among the poorest and younger infants. Age- and length-adjusted height was greater by 1.1 cm (26.4 cm in the intervention group Vs 25.3 cm in the crossover intervention group) among infants younger than 6 months at baseline and who lived in the poorest households. After 1 year, mean hemoglobin values were higher in the intervention group (11.12 g/dL; 95% confidence interval [CI], 10.9-11.3 g/dL) than in the crossover intervention group (10.75 g/dL; 95% CI, 10.5-11.0 g/dL) who had not yet received the benefits of the intervention (P=.01). There were no differences in hemoglobin levels between the 2 groups at year 2 after both groups were receiving the intervention. The age-adjusted rate of anemia (hemoglobin level <11 g/dL) in 1999 was higher in the crossover intervention group than in the intervention group (54.9% vs 44.3%; P=.03), whereas in 2000 the difference was not significant (23.0% vs 25.8%, respectively; P=.40). Conclusion Progresa, a large-scale, incentive-based development program with a nutritional intervention, is associated with better growth and lower rates of anemia in low-income, rural infants and children in Mexico.	Ctr Invest Nutr & Salud, Inst Nacl Salud Publ, Cuernavaca 62508, Morelos, Mexico; Cornell Univ, Div Nutr Sci, New York, NY USA	Instituto Nacional de Salud Publica; Cornell University	Rivera, JA (corresponding author), Ctr Invest Nutr & Salud, Inst Nacl Salud Publ, Av Univ 655,Colonia Santa Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.	jrivera@correo.insp.mx	Villalpando, Salvador/AAS-3874-2021; Sotres-Alvarez, Daniela/O-9085-2016; DeMarcus, Forrest/O-9190-2016	Villalpando, Salvador/0000-0001-6429-3816; Sotres-Alvarez, Daniela/0000-0002-3226-6140; Rivera, Juan A./0000-0003-2586-4908				[Anonymous], 1999, DEV FREEDOM; Barquera S, 2001, SALUD PUBLICA MEXICO, V43, P464, DOI 10.1590/S0036-36342001000500011; BEATON GH, 1982, AM J CLIN NUTR, V35, P864, DOI 10.1093/ajcn/35.4.864; BEHRMAN JR, RANDOMNESS EXPT SAMP; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Caulfield Laura E., 1999, Food and Nutrition Bulletin, V20, P183; Caulfield LE, 2001, NESTLE NUTR WORKS SE, V47, P375; FISHMAN S, IN PRESS COMP QUANTI; GERTLER P, UNPUB LANCET; GERTLER PJ, FINAL REPORT IMPACT; GWATKIND R, 1980, SOC SCI MED C, V14, P121; Habicht JP, 1999, INT J EPIDEMIOL, V28, P10, DOI 10.1093/ije/28.1.10; HABICHT JP, 1974, B OFIC SANIT PANAM, V75, P375; Habicht JP, 1979, EVALUATING IMPACT NU; Hinkelman K, 1994, DESIGN ANAL EXPT; HODDINOTT J, 2003, 150 INT FOOD POL RES; HOORWEG J, 1988, FOOD POLICY, V13, P199, DOI 10.1016/0306-9192(88)90032-2; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Lohman T. G., 1998, ANTROPOMETRIC STANDA; LOHR SL, 1999, SAMPLING DESIGN ANAL, P241; MARDIA KV, 2000, MULTIVARIATE ANAL, V213, P216; MARTORELL R, 1995, J NUTR, V125, pS1127, DOI 10.1093/jn/125.suppl_4.1127S; MURRAY DM, 1998, DESIGN ANAL GROUP RA, P364; PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130; RAUDENBUSH SW, 2002, HIERARCHICAL LINEAR, P26; RIVERA J, 1999, I NACL SALUD PUBLICA, P7; Rivera JA, 2003, SALUD PUBLICA MEXICO, V45, pS565; Rivera JA, 2003, J NUTR, V133, p4010S, DOI 10.1093/jn/133.11.4010S; Rivera-Dommarco JA, 2001, NESTLE NUTR WORKS SE, V47, P281; RIVERADOMMARCO J, 1995, SALUD PUBLICA MEXICO, V37, P95; Rosado Jorge L., 2000, Food and Nutrition Bulletin, V21, P30; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P144; RUIZARGUELLES GJ, 1981, REV INVEST CLIN, V33, P191; SCHROEDER DG, 1995, J NUTR, V125, pS1051; *SIST NAC VIG EP, 2003, EPIDEMIIOLOGIA, V14; Skoufias E., 1999, EVALUATION SELECTION; Tay J, 1995, Bol Chil Parasitol, V50, P10; Turner L, 2002, NUTR REV, V60, pS16, DOI 10.1301/002966402320285038; *UN ADM COMM COORD, 2000, 4 REP WORLD NUTR SIT; Zwart A, 1996, J CLIN PATHOL, V49, P271, DOI 10.1136/jcp.49.4.271; [No title captured]	41	273	282	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2563	2570		10.1001/jama.291.21.2563	http://dx.doi.org/10.1001/jama.291.21.2563			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	825EM	15173147				2022-12-28	WOS:000221738800019
J	Egli, F; Walter, R				Egli, F; Walter, R			Vitiligo and pernicious anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kantonsspital, CH-7000 Chur, Switzerland	Kantonsspital Aarau AG (KSA)	Egli, F (corresponding author), Kantonsspital, CH-7000 Chur, Switzerland.		Walter, Roland/C-1064-2008	Walter, Roland/0000-0002-9268-3341					0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2698	2698		10.1056/NEJMicm990602	http://dx.doi.org/10.1056/NEJMicm990602			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215486				2022-12-28	WOS:000222199000011
J	Yusa, K; Horie, K; Kondoh, G; Kouno, M; Maeda, Y; Kinoshita, T; Takeda, J				Yusa, K; Horie, K; Kondoh, G; Kouno, M; Maeda, Y; Kinoshita, T; Takeda, J			Genome-wide phenotype analysis in ES cells by regulated disruption of Bloom's syndrome gene	NATURE			English	Article							EMBRYONIC STEM-CELLS; EXPRESSION CLONING; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; HUMAN BLASTOCYSTS; MICE; SCREEN; LINES; LOCUS; FATE	The chief limitation of phenotype-based genetic screening in mammalian systems is the diploid nature of the genome. Cells deficient in the Bloom's syndrome gene (Blm) show an increased rate of loss of heterozygosity(1-3). Here we have used a tetracycline-regulated Blm allele (Blm(tet)) to introduce bi-allelic mutations across the genome in mouse embryonic stem (ES) cells. Transient loss of Blm expression induces homologous recombination not only between sister chromatids but also between homologous chromosomes. We considered that the phenotype of ES cells bearing bi-allelic mutations would be maintained after withdrawal of the tetracycline analogue doxycycline. Indeed, a combination of N-ethyl-N-nitrosourea mutagenesis and transient loss of Blm expression enabled us to generate an ES cell library with genome-wide bi-allelic mutations. The library was evaluated by screening for mutants of glycosylphosphatidylinositol-anchor biosynthesis, which involves at least 23 genes distributed throughout the genome. Mutants derived from 12 different genes were obtained and two unknown mutants were simultaneously isolated. Our results indicate that phenotype-based genetic screening with Blm(tet) is very efficient and raises possibilities for identifying gene functions in ES cells.	Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Suita, Osaka 5650871, Japan; Osaka Univ, Collaborat Res Ctr Adv Sci & Technol, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Takeda, J (corresponding author), Osaka Univ, Grad Sch Med, Dept Social & Environm Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	takeda@mr-envi.med.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009	Horie, Kyoji/0000-0001-9036-8180				Bond CT, 2000, SCIENCE, V289, P1942, DOI 10.1126/science.289.5486.1942; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen YJ, 2000, NAT GENET, V24, P314, DOI 10.1038/73557; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; GRODEN J, 1990, P NATL ACAD SCI USA, V87, P4315, DOI 10.1073/pnas.87.11.4315; GUPTA RS, 1978, CELL, V14, P1007, DOI 10.1016/0092-8674(78)90354-9; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Koike H, 2002, EMBO REP, V3, P433, DOI 10.1093/embo-reports/kvf097; Kondoh G, 1999, FEBS LETT, V458, P299, DOI 10.1016/S0014-5793(99)01172-2; Kyba M, 2003, EXP HEMATOL, V31, P994, DOI 10.1016/j.exphem.2003.08.002; Lefebvre L, 2001, NAT GENET, V27, P257, DOI 10.1038/85808; Liu PT, 2002, NAT GENET, V30, P66, DOI 10.1038/ng788; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luria SE, 1943, GENETICS, V28, P491; Munroe RJ, 2000, NAT GENET, V24, P318, DOI 10.1038/73563; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	26	63	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					896	899		10.1038/nature02646	http://dx.doi.org/10.1038/nature02646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215867				2022-12-28	WOS:000222213000046
J	Shah, J				Shah, J			Recent developments - Criteria influencing the clinical uptake of pharmacogenomic strategies	BMJ-BRITISH MEDICAL JOURNAL			English	Review									London Sch Econ & Polit Sci, Dept Social Policy, London WC2A 2AE, England	University of London; London School Economics & Political Science	Shah, J (corresponding author), London Sch Econ & Polit Sci, Dept Social Policy, London WC2A 2AE, England.	jai.shah-alumni@lse.ac.uk		Shah, Jai/0000-0002-7549-6990				Birmingham K, 2001, NAT MED, V7, P262, DOI 10.1038/85364; BRANCA M, BIO IT WORLD 2002; Bristol L. A., 2002, Pharmacogenomics Journal, V2, P83, DOI 10.1038/sj.tpj.6500079; Burke W, 2002, AM J EPIDEMIOL, V156, P311, DOI 10.1093/aje/kwf055; Evans JP, 2001, BMJ-BRIT MED J, V322, P1052, DOI 10.1136/bmj.322.7293.1052; Hughes AR, 2004, PHARMACOGENOMICS, V5, P203, DOI 10.1517/phgs.5.2.203.27481; Issa AM, 2002, NAT REV DRUG DISCOV, V1, P300, DOI 10.1038/nrd771; Krynetski E, 2003, ONCOGENE, V22, P7403, DOI 10.1038/sj.onc.1206944; Lindpaintner K, 2002, PHARMACOGENOMICS, V3, P835, DOI 10.1517/14622416.3.6.835; Marshall E, 2003, SCIENCE, V302, P588, DOI 10.1126/science.302.5645.588; Melzer David, 2003, MY VERY OWN MED WHAT; Moriguchi H, 2002, HEPATOLOGY, V36, P177, DOI 10.1053/jhep.2002.33895; *NAT I CLIN EXC, 2002, 34 NAT I CLIN EXC; Norton RM, 2001, DRUG DISCOV TODAY, V6, P180, DOI 10.1016/S1359-6446(00)01648-2; OWENS J, 2001, DRUG DISCOV TODAY, V6, P450; Phillips KA, 2003, PHARMACOGENOMICS, V4, P231, DOI 10.1517/phgs.4.3.231.22691; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; Robertson JA, 2002, HEALTH AFFAIR, V21, P155, DOI 10.1377/hlthaff.21.4.155; *ROCH DIAGN, 2003, ROCH DIAGN LAUNCH AM; Rothstein MA, 2001, NAT REV GENET, V2, P228, DOI 10.1038/35056075; Shah J, 2003, NAT BIOTECHNOL, V21, P747, DOI 10.1038/nbt0703-747; Tollman PA, 2001, REVOLUTION R D GENOM; van Aken Jan, 2003, Am J Pharmacogenomics, V3, P149, DOI 10.2165/00129785-200303030-00001; Veenstra DL, 2000, AAPS PHARMSCI, V2, part. no.; WARD SJ, 2001, BIOTECHNIQUES, P64; Wolf CR, 1999, BRIT MED BULL, V55, P366, DOI 10.1258/0007142991902439	26	30	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1482	1486		10.1136/bmj.328.7454.1482	http://dx.doi.org/10.1136/bmj.328.7454.1482			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205293	Green Submitted, Green Published			2022-12-28	WOS:000222244600019
J	Edwards, JCW; Szczepanski, L; Szechinski, J; Filipowicz-Sosnowska, A; Emery, P; Close, DR; Stevens, RM; Shaw, T				Edwards, JCW; Szczepanski, L; Szechinski, J; Filipowicz-Sosnowska, A; Emery, P; Close, DR; Stevens, RM; Shaw, T			Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOCYTES; DISEASE; PATHOGENESIS; IMPROVEMENT; MECHANISMS; TRIALS	Background: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. Methods: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (greater/equal 10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). Results: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P lessthan/equal 0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P lessthan/equal 0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. Conclusions: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.	UCL, Ctr Rheumatol, London W1P 9PG, England; Med Univ Sch Lublin, Lublin, Poland; Univ Sch Wroclaw, Wroclaw, Poland; Inst Rheumatol, Warsaw, Poland; Leeds Royal Infirm, Leeds, W Yorkshire, England; Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England; Roche, Nutley, NJ USA	University of London; University College London; Roche Holding; Roche Holding	Edwards, JCW (corresponding author), UCL, Ctr Rheumatol, 4th Fl,Arthur Stanley House,40-50 Tottenham St, London W1P 9PG, England.	jo.edwards@ucl.ac.uk						Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Dorner T, 2003, CURR OPIN RHEUMATOL, V15, P246, DOI 10.1097/00002281-200305000-00011; Edwards JCW, 2001, RHEUMATOLOGY, V40, P205, DOI 10.1093/rheumatology/40.2.205; Edwards JCW, 1999, IMMUNOLOGY, V97, P188; Emery P, 2003, ARTHRITIS RHEUM, V48, pS439; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Gause A, 2001, BIODRUGS, V15, P73, DOI 10.2165/00063030-200115020-00001; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Leandro MJ, 2002, ANN RHEUM DIS, V61, P883, DOI 10.1136/ard.61.10.883; McLaughlin P, 1999, SEMIN ONCOL, V26, P79; PANAYI GS, 1993, BRIT J RHEUMATOL, V32, P4; Pincus T, 1989, Scand J Rheumatol Suppl, V79, P67; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Reparon-Schuijt CC, 2001, ARTHRITIS RHEUM, V44, P2029, DOI 10.1002/1529-0131(200109)44:9<2029::AID-ART352>3.0.CO;2-2; Shiokawa S, 2003, SCAND J RHEUMATOL, V32, P12, DOI 10.1080/03009740310000346; Takemura S, 2001, J IMMUNOL, V167, P4710, DOI 10.4049/jimmunol.167.8.4710; TIGHE H, 1997, TXB RHEUMATOLOGY, V1, P241; van Gestel AM, 1999, J RHEUMATOL, V26, P705; VANZEBEN D, 1992, ANN RHEUM DIS, V51, P1029, DOI 10.1136/ard.51.9.1029; Zhang ZX, 2001, RHEUM DIS CLIN N AM, V27, P335, DOI 10.1016/S0889-857X(05)70205-2	21	1905	2061	2	125	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2572	2581		10.1056/NEJMoa032534	http://dx.doi.org/10.1056/NEJMoa032534			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201414	Green Published			2022-12-28	WOS:000222054700008
J	Astrow, AB; Sulmasy, DP				Astrow, AB; Sulmasy, DP			Spirituality and the patient-physician relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER-PATIENTS; OF-LIFE; ONCOLOGY; ATTITUDES; FAITH; CARE		St Vincents Hosp & Med Ctr, New York, NY 10011 USA	Saint Vincents Hospital Manhattan	Astrow, AB (corresponding author), St Vincents Hosp & Med Ctr, New York, NY 10011 USA.							DAALEMAN TP, 1994, J FAM PRACTICE, V39, P564; Fisch MJ, 2003, J CLIN ONCOL, V21, P2754, DOI 10.1200/JCO.2003.06.093; Kash KM, 2000, ONCOLOGY-NY, V14, P1621; KING DE, 1994, J FAM PRACTICE, V39, P349; Kristeller JL, 1999, PSYCHO-ONCOLOGY, V8, P451, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<451::AID-PON422>3.3.CO;2-V; MAUGANS TA, 1991, J FAM PRACTICE, V32, P210; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; Moadel A, 1999, PSYCHO-ONCOL, V8, P378, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<378::AID-PON406>3.0.CO;2-A; Monroe MH, 2003, ARCH INTERN MED, V163, P2751, DOI 10.1001/archinte.163.22.2751; Sered S, 1999, MED ANTHROPOL Q, V13, P223, DOI 10.1525/maq.1999.13.2.223; Silvestri GA, 2003, J CLIN ONCOL, V21, P1379, DOI 10.1200/JCO.2003.08.036; Sulmasy Daniel P, 2002, Gerontologist, V42 Spec No 3, P24	12	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2884	2884		10.1001/jama.291.23.2884	http://dx.doi.org/10.1001/jama.291.23.2884			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	828GT	15199045				2022-12-28	WOS:000221962500040
J	Althabe, F; Belizan, JM; Villar, J; Alexander, S; Bergel, E; Ramos, S; Romero, M; Donner, A; Lindmark, G; Langer, A; Farnot, U; Cecatti, JG; Carroli, G; Kestler, E				Althabe, F; Belizan, JM; Villar, J; Alexander, S; Bergel, E; Ramos, S; Romero, M; Donner, A; Lindmark, G; Langer, A; Farnot, U; Cecatti, JG; Carroli, G; Kestler, E		Latin Am Caesarean Section Study G	Mandatory second opinion to reduce rates of unnecessary caesarean sections in Latin America: a cluster randomised controlled trial	LANCET			English	Article							GENERAL-PRACTITIONERS; DELIVERY; BRAZIL; TRENDS	Background Latin America has a high rate of caesarean sections. We tested the hypothesis that a hospital policy of mandatory second opinion, based on the best existing scientific evidence, reduces the hospital caesarean section rate by 25%, without increasing maternal and perinatal morbidity and mortality. Methods 36 hospitals in Argentina (18), Brazil (eight), Cuba (four), Guatemala (two), and Mexico (four), were randomly assigned to intervention or control in a matched pair design. All physicians in the intervention hospitals deciding a nonemergency caesarean section had to follow a policy of mandatory second opinion. The primary outcome was the overall caesarean section rate in the hospitals after a 6-month implementation period. We also assessed women's satisfaction with labour and delivery care and physicians' acceptance of the second opinion policy. Findings A total of 34 hospitals attending 149 276 deliveries were randomised and completed the protocol. The mandatory second opinion policy was associated with a small but significant reduction in rates of caesarean section (relative rate reduction 7.3%; 95% Cl 0.2-14.5), mostly in intrapartum sections (12.6%; 0.6-24.7). Other maternal and neonatal outcomes and women's perceptions and satisfaction with the process of care were similarly distributed between the groups. Interpretation In hospitals applying this policy of second opinion, 22 intrapartum caesarean sections could be prevented per 1000 deliveries, without affecting maternal or perinatal morbidity, and without affecting mothers' satisfaction with the care process.	WHO, Pan Amer Hlth Org, Latin Amer Ctr Perinatol, Montevideo, Uruguay; WHO, ENDP,UNFPA, World Bank Special Programme Res Dev & Res Traini, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland; Free Univ Brussels, Ecole Sante Publ, Brussels, Belgium; Ctr Study State & Soc, Buenos Aires, DF, Argentina; Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; Univ Uppsala, Dept Obstet & Gynaecol, S-75105 Uppsala, Sweden; Populat Council, Reg Off Latin Amer & Caribbean, Mexico City, DF, Mexico; Hosp Ginecoobstet Amer Arias, Havana, Cuba; Univ Campinas, Ctr Studies Maternal & Child Hlth Campinas, Campinas, SP, Brazil; Ctr Rosarino Estudios Perinatales, Rosario, Santa Fe, Argentina; Epidemiol Res Ctr Reprod & Sexual Hlth, Guatemala City, Guatemala	Pan American Health Organization; World Health Organization; The World Bank; United Nations Population Fund; World Health Organization; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Western University (University of Western Ontario); Uppsala University; Universidade Estadual de Campinas	Althabe, F (corresponding author), Hosp Clin Montevideo, Latin Amer Ctr Perinatol, Av Italia S-N Casilla de Correos 627, Montevideo 11000, Uruguay.	althabef@clap.ops-oms.org	Sandall, Jane/D-4146-2009; Cecatti, Jose Guilherme/M-5945-2013	Sandall, Jane/0000-0003-2000-743X; Cecatti, Jose Guilherme/0000-0003-1285-8445; Romero, Mariana/0000-0003-4272-3138; Belizan, Jose/0000-0002-8412-3010				Ballacci F, 1996, Epidemiol Prev, V20, P105; BARROS FC, 1991, LANCET, V338, P167, DOI 10.1016/0140-6736(91)90149-J; Belizan JM, 1999, BMJ-BRIT MED J, V319, P1397, DOI 10.1136/bmj.319.7222.1397; Chez RA, 1997, J REPROD MED, V42, P658; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; FAUNDES A, 1993, HEALTH POLICY PLANN, V8, P33, DOI 10.1093/heapol/8.1.33; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Kristensen MO, 1998, ACTA OBSTET GYN SCAN, V77, P951; Murray SF, 1997, BIRTH-ISS PERINAT C, V24, P258, DOI 10.1111/j.1523-536X.1997.tb00600.x; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; NOTZON FC, 1994, AM J OBSTET GYNECOL, V170, P495, DOI 10.1016/S0002-9378(94)70217-9; ROSS S, 2001, ADV HDB METHODS EVID, P38; *SAS I, 1997, SAS REL 6; Sloan NL, 2000, INT J GYNECOL OBSTET, V69, P229, DOI 10.1016/S0020-7292(00)00192-2; Sprent P, 1993, APPL NONPARAMETRIC S; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5; Vlek JFM, 2003, BRIT J GEN PRACT, V53, P108; Walker R, 2002, BIRTH-ISS PERINAT C, V29, P28, DOI 10.1046/j.1523-536X.2002.00153.x; *WHO DEP REPR HLTH, 1998, WHO REPR HLTH LIBR; Wolfram S., 1994, PUBLIC CITIZEN HLTH, V10, P1	20	120	133	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	2004	363	9425					1934	1940		10.1016/S0140-6736(04)16406-4	http://dx.doi.org/10.1016/S0140-6736(04)16406-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194252				2022-12-28	WOS:000221962800007
J	Woo, PCY; Lau, SKP; Teng, JLL; Que, TL; Yung, RWH; Luk, WK; Lai, RWM; Hui, WT; Wong, SSY; Yau, HH; Yuen, KY				Woo, PCY; Lau, SKP; Teng, JLL; Que, TL; Yung, RWH; Luk, WK; Lai, RWM; Hui, WT; Wong, SSY; Yau, HH; Yuen, KY		L hongkongensis study grp	Association of Laribacter hongkongensis in community-acquired gastroenteritis with travel and eating fish: a multicentre case-control study	LANCET			English	Article							MARROW TRANSPLANT RECIPIENTS; HONG-KONG; SP-NOV.; BACTEREMIA; PATIENT; GENE; IDENTIFICATION; DIARRHEA; SEROTYPE; EMPYEMA	Background Laribacter hongkongensis has been recovered from several patients with gastroenteritis. However, the causative role of this organism in human gastroenteritis is still unproven, and sources of the bacterium are unknown. We undertook a multicentre case-control study to investigate the association of L hongkongensis with gastroenteritis. Methods Faecal samples from patients with community-acquired gastroenteritis and controls were cultured for L hongkongensis. Targeted food surveillance was done to identify potential sources of this bacterium. All isolates of this organism from patients and food items were characterised by pulsed-field gel electrophoresis and ribotyping. Findings During a 4-month period, L hongkongensis was recovered from 17 of 3788 patients with community-acquired gastroenteritis, but was absent in 1894 controls (p=0.001). Those who were culture-positive for this bacterium had a recent history of travel (ten [59%] patients vs two [6%] of 34 matched controls, p<0.0001), of fish consumption (16 [94%] vs 19 [56%], p=0.009), and of eating minced freshwater fish meat (five [29%] vs one [3%], p=0.012). We recovered 25 L hongkongensis isolates from intestinal samples of freshwater fish and two from minced freshwater fish meat. Bacteria with the same pulsed-field gel electrophoretic pattern and ribotype were recovered from one patient and a sample of minced freshwater fish meat, which was from the same retail market recently visited by the patient. We did not see this particular combination of electrophoretic pattern and ribotype in any other isolates. Interpretation L hongkongensis is associated with community-acquired gastroenteritis and traveller's diarrhoea. However, its causative role has not been shown. Freshwater fish is one source of this bacterium.	Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Microbiol, Tuen Mun, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Accid & Emergency, Tuen Mun, Hong Kong, Peoples R China; Pamela Youde Nethersole Eastern Hosp, Dept Microbiol, Chai Wan, Hong Kong, Peoples R China; Tseun Kwan O Hosp, Dept Microbiol, Tseun Kwan O, Hong Kong, Peoples R China; United Christian Hosp, Dept Microbiol, Kwun Tong, Hong Kong, Peoples R China	University of Hong Kong; Tuen Mun Hospital; Tuen Mun Hospital; Pamela Youde Nethersole Eastern Hospital; United Christian Hospital	Yuen, KY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.	kyyuen@hkucc.hku.hk	Wong, Samson/C-4446-2009; Lau, Susanna/C-4321-2009; Yuen, Kwok Yung/C-4465-2009; Teng, Lee Lee/C-4415-2009; Woo, Patrick Chiu Yat/C-4449-2009	Teng, Lee Lee/0000-0002-3912-4057; Woo, Patrick Chiu Yat/0000-0001-9401-1832; Yuen, Kwok-yung/0000-0002-2083-1552				Baron E.J., 1999, MANUAL CLIN MICROBIO, V7th; BROUWER J, 1993, CLIN CHEM, V39, P2531; CHIU EKW, 1994, TRANSFUSION, V34, P950, DOI 10.1046/j.1537-2995.1994.341195065031.x; Chiu SS, 2001, ANTIMICROB AGENTS CH, V45, P2765, DOI 10.1128/AAC.45.10.2765-2770.2001; Chow KH, 2001, J CLIN MICROBIOL, V39, P2594, DOI 10.1128/JCM.39.7.2594-2597.2001; Lau SKP, 2003, J CLIN MICROBIOL, V41, P4839, DOI 10.1128/JCM.41.10.4839-4841.2003; Pantosti A, 1997, J CLIN MICROBIOL, V35, P2482, DOI 10.1128/JCM.35.10.2482-2486.1997; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Svenungsson B, 2000, CLIN INFECT DIS, V30, P770, DOI 10.1086/313770; Wong SSY, 1998, J GASTROEN HEPATOL, V13, pS289, DOI 10.1111/j.1440-1746.1998.tb01895.x; WONG SSY, 1994, EPIDEMIOL INFECT, V113, P425, DOI 10.1017/S0950268800068436; Woo PCY, 2000, J CLIN MICROBIOL, V38, P3515, DOI 10.1128/JCM.38.9.3515-3517.2000; Woo PCY, 2003, DIAGN MICR INFEC DIS, V47, P551, DOI 10.1016/S0732-8893(03)00161-5; Woo PCY, 2002, J CLIN MICROBIOL, V40, P1219, DOI 10.1128/JCM.40.4.1219-1224.2002; Woo PCY, 2002, J CLIN MICROBIOL, V40, P265, DOI 10.1128/JCM.40.1.265-267.2002; Woo PCY, 2002, J CLIN MICROBIOL, V40, P805, DOI 10.1128/JCM.40.3.805-810.2002; Woo PCY, 2001, J CLIN MICROBIOL, V39, P3147, DOI 10.1128/JCM.39.9.3147-3155.2001; Woo PCY, 1998, CLIN INFECT DIS, V27, P382, DOI 10.1086/514659; Woo PCY, 2001, J CLIN MICROBIOL, V39, P1190, DOI 10.1128/JCM.39.3.1190-1194.2001; Xiol X, 1996, HEPATOLOGY, V23, P719, DOI 10.1053/jhep.1996.v23.pm0008666323; YAM WC, 1994, LANCET, V344, P404, DOI 10.1016/S0140-6736(94)91429-X; Yuen KY, 1998, DIAGN MICR INFEC DIS, V30, P75, DOI 10.1016/S0732-8893(97)00213-7; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Yuen KY, 2001, J CLIN MICROBIOL, V39, P4227, DOI 10.1128/JCM.39.12.4227-4232.2001	24	76	93	2	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1941	1947		10.1016/S0140-6736(04)16407-6	http://dx.doi.org/10.1016/S0140-6736(04)16407-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194253				2022-12-28	WOS:000221962800008
J	Spaldin, NA				Spaldin, NA			Fundamental size limits in ferroelectricity	SCIENCE			English	Editorial Material							ULTRATHIN FILMS		Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Spaldin, NA (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.	nicola@mrl.ucsb.edu	Spaldin, Nicola A/A-1017-2010	Spaldin, Nicola A/0000-0003-0709-9499				Ahn CH, 2004, SCIENCE, V303, P488, DOI 10.1126/science.1092508; Dawber M, 2003, J PHYS-CONDENS MAT, V15, pL393, DOI 10.1088/0953-8984/15/24/106; Ghosez P, 2000, APPL PHYS LETT, V76, P2767, DOI 10.1063/1.126469; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; Meyer B, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.205426; Shaw TM, 2000, ANNU REV MATER SCI, V30, P263, DOI 10.1146/annurev.matsci.30.1.263	7	115	119	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1606	1607		10.1126/science.1099822	http://dx.doi.org/10.1126/science.1099822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192206				2022-12-28	WOS:000221934300026
J	Elliott, P; McKenna, WJ				Elliott, P; McKenna, WJ			Hypertrophic cardiomyopathy	LANCET			English	Review							LEFT-VENTRICULAR HYPERTROPHY; SEPTAL MYOCARDIAL ABLATION; BLOOD-PRESSURE RESPONSE; SUDDEN CARDIAC DEATH; MYOSIN HEAVY-CHAIN; BINDING PROTEIN-C; OBSTRUCTIVE CARDIOMYOPATHY; CLINICAL-COURSE; FOLLOW-UP; NONINVASIVE ASSESSMENT	Hypertrophic cardiomyopathy is a common genetically transmitted disease, defined clinically by the presence of unexplained left ventricular hypertrophy. The disease has a varied clinical course and outcome; many patients have little or no discernible cardiovascular symptoms, whereas others have profound exercise limitation and recurrent arrhythmias. The overall risk of disease-related complications such as sudden death, endstage heart failure, and fatal stroke is roughly 1-2% per year, but the absolute risk in individuals varies as a function of underlying genetic abnormality, age, myocardial pathology, and other pathophysiological abnormalities such as impaired peripheral vascular responses. Genetic counselling and clinical risk stratification are relevant to all patients, but many therapeutic interventions, including septal alcohol ablation, septal myectomy, and implantable cardioverter defibrillators, are appropriate only in particular patient subsets. We review the management of patients with unexplained myocardial hypertrophy, considering the influence of underlying genetic and pathophysiological substrates on clinical decision-making.	UCL, London, England	University of London; University College London	McKenna, WJ (corresponding author), Natl Heart Hosp, 16-18 Westmoreland St, London W1G 8PH, England.	william.mckenna@uclh.org	Elliott, Perry/AAR-3430-2020; McKenna, William John/C-3243-2008	Elliott, Perry/0000-0003-3383-3984; McKenna, William John/0000-0001-7994-2460				Ackerman MJ, 2002, J AM COLL CARDIOL, V39, P2042, DOI 10.1016/S0735-1097(02)01900-9; ALFONSO F, 1989, BRIT HEART J, V61, P178; Autore C, 2002, J AM COLL CARDIOL, V40, P1864, DOI 10.1016/S0735-1097(02)02495-6; Betocchi S, 2002, PACE, V25, P1433, DOI 10.1046/j.1460-9592.2002.01433.x; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BROCK R, 1957, Guys Hosp Rep, V106, P221; BRUMBACK RA, 1986, ARCH NEUROL-CHICAGO, V43, P189, DOI 10.1001/archneur.1986.00520020075026; BURCH M, 1992, BRIT HEART J, V68, P586; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; Cecchi F, 2003, NEW ENGL J MED, V349, P1027, DOI 10.1056/NEJMoa025050; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; CECCHI F, 1989, J AM COLL CARDIOL, V13, P1283, DOI 10.1016/0735-1097(89)90302-1; Cecchi F, 1998, HEART, V79, P331, DOI 10.1136/hrt.79.4.331; CHIKAMORI T, 1990, AM J CARDIOL, V65, P478, DOI 10.1016/0002-9149(90)90814-H; CHILD JS, 1986, J AM COLL CARDIOL, V7, P1370, DOI 10.1016/S0735-1097(86)80159-0; CHOUDHURY L, 2002, J AM COLL CARDIOL, V53, P121; Ciampi Q, 2002, J AM COLL CARDIOL, V40, P278, DOI 10.1016/S0735-1097(02)01950-2; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COUNIHAN PJ, 1991, CIRCULATION, V84, P686, DOI 10.1161/01.CIR.84.2.686; Crilley JG, 2003, J AM COLL CARDIOL, V41, P1776, DOI 10.1016/S0735-1097(02)03009-7; DAVIES MJ, 1995, HISTOPATHOLOGY, V26, P493, DOI 10.1111/j.1365-2559.1995.tb00267.x; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Elliott PM, 1996, HEART, V75, P179, DOI 10.1136/hrt.75.2.179; Elliott PM, 1999, HEART, V81, P441, DOI 10.1136/hrt.81.4.441; Elliott PM, 1999, J AM COLL CARDIOL, V33, P1596, DOI 10.1016/S0735-1097(99)00056-X; Elliott PM, 2001, LANCET, V357, P420, DOI 10.1016/S0140-6736(00)04005-8; Elliott PM, 2000, J AM COLL CARDIOL, V36, P2212, DOI 10.1016/S0735-1097(00)01003-2; EPSTEIN SE, 1981, CIRCULATION, V64, P437, DOI 10.1161/01.CIR.64.3.437; Faber L, 2000, HEART, V83, P326, DOI 10.1136/heart.83.3.326; Faber L, 1998, CIRCULATION, V98, P2415, DOI 10.1161/01.CIR.98.22.2415; FACTOR SM, 1991, J AM COLL CARDIOL, V17, P1343, DOI 10.1016/S0735-1097(10)80145-7; FANANAPAZIR L, 1989, CIRCULATION, V80, P1259, DOI 10.1161/01.CIR.80.5.1259; Firoozi S, 2003, HEART, V89, P710, DOI 10.1136/heart.89.7.710; Firoozi S, 2002, EUR HEART J, V23, P1617, DOI 10.1053/euhj.2002.3285; FRANK S, 1968, CIRCULATION, V37, P759, DOI 10.1161/01.CIR.37.5.759; Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0; Gadler F, 1999, EUR HEART J, V20, P1044, DOI 10.1053/euhj.1998.1331; Geier C, 2003, CIRCULATION, V107, P1390, DOI 10.1161/01.CIR.0000056522.82563.5F; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Gietzen FH, 1999, EUR HEART J, V20, P1342, DOI 10.1053/euhj.1999.1520; GOODWIN JF, 1960, BRIT HEART J, V22, P403; HADA Y, 1987, AM J CARDIOL, V59, P183, DOI 10.1016/S0002-9149(87)80107-8; HALLOPEAU L, 1869, GAZ MED PARIS, V24, P683; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; Holmgren D, 2003, EUR HEART J, V24, P280, DOI 10.1016/S0195-668X(02)00387-1; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; Jones S, 1998, HEART, V80, P60, DOI 10.1136/hrt.80.1.60; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Kappenberger L, 1997, EUR HEART J, V18, P1249; KENNA WJ, 1981, BRIT HEART J, V46, P168; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; KLUES HG, 1992, CIRCULATION, V85, P1651, DOI 10.1161/01.CIR.85.5.1651; Knight C, 1997, CIRCULATION, V95, P2075, DOI 10.1161/01.CIR.95.8.2075; Kofflard MJM, 2003, J AM COLL CARDIOL, V41, P987, DOI 10.1016/S0735-1097(02)03004-8; KRIKLER DM, 1980, BRIT HEART J, V43, P245; Lakkis NM, 2000, J AM COLL CARDIOL, V36, P852, DOI 10.1016/S0735-1097(00)00767-1; Legius E, 2002, J MED GENET, V39, P571, DOI 10.1136/jmg.39.8.571; LEMERY R, 1990, J AM COLL CARDIOL, V16, P368, DOI 10.1016/0735-1097(90)90587-F; LIOUVILLE H, 1869, GAZ MED PARIS, V24, P161; Lipshultz SE, 2003, NEW ENGL J MED, V348, P1647, DOI 10.1056/NEJMoa021715; Maki S, 1998, AM J CARDIOL, V82, P774, DOI 10.1016/S0002-9149(98)00455-X; Marian AJ, 2001, J MOL CELL CARDIOL, V33, P655, DOI 10.1006/jmcc.2001.1340; MARON BJ, 1983, EUR HEART J, V4, P175, DOI 10.1093/eurheartj/4.suppl_F.175; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2000, CIRCULATION, V102, P858; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; MARON BJ, 1979, CIRCULATION, V60, P685, DOI 10.1161/01.CIR.60.3.685; MARON BJ, 1983, AM J CARDIOL, V51, P189, DOI 10.1016/S0002-9149(83)80034-4; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; Maron BJ, 1998, CIRCULATION, V98, P2505, DOI 10.1161/01.CIR.98.23.2505; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; Maron BJ, 2003, EUR HEART J, V24, P1965, DOI 10.1016/S0195-668X(03)00479-2; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; Maron BJ, 2002, J AM COLL CARDIOL, V39, P301, DOI 10.1016/S0735-1097(01)01727-2; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; MARON BJ, 1994, AM J CARDIOL, V73, P577, DOI 10.1016/0002-9149(94)90337-9; MARON BJ, 1981, AM J CARDIOL, V48, P252, DOI 10.1016/0002-9149(81)90604-4; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; Maron BJ, 2001, J AM COLL CARDIOL, V38, P315, DOI 10.1016/S0735-1097(01)01386-9; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; Maron BJ, 1998, AM J CARDIOL, V81, P1339; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; Maron MS, 2003, NEW ENGL J MED, V348, P295, DOI 10.1056/NEJMoa021332; Mazur W, 2001, CIRCULATION, V103, P1492; MCKENNA WJ, 1984, ARCH DIS CHILD, V59, P971, DOI 10.1136/adc.59.10.971; McKenna WJ, 1997, HEART, V77, P130, DOI 10.1136/hrt.77.2.130; MCKENNA WJ, 1985, BRIT HEART J, V53, P412; MCKENNA WJ, 1990, BRIT HEART J, V63, P287; Minamisawa S, 2003, BIOCHEM BIOPH RES CO, V304, P1, DOI 10.1016/S0006-291X(03)00526-6; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Monserrat L, 2003, J AM COLL CARDIOL, V42, P873, DOI 10.1016/S0735-1097(03)00827-1; Moon JCC, 2003, J AM COLL CARDIOL, V41, P1561, DOI 10.1016/S0735-1097(03)00189-X; MORROW AG, 1975, CIRCULATION, V52, P88, DOI 10.1161/01.CIR.52.1.88; Mozaffarian D, 2001, CLIN CARDIOL, V24, P2, DOI 10.1002/clc.4960240102; Nagueh SF, 2001, J AM COLL CARDIOL, V38, P1701, DOI 10.1016/S0735-1097(01)01614-X; Nagueh SF, 2001, CIRCULATION, V104, P128, DOI 10.1161/01.CIR.104.2.128; Nagueh SF, 2000, CIRCULATION, V102, P1346, DOI 10.1161/01.CIR.102.12.1346; Niimura H, 2002, CIRCULATION, V105, P446, DOI 10.1161/hc0402.102990; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; Nugent AW, 2003, NEW ENGL J MED, V348, P1639, DOI 10.1056/NEJMoa021737; Okeie K, 2000, J AM COLL CARDIOL, V36, P856, DOI 10.1016/S0735-1097(00)00818-4; Olivotto I, 2003, J AM COLL CARDIOL, V41, P315, DOI 10.1016/S0735-1097(02)02713-4; Olivotto I, 2001, CIRCULATION, V104, P2517, DOI 10.1161/hc4601.097997; Olivotto I, 1999, J AM COLL CARDIOL, V33, P2044, DOI 10.1016/S0735-1097(99)00094-7; Pak PH, 1996, CIRCULATION, V94, P52, DOI 10.1161/01.CIR.94.1.52; Palka P, 1997, J AM COLL CARDIOL, V30, P760, DOI 10.1016/S0735-1097(97)00231-3; PANZA JA, 1992, J AM COLL CARDIOL, V19, P91, DOI 10.1016/0735-1097(92)90057-T; Paz R, 1996, NEW ENGL J MED, V335, P938, DOI 10.1056/NEJM199609263351305; Pelliccia A, 2000, CIRCULATION, V102, P278; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; POLLICK C, 1988, AM J CARDIOL, V62, P1252, DOI 10.1016/0002-9149(88)90269-X; POLLICK C, 1988, AM J CARDIOL, V62, P1248, DOI 10.1016/0002-9149(88)90268-8; Qin JX, 2001, J AM COLL CARDIOL, V38, P1994; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; ROBINSON K, 1990, J AM COLL CARDIOL, V15, P1279, DOI 10.1016/S0735-1097(10)80014-2; Sachdev B, 2002, CIRCULATION, V105, P1407, DOI 10.1161/01.CIR.0000012626.81324.38; Sadoul N, 1997, CIRCULATION, V96, P2987, DOI 10.1161/01.CIR.96.9.2987; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; Saumarez RC, 2003, CIRCULATION, V107, P2595, DOI 10.1161/01.CIR.0000068342.96569.A1; SAVAGE DD, 1978, CIRCULATION, V58, P402, DOI 10.1161/01.CIR.58.3.402; SAVAGE DD, 1983, J CARDIOVASC ULTRAS, V2, P41; SCHOENDUBE FA, 1995, CIRCULATION, V92, P122, DOI 10.1161/01.CIR.92.9.122; SCHULTE HD, 1993, J THORAC CARDIOV SUR, V106, P709, DOI 10.1016/S0022-5223(19)33715-8; Seggewiss H, 1998, J AM COLL CARDIOL, V31, P252, DOI 10.1016/S0735-1097(97)00508-1; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SHAH PM, 1969, CIRCULATION, V40, P3, DOI 10.1161/01.CIR.40.1.3; SHAPIRO LM, 1983, J AM COLL CARDIOL, V2, P437, DOI 10.1016/S0735-1097(83)80269-1; SHAPIRO LM, 1985, EUR HEART J, V6, P967, DOI 10.1093/oxfordjournals.eurheartj.a061796; Sharma S, 1999, BRIT J SPORT MED, V33, P319, DOI 10.1136/bjsm.33.5.319; Sharma S, 2000, AM J CARDIOL, V86, P162, DOI 10.1016/S0002-9149(00)00854-7; Sharma S, 2000, J AM COLL CARDIOL, V36, P864, DOI 10.1016/S0735-1097(00)00816-0; SHERRID M, 1988, AM J CARDIOL, V62, P1085, DOI 10.1016/0002-9149(88)90553-X; Shirani J, 2000, J AM COLL CARDIOL, V35, P36, DOI 10.1016/S0735-1097(99)00492-1; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Spirito P, 1999, CIRCULATION, V99, P2132, DOI 10.1161/01.CIR.99.16.2132; Spirito P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; STAFFORD WJ, 1986, J AM COLL CARDIOL, V7, P701, DOI 10.1016/S0735-1097(86)80484-3; TANAKA M, 1987, CIRCULATION, V75, P1130, DOI 10.1161/01.CIR.75.6.1130; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; TEARE D, 1958, BRIT HEART J, V20, P1; Thaman R, 2003, HEART, V89, P752, DOI 10.1136/heart.89.7.752; Varnava AM, 2000, HEART, V84, P476, DOI 10.1136/heart.84.5.476; Vinereanu D, 2001, AM J CARDIOL, V88, P53, DOI 10.1016/S0002-9149(01)01585-5; WALLER BF, 1981, AM HEART J, V102, P790, DOI 10.1016/0002-8703(81)90109-5; Watkins H, 2003, CIRCULATION, V107, P1344, DOI 10.1161/01.CIR.0000057860.52586.9C; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WIGLE ED, 1962, CIRCULATION, V26, P325, DOI 10.1161/01.CIR.26.3.325; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; WILLIAMS WG, 1987, CIRCULATION, V76, P104; YAMAGUCHI H, 1979, AM J CARDIOL, V44, P401, DOI 10.1016/0002-9149(79)90388-6	159	398	421	0	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1881	1891		10.1016/S0140-6736(04)16358-7	http://dx.doi.org/10.1016/S0140-6736(04)16358-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183628				2022-12-28	WOS:000221822300022
J	Steinbrook, R				Steinbrook, R			Waiting for plan B - The FDA and nonprescription use of emergency contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Drazen JM, 2004, NEW ENGL J MED, V350, P1561, DOI 10.1056/NEJMe048057; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Jones RK, 2002, PERSPECT SEX REPRO H, V34, P294, DOI 10.2307/3097748; Raymond EG, 2004, CONTRACEPTION, V69, P367, DOI 10.1016/j.contraception.2004.02.003; Trussell J, 2004, AM J OBSTET GYNECOL, V190, pS30, DOI 10.1016/j.ajog.2004.01.063	5	25	27	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2327	2329		10.1056/NEJMp048135	http://dx.doi.org/10.1056/NEJMp048135			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175432				2022-12-28	WOS:000221754200001
J	Kaul, R; Kimani, J; Nagelkerke, NJ; Fonck, K; Ngugi, EN; Keli, F; MacDonald, KS; Maclean, IW; Bwayo, JJ; Temmerman, M; Ronald, AR; Moses, S				Kaul, R; Kimani, J; Nagelkerke, NJ; Fonck, K; Ngugi, EN; Keli, F; MacDonald, KS; Maclean, IW; Bwayo, JJ; Temmerman, M; Ronald, AR; Moses, S		Kibera HIV Study Grp	Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; COMMUNITY-BASED TRIALS; RISK-FACTORS; TRANSMISSION; PREVENTION; DISEASES; FEMALE; UGANDA; INTERVENTIONS; RAKAI	Context Sexually transmitted infections (STIs) are common in female sex workers (FSWs) and may enhance susceptibility to infection with human immunodeficiency virus type 1 (HIV-1). Objective To examine regular antibiotic prophylaxis in FSWs as a strategy. for reducing the incidence of bacterial STIs and HIV-1. Design, Setting, and Participants :Randomized, double-blind, placebo-controlled trial conducted between 1998-2002 among FSWs in an urban slum area of Nairobi, Kenya. Of 890 FSWs screened, 466 who were seronegative for HIV-1 infection were enrolled and randomly assigned to receive azithromycin (n=230) or placebo (n=236). Groups were well matched at baseline for sexual risk taking and STI rates. Intervention Monthly oral administration of 1 g of azithromycin or identical placebo, as directly observed therapy. All participants were provided with free condoms, risk-reduction counseling, and STI case management. Main Outcome Measures The primary, study end point was incidence of HIV-1 infection. Secondary end points were the incidence of STIs due to Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Treponema pallidum, and Haemophilus ducreyi, as well as bacterial vaginosis. Analysis of herpes simplex virus type 2 (HSV-2) infection was performed post hoc. Results Seventy-three percent of participants (n=341) were followed up for 2 or more years or until they reached an administrative trial end point. Incidence of HIV-1 did not differ between treatment and placebo groups (4% [19 cases per 473 person-years of follow-up] vs 3.2% [16 cases per 495 person-years of follow-up] rate ratio [RR], 1.2; 95% CI, 0.6-2.5). Incident HIV-1 infection was associated with preceding infection with N gonorrhoeae (rate ratio [RR], 4.9; 95% CI, 1.7-14.3) or C trachomatis (RR, 3.0; 95% CI, 1.1-8.9). There was a reduced incidence in the treatment group of infection with N gonorrhoeae (RR, 0:46; 95% CI, 0.31-0.68), C trachomatis (RR, 0.38; 95% CI, 0.26-0.57), and T vaginalis (RR, 0.56;,95% CI, 0.40-0.78). The seroprevalence of HSV-2 infection at enrollment was 72.7%, and HSV-2 infection at baseline was independently associated with HIV-1 acquisition (RR, 6.3; 95% CI, 1.5-27.1). Conclusions Despite an association between bacterial STIs and acquisition of HIV-1 infection, the addition of monthly azithromycin prophylaxis to established HIV-1 risk reduction strategies substantially reduced the incidence of STIs but did not reduce the incidence of HIV-1. Prevalent HSV-2 infection may have been an important cofactor in acquisition of HIV-1.	Univ Toronto, Div Clin Sci, R Samuel McLaughlin Fdn Mol Med, Dept Med,Univ Hlth Network, Toronto, ON M5S 1A8, Canada; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Univ Nairobi, Dept Community Med, Nairobi, Kenya; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; Univ Manitoba, Dept Community Hlth Sci & Med, Winnipeg, MB, Canada; State Univ Ghent, Dept Obstet & Gynaecol, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Nairobi; University of Nairobi; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Manitoba; University of Manitoba; Ghent University	Kaul, R (corresponding author), Univ Toronto, Div Clin Sci, R Samuel McLaughlin Fdn Mol Med, Dept Med,Univ Hlth Network, Med Sci Bldg 6356, Toronto, ON M5S 1A8, Canada.	rupert.kaul@utoronto.ca	MacDonald, Kelly S/L-3315-2019	Ronald, Allan/0000-0002-5746-3490; Kaul, Rupert/0000-0002-1586-4093				Abellanosa I, 1996, SEX TRANSM DIS, V23, P407, DOI 10.1097/00007435-199609000-00011; Alary M, 2001, B WORLD HEALTH ORGAN, V79, P59; Boily MC, 2000, AIDS, V14, P2583, DOI 10.1097/00002030-200011100-00022; CAMERON DW, 1989, LANCET, V2, P403; Cohen M S, 1998, Int J Infect Dis, V3, P1, DOI 10.1016/S1201-9712(98)90087-X; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001; Duran J M, 2000, Expert Opin Pharmacother, V1, P489, DOI 10.1517/14656566.1.3.489; Fonck K, 2000, INT J STD AIDS, V11, P804, DOI 10.1258/0956462001915327; GHYS PD, 1997, AIDS, V11, P85; Gray RH, 1999, AIDS, V13, P2113, DOI 10.1097/00002030-199910220-00015; Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hudson CP, 2001, B WORLD HEALTH ORGAN, V79, P48; Kamali A, 2003, LANCET, V361, P645, DOI 10.1016/S0140-6736(03)12598-6; Kaul R, 2002, J ACQ IMMUN DEF SYND, V30, P69, DOI 10.1097/00042560-200205010-00009; Kaul R, 1997, SEX TRANSM DIS, V24, P387, DOI 10.1097/00007435-199708000-00001; Lowndes CM, 2000, AIDS, V14, P2523, DOI 10.1097/00002030-200011100-00015; MARTIN HL, 1994, AIDS RES HUM RETROV, V10, pS235; Ngugi EN, 1996, J INFECT DIS, V174, pS240, DOI 10.1093/infdis/174.Supplement_2.S240; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PLUMMER FA, 1991, AIDS, V5, pS169; Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; Steen R, 2000, SEX TRANSM DIS, V27, P1, DOI 10.1097/00007435-200001000-00001; Stephenson JM, 2003, LANCET, V361, P633, DOI 10.1016/S0140-6736(03)12613-X; Sutton, 2000, Curr Infect Dis Rep, V2, P539, DOI 10.1007/s11908-000-0058-0; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; Wald A, 2003, J INFECT DIS, V187, P1509, DOI 10.1086/374976; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3	32	190	196	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2555	2562		10.1001/jama.291.21.2555	http://dx.doi.org/10.1001/jama.291.21.2555			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173146				2022-12-28	WOS:000221738800018
J	Turner, L				Turner, L			Bioethics needs to rethink its agenda	BRITISH MEDICAL JOURNAL			English	Editorial Material									McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada	McGill University	Turner, L (corresponding author), McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada.	leigh.turner@mcgill.ca		Turner, Leigh/0000-0001-7283-6809					0	20	20	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					175	175		10.1136/bmj.328.7432.175	http://dx.doi.org/10.1136/bmj.328.7432.175			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	15202475	Green Published			2022-12-28	WOS:000188249900060
J	Chen, JY; Bottjer, DJ; Oliveri, P; Dornbos, SQ; Gao, F; Ruffins, S; Chi, HM; Li, CW; Davidson, EH				Chen, JY; Bottjer, DJ; Oliveri, P; Dornbos, SQ; Gao, F; Ruffins, S; Chi, HM; Li, CW; Davidson, EH			Small bilaterian fossils from 40 to 55 million years before the Cambrian	SCIENCE			English	Article							NEOPROTEROZOIC SNOWBALL EARTH; DOUSHANTUO FORMATION; CONSTRAINTS; CHINA; PLATYHELMINTHES; PHOSPHORITES; EVOLUTION; EMBRYOS; MEMBERS; AGE	Ten phosphatized specimens of a small (<180 micrometers) animal displaying clear bilaterian features have been recovered from the Doushantuo Formation, China, dating from 40 to 55 million years before the Cambrian. Seen in sections, this animal (Vernanimalcula guizhouena gen. et sp. nov.) had paired coeloms extending the length of the gut; paired external pits that could be sense organs; bilateral, anterior-posterior organization; a ventrally directed anterior mouth with thick walled pharynx; and a triploblastic structure. The structural complexity is that of an adult rather than a larval form. These fossils provide the first evidence confirming the phylogenetic inference that Bilateria arose well before the Cambrian.	Nanjing Inst Geol & Paleontol, Nanjing 210008, Peoples R China; Nanjing Univ, Coll Life Sci, Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China; Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; SE Univ, Dept Biol Sci & Med Engn, Nanjing 210096, Peoples R China; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	Chinese Academy of Sciences; Nanjing Institute of Geology & Paleontology, CAS; Nanjing University; University of Southern California; California Institute of Technology; Southeast University - China; National Tsing Hua University	Chen, JY (corresponding author), Nanjing Inst Geol & Paleontol, Nanjing 210008, Peoples R China.	chenjunyuan@163.net; dbottjer@usc.edu	Gao, Fremont/AFQ-0003-2022	Gao, Fremont/0000-0001-8764-1107; Oliveri, Paola/0000-0002-3477-8529				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Baguna J, 2001, INT J DEV BIOL, V45, pS133; Barfod GH, 2002, EARTH PLANET SC LETT, V201, P203, DOI 10.1016/S0012-821X(02)00687-8; Brusca RC, 2003, INVERTEBRATES; Chen DF, 2003, CHEM GEOL, V201, P103, DOI 10.1016/S0009-2541(03)00235-3; Chen Junyuan, 1997, Bulletin of the National Museum of Natural Science (Taichung), V10, P11; Chen JY, 2000, P NATL ACAD SCI USA, V97, P4457, DOI 10.1073/pnas.97.9.4457; Chen JY, 2002, DEV BIOL, V248, P182, DOI 10.1006/dbio.2002.0714; Davidson E. H., 2001, DEV EVOLUTION; DORNBOS SQ, 2002, GSA ABSTR PROG, V34, P75; Erwin DH, 2002, DEVELOPMENT, V129, P3021; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; GAO F, 2003, GSA ABSTR PROG, V35, P187; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; HALANYCH KM, 1995, SCIENCE, V267, P1642; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Jondelius U, 2002, ZOOL SCR, V31, P201, DOI 10.1046/j.1463-6409.2002.00090.x; KIMURA H, 2003, GSA ABSTR PROG, V35, P187; Knoll AH, 2003, LIFE YOUNG PLANET 1; Martin MW, 2000, SCIENCE, V288, P841, DOI 10.1126/science.288.5467.841; Peterson KJ, 2004, P NATL ACAD SCI USA, V101, P6536, DOI 10.1073/pnas.0401670101; Ruiz-Trillo I, 1999, SCIENCE, V283, P1919, DOI 10.1126/science.283.5409.1919; Runnegar B, 2000, NATURE, V405, P403, DOI 10.1038/35013168; Xiao SH, 2000, J PALEONTOL, V74, P767, DOI 10.1666/0022-3360(2000)074<0767:PAEFTN>2.0.CO;2; Xiao SH, 2000, P NATL ACAD SCI USA, V97, P13684, DOI 10.1073/pnas.250491697; Yuan X.L., 2002, DOUSHANTUO FOSSILS L, P1; ZHANG Y, 1998, PALEONTOL SOC MEM, V50, P1; ZHAO Z, 1988, CHINA U GEOL PRESS, P1	29	150	188	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					218	222		10.1126/science.1099213	http://dx.doi.org/10.1126/science.1099213			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15178752				2022-12-28	WOS:000222501000045
J	Schuit, SCE; Oei, HHS; Witteman, JCM; van Kessel, CHG; van Meurs, JBJ; Nijhuis, RL; van Leeuwen, JPTM; de Jong, FH; Zillikens, MC; Hofman, A; Pols, HAP; Uitterlinden, AG				Schuit, SCE; Oei, HHS; Witteman, JCM; van Kessel, CHG; van Meurs, JBJ; Nijhuis, RL; van Leeuwen, JPTM; de Jong, FH; Zillikens, MC; Hofman, A; Pols, HAP; Uitterlinden, AG			Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY-DISEASE; NITRIC-OXIDE SYNTHASE; POSTMENOPAUSAL WOMEN; ASSOCIATION; ESTRADIOL; HAPLOTYPE; HEALTHY; MEN; PREMENOPAUSAL; REPLACEMENT	Context The role of estrogens in ischemic heart disease (IHD) is uncertain. Evidence suggests that genetic variations in the estrogen receptor alpha (ESR1) gene may influence IHD risk, but the role of common sequence variations in the ESR1 gene is unclear. Objective To determine whether the ESR1 haplotype created by the c.454-397T>C (Pvull) and c.454-351A>G (Xbal) polymorphisms is associated with myocardial infarction (MI) and IHD risk. Design, Setting, and Participants In 2617 men and 3791 postmenopausal women from The Rotterdam Study (enrollment between 1989-1993 and follow-up to January 2000), a population-based, prospective cohort study of participants aged 55 years and older, ESR1 c.454-397T>C and c.454-351A>G haplotypes were determined. Detailed interviews and physical examinations were performed, blood samples were obtained, and cardiovascular risk factors were assessed. Main Outcome Measure The primary outcome was MI and IHD defined as MIs, revascularization procedures, and IHD mortality. Results Approximately 29% of women and 28.2% of men were homozygous carriers of the ESR1 haplotype 1 (-397 T and -351 A) allele, 49% of women and 50% of men were heterozygous carriers, and 22% of women and 21.4% of men were noncarriers. During a mean follow-up of 7.0 years, 285 participants (115 women; 170 men) had MI, and 440 (168 women; 272 men) had an IHD event, of which 97 were fatal. After adjustment for known cardiovascular risk factors, female heterozygous carriers of haplotype 1 had an increased risk of MI (event rate, 2.8%; relative risk [RR], 2.23; 95% confidence interval [CI], 1.13-4.43) compared with noncarriers (event rate, 1.3%), whereas homozygous carriers had an increased risk (event rate, 3.2%; RR, 2.48; 950/c Cl, 1.22-5.03). For IHD events, we observed a similar association. In women, the effect of haplotype 1 on fatal IHD was larger than on nonfatal IHD. In men, the ESR1 haplotypes were not associated with an increased risk of MI (event rate, 5.7%; RR, 0.93; 95% Cl, 0.59-1.46 for heterozygous carriers; and event rate, 5.1%; RR, 0.82; 95% Cl, 0.49-1.38 for homozygous carriers) compared with noncarriers (event rate, 5.8%) and were not associated with an increased risk of IHD. Conclusions In this population-based, prospective cohort study, postmenopausal women who carry ESR1 haplotype 1 (c.454-397 T allele and c.454-351 A allele) have an increased risk of MI and IHD, independent of known cardiovascular risk factors. in men, no association was observed.	Erasmus MC, Dept Internal Med, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Pols, HAP (corresponding author), Erasmus MC, Dept Internal Med, POB 1738, NL-3000 DR Rotterdam, Netherlands.	h.pols@erasmusmc.nl	De Jong, Frank H/A-9876-2011; van Leeuwen, Johannes/D-5015-2014	De Jong, Frank H/0000-0003-3578-1065; van Leeuwen, Johannes/0000-0002-2282-4006; van Meurs, Joyce/0000-0001-6245-2123				Albagha OME, 2001, J BONE MINER RES, V16, P128, DOI 10.1359/jbmr.2001.16.1.128; ANDERSEN TI, 1994, HUM GENET, V94, P665; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Becherini L, 2000, HUM MOL GENET, V9, P2043, DOI 10.1093/hmg/9.13.2043; Bergink AP, 2003, ARTHRITIS RHEUM, V48, P1913, DOI 10.1002/art.11046; Brouchet L, 2001, CIRCULATION, V103, P423; BRUYNE MC, 1997, J CLIN EPIDEMIOL, V50, P947; BRUYNE MC, 1997, EPIDEMIOLOGY, V8, P495; Chalmers J, 1999, J HYPERTENS, V17, P151; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Deng HW, 2000, J CLIN ENDOCR METAB, V85, P2748, DOI 10.1210/jc.85.8.2748; Fricker J, 1999, MOL MED TODAY, V5, P505, DOI 10.1016/S1357-4310(99)01617-2; GENT CM, 1977, CLIN CHIM ACTA, V75, P243; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Hedges YK, 1999, CIRCULATION, V99, P2688, DOI 10.1161/01.CIR.99.20.2688; Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88; Herrington DM, 2002, NEW ENGL J MED, V346, P967, DOI 10.1056/NEJMoa012952; HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014-5793(95)00124-R; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kunnas TA, 2000, BRIT MED J, V321, P273, DOI 10.1136/bmj.321.7256.273; Langdahl BL, 2000, J BONE MINER RES, V15, P2222, DOI 10.1359/jbmr.2000.15.11.2222; LEHRER S, 1993, HYPERTENSION, V21, P439, DOI 10.1161/01.HYP.21.4.439; Lehtimaki T, 2002, EUR J CLIN INVEST, V32, P400, DOI 10.1046/j.1365-2362.2002.01010.x; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Lu H, 2002, ARTERIOSCL THROM VAS, V22, P817, DOI 10.1161/01.ATV.0000014424.18209.21; Matsubara Y, 1997, ARTERIOSCL THROM VAS, V17, P3006, DOI 10.1161/01.ATV.17.11.3006; Maxwell SRJ, 1998, BASIC RES CARDIOL, V93, P79; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; McNeill AM, 1999, STROKE, V30, P2186, DOI 10.1161/01.STR.30.10.2186; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Schuit SCE, 2004, J CLIN ENDOCR METAB, V89, P303, DOI 10.1210/jc.2003-031095; Shearman AM, 2003, JAMA-J AM MED ASSOC, V290, P2263, DOI 10.1001/jama.290.17.2263; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Sudhir K, 1997, CIRCULATION, V96, P3774; van Meurs JBJ, 2003, HUM MOL GENET, V12, P1745, DOI 10.1093/hmg/ddg176; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Weel AEAM, 1999, J CLIN ENDOCR METAB, V84, P3146, DOI 10.1210/jc.84.9.3146; *WHO, 1985, TECHN REP SER, V727; World Health Organization, 1992, INT CLASS DIS 10 REV; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	47	194	197	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2969	2977		10.1001/jama.291.24.2969	http://dx.doi.org/10.1001/jama.291.24.2969			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213208	Bronze			2022-12-28	WOS:000222184600026
J	Weber, MA; Julius, S; Kjeldsen, SE; Brunner, HR; Ekman, S; Hansson, L; Hua, TS; Laragh, JH; McInnes, GT; Mitchell, L; Plat, F; Schork, MA; Smith, B; Zanchetti, A				Weber, MA; Julius, S; Kjeldsen, SE; Brunner, HR; Ekman, S; Hansson, L; Hua, TS; Laragh, JH; McInnes, GT; Mitchell, L; Plat, F; Schork, MA; Smith, B; Zanchetti, A			Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial	LANCET			English	Article							PREVENTION	The Valsartan Anti hypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension. But inequalities in blood pressure, favouring amlodipine, throughout the multiyear trial precluded comparison of outcomes. A technique of serial median matching, applied at 6 months when treatment adjustments intended to achieve control of blood pressure were complete, created 5006 valsartan-amlodipine patient pairs matched exactly for systolic blood pressure, age, sex, and the presence or absence of previous coronary disease, stroke, or diabetes. Subsequent combined cardiac events, myocardial infarction, stroke, and mortality were almost identical in the two cohorts, but admission to hospital for heart failure was significantly lower with valsartan. Reaching blood pressure control (systolic <140 mm Hg) by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just I month of treatment predicted events and survival.	SUNY, Brooklyn, NY 11203 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Ullevaal Univ Hosp, Oslo, Norway; Univ Lausanne, CH-1015 Lausanne, Switzerland; Uppsala Univ, S-75105 Uppsala, Sweden; Novartis Pharmaceut, Basel, Switzerland; Novartis Pharmaceut, E Hanover, NJ USA; Cornell Med Ctr, New York, NY USA; Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland; Osped Maggiore, Ist Auxol Italiano, Milan, Italy; Univ Milan, I-20122 Milan, Italy	State University of New York (SUNY) System; SUNY Maritime College; University of Michigan System; University of Michigan; University of Oslo; University of Lausanne; Uppsala University; Novartis; Novartis; Cornell University; University of Glasgow; IRCCS Istituto Auxologico Italiano; University of Milan	Weber, MA (corresponding author), SUNY, Brooklyn, NY 11203 USA.			zanchetti, alberto/0000-0003-4796-7959				Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; JULIUS S, 2004, LANCET          0614; Maillard MP, 2002, CLIN PHARMACOL THER, V71, P68, DOI 10.1067/mcp.2002.121425; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; Mann Jessica, 1998, Blood Pressure, V7, P176; Staessen JA, 2003, J HYPERTENS, V21, P1055, DOI 10.1097/00004872-200306000-00002; 2003, JAMA, V289, P2560	7	461	493	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2049	2051		10.1016/S0140-6736(04)16456-8	http://dx.doi.org/10.1016/S0140-6736(04)16456-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207957				2022-12-28	WOS:000222159800013
J	Holden, C				Holden, C			Long hours aside, respondents say jobs offer 'as much fun as you can have'	SCIENCE			English	News Item																		2001, SCIENCE         1012, P396	1	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1830	+		10.1126/science.304.5678.1830	http://dx.doi.org/10.1126/science.304.5678.1830			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205539				2022-12-28	WOS:000222089500053
J	Levasseur-Regourd, AC				Levasseur-Regourd, AC			Cometary dust unveiled	SCIENCE			English	Editorial Material							COMA; FRAGMENTS; 1P/HALLEY		Univ Paris 06, F-91371 Verrieres Le Buisson, France; Univ Paris 06, F-91371 Verrieres Le Buisson, France; Aeron CNRS, IPSL, F-91371 Verrieres Le Buisson, France	UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)	Levasseur-Regourd, AC (corresponding author), Univ Paris 06, BP 3, F-91371 Verrieres Le Buisson, France.	anny-chantal.levasseur@aerov.jussieu.fr						Brownlee DE, 2004, SCIENCE, V304, P1764, DOI 10.1126/science.1097899; CLARK BC, UNPUB; Desvoivres E, 2000, ICARUS, V144, P172, DOI 10.1006/icar.1999.6272; Fulle M, 2000, ASTRON J, V119, P1968, DOI 10.1086/301285; Greenberg J., 1982, COMETS, P131; Kissel J, 2004, SCIENCE, V304, P1774, DOI 10.1126/science.1098836; KISSEL J, 1986, NATURE, V321, P336, DOI 10.1038/321336a0; Levasseur-Regourd AC, 1999, ASTRON ASTROPHYS, V348, P636; McBride N, 1997, MON NOT R ASTRON SOC, V289, P535, DOI 10.1093/mnras/289.3.535; MCDONNELL JAM, 1987, ASTRON ASTROPHYS, V187, P719; Sekanina Z, 2004, SCIENCE, V304, P1769, DOI 10.1126/science.1098388; Tuzzolino AJ, 2004, SCIENCE, V304, P1776, DOI 10.1126/science.1098759; Weaver HA, 2004, SCIENCE, V304, P1760	13	19	20	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1762	1763		10.1126/science.1100601	http://dx.doi.org/10.1126/science.1100601			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205523				2022-12-28	WOS:000222089500034
J	Huang, MS; Harris, NL; D'Angelo, HA; Hasserjian, RP; Weinstein, H				Huang, MS; Harris, NL; D'Angelo, HA; Hasserjian, RP; Weinstein, H			A 12-year-old boy with fatigue and eosinophilia - Precursor B-cell acute lymphoblastic leukemia with eosinophilia and the t(5;14)(q31;q32) translocation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE LYMPHOCYTIC-LEUKEMIA; LOFFLERS ENDOCARDITIS; ADRENAL INSUFFICIENCY; INTERLEUKIN-3 GENE; HYPEREOSINOPHILIA; MECHANISMS; CHILDREN; DISEASE		Massachusetts Gen Hosp, Div Pediat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Huang, MS (corresponding author), Massachusetts Gen Hosp, Div Pediat Oncol, Boston, MA 02114 USA.							ACKERMAN SJ, 2000, HEMATOLOGY BASIC PRI, P702; Angelis M, 1996, J AM COLL SURGEONS, V183, P589; Bain BJ, 1996, BRIT J HAEMATOL, V95, P2; Bain BJ, 2000, CURR OPIN HEMATOL, V7, P21, DOI 10.1097/00062752-200001000-00005; Beishuizen A, 1999, LANCET, V353, P1675, DOI 10.1016/S0140-6736(99)01346-X; CLAUW DJ, 1995, RHEUM DIS CLIN N AM, V21, P231; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Donahue TP, 2002, CLIN CARDIOL, V25, P345, DOI 10.1002/clc.4950250708; Eapen RS, 2001, PEDIATR CARDIOL, V22, P426, DOI 10.1007/s00246-001-0021-3; FITZPATRICK TB, 2001, COLOR ATLAS SYNOPSIS, P564; Friedmann A M, 2000, Oncologist, V5, P321, DOI 10.1634/theoncologist.5-4-321; GRIMALDI JC, 1989, BLOOD, V73, P2081; HOGAN TF, 1987, J CLIN ONCOL, V5, P382, DOI 10.1200/JCO.1987.5.3.382; Horenstein MS, 2002, PEDIATRICS, V110, P1014, DOI 10.1542/peds.110.5.1014; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; Kobayashi S, 2002, ALLERGY, V57, P950, DOI 10.1034/j.1398-9995.2002.23479.x; MEEKER TC, 1990, BLOOD, V76, P285; MILLER KB, 2000, HEMATOLOGY BASIC PRI, P999; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; PANUSH RS, 1971, ANN INTERN MED, V75, P199, DOI 10.7326/0003-4819-75-2-199; PEARSON RD, 2000, MANDELL DOUGLAS BENN, V1, P1136; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Schwartz RS, 2003, NEW ENGL J MED, V348, P1199, DOI 10.1056/NEJMp030019; Shuster J, 1999, CANC RES THER CONTRO, V9, P101; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Stewart PM, 2003, WILLIAMS TXB ENDOCRI, P491; Thomeer R, 1999, EUR RESPIR J, V13, P930, DOI 10.1034/j.1399-3003.1999.13d38.x; Thurlow PJ, 2003, INTERN MED J, V33, P136; Vardiman J., 2001, WHO CLASSIFICATION T, V3; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759	33	9	10	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2604	2612		10.1056/NEJMcpc049009	http://dx.doi.org/10.1056/NEJMcpc049009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201418				2022-12-28	WOS:000222054700013
J	Klein, S; Fontana, L; Young, VL; Coggan, AR; Kilo, C; Patterson, BW; Mohammed, BS				Klein, S; Fontana, L; Young, VL; Coggan, AR; Kilo, C; Patterson, BW; Mohammed, BS			Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-VOLUME LIPOSUCTION; TUMOR-NECROSIS-FACTOR; FREE FATTY-ACIDS; WEIGHT-LOSS; ADIPOSE-TISSUE; OBESE WOMEN; LIPID-METABOLISM; GLUCOSE-METABOLISM; WHOLE-BODY; REDUCTION	Background: Liposuction has been proposed as a potential treatment for the metabolic complications of obesity. We evaluated the effect of large-volume abdominal liposuction on metabolic risk factors for coronary heart disease in women with abdominal obesity. Methods: We evaluated the insulin sensitivity of liver, skeletal muscle, and adipose tissue (with a euglycemic-hyperinsulinemic clamp procedure and isotope-tracer infusions) as well as levels of inflammatory mediators and other risk factors for coronary heart disease in 15 obese women before and 10 to 12 weeks after abdominal liposuction. Eight of the women had normal glucose tolerance (mean [+/-SD] body-mass index, 35.1+/-2.4), and seven had type 2 diabetes (body-mass index, 39.9+/-5.6). Results: Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent in the subjects with normal glucose tolerance and 28 percent in those with diabetes; those with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3 percent decrease in total fat, P=0.002), and those with type 2 diabetes lost 10.5+/-3.3 kg of fat (19+/-2 percent decrease in total fat, P<0.001). Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C-reactive protein, interleukin-6, tumor necrosis factor (alpha), and adiponectin; and did not significantly affect other risk factors for coronary heart disease (blood pressure and plasma glucose, insulin, and lipid concentrations) in either group. Conclusions: Abdominal liposuction does not significantly improve obesity-associated metabolic abnormalities. Decreasing adipose tissue mass alone will not achieve the metabolic benefits of weight loss.	Washington Univ, Sch Med, Ctr Human Nutr, St Louis, MO 63110 USA; Ist Super Sanita, Div Food Sci Human Nutr & Hlth, I-00161 Rome, Italy	Washington University (WUSTL); Istituto Superiore di Sanita (ISS)	Klein, S (corresponding author), Washington Univ, Sch Med, Ctr Human Nutr, 660 S Euclid Ave,Campus Box 8031, St Louis, MO 63110 USA.		Fontana, Luigi/A-8371-2013; Fontana, Luigi/K-4773-2013; Coggan, Andrew R/B-2117-2010	Coggan, Andrew R/0000-0002-7723-8872; Fontana, Luigi/0000-0001-8500-5537; Patterson, Bruce W/0000-0001-9261-0233	NCRR NIH HHS [RR-00954, RR-00036] Funding Source: Medline; NICHD NIH HHS [HD 01459] Funding Source: Medline; NIDDK NIH HHS [DK 37948, DK 56341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037948, P30DK056341] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE N, 1995, J CLIN INVEST, V96, P88, DOI 10.1172/JCI118083; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; American Society for Aesthetic Plastic Surgery, COSM SURG NAT DAT BA; BALLOR DL, 1994, INT J OBESITY, V18, P35; Berntorp E, 1998, J INTERN MED, V243, P197; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Commons GW, 2001, PLAST RECONSTR SURG, V108, P1753, DOI 10.1097/00006534-200111000-00050; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Dandona P, 1998, J CLIN ENDOCR METAB, V83, P2907, DOI 10.1210/jc.83.8.2907; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Giese SY, 2001, PLAST RECONSTR SURG, V108, P510, DOI 10.1097/00006534-200108000-00035; Gonzalez-Ortiz M, 2002, HORM METAB RES, V34, P446, DOI 10.1055/s-2002-33603; Goodpaster BH, 2000, METABOLISM, V49, P467, DOI 10.1016/S0026-0495(00)80010-4; Horowitz JF, 2001, AM J CLIN NUTR, V73, P517; Horowitz JF, 1999, AM J PHYSIOL-ENDOC M, V276, pE278, DOI 10.1152/ajpendo.1999.276.2.E278; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; Klein S, 2002, GASTROENTEROLOGY, V123, P882, DOI 10.1053/gast.2002.35514; Klein S, 2002, GASTROENTEROLOGY, V123, P1752; Klein S, 1996, AM J PHYSIOL-ENDOC M, V270, pE739; KNITTLE JL, 1972, DIABETES, V21, P754, DOI 10.2337/diab.21.6.754; Krssak M, 1999, DIABETOLOGIA, V42, P386; LAMBERT EV, 1991, AESTHET PLAST SURG, V15, P105, DOI 10.1007/BF02273842; Matarasso A, 2001, JAMA-J AM MED ASSOC, V285, P266, DOI 10.1001/jama.285.3.266; Matarasso A, 1998, PLAST RECONSTR SURG, V102, P1686, DOI 10.1097/00006534-199810000-00057; MLADICK RA, 1990, PLAST RECONSTR SURG, V86, P84, DOI 10.1097/00006534-199007000-00013; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Purnell JQ, 2000, J CLIN ENDOCR METAB, V85, P977, DOI 10.1210/jc.85.3.977; SAMDAL F, 1995, AESTHET PLAST SURG, V19, P131, DOI 10.1007/BF00450248; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; Tiikkainen M, 2003, DIABETES, V52, P701, DOI 10.2337/diabetes.52.3.701; Trott SA, 1998, PLAST RECONSTR SURG, V102, P2220, DOI 10.1097/00006534-199811000-00063; Uusitupa M, 2003, DIABETES, V52, P2532, DOI 10.2337/diabetes.52.10.2532; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815; YANG WS, 2002, J CLIN ENDOCR METAB, V87, P1626; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	42	521	552	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2549	2557		10.1056/NEJMoa033179	http://dx.doi.org/10.1056/NEJMoa033179			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201411				2022-12-28	WOS:000222054700005
J	Pouille, F; Scanziani, M				Pouille, F; Scanziani, M			Routing of spike series by dynamic circuits in the hippocampus	NATURE			English	Article							RAT HIPPOCAMPUS; PYRAMIDAL CELLS; SYNAPTIC ORGANIZATION; TOTAL NUMBER; CA1 AREA; INTERNEURONS; NEURONS; INHIBITION; SYNAPSES; RECEPTOR	Recurrent inhibitory loops are simple neuronal circuits found in the central nervous system, yet little is known about the physiological rules governing their activity. Here we use simultaneous somatic and dendritic recordings in rat hippocampal slices to show that during a series of action potentials in pyramidal cells recurrent inhibition rapidly shifts from their soma to the apical dendrites. Two distinct inhibitory circuits are sequentially recruited to produce this shift: one, time-locked with submillisecond precision to the onset of the action potential series, transiently inhibits the somatic and perisomatic regions of pyramidal cells; the other, activated in proportion to the rate of action potentials in the series, durably inhibits the distal apical dendrites. These two operating modes result from the synergy between pre- and postsynaptic properties of excitatory synapses onto recurrent inhibitory neurons with distinct projection patterns. Thus, the onset of a series of action potentials and the rate of action potentials in the series are selectively captured and transformed into different spatial patterns of recurrent inhibition.	Univ Calif San Diego, Neurobiol Sect, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Scanziani, M (corresponding author), Univ Calif San Diego, Neurobiol Sect, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	massimo@ucsd.edu						Adrian E.D., 1928, BASIS SENSATION ACTI; ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; Ali AB, 1998, J PHYSIOL-LONDON, V507, P201, DOI 10.1111/j.1469-7793.1998.201bu.x; Ali AB, 1998, J PHYSIOL-LONDON, V507, P185, DOI 10.1111/j.1469-7793.1998.185bu.x; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; Arai AC, 2002, J PHARMACOL EXP THER, V303, P1075, DOI 10.1124/jpet.102.040360; Banks MI, 2000, NEURON, V25, P449, DOI 10.1016/S0896-6273(00)80907-1; Beierlein M, 2003, J NEUROPHYSIOL, V90, P2987, DOI 10.1152/jn.00283.2003; Buhl EH, 1996, HIPPOCAMPUS, V6, P294; Dayan P, 2001, COMPUTATIONAL NEUROS; DINGLEDINE R, 1980, BRAIN RES, V185, P277, DOI 10.1016/0006-8993(80)91068-9; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Fricker D, 2000, NEURON, V28, P559, DOI 10.1016/S0896-6273(00)00133-1; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; Gulyas AI, 1999, J NEUROSCI, V19, P10082; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P225, DOI 10.1152/jn.1961.24.3.225; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Losonczy A, 2002, J PHYSIOL-LONDON, V542, P193, DOI 10.1113/jphysiol.2002.020024; MACCAFERRI G, 1995, NEURON, V15, P137, DOI 10.1016/0896-6273(95)90071-3; Megias M, 2001, NEUROSCIENCE, V102, P527, DOI 10.1016/S0306-4522(00)00496-6; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; Rieke F., 1997, SPIKES EXPLORING NEU; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Toth K, 2000, J NEUROSCI, V20, P8279, DOI 10.1523/JNEUROSCI.20-22-08279.2000	31	311	345	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					717	723		10.1038/nature02615	http://dx.doi.org/10.1038/nature02615			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15170216				2022-12-28	WOS:000222059900028
J	Duke, T				Duke, T			Clinical care for seriously ill children in district hospitals: a global public-health issue	LANCET			English	Editorial Material							COUNTRIES; QUALITY		Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Ctr Int Child Hlth, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne	Duke, T (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Ctr Int Child Hlth, Parkville, Vic 3052, Australia.	trevor.duke@rch.org.au						Duke T, 2003, ARCH DIS CHILD, V88, P563, DOI 10.1136/adc.88.7.563; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Tugwell P, 2004, LANCET, V363, P836, DOI 10.1016/S0140-6736(04)15772-3; *WHO, 2004, MULT COUNTR EV INT M	4	7	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	2004	363	9425					1922	1923		10.1016/S0140-6736(04)16438-6	http://dx.doi.org/10.1016/S0140-6736(04)16438-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194249				2022-12-28	WOS:000221962800004
J	Zhu, Z; Zheng, T; Homer, RJ; Kim, YK; Chen, NY; Cohn, L; Hamid, Q; Elias, JA				Zhu, Z; Zheng, T; Homer, RJ; Kim, YK; Chen, NY; Cohn, L; Hamid, Q; Elias, JA			Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation	SCIENCE			English	Article							PARASITE CHITINASE; ALLERGY; IDENTIFICATION	Chitin is a surface component of parasites and insects, and chitinases are induced in lower life forms during infections with these agents. Although chitin itself does not exist in humans, chitinases are present in the human genome. We show here that acidic mammalian chitinase (AMCase) is induced via a T helper-2 (Th2) specific, interleukin-13 (IL-13) -mediated pathway in epithelial cells and macrophages in an aeroallergen asthma model and expressed in exaggerated quantities in human asthma. AMCase neutralization ameliorated Th2 inflammation and airway hyperresponsiveness, in part by inhibiting IL-13 pathway activation and chemokine induction. AMCase may thus be an important mediator of IL-13-induced responses in Th2-dominated disorders such as asthma.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; VA CT Hlth Care Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA; McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; McGill University	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 300 Cedar St,TAC S-441, New Haven, CT 06520 USA.	jack.elias@yale.edu	homer, robert/P-3884-2019	homer, robert/0000-0002-2055-5885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066571, R01HL074095, R01HL064242, R01HL061904] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-66571, R01-HL-64242, R01-HL-61904, R01-HL-074095, P50-HL-56] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Dessens JT, 2001, INFECT IMMUN, V69, P4041, DOI 10.1128/IAI.69.6.4041-4047.2001; Herrera-Estrella A, 1999, EXS, V87, P171; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Palli Sr, 1999, EXS, V87, P85; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Seferian PG, 2000, VACCINE, V19, P661, DOI 10.1016/S0264-410X(00)00248-6; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shahabuddin M, 1999, EXS, V87, P223; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Spindler KD, 1997, ARCH INSECT BIOCHEM, V36, P223, DOI 10.1002/(SICI)1520-6327(1997)36:3<223::AID-ARCH6>3.0.CO;2-U; Spindler KD, 1999, EXS, V87, P201; Strong P, 2002, CLIN EXP ALLERGY, V32, P1794, DOI 10.1046/j.1365-2222.2002.01551.x; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Webb DC, 2001, J BIOL CHEM, V276, P41969, DOI 10.1074/jbc.M106223200; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	18	641	689	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1678	1682		10.1126/science.1095336	http://dx.doi.org/10.1126/science.1095336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192232				2022-12-28	WOS:000221934300053
J	Borodinsky, LN; Root, CM; Cronin, JA; Sann, SB; Gu, XN; Spitzer, NC				Borodinsky, LN; Root, CM; Cronin, JA; Sann, SB; Gu, XN; Spitzer, NC			Activity-dependent homeostatic specification of transmitter expression in embryonic neurons	NATURE			English	Article							CULTURED SYMPATHETIC NEURONS; SPONTANEOUS CA2+ TRANSIENTS; HOMEODOMAIN PROTEIN; SPINAL NEURONS; GENE-EXPRESSION; MOTOR-NEURONS; TRANSCRIPTION FACTORS; MESSENGER-RNAS; GROWTH CONES; DIFFERENTIATION	Neurotransmitters are essential for interneuronal signalling, and the specification of appropriate transmitters in differentiating neurons has been related to intrinsic neuronal identity and to extrinsic signalling proteins. Here we show that altering the distinct patterns of Ca2+ spike activity spontaneously generated by different classes of embryonic spinal neurons in vivo changes the transmitter that neurons express without affecting the expression of markers of cell identity. Regulation seems to be homeostatic: suppression of activity leads to an increased number of neurons expressing excitatory transmitters and a decreased number of neurons expressing inhibitory transmitters; the reverse occurs when activity is enhanced. The imposition of specific spike frequencies in vitro does not affect labels of cell identity but again specifies the expression of transmitters that are inappropriate for the markers they express, during an early critical period. The results identify a new role of patterned activity in development of the central nervous system.	Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Borodinsky, LN (corresponding author), Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA.	lborodin@biomail.ucsd.edu		Spitzer, Nicholas/0000-0002-3523-1103				Appel B, 1995, DEVELOPMENT, V121, P4117; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; BERNHARDT RR, 1992, J COMP NEUROL, V326, P263, DOI 10.1002/cne.903260208; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BIXBY JL, 1984, J PHYSIOL-LONDON, V353, P143, DOI 10.1113/jphysiol.1984.sp015328; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Brosenitsch TA, 2002, MOL CELL NEUROSCI, V20, P447, DOI 10.1006/mcne.2002.1135; Chub N, 1998, J NEUROSCI, V18, P294; Defazio RA, 2000, NEUROSCIENCE, V99, P297, DOI 10.1016/S0306-4522(00)00191-3; DIEFENBACH TJ, 1995, DEV BIOL, V167, P282, DOI 10.1006/dbio.1995.1023; FURSHPAN EJ, 1976, P NATL ACAD SCI USA, V73, P4225, DOI 10.1073/pnas.73.11.4225; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; GROVES AK, 1995, DEVELOPMENT, V121, P887; GU XN, 1994, J NEUROSCI, V14, P6325; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Gutierrez R, 2003, J NEUROSCI, V23, P5594; Hanson MG, 2003, J NEUROSCI, V23, P587, DOI 10.1523/JNEUROSCI.23-02-00587.2003; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HENDERSON LP, 1984, J NEUROSCI, V4, P3140; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; Li WC, 2001, J COMP NEUROL, V441, P248, DOI 10.1002/cne.1410; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Marek KW, 2000, NEURON, V25, P537, DOI 10.1016/S0896-6273(00)81058-2; Milner LD, 1999, J NEUROSCI, V19, P3007; NAWA H, 1990, NEURON, V4, P269, DOI 10.1016/0896-6273(90)90101-K; Okada T, 2002, DEV BIOL, V244, P278, DOI 10.1006/dbio.2002.0585; Pierani A, 2001, NEURON, V29, P367, DOI 10.1016/S0896-6273(01)00212-4; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; RIBERA AB, 1989, NEURON, V2, P1055, DOI 10.1016/0896-6273(89)90229-8; Schneider C, 1999, NEURON, V24, P861, DOI 10.1016/S0896-6273(00)81033-8; Snyder SH, 2000, AM J PSYCHIAT, V157, P1738, DOI 10.1176/appi.ajp.157.11.1738; Somasekhar T, 1997, DEV BRAIN RES, V99, P208, DOI 10.1016/S0165-3806(97)00011-4; SOMOGYI R, 1995, J NEUROSCI, V15, P2575; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; WALICKE PA, 1981, J NEUROSCI, V1, P343; Watt SD, 2000, MOL CELL NEUROSCI, V16, P376, DOI 10.1006/mcne.2000.0871; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	50	297	304	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					523	530		10.1038/nature02518	http://dx.doi.org/10.1038/nature02518			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175743				2022-12-28	WOS:000221767700030
J	Mungall, JE; Ames, DE; Hanley, JJ				Mungall, JE; Ames, DE; Hanley, JJ			Geochemical evidence from the Sudbury structure for crustal redistribution by large bolide impacts	NATURE			English	Article							IGNEOUS COMPLEX	Deformation and melting of the crust during the formation of large impact craters must have been important during the Earth's early evolution, but such processes remain poorly understood(1). The 1.8-billion-year-old Sudbury structure(2) in Ontario, Canada, is greater than 200 km in diameter and preserves a complete impact section, including shocked basement rocks, an impact melt sheet and fallback material(3,4). It has generally been thought that the most voluminous impact melts represent the average composition of the continental crust(4), but here we show that the melt sheet now preserved as the Sudbury Igneous Complex is derived predominantly from the lower crust. We therefore infer that the hypervelocity impact caused a partial inversion of the compositional layering of the continental crust. Using geochemical data, including platinum-group-element abundances, we also show that the matrix of the overlying clast-laden Onaping Formation represents a mixture of the original surficial sedimentary strata, shock-melted lower crust and the impactor itself.	Univ Toronto, Dept Geol, Toronto, ON M5S 3B1, Canada; Nat Resources Canada, Geol Survey Canada, Ottawa, ON K1A 0E8, Canada	University of Toronto; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Mungall, JE (corresponding author), Univ Toronto, Dept Geol, 22 Russell St, Toronto, ON M5S 3B1, Canada.	mungall@geology.utoronto.ca						ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Ames DE, 1998, GEOLOGY, V26, P447, DOI 10.1130/0091-7613(1998)026<0447:DOARHS>2.3.CO;2; Ames DE, 2002, ECON GEOL BULL SOC, V97, P1541, DOI 10.2113/97.7.1541; Bunch TE, 1999, GEOL S AM S, P331; Campins H, 1998, METEORIT PLANET SCI, V33, P1201, DOI 10.1111/j.1945-5100.1998.tb01305.x; COLEMAN AP, 2003, SUDBURY NICKEL DEPOS, P253; COLODNER DC, 1992, NATURE, V358, P402, DOI 10.1038/358402a0; COWAN EJ, 1994, ONTARIO GEOL SURV SP, V5, P45; Dickin AP, 1999, GEOL S AM S, P361; DIETZ RS, 1964, J GEOL, V72, P412, DOI 10.1086/626999; Gao S, 1998, GEOCHIM COSMOCHIM AC, V62, P1959, DOI 10.1016/S0016-7037(98)00121-5; GRIEVE RAF, 1991, J GEOPHYS RES-PLANET, V96, P22753, DOI 10.1029/91JE02513; GRIEVE RAF, 1992, METEORITICS, V27, P526, DOI 10.1111/j.1945-5100.1992.tb01074.x; Heymann D, 1999, GEOL S AM S, P345; Ivanov BA, 1999, GEOL S AM S, P389; KROGH TE, 1984, ONTARIO GEOLOGICAL S, V1, P431; Lightfoot PC, 1997, ECON GEOL BULL SOC, V92, P289, DOI 10.2113/gsecongeo.92.3.289; Lightfoot PC, 2002, ECON GEOL BULL SOC, V97, P1419, DOI 10.2113/97.7.1419; Masaitis VL, 1999, GEOL S AM S, P317; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; Melosh HJ, 1999, ANNU REV EARTH PL SC, V27, P385, DOI 10.1146/annurev.earth.27.1.385; MUNGALL JE, 2003, 38 ANN GSA NE DIV M, P23; PATAVA J, 2003, MINER DEPOSITA, V38, P775; Pierazzo E, 1997, ICARUS, V127, P408, DOI 10.1006/icar.1997.5713; Pope KO, 2004, METEORIT PLANET SCI, V39, P97, DOI 10.1111/j.1945-5100.2004.tb00052.x; Richardson T., 2002, ONT GEOL SURV OPEN F, V6100, P35; Ripley EM, 2001, GEOCHIM COSMOCHIM AC, V65, P2965, DOI 10.1016/S0016-7037(01)00635-4; Schneider DA, 2002, CAN J EARTH SCI, V39, P999, DOI 10.1139/E02-016; Therriault AM, 2002, ECON GEOL BULL SOC, V97, P1521, DOI 10.2113/97.7.1521; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217, DOI 10.1016/0016-7037(95)00038-2	30	57	58	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					546	548		10.1038/nature02577	http://dx.doi.org/10.1038/nature02577			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175748				2022-12-28	WOS:000221767700035
J	Pietrangelo, A				Pietrangelo, A			Medical progress - Hereditary hemochromatosis - A new look at an old disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; ANTIMICROBIAL PEPTIDE HEPCIDIN; TRANSFERRIN RECEPTOR-2 GENE; IRON OVERLOAD; IDIOPATHIC HEMOCHROMATOSIS; PROTEIN HFE; JUVENILE HEMOCHROMATOSIS; CLINICAL EXPRESSION; C282Y HOMOZYGOTES; NATURAL-HISTORY		Univ Modena Reggio Emilia Policlin, Dept Internal Med, Ctr Hemochromatosis Hereditary Liver Dis, Modena, Italy	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital	Pietrangelo, A (corresponding author), Univ Modena, Dept Med, Via Pozzo 71, I-41100 Modena, Italy.	pietrangelo.antonello@unimore.it	Girelli, Domenico/B-1183-2008; Pietrangelo, Antonello/K-1517-2016	Girelli, Domenico/0000-0001-9684-1899; Pietrangelo, Antonello/0000-0002-7411-935X	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Ajioka RS, 2003, BLOOD, V101, P3351, DOI 10.1182/blood-2002-11-3453; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; Arden KE, 2003, GUT, V52, P1215, DOI 10.1136/gut.52.8.1215; Asberg A, 2001, SCAND J GASTROENTERO, V36, P1108; ASTALDI G, 1966, BLOOD-J HEMATOL, V28, P70, DOI 10.1182/blood.V28.1.70.70; Beutler E, 2003, BLOOD, V101, P3347, DOI 10.1182/blood-2002-06-1747; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; BOTHWELL TH, 1995, NUTR REV, V53, P237, DOI 10.1111/j.1753-4887.1995.tb05480.x; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Brown AS, 2001, GENET MED, V3, P109, DOI 10.1097/00125817-200103000-00004; Bulaj ZJ, 2000, NEW ENGL J MED, V343, P1529, DOI 10.1056/NEJM200011233432104; Cairo G, 1997, BLOOD, V89, P2546, DOI 10.1182/blood.V89.7.2546; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; CAVILL I, 1979, CLIN SCI, V56, P223, DOI 10.1042/cs0560223; Cazzola M, 1998, BLOOD, V92, P2979, DOI 10.1182/blood.V92.8.2979; CAZZOLA M, 1983, HUM GENET, V65, P149, DOI 10.1007/BF00286653; COOK JD, 1973, AM J PATHOL, V72, P337; Cox TM, 2002, BLOOD CELL MOL DIS, V29, P411, DOI 10.1006/bcmd.2002.0580; CROSBY WH, 1963, BLOOD, V22, P441, DOI 10.1182/blood.V22.4.441.441; Davies PS, 2003, BIOCHEM J, V373, P145, DOI 10.1042/BJ20030202; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; *EASL, 2000, J HEPATOL, V33, P496; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FILLET G, 1989, BLOOD, V74, P844; FINCH SC, 1955, MEDICINE, V34, P381, DOI 10.1097/00005792-195512000-00001; Fleming RE, 2002, P NATL ACAD SCI USA, V99, P10653, DOI 10.1073/pnas.162360699; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Gehrke SG, 2003, BLOOD, V102, P371, DOI 10.1182/blood-2002-11-3610; Girelli D, 2002, GASTROENTEROLOGY, V122, P1295, DOI 10.1053/gast.2002.32984; Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0; Gochee PA, 2002, GASTROENTEROLOGY, V122, P1191; Gordeuk VR, 2003, BLOOD CELL MOL DIS, V31, P299, DOI 10.1016/S1079-9796(03)00164-5; Griffiths WJH, 2003, J HISTOCHEM CYTOCHEM, V51, P613, DOI 10.1177/002215540305100507; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hattori A, 2003, HEPATOL RES, V26, P154, DOI 10.1016/S1386-6346(03)00086-X; HAYASHI A, 1993, AM J HUM GENET, V53, P201; Hofmann WK, 2002, BLOOD, V100, P1099, DOI 10.1182/blood-2002-04-1077; Kato J, 2001, AM J HUM GENET, V69, P191, DOI 10.1086/321261; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kawabata H, 2000, J BIOL CHEM, V275, P16618, DOI 10.1074/jbc.M908846199; Knisely AS, 2003, GASTROENTEROL CLIN N, V32, P877, DOI 10.1016/S0889-8553(03)00050-5; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; LAMON JM, 1979, GASTROENTEROLOGY, V76, P178; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; LYNCH SR, 1989, BLOOD, V74, P2187; Mattman A, 2002, BLOOD, V100, P1075, DOI 10.1182/blood-2002-01-0133; *MCK NATH I GEN ME, 2000, ONL MEND INH MAN OMI; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; Merryweather-Clarke AT, 2003, HUM MOL GENET, V12, P2241, DOI 10.1093/hmg/ddg225; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; Morrison ED, 2003, ANN INTERN MED, V139, P235, DOI 10.7326/0003-4819-139-3-200308050-00022; Morrison ED, 2003, ANN INTERN MED, V138, P627, DOI 10.7326/0003-4819-138-8-200304150-00008; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nicolas G, 2003, NAT GENET, V34, P97, DOI 10.1038/ng1150; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; Pietrangelo A, 1998, J HEPATOL, V29, P502, DOI 10.1016/S0168-8278(98)80074-3; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P1963; Pietrangelo A, 1999, NEW ENGL J MED, V341, P725, DOI 10.1056/NEJM199909023411003; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Pointon JJ, 2000, GENET TEST, V4, P151, DOI 10.1089/10906570050114867; Powell Lawrie W, 2002, Semin Gastrointest Dis, V13, P80; Rochette J, 1999, AM J HUM GENET, V64, P1056, DOI 10.1086/302318; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; ROFLS A, 2002, AM J PHYSIOL-GASTR L, V282, pG598; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Sheldon J. H., 1935, HAEMOCHROMATOSIS; SIMON M, 1974, NOUV PRESSE MED, V4, P1432; SIMON M, 1987, AM J HUM GENET, V41, P89; SMITH PM, 1969, CLIN SCI, V37, P519; Tavill AS, 2001, HEPATOLOGY, V33, P1321, DOI 10.1053/jhep.2001.24783; Troisier M, 1871, B SOC ANAT PARIS, V44, P231; Trousseau A, 1865, CLIN MED HOTEL PARIS, V2, P663; von Recklinghausen FD, 1889, TAGEBL VERSAMML NATU, V62, P324; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Waheed A, 2002, P NATL ACAD SCI USA, V99, P3117, DOI 10.1073/pnas.042701499; Wallace DF, 2002, J HEPATOL, V36, P474, DOI 10.1016/S0168-8278(01)00304-X; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200; Willis G, 1999, LANCET, V354, P221, DOI 10.1016/S0140-6736(99)02195-9; Wojcik JP, 2002, CAN J GASTROENTEROL, V16, P297, DOI 10.1155/2002/161569; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zhang AS, 2003, P NATL ACAD SCI USA, V100, P9500, DOI 10.1073/pnas.1233675100; Zoller H, 2001, GASTROENTEROLOGY, V120, P1412, DOI 10.1053/gast.2001.24033	101	668	693	2	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2383	2397		10.1056/NEJMra031573	http://dx.doi.org/10.1056/NEJMra031573			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175440				2022-12-28	WOS:000221754200009
J	Demyttenaere, K; Bruffaerts, R; Posada-Villa, J; Gasquet, I; Kovess, V; Lepine, JP; Angermeyer, MC; Bernert, S; de Girolamo, G; Morosini, P; Polidori, G; Kikkawa, T; Kawakami, N; Ono, Y; Takeshima, T; Uda, H; Karam, EG; Fayyad, JA; Karam, AN; Mneimneh, ZN; Medina-Mora, ME; Borges, G; Lara, C; de Graaf, R; Ormel, J; Gureje, O; Shen, YC; Huang, YQ; Zhang, MY; Alonso, J; Haro, JM; Vilagut, G; Bromet, EJ; Gluzman, S; Webb, C; Kessler, RC; Merikangas, KR; Anthony, JC; Von Korff, MR; Wang, PS; Alonso, J; Brugha, TS; Aguilar-Gaxiola, S; Lee, S; Heeringa, S; Pennell, BE; Zaslavsky, AM; Ustun, TB; Chatterji, S				Demyttenaere, K; Bruffaerts, R; Posada-Villa, J; Gasquet, I; Kovess, V; Lepine, JP; Angermeyer, MC; Bernert, S; de Girolamo, G; Morosini, P; Polidori, G; Kikkawa, T; Kawakami, N; Ono, Y; Takeshima, T; Uda, H; Karam, EG; Fayyad, JA; Karam, AN; Mneimneh, ZN; Medina-Mora, ME; Borges, G; Lara, C; de Graaf, R; Ormel, J; Gureje, O; Shen, YC; Huang, YQ; Zhang, MY; Alonso, J; Haro, JM; Vilagut, G; Bromet, EJ; Gluzman, S; Webb, C; Kessler, RC; Merikangas, KR; Anthony, JC; Von Korff, MR; Wang, PS; Alonso, J; Brugha, TS; Aguilar-Gaxiola, S; Lee, S; Heeringa, S; Pennell, BE; Zaslavsky, AM; Ustun, TB; Chatterji, S		WHO World Mental Hlth Survey Conso	Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CROSS-NATIONAL EPIDEMIOLOGY; INTERNATIONAL DIAGNOSTIC INTERVIEW; R PSYCHIATRIC-DISORDERS; UNITED-STATES; LIFETIME PREVALENCE; GENERAL-POPULATION; COMORBIDITY-SURVEY; CATCHMENT-AREA; VALIDITY; PSYCHOSIS	Context Little is known about the extent or severity of untreated mental disorders, especially in less-developed countries. Objective To estimate prevalence, severity, and treatment of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) mental disorders in 14 countries (6 less developed, 8 developed) in the World Health Organization (WHO) World Mental Health (WMH) Survey Initiative. Design, Setting, and Participants Face-to-face household surveys of 60463 community adults conducted from 2001-2003 in 14 countries in the Americas, Europe, the Middle East, Africa, and Asia. Main Outcome Measures The DSM-IV disorders, severity, and treatment were assessed with the WMH version of the WHO Composite International Diagnostic Interview (WMH-CIDI), a fully structured, lay-administered psychiatric diagnostic interview. Results The prevalence of having any WMH-CIDI/DSM-IV disorder in the prior year varied widely, from 4.3% in Shanghai to 26.4% in the United States, with an interquartile range (IQR) of 9.1%-16.9%. Between 33.1% (Colombia) and 80.9% (Nigeria) of 12-month cases were mild (IQR, 40.2%-53.3%). Serious disorders were associated with substantial role disability. Although disorder severity was correlated with probability of treatment in almost all countries, 35.5%.to 50.3% of serious cases in developed countries and 76.3% to 85.4% in less-developed countries received no treatment in the 12 months before the interview. Due to the high prevalence of mild and subthreshold cases, the number of those who received treatment far exceeds the number of untreated serious cases in every country. Conclusions Reallocation of treatment resources could substantially decrease the problem of unmet need for treatment of mental disorders among serious cases. Structural barriers exist to this reallocation. Careful consideration needs to be given to the value of treating some mild cases,. especially those at risk for progressing to more serious disorders.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kessler, RC (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Londwood Ave, Boston, MA 02115 USA.	kessler@hcp.med.harvard; ustunb@who.int	Adewuya, Abiodun/N-4997-2017; Lee, Sing/O-2136-2015; Medina-Mora, María Elena I/T-5937-2018; Haro, Josep Maria/D-1423-2011; Ormel, Johan/C-6094-2013; Posada-Villa, Jose/AAA-2355-2019; Mneimneh, Zeina/ABG-3516-2020; Brugha, Traolach/T-9326-2019; Alonso, Jordi/A-5514-2010; ormel, johan/AAC-5584-2019; CHATTERJI, Somnath/ABE-6832-2020; Young, Alexander/A-1523-2009; Gureje, Oye/J-1183-2014; BRUFFAERTS, RONNY/AAA-2364-2021; Vilagut, Gemma/N-8718-2014; demyttenaere, koen/AAG-4716-2021; de Girolamo, Giovanni/K-3062-2016; Anthony, Jim/H-3637-2011	Adewuya, Abiodun/0000-0002-7611-6953; Medina-Mora, María Elena I/0000-0001-9300-0752; Haro, Josep Maria/0000-0002-3984-277X; Posada-Villa, Jose/0000-0001-5840-3118; Brugha, Traolach/0000-0002-9786-9591; Alonso, Jordi/0000-0001-8627-9636; ormel, johan/0000-0002-5463-037X; Young, Alexander/0000-0002-9367-9213; Gureje, Oye/0000-0003-0094-5947; BRUFFAERTS, RONNY/0000-0002-0330-3694; Vilagut, Gemma/0000-0002-3714-226X; de Girolamo, Giovanni/0000-0002-1611-8324; Anthony, Jim/0000-0001-7176-0929; /0000-0002-8421-8263; VonKorff, Michael/0000-0001-5386-8477; Borges, Guilherme/0000-0002-3269-0507; Merikangas, Kathkeen/0000-0002-4667-2414	NIDA NIH HHS [K05 DA015799, R01 DA016558] Funding Source: Medline; NIMH NIH HHS [R13 MH066849-02, R01 MH069864-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R13MH066849, R01MH069864, Z01MH002806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA015799, R01DA016558] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alegria M, 2000, ARCH GEN PSYCHIAT, V57, P383, DOI 10.1001/archpsyc.57.4.383; ALLGULANDER C, 1989, AM J PUBLIC HEALTH, V79, P1006, DOI 10.2105/AJPH.79.8.1006; Alonso J, 2002, INT J METH PSYCH RES, V11, P55, DOI 10.1002/mpr.123; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andrade L, 2002, SOC PSYCH PSYCH EPID, V37, P316, DOI 10.1007/s00127-002-0551-x; ANDRADE L, 1996, 7 C INT FED PSYCH EP; [Anonymous], 2000, Bull World Health Organ, V78, P413; [Anonymous], 1996, GLOBAL BURDEN DIS CO; BEBBINGTON P, 1995, INT J METHOD PSYCH, V5, P11; Bijl RV, 1998, SOC PSYCH PSYCH EPID, V33, P581, DOI 10.1007/s001270050097; Bijl RV, 2003, HEALTH AFFAIR, V22, P122, DOI 10.1377/hlthaff.22.3.122; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P24, DOI 10.1111/j.1600-0447.1988.tb08544.x; Caraveo J, 1998, SALUD MENT, V21, P48; EATON WW, 1992, AM J EPIDEMIOL, V135, P1051, DOI 10.1093/oxfordjournals.aje.a116399; EATON WW, 1991, J NERV MENT DIS, V179, P689, DOI 10.1097/00005053-199111000-00007; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; Hagnell O., 1966, PROSPECTIVE STUDY IN; HWU HG, 1989, ACTA PSYCHIAT SCAND, V79, P136, DOI 10.1111/j.1600-0447.1989.tb08581.x; Katz SJ, 1997, INQUIRY-J HEALTH CAR, V34, P38; Keith S. J., 1991, PSYCHIAT DISORDERS A, P33; Kendler KS, 1996, ARCH GEN PSYCHIAT, V53, P1022; Kessler R.C., 1998, MENTAL HLTH US 1998, P99; KESSLER RC, 1993, AM J COMMUN PSYCHOL, V21, P607, DOI 10.1007/BF00942174; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P1117, DOI 10.1001/archpsyc.60.11.1117; Kessler RC, 1997, PSYCHOL MED, V27, P861, DOI 10.1017/S0033291797004807; Kessler RC, 1999, ACTA PSYCHIAT SCAND, V99, P2, DOI 10.1111/j.1600-0447.1999.tb05378.x; Kessler RC, 2001, J OCCUP ENVIRON MED, V43, P218, DOI 10.1097/00043764-200103000-00009; Kessler RC, 1997, NEW ENGL J MED, V336, P551, DOI 10.1056/NEJM199702203360806; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KESSLER RC, IN PRESS INT J METHO; KYLYC C, 1998, MENTAL HLTH PROFILE; Langner T., 1963, LIFE STRESS MENTAL H; Leighton Alexander H., 1959, MY NAME IS LEGION, V1; Leon AC, 1997, INT J PSYCHIAT MED, V27, P93, DOI 10.2190/T8EM-C8YH-373N-1UWD; LEPINE J P, 1989, Psychiatrie and Psychobiologie, V4, P267; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; REGIER DA, 2000, UNMET NEED PSYCHIAT; *RES TRIANG I, 2002, SUDAAN COMP PROGR VE; Robins L.N., 1991, PSYCHIAT DISORDERS A; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Simon GE, 2002, PSYCHOL MED, V32, P585, DOI 10.1017/S0033291702005457; SPENGLER PA, 1988, COMPR PSYCHIAT, V29, P309, DOI 10.1016/0010-440X(88)90054-5; Vega WA, 1998, ARCH GEN PSYCHIAT, V55, P771, DOI 10.1001/archpsyc.55.9.771; VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173; Weissman MM, 1996, INT CLIN PSYCHOPHARM, V11, P9, DOI 10.1097/00004850-199606003-00003; Weissman MM, 1997, ARCH GEN PSYCHIAT, V54, P305; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; WEISSMAN MM, 1994, J CLIN PSYCHIAT, V55, P5; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; *WHO, 1999, UKR COUNTR HLTH REP; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; Wittchen HU, 1998, EUR ADDICT RES, V4, P18, DOI 10.1159/000018921; Wolter K. M., 1985, INTRO VARIANCE ESTIM; *WORLD BANK, 2003, WORLD DEV IND 2003	57	2184	2286	8	240	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2581	2590		10.1001/jama.291.21.2581	http://dx.doi.org/10.1001/jama.291.21.2581			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	825EM	15173149	Bronze			2022-12-28	WOS:000221738800021
J	Beaglehole, R; Bonita, R; Horton, R; Adams, O; McKee, M				Beaglehole, R; Bonita, R; Horton, R; Adams, O; McKee, M			Public health in the new era: improving health through collective action	LANCET			English	Editorial Material							EPIDEMIOLOGY		WHO, Evidence Informat & Policy, CH-1211 Geneva 27, Switzerland; Lancet, London, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Beaglehole, R (corresponding author), WHO, Evidence Informat & Policy, CH-1211 Geneva 27, Switzerland.	beagleholer@who.int	McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				[Anonymous], 1997, LANCET, V350, P229; [Anonymous], 2000, DEV FREEDOM; Beaglehole R, 2001, LANCET, V358, P661, DOI 10.1016/S0140-6736(01)05784-1; Beaglehole R., 2003, GLOBAL PUBLIC HLTH N; Beaglehole Robert, 2004, PUBLIC HLTH CROSSROA; Gostin LO, 2001, AM J PUBLIC HEALTH, V91, P1365, DOI 10.2105/AJPH.91.9.1365; Hamlin C, 2002, INT J EPIDEMIOL, V31, P915, DOI 10.1093/ije/31.5.915; HAMLIN C, 2002, OXFORD TXB PUBLIC HL; Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776; Lawlor DA, 2003, AM J PUBLIC HEALTH, V93, P266, DOI 10.2105/AJPH.93.2.266; LEE L, 2003, GLOBAL PUBLIC HLTH N; McKee Martin, 2001, INT COOPERATION HLTH; McKinlay JB, 1999, AM J PUBLIC HEALTH, V89, P295, DOI 10.2105/AJPH.89.3.295; McMichael AJ, 1999, AM J EPIDEMIOL, V149, P887; MILBURN A, 2002, TACKLING HLTH INEQUA; MILIO N, 2000, PUBLIC HLTH MARKET F; PORTER D, 1992, HIST SCI, V30, P137, DOI 10.1177/007327539203000202; POWLES J, 2002, OXFORD TXB PUBLIC HL; RAEBURN J, 2003, GLOBAL PUBLIC HLTH N; Roberts M, 2002, LANCET, V359, P1055, DOI 10.1016/S0140-6736(02)08097-2; Sahn DE, 2003, WORLD DEV, V31, P23, DOI 10.1016/S0305-750X(02)00121-3; SCUTCHFIELD FD, 2003, GLOBAL PUBLIC HLTH N; VINOGRADOV NA, 1947, HLTH PROTECTION WORK; Waitzkin H, 2001, LANCET, V358, P315, DOI 10.1016/S0140-6736(01)05488-5; WIKLER D, 2003, GLOBAL PUBLIC HLTH N; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; 2002, LANCET, V359, P2211	28	91	96	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2084	2086		10.1016/S0140-6736(04)16461-1	http://dx.doi.org/10.1016/S0140-6736(04)16461-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	830YJ	15207962				2022-12-28	WOS:000222159800026
J	Goldacre, MJ; Roberts, SE				Goldacre, MJ; Roberts, SE			Hospital admission for acute pancreatitis in an English population, 1963-98: database study of incidence and mortality	BRITISH MEDICAL JOURNAL			English	Article							ETIOLOGY; ENGLAND; COUNTY; EPIDEMIOLOGY; PATTERNS; DISEASES; SCOTLAND; AUDIT	Objectives To investigate trends in the incidence of acute pancreatitis resulting in admission to hospital, and mortality after admission, from 1963 to 1998. Design Analysis of hospital inpatient statistics for acute pancreatitis, linked to data from death certificates. Setting Southern England. Subjects 5312 people admitted to hospital with acute pancreatitis. Main outcome measures Incidence rates for admission to hospital, case fatality rates at 0-29 and 30-364 days after admission, and standardised mortality ratios at monthly intervals up to one year after admission. Results The incidence of acute pancreatitis with admission to hospital increased from 1963-98: age standardised incidence rates were 4.9 per 100 000 population in 1963-74,7.7 in 1975-86, and 9.8 in 1987-98. Age standardised case fatality rates within 30 days of admission were 14.2% in 1963-74,7.6% in 1975-86, and 6.7% in 1987-98. From 1975-98, standardised mortality ratios at 30 days were 30 in men and 31 in women (compared with the general population of equivalent age in the same period = 1), and they remained significantly increased until month 5 for men and month 6 for women. Conclusions Incidence rates for acute pancreatitis with admission to hospital rose in both men and women from 1963 to 1998, particularly among younger age groups. This probably reflects, at least in part, an increase in alcoholic pancreatitis. Mortality after admission has not declined since the 1970s. This presumably reflects the fact that no major innovations in the treatment of acute pancreatitis have been introduced. Pancreatitis remains a disease with a poor prognosis during the acute phase.	Univ Oxford, Unit Hlth Care Epidemiol, Dept Publ Hlth, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Unit Hlth Care Epidemiol, Dept Publ Hlth, Old Rd, Oxford OX3 7LF, England.	michael.goldacre@dphpc.ox.ac.uk						Appelros S, 1999, BRIT J SURG, V86, P465, DOI 10.1046/j.1365-2168.1999.01049.x; BOURKE JB, 1975, LANCET, V2, P967; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; Eland IA, 2000, SCAND J GASTROENTERO, V35, P1110; Floyd A, 2002, SCAND J GASTROENTERO, V37, P1461, DOI 10.1080/003655202762671369; Go Vay Liang W., 1994, P235; Gronroos JM, 1999, HEPATO-GASTROENTEROL, V46, P2572; Halvorsen FA, 1996, SCAND J GASTROENTERO, V31, P411, DOI 10.3109/00365529609006419; JOHNSON CD, 1991, GUT, V32, P1401, DOI 10.1136/gut.32.11.1401; LANKISCH PG, 1989, DIGESTION, V44, P20, DOI 10.1159/000199888; Lankisch PG, 2002, PANCREATOLOGY, V2, P469, DOI 10.1159/000064713; MANN DV, 1994, BRIT J SURG, V81, P890, DOI 10.1002/bjs.1800810632; McKay CJ, 1999, BRIT J SURG, V86, P1302, DOI 10.1046/j.1365-2168.1999.01246.x; MERO M, 1982, ANN CHIR GYNAECOL FE, V71, P126; *NAT STAT, 2001, LIV BRIT RES 2000 GE, P159; OSULLIVAN JN, 1972, GASTROENTEROLOGY, V62, P373; Secknus R, 2000, CHIRURG, V71, P249; THOMSON SR, 1987, BRIT J SURG, V74, P398, DOI 10.1002/bjs.1800740526; Tinto A, 2002, ALIMENT PHARM THER, V16, P2097, DOI 10.1046/j.1365-2036.2002.01367.x; Toh SKC, 2000, GUT, V46, P239, DOI 10.1136/gut.46.2.239; Tran D. D., 1994, Digestion, V55, P342; TRAPNELL JE, 1975, BRIT MED J, V2, P179, DOI 10.1136/bmj.2.5964.179; WILSON C, 1990, BRIT J SURG, V77, P731, DOI 10.1002/bjs.1800770705; [No title captured]	24	157	162	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	2004	328	7454					1466	1469		10.1136/bmj.328.7454.1466	http://dx.doi.org/10.1136/bmj.328.7454.1466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205290	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000222244600015
J	Tsokos, GC				Tsokos, GC			B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Walter Reed Army Inst Res, Silver Spring, MD 20910 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Tsokos, GC (corresponding author), Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.		tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360				Shlomchik MJ, 2001, NAT REV IMMUNOL, V1, P147, DOI 10.1038/35100573; Silverman GJ, 2003, ARTHRITIS RHEUM-US, V48, P1484, DOI 10.1002/art.10947; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109	3	63	69	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2546	2548		10.1056/NEJMp048114	http://dx.doi.org/10.1056/NEJMp048114			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201410				2022-12-28	WOS:000222054700004
J	Zhang, KQ; Liu, XY				Zhang, KQ; Liu, XY			In situ observation of colloidal monolayer nucleation driven by an alternating electric field	NATURE			English	Article							GROWTH	The nucleation of crystalline materials is a hotly debated subject in the physical sciences(1). Despite the emergence of several theories in recent decades(2-7), much confusion still surrounds the dynamic processes of nucleation(5-7). This has been due in part to the limitations of existing experimental evidence. Charged colloidal suspensions have been used as experimental model systems for the study of crystal nucleation and structural phase transitions(8-12), as their crystallization phase diagram is analogous to that of atomic and molecular systems, but they can be visualized using microscopy. Previously, three-dimensional imaging of colloidal nucleation dynamics was achieved using confocal microscopy(13). However, the limited temporal resolution of the confocal microscope is of concern when trying to capture real-time colloidal crystal nucleation events. Moreover, as the thermodynamic driving force has remained undefined, data on key factors such as the critical nuclei size are at best semiquantitative(13). Here we present real-time direct imaging and quantitative measurements of the pre- and post-nucleation processes of colloidal spheres, and the kinetics of nucleation driven by an alternating electric field, under well-defined thermodynamic driving forces. Our imaging approach could facilitate the observation of other rarely observed phenomena, such as defect and grain-boundary formation(14) and the effects of foreign particles during crystallization(15). Furthermore, it may prove useful in identifying optical and biological technologies based on colloids(16-21).	Natl Univ Singapore, Dept Phys, Singapore 117542, Singapore	National University of Singapore	Liu, XY (corresponding author), Natl Univ Singapore, Dept Phys, 2 Sci Dr 3, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Zhang, Ke-Qin/C-2068-2008; Zhou, Weiqian/B-8991-2011; Liu, XY/E-5090-2010; Li, Jingliang/A-6039-2011	Liu, XY/0000-0002-4747-1251; Li, Jingliang/0000-0003-0709-2246				Abraham F.F, 1974, HOMOGENEOUS NUCL THE; Auer S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.015703; Bowles RK, 2000, J CHEM PHYS, V113, P4524, DOI 10.1063/1.1288802; Cacciuto A, 2004, NATURE, V428, P404, DOI 10.1038/nature02397; Chernov A.A., 1984, MODERN CRYSTALLOGRAP; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; Fowler R.H., 1960, STAT THERMODYNAMICS; Gasser U, 2001, SCIENCE, V292, P258, DOI 10.1126/science.1058457; Kashchiev D., 2000, NUCL BASIC THEORY AP; Khopade AJ, 2002, BIOMACROMOLECULES, V3, P1154, DOI 10.1021/bm025562k; Kumacheva E, 2002, ADV MATER, V14, P221, DOI 10.1002/1521-4095(20020205)14:3<221::AID-ADMA221>3.0.CO;2-V; LAAKSONEN A, 1995, ANNU REV PHYS CHEM, V46, P489, DOI 10.1146/annurev.pc.46.100195.002421; Larsen AE, 1997, NATURE, V385, P230, DOI 10.1038/385230a0; Liu JQ, 2001, BOT BULL ACAD SINICA, V42, P61; Liu XY, 1997, J CHEM PHYS, V106, P1870, DOI 10.1063/1.473325; Lucadamo G, 2003, SCIENCE, V300, P1272, DOI 10.1126/science.1083890; Lumsdon SO, 2003, APPL PHYS LETT, V82, P949, DOI 10.1063/1.1541114; McGraw R, 1996, PHYS REV LETT, V76, P2754, DOI 10.1103/PhysRevLett.76.2754; Norris DJ, 2001, ADV MATER, V13, P371, DOI 10.1002/1521-4095(200103)13:6<371::AID-ADMA371>3.0.CO;2-K; Palberg T, 1999, J PHYS-CONDENS MAT, V11, pR323, DOI 10.1088/0953-8984/11/28/201; Pan GS, 1997, PHYS REV LETT, V78, P3860, DOI 10.1103/PhysRevLett.78.3860; PUSEY PN, 1991, LIQUIDS FREEZING GLA, pCH5; SATO K, 2001, ADV CRYSTAL GROWTH; SKRIPOV VP, 1981, CURRENT TOPICS MAT S, V2, P328; Stiles PJ, 1998, J COLLOID INTERF SCI, V202, P562, DOI 10.1006/jcis.1998.5443; Trau M, 1996, SCIENCE, V272, P706, DOI 10.1126/science.272.5262.706; TRAU M, 1995, NATURE, V374, P437, DOI 10.1038/374437a0; Velev OD, 1999, LANGMUIR, V15, P3693, DOI 10.1021/la981729c; Yeh SR, 1997, NATURE, V386, P57, DOI 10.1038/386057a0; Yethiraj A, 2003, NATURE, V421, P513, DOI 10.1038/nature01328	30	182	187	4	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					739	743		10.1038/nature02630	http://dx.doi.org/10.1038/nature02630			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201905				2022-12-28	WOS:000222059900033
J	Kraus, M; Alimzhanov, MB; Rajewsky, N; Rajewsky, K				Kraus, M; Alimzhanov, MB; Rajewsky, N; Rajewsky, K			Survival of resting mature B lymphocytes depends on BCR signaling via the Ig alpha/beta heterodimer	CELL			English	Article							CELL ANTIGEN RECEPTOR; NF-KAPPA-B; CLONAL SELECTION; ACTIVATION MOTIF; IN-VIVO; MICE; BETA; IMMUNOGLOBULIN; IMMATURE; MATURATION	We previously showed that type I interferon-induced, Cre-mediated ablation of surface BCR expression in mature B cells through Ig-heavy chain deletion results in apoptosis of these cells. This led to the hypothesis that survival signals from the BCR are vital for mature B cells. Here, we test two critical assumptions of this model. First, we demonstrate loss of mature B cells upon induced mutation of a signaling module of the BCR, not precluding BCR surface expression. Second, we show that the cells are also lost upon BCR inactivation in the absence of an exogenous inducer like interferon, excluding that cell death depends on previous cellular activation by the latter. Kinetic data demonstrate that BCR-less mature B cells have a severely reduced lifespan, with a half-life of 3-6 days. Together these results establish that BCR signaling is required to keep resting mature B cells alive in vivo.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Cologne, Inst Genet, D-50931 Cologne, Germany; NYU, Dept Biol, New York, NY 10003 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Cologne; New York University	Rajewsky, K (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	rajewsky@cbr.med.harvard.edu		Rajewsky, Klaus/0000-0002-6633-6370; Rajewsky, Nikolaus/0000-0002-4785-4332	PHS HHS [R01-A1054636-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON J, 1991, P NATL ACAD SCI USA, V88, P2070, DOI 10.1073/pnas.88.6.2070; Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; Braun D, 2002, INT IMMUNOL, V14, P411, DOI 10.1093/intimm/14.4.411; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Gerondakis S, 2003, SEMIN IMMUNOL, V15, P159, DOI 10.1016/S1044-5323(03)00036-8; Gorelik L, 2003, J EXP MED, V198, P937, DOI 10.1084/jem.20030789; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hao ZY, 2001, J EXP MED, V194, P1151, DOI 10.1084/jem.194.8.1151; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kraus M, 1999, IMMUNITY, V11, P537, DOI 10.1016/S1074-7613(00)80129-6; Kraus M, 2001, J EXP MED, V194, P455, DOI 10.1084/jem.194.4.455; Krueger A, 2003, IMMUNOL REV, V193, P58, DOI 10.1034/j.1600-065X.2003.00047.x; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kurosaki T, 2002, CURR OPIN IMMUNOL, V14, P341, DOI 10.1016/S0952-7915(02)00344-8; Labrecque N, 2001, IMMUNITY, V15, P71, DOI 10.1016/S1074-7613(01)00170-4; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Levine MH, 2000, P NATL ACAD SCI USA, V97, P2743, DOI 10.1073/pnas.050552997; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Meffre E, 2002, P NATL ACAD SCI USA, V99, P11334, DOI 10.1073/pnas.172369999; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Pelanda R, 2002, J IMMUNOL, V169, P865, DOI 10.4049/jimmunol.169.2.865; Polic B, 2001, P NATL ACAD SCI USA, V98, P8744, DOI 10.1073/pnas.141218898; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reichlin A, 2001, J EXP MED, V193, P13, DOI 10.1084/jem.193.1.13; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Reth M, 2000, IMMUNOL REV, V176, P10; Ruland J, 2003, IMMUNOL REV, V193, P93, DOI 10.1034/j.1600-065X.2003.00049.x; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Smith SH, 2003, J IMMUNOL, V170, P5820, DOI 10.4049/jimmunol.170.12.5820; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Takahashi K, 1997, J IMMUNOL, V159, P1557; Torres RM, 1999, IMMUNITY, V11, P527, DOI 10.1016/S1074-7613(00)80128-4; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; Wang Y, 2002, AM J MED GENET, V108, P333, DOI 10.1002/ajmg.10296; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963	52	421	443	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					787	800		10.1016/j.cell.2004.05.014	http://dx.doi.org/10.1016/j.cell.2004.05.014			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186779	Bronze			2022-12-28	WOS:000222048400011
J	Pannetier, M; Fermon, C; Le Goff, G; Simola, J; Kerr, E				Pannetier, M; Fermon, C; Le Goff, G; Simola, J; Kerr, E			Femtotesla magnetic field measurement with magnetoresistive sensors	SCIENCE			English	Article							NOISE; MAGNETOMETER; ELECTRONICS; FEEDBACK	The measurement of magnetic fields in the femtotesla (fT, 10(-15) tesla) range is important for applications such as magnetometry, quantum computing, solid-state nuclear magnetic resonance, and magnetoencephalography. The only sensors capable of detecting these very small fields have been based on low-temperature superconducting quantum interference devices operating at 4.2 kelvin. We present a magnetic field sensor that combines a superconducting flux-to-field transformer with a low-noise giant magnetoresistive sensor. The sensor can be operated up to 77 kelvin. Our small-size prototype provides the capability of measuring 32 fT.	CEA Saclay, SPEC, DRECAM, F-91191 Gif Sur Yvette, France; Elekta Neuromag Oy, FIN-00511 Helsinki, Finland; Univ Dublin Trinity Coll, Dept Phys, SFI Lab, Dublin 2, Ireland	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Elekta; Trinity College Dublin	Pannetier, M (corresponding author), CEA Saclay, SPEC, DRECAM, F-91191 Gif Sur Yvette, France.	mp@drecam.saclay.cea.fr		Pannetier Lecoeur, Myriam/0000-0001-8348-1556				BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Barthelmess HJ, 2001, IEEE T APPL SUPERCON, V11, P657, DOI 10.1109/77.919430; Bowen M, 2003, APPL PHYS LETT, V82, P233, DOI 10.1063/1.1534619; Brandt EH, 2000, PHYS REV LETT, V85, P4164, DOI 10.1103/PhysRevLett.85.4164; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; DRUNG D, 1990, APPL PHYS LETT, V57, P406, DOI 10.1063/1.103650; Gallop J, 2003, SUPERCOND SCI TECH, V16, P1575, DOI 10.1088/0953-2048/16/12/055; HOOGE FN, 1976, PHYSICA B & C, V83, P14, DOI 10.1016/0378-4363(76)90089-9; Kominis IK, 2003, NATURE, V422, P596, DOI 10.1038/nature01484; Landau L. D., 1960, COURSE THEORETICAL P, V8; Linzen S, 2002, PHYSICA C, V372, P146, DOI 10.1016/S0921-4534(02)00640-8; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; PANNETIER M, UNPUB; Reutler P, 2000, PHYS REV B, V62, P11619, DOI 10.1103/PhysRevB.62.11619; SALMELIN R, 1994, NATURE, V368, P463, DOI 10.1038/368463a0; SEPPA H, 1991, IEEE T MAGN, V27, P2488, DOI 10.1109/20.133723; Viret M, 1997, EUROPHYS LETT, V39, P545, DOI 10.1209/epl/i1997-00391-2; Weinstock H., 2012, SQUID SENSORS FUNDAM, V329; 95628; 0528885; 5488295; 3508953	22	204	217	6	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1648	1650		10.1126/science.1096841	http://dx.doi.org/10.1126/science.1096841			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192222				2022-12-28	WOS:000221934300043
J	Sorensen, TLM; Moller, JV; Nissen, P				Sorensen, TLM; Moller, JV; Nissen, P			Phosphoryl transfer and calcium ion occlusion in the calcium pump	SCIENCE			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASE; CA2+ OCCLUSION; TRANSPORT; DOMAIN; SITES; DISSOCIATION; INTERMEDIATE; RESOLUTION; PROGRAM	A tight coupling between adenosine triphosphate (ATP) hydrolysis and vectorial ion transport has to be maintained by ATP-consuming ion pumps. We report two crystal structures of Ca2+-bound sarco(endo) plasmic reticulum Ca2+- adenosine triphosphatase (SERCA) at 2.6 and 2.9 angstrom resolution in complex with (i) a nonhydrolyzable ATP analog [adenosine (beta-gamma methylene) triphosphate] and (ii) adenosine diphosphate plus aluminum fluoride. SERCA reacts with ATP by an associative mechanism mediated by two Mg2+ ions to form an aspartyl-phosphorylated intermediate state (Ca-2- E1 similar to P). The conformational changes that accompany the reaction with ATP pull the transmembrane helices 1 and 2 and close a cytosolic entrance for Ca2+, thereby preventing backflow before Ca2+ is released on the other side of the membrane.	Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Moller, JV (corresponding author), Aarhus Univ, Dept Biophys, Ole Worms Alle 185, DK-8000 Aarhus C, Denmark.	jvm@biophys.au.dk; nissen@imsb.au.dk	Nissen, Poul/D-5774-2014; Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Nissen, Poul/0000-0003-0948-6628; Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; COAN C, 1994, BIOCHEMISTRY-US, V33, P3722, DOI 10.1021/bi00178a032; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LAUGER P, 1991, ELECTROGENIC PUMPS; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Sorensen T. J., UNPUB; SUMIDA M, 1974, J BIOCHEM-TOKYO, V75, P283, DOI 10.1093/oxfordjournals.jbchem.a130396; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; VILSEN B, 1992, J BIOL CHEM, V267, P25739; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	25	366	374	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1672	1675		10.1126/science.1099366	http://dx.doi.org/10.1126/science.1099366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192230				2022-12-28	WOS:000221934300051
J	Karpe, F; Frayn, KN				Karpe, F; Frayn, KN			The nicotinic acid receptor - a new mechanism for an old drug	LANCET			English	Review							NONESTERIFIED FATTY-ACIDS; PUMA-G; GLUCOSE; SUPPRESSION; METABOLISM; MORTALITY; ACIPIMOX		Univ Oxford, Churchill Hosp, Nuffield Dept Clin Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England	University of Oxford	Karpe, F (corresponding author), Univ Oxford, Churchill Hosp, Nuffield Dept Clin Med, Oxford Ctr Diabet Endocrinol & Metab, S Parks Rd, Oxford OX3 7LJ, England.	Fredrik.Karpe@ocdem.ox.ac.uk		Karpe, Fredrik/0000-0002-2751-1770				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; Beysen C, 2002, DIABETOLOGIA, V45, P1533, DOI 10.1007/s00125-002-0964-9; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1962, ACTA MED SCAND, V172, P641; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CARLSON LA, 1964, LIFE SCI, V3, P867, DOI 10.1016/0024-3205(64)90149-3; Charles MA, 1997, DIABETOLOGIA, V40, P1101, DOI 10.1007/s001250050793; DAVOREN PM, 1995, DIABETES NUTR METAB, V8, P17; Frayn KN, 2003, BIOCHEM SOC T, V31, P1115, DOI 10.1042/BST0311115; FULCHER GR, 1992, DIABETES, V41, P1400, DOI 10.2337/diabetes.41.11.1400; GREENOUGH WB, 1967, LANCET, V2, P1334; Hawkins M, 2003, DIABETES, V52, P2748, DOI 10.2337/diabetes.52.11.2748; KUMAR S, 1994, LANCET, V343, P1073, DOI 10.1016/S0140-6736(94)90184-8; Lafontan M, 2003, TRENDS PHARMACOL SCI, V24, P276, DOI 10.1016/S0165-6147(03)00132-9; Lorenzen A, 2001, MOL PHARMACOL, V59, P349, DOI 10.1124/mol.59.2.349; MANN CJ, 1991, J CLIN INVEST, V88, P2059, DOI 10.1172/JCI115535; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; PAOLISSO G, 1995, DIABETOLOGIA, V38, P1213, DOI 10.1007/BF00422371; RANDLE PJ, 1963, LANCET, V1, P785; Rubic T, 2004, BIOCHEM PHARMACOL, V67, P411, DOI 10.1016/j.bcp.2003.09.014; Schaub A, 2001, EUR J IMMUNOL, V31, P3714, DOI 10.1002/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; WORM D, 1994, J CLIN ENDOCR METAB, V78, P717, DOI 10.1210/jc.78.3.717	26	141	151	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1892	1894		10.1016/S0140-6736(04)16359-9	http://dx.doi.org/10.1016/S0140-6736(04)16359-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183629				2022-12-28	WOS:000221822300023
J	Marwick, C				Marwick, C			Mother accused of murder after refusing caesarean section	BRITISH MEDICAL JOURNAL			English	News Item																			0	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					663	663		10.1136/bmj.328.7441.663-b	http://dx.doi.org/10.1136/bmj.328.7441.663-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15206080	Green Published			2022-12-28	WOS:000220392700012
J	Cohen, HY; Miller, C; Bitterman, KJ; Wall, NR; Hekking, B; Kessler, B; Howitz, KT; Gorospe, M; de Cabo, R; Sinclair, DA				Cohen, HY; Miller, C; Bitterman, KJ; Wall, NR; Hekking, B; Kessler, B; Howitz, KT; Gorospe, M; de Cabo, R; Sinclair, DA			Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase	SCIENCE			English	Article							LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; AGING PROCESS; APOPTOSIS; P53; SENESCENCE; LONGEVITY; KU70; NAD; BAX	A major cause of aging is thought to result from the cumulative effects of cell loss over time. In yeast, caloric restriction (CR) delays aging by activating the Sir2 deacetylase. Here we show that expression of mammalian Sir2 (SIRT1) is induced in CR rats as well as in human cells that are treated with serum from these animals. Insulin and insulin-like growth factor 1 (IGF-1) attenuated this response. SIRT1 deacetylates the DNA repair factor Ku70, causing it to sequester the proapoptotic factor Bax away from mitochondria, thereby inhibiting stress-induced apoptotic cell death. Thus, CR could extend life-span by inducing SIRT1 expression and promoting the long-term survival of irreplaceable cells.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; BIOMOL Res Labs, Plymouth Meeting, PA 19462 USA; NIA, Cellular & Mol Biol Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; NIA, Lab Expt Gerontol, Gerontol Res Ctr, Baltimore, MD 21224 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	david_sinclair@hms.harvard.edu	de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/E-7996-2010; Wall, Nathan R./H-7368-2015; Kessler, Benedikt/AAY-8614-2021; de Cabo, Rafael/J-5230-2016	de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0003-2830-5693; Wall, Nathan R./0000-0002-3235-4386; Kessler, Benedikt/0000-0002-8160-2446; Sinclair, David/0000-0002-9936-436X; Cohen, Haim Y./0000-0002-6613-8710; de Cabo, Rafael/0000-0002-3354-2442	NATIONAL CANCER INSTITUTE [F32CA097802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000368, R01AG019972, Z01AG000511, R01AG019719, R37AG028730, P01AG027916, R01AG028730] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA097802] Funding Source: Medline; NIA NIH HHS [AG19972-02, R01 AG019719, R37 AG028730, R01 AG019972, R01 AG028730, P01 AG027916, AG19719-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Ando K, 2002, MICROSC RES TECHNIQ, V59, P293, DOI 10.1002/jemt.10207; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BRUNET A, 2004, SCIENCE, V203, P530; Campisi J, 2003, EXP GERONTOL, V38, P5, DOI 10.1016/S0531-5565(02)00152-3; COHEN HT, UNPUB; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; ECABO R, 2003, EXP GERONTOL, V38, P631; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Zhang YP, 2002, MECH AGEING DEV, V123, P245, DOI 10.1016/S0047-6374(01)00349-9	24	1515	1614	3	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					390	392		10.1126/science.1099196	http://dx.doi.org/10.1126/science.1099196			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15205477				2022-12-28	WOS:000222662400036
J	Hembacher, S; Giessibl, FJ; Mannhart, J				Hembacher, S; Giessibl, FJ; Mannhart, J			Force microscopy with light-atom probes	SCIENCE			English	Article							SILICON (111)-(7X7) SURFACE; ELECTRONIC-STRUCTURE; RESOLUTION	The charge distribution in atoms with closed electron shells is spherically symmetric, whereas atoms with partially filled shells can form covalent bonds with pointed lobes of increased charge density. Covalent bonding in the bulk can also affect surface atoms, leading to four tiny humps spaced by less than 100 picometers in the charge density of adatoms on a (001) tungsten surface. We imaged these charge distributions by means of atomic force microscopy with the use of a light-atom probe (a graphite atom), which directly measured high-order force derivatives of its interaction with a tungsten tip. This process revealed features with a lateral distance of only 77 picometers.	Univ Augsburg, Inst Phys, D-86135 Augsburg, Germany	University of Augsburg	Giessibl, FJ (corresponding author), Univ Augsburg, Inst Phys, D-86135 Augsburg, Germany.	franz.giessibl@physik.uni-augsburg.de	Giessibl, Franz J/K-8022-2013	Giessibl, Franz J/0000-0002-5585-1326; Mannhart, Jochen/0000-0001-6331-2640				ALBRECHT TR, 1987, J APPL PHYS, V62, P2599, DOI 10.1063/1.339435; ALBRECHT TR, 1991, J APPL PHYS, V69, P668, DOI 10.1063/1.347347; Ashcroft N.W., 1976, SOLID STATE PHYS; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG GK, 1987, PHYS SCRIPTA, VT19A, P53, DOI 10.1088/0031-8949/1987/T19A/008; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; Chen C. J., 1993, INTRO SCANNING TUNNE; Durig U, 1999, APPL PHYS LETT, V75, P433, DOI 10.1063/1.124399; Durig U, 2000, APPL PHYS LETT, V76, P1203, DOI 10.1063/1.125983; Durig U, 2000, NEW J PHYS, V2, P51, DOI 10.1088/1367-2630/2/1/005; Eguchi T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.266105; Feynman RP, 1939, PHYS REV, V56, P340, DOI 10.1103/PhysRev.56.340; FINK HW, 1986, IBM J RES DEV, V30, P460, DOI 10.1147/rd.305.0460; Garcia R, 2002, SURF SCI REP, V47, P197, DOI 10.1016/S0167-5729(02)00077-8; Giessibl FJ, 2000, SCIENCE, V289, P422, DOI 10.1126/science.289.5478.422; Giessibl FJ, 2000, APPL PHYS LETT, V76, P1470, DOI 10.1063/1.126067; GIESSIBL FJ, 1995, SCIENCE, V267, P68, DOI 10.1126/science.267.5194.68; Hembacher S, 2003, P NATL ACAD SCI USA, V100, P12539, DOI 10.1073/pnas.2134173100; HEMBACHER S, 2003, THESIS AUGSBURG U AU; HEMBACHER S, UNPUB; Herz M, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.045301; Hofer WA, 2003, REV MOD PHYS, V75, P1287, DOI 10.1103/RevModPhys.75.1287; Huang MH, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.256101; KITAMURA S, 1995, JPN J APPL PHYS 2, V34, pL145, DOI 10.1143/JJAP.34.L145; Lantz MA, 2000, PHYS REV LETT, V84, P2642, DOI 10.1103/PhysRevLett.84.2642; Lantz MA, 2001, SCIENCE, V291, P2580, DOI 10.1126/science.1057824; MATTHEISS LF, 1984, PHYS REV B, V29, P5372, DOI 10.1103/PhysRevB.29.5372; MIZES H, 1987, THESIS STANFORD U ST; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; OHNISHI S, 1989, SOLID STATE COMMUN, V71, P391, DOI 10.1016/0038-1098(89)90777-1; OWEN J, 1966, REP PROG PHYS, V29, P675, DOI 10.1088/0034-4885/29/2/306; PAULING L, 1948, NATURE CHEM BOND, pCH11; POSTERNAK M, 1980, PHYS REV B, V21, P5601, DOI 10.1103/PhysRevB.21.5601; STOLL E, 1984, SURF SCI, V143, pL411, DOI 10.1016/0039-6028(84)90540-5	34	128	130	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					380	383		10.1126/science.1099730	http://dx.doi.org/10.1126/science.1099730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15192156	Green Published			2022-12-28	WOS:000222662400033
J	Dawson, AJ				Dawson, AJ			Commentary: Methodological reasons for not gaining prior informed consent are sometimes justified	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Keele, Ctr Profess Eth, Keele ST5 5BG, Staffs, England	Keele University	Dawson, AJ (corresponding author), Univ Keele, Ctr Profess Eth, Keele ST5 5BG, Staffs, England.	a.j.dawson@keele.ac.uk		Dawson, Angus/0000-0002-8533-4987				Boter H, 2004, BRIT MED J, V329, P86, DOI 10.1136/bmj.38041.636250.EE; Boter H, 2003, BRIT MED J, V327, P284, DOI 10.1136/bmj.327.7409.284; Council for International Organizations of Medical Sciences WHO, 2002, INT ETH GUID BIOM RE; Dennis M, 2003, BRIT MED J, V327, P286, DOI 10.1136/bmj.327.7409.286; Doyal L, 1997, BMJ-BRIT MED J, V314, P1107, DOI 10.1136/bmj.314.7087.1107; McLean S, 1997, BRIT MED J, V314, P1076, DOI 10.1136/bmj.314.7087.1076; [No title captured]	7	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	2004	329	7457					87	87		10.1136/bmj.38112.692211.F7	http://dx.doi.org/10.1136/bmj.38112.692211.F7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15210570	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222645000024
J	Costanzo, M; Nishikawa, JL; Tang, XL; Millman, JS; Schub, O; Breitkreuz, K; Dewar, D; Rupes, I; Andrews, B; Tyers, M				Costanzo, M; Nishikawa, JL; Tang, XL; Millman, JS; Schub, O; Breitkreuz, K; Dewar, D; Rupes, I; Andrews, B; Tyers, M			CDK activity antagonizes Whi5, an inhibitor of G1/S transcription in yeast	CELL			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; CELL-CYCLE; RETINOBLASTOMA PROTEIN; SYSTEMATIC IDENTIFICATION; CLN2 TRANSCRIPTION; MASS-SPECTROMETRY; GENETIC-ANALYSIS; G(1) CONTROL; FACTOR SWI6; S-PHASE	Cyclin-dependent kinase (CDK) activity initiates the eukaryotic cell division cycle by turning on a suite of gene expression in late G1 phase. In metazoans, CDK-dependent phosphorylation of the retinoblastoma tumor suppressor protein (Rb) alleviates repression of E2F and thereby activates G1/S transcription. However, in yeast, an analogous G1 phase target of CDK activity has remained elusive. Here we show that the cell size regulator Whi5 inhibits G1/S transcription and that this inhibition is relieved by CDK-mediated phosphorylation. Deletion of WH15 bypasses the requirement for upstream activators of the G1/S transcription factors SBF/MBF and thereby accelerates the G1/S transition. Whi5 is recruited to G1/S promoter elements via its interaction with SBF/MBF in vivo and in vitro. In late G1 phase, CDK-dependent phosphorylation dissociates Whi5 from SBF and drives Whi5 out of the nucleus. Elimination of CDK activity at the end of mitosis allows Whi5 to reenter the nucleus to again repress G1/S transcription. These findings harmonize G1/S control in eukaryotes.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Tyers, M (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	tyers@mshri.on.ca	Tyers, Michael/ABE-3194-2021	Millman, Jonathan/0000-0002-1766-2348				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Baetz K, 2001, MOL CELL BIOL, V21, P6515, DOI 10.1128/MCB.21.19.6515-6528.2001; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geymonat M, 2004, MOL CELL BIOL, V24, P2277, DOI 10.1128/MCB.24.6.2277-2285.2004; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harrington LA, 1996, NUCLEIC ACIDS RES, V24, P558, DOI 10.1093/nar/24.4.558; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hinds PW, 2003, CANCER CELL, V3, P305, DOI 10.1016/S1535-6108(03)00084-9; Ho W, 1999, MOL CELL BIOL, V19, P5267; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Jeoung DI, 1998, MOL CELL BIOL, V18, P433, DOI 10.1128/MCB.18.1.433; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; Johnston JB, 1902, J COMP NEUROL, V12, P1, DOI 10.1002/cne.910120102; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Macpherson N, 2000, GENETICS, V154, P1561; Makhnevych T, 2003, CELL, V115, P813, DOI 10.1016/S0092-8674(03)00986-3; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nash RS, 2001, GENETICS, V157, P1469; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Queralt E, 2003, MOL CELL BIOL, V23, P3126, DOI 10.1128/MCB.23.9.3126-3140.2003; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sedgwick SG, 1998, J MOL BIOL, V281, P763, DOI 10.1006/jmbi.1998.1996; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; Sidorova JM, 2002, GENETICS, V160, P123; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Umen JG, 2001, GENE DEV, V15, P1652, DOI 10.1101/gad.892101; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wijnen H, 2002, MOL CELL BIOL, V22, P4402, DOI 10.1128/MCB.22.12.4402-4418.2002; Wijnen H, 1999, GENETICS, V153, P1131; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2	63	322	327	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					899	913		10.1016/j.cell.2004.05.024	http://dx.doi.org/10.1016/j.cell.2004.05.024			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210111	Bronze			2022-12-28	WOS:000222300200008
J	Kimel, AV; Kirilyuk, A; Tsvetkov, A; Pisarev, RV; Rasing, T				Kimel, AV; Kirilyuk, A; Tsvetkov, A; Pisarev, RV; Rasing, T			Laser-induced ultrafast spin reorientation in the antiferromagnet TmFeO3	NATURE			English	Article							RARE-EARTH ORTHOFERRITES	All magnetically ordered materials can be divided into two primary classes: ferromagnets(1,2) and antiferromagnets(3). Since ancient times, ferromagnetic materials have found vast application areas(4), from the compass to computer storage and more recently to magnetic random access memory and spintronics(5). In contrast, antiferromagnetic (AFM) materials, though representing the overwhelming majority of magnetically ordered materials, for a long time were of academic interest only. The fundamental difference between the two types of magnetic materials manifests itself in their reaction to an external magnetic field-in an antiferromagnet, the exchange interaction leads to zero net magnetization. The related absence of a net angular momentum should result in orders of magnitude faster AFM spin dynamics(6,7). Here we show that, using a short laser pulse, the spins of the antiferromagnet TmFeO3 can indeed be manipulated on a timescale of a few picoseconds, in contrast to the hundreds of picoseconds in a ferromagnet(8-12). Because the ultrafast dynamics of spins in antiferromagnets is a key issue for exchange-biased devices(13), this finding can expand the now limited set of applications for AFM materials.	Univ Nijmegen, NSRIM Inst, NL-6525 ED Nijmegen, Netherlands; AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia	Radboud University Nijmegen; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Ioffe Physical Technical Institute	Rasing, T (corresponding author), Univ Nijmegen, NSRIM Inst, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	th.rasing@sci.kun.nl	Kimel, Alexey/D-5112-2012; Kirilyuk, Andrei/D-7798-2012; Rasing, Theo/D-5207-2012	Kimel, Alexey/0000-0002-0709-042X; Kirilyuk, Andrei/0000-0003-1479-9872; Rasing, Theo/0000-0002-6656-5528				Andreev A. F., 1980, Soviet Physics - Uspekhi, V23, P21, DOI 10.1070/PU1980v023n01ABEH004859; BELOV KP, 1969, FIZ TVERD TELA+, V11, P935; BURZO E, 1996, LANDOLTBORNSTEIN N F, V27, P200; FERRE J, 1984, REP PROG PHYS, V47, P513, DOI 10.1088/0034-4885/47/5/002; Gerrits T, 2002, NATURE, V418, P509, DOI 10.1038/nature00905; HORNER H, 1968, PHYS REV LETT, V20, P845, DOI 10.1103/PhysRevLett.20.845; Ju GP, 1999, PHYS REV LETT, V82, P3705, DOI 10.1103/PhysRevLett.82.3705; Kimel AV, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.287401; Kimel AV, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.201103; KITTEL C, 1951, PHYS REV, V82, P565, DOI 10.1103/PhysRev.82.565; Landau LD., 1935, PHYS SOVIETUNION, V8, P153, DOI DOI 10.1016/B978-0-08-036364-6.50008-9; Landau LD., 1984, ELECTRODYNAMICS CONT; Neel, 1936, ANN PHYS-PARIS, V5, P232; Ney O, 2002, APPL PHYS B-LASERS O, V74, P741, DOI 10.1007/s00340-002-0926-4; Roukes ML, 2001, NATURE, V411, P747, DOI 10.1038/35081213; Schumacher HW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.017201; Schumacher HW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.017204; SHAPIRO SM, 1974, PHYS REV B, V10, P2014, DOI 10.1103/PhysRevB.10.2014; Skumryev V, 2003, NATURE, V423, P850, DOI 10.1038/nature01687; Stoner E. C., 1934, MAGNETISM MATTER; Tokura Y, 1999, J MAGN MAGN MATER, V200, P1, DOI 10.1016/S0304-8853(99)00352-2; Vonsovskii S. V., 1974, MAGNETISM; Weiss P, 1907, J PHYS, V6, P661, DOI [10.1051/jphystap:019070060066100, DOI 10.1051/JPHYSTAP:019070060066100]; WHITE RL, 1969, J APPL PHYS, V40, P1061, DOI 10.1063/1.1657530; YOSIDA K, 1998, THEORY MAGNETISM, P125	27	477	489	10	243	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					850	853		10.1038/nature02659	http://dx.doi.org/10.1038/nature02659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215858				2022-12-28	WOS:000222213000035
J	Bacaner, N; Stauffer, B; Boulware, DR; Walker, PF; Keystone, JS				Bacaner, N; Stauffer, B; Boulware, DR; Walker, PF; Keystone, JS			Travel medicine considerations for North American immigrants visiting friends and relatives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SUB-SAHARAN AFRICA; HEPATITIS-A; IMPORTED MALARIA; UNITED-STATES; DEVELOPING-COUNTRIES; PERSONAL PROTECTION; NONIMMUNE TRAVELERS; PRIMARY-CARE; DOUBLE-BLIND; HEALTH-CARE	Context In the United States, 10% of the population was born outside of its borders. Immigrants and their children frequently return to visit their homeland, referred to as visiting friends and relatives (VFRs). They account for a disproportionately high volume of international travel. Evidence Acquisition Searches of MEDLINE, World Health Organization, Centers for Disease Control and Prevention, International Society of Travel Medicine, and American Society of Tropical Medicine computerized databases, conference proceedings and abstracts, US Census Bureau, bibliographies of pertinent articles, and travel medicine texts. Priority was given to recent (1996-2003) evidence, addressing VFR travelers. General sources including travel medicine and immigrant health were also used. Evidence Synthesis Immigrants visiting friends and relatives experience excessive rates of travel-related morbidity and mortality. Lack of pretravel care is common due to patient and clinician barriers to care, preexisting health beliefs, and incomplete childhood vaccinations. Travel patterns increase risk with VFRs traveling to high-risk destinations. Susceptibility to infectious and noninfectious illnesses is often increased because of multiple preexisting medical problems and extremes of age. Infectious diseases differ in etiology and magnitude from those of traditional travelers. For example with malaria, VFRs are frequently prescribed inappropriate prophylaxis or take none at all, have longer stays, spend time in high-risk areas, and do not appropriately adhere to chemoprophylaxis regimens. Effective pretravel health advice, guidelines, and services for this high-risk population are essential. There are already a number of useful and readily available databases that may aid clinicians in providing optimal travel-related preventive and therapeutic care. Conclusions Immigrants who are visitors of friends and relatives in other countries account for a high volume of international travelers and are at markedly increased risk of travel-related illness. New strategies are needed to properly address the needs of VFR travelers. Pretravel services should be convenient, accessible, affordable, culturally competent, and if possible, located within clinics serving immigrant populations. Clinicians caring for VFRs should be knowledgeable about their travel-related risks and have access to regularly updated, detailed pretravel health information.	Univ Minnesota, Dept Internal Med, Community Univ Hlth Care Ctr, Minneapolis, MN USA; Univ Minnesota, Div Infect Dis & Internal Med, Minneapolis, MN USA; Ctr Int Hlth, St Paul, MN USA; Int Travel Clin, St Paul, MN USA; Univ Toronto, Dept Med, Div Infect Dis, Ctr Travel & Trop Med, Toronto, ON, Canada	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Toronto	Keystone, JS (corresponding author), Toronto Gen Hosp, Ctr Travel & Trop Med, 200 Elizabeth St,ES 9-411A, Toronto, ON M5G 2C4, Canada.	Jay.Keystone@utoronto.ca	Boulware, David R/GRS-0999-2022; Boulware, David R/AAF-7124-2021; Boulware, David/B-5516-2011; Boulware, David/I-4533-2013	Boulware, David R/0000-0002-4715-0060; 				Adachi JA, 2003, CLIN INFECT DIS, V37, P1165, DOI 10.1086/378746; Andrews CN, 1999, E AFR MED J, V76, P189; ANSDELL V, 2004, TRAVEL MED, P443; Backer H, 2001, J TRAVEL MED, V8, P247; Badrinath P, 1998, BRIT MED J, V316, P1746, DOI 10.1136/bmj.316.7146.1746a; Barbier HM, 2003, J TRAVEL MED, V10, P29, DOI 10.2310/7060.2003.30550; Barnett ED, 2003, J TRAVEL MED, V10, P11, DOI 10.2310/7060.2003.30663; Barnett ED, 2002, CLIN INFECT DIS, V35, P403, DOI 10.1086/341772; Batra Y, 2002, B WORLD HEALTH ORGAN, V80, P728; Bauer IL, 2003, J TRAVEL MED, V10, P350, DOI 10.2310/7060.2003.9366; BEHRENS RH, 1995, BRIT MED J, V311, P193, DOI 10.1136/bmj.311.6998.193a; BEHRENS RH, 2004, TRAVEL MED, P281; Boulware DR, 2003, AM J MED, V114, P288, DOI 10.1016/S0002-9343(02)01494-8; CAMPBELL H, 1987, J ROY COLL GEN PRACT, V37, P70; Casalino E, 2002, ARCH INTERN MED, V162, P1625, DOI 10.1001/archinte.162.14.1625; Castelli F, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P261; *CDCP, 2002, REP TUB US 2002; Chatchatee P, 2002, ASIAN PAC J ALLERGY, V20, P53; CHAUDHARY RK, 1981, CAN MED ASSOC J, V125, P1243; Christenson JC, 2001, J TRAVEL MED, V8, P1; Chuang SK, 2002, B WORLD HEALTH ORGAN, V80, P585; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Cobelens FGJ, 2000, LANCET, V356, P461, DOI 10.1016/S0140-6736(00)02554-X; Correia JD, 2001, J TRAVEL MED, V8, P263, DOI 10.2310/7060.2001.24033; De Schryver A, 1989, World Health Stat Q, V42, P90; Deardorff T L, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P146; Dijkshoorn H, 2003, Ned Tijdschr Geneeskd, V147, P658; dos Santos CC, 1999, CAN MED ASSOC J, V160, P195; Duval B, 2003, J TRAVEL MED, V10, P4, DOI 10.2310/7060.2003.30659; Eisenman DP, 2003, JAMA-J AM MED ASSOC, V290, P627, DOI 10.1001/jama.290.5.627; FISCHER PR, 2004, TRAVEL MED, P221; Hammond B, 2000, AM J INFECT CONTROL, V28, P340, DOI 10.1067/mic.2000.107276; HEDLEY AJ, 2001, TXB TRAVEL MED HLTH, P71; Hoge CW, 1998, CLIN INFECT DIS, V26, P341, DOI 10.1086/516303; HOLTZ TH, 2001, AM SOC TROP MED ANN; HORVATH LL, 2003, 52 AM SOC TROP MED H, P26; Hughes NJ, 2000, J TRAVEL MED, V7, P138; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; Jelinek T, 1999, LANCET, V354, P1609, DOI 10.1016/S0140-6736(99)01969-8; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Kolars JC, 2002, J TRAVEL MED, V9, P198, DOI 10.2310/7060.2002.24042; Koopmans M, 2004, INT J FOOD MICROBIOL, V90, P23, DOI 10.1016/S0168-1605(03)00169-7; Kosuwan Pensri, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P650; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; Krause E, 1999, J TRAVEL MED, V6, P163, DOI 10.1111/j.1708-8305.1999.tb00854.x; Ladhani S, 2003, PEDIATR INFECT DIS J, V22, P814, DOI 10.1097/01.inf.0000086401.13592.79; Laver SM, 2001, J TRAVEL MED, V8, P298, DOI 10.2310/7060.2001.23975; Leake JAD, 2002, B WORLD HEALTH ORGAN, V80, P342; Lee BW, 1998, TROP MED INT HEALTH, V3, P886; Lee KK, 2000, WESTERN J MED, V173, P325, DOI 10.1136/ewjm.173.5.325; LILLIE TH, 1988, J MED ENTOMOL, V25, P475, DOI 10.1093/jmedent/25.6.475; Lobato MN, 1998, AM J RESP CRIT CARE, V158, P1871, DOI 10.1164/ajrccm.158.6.9804106; Long R, 1999, CAN MED ASSOC J, V160, P1185; Macfarlane S, 2000, LANCET, V356, P841, DOI 10.1016/S0140-6736(00)02664-7; Mahon BE, 1996, JAMA-J AM MED ASSOC, V276, P307, DOI 10.1001/jama.276.4.307; McCarthy M, 2001, LANCET, V357, P862, DOI 10.1016/S0140-6736(05)71796-7; McInnes R, 2002, J TRAVEL MED, V9, P297, DOI 10.2310/7060.2002.30168; Mensah P, 2002, B WORLD HEALTH ORGAN, V80, P546; Minodier P, 2003, J TRAVEL MED, V10, P318, DOI 10.2310/7060.2003.9284; Morris JG, 2003, CLIN INFECT DIS, V37, P272, DOI 10.1086/375600; NAGY G, 1984, J MED VIROL, V13, P93, DOI 10.1002/jmv.1890130111; Newton P, 2001, LANCET, V357, P1948, DOI 10.1016/S0140-6736(00)05085-6; Newton PN, 2002, BRIT MED J, V324, P800, DOI 10.1136/bmj.324.7341.800; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; Pancharoen C, 2001, WILD ENVIRON MED, V12, P239, DOI 10.1580/1080-6032(2001)012[0239:REITC]2.0.CO;2; Petersen E, 2000, J TRAVEL MED, V7, P79; PHANUPHAK P, 1994, ANN MED INTERNE, V145, P409; Poovorawan Y, 2000, ASIAN PAC J ALLERGY, V18, P249; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Robbins JB, 2003, B WORLD HEALTH ORGAN, V81, P745; Ruttimann RW, 2002, J TRAVEL MED, V9, P220; Ryan ET, 2000, NEW ENGL J MED, V342, P1716, DOI 10.1056/NEJM200006083422306; Sawayama Y, 1999, J Epidemiol, V9, P350; Saywell T, 2002, FAR E EC REV    0221, V165, P34; Schlagenhauf P, 2003, BMJ-BRIT MED J, V327, P1078, DOI 10.1136/bmj.327.7423.1078; Schlagenhauf P, 2003, J TRAVEL MED, V10, P106, DOI 10.2310/7060.2003.31764; SCHLAGENHAUF P, 1994, J TROP MED HYG, V97, P151; SCHRECK CE, 1989, J AM MOSQUITO CONTR, V5, P247; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; SILVERS MJ, 2001, AM SOC TROP MED ANN; Stauffer WM, 2004, J TRAVEL MED, V11, P157; Stauffer WM, 2002, PRIMARY CARE, V29, P879, DOI 10.1016/S0095-4543(02)00035-0; Stauffer WM, 2001, J TRAVEL MED, V8, P254; Steffen R, 2003, J TRAVEL MED, V10, P38, DOI 10.2310/7060.2003.30672; Steffen R, 1999, JAMA-J AM MED ASSOC, V281, P811, DOI 10.1001/jama.281.9.811; STEINBERG E, 2000, AM SOC TROP MED HYG, V60; Strine TW, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e15; Tasbakan MI, 2003, TROP DOCT, V33, P151; Taylor RB, 2001, LANCET, V357, P1933, DOI 10.1016/S0140-6736(00)05065-0; Thomson MM, 2001, CLIN INFECT DIS, V32, P1732, DOI 10.1086/320764; *UN DEP EC SOC AFF, 2002, INT MIGR REP 2002; *US BUR CENS, 2001, PROF BORN OUTS US PO; *US DEP COMM, 2002 PROF US RES TRA; *US DEP HHS, 2003, HLTH INF INT TRAV 20; *US DEP HOM SEC, 2003, YB IMM STAT 2002; Valerio L, 2003, Aten Primaria, V32, P330; von Sonnenburg F, 2000, LANCET, V356, P133, DOI 10.1016/S0140-6736(00)02451-X; Walker PF, 1999, MED CLIN N AM, V83, P1103; Wellems TE, 2003, NEW ENGL J MED, V349, P1496, DOI 10.1056/NEJMp038127; White C G, 2001, J Sch Nurs, V17, P258; *WHO, 55 WORLD HLTH ASS GL; *WHO, 2002, 104 WHO; WHO, 2003, WHO COMM DIS SURV RE; *WHO, 2003, PREV HLTH CAR ASS HI; *WHO, 2001, EM W135 MEN DIS REP; *WHO, 2001, 99 WHO; Winer L, 2002, J TRAVEL MED, V9, P227, DOI 10.2310/7060.2002.24202; World Health Organization, 2002, WHO TRADITIONAL MED, P1; World Health Organization, WHO INT TRAV HLTH; Young EJ, 2003, PRINCIPLES PRACTICE, P877; Zuckerman JN, 2002, BMJ-BRIT MED J, V325, P260, DOI 10.1136/bmj.325.7358.260; 1995, B WHO, V73, P215; [No title captured]; 2003, MMWR MORB MORTAL WKL, V52, P908; 1988, NETWORK, V10, P6; 2003, FDA CONSUMER MAGAZIN, V37, P7; 2003, WEEKLY EPIDEMIOLOGIC, V133, P294; 2002, MMWR MORB MORTAL WKL, V51, P921	119	163	167	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2856	2864		10.1001/jama.291.23.2856	http://dx.doi.org/10.1001/jama.291.23.2856			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199037				2022-12-28	WOS:000221962500032
J	Stevens, SM; Elliott, G; Chan, KJ; Egger, MJ; Ahmed, KM				Stevens, SM; Elliott, G; Chan, KJ; Egger, MJ; Ahmed, KM			Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							VEIN THROMBOSIS; COMPRESSION ULTRASONOGRAPHY; DIAGNOSTIC MANAGEMENT; IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; CLINICAL VALIDITY; INITIAL TREATMENT; LOWER-EXTREMITY; D-DIMER; HEPARIN	Background: Negative results on simplified compression ultrasonography cannot rule out symptomatic deep venous thrombosis (DVT) without further testing, such as repeated ultrasonography several days later. Repeated testing is costly and inconvenient, and patients are sometimes less likely to return for follow-up tests. Objective: To determine the rate of venous thromboembolism when anticoagulation is withheld in patients with symptoms of DVT of the leg after negative results on a single examination with comprehensive duplex ultrasonography. Design: Prospective clinical cohort study. Setting: Peripheral vascular laboratory of a tertiary care academic hospital. Patients: 445 consecutive patients in whom a first episode of symptomatic DVT was suspected. Intervention: The researchers examined the entire leg with comprehensive duplex ultrasonography, using compression and Doppler techniques. Anticoagulation was withheld from the group with negative results. Patients were observed for thromboembolic events for 3 months. Measurements: All patients who had new or progressive symptoms or signs of venous thromboembolism during follow-up underwent objective testing. Results: Comprehensive duplex ultrasonography yielded normal results in 384 patients (86.3%) and showed DVT in 61 patients (13.7%). Nineteen cases of DVT (31.1%) were isolated to the deep veins of the calf. Nine patients in the negative cohort (2.3%) were excluded from analysis because they received anticoagulation for reasons unrelated to venous thromboembolism. Three of 375 patients (0.80% [95% CI, 0.16% to 2.33%]) in the normal cohort had symptomatic venous thrombosis during the 3-month follow-up. All 384 patients in the negative cohort completed follow-up. Limitations: The study was conducted at a single tertiary care center by a peripheral vascular staff with substantial experience in duplex ultrasonography, which may limit the applicability of the results to other institutions. Pregnant patients were excluded. Conclusions: It is safe to withhold anticoagulation after negative results on comprehensive duplex ultrasonography in nonpregnant patients with a suspected first episode of symptomatic DVT of the leg. New or progressive symptoms should prompt further testing.	Univ Utah, LDS Hosp, Dept Med, Salt Lake City, UT 84143 USA; Franklin Sq Hosp Ctr, Baltimore, MD USA	Utah System of Higher Education; University of Utah	Stevens, SM (corresponding author), Univ Utah, LDS Hosp, Dept Med, 8th Ave & C St, Salt Lake City, UT 84143 USA.	scott.stevens@ihc.com		Egger, Marlene/0000-0001-8886-7837				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; Bates SM, 2003, ANN INTERN MED, V138, P787, DOI 10.7326/0003-4819-138-10-200305200-00006; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; Elias A, 2003, THROMB HAEMOSTASIS, V89, P221; Fraser JD, 1999, RADIOLOGY, V211, P9, DOI 10.1148/radiology.211.1.r99ap459; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Kraaijenhagen RA, 2002, ARCH INTERN MED, V162, P907, DOI 10.1001/archinte.162.8.907; Lensing Anthonie W. A., 1996, P115; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; Perrier A, 2001, ANN INTERN MED, V135, P88, DOI 10.7326/0003-4819-135-2-200107170-00008; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Schellong SM, 2003, THROMB HAEMOSTASIS, V89, P228; Schwarz T, 2002, CLIN APPL THROMB-HEM, V8, P45, DOI 10.1177/107602960200800106; Sumner DS, 1993, VASCULAR DIAGNOSIS, P785; TALBOT SR, 1988, SEMIN ULTRASOUND CT, V9, P295; VOGEL P, 1987, RADIOLOGY, V163, P747, DOI 10.1148/radiology.163.3.3554344; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Wolf B, 2000, BRIT J SURG, V87, P1525, DOI 10.1046/j.1365-2168.2000.01567.x; ZHOU XH, 1994, STAT MED, V13, P1737, DOI 10.1002/sim.4780131705	34	97	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					985	991		10.7326/0003-4819-140-12-200406150-00007	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197015				2022-12-28	WOS:000222055500001
J	Feinstein, P; Mombaerts, P				Feinstein, P; Mombaerts, P			A contextual model for axonal sorting into glomeruli in the mouse olfactory system	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; SENSORY NEURONS; GENE-EXPRESSION; BULB; MICE; VOMERONASAL; PROJECTIONS; EPITHELIUM; MAP; ORGANIZATION	No models fully account for how odorant receptors (ORs) function in the guidance of axons of olfactory sensory neurons (OSNs) to glomeruli in the olfactory bulb. Here, we use gene targeting in mice to demonstrate that the OR amino acid sequence imparts OSN axons with an identity that allows them to coalesce into glomeruli. Replacements between the coding regions of the M71 and M72 OR genes reroute axons to their respective glomeruli. A series of M71-M72 hybrid ORs uncover a spectrum of glomerular phenotypes, leading to the concept that the identity of OSN axons is revealed depending on what other axons are present. Naturally occurring amino acid polymorphisms in other ORs also produce distinct axonal identities. These critical amino acid residues are distributed throughout the protein and reside predominantly within transmembrane domains. We propose a contextual model for axon guidance in which ORs mediate homotypic interactions between like axons.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Feinstein, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	feinstp@rockefeller.edu; peter@rockefeller.edu	Zufall, Frank/AAE-5290-2021	Zufall, Frank/0000-0002-4383-8618				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P828; Conzelmann S, 2001, EUR J NEUROSCI, V14, P1623, DOI 10.1046/j.0953-816x.2001.01788.x; Cutforth T, 2003, CELL, V114, P311, DOI 10.1016/S0092-8674(03)00568-3; Ebrahimi FAW, 2000, CURR BIOL, V10, P219, DOI 10.1016/S0960-9822(00)00342-0; Feinstein P, 2004, CELL, V117, P833, DOI 10.1016/j.cell.2004.05.013; Ishii T, 2001, GENES CELLS, V6, P71, DOI 10.1046/j.1365-2443.2001.00398.x; Iwema CL, 2004, J NEUROSCI, V24, P356, DOI 10.1523/JNEUROSCI.1219-03.2004; Lane RP, 2001, P NATL ACAD SCI USA, V98, P7390, DOI 10.1073/pnas.131215398; Mohler WA, 1996, P NATL ACAD SCI USA, V93, P12423, DOI 10.1073/pnas.93.22.12423; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 2004, CURR OPIN NEUROBIOL, V14, P31, DOI 10.1016/j.conb.2004.01.014; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 2001, NAT NEUROSCI, V4, P1192, DOI 10.1038/nn751; Nakatani H, 2003, EUR J NEUROSCI, V18, P2425, DOI 10.1046/j.1460-9568.2003.02998.x; Norlin EM, 2001, MOL CELL NEUROSCI, V18, P283, DOI 10.1006/mcne.2001.1019; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Potter SM, 2001, J NEUROSCI, V21, P9713, DOI 10.1523/JNEUROSCI.21-24-09713.2001; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Royal SJ, 1999, J NEUROSCI, V19, P9856; St John JA, 2003, J COMP NEUROL, V464, P131, DOI 10.1002/cne.10777; Strotmann J, 2000, J NEUROSCI, V20, P6927, DOI 10.1523/JNEUROSCI.20-18-06927.2000; Taniguchi M, 2003, J NEUROSCI, V23, P1390, DOI 10.1523/JNEUROSCI.23-04-01390.2003; Treloar H, 1997, J NEUROBIOL, V32, P643, DOI 10.1002/(SICI)1097-4695(19970620)32:7<643::AID-NEU1>3.0.CO;2-4; Treloar HB, 2002, J NEUROSCI, V22, P2469, DOI 10.1523/JNEUROSCI.22-07-02469.2002; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Walz A, 2002, J NEUROSCI, V22, P4025, DOI 10.1523/JNEUROSCI.22-10-04025.2002; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Xie SY, 2000, MAMM GENOME, V11, P1070, DOI 10.1007/s003350010217; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; Zhang XM, 2004, GENOMICS, V83, P802, DOI 10.1016/j.ygeno.2003.10.009; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X	40	237	239	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					817	831		10.1016/j.cell.2004.05.011	http://dx.doi.org/10.1016/j.cell.2004.05.011			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186781	Bronze			2022-12-28	WOS:000222048400013
J	Apfel, CC; Korttila, K; Abdalla, M; Kerger, H; Turan, A; Vedder, I; Zernak, C; Danner, K; Jokela, R; Pocock, SJ; Trenkler, S; Kredel, M; Biedler, A; Sessler, DI; Roewer, N				Apfel, CC; Korttila, K; Abdalla, M; Kerger, H; Turan, A; Vedder, I; Zernak, C; Danner, K; Jokela, R; Pocock, SJ; Trenkler, S; Kredel, M; Biedler, A; Sessler, DI; Roewer, N		IMPACT Investigators	A factorial trial of six interventions for the prevention of postoperative nausea and vomiting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			SUPPLEMENTAL OXYGEN; COST-EFFECTIVENESS; ONDANSETRON; DROPERIDOL; EFFICACY; DEXAMETHASONE; ANESTHESIA; MANAGEMENT; EMPHYSEMA; REDUCE	BACKGROUND Untreated, one third of patients who undergo surgery will have postoperative nausea and vomiting. Although many trials have been conducted, the relative benefits of prophylactic antiemetic interventions given alone or in combination remain unknown. METHODS We enrolled 5199 patients at high risk for postoperative nausea and vomiting in a randomized, controlled trial of factorial design that was powered to evaluate interactions among as many as three antiemetic interventions. Of these patients, 4123 were randomly assigned to 1 of 64 possible combinations of six prophylactic interventions: 4 mg of ondansetron or no ondansetron; 4 mg of dexamethasone or no dexamethasone; 1.25 mg of droperidol or no droperidol; propofol or a volatile anesthetic; nitrogen or nitrous oxide; and remifentanil or fentanyl. The remaining patients were randomly assigned with respect to the first four interventions. The primary outcome was nausea and vomiting within 24 hours after surgery, which was evaluated blindly. Results Ondansetron, dexamethasone, and droperidol each reduced the risk of postoperative nausea and vomiting by about 26 percent. Propofol reduced the risk by 19 percent, and nitrogen by 12 percent; the risk reduction with both of these agents ( i.e., total intravenous anesthesia) was thus similar to that observed with each of the antiemetics. All the interventions acted independently of one another and independently of the patients' baseline risk. Consequently, the relative risks associated with the combined interventions could be estimated by multiplying the relative risks associated with each intervention. Absolute risk reduction, though, was a critical function of patients' baseline risk. CONCLUSIONS Because antiemetic interventions are similarly effective and act independently, the safest or least expensive should be used first. Prophylaxis is rarely warranted in low-risk patients, moderate-risk patients may benefit from a single intervention, and multiple interventions should be reserved for high-risk patients.	Univ Wurzburg, Wurzburg, Germany; Univ Louisville, Louisville, KY 40292 USA; Univ Helsinki, Cent Hosp, Helsinki, Finland; London Sch Hyg & Trop Med, London WC1, England; Univ Klin Mannheim, Mannheim, Germany; Trakya Univ Hosp, Edirne, Turkey; Bodelschwingsche Anstalten Bethel, Bielefeld, Germany; Kreiskrankenhaus Garmisch Partenkirchen, Garmisch Partenkirchen, Germany; Westpfalz Klinikum, Kaiserslautern, Germany; Reiman Univ Hosp, Presov, Slovakia; Univ Saarlandes Kliniken, Homburg, Germany	University of Wurzburg; University of Louisville; University of Helsinki; Helsinki University Central Hospital; University of London; London School of Hygiene & Tropical Medicine; Trakya University; Westpfalz-Klinikum GmbH; Universitatsklinikum des Saarlandes	Apfel, CC (corresponding author), Outcomes Res Inst, 501 E Broadway,Suite 210, Louisville, KY 40202 USA.	apfel@ponv.org	Sessler, Daniel/D-3504-2011; Jokela, Ritva/E-1286-2013; Sneyd, John/AFV-7886-2022; Sneyd, John Robert/B-2957-2012; Sneyd, John/AFV-7887-2022	Sessler, Daniel/0000-0001-9932-3077; Sneyd, John/0000-0003-3546-9856; Sneyd, John Robert/0000-0003-3546-9856; Sneyd, John/0000-0003-3546-9856; Kredel, Markus/0000-0003-2183-033X	NIGMS NIH HHS [GM 061655, R01 GM061655-03, R01 GM061655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2003, CONTROL CLIN TRIALS, V24, P736, DOI 10.1016/S0197-2456(03)00107-7; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; BREMNER WGM, 1993, BRIT J ANAESTH, V71, P296, DOI 10.1093/bja/71.2.296; Darkow T, 2001, PHARMACOTHERAPY, V21, P540, DOI 10.1592/phco.21.6.540.34543; Divatia JV, 1996, ANESTHESIOLOGY, V85, P1055, DOI 10.1097/00000542-199611000-00014; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Gan TJ, 2002, ANESTHESIOLOGY, V97, P287, DOI 10.1097/00000542-200207000-00059; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; Goll V, 2001, ANESTH ANALG, V92, P112, DOI 10.1097/00000539-200101000-00022; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Joris JL, 2003, BRIT J ANAESTH, V91, P857, DOI 10.1093/bja/aeg267; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kovac AL, 1999, J CLIN ANESTH, V11, P453, DOI 10.1016/S0952-8180(99)00067-7; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Lim BSL, 1999, ANAESTH INTENS CARE, V27, P371, DOI 10.1177/0310057X9902700407; Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; MELNICK B, 1989, ANESTH ANALG, V69, P748; Pierre S, 2002, CAN J ANAESTH, V49, P237, DOI 10.1007/BF03020521; Purhonen S, 2003, ANESTH ANALG, V96, P91, DOI 10.1097/00000539-200301000-00020; Schumann R, 1999, ANESTH ANALG, V89, P796; Scuderi PE, 2000, ANESTH ANALG, V91, P1408, DOI 10.1097/00000539-200012000-00020; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Sneyd JR, 1998, EUR J ANAESTH, V15, P433, DOI 10.1097/00003643-199807000-00009; Tang J, 1998, ANESTH ANALG, V86, P274, DOI 10.1097/00000539-199802000-00010; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P4, DOI 10.1034/j.1399-6576.2001.450102.x; Wang JJ, 2000, ANESTH ANALG, V91, P136, DOI 10.1097/00000539-200007000-00025; Watcha M.F., 2002, ANESTHESIOL CLIN N A, V20, P709; Watcha MF, 2000, ANESTHESIOLOGY, V92, P931, DOI 10.1097/00000542-200004000-00007	35	869	945	4	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2441	2451		10.1056/NEJMoa032196	http://dx.doi.org/10.1056/NEJMoa032196			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	827GH	15190136	Green Accepted			2022-12-28	WOS:000221887200003
J	Egan, CA; Florell, SR				Egan, CA; Florell, SR			Cicatricial pemphigoid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Egan, CA (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.								0	1	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2499	2499		10.1056/NEJMicm990299	http://dx.doi.org/10.1056/NEJMicm990299			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190142				2022-12-28	WOS:000221887200009
J	Kingston, T; Rossiter, SJ				Kingston, T; Rossiter, SJ			Harmonic-hopping in Wallacea's bats	NATURE			English	Article							GREATER HORSESHOE BATS; RHINOLOPHUS-FERRUMEQUINUM; SPECIATION	Evolutionary divergence between species is facilitated by ecological shifts, and divergence is particularly rapid when such shifts also promote assortative mating(1-3). Horseshoe bats are a diverse OldWorld family ( Rhinolophidae) that have undergone a rapid radiation in the past 5 million years(4). These insectivorous bats use a predominantly pure-tone echolocation call matched to an auditory fovea ( an over-representation of the pure-tone frequency in the cochlea and inferior colliculus(5,6)) to detect the minute changes in echo amplitude and frequency generated when an insect flutters its wings(7). The emitted signal is the accentuated second harmonic of a series in which the fundamental and remaining harmonics are filtered out(8). Here we show that three distinct, sympatric size morphs of the large-eared horseshoe bat (Rhinolophus philippinensis) echolocate at different harmonics of the same fundamental frequency. These morphs have undergone recent genetic divergence, and this process has occurred in parallel more than once(9). We suggest that switching harmonics creates a discontinuity in the bats' perception of available prey that can initiate disruptive selection(1). Moreover, because call frequency in horseshoe bats has a dual function in resource acquisition and communication, ecological selection on frequency might lead to assortative mating and ultimately reproductive isolation and speciation, regardless of external barriers to gene flow(1-3).	Boston Univ, Dept Geog, Boston, MA 02215 USA; Univ London, Sch Biol Sci, London E1 4NS, England; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	Boston University; University of London; University of Bristol	Kingston, T (corresponding author), Boston Univ, Dept Geog, Boston, MA 02215 USA.	tigga@bu.edu	Rossiter, Stephen J/E-2111-2011	Kingston, Tigga/0000-0003-3552-5352; Rossiter, Stephen/0000-0002-3881-4515	Natural Environment Research Council [NER/I/S/2002/00732] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Andrews MM, 2003, ACTA CHIROPTEROL, V5, P221, DOI 10.3161/001.005.0212; [Anonymous], 2008, AUSTR BATS; BRUNS V, 1976, J COMP PHYSIOL, V106, P77, DOI 10.1007/BF00606573; Cooper SJB, 1998, AUST J ZOOL, V46, P203, DOI 10.1071/ZO97056; Dawson K., 2000, Journal of Computing in Teacher Education, V17, P4; Fenton M.B., 1985, COMMUNICATION CHIROP; Francis Charles M., 1998, P169; HARTLEY DJ, 1988, J ACOUST SOC AM, V84, P1201, DOI 10.1121/1.396621; Houston R. D., 2004, ECHOLOCATION BATS DO, P339, DOI DOI 10.1016/0370-1573(95)00083-6; Jones G., 2004, ECHOLOCATION BATS DO, P345; KOBER R, 1990, J ACOUST SOC AM, V87, P882, DOI 10.1121/1.398898; LAWRENCE BD, 1982, J ACOUST SOC AM, V71, P585, DOI 10.1121/1.387529; LONG GR, 1975, J COMP PHYSIOL, V100, P211, DOI 10.1007/BF00614531; MATSUMURA S, 1981, J MAMMAL, V62, P20, DOI 10.2307/1380474; *NATO ADV STUD I M, 1966, COURS ET OTAN SYST S, V2, P939; Nichols RA, 2001, MOL ECOL, V10, P593, DOI 10.1046/j.1365-294x.2001.01204.x; Pye J. David, 1993, Bioacoustics, V4, P271; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Rossiter SJ, 1999, MOL ECOL, V8, P1959, DOI 10.1046/j.1365-294x.1999.00778-2.x; RUBSAMEN R, 1990, J COMP PHYSIOL A, V167, P771; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; Schluter D, 2001, TRENDS ECOL EVOL, V16, P372, DOI 10.1016/S0169-5347(01)02198-X; SCHNITZLER HU, 1987, RECENT ADV STUDY BAT, P226; SCHULLER G, 1979, J COMP PHYSIOL, V132, P47, DOI 10.1007/BF00617731; SERVENT AG, 2003, HORSESHOE BATS WORLD, pR12; SIMMONS NB, IN PRESS MAMMAL SPEC; Stanley HF, 1996, MOL BIOL EVOL, V13, P368, DOI 10.1093/oxfordjournals.molbev.a025596; Vater Marianne, 2000, P137, DOI 10.1017/CBO9780511541872.005; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7; WILKINSON GS, 1991, GENETICS, V128, P607	30	127	139	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					654	657		10.1038/nature02487	http://dx.doi.org/10.1038/nature02487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190351				2022-12-28	WOS:000221912600039
J	Pfister, DG; Benson, AB; Somerfield, MR				Pfister, DG; Benson, AB; Somerfield, MR			Clinical practice - Surveillance strategies after curative treatment of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; FOLLOW-UP; RANDOMIZED-TRIAL; RADICAL SURGERY; COLON-CANCER; CARCINOEMBRYONIC ANTIGEN; RESECTION; GUIDELINES; COST; CHEMOTHERAPY		Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, New York, NY 10021 USA; Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Amer Soc Clin Oncol, Canc Policy & Clin Affairs Dept, Alexandria, VA USA	Memorial Sloan Kettering Cancer Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; American Society of Clinical Oncology	Pfister, DG (corresponding author), Mem Hosp, Box 188,1275 York Ave, New York, NY 10021 USA.	pfisterd@mskcc.org						[Anonymous], 2003, J NATL COMPR CANC NE, V1, P40; [Anonymous], 2003, J NATL COMPR CANC NE, V1, P54; Benson AB, 2000, J CLIN ONCOL, V18, P3586, DOI 10.1200/JCO.2000.18.20.3586; Berman JM, 2000, LANCET, V355, P395, DOI 10.1016/S0140-6736(99)06552-6; Cooper GS, 1999, CANCER-AM CANCER SOC, V85, P2124, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2124::AID-CNCR5>3.0.CO;2-L; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; Deyo RA, 2002, ANNU REV PUBL HEALTH, V23, P23, DOI 10.1146/annurev.publhealth.23.092101.134534; Earle CC, 2003, ANN ONCOL, V14, P400, DOI 10.1093/annonc/mdg101; Figueredo A, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-26; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; GLIMELIUS B, 1992, J CLIN ONCOL, V10, P904, DOI 10.1200/JCO.1992.10.6.904; Goldberg RM, 1998, ANN INTERN MED, V129, P27, DOI 10.7326/0003-4819-129-1-199807010-00007; Graham RA, 1998, ANN SURG, V228, P59, DOI 10.1097/00000658-199807000-00009; Green RJ, 2002, ANN INTERN MED, V136, P261, DOI 10.7326/0003-4819-136-4-200202190-00005; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Helm James, 2003, Cancer Control, V10, P193; Jeffery GM, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002200; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kattlove H, 2003, CA-CANCER J CLIN, V53, P315; Kattlove H, 2003, CA-CANCER J CLIN, V53, P172, DOI 10.3322/canjclin.53.3.172; Kemeny N, 1999, NEW ENGL J MED, V341, P2039, DOI 10.1056/NEJM199912303412702; Kievit J, 2000, EUR J SURG ONCOL, V26, P322, DOI 10.1053/ejso.1999.0893; Kjeldsen BJ, 1997, BRIT J SURG, V84, P666; Kjeldsen BJ, 1997, INT J COLORECTAL DIS, V12, P329, DOI 10.1007/s003840050118; Kjeldsen BJ, 1999, SCAND J GASTROENTERO, V34, P509, DOI 10.1080/003655299750026254; Knopf KB, 2001, GASTROINTEST ENDOSC, V54, P563, DOI 10.1067/mge.2001.118949; LENNON T, 1995, NOTT INT COL CANC S; Loprinzi CL, 2000, J CLIN ONCOL, V18, P2345, DOI 10.1200/JCO.2000.18.11.2345; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; MCCALL JL, 1994, DIS COLON RECTUM, V37, P875, DOI 10.1007/BF02052591; OHLSSON B, 1995, DIS COLON RECTUM, V38, P619, DOI 10.1007/BF02054122; Pietra N, 1998, DIS COLON RECTUM, V41, P1127, DOI 10.1007/BF02239434; Plate S, 2001, ANN ONCOL, V12, P1053; Renehan AG, 2004, BRIT MED J, V328, P81, DOI 10.1136/bmj.328.7431.81; Renehan AG, 2002, BMJ-BRIT MED J, V324, P813, DOI 10.1136/bmj.324.7341.813; Rotondano G, 1997, BRIT J RADIOL, V70, P567, DOI 10.1259/bjr.70.834.9227247; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sandler RS, 2003, NEW ENGL J MED, V348, P1939; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; Schrag D, 1999, GASTROENTEROLOGY, V117, P1005, DOI 10.1016/S0016-5085(99)70359-8; Secco GB, 2002, EUR J SURG ONCOL, V28, P418, DOI 10.1053/ejso.2001.1250; Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8; Stiggelbout AM, 1997, BRIT J CANCER, V75, P914, DOI 10.1038/bjc.1997.161; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837; Willkomm P, 2000, J NUCL MED, V41, P1657; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1995, B WORLD HEALTH ORGAN, V73, P7; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 2003, J NATL COMPR CANC NE, V1, P72	52	107	113	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2375	2382		10.1056/NEJMcp010529	http://dx.doi.org/10.1056/NEJMcp010529			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175439				2022-12-28	WOS:000221754200008
J	Recker, M; Nee, S; Bull, PC; Kinyanjui, S; Marsh, K; Newbold, C; Gupta, S				Recker, M; Nee, S; Bull, PC; Kinyanjui, S; Marsh, K; Newbold, C; Gupta, S			Transient cross-reactive immune responses can orchestrate antigenic variation in malaria	NATURE			English	Article							VARIANT SURFACE-ANTIGENS; PLASMODIUM-FALCIPARUM INFECTIONS; MATHEMATICAL-MODEL; ANTIBODY-RESPONSES; CHILDREN; ERYTHROCYTES; DYNAMICS; TRYPANOSOMES; PROTECTION; SELECTION	The malaria parasite Plasmodium falciparum has evolved to prolong its duration of infection by antigenic variation of a major immune target on the surface of the infected red blood cell. This immune evasion strategy depends on the sequential, rather than simultaneous, appearance of immunologically distinct variants. Although the molecular mechanisms by which a single organism switches between variants are known in part(1-3), it remains unclear how an entire population of parasites within the host can synchronize expression to avoid rapidly exhausting the variant repertoire. Here we show that short-lived, partially cross-reactive immune responses to parasite-infected erythrocyte surface antigens can produce a cascade of sequentially dominant antigenic variants, each of which is the most immunologically distinct from its preceding types. This model reconciles several previously unexplained and apparently conflicting epidemiological observations by demonstrating that individuals with stronger cross-reactive immune responses can, paradoxically, be more likely to sustain chronic infections. Antigenic variation has always been seen as an adaptation of the parasite to evade host defence: we show that the coordination necessary for the success of this strategy might be provided by the host.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Edinburgh, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 9DS, England; Kenya Govt Med Res Ctr, Kilifi, Kenya	University of Oxford; University of Edinburgh; University of Oxford; Kenya Medical Research Institute	Gupta, S (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	sunetra.gupta@zoology.ox.ac.uk		Bull, Peter/0000-0002-7674-6752; Recker, Mario/0000-0001-9489-1315				AGUR Z, 1989, P NATL ACAD SCI USA, V86, P9626, DOI 10.1073/pnas.86.23.9626; Antia R, 1996, P NATL ACAD SCI USA, V93, P985, DOI 10.1073/pnas.93.3.985; Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991; Bull PC, 1999, INFECT IMMUN, V67, P733, DOI 10.1128/IAI.67.2.733-739.1999; Bull PC, 2002, J INFECT DIS, V185, P1688, DOI 10.1086/340420; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Chattopadhyay R, 2003, INFECT IMMUN, V71, P597, DOI 10.1128/IAI.71.2.597-604.2003; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Dodoo D, 2001, INFECT IMMUN, V69, P3713, DOI 10.1128/IAI.69.6.3713-3718.2001; Frank SA, 1999, P ROY SOC B-BIOL SCI, V266, P1397, DOI 10.1098/rspb.1999.0793; Gamain B, 2001, P NATL ACAD SCI USA, V98, P2664, DOI 10.1073/pnas.041602598; Giha HA, 1999, INFECT IMMUN, V67, P4092, DOI 10.1128/IAI.67.8.4092-4098.1999; Giha HA, 2000, IMMUNOL LETT, V71, P117, DOI 10.1016/S0165-2478(99)00173-X; Gog JR, 2002, P NATL ACAD SCI USA, V99, P17209, DOI 10.1073/pnas.252512799; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; Haraguchi Y, 1997, PHILOS T R SOC B, V352, P11, DOI 10.1098/rstb.1997.0002; Kinyanjui SM, 2003, J INFECT DIS, V187, P667, DOI 10.1086/373994; KOSINSKI RJ, 1980, PARASITOLOGY, V80, P343, DOI 10.1017/S0031182000000809; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; Molineaux L, 2001, PARASITOLOGY, V122, P379, DOI 10.1017/S0031182001007533; Molineaux L, 1980, THE GARKI PROJECT; Newbold CI, 1999, CURR OPIN MICROBIOL, V2, P420, DOI 10.1016/S1369-5274(99)80074-5; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; Ofori MF, 2002, INFECT IMMUN, V70, P2982, DOI 10.1128/IAI.70.6.2982-2988.2002; Paget-McNicol S, 2002, PARASITOLOGY, V124, P225, DOI 10.1017/S0031182001001160; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Tebo AE, 2002, AM J TROP MED HYG, V67, P597, DOI 10.4269/ajtmh.2002.67.597	28	130	132	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					555	558		10.1038/nature02486	http://dx.doi.org/10.1038/nature02486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175751				2022-12-28	WOS:000221767700038
J	Wu, LJ; Errington, J				Wu, LJ; Errington, J			Coordination of cell division and chromosome segregation by a nucleoid occlusion protein in Bacillus subtillis	CELL			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; PROPER PLACEMENT; SITE SELECTION; MINICELL LOCUS; RING FORMATION; MINE RING; FTSZ; GENE; LOCALIZATION	A range of genetical and physiological experiments have established that diverse bacterial cells possess a function called nucleoid occlusion, which acts to prevent cell division in the vicinity of the nucleoid. We have identified a specific effector of nucleoid occlusion in Bacillus subtilis, Noc (YyaA), as an inhibitor of division that is also a nonspecific DNA binding protein. Under various conditions in which the cell cycle is perturbed, Noc prevents the division machinery from assembling in the vicinity of the nucleoid. Unexpectedly, cells lacking both Noc and the Min system (which prevents division close to the cell poles) are blocked for division, apparently because they establish multiple nonproductive accumulations of division proteins. The results help to explain how B. subtilis specifies the division site under a range of conditions and how it avoids catastrophic breakage of the chromosome by division through the nucleoid.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Wu, LJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.	jeff.errington@path.ox.ac.uk	Errington, Jeff/G-1832-2011	Errington, Jeff/0000-0002-6977-9388; Wu, Ling Juan/0000-0003-2432-8820				BROWN NC, 1971, J MOL BIOL, V59, P1, DOI 10.1016/0022-2836(71)90409-8; Cha JH, 1997, J BACTERIOL, V179, P1671, DOI 10.1128/jb.179.5.1671-1683.1997; Cook WR, 1999, J BACTERIOL, V181, P1900, DOI 10.1128/JB.181.6.1900-1905.1999; Daniel RA, 1996, J BACTERIOL, V178, P2343, DOI 10.1128/jb.178.8.2343-2350.1996; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; Edwards DH, 1997, MOL MICROBIOL, V24, P905, DOI 10.1046/j.1365-2958.1997.3811764.x; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; FOLEY M, 1989, MOL MICROBIOL, V3, P1329, DOI 10.1111/j.1365-2958.1989.tb00114.x; Fu XL, 2001, P NATL ACAD SCI USA, V98, P980, DOI 10.1073/pnas.031549298; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gueiros FJ, 2002, GENE DEV, V16, P2544, DOI 10.1101/gad.1014102; Hale CA, 2001, EMBO J, V20, P1563, DOI 10.1093/emboj/20.7.1563; Hamoen LW, 2003, J BACTERIOL, V185, P693, DOI 10.1128/JB.185.2.693-697.2003; Harry EJ, 1999, MOL MICROBIOL, V33, P33, DOI 10.1046/j.1365-2958.1999.01439.x; Harry EJ, 2001, MOL MICROBIOL, V40, P795, DOI 10.1046/j.1365-2958.2001.02370.x; Hu ZL, 1999, P NATL ACAD SCI USA, V96, P14819, DOI 10.1073/pnas.96.26.14819; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 2001, MOL CELL, V7, P1337, DOI 10.1016/S1097-2765(01)00273-8; Kawai Y, 2003, MOL MICROBIOL, V47, P1113, DOI 10.1046/j.1365-2958.2003.03360.x; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Margolin W, 2001, CURR OPIN MICROBIOL, V4, P647, DOI 10.1016/S1369-5274(01)00264-8; Marston AL, 1998, GENE DEV, V12, P3419, DOI 10.1101/gad.12.21.3419; Moriya S, 1998, MOL MICROBIOL, V29, P179, DOI 10.1046/j.1365-2958.1998.00919.x; MULDER E, 1989, J BACTERIOL, V171, P4303, DOI 10.1128/JB.171.8.4303-4314.1989; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; Pichoff S, 2002, EMBO J, V21, P685, DOI 10.1093/emboj/21.4.685; Quisel JD, 2001, J BACTERIOL, V183, P6573, DOI 10.1128/JB.183.22.6573-6578.2001; Rajagopalan S, 2003, TRENDS GENET, V19, P403, DOI 10.1016/S0168-9525(03)00149-5; Raskin DM, 1997, CELL, V91, P685, DOI 10.1016/S0092-8674(00)80455-9; Regamey A, 2000, MOL MICROBIOL, V38, P423, DOI 10.1046/j.1365-2958.2000.02130.x; Rowland SL, 1997, MOL MICROBIOL, V23, P295, DOI 10.1046/j.1365-2958.1997.2141580.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; Sharpe ME, 1998, J BACTERIOL, V180, P547, DOI 10.1128/JB.180.3.547-555.1998; Shih YL, 2003, P NATL ACAD SCI USA, V100, P7865, DOI 10.1073/pnas.1232225100; Sievers J, 2002, J BACTERIOL, V184, P1102, DOI 10.1128/jb.184.4.1102-1111.2002; WOLDRINGH CL, 1990, RES MICROBIOL, V141, P39, DOI 10.1016/0923-2508(90)90096-9; Woldringh CL, 2002, MOL MICROBIOL, V45, P17, DOI 10.1046/j.1365-2958.2002.02993.x; Wu LJ, 2003, MOL MICROBIOL, V49, P1463, DOI 10.1046/j.1365-2958.2003.03643.x; Yu XC, 2000, J BACTERIOL, V182, P6203, DOI 10.1128/JB.182.21.6203-6213.2000; Yu XC, 1999, MOL MICROBIOL, V32, P315, DOI 10.1046/j.1365-2958.1999.01351.x	43	302	309	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					915	925		10.1016/j.cell.2004.06.002	http://dx.doi.org/10.1016/j.cell.2004.06.002			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210112	Bronze			2022-12-28	WOS:000222300200009
J	Lindholm, LH				Lindholm, LH			Valsartan treatment of hypertension - does VALUE add value?	LANCET			English	Editorial Material							END-POINT REDUCTION; LOSARTAN INTERVENTION; TRIAL; RISK		Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden	Umea University	Lindholm, LH (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.	LarsH.Lindholm@fammed.umu.se						Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Kjeldsen SE, 2001, BLOOD PRESSURE, V10, P83, DOI 10.1080/08037050152112069; Lindholm LH, 2002, J HYPERTENS, V20, P1879, DOI 10.1097/00004872-200209000-00035; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; Yusuf S, 2000, NEW ENGL J MED, V342, P145	5	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2010	2011		10.1016/S0140-6736(04)16484-2	http://dx.doi.org/10.1016/S0140-6736(04)16484-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207946				2022-12-28	WOS:000222159800002
J	Bucchi, M; Neresini, F				Bucchi, M; Neresini, F			Biotechnology - Why are people hostile to biotechnologies?	SCIENCE			English	Editorial Material									Univ Trent, Dipartimento Sci Umana & Sociali, I-38100 Trent, Italy; Univ Padua, Dipartimento Sociol, I-35122 Padua, Italy	University of Trento; University of Padua	Bucchi, M (corresponding author), Univ Trent, Dipartimento Sci Umana & Sociali, Via Verdi 26, I-38100 Trent, Italy.	mbucchi@soc.unitn.it; federico.neresini@unipd.it	Bucchi, Massimiano/K-1824-2017	NERESINI, FEDERICO/0000-0003-3918-2588				Bucchi M, 2002, NATURE, V416, P261, DOI 10.1038/416261a	1	21	22	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1749	1749		10.1126/science.1095861	http://dx.doi.org/10.1126/science.1095861			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205516				2022-12-28	WOS:000222089500027
J	Mervis, J; Holden, C				Mervis, J; Holden, C			Great expectations on the job front - Introduction	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1829	1829		10.1126/science.304.5678.1829	http://dx.doi.org/10.1126/science.304.5678.1829			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205538				2022-12-28	WOS:000222089500052
J	Patel, R; Trampuz, A				Patel, R; Trampuz, A			Infections transmitted through musculoskeletal-tissue allografts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Coll Med, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Clin Microbiol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Patel, R (corresponding author), Mayo Clin, Coll Med, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA.		Trampuz, Andrej/K-9633-2013						0	38	40	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2544	2546		10.1056/NEJMp048090	http://dx.doi.org/10.1056/NEJMp048090			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201409				2022-12-28	WOS:000222054700003
J	Fortin, AH; Barnett, KG				Fortin, AH; Barnett, KG			Medical school curricula in spirituality and medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; ATTITUDES		Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Fortin, AH (corresponding author), Yale Univ, Sch Med, New Haven, CT 06510 USA.							Brokaw JJ, 2002, ACAD MED, V77, P876, DOI 10.1097/00001888-200209000-00013; Deloney L A, 2000, Acad Med, V75, P513, DOI 10.1097/00001888-200005000-00032; Graham-Pole J, 2001, ACAD MED, V76, P662, DOI 10.1097/00001888-200106000-00024; Graves Darci L, 2002, Acad Med, V77, P1167, DOI 10.1097/00001888-200211000-00035; Green ML, 1999, ACAD MED, V74, P686, DOI 10.1097/00001888-199906000-00017; Green ML, 2001, ANN INTERN MED, V135, P889, DOI 10.7326/0003-4819-135-10-200111200-00009; Hebert RS, 2003, ACAD MED, V78, P61, DOI 10.1097/00001888-200301000-00012; Hull SK, 2001, ACAD MED, V76, P520, DOI 10.1097/00001888-200105000-00053; *J TEMPL FDN, J TEMPL FDN SPIR HLT; King DE, 2004, TEACH LEARN MED, V16, P64, DOI 10.1207/s15328015tlm1601_13; Lie Desiree, 2002, Acad Med, V77, P1170, DOI 10.1097/00001888-200211000-00039; Lypson ML, 2002, ACAD MED, V77, pS10, DOI 10.1097/00001888-200210001-00004; Montgomery K, 2003, ACAD MED, V78, P958, DOI 10.1097/00001888-200310000-00003; Musick DW, 2003, ACAD PSYCHIATR, V27, P67, DOI 10.1176/appi.ap.27.2.67; Puchalski CM, 1998, ACAD MED, V73, P970, DOI 10.1097/00001888-199809000-00015; Quill Timothy E, 2003, J Palliat Med, V6, P365, DOI 10.1089/109662103322144682; Tang TS, 2002, ACAD MED, V77, P578, DOI 10.1097/00001888-200206000-00019	17	59	62	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2883	2883		10.1001/jama.291.23.2883	http://dx.doi.org/10.1001/jama.291.23.2883			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	828GT	15199044				2022-12-28	WOS:000221962500039
J	Reddy, KS				Reddy, KS			Cardiovascular disease in non-Western countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									All India Inst Med Sci, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Reddy, KS (corresponding author), All India Inst Med Sci, New Delhi, India.							[Anonymous], 1996, GLOBAL BURDEN DIS CO; Reddy KS, 2002, PUBLIC HEALTH NUTR, V5, P231, DOI 10.1079/PHN2001298; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	3	280	291	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2438	2440		10.1056/NEJMp048024	http://dx.doi.org/10.1056/NEJMp048024			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190135				2022-12-28	WOS:000221887200002
J	Lewis, CL; Coffroth, MA				Lewis, CL; Coffroth, MA			The acquisition of exogenous algal symbionts by an octocoral after bleaching	SCIENCE			English	Article							ZOOXANTHELLAE; DIVERSITY; ECOLOGY; CORALS; SYMBIODINIUM; SPECIFICITY; EVOLUTION	Episodes of coral bleaching (loss of the symbiotic dinoflagellates) and coral mortality have occurred with increasing frequency over the past two decades. Although some corals recover from bleaching events, the source of the repopulating symbionts is unknown. Here we show that after bleaching, the adult octocoral Briareum sp. acquire dinoflagellate symbionts (Symbiodinium sp.) from the environment. Uptake of exogenous symbionts provides a mechanism for response to changes in the environment and resilience in the symbiosis.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Coffroth, MA (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.	coffroth@buffalo.edu						Baker AC, 2001, NATURE, V411, P765, DOI 10.1038/35081151; Baker AC, 2004, CORAL HEALTH AND DISEASE, P177; Baker AC, 2003, ANNU REV ECOL EVOL S, V34, P661, DOI 10.1146/annurev.ecolsys.34.011802.132417; BILLINGHURST Z, 1997, P 8 INT COR REEF S, V2, P1291; Buddemeier RW, 2004, CORAL HEALTH AND DISEASE, P427; BUDDEMEIER RW, 1993, BIOSCIENCE, V43, P320, DOI 10.2307/1312064; Coffroth MA, 2001, MAR ECOL PROG SER, V222, P85, DOI 10.3354/meps222085; Davy SK, 1997, BIOL BULL, V192, P208, DOI 10.2307/1542715; Diekmann OE, 2002, MAR ECOL PROG SER, V227, P221, DOI 10.3354/meps227221; Douglas AE, 2003, MAR POLLUT BULL, V46, P385, DOI 10.1016/S0025-326X(03)00037-7; Goulet TL, 2003, MAR ECOL PROG SER, V250, P117, DOI 10.3354/meps250117; Muller-Parker Gisele, 1997, LIFE DEATH CORAL REE, p97 100; Muscatine L., 1990, P75; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; ROWAN R, 1995, P NATL ACAD SCI USA, V92, P2850, DOI 10.1073/pnas.92.7.2850; Rowan R, 1997, NATURE, V388, P265, DOI 10.1038/40843; Rowan R, 1998, J PHYCOL, V34, P407, DOI 10.1046/j.1529-8817.1998.340407.x; Santos SR, 2003, MAR BIOTECHNOL, V5, P130, DOI 10.1007/s10126-002-0076-9; Savage AM, 2002, MAR ECOL PROG SER, V244, P27, DOI 10.3354/meps244027; Stanley GD, 2003, EARTH-SCI REV, V60, P195, DOI 10.1016/S0012-8252(02)00104-6; Toller WW, 2001, BIOL BULL-US, V201, P360, DOI 10.2307/1543614; van Oppen MJH, 2001, P ROY SOC B-BIOL SCI, V268, P1759, DOI 10.1098/rspb.2001.1733; [No title captured]	23	100	106	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1490	1492		10.1126/science.1097323	http://dx.doi.org/10.1126/science.1097323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178798				2022-12-28	WOS:000221795800040
J	Wang, LY; Vysotsky, MO; Bogdan, A; Bolte, M; Bohmer, V				Wang, LY; Vysotsky, MO; Bogdan, A; Bolte, M; Bohmer, V			Multiple catenanes derived from calix[4] arenes	SCIENCE			English	Article							MOLECULAR MACHINES; CAPSULES; MOTORS	A multicatenane is described in which two belts consisting of four annelated rings attached to the wide rims of two calix[4]arenes are interwoven in such a way that each ring of one belt penetrates two adjacent rings of the other belt and vice versa. The key step of the synthesis of this [8]catenane is the exclusive formation of preorganized heterodimers between a multimacrocyclic tetraurea calix[ 4] arene and an "open-chain" tetraurea calix[4] arene containing eight omega-alkenyl groups. When a tetraurea calix[4] arene containing four alkenyl groups is used, a bis-[3]catenane is formed analogously.	Univ Mainz, Fachbereich Chem & Pharm, Abt Lehramt Chem, D-55099 Mainz, Germany; Univ Frankfurt, Inst Organ Chem, Fachbereich Chem & Pharmazeut Wissensch, D-60439 Frankfurt, Germany	Johannes Gutenberg University of Mainz; Goethe University Frankfurt	Bohmer, V (corresponding author), Univ Mainz, Fachbereich Chem & Pharm, Abt Lehramt Chem, Duesbergweg 10-14, D-55099 Mainz, Germany.	vboehmer@mail.uni-mainz.de	Wang, Leyong/B-3790-2012; Vysotsky, Myroslav O./D-8424-2012	Wang, Leyong/0000-0001-5775-3714; Vysotsky, Myroslav O./0000-0001-6724-8877				ASHTON PR, 1991, J CHEM SOC CHEM COMM, P1677, DOI 10.1039/c39910001677; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BOGDAN A, IN PRESS CHEM EUR J; Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Dietrich-Buchecker C., 1999, MOL CATENANES ROTAXA, P107; Kuck D, 1997, LIEBIGS ANN-RECL, P1043; Loren JC, 2003, ANGEW CHEM INT EDIT, V42, P5702, DOI 10.1002/anie.200352562; Rebek J, 2000, CHEM COMMUN, P637, DOI 10.1039/a910339m; Sauvage, 1999, MOL CATENANES ROTAXA; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Schalley CA, 2001, ACCOUNTS CHEM RES, V34, P465, DOI 10.1021/ar000179i; Voet D., 2002, FUNDAMENTALS BIOCH 2, V1st; Vysotsky MO, 2003, CHEM-EUR J, V9, P3375, DOI 10.1002/chem.200304912; Vysotsky MO, 2001, CHEM-EUR J, V7, P4403, DOI 10.1002/1521-3765(20011015)7:20<4403::AID-CHEM4403>3.0.CO;2-J; VYSOTSKY MO, IN PRESS CHEM COMMUN; WALBA DM, 1982, J AM CHEM SOC, V104, P3219, DOI 10.1021/ja00375a051; Wikoff WR, 2000, SCIENCE, V289, P2129, DOI 10.1126/science.289.5487.2129	18	166	167	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1312	1314		10.1126/science.1096688	http://dx.doi.org/10.1126/science.1096688			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166377				2022-12-28	WOS:000221669600051
J	Simon, MC				Simon, MC			Siah proteins, HIF prolyl hydroxylases, and the physiological response to hypoxia	CELL			English	Editorial Material							VHL; HIF-1-ALPHA; PATHWAY; ALPHA	New evidence suggests that at least two members of the family of hypoxia-inducible factor (HIF) prolyl hydroxylases that regulate HIF stability in response to oxygen (O-2) availability are also targeted for proteosome-dependent degradation by the E3 ubiquitin ligases Siah1a and Siah2. This preview examines cellular responses to O-2 deprivation (hypoxia) and the complexity of the regulation of the HIF O-2 sensing pathway in mammals.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine	Simon, MC (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Simon, Celeste/AAG-3941-2021					Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Schumacker PT, 2002, AM J PHYSIOL-LUNG C, V283, pL918, DOI 10.1152/ajplung.00205.2002; Semenza GL, 2000, GENE DEV, V14, P1983; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	10	20	24	1	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	2004	117	7					851	853		10.1016/j.cell.2004.06.010	http://dx.doi.org/10.1016/j.cell.2004.06.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210106	Bronze			2022-12-28	WOS:000222300200003
J	Imhoff, ML; Bounoua, L; Ricketts, T; Loucks, C; Harriss, R; Lawrence, WT				Imhoff, ML; Bounoua, L; Ricketts, T; Loucks, C; Harriss, R; Lawrence, WT			Global patterns in human consumption of net primary production	NATURE			English	Article							HUMAN APPROPRIATION; MODEL	The human population and its consumption profoundly affect the Earth's ecosystems(1,2). A particularly compelling measure of humanity's cumulative impact is the fraction of the planet's net primary production that we appropriate for our own use(3,4). Net primary production-the net amount of solar energy converted to plant organic matter through photosynthesis-can be measured in units of elemental carbon and represents the primary food energy source for the world's ecosystems. Human appropriation of net primary production, apart from leaving less for other species to use, alters the composition of the atmosphere(5), levels of biodiversity(6), energy flows within food webs(7) and the provision of important ecosystem services(8). Here we present a global map showing the amount of net primary production required by humans and compare it to the total amount generated on the landscape. We then derive a spatial balance sheet of net primary production 'supply' and 'demand' for the world. We show that human appropriation of net primary production varies spatially from almost zero to many times the local primary production. These analyses reveal the uneven footprint of human consumption and related environmental impacts, indicate the degree to which human populations depend on net primary production 'imports' and suggest policy options for slowing future growth of human appropriation of net primary production.	NASA, Goddard Space Flight Ctr, Biospher Sci Branch, Greenbelt, MD 20771 USA; Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20742 USA; World Wildlife Fund, Washington, DC 20037 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Natl Ctr Atmospher Res, Foothills Lab, Environm & Societal Impacts Grp, Boulder, CO 80307 USA; Bowie State Univ, Dept Nat Sci, Bowie, MD 20715 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Maryland; University of Maryland College Park; World Wildlife Fund; Stanford University; National Center Atmospheric Research (NCAR) - USA; University System of Maryland; Bowie State University	Imhoff, ML (corresponding author), NASA, Goddard Space Flight Ctr, Biospher Sci Branch, Greenbelt, MD 20771 USA.	Marc.L.Imhoff@nasa.gov	Imhoff, Michael/B-5119-2015; Noojipady, Praveen/B-2511-2010	Imhoff, Michael/0000-0001-6037-6446; 				*COUNC AGR SCI TEC, 1999, R135 COUNC AGR SCI T; Cramer W, 1999, GLOBAL CHANGE BIOL, V5, P1, DOI 10.1046/j.1365-2486.1999.00009.x; *CTR INT EARTH SCI, 2000, GRIDD POP WORLD GPW; Daily GC., 1997, ISSUES ECOL, V2, P1; DEPADUA DB, 1978, ACCELERATING AGR DEV, P135; Field CB, 2001, SCIENCE, V294, P2490, DOI 10.1126/science.1066317; Haberl H, 2002, SCIENCE, V296, P1968, DOI 10.1126/science.296.5575.1968; Haberl H, 1997, AMBIO, V26, P143; HOLDREN JP, 1974, AM SCI, V62, P282; INCE PJ, 2000, FPLRN0272 USDA FOR S; LIETH H, 1975, PRIMARY PRODUCTIVITY, P119; Luck MA, 2001, ECOSYSTEMS, V4, P782, DOI 10.1007/s10021-001-0046-8; O'Neill RV, 2000, BIOSCIENCE, V50, P333, DOI 10.1641/0006-3568(2000)050[0333:HEAAKS]2.3.CO;2; OLTJEN JW, 1992, COMPUTERS IN AGRICULTURAL EXTENSION PROGRAMS, P59; POTTER CS, 1993, GLOBAL BIOGEOCHEM CY, V7, P811, DOI 10.1029/93GB02725; PULKKI RE, 1997, GFSSWP06 UNFAO FOR P; Rojstaczer S, 2001, SCIENCE, V294, P2549, DOI 10.1126/science.1064375; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; Sere C, 1996, 127 FAO; SKOG KE, 1998, P N AM FOR COMM; Slayback DA, 2003, GLOBAL CHANGE BIOL, V9, P1, DOI 10.1046/j.1365-2486.2003.00507.x; Smil V., 1983, BIOMASS ENERGIES RES, P1, DOI [10.1007/978-1-4613-3691-4, DOI 10.1007/978-1-4613-3691-4]; *UN FAO, 2001, FAOSTAT 2001 DAT; *UN POP DIV, 2003, WORLD POP PROSP 2000; van den Bergh JCJM, 1999, ECOL ECON, V29, P61, DOI 10.1016/S0921-8009(99)00032-4; VITOUSEK PM, 1986, BIOSCIENCE, V36, P368, DOI 10.2307/1310258; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Wackernagel M, 2002, P NATL ACAD SCI USA, V99, P9266, DOI 10.1073/pnas.142033699; [No title captured]	29	435	466	17	356	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					870	873		10.1038/nature02619	http://dx.doi.org/10.1038/nature02619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215863	Green Published			2022-12-28	WOS:000222213000041
J	Morgentaler, B				Morgentaler, B			A 66-year-old man with sexual dysfunction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TESTOSTERONE-REPLACEMENT THERAPY; INFLATABLE PENILE PROSTHESIS; NORMALIZES ANDROGEN LEVELS; PROSTATE-SPECIFIC ANTIGEN; HORMONE-BINDING GLOBULIN; CORONARY-ARTERY DISEASE; ERECTILE DYSFUNCTION; HYPOGONADAL MEN; BODY-COMPOSITION; DOUBLE-BLIND		Mens Hlth Boston, Brookline, MA 02445 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard Medical School	Morgentaler, B (corresponding author), Mens Hlth Boston, 1 Brookline Pl,Suite 624, Brookline, MA 02445 USA.	amorgent@yahoo.com						Arruda-Olson AM, 2002, JAMA-J AM MED ASSOC, V287, P719, DOI 10.1001/jama.287.6.719; Bacon CG, 2003, ANN INTERN MED, V139, P161, DOI 10.7326/0003-4819-139-3-200308050-00005; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; BENNETT AH, 1991, J UROLOGY, V146, P1564, DOI 10.1016/S0022-5347(17)38167-3; Bhasin S, 2003, J ANDROL, V24, P299; Blander DS, 2000, INT J IMPOT RES, V12, P165, DOI 10.1038/sj.ijir.3900525; Brock GB, 2002, J UROLOGY, V168, P1332, DOI 10.1016/S0022-5347(05)64442-4; Carson CC, 2000, J UROLOGY, V164, P376, DOI 10.1016/S0022-5347(05)67364-8; CARTER HB, 1995, PROSTATE, V27, P25, DOI 10.1002/pros.2990270106; CHAMNESS SL, 1995, FERTIL STERIL, V63, P1101, DOI 10.1016/S0015-0282(16)57555-4; Chew KK, 2000, INT J IMPOT RES, V12, P41, DOI 10.1038/sj.ijir.3900457; Corbin JD, 2002, UROLOGY, V60, P4, DOI 10.1016/S0090-4295(02)01686-2; de Tejada IS, 2002, INT J IMPOT RES, V14, pS6, DOI 10.1038/sj/ijir/3900790; DeBusk R, 2000, AM J CARDIOL, V86, p62F; Dobs AS, 1999, J CLIN ENDOCR METAB, V84, P3469, DOI 10.1210/jc.84.10.3469; Dula E, 2001, EUR UROL, V39, P558, DOI 10.1159/000052503; Dunn KM, 1998, FAM PRACT, V15, P519, DOI 10.1093/fampra/15.6.519; English KM, 2000, CIRCULATION, V102, P1906, DOI 10.1161/01.CIR.102.16.1906; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gillies HC, 2002, INT J CARDIOL, V86, P131, DOI 10.1016/S0167-5273(02)00421-7; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Goldstein I, 1997, J UROLOGY, V157, P833, DOI 10.1016/S0022-5347(01)65058-4; Guay AT, 2002, INT J IMPOT RES, V14, P25, DOI 10.1038/sj.ijir.3900803; Gyllenborg J, 2001, METABOLISM, V50, P882, DOI 10.1053/meta.2001.24916; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Hatzichristou DG, 1998, J UROLOGY, V159, P1921, DOI 10.1016/S0022-5347(01)63197-5; Heikkila R, 1999, CANCER, V86, P312, DOI 10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.3.CO;2-Z; Hellstrom WJG, 2002, J ANDROL, V23, P763; Herrmann HC, 2000, NEW ENGL J MED, V342, P1622, DOI 10.1056/NEJM200006013422201; Hoffman MA, 2000, J UROLOGY, V163, P824, DOI 10.1016/S0022-5347(05)67812-3; Hsing AW, 2001, EPIDEMIOL REV, V23, P42, DOI 10.1093/oxfordjournals.epirev.a000795; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; KARACAN I, 1978, AM J PSYCHIAT, V135, P191; Kawanishi Y, 2001, INT J IMPOT RES, V13, P100, DOI 10.1038/sj.ijir.3900642; Khoudary KP, 1997, J LONG-TERM EFF MED, V7, P55; Kloner RA, 2003, AM J CARDIOL, V92, p37M, DOI 10.1016/S0002-9149(03)00074-2; Kloner RA, 2001, AM J HYPERTENS, V14, P70, DOI 10.1016/S0895-7061(00)01177-8; Koskimaki J, 2000, J UROLOGY, V164, P367, DOI 10.1016/S0022-5347(05)67362-4; Levine LA, 2001, J UROLOGY, V166, P932, DOI 10.1016/S0022-5347(05)65867-3; Lewis RW, 1997, WORLD J UROL, V15, P78, DOI 10.1007/BF01275162; Linet OI, 1996, NEW ENGL J MED, V334, P873, DOI 10.1056/NEJM199604043341401; Lue TF, 2000, NEW ENGL J MED, V342, P1802, DOI 10.1056/NEJM200006153422407; LUE TF, 1985, RADIOLOGY, V155, P777, DOI 10.1148/radiology.155.3.3890009; Marumo K, 2001, INT J UROL, V8, P53, DOI 10.1046/j.1442-2042.2001.00258.x; McNicholas TA, 2003, BJU INT, V91, P69, DOI 10.1046/j.1464-410X.2003.04016.x; MORGANTALER A, 1978, HORM BEHAV, V11, P61, DOI 10.1016/0018-506X(78)90058-2; Morgentaler A, 1999, LANCET, V354, P1713, DOI 10.1016/S0140-6736(99)06586-1; Morgentaler A, 2004, NEW ENGL J MED, V350, P2005; Morgentaler A, 1996, JAMA-J AM MED ASSOC, V276, P1904, DOI 10.1001/jama.276.23.1904; MORGENTALER A, 2003, VIAGRA MYTH SUPRISIN; Morley JE, 1997, METABOLISM, V46, P410, DOI 10.1016/S0026-0495(97)90057-3; Morley JE, 2002, METABOLISM, V51, P554, DOI 10.1053/meta.2002.31975; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; Parazzini F, 2000, EUR UROL, V37, P43, DOI 10.1159/000020098; Porst H, 2003, UROLOGY, V62, P121, DOI 10.1016/S0090-4295(03)00359-5; Porst H, 1997, INT J IMPOT RES, V9, P187, DOI 10.1038/sj.ijir.3900318; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; Rajpurkar A, 2003, J UROLOGY, V170, P159, DOI 10.1097/01.ju.0000072524.82345.6d; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; Rhoden EL, 2003, J UROLOGY, V170, P2348, DOI 10.1097/01.ju.0000091104.71869.8e; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Safarinejad MR, 2003, INT J IMPOT RES, V15, P246, DOI 10.1038/sj.ijir.3901024; Schroder FH, 2003, NEW ENGL J MED, V349, P393, DOI 10.1056/NEJMe030073; Sexton WJ, 1998, J UROLOGY, V159, P811, DOI 10.1016/S0022-5347(01)63739-X; Shakir SAW, 2001, BRIT MED J, V322, P651, DOI 10.1136/bmj.322.7287.651; Silvestri A, 2003, EUR HEART J, V24, P1928, DOI 10.1016/j.ehj.2003.08.016; Solomon H, 2003, INT J CLIN PRACT, V57, P96; Steidle C, 2003, J CLIN ENDOCR METAB, V88, P2673, DOI 10.1210/jc.2002-021058; Thadani U, 2002, J AM COLL CARDIOL, V40, P2006, DOI 10.1016/S0735-1097(02)02563-9; THOMPSON PDR, 2004, PHYS DESK REFERENCE, P2664; TIEFER L, 1995, UROL CLIN N AM, V22, P767; Vickers MA, 2002, INT J IMPOT RES, V14, P466, DOI 10.1038/sj.ijir.3900910; VIRAG R, 1991, J UROLOGY, V145, P287, DOI 10.1016/S0022-5347(17)38316-7; VIRAG R, 1982, LANCET, V2, P938; VONHEYDEN B, 1993, J UROLOGY, V150, P1825, DOI 10.1016/S0022-5347(17)35906-2; Wang C, 2000, J CLIN ENDOCR METAB, V85, P2839, DOI 10.1210/jc.85.8.2839; Webb CM, 1999, CIRCULATION, V100, P1690, DOI 10.1161/01.CIR.100.16.1690; WESTABY D, 1977, LANCET, V2, P261; Whitsel EA, 2001, AM J MED, V111, P261, DOI 10.1016/S0002-9343(01)00833-6; Wysowski DK, 2002, AM J CARDIOL, V89, P1331, DOI 10.1016/S0002-9149(02)02342-1	82	18	18	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2994	3003		10.1001/jama.291.24.2994	http://dx.doi.org/10.1001/jama.291.24.2994			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213212				2022-12-28	WOS:000222184600030
J	Hudspith, J; Rayatt, S				Hudspith, J; Rayatt, S			ABC of burns - First aid and treatment of minor burns	BRITISH MEDICAL JOURNAL			English	Review									Chelsea & Westminster Hosp, Burns Ctr, London, England; W Midlands Training Scheme, Birmingham, W Midlands, England	Imperial College London	Hudspith, J (corresponding author), Chelsea & Westminster Hosp, Burns Ctr, London, England.							DAVIES JWL, 1982, BURNS, V9, P1, DOI 10.1016/0305-4179(82)90127-9; Herndon DN, 2018, TOTAL BURN CARE; *NAT BURN CAR REV, 2001, STAND STRAT BURN CAR, P68; Settle J. A., 1996, PRINCIPLES PRACTICE; Slater R M, 1971, Br J Plast Surg, V24, P296, DOI 10.1016/S0007-1226(71)80074-7; WILSON G, 1987, BRIT MED J, V294, P556, DOI 10.1136/bmj.294.6571.556	6	64	68	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	2004	328	7454					1487	1489		10.1136/bmj.328.7454.1487	http://dx.doi.org/10.1136/bmj.328.7454.1487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205294	Green Published			2022-12-28	WOS:000222244600023
J	Mokari, T; Rothenberg, E; Popov, I; Costi, R; Banin, U				Mokari, T; Rothenberg, E; Popov, I; Costi, R; Banin, U			Selective growth of metal tips onto semiconductor quantum rods and tetrapods	SCIENCE			English	Article							NANOPARTICLES; SELENIDE	We show the anisotropic selective growth of gold tips onto semiconductor (cadmium selenide) nanorods and tetrapods by a simple reaction. The size of the gold tips can be controlled by the concentration of the starting materials. The new nanostructures display modified optical properties caused by the strong coupling between the gold and semiconductor parts. The gold tips show increased conductivity as well as selective chemical affinity for forming self-assembled chains of rods. Such gold-tipped nanostructures provide natural contact points for self-assembly and for electrical devices and can solve the difficult problem of contacting colloidal nanorods and tetrapods to the external world.	Hebrew Univ Jerusalem, Inst Chem, Farkas Ctr Light Induced Proc, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Ctr Nanosci & Nanotechnol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Banin, U (corresponding author), Hebrew Univ Jerusalem, Inst Chem, Farkas Ctr Light Induced Proc, IL-91904 Jerusalem, Israel.	banin@chem.ch.huji.ac.il	MOKARI, TALEB/F-1685-2012; Rothenberg, Eli/A-6879-2009	Rothenberg, Eli/0000-0002-1382-1380; Banin, Uri/0000-0003-1698-2128				Banin U, 2003, ANNU REV PHYS CHEM, V54, P465, DOI 10.1146/annurev.physchem.54.011002.103838; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Caswell KK, 2003, J AM CHEM SOC, V125, P13914, DOI 10.1021/ja037969i; CRETIER JE, 1973, MATER RES BULL, V8, P1427, DOI 10.1016/0025-5408(73)90027-5; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; Dumestre F, 2004, SCIENCE, V303, P821, DOI 10.1126/science.1092641; Fan CH, 2003, P NATL ACAD SCI USA, V100, P6297, DOI 10.1073/pnas.1132025100; Goldberger J, 2003, NATURE, V422, P599, DOI 10.1038/nature01551; Gomez S, 2000, CHEM COMMUN, P1945, DOI 10.1039/b005327i; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Heinze S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.106801; Javey A, 2003, NATURE, V424, P654, DOI 10.1038/nature01797; Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541; Jones RM, 2001, P NATL ACAD SCI USA, V98, P14769, DOI 10.1073/pnas.251555298; Kan S, 2003, NAT MATER, V2, P155, DOI 10.1038/nmat830; Keren K, 2003, SCIENCE, V302, P1380, DOI 10.1126/science.1091022; Klein DL, 1997, NATURE, V389, P699, DOI 10.1038/39535; Manna L, 2000, J AM CHEM SOC, V122, P12700, DOI 10.1021/ja003055+; Manna L, 2003, NAT MATER, V2, P382, DOI 10.1038/nmat902; Mokari T, 2003, CHEM MATER, V15, P3955, DOI 10.1021/cm034173+; Nahum E, 2004, NANO LETT, V4, P103, DOI 10.1021/nl034928b; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Peng ZA, 2001, J AM CHEM SOC, V123, P1389, DOI 10.1021/ja0027766; Talapin DV, 2003, NANO LETT, V3, P1677, DOI 10.1021/nl034815s; Tang ZY, 2002, SCIENCE, V297, P237, DOI 10.1126/science.1072086; Wu YY, 2002, NANO LETT, V2, P83, DOI 10.1021/nl0156888; Yamamoto M, 2003, J MATER CHEM, V13, P2064, DOI 10.1039/b307092a; Yan H, 2003, SCIENCE, V301, P1882, DOI 10.1126/science.1089389	28	950	974	7	362	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1787	1790		10.1126/science.1097830	http://dx.doi.org/10.1126/science.1097830			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205530				2022-12-28	WOS:000222089500041
J	Young, IM; Crawford, JW				Young, IM; Crawford, JW			Interactions and self-organization in the soil-microbe complex	SCIENCE			English	Review							SOLUTE TRANSPORT; SCIENCE; MODEL	Soil is the most complicated biomaterial on the planet. As with any material, the physical habitat is of prime importance in determining and regulating biological activity. However, until recently the opaque nature of soil has meant that any interrogation of its interior architecture has been relatively rudimentary, restricted to simple qualitative expressions of the physical heterogeneity that fail to relate to any specific function. However, new techniques and insights into the biophysical and biochemical processes of this inner space are leading to the developments of theoretical frameworks and experimental approaches that will allow us to sustainably manage Earth's most important resource. We introduce the concept that the soil-microbe system is self-organized and suggest new priorities for research based on an integrative approach that combines biochemistry and biophysics.	Univ Abertay, SIMBIOS, Dundee DD1 1HG, Scotland	University of Abertay Dundee	Young, IM (corresponding author), Univ Abertay, SIMBIOS, Bell St, Dundee DD1 1HG, Scotland.	imy@tay.ac.uk	Young, Iain McEwing/C-9210-2011	Young, Iain McEwing/0000-0002-7588-9006; Crawford, John/0000-0002-7139-0355				Arah JRM, 1995, EUR J SOIL SCI, V46, P507, DOI 10.1111/j.1365-2389.1995.tb01347.x; Baveye P, 1998, SOIL SCI SOC AM J, V62, P1469, DOI 10.2136/sssaj1998.03615995006200050046x; Baveye P., 1998, FRACTALS SOIL SCI AD; Bejat L, 2000, SOIL SCI SOC AM J, V64, P818, DOI 10.2136/sssaj2000.643818x; Bunde A., 1991, FRACTALS DISORDERED; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Crawford JW, 1997, EUR J SOIL SCI, V48, P643, DOI 10.1046/j.1365-2389.1997.00118.x; CRAWFORD JW, 1996, INT UNION PURE APPL, V4; CRESTANA S, 1986, SOIL SCI, V142, P56, DOI 10.1097/00010694-198607000-00008; Ettema CH, 2002, TRENDS ECOL EVOL, V17, P177, DOI 10.1016/S0169-5347(02)02496-5; Favis-Mortlock D, 1998, COMPUT GEOSCI-UK, V24, P353, DOI 10.1016/S0098-3004(97)00116-7; FOSTER RC, 1988, BIOL FERT SOILS, V6, P189, DOI 10.1007/BF00260816; Franklin RB, 2003, FEMS MICROBIOL ECOL, V44, P335, DOI 10.1016/S0168-6496(03)00074-6; Hartmann A, 1998, SOIL TILL RES, V47, P67, DOI 10.1016/S0167-1987(98)00074-9; Keil FJ, 1999, CATAL TODAY, V53, P245, DOI 10.1016/S0920-5861(99)00119-4; LeBissonnais Y, 1996, EUR J SOIL SCI, V47, P425, DOI 10.1111/j.1365-2389.1996.tb01843.x; LETEY J, 1991, AUST J SOIL RES, V29, P699, DOI 10.1071/SR9910699; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; MEAKIN P, 1990, MATER RES SOC SYMP P, V180, P141, DOI 10.1557/PROC-180-141; Nunan N, 2002, MICROBIAL ECOL, V44, P296, DOI 10.1007/s00248-002-2021-0; Nunan N, 2003, FEMS MICROBIOL ECOL, V44, P203, DOI 10.1016/S0168-6496(03)00027-8; OUESSAR M, 1993, SOIL TECHNOL, V6, P329, DOI 10.1016/0933-3630(93)90023-8; Rappoldt C, 1999, GEODERMA, V88, P329, DOI 10.1016/S0016-7061(98)00112-8; Stirzaker RJ, 1996, PLANT SOIL, V185, P151, DOI 10.1007/BF02257571; TISDALL JM, 1982, J SOIL SCI, V23, P821; Vogel HJ, 2000, EUR J SOIL SCI, V51, P99, DOI 10.1046/j.1365-2389.2000.00275.x; Young IM, 2001, SOIL TILL RES, V61, P33, DOI 10.1016/S0167-1987(01)00188-X; Young IM, 2001, PROTIST, V152, P123, DOI 10.1078/1434-4610-00050; Young IM, 2000, SOIL TILL RES, V53, P201, DOI 10.1016/S0167-1987(99)00106-3; Zhang XX, 2002, ADV WATER RESOUR, V25, P1, DOI 10.1016/S0309-1708(01)00047-1	30	554	610	17	424	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1634	1637		10.1126/science.1097394	http://dx.doi.org/10.1126/science.1097394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192219				2022-12-28	WOS:000221934300039
J	Herndon, DN; Tompkins, RG				Herndon, DN; Tompkins, RG			Support of the metabolic response to burn injury	LANCET			English	Review							HUMAN GROWTH-HORMONE; MUSCLE PROTEIN-SYNTHESIS; RESTING ENERGY-EXPENDITURE; MAJOR THERMAL-INJURY; ACUTE-PHASE RESPONSE; WHOLE-BODY LEUCINE; PLASMA ARGININE; ADULT MEN; FACTOR-I; SYSTEMIC RESPONSES	Severe burn causes metabolic disturbances that can last for a year after injury; persistent and profound catabolism hampers rehabilitative efforts and delays the meaningful return of individuals to society. The simplest, effective anabolic strategies for severe burn injuries are: early excision and grafting of the wound; prompt treatment of sepsis; maintenance of environmental temperature at 30-32degreesC; continuous feeding of a high carbohydrate, high protein diet, preferably by the enteral route; and early institution of vigorous and aerobic resistive exercise programmes. To further keep erosion of lean body mass to a minimum, administration of anabolic agents, recombinant human growth hormone, insulin, oxandrolone, or anticatabolic drugs such as propranolol are alternative approaches. Exogenous continuous low-dose insulin infusion, beta blockade with propranolol, and use of the synthetic testosterone analogue oxandrolone are the most cost effective and least toxic pharmacological treatments to date.	Shriners Hosp Children, Galveston, TX 77550 USA; Shriners Hosp Children, Boston, MA 02114 USA		Herndon, DN (corresponding author), Shriners Hosp Children, 815 Market St, Galveston, TX 77550 USA.	dherndon@utmb.edu	Herndon, David/AAC-3354-2020					Aarsland A, 1998, J CLIN INVEST, V101, P2233, DOI 10.1172/JCI200; Aarsland A, 1996, ANN SURG, V223, P777, DOI 10.1097/00000658-199606000-00016; ASCH MJ, 1973, ANN SURG, V178, P218, DOI 10.1097/00000658-197308000-00020; Baron P. W., 1997, Journal of Burn Care and Rehabilitation, V18, P223, DOI 10.1097/00004630-199705000-00008; BARR PO, 1968, LANCET, V1, P164; Barret JP, 1999, PLAST RECONSTR SURG, V104, P726, DOI 10.1097/00006534-199909030-00017; Barret JP, 2001, J TRAUMA, V51, P736, DOI 10.1097/00005373-200110000-00019; Barret JP, 2000, PLAST RECONSTR SURG, V105, P62, DOI 10.1097/00006534-200001000-00010; BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005; CALDWELL FT, 1962, ANN SURG, V155, P119, DOI 10.1097/00000658-196201000-00014; Carter EA, 1996, METABOLISM, V45, P1161, DOI 10.1016/S0026-0495(96)90017-7; CASTILLO L, 1995, AM J PHYSIOL-ENDOC M, V268, pE360, DOI 10.1152/ajpendo.1995.268.2.E360; CASTILLO L, 1994, METABOLISM, V43, P114, DOI 10.1016/0026-0495(94)90166-X; CASTILLO L, 1993, P NATL ACAD SCI USA, V90, P7749, DOI 10.1073/pnas.90.16.7749; CASTILLO L, 1994, P NATL ACAD SCI USA, V91, P6393, DOI 10.1073/pnas.91.14.6393; CIOFFI WG, 1994, ANN SURG, V220, P310, DOI 10.1097/00000658-199409000-00007; CLEMMONS DR, 1992, J CLIN ENDOCR METAB, V75, P234, DOI 10.1210/jc.75.1.234; CONWAY JM, 1980, AM J PHYSIOL, V239, pE192, DOI 10.1152/ajpendo.1980.239.3.E192; CORTIELLA J, 1992, AM J CLIN NUTR, V56, P517, DOI 10.1093/ajcn/56.3.517; Cucuzzo NA, 2001, J BURN CARE REHABIL, V22, P214, DOI 10.1097/00004630-200105000-00006; CURRERI PW, 1974, J AM DIET ASSOC, V65, P415; Demling RH, 2000, J CRIT CARE, V15, P12, DOI 10.1053/jcrc.2000.0150012; DESAI MH, 1990, ANN SURG, V211, P753, DOI 10.1097/00000658-199006000-00015; Dickerson RN, 2002, JPEN-PARENTER ENTER, V26, P17, DOI 10.1177/014860710202600117; DOMINIONI L, 1985, JPEN-PARENTER ENTER, V9, P269, DOI 10.1177/0148607185009003269; Ferrando AA, 1999, ANN SURG, V229, P11, DOI 10.1097/00000658-199901000-00002; Ferrando AA, 2001, CRIT CARE MED, V29, P1936, DOI 10.1097/00003246-200110000-00015; FUKAGAWA NK, 1989, AM J PHYSIOL, V256, pE288, DOI 10.1152/ajpendo.1989.256.2.E288; GOODALL M, 1957, ANN SURG, V145, P479, DOI 10.1097/00000658-195704000-00004; GORAN MI, 1990, AM J PHYSIOL, V259, pE576, DOI 10.1152/ajpendo.1990.259.4.E576; GORE D C, 1990, Journal of Burn Care and Rehabilitation, V11, P400, DOI 10.1097/00004630-199009000-00005; GORE DC, 1991, ANN SURG, V213, P568, DOI 10.1097/00000658-199106000-00006; GRAY DT, 1982, AM J SURG, V144, P76, DOI 10.1016/0002-9610(82)90605-5; HARRISON TS, 1967, ANN SURG, V165, P169, DOI 10.1097/00000658-196702000-00002; Hart DW, 2003, J TRAUMA, V54, P755, DOI 10.1097/01.TA.0000060260.61478.A7; Hart DW, 2002, ANN SURG, V235, P152, DOI 10.1097/00000658-200201000-00020; Hart DW, 2001, CRIT CARE MED, V29, P1318, DOI 10.1097/00003246-200107000-00004; Hart DW, 2001, ANN SURG, V233, P827, DOI 10.1097/00000658-200106000-00013; Hart DW, 2001, ANN SURG, V233, P556, DOI 10.1097/00000658-200104000-00012; Hart DW, 2000, ANN SURG, V232, P455, DOI 10.1097/00000658-200010000-00001; Hart DW, 2000, SURGERY, V128, P312, DOI 10.1067/msy.2000.108059; HEIMBACH D, 1988, ANN SURG, V208, P313, DOI 10.1097/00000658-198809000-00008; Herndon D N, 1989, J Burn Care Rehabil, V10, P309, DOI 10.1097/00004630-198907000-00004; Herndon DN, 1999, ANN SURG, V229, P713, DOI 10.1097/00000658-199905000-00014; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HERNDON DN, 1989, ANN SURG, V209, P547, DOI 10.1097/00000658-198905000-00006; HERNDON DN, 1995, ANN SURG, V221, P649, DOI 10.1097/00000658-199506000-00004; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HERNDON DN, 1987, J TRAUMA, V27, P195, DOI 10.1097/00005373-198702000-00018; HERNDON DN, 1994, ARCH SURG-CHICAGO, V129, P1301; HERNDON DN, 1988, ANN SURG, V208, P484, DOI 10.1097/00000658-198810000-00010; Hildreth M A, 1989, J Burn Care Rehabil, V10, P523, DOI 10.1097/00004630-198911000-00012; Hildreth M A, 1988, J Burn Care Rehabil, V9, P616, DOI 10.1097/00004630-198811000-00009; HILDRETH MA, 1987, J TRAUMA, V27, P188, DOI 10.1097/00005373-198702000-00016; Hildreth Marsha A., 1993, Journal of Burn Care and Rehabilitation, V14, P108, DOI 10.1097/00004630-199301000-00023; HOERR RA, 1993, AM J PHYSIOL, V264, pE567, DOI 10.1152/ajpendo.1993.264.4.E567; HONEYCUTT D, 1992, Journal of Burn Care and Rehabilitation, V13, P181, DOI 10.1097/00004630-199203000-00001; HORBER FF, 1990, J CLIN INVEST, V86, P265, DOI 10.1172/JCI114694; JAHOOR F, 1988, METABOLISM, V37, P330, DOI 10.1016/0026-0495(88)90132-1; JAKSIC T, 1987, METABOLISM, V36, P1040, DOI 10.1016/0026-0495(87)90023-0; JAKSIC T, 1991, AM J CLIN NUTR, V54, P408, DOI 10.1093/ajcn/54.2.408; Jarrar D, 1997, ARCH SURG-CHICAGO, V132, P1171; Jeejeebhoy KN, 2001, AM J CLIN NUTR, V74, P160; JEFFRIES M K, 1992, Journal of Burn Care and Rehabilitation, V13, P391, DOI 10.1097/00004630-199207000-00001; Jeschke MG, 2000, ANN SURG, V231, P246, DOI 10.1097/00000658-200002000-00014; Jeschke MG, 2000, CRIT CARE MED, V28, P1578, DOI 10.1097/00003246-200005000-00053; KINNEY JM, 1968, ANN SURG, V168, P459, DOI 10.1097/00000658-196809000-00013; Klein GL, 1999, J CLIN DENSITOM, V2, P11, DOI 10.1385/JCD:2:1:11; Klein GL, 1998, MAGNESIUM RES, V11, P103; Klein GL, 1998, J CLIN ENDOCR METAB, V83, P21, DOI 10.1210/jc.83.1.21; Klein GL, 1997, HORM RES, V48, P83, DOI 10.1159/000191334; KLEIN GL, 1995, J PEDIATR-US, V126, P252, DOI 10.1016/S0022-3476(95)70553-8; Klein GL, 2000, PEDIATR NEPHROL, V14, P301, DOI 10.1007/s004670050763; KNOX J, 1995, J TRAUMA, V39, P526; Low JFA, 2001, BURNS, V27, P447, DOI 10.1016/S0305-4179(00)00164-9; Low JFA, 1999, LANCET, V354, P1789, DOI 10.1016/S0140-6736(99)02741-5; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MATTHEWS DE, 1993, AM J PHYSIOL, V264, pE109, DOI 10.1152/ajpendo.1993.264.1.E109; MATTHEWS DE, 1980, AM J PHYSIOL, V238, pE473, DOI 10.1152/ajpendo.1980.238.5.E473; MELVILLE S, 1989, METABOLISM, V38, P248, DOI 10.1016/0026-0495(89)90083-8; MERRELL SW, 1987, AM J SURG, V154, P623, DOI 10.1016/0002-9610(87)90229-7; MILNER EA, 1994, J TRAUMA, V37, P167, DOI 10.1097/00005373-199408000-00001; MINIFEE PK, 1989, J PEDIATR SURG, V24, P806, DOI 10.1016/S0022-3468(89)80541-X; Mlcak Ronald P., 1993, Journal of Burn Care and Rehabilitation, V14, P427, DOI 10.1097/00004630-199307000-00004; MOCHIZUKI H, 1984, ANN SURG, V200, P297, DOI 10.1097/00000658-198409000-00007; Morio B, 2002, ANN SURG, V236, P218, DOI 10.1097/00000658-200208000-00010; MOTIL KJ, 1981, METABOLISM, V30, P783, DOI 10.1016/0026-0495(81)90024-X; MOTIL KJ, 1981, AM J PHYSIOL, V240, pE712, DOI 10.1152/ajpendo.1981.240.6.E712; NEWSON TW, 1973, ANN SURG, P178; Patterson BW, 1997, METABOLISM, V46, P573, DOI 10.1016/S0026-0495(97)90196-7; PELLETIER V, 1991, AM J CLIN NUTR, V54, P395, DOI 10.1093/ajcn/54.2.395; Purdue Gary F., 1997, Journal of Burn Care and Rehabilitation, V18, P52, DOI 10.1097/00004630-199701000-00009; PURDUE GF, 1987, J TRAUMA, V27, P155; Ramirez RJ, 1998, ANN SURG, V228, P439, DOI 10.1097/00000658-199810000-00001; REESE W, 1956, J CLIN INVEST, V35, P62; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Rose J. Keith, 1997, Journal of Burn Care and Rehabilitation, V18, P338, DOI 10.1097/00004630-199707000-00011; RUTAN RL, 1990, ARCH SURG-CHICAGO, V125, P392; SAFFLE JR, 2002, TOTAL BURN CARE, P275; SAKURAI Y, 1995, ANN SURG, V222, P283, DOI 10.1097/00000658-199509000-00007; Sheffield-Moore M, 1999, J CLIN ENDOCR METAB, V84, P2705, DOI 10.1210/jc.84.8.2705; Sheridan RL, 2000, JAMA-J AM MED ASSOC, V283, P69, DOI 10.1001/jama.283.1.69; Sheridan RL, 1998, JPEN-PARENTER ENTER, V22, P212, DOI 10.1177/0148607198022004212; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; Spies M, 2002, CRIT CARE MED, V30, P83, DOI 10.1097/00003246-200201000-00013; STORCH KJ, 1988, AM J PHYSIOL, V255, pE322, DOI 10.1152/ajpendo.1988.255.3.E322; Suman OE, 2002, J BURN CARE REHABIL, V23, P288, DOI 10.1097/00004630-200207000-00013; Suman OE, 2001, J APPL PHYSIOL, V91, P1168, DOI 10.1152/jappl.2001.91.3.1168; Takagi K, 1998, ANN SURG, V228, P106, DOI 10.1097/00000658-199807000-00016; Takagi K, 1998, J TRAUMA, V44, P517, DOI 10.1097/00005373-199803000-00018; Takagi K, 1997, J SURG RES, V69, P166, DOI 10.1006/jsre.1997.5066; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; THOMPSON GN, 1989, AM J PHYSIOL, V256, pE631, DOI 10.1152/ajpendo.1989.256.5.E631; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANDLIETG, 1987, J CLIN ENDOCR METAB, V65, P876; Wainwright David, 1996, Journal of Burn Care and Rehabilitation, V17, P124, DOI 10.1097/00004630-199603000-00006; WILMORE DW, 1976, ANN SURG, V183, P314, DOI 10.1097/00000658-197603000-00018; WILMORE DW, 1978, SURG CLIN N AM, V58, P1173; WILMORE DW, 1980, JPEN-PARENTER ENTER, V4, P147, DOI 10.1177/0148607180004002147; WILMORE DW, 1971, SURG GYNECOL OBSTETR, V132, P881; WILMORE DW, 1975, J APPL PHYSIOL, V38, P593, DOI 10.1152/jappl.1975.38.4.593; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; WILMORE DW, 1977, ANN SURG, V186, P444, DOI 10.1097/00000658-197710000-00006; Wolf SE, 1997, ARCH SURG-CHICAGO, V132, P1310; WOLFE RR, 1983, ANN SURG, V197, P163, DOI 10.1097/00000658-198302000-00007; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; WOLFE RR, 1987, ANN SURG, V206, P214, DOI 10.1097/00000658-198708000-00016; YOUNG VR, 1991, AM J CLIN NUTR, V54, P377, DOI 10.1093/ajcn/54.2.377; YU YM, 1995, AM J CLIN NUTR, V62, P960, DOI 10.1093/ajcn/62.5.960; YU YM, 1993, J TRAUMA, V35, P1, DOI 10.1097/00005373-199307000-00001; Yu YM, 2001, AM J PHYSIOL-ENDOC M, V280, pE509, DOI 10.1152/ajpendo.2001.280.3.E509; YU YM, 1995, METABOLISM, V44, P659, DOI 10.1016/0026-0495(95)90125-6; Yu YM, 1999, JPEN-PARENTER ENTER, V23, P160, DOI 10.1177/0148607199023003160; YU YM, 1991, P 23 ANN M AM BURN A, P78; ZAWACKI B E, 1970, Annals of Surgery, V171, P236, DOI 10.1097/00000658-197002000-00011; ZELLO GA, 1992, J NUTR, V122, P1000, DOI 10.1093/jn/122.4.1000	136	317	331	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1895	1902		10.1016/S0140-6736(04)16360-5	http://dx.doi.org/10.1016/S0140-6736(04)16360-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183630				2022-12-28	WOS:000221822300024
J	Witten, E				Witten, E			When symmetry breaks down	NATURE			English	Editorial Material									Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Witten, E (corresponding author), Inst Adv Study, Sch Nat Sci, Olden Lane, Princeton, NJ 08540 USA.							Gunion J. F., 1990, HIGGS HUNTERS GUIDE; KANE GL, 2001, SUPERSYMMETRY UNVEIL; PESKIN M, STANDARD MODEL	3	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	2004	429	6991					507	508		10.1038/429507a	http://dx.doi.org/10.1038/429507a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175731				2022-12-28	WOS:000221767700020
J	Hummel, M; Bonifacio, E; Schmid, S; Walter, M; Knopff, A; Ziegler, AG				Hummel, M; Bonifacio, E; Schmid, S; Walter, M; Knopff, A; Ziegler, AG			Brief communication: Early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents	ANNALS OF INTERNAL MEDICINE			English	Article							BETA-CELL AUTOIMMUNITY; YOUNG DAISY; RISK; MELLITUS; CHILDREN; DISEASE; PATHOGENESIS; ASSOCIATION; EXPOSURE; BABYDIAB	Background: The development of type 1 diabetes mellitus is preceded by autoimmunity against islet beta cells. Objective: To determine the risk for islet autoimmunity and childhood diabetes in offspring of affected parents. Design: Prospective cohort study. Setting: German BABYDIAB study. Participants: 1610 offspring of parents with type 1 diabetes. Measurements: Autoantibodies to islet autoantigens were measured at 9 months, 2 years, 5 years, and 8 years of age. Results: By 5 years of age, the frequency of islet autoantibodies was 5.9% (95% Cl, 4.6% to 7.2%), the frequency of multiple islet autoantibodies was 3.5% (Cl, 2.5% to 4.5%), and the frequency of diabetes was 1.5% (Cl, 0.9% to 2.1%). The risk for diabetes was highest in offspring with multiple autoantibodies (40% within 5 years vs. 3% in offspring with single autoantibodies; P = 0.005). Progression to multiple islet autoantibodies was fastest in children who were autoantibody positive by age 2 years (P < 0.001), and progression to diabetes was inversely related to the age of positivity for multiple autoantibodies (P = 0.02). Limitations: The findings are limited to childhood diabetes in affected families. Conclusions: Childhood autoimmune diabetes is associated with autoimmunity that starts before 2 years of age.	Diabet Res Inst, D-80804 Munich, Germany; Ist Sci San Raffaele, Milan, Italy; Acad Hosp Schwabing, Munich, Germany	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ziegler, AG (corresponding author), Diabet Res Inst, Kolner Pl 1, D-80804 Munich, Germany.	anziegler@lrz.uni-muenchen.de	Bonifacio, Ezio/E-7700-2010; Hummel, Sandra/Q-3538-2016; Ziegler, Anette-Gabriele/M-4614-2014	Bonifacio, Ezio/0000-0002-8704-4713; Ziegler, Anette-Gabriele/0000-0002-6290-5548				ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Bingley PJ, 2003, DIABETES, V52, P1128, DOI 10.2337/diabetes.52.5.1128; Colman PG, 2000, DIABETOLOGIA, V43, P203, DOI 10.1007/s001250050030; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Green A, 2000, LANCET, V355, P873; Greener M, 2000, MOL MED TODAY, V6, P3, DOI 10.1016/S1357-4310(99)01625-1; Honeyman MC, 2000, DIABETES, V49, P1319, DOI 10.2337/diabetes.49.8.1319; Karvonen M, 1999, DIABETES CARE, V22, P1066, DOI 10.2337/diacare.22.7.1066; Knip M, 2003, DIABETES, V52, pA7; Naserke HE, 1999, J CLIN ENDOCR METAB, V84, P1239, DOI 10.1210/jc.84.4.1239; Nejentsev S, 1999, DIABETIC MED, V16, P985, DOI 10.1046/j.1464-5491.1999.00186.x; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Norris JM, 1996, JAMA-J AM MED ASSOC, V276, P609, DOI 10.1001/jama.276.8.609; Rewers M, 1996, J AUTOIMMUN, V9, P405, DOI 10.1006/jaut.1996.0055; Salminen K, 2003, J MED VIROL, V69, P91, DOI 10.1002/jmv.10260; Ziegler AG, 2003, JAMA-J AM MED ASSOC, V290, P1721, DOI 10.1001/jama.290.13.1721; ZIEGLER AG, 1993, DIABETOLOGIA, V36, P402, DOI 10.1007/BF00402275; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	19	118	120	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					882	886		10.7326/0003-4819-140-11-200406010-00009	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172902				2022-12-28	WOS:000221680600004
J	Williamson, DF; Vinicor, F; Bowman, BA				Williamson, DF; Vinicor, F; Bowman, BA		Centers Dis Cotrol Prevent	Primary prevention of type 2 diabetes mellitus by lifestyle intervention: Implications for health policy	ANNALS OF INTERNAL MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; 10-YEAR FOLLOW-UP; US; POPULATION; PREVALENCE; PROMOTION; BURDEN; IMPACT; DISEASE; ETHICS	More than 18 million Americans currently have diabetes mellitus. The economic and human cost of the disease is devastating. In the United States, diabetes is the most common cause of blindness among working-age adults, the most common cause of nontraumatic amputations and end-stage renal disease, and the sixth most common cause of death. For the cohort of Americans born in 2000, the estimated lifetime risk for diabetes is more than 1 in 3. In the next 50 years, the number of diagnosed cases of diabetes is predicted to increase by 165% in the United States, with the largest relative increases seen among African Americans, American Indians, Alaska Natives, Asian and Pacific islanders, and Hispanic/Latino persons. Compelling scientific evidence indicates that lifestyle change prevents or delays the occurrence of type 2 diabetes in high-risk groups. This body of evidence from randomized, controlled trials conducted in 3 countries has definitively established that maintenance of modest weight loss through diet and physical activity reduces the incidence of type 2 diabetes in high-risk persons by about 40% to 60% over 3 to 4 years. The number of persons at high risk for type 2 diabetes is similar to the number of persons who have diabetes. This paper summarizes scientific evidence supporting lifestyle intervention to prevent type 2 diabetes and discusses major policy challenges to broad implementation of lifestyle intervention in the health system.	Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Bowman, BA (corresponding author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Highway NE,MS K10, Atlanta, GA 30341 USA.							American Diabetes Association, 2004, DIABETES CARE, V27, pS11, DOI [10.2337/diacare.27.2007.S11, DOI 10.2337/DIACARE.27.2007.S11]; [Anonymous], 2003, DIABETES CARE, V26, P36; Becker M H, 1986, Public Health Rev, V14, P15; Benjamin SM, 2003, DIABETES CARE, V26, P645, DOI 10.2337/diacare.26.3.645; Berg AO, 2003, ANN INTERN MED, V138, P212, DOI 10.7326/0003-4819-138-3-200302040-00014; Boyle JP, 2001, DIABETES CARE, V24, P1936, DOI 10.2337/diacare.24.11.1936; Bray GA, 1999, DIABETES CARE, V22, P623; *CDCP, 2004, NAT DIAB FACT SHEET; Cohen JS, 2001, ARCH INTERN MED, V161, P880, DOI 10.1001/archinte.161.6.880; Culyer AJ, 2001, J MED ETHICS, V27, P217, DOI 10.1136/jme.27.4.217; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; Engelgau MM, 1998, JAMA-J AM MED ASSOC, V280, P1757; Engelgau MM, 2002, DIABETES CARE, V25, P2098, DOI 10.2337/diacare.25.11.2098; Fisher EB, 2002, DIABETES CARE, V25, P599, DOI 10.2337/diacare.25.3.599; Fontaine KR, 1999, QUAL LIFE RES, V8, P275, DOI 10.1023/A:1008835602894; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Franz MJ, 2002, J AM DIET ASSOC, V102, P109, DOI 10.1016/S0002-8223(02)90031-3; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gold MR, 1996, COST EFFECTIVENESS H; Guthrie C, 2001, BRIT MED J, V323, P997, DOI 10.1136/bmj.323.7319.997; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; JARRETT RJ, 1979, DIABETOLOGIA, V16, P25, DOI 10.1007/BF00423146; Joslin EP, 1921, J AMER MED ASSOC, V76, P79; Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Koenigsberg MR, 2004, AM FAM PHYSICIAN, V69, P309; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; McGinnis JM, 2001, AM J HEALTH PROMOT, V15, P391, DOI 10.4278/0890-1171-15.5.391; Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1884, DOI 10.1001/jama.290.14.1884; *NAT CTR HLTH STAT, 2002, HLTH US 2002 CHARTB, P28; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Petersen M, 2003, DIABETES CARE, V26, P917; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; Rolka DB, 2001, DIABETES CARE, V24, P1899, DOI 10.2337/diacare.24.11.1899; ROSE G, 1989, ANN MED, V21, P409, DOI 10.3109/07853898909149231; SARTOR G, 1980, DIABETES, V29, P41, DOI 10.2337/diabetes.29.1.41; Saydah SH, 2002, DIABETES CARE, V25, P1940, DOI 10.2337/diacare.25.11.1940; Scharli AF, 1998, PEDIATR SURG INT, V13, P1; Segal L, 1998, HEALTH PROMOT INT, V13, P197, DOI 10.1093/heapro/13.3.197; Sherwin RS, 2002, DIABETES CARE, V25, P742; Shiell A, 1996, HEALTH ECON, V5, P241, DOI 10.1002/(SICI)1099-1050(199605)5:3<241::AID-HEC197>3.3.CO;2-7; Sindall C, 2001, HEALTH PROMOT INT, V16, P215, DOI 10.1093/heapro/16.3.215; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; Swinburn B, 2001, BMJ-BRIT MED J, V323, P997; Tataranni PA, 2001, NEW ENGL J MED, V344, P1390, DOI 10.1056/NEJM200105033441809; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; *USDA US DEP HHS, 2000, NUTR YOUR HLTH DIET; Vinicor F, 1998, DIABETES CARE, V21, pC15, DOI 10.2337/diacare.21.3.C15; VINICOR F, 2001, CURRENT OPINION ENDO, V8, P58; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; 2002, DIABETES ED, V28, P964	55	94	98	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					951	957		10.7326/0003-4819-140-11-200406010-00036	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00036			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824IS	15172920				2022-12-28	WOS:000221680600026
J	Franks, ME; Macpherson, GR; Figg, WD				Franks, ME; Macpherson, GR; Figg, WD			Thalidomide	LANCET			English	Review							LOW-DOSE THALIDOMIDE; PHASE-II TRIAL; REFRACTORY MULTIPLE-MYELOMA; RENAL-CELL CARCINOMA; NECROSIS-FACTOR-ALPHA; INDEPENDENT PROSTATE-CANCER; TOXIC EPIDERMAL NECROLYSIS; IMMUNODEFICIENCY-VIRUS INFECTION; SYSTEMIC LUPUS-ERYTHEMATOSUS; SINGLE-AGENT THALIDOMIDE		NCI, Mol Pharmacol Sect, Canc Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20030 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Figg, WD (corresponding author), NCI, Mol Pharmacol Sect, Canc Therapeut Branch, Ctr Canc Res,NIH, 9000 Rockville Pike, Bethesda, MD 20030 USA.	wdfigg@helix.nih.gov	Figg, William D/M-2411-2016		NATIONAL CANCER INSTITUTE [Z01SC006538, ZIASC006538] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agoston I, 2002, J CARD FAIL, V8, P306, DOI 10.1054/jcaf.2002.128684; Ahmad I, 2002, BONE MARROW TRANSPL, V29, P577, DOI 10.1038/sj.bmt.1703522; Alexanian R, 2002, ANN ONCOL, V13, P1116, DOI 10.1093/annonc/mdf188; Amato RJ, 2003, CRIT REV ONCOL HEMAT, V46, pS59, DOI 10.1016/S1040-8428(03)00065-9; Anagnostopoulos A, 2003, BRIT J HAEMATOL, V121, P768, DOI 10.1046/j.1365-2141.2003.04345.x; Ando L, 2002, CANCER BIOL THER, V1, P669, DOI 10.4161/cbt.318; Ando Y, 2002, CLIN CANCER RES, V8, P1964; Arora M, 2001, BIOL BLOOD MARROW TR, V7, P265, DOI 10.1053/bbmt.2001.v7.pm11400948; ATRA E, 1993, CLIN EXP RHEUMATOL, V11, P487; Badros A, 2002, LEUKEMIA LYMPHOMA, V43, P1267, DOI 10.1080/10428190290026321; Baidas SM, 2000, J CLIN ONCOL, V18, P2710, DOI 10.1200/JCO.2000.18.14.2710; Bariol C, 2002, J GASTROEN HEPATOL, V17, P135, DOI 10.1046/j.1440-1746.2002.02564.x; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; Barlogie B, 2001, SEMIN ONCOL, V28, P577; Barosi G, 2001, BRIT J HAEMATOL, V114, P78, DOI 10.1046/j.1365-2141.2001.02918.x; Bauditz J, 2002, GUT, V50, P196, DOI 10.1136/gut.50.2.196; Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X; Baughman RP, 2002, CHEST, V122, P227, DOI 10.1378/chest.122.1.227; Behrens Robert J, 2003, Am J Ther, V10, P228, DOI 10.1097/00045391-200305000-00011; Bertolini F, 2001, ANN ONCOL, V12, P987, DOI 10.1023/A:1011141009812; BESSIS D, 1992, LANCET, V339, P549, DOI 10.1016/0140-6736(92)90365-A; Blade J, 2001, SEMIN ONCOL, V28, P588, DOI 10.1043/sonc.2001.28610; Bruera E, 1999, ANN ONCOL, V10, P857, DOI 10.1023/A:1008329821941; Canepa L, 2001, BRIT J HAEMATOL, V115, P313, DOI 10.1046/j.1365-2141.2001.03072.x; CARLESIMO M, 1995, J AM ACAD DERMATOL, V32, P866, DOI 10.1016/0190-9622(95)91549-4; Cavo M, 2002, BLOOD, V100, P2272, DOI 10.1182/blood-2002-06-1674; Chao N J, 1996, Biol Blood Marrow Transplant, V2, P86; Chaudhry V, 2002, NEUROLOGY, V59, P1872, DOI 10.1212/01.WNL.0000037480.59194.85; Coleman M, 2003, SEMIN ONCOL, V30, P270, DOI 10.1053/sonc.2003.50044; Coleman M, 2002, LEUKEMIA LYMPHOMA, V43, P1777, DOI 10.1080/1042819021000006303; Daliani DD, 2002, CANCER, V95, P758, DOI 10.1002/cncr.10740; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Daniel TO, 1999, CANCER RES, V59, P4574; Davey PP, 2000, QJM-INT J MED, V93, P305, DOI 10.1093/qjmed/93.5.305; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; Deaner P, 1998, PALLIATIVE MED, V12, P208, DOI 10.1177/026921639801200312; Desai AA, 2002, CANCER, V95, P1629, DOI 10.1002/cncr.10847; Dimopoulos MA, 2003, J CLIN ONCOL, V21, P4444, DOI 10.1200/JCO.2003.07.200; Dimopoulos MA, 2003, SEMIN ONCOL, V30, P265, DOI 10.1053/sonc.2003.50079; Dimopoulos MA, 2001, ANN ONCOL, V12, P991, DOI 10.1023/A:1011132808904; Dimopoulos MA, 2001, J CLIN ONCOL, V19, P3596, DOI 10.1200/JCO.2001.19.16.3596; Drake MJ, 2003, BRIT J CANCER, V88, P822, DOI 10.1038/sj.bjc.6600817; Ehrenpreis ED, 1999, GASTROENTEROLOGY, V117, P1271, DOI 10.1016/S0016-5085(99)70276-3; Eisen T, 2000, BRIT J CANCER, V82, P812, DOI 10.1054/bjoc.1999.1004; Eisen TG, 2000, ONCOLOGY-NY, V14, P17; Elliott MA, 2002, BRIT J HAEMATOL, V117, P288, DOI 10.1046/j.1365-2141.2002.03443.x; Escudier B, 2002, ANN ONCOL, V13, P1029, DOI 10.1093/annonc/mdf213; Estines O, 2001, ANN DERMATOL VENER, V128, P611; Fife K, 1998, INT J STD AIDS, V9, P751, DOI 10.1258/0956462981921512; Figg WD, 2001, SEMIN ONCOL, V28, P62, DOI 10.1053/sonc.2001.26904; Figg WD, 2001, CLIN CANCER RES, V7, P1888; Fine HA, 2000, J CLIN ONCOL, V18, P708, DOI 10.1200/JCO.2000.18.4.708; Fowler R, 2001, AM J HEMATOL, V66, P300, DOI 10.1002/ajh.1062; FREDERICKSON RCA, 1977, J PHARMACOL EXP THER, V203, P240; Fujita J, 2001, CLIN CANCER RES, V7, P3349; Govindarajan R, 2000, LANCET, V356, P566, DOI 10.1016/S0140-6736(00)02586-1; Govindarajan R, 2002, ONCOLOGY-NY, V16, P23; GOVINDARAJAN R, 2003, P AN M AM SOC CLIN, V22, P249; GRABSTAL.H, 1965, CLIN PHARMACOL THER, V6, P298; GUNZLER V, 1992, DRUG SAFETY, V7, P116; Gutheil J, 2000, BRIT J HAEMATOL, V110, P754, DOI 10.1046/j.1365-2141.2000.02239-11.x; GUTIERREZRODRIGUEZ O, 1989, J RHEUMATOL, V16, P158; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamuryudan V, 1998, ANN INTERN MED, V128, P443, DOI 10.7326/0003-4819-128-6-199803150-00004; HAMZA MH, 1986, CLIN RHEUMATOL, V5, P365, DOI 10.1007/BF02054255; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Horne MK, 2003, PHARMACOTHERAPY, V23, P315, DOI 10.1592/phco.23.3.315.32106; Horowitz SB, 1999, PHARMACOTHERAPY, V19, P1177, DOI 10.1592/phco.19.15.1177.30571; Huizinga TWJ, 1996, ANN RHEUM DIS, V55, P833, DOI 10.1136/ard.55.11.833; Hus M, 2001, HAEMATOLOGICA, V86, P404; Hwu WJ, 2001, LANCET ONCOL, V2, P634, DOI 10.1016/S1470-2045(01)00522-8; Hwu WJ, 2002, J CLIN ONCOL, V20, P2610, DOI 10.1200/JCO.2002.09.034; IYER CGS, 1971, B WORLD HEALTH ORGAN, V45, P719; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Juliusson G, 2000, BRIT J HAEMATOL, V109, P89, DOI 10.1046/j.1365-2141.2000.01983.x; Kane S, 2002, J CLIN GASTROENTEROL, V35, P149, DOI 10.1097/00004836-200208000-00006; Kaplan G, 2000, AIDS RES HUM RETROV, V16, P1345, DOI 10.1089/08892220050140892; Karim MY, 2001, LUPUS, V10, P188, DOI 10.1191/096120301677213822; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; KELSEY FO, 1988, TERATOLOGY, V38, P221, DOI 10.1002/tera.1420380305; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Kneller A, 2000, BRIT J HAEMATOL, V108, P391; KNOP J, 1983, BRIT J DERMATOL, V108, P461, DOI 10.1111/j.1365-2133.1983.tb04600.x; Koc S, 2000, BLOOD, V96, P3995, DOI 10.1182/blood.V96.12.3995.h8003995_3995_3996; Kurdziel, 2000, Clin Positron Imaging, V3, P144, DOI 10.1016/S1095-0397(00)00056-X; Leleu X, 2002, BLOOD, V100, P1519, DOI 10.1182/blood-2002-05-1527; LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303; Little RF, 2000, J CLIN ONCOL, V18, P2593, DOI 10.1200/JCO.2000.18.13.2593; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Marriott JB, 1997, DRUG DISCOV TODAY, V2, P273; Marriott JB, 2002, CLIN EXP IMMUNOL, V130, P75, DOI 10.1046/j.1365-2249.2002.01954.x; Marx GM, 2001, J NEURO-ONCOL, V54, P31, DOI 10.1023/A:1012554328801; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Meierhofer C, 2001, BIODRUGS, V15, P681, DOI 10.2165/00063030-200115100-00005; MELLIN GW, 1962, NEW ENGL J MED, V267, P1238, DOI 10.1056/NEJM196212132672407; Mileshkin L, 2003, BLOOD, V102, P69, DOI 10.1182/blood-2002-09-2846; Minor DR, 2002, INVEST NEW DRUG, V20, P389, DOI 10.1023/A:1020669705369; Moehler TM, 2001, BLOOD, V98, P3846, DOI 10.1182/blood.V98.13.3846; Molloy FM, 2001, MUSCLE NERVE, V24, P1050, DOI 10.1002/mus.1109; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Motzer RJ, 2002, J CLIN ONCOL, V20, P302, DOI 10.1200/JCO.20.1.302; Neben K, 2001, BRIT J HAEMATOL, V115, P605, DOI 10.1046/j.1365-2141.2001.03142.x; Neben K, 2001, CLIN CANCER RES, V7, P2675; Ng SSW, 2003, CANCER RES, V63, P3189; Ossandon A, 2002, CLIN EXP RHEUMATOL, V20, P709; Palumbo A, 2001, HAEMATOLOGICA, V86, P399; PATERSON DL, 1995, CLIN INFECT DIS, V20, P250, DOI 10.1093/clinids/20.2.250; Petrylak DP, 1999, SEMIN ONCOL, V26, P28; Peuckmann V, 2000, DRUGS, V60, P273, DOI 10.2165/00003495-200060020-00003; Piccaluga Pier Paolo, 2002, Haematologica, V87, pELT18; Piccaluga PP, 2002, LEUKEMIA, V16, P1609, DOI 10.1038/sj.leu.2402596; Price DK, 2002, THER DRUG MONIT, V24, P104, DOI 10.1097/00007691-200202000-00017; Rajkumar S V, 2001, Expert Rev Anticancer Ther, V1, P20, DOI 10.1586/14737140.1.1.20; Rajkumar SV, 2000, NEW ENGL J MED, V343, P972, DOI 10.1056/NEJM200009283431315; Rajkumar SV, 2000, MAYO CLIN PROC, V75, P897, DOI 10.4065/75.9.897; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038/sj.leu.2402866; Rajkumar SV, 2001, ONCOLOGY-NY, V15, P867; Ramirez-Amador VA, 1999, CLIN INFECT DIS, V28, P892, DOI 10.1086/515222; Raza A, 2001, BLOOD, V98, P958, DOI 10.1182/blood.V98.4.958; REVUZ J, 1990, ARCH DERMATOL, V126, P923, DOI 10.1001/archderm.126.7.923; Richardson P, 2002, ANNU REV MED, V53, P629, DOI 10.1146/annurev.med.53.082901.104043; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Rowland TL, 1998, IMMUNOPHARMACOLOGY, V40, P11, DOI 10.1016/S0162-3109(98)00010-1; Sabate JM, 2002, ALIMENT PHARM THER, V16, P1117, DOI 10.1046/j.1365-2036.2002.01273.x; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; Scoville CD, 2001, CLIN EXP RHEUMATOL, V19, P360; Shek LPC, 2002, BIOMED PHARMACOTHER, V56, P31, DOI 10.1016/S0753-3322(01)00154-8; SHESKIN J, 1980, INT J DERMATOL, V19, P318, DOI 10.1111/j.1365-4362.1980.tb00342.x; Short SC, 2001, J NEURO-ONCOL, V51, P41, DOI 10.1023/A:1006414804835; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Singhal S, 2001, BIODRUGS, V15, P163, DOI 10.2165/00063030-200115030-00003; Sinibaldi VJ, 2002, CANCER-AM CANCER SOC, V94, P1457, DOI 10.1002/cncr.10350; Stebbing J, 2001, BRIT J CANCER, V85, P953, DOI 10.1054/bjoc.2001.2025; Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3; Strasser K, 2002, BLOOD REV, V16, P207, DOI 10.1016/S0268-960X(02)00031-0; Teo SK, 2002, MICROBES INFECT, V4, P1193, DOI 10.1016/S1286-4579(02)01645-3; Thomas DA, 2000, CURR OPIN ONCOL, V12, P564, DOI 10.1097/00001622-200011000-00009; Tosi P, 2002, HAEMATOLOGICA, V87, P408; Trojan A, 2003, ANN ONCOL, V14, P501, DOI 10.1093/annonc/mdg095; Tseng JE, 2001, CANCER-AM CANCER SOC, V92, P2364, DOI 10.1002/1097-0142(20011101)92:9<2364::AID-CNCR1584>3.0.CO;2-P; Vasiliauskas EA, 1999, GASTROENTEROLOGY, V117, P1278, DOI 10.1016/S0016-5085(99)70277-5; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; Wines Nina Y, 2002, Australas J Dermatol, V43, P229, DOI 10.1046/j.1440-0960.2002.00608.x; Wnendt S, 1996, CHIRALITY, V8, P390, DOI 10.1002/(SICI)1520-636X(1996)8:5<390::AID-CHIR6>3.0.CO;2-I; Wolkenstein P, 1998, LANCET, V352, P1586, DOI 10.1016/S0140-6736(98)02197-7; Yakoub-Agha I, 2000, Hematol J, V1, P186, DOI 10.1038/sj.thj.6200031; Yakoub-Agha Ibrahim, 2002, Hematol J, V3, P185, DOI 10.1038/sj.thj.6200175; Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301; Zangari M, 2002, BLOOD, V100, P1168, DOI 10.1182/blood-2002-01-0335; Zeldis JB, 1999, CLIN THER, V21, P319, DOI 10.1016/S0149-2918(00)88289-2; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598; Zorat F, 2001, BRIT J HAEMATOL, V115, P881, DOI 10.1046/j.1365-2141.2001.03204.x	158	427	454	6	93	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1802	1811		10.1016/S0140-6736(04)16308-3	http://dx.doi.org/10.1016/S0140-6736(04)16308-3			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172781	Green Submitted			2022-12-28	WOS:000221705800024
J	Cappuccio, FP; Kerry, SM; Forbes, L; Donald, A				Cappuccio, FP; Kerry, SM; Forbes, L; Donald, A			Blood pressure control by home monitoring: meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; HYPERTENSION MANAGEMENT; PUBLICATION BIAS; PATIENT; STROKE; CARE; EDUCATION; OFFICE	Objective To determine the effect of home blood pressure monitoring on blood pressure levels and proportion achieving targets in people with essential hypertension. Design Meta-analysis of 18 randomised controlled trials. Participants 1359 people with essential hypertension allocated to home blood pressure monitoring and 1355 allocated to the "control" group seen in the healthcare system for 2-36 months. Main outcome measures Differences in systolic (n = 13 studies), diastolic (n = 16), or mean (n = 3) blood pressures, and proportion of patients achieving targets (n = 6), between intervention and control groups. Results Systolic blood pressure was lower in people with hypertension who had home blood pressure monitoring than in those who had standard blood pressure monitoring in the healthcare system (standardised mean difference 4.2 (95% confidence interval 1.5 to 6.9) mm Hg), diastolic blood pressure was lower by 2.4 (1.2 to 3.5) nun Hg, and mean blood pressure was lower by 4.4 (2.0 to 6.8) mm Hg. The relative risk of blood pressure above predetermined targets was lower in people with home blood pressure monitoring (risk ratio 0.90, 0.80 to 1.00). When publication bias was allowed for, the differences were attenuated: 2.2 (-0.9 to 5.3) mm Hg for systolic blood pressure and 1.9 (0.6 to 3.2) rum Hg for diastolic blood pressure. Conclusions Blood pressure control in people with hypertension (assessed in the clinic) and the proportion achieving targets are increased when home blood pressure monitoring is used compared with standard blood pressure monitoring in the healthcare system. The reasons for this are not clear. The difference in blood pressure control between the two methods is small but likely to contribute to an important reduction in vascular complications in the hypertensive population.	St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England; Bazian Ltd, London N1 1QP, England	St Georges University London	Cappuccio, FP (corresponding author), St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England.	f.cappuccio@sghms.ac.uk	Cappuccio, Francesco/D-3028-2009; Forbes, Lindsay/X-4632-2019; Forbes, Lindsay J/E-3586-2010; Cappuccio, Francesco Paolo/ABF-1094-2020	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Forbes, Lindsay/0000-0002-4654-9520				Artinian NT, 2001, HEART LUNG, V30, P191, DOI 10.1067/mhl.2001.112684; Aylett M, 1999, BRIT J GEN PRACT, V49, P725; Bailey B, 1999, J HUM HYPERTENS, V13, P147, DOI 10.1038/sj.jhh.1000758; BINSTOCK ML, 1988, AM J HYPERTENS, V1, pS192, DOI 10.1093/ajh/1.3.192S; Broege PA, 2001, BLOOD PRESS MONIT, V6, P139, DOI 10.1097/00126097-200106000-00004; Brueren MM, 1998, BRIT J GEN PRACT, V48, P1585; CARNAHAN JE, 1975, AM J MED SCI, V269, P69, DOI 10.1097/00000441-197501000-00008; CARTWRIGHT W, 1992, BRIT J OBSTET GYNAEC, V99, P182, DOI 10.1111/j.1471-0528.1992.tb14495.x; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Du XL, 1997, BMJ-BRIT MED J, V314, P272, DOI 10.1136/bmj.314.7076.272; EARP JAL, 1982, AM J PUBLIC HEALTH, V72, P1146, DOI 10.2105/AJPH.72.10.1146; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Friedman RH, 1996, AM J HYPERTENS, V9, P285, DOI 10.1016/0895-7061(95)00353-3; GLANZ K, 1981, MED CARE, V19, P141, DOI 10.1097/00005650-198102000-00002; HAYNES RB, 1976, LANCET, V1, P1265; JOHNSON AL, 1978, CAN MED ASSOC J, V119, P1034; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Little P, 2002, BRIT MED J, V325, P258, DOI 10.1136/bmj.325.7358.258; Little P, 2002, BMJ-BRIT MED J, V325, P254, DOI 10.1136/bmj.325.7358.254; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mehos BM, 2000, PHARMACOTHERAPY, V20, P1384, DOI 10.1592/phco.20.17.1384.34891; MIDANIK LT, 1991, PUBLIC HEALTH REP, V106, P85; MUHLHAUSER I, 1993, CLIN EXP HYPERTENS, V15, P125, DOI 10.3109/10641969309041615; Nordmann A, 1999, BMJ-BRIT MED J, V319, P1172, DOI 10.1136/bmj.319.7218.1172; PIERCE JP, 1984, PREV MED, V13, P185, DOI 10.1016/0091-7435(84)90050-1; Primatesta P, 2001, HYPERTENSION, V38, P827, DOI 10.1161/hyp.38.4.827; Qizilbash N, 1995, LANCET, V346, P1647; Rickerby J, 2002, J HUM HYPERTENS, V16, P469, DOI 10.1038/sj.jhh.1001423; Rogers MAM, 2001, ANN INTERN MED, V134, P1024, DOI 10.7326/0003-4819-134-11-200106050-00008; Ross-McGill H, 2000, BRIT J OBSTET GYNAEC, V107, P217, DOI 10.1111/j.1471-0528.2000.tb11692.x; SOGHIKIAN K, 1992, MED CARE, V30, P855, DOI 10.1097/00005650-199209000-00009; Staessen JA, 2004, JAMA-J AM MED ASSOC, V291, P955, DOI 10.1001/jama.291.8.955; STAHL SM, 1984, AM J PUBLIC HEALTH, V74, P704, DOI 10.2105/AJPH.74.7.704; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; Sutton AJ, 2000, STAT METHODS MED RES, V9, P421, DOI 10.1191/096228000701555244; Vetter W, 2000, J HUM HYPERTENS, V14, P235, DOI 10.1038/sj.jhh.1000977; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Yarows SA, 2000, ARCH INTERN MED, V160, P1251, DOI 10.1001/archinte.160.9.1251; Yarows SA, 2002, AM J HYPERTENS, V15, P93, DOI 10.1016/S0895-7061(01)02277-4; Zarnke KB, 1997, AM J HYPERTENS, V10, P58, DOI 10.1016/S0895-7061(96)00305-6	41	331	338	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	2004	329	7458					145	148A		10.1136/bmj.38121.684410.AE	http://dx.doi.org/10.1136/bmj.38121.684410.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15194600	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222832300020
J	Han, JDJ; Bertin, N; Hao, T; Goldberg, DS; Berriz, GF; Zhang, LV; Dupuy, D; Walhout, AJM; Cusick, ME; Roth, FP; Vidal, M				Han, JDJ; Bertin, N; Hao, T; Goldberg, DS; Berriz, GF; Zhang, LV; Dupuy, D; Walhout, AJM; Cusick, ME; Roth, FP; Vidal, M			Evidence for dynamically organized modularity in the yeast protein-protein interaction network	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENOME; SCALE; IDENTIFICATION; ROBUSTNESS; MAP	In apparently scale-free protein-protein interaction networks, or 'interactome' networks(1,2), most proteins interact with few partners, whereas a small but significant proportion of proteins, the 'hubs', interact with many partners. Both biological and nonbiological scale-free networks are particularly resistant to random node removal but are extremely sensitive to the targeted removal of hubs(1). A link between the potential scale-free topology of interactome networks and genetic robustness(3,4) seems to exist, because knockouts of yeast genes(5,6) encoding hubs are approximately threefold more likely to confer lethality than those of non-hubs(1). Here we investigate how hubs might contribute to robustness and other cellular properties for protein protein interactions dynamically regulated both in time and in space. We uncovered two types of hub: 'party' hubs, which interact with most of their partners simultaneously, and 'date' hubs, which bind their different partners at different times or locations. Both in silico studies of network connectivity and genetic interactions described in vivo support a model of organized modularity in which date hubs organize the proteome, connecting biological processes-or modules(7)-to each other, whereas party hubs function inside modules.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Vidal, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Syst Biol, 44 Binney St, Boston, MA 02115 USA.	marc_vidal@dfci.harvard.edu	Bertin, Nicolas/O-9602-2019; Dupuy, Denis/M-7299-2014; Roth, Frederick P/H-6308-2011; Bertin, Nicolas/C-3025-2008	Bertin, Nicolas/0000-0002-9835-9606; Walhout, Marian/0000-0001-5587-3608; Han, Jing-Dong J./0000-0002-9270-7139; Roth, Frederick/0000-0002-6628-649X; Dupuy, Denis/0000-0002-4781-5595				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ideker T, 2003, TRENDS BIOTECHNOL, V21, P255, DOI 10.1016/S0167-7799(03)00115-X; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kemmeren P, 2002, MOL CELL, V9, P1133, DOI 10.1016/S1097-2765(02)00531-2; Le Pont F, 2003, SEX TRANSM DIS, V30, P6, DOI 10.1097/00007435-200301000-00002; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Papin JA, 2003, TRENDS BIOCHEM SCI, V28, P250, DOI 10.1016/S0968-0004(03)00064-1; Snel B, 2002, P NATL ACAD SCI USA, V99, P5890, DOI 10.1073/pnas.092632599; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	28	1285	1332	4	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					88	93		10.1038/nature02555	http://dx.doi.org/10.1038/nature02555			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15190252				2022-12-28	WOS:000222356800049
J	Shumaker, SA; Legault, C; Kuller, L; Rapp, SR; Thal, L; Lane, DS; Fillit, H; Stefanick, ML; Hendrix, SL; Lewis, CE; Masaki, K; Coker, LH				Shumaker, SA; Legault, C; Kuller, L; Rapp, SR; Thal, L; Lane, DS; Fillit, H; Stefanick, ML; Hendrix, SL; Lewis, CE; Masaki, K; Coker, LH		Women's Hlth Initiative Memory Stu	Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women - Women's Health Initiative Memory Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; MIDLIFE BLOOD-PRESSURE; SILENT BRAIN INFARCTS; ALZHEIMERS-DISEASE; OLDER WOMEN; CARDIOVASCULAR HEALTH; PLUS PROGESTIN; DOUBLE-BLIND; RISK-FACTORS	Context The Women's Health Initiative Memory Study (WHIMS) previously found increased risk for dementia and no effect on mild cognitive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA). Objective To determine the effects of CEE alone and CEE plus MPA on incidence of probable dementia and MCI in older women. Design, Setting, and Participants Randomized, double-blind, placebo-controlled clinical trials of CEE (estrogen-alone trial) or CEE plus MPA (estrogen plus progestin trial) in community-dwelling women aged 65 to 79 years, conducted from June 1995 to July 8, 2002 (estrogen plus progestin; n=4532), or to February 29, 2004 (estrogen-alone; n=2947), in 39 of the 40 WHI clinical centers. Interventions In the estrogen-alone trial, 1 daily tablet containing either 0.625 mg/d of CEE vs matching placebo; in the estrogen plus progestin trial, 1 daily tablet containing CEE (0.625 mg/d) plus MPA (2.5 mg/d) vs matching placebos. Main Outcome Measures Probable dementia and MCI. Results In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). Incidence rates for probable dementia in the estrogen-alone trial were statistically similar to those in the estrogen plus progestin trial (45 vs 22 per 10000 person-years for CEE plus MPA vs placebo, respectively; P=.11). When data were pooled per the original WHIMS protocol, the overall HR for probable dementia was 1.76 (95% Cl, 1.19-2.60; P=.005). After excluding participants with baseline Modified Mini-Mental State Examination scores at or below the screening cut point, the HR was 1.77 (95% Cl, 0.74-4.23; P=.20) in the estrogen-alone trial and 2.19 (95% Cl, 1.25-3.84; P=.006) in the pooled trials. In the estrogen-alone trial, 76 participants were diagnosed with MCI in the CEE group vs 58 in the placebo group (HR, 1.34; 95% Cl 0.95-1.89). In the combined trial data, the HR was similar (1.25; 95% Cl, 0.97-1.60). In the estrogen-alone trial, 93 participants receiving CEE were diagnosed with either probable dementia or MCI vs 69 receiving placebo (HR, 1.38; 95% Cl, 1.01-1.89; P=.04). Conclusions Estrogen therapy alone did not reduce dementia or MCI incidence and increased the risk for both end points combined. Pooling data for estrogen alone and estrogen plus progestin resulted in increased risks for both end points. Use of hormone therapy to prevent dementia or cognitive decline in women 65 years of age or older is not recommended.	Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Inst Study Aging, New York, NY USA; Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynecol, Detroit, MI USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Hawaii, Dept Geriatr Med, Honolulu, HI 96822 USA	Wake Forest University; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Diego; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stanford University; Wayne State University; University of Alabama System; University of Alabama Birmingham; University of Hawaii System	Shumaker, SA (corresponding author), Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.	sshumake@wfubmc.edu						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Beck TJ, 2001, J BONE MINER RES, V16, P2103, DOI 10.1359/jbmr.2001.16.11.2103; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Bryan RN, 1997, RADIOLOGY, V202, P47, DOI 10.1148/radiology.202.1.8988191; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; COX DR, 1972, J R STAT SOC B, V34, P187; Esiri MM, 2001, LANCET, V357, P169; Fisk JD, 2003, NEUROLOGY, V61, P1179, DOI 10.1212/01.WNL.0000089238.07771.C7; GANGULI M, 1993, J GERONTOL, V48, pM152, DOI 10.1093/geronj/48.4.M152; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; Iadecola C, 2003, STROKE, V34, P335, DOI 10.1161/01.STR.0000054050.51530.76; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Linzmayer L, 2001, ARZNEIMITTEL-FORSCH, V51, P238; Longstreth WT, 2002, STROKE, V33, P2376, DOI 10.1161/01.STR.0000032241.58727.49; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Steffens DC, 1999, J AM GERIATR SOC, V47, P1171, DOI 10.1111/j.1532-5415.1999.tb05195.x; Swan GE, 1998, NEUROLOGY, V51, P986, DOI 10.1212/WNL.51.4.986; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; *US FDA, FDA UPD HORM THER IN; Vermeer SE, 2002, STROKE, V33, P21, DOI 10.1161/hs0102.101629; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123	50	906	939	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2947	2958		10.1001/jama.291.24.2947	http://dx.doi.org/10.1001/jama.291.24.2947			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213206				2022-12-28	WOS:000222184600024
J	Grantham, BA; Chan, F; Nielsen, KJ; Fox, DS; Barth, JA; Huyer, A; Lubchenco, J; Menge, BA				Grantham, BA; Chan, F; Nielsen, KJ; Fox, DS; Barth, JA; Huyer, A; Lubchenco, J; Menge, BA			Upwelling-driven nearshore hypoxia signals ecosystem and oceanographic changes in the northeast Pacific	NATURE			English	Article							CALIFORNIA CURRENT; ART.; OREGON; OCEAN; CHLOROPHYLL; SHELF	Seasonal development of dissolved-oxygen deficits (hypoxia) represents an acute system-level perturbation to ecological dynamics and fishery sustainability in coastal ecosystems around the globe(1-3). Whereas anthropogenic nutrient loading has increased the frequency and severity of hypoxia in estuaries and semi-enclosed seas(3,4), the occurrence of hypoxia in open-coast upwelling systems reflects ocean conditions that control the delivery of oxygen-poor and nutrient-rich deep water onto continental shelves(1). Upwelling systems support a large proportion of the world's fisheries(5), therefore understanding the links between changes in ocean climate, upwelling-driven hypoxia and ecological perturbations is critical. Here we report on the unprecedented development of severe inner-shelf (<70 m) hypoxia and resultant mass die-offs of fish and invertebrates within the California Current System. In 2002, cross-shelf transects revealed the development of abnormally low dissolved-oxygen levels as a response to anomalously strong flow of subarctic water into the California Current System. Our findings highlight the sensitivity of inner-shelf ecosystems to variation in ocean conditions, and the potential impacts of climate change on marine communities.	Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; Washington State Dept Ecol, Coastal & Estuarine Assessment Unit, Olympia, WA 98504 USA; Sonoma State Univ, Dept Biol, Rohnert Pk, CA 94928 USA; Oregon Dept Fish & Wildlife, Marine Resources Program, Newport, OR 97365 USA	Oregon State University; Oregon State University; California State University System; Sonoma State University	Chan, F (corresponding author), Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA.	chanft@science.oregonstate.edu	Nielsen, Karina Johanne/AAQ-6430-2020; Menge, Bruce/I-6571-2012	Nielsen, Karina/0000-0002-7438-0240				BAILEY GW, 1985, S AFRICAN J MARINE S, V3, P197; BAKUN A, 1990, SCIENCE, V247, P198, DOI 10.1126/science.247.4939.198; Barth JA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017511; Chavez FP, 2003, SCIENCE, V299, P217, DOI 10.1126/science.1075880; Diaz RJ, 1995, OCEANOGR MAR BIOL, V33, P245; Diaz RJ, 2001, J ENVIRON QUAL, V30, P275, DOI 10.2134/jeq2001.302275x; DILLMAN T, 2002, ABUNDANCE FISH AREA; FLEISCHBEIN J, 2003, US GLOBEC; FOX DS, 2000, OREGON DEP FISH WILD; HUYER A, 1983, PROG OCEANOGR, V12, P259, DOI 10.1016/0079-6611(83)90010-1; HUYER A, 1974, Tethys, V6, P391; KAMYKOWSKI D, 1990, DEEP-SEA RES, V37, P1861, DOI 10.1016/0198-0149(90)90082-7; Kosro PM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017436; Morales CE, 1999, J MAR RES, V57, P909, DOI 10.1357/002224099321514097; Murphree T, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017303; Naqvi SWA, 2000, NATURE, V408, P346, DOI 10.1038/35042551; *NAT MAR FISH SERV, 1999, NMFSFSPO41 NOAA US D; *NAT RES COUNC, 2000, COAST WAT UND RED EF; Oke PR, 2002, J PHYS OCEANOGR, V32, P1360, DOI 10.1175/1520-0485(2002)032<1360:AMSOTT>2.0.CO;2; OMALLEY R, 2003, SEASOAR OBSERVATIONS; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; Rabalais NN, 2001, COAST EST S, V58, P1; REELAND HJ, 2003, GEOPHYS RES LETT, V30, P1141, DOI DOI 10.1029/2002GL016663; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; Strub PT, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017513; Thomas AC, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017409; Wheeler PA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017395	27	401	416	12	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					749	754		10.1038/nature02605	http://dx.doi.org/10.1038/nature02605			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201908				2022-12-28	WOS:000222059900036
J	Picard, F; Kurtev, M; Chung, NJ; Topark-Ngarm, A; Senawong, T; de Oliveira, RM; Leid, M; McBurney, MW; Guarente, L				Picard, F; Kurtev, M; Chung, NJ; Topark-Ngarm, A; Senawong, T; de Oliveira, RM; Leid, M; McBurney, MW; Guarente, L			Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma	NATURE			English	Article							CEREVISIAE LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES; ADIPOSE-TISSUE; RECEPTOR; DIFFERENTIATION; ADIPOGENESIS	Calorie restriction extends lifespan in organisms ranging from yeast to mammals(1). In yeast, the SIR2 gene mediates the life-extending effects of calorie restriction(2). Here we show that the mammalian SIR2 orthologue, Sirt1 (sirtuin 1), activates a critical component of calorie restriction in mammals; that is, fat mobilization in white adipocytes. Upon food withdrawal Sirt1 protein binds to and represses genes controlled by the fat regulator PPAR-gamma (peroxisome proliferator-activated receptor-gamma), including genes mediating fat storage. Sirt1 represses PPAR-gamma by docking with its cofactors NCoR (nuclear receptor co-repressor) and SMRT ( silencing mediator of retinoid and thyroid hormone receptors). Mobilization of fatty acids from white adipocytes upon fasting is compromised in Sirt1(+/-) mice. Repression of PPAR-gamma by Sirt1 is also evident in 3T3-L1 adipocytes, where overexpression of Sirt1 attenuates adipogenesis, and RNA interference of Sirt1 enhances it. In differentiated fat cells, upregulation of Sirt1 triggers lipolysis and loss of fat. As a reduction in fat is sufficient to extend murine lifespan(3), our results provide a possible molecular pathway connecting calorie restriction to life extension in mammals.	MIT, Dept Biol, Cambridge, MA 02139 USA; Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA; Univ Porto, ICBAS, Grad Program Basic & Appl Biol, P-4099003 Oporto, Portugal; Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON K1H 1C4, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 1C4, Canada	Massachusetts Institute of Technology (MIT); Oregon State University; Oregon State University; Universidade do Porto; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu	de Oliveira, Rita M/E-9696-2015	de Oliveira, Rita M/0000-0002-0970-4501	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060852] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060852, R01 GM060852-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gabriely I, 2001, MECH AGEING DEV, V122, P1565, DOI 10.1016/S0047-6374(01)00287-1; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; MARETTE A, 1991, AM J PHYSIOL, V261, pE204, DOI 10.1152/ajpendo.1991.261.2.E204; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Miles PDG, 2003, AM J PHYSIOL-ENDOC M, V284, pE618, DOI 10.1152/ajpendo.00312.2002; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Weindruch R., 1988, RETARDATION AGING DI	30	1546	1674	2	187	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					771	776		10.1038/nature02583	http://dx.doi.org/10.1038/nature02583			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15175761	Green Accepted			2022-12-28	WOS:000222059900041
J	Montoya, JG; Liesenfeld, O				Montoya, JG; Liesenfeld, O			Toxoplasmosis	LANCET			English	Review							POLYMERASE-CHAIN-REACTION; TO-CHILD TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; IMMUNOGLOBULIN-M ANTIBODIES; CONGENITAL TOXOPLASMOSIS; GONDII INFECTION; PRENATAL-DIAGNOSIS; ACQUIRED TOXOPLASMOSIS; PREGNANT-WOMEN; ENCEPHALITIS	Toxoplasma gondii is a protozoan parasite that infects up to a third of the world's population. Infection is mainly acquired by ingestion of food or water that is contaminated with oocysts shed by cats or by eating undercooked or raw meat containing tissue cysts. Primary infection is usually subclinical but in some patients cervical lymphadenopathy or ocular disease can be present. Infection acquired during pregnancy may cause severe damage to the fetus. In immunocompromised patients, reactivation of latent disease can cause life-threatening encephalitis. Diagnosis of toxoplasmosis can be established by direct detection of the parasite or by serological techniques. The most commonly used therapeutic regimen, and probably the most effective, is the combination of pyrimethamine with sulfadiazine and folinic acid. This Seminar provides an overview and update on management of patients with acute infection, pregnant women who acquire infection during gestation, fetuses or infants who are congenitally infected, those with ocular disease, and immunocompromised individuals. Controversy about the effectiveness of primary and secondary prevention in pregnant women is discussed. Important topics of current and future research are presented.	Charite Univ Med Berlin, Inst Infect Med, Dept Med Microbiol & Immunol Infect, D-12203 Berlin, Germany; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Palo Alto Med Fdn Res Inst, Palo Alto, CA USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; Stanford University; Palo Alto Medical Foundation Research Institute	Liesenfeld, O (corresponding author), Charite Univ Med Berlin, Inst Infect Med, Dept Med Microbiol & Immunol Infect, Campus Benjamin Franklin,Hindenburgdamm 27, D-12203 Berlin, Germany.	oliver.liesenfeld@charite.de		Montoya, Jose G/0000-0002-3378-8071				Ajzenberg D, 2002, J INFECT DIS, V186, P684, DOI 10.1086/342663; ASPOCK H, 1992, SCAND J INFECT DIS, P32; Bahia-Oliveira LMG, 2003, EMERG INFECT DIS, V9, P55; BALSARI A, 1980, J CLIN PATHOL, V33, P640, DOI 10.1136/jcp.33.7.640; Barragan A, 2002, J EXP MED, V195, P1625, DOI 10.1084/jem.20020258; Bhopale GM, 2003, MICROBES INFECT, V5, P457, DOI 10.1016/S1286-4579(03)00048-0; Bliss SK, 1999, J IMMUNOL, V162, P7369; Bowie WR, 1997, LANCET, V350, P173, DOI 10.1016/S0140-6736(96)11105-3; BREZIN AP, 1990, AM J OPHTHALMOL, V110, P599, DOI 10.1016/S0002-9394(14)77055-2; BROOKS RG, 1986, HOSPITAL INFECTIONS, P581; BULOW R, 1991, J IMMUNOL, V147, P3496; Burnett AJ, 1998, OPHTHALMOLOGY, V105, P1032, DOI 10.1016/S0161-6420(98)96004-3; BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X; CAZENAVE J, 1991, J CLIN PATHOL, V44, P1037, DOI 10.1136/jcp.44.12.1037-a; CHARDES T, 1994, J IMMUNOL, V153, P4596; CHARDES T, 1990, INFECT IMMUN, V58, P1240; Chirgwin K, 2002, CLIN INFECT DIS, V34, P1243, DOI 10.1086/339551; CONLEY FK, 1981, HUM PATHOL, V12, P690, DOI 10.1016/S0046-8177(81)80170-0; Cook AJC, 2000, BRIT MED J, V321, P142, DOI 10.1136/bmj.321.7254.142; CORNELISSEN AWCA, 1984, PARASITOLOGY, V88, P531, DOI 10.1017/S0031182000054792; Costa JM, 2001, PRENATAL DIAG, V21, P85, DOI 10.1002/1097-0223(200102)21:2&lt;85::AID-PD18&gt;3.0.CO;2-1; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DANNEMANN BR, 1990, J CLIN MICROBIOL, V28, P1928, DOI 10.1128/JCM.28.9.1928-1933.1990; DeBoer JH, 1996, AM J OPHTHALMOL, V121, P650, DOI 10.1016/S0002-9394(14)70631-2; DECOSTER A, 1991, J CLIN MICROBIOL, V29, P2291, DOI 10.1128/JCM.29.10.2291-2295.1991; Denkers EY, 1998, CLIN MICROBIOL REV, V11, P569, DOI 10.1128/CMR.11.4.569; DEPAOLI P, 1992, J CLIN MICROBIOL, V30, P729, DOI 10.1128/JCM.30.3.729-731.1992; DESMONTS G, 1965, REV FR ETUD CLIN BIO, V10, P952; DESMONTS G, 1981, J CLIN MICROBIOL, V14, P486, DOI 10.1128/JCM.14.5.486-491.1981; Desmonts G, 1985, Prog Clin Biol Res, V163B, P333; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; DORFMAN RF, 1973, NEW ENGL J MED, V289, P878, DOI 10.1056/NEJM197310252891702; Dubey JP, 2002, J PARASITOL, V88, P1234, DOI 10.1645/0022-3395(2002)088[1234:HPOVTG]2.0.CO;2; DUBEY JP, 1970, J EXP MED, V132, P636, DOI 10.1084/jem.132.4.636; Dunn D, 1999, LANCET, V353, P1829, DOI 10.1016/S0140-6736(98)08220-8; DUPOUYCAMET J, 1993, J CLIN MICROBIOL, V31, P1866, DOI 10.1128/JCM.31.7.1866-1869.1993; Eskild A, 1996, J Med Screen, V3, P188; Fardeau C, 2002, AM J OPHTHALMOL, V134, P196, DOI 10.1016/S0002-9394(02)01500-3; Filisetti D, 2003, J CLIN MICROBIOL, V41, P4826, DOI 10.1128/JCM.41.10.4826-4828.2003; Forestier F, 1998, PRENATAL DIAG, V18, P407, DOI 10.1002/(SICI)1097-0223(199804)18:4&lt;407::AID-PD259&gt;3.0.CO;2-7; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; Foulon W, 1999, AM J OBSTET GYNECOL, V180, P410, DOI 10.1016/S0002-9378(99)70224-3; Fox BA, 2002, NATURE, V415, P926, DOI 10.1038/415926a; Frenkel J. K., 1973, The coccidia,, P343; FRENKEL JK, 1974, B NEW YORK ACAD MED, V50, P182; Fuentes I, 1996, J CLIN MICROBIOL, V34, P2368, DOI 10.1128/JCM.34.10.2368-2371.1996; Gavinet MF, 1997, J CLIN MICROBIOL, V35, P1276, DOI 10.1128/JCM.35.5.1276-1277.1997; Gay-Andrieu F, 2003, PRENATAL DIAG, V23, P558, DOI 10.1002/pd.632; Giaquinto C, 1996, EUR J OBSTET GYN R B, V68, P93; Gilbert R, 2003, BJOG-INT J OBSTET GY, V110, P112, DOI 10.1016/S1470-0328(02)02325-X; Gilbert R, 2001, EPIDEMIOL INFECT, V127, P113, DOI 10.1017/S095026880100560X; Gilbert RE, 2001, INT J EPIDEMIOL, V30, P1303, DOI 10.1093/ije/30.6.1303; Gras L, 2001, INT J EPIDEMIOL, V30, P1309, DOI 10.1093/ije/30.6.1309; Grigg ME, 2001, SCIENCE, V294, P161, DOI 10.1126/science.1061888; GROVER CM, 1990, J CLIN MICROBIOL, V28, P2297, DOI 10.1128/JCM.28.10.2297-2301.1990; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HEDMAN K, 1989, J INFECT DIS, V159, P736, DOI 10.1093/infdis/159.4.736; HITT JA, 1992, J CLIN MICROBIOL, V30, P3181, DOI 10.1128/JCM.30.12.3181-3184.1992; HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102; Holland GN, 2002, AM J OPHTHALMOL, V134, P102, DOI 10.1016/S0002-9394(02)01526-X; Holland GN, 1999, AM J OPHTHALMOL, V128, P502, DOI 10.1016/S0002-9394(99)00263-9; HOLLAND GN, 1996, OCULAR INFECT IMMUNI, P1183; HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561; Ismael AB, 2003, INFECT IMMUN, V71, P6222, DOI 10.1128/IAI.71.11.6222-6228.2003; Israelski D M, 1993, Curr Clin Top Infect Dis, V13, P322; Jenum PA, 1997, J CLIN MICROBIOL, V35, P1972, DOI 10.1128/JCM.35.8.1972-1977.1997; Jenum PA, 1998, J CLIN MICROBIOL, V36, P2900, DOI 10.1128/JCM.36.10.2900-2906.1998; Jones JL, 2001, AM J EPIDEMIOL, V154, P357, DOI 10.1093/aje/154.4.357; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; KAYHOE DE, 1957, NEW ENGL J MED, V257, P1247, DOI 10.1056/NEJM195712262572601; KIMBALL AC, 1971, AM J OBSTET GYNECOL, V111, P211, DOI 10.1016/0002-9378(71)90892-1; Kong JT, 2003, J INFECT DIS, V187, P1484, DOI 10.1086/374647; LAPPALAINEN M, 1993, J INFECT DIS, V167, P691, DOI 10.1093/infdis/167.3.691; Lebech M, 1999, LANCET, V353, P1834, DOI 10.1016/S0140-6736(98)11281-3; Liesenfeld O, 1997, J CLIN MICROBIOL, V35, P174, DOI 10.1128/JCM.35.1.174-178.1997; Liesenfeld O, 2001, AM J OBSTET GYNECOL, V184, P140, DOI 10.1067/mob.2001.108341; Liesenfeld O, 1999, IMMUNOBIOLOGY, V201, P229, DOI 10.1016/S0171-2985(99)80063-1; Liesenfeld O, 2001, J INFECT DIS, V183, P1248, DOI 10.1086/319672; LIESENFELD O, 2001, INFECT DIS WOMEN, P57; Luder CGK, 1998, CLIN EXP IMMUNOL, V112, P308; Luder CGK, 2003, J NEUROIMMUNOL, V134, P12, DOI 10.1016/S0165-5728(02)00320-X; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; LUFT BJ, 1986, TRANSPLANT P, V18, P1871; LUFT BJ, 1983, LANCET, V1, P781; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; Mariuz P, 1997, Semin Respir Infect, V12, P40; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; Meissner M, 2002, SCIENCE, V298, P837, DOI 10.1126/science.1074553; Mele A, 2002, BONE MARROW TRANSPL, V29, P691, DOI 10.1038/sj.bmt.1703425; MINEO JR, 1993, J IMMUNOL, V150, P3951; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P555, DOI 10.1016/S0002-9378(97)70547-7; Montoya J.G., 2000, PRINCIPLES PRACTICE, P2858; Montoya JG, 1997, CLIN INFECT DIS, V24, P676, DOI 10.1093/clind/24.4.676; Montoya JG, 1996, CLIN INFECT DIS, V23, P277, DOI 10.1093/clinids/23.2.277; Montoya JG, 2002, J INFECT DIS, V185, pS73, DOI 10.1086/338827; Montoya JG, 2002, J CLIN MICROBIOL, V40, P2504, DOI 10.1128/JCM.40.7.2504-2508.2002; MONTOYA JG, 1995, CLIN INFECT DIS, V20, P781, DOI 10.1093/clinids/20.4.781; Montoya JG, 1999, OPHTHALMOLOGY, V106, P1554, DOI 10.1016/S0161-6420(99)90453-0; Montoya JG, 1996, INFECT IMMUN, V64, P176, DOI 10.1128/IAI.64.1.176-181.1996; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; NAOT Y, 1981, J PEDIATR-US, V98, P32, DOI 10.1016/S0022-3476(81)80528-8; Nash PB, 1998, J IMMUNOL, V160, P1824; Nielsen HV, 1999, INFECT IMMUN, V67, P6358; Petersen E, 1998, VACCINE, V16, P1283, DOI 10.1016/S0264-410X(98)00039-5; Petersen E, 1999, ACTA PAEDIATR, V88, P36, DOI 10.1080/080352599750029349; Pinon JM, 2001, J CLIN MICROBIOL, V39, P2267, DOI 10.1128/JCM.39.6.2267-2271.2001; PINON JM, 1990, J CLIN MICROBIOL, V28, P1739, DOI 10.1128/JCM.28.8.1739-1743.1990; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; RAISANEN SA, 1978, MED HYPOTHESES, V4, P367, DOI 10.1016/0306-9877(78)90072-5; REMINGTO.JS, 1970, ANN NY ACAD SCI, V174, P1006, DOI 10.1111/j.1749-6632.1970.tb45622.x; Remington JS, 2001, INFECT DIS FETUS NEW, P205; Roberts A, 2001, EUR J CLIN MICROBIOL, V20, P467; ROBERTS CW, 1995, INFECT IMMUN, V63, P2549, DOI 10.1128/IAI.63.7.2549-2555.1995; Romand S, 2001, OBSTET GYNECOL, V97, P296, DOI 10.1016/S0029-7844(00)01118-2; SABIN AB, 1948, SCIENCE, V108, P660, DOI 10.1126/science.108.2815.660; SCALISE F, 1992, IMMUNOLOGY, V76, P668; Shaw MK, 1998, PARASITOLOGY, V117, P435, DOI 10.1017/S0031182098003278; SIBLEY LD, 1992, NATURE, V359, P82, DOI 10.1038/359082a0; SIEGEL JP, 1983, J CLIN MICROBIOL, V18, P63, DOI 10.1128/JCM.18.1.63-70.1983; SIEGEL SE, 1971, BLOOD-J HEMATOL, V37, P388, DOI 10.1182/blood.V37.4.388.388; Silveira C, 2002, AM J OPHTHALMOL, V134, P41, DOI 10.1016/S0002-9394(02)01527-1; Smith KL, 1996, CLIN INFECT DIS, V23, P1182, DOI 10.1093/clinids/23.5.1182; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STEPICKBIEK P, 1990, J INFECT DIS, V162, P270, DOI 10.1093/infdis/162.1.270; Su C, 2003, SCIENCE, V299, P414, DOI 10.1126/science.1078035; Su CL, 2002, P NATL ACAD SCI USA, V99, P10753, DOI 10.1073/pnas.172117099; Suzuki Y, 1996, J INFECT DIS, V173, P265, DOI 10.1093/infdis/173.1.265; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; Swisher C N, 1994, Semin Pediatr Neurol, V1, P4; TEUTSCH SM, 1979, NEW ENGL J MED, V300, P695, DOI 10.1056/NEJM197903293001302; Thulliez P, 2001, INT J EPIDEMIOL, V30, P1315, DOI 10.1093/ije/30.6.1315; Torre D, 1998, ANTIMICROB AGENTS CH, V42, P1346, DOI 10.1128/AAC.42.6.1346; Vogel N, 1996, CLIN INFECT DIS, V23, P1055, DOI 10.1093/clinids/23.5.1055; Wallon M, 1999, BRIT MED J, V318, P1511, DOI 10.1136/bmj.318.7197.1511; WALTON BC, 1966, AM J TROP MED HYG, V15, P149, DOI 10.4269/ajtmh.1966.15.149; WEISS LM, 1992, HUM PATHOL, V23, P154, DOI 10.1016/0046-8177(92)90236-V; WILSON CB, 1980, PEDIATRICS, V66, P767; Wilson M, 1997, J CLIN MICROBIOL, V35, P3112, DOI 10.1128/JCM.35.12.3112-3115.1997; WONG SY, 1993, J CLIN MICROBIOL, V31, P2952, DOI 10.1128/JCM.31.11.2952-2959.1993; WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853; Wong SY, 1999, TXB AIDS MED, P225	143	2238	2415	8	337	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1965	1976		10.1016/S0140-6736(04)16412-X	http://dx.doi.org/10.1016/S0140-6736(04)16412-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194258				2022-12-28	WOS:000221962800019
J	Shellito, PC; Clark, JW; Willett, CG; Caplan, AP; Brugge, W; Russell, P; Warshaw, AL; Cusack, JC				Shellito, PC; Clark, JW; Willett, CG; Caplan, AP; Brugge, W; Russell, P; Warshaw, AL; Cusack, JC			Case 18-2004: A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum - Adenocarcinoma of the rectum, stage T3N2M0	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TOTAL MESORECTAL EXCISION; METASTATIC COLORECTAL-CANCER; LYMPH-NODE METASTASES; SPHINCTER PRESERVATION; COLOANAL ANASTOMOSIS; RADIATION-THERAPY; RANDOMIZED-TRIAL; ADJUVANT THERAPY; LOCAL EXCISION; FLUOROURACIL		Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Hematol Oncol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Shellito, PC (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.							Church RD, 2003, BRIT J SURG, V90, P1055, DOI 10.1002/bjs.4297; DEGRAMONT A, 2003, P AN M AM SOC CLIN, V22, P253; Dennett ER, 1999, DIS COLON RECTUM, V42, P804, DOI 10.1007/BF02236940; Douillard JY, 2000, LANCET, V355, P1372; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Harisinghani MG, 2003, NEW ENGL J MED, V349, P1010; Heald RJ, 1998, ARCH SURG-CHICAGO, V133, P894, DOI 10.1001/archsurg.133.8.894; Hida J, 1997, J AM COLL SURGEONS, V184, P584; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Mellgren A, 2000, DIS COLON RECTUM, V43, P1064, DOI 10.1007/BF02236551; Nagtegaal ID, 2002, J CLIN ONCOL, V20, P1729, DOI 10.1200/JCO.2002.07.010; Ng AK, 1997, CANCER, V79, P671, DOI 10.1002/(SICI)1097-0142(19970215)79:4<671::AID-CNCR3>3.0.CO;2-H; OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803; Read TE, 1999, ARCH SURG-CHICAGO, V134, P670, DOI 10.1001/archsurg.134.6.670; ROH MS, 2001, P AN M AM SOC CLIN, V20, pA123; Ruo L, 1999, DIS COLON RECTUM, V42, P563, DOI 10.1007/BF02234129; Sauer R., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS124, DOI 10.1016/S0360-3016(03)00824-1; Sauer R, 2001, STRAHLENTHER ONKOL, V177, P173, DOI 10.1007/PL00002396; Schmoll HJ, 2002, SEMIN ONCOL, V29, P34, DOI 10.1053/sonc.2002.35531; SCOTT N, 1995, BRIT J SURG, V82, P1031, DOI 10.1002/bjs.1800820808; Sengupta S, 2001, DIS COLON RECTUM, V44, P1345, DOI 10.1007/BF02234796; Sterk P, 2000, INT J COLORECTAL DIS, V15, P225, DOI 10.1007/s003840000237; Tepper JE, 2002, J CLIN ONCOL, V20, P1744, DOI 10.1200/JCO.2002.07.132; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; Wagman R, 1998, INT J RADIAT ONCOL, V42, P51, DOI 10.1016/S0360-3016(98)00180-1; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Zhu AX, 2003, SEMIN RADIAT ONCOL, V13, P454, DOI 10.1016/S1053-4296(03)00048-1	29	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2500	2509		10.1056/NEJMcpc049007	http://dx.doi.org/10.1056/NEJMcpc049007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190143				2022-12-28	WOS:000221887200011
J	Purcell, B; Samuelsson, S; Hahn, SJM; Ehrhard, I; Heuberger, S; Camaroni, I; Charlett, A; Stuart, JM				Purcell, B; Samuelsson, S; Hahn, SJM; Ehrhard, I; Heuberger, S; Camaroni, I; Charlett, A; Stuart, JM			Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; HOUSEHOLD CONTACTS; CHEMOPROPHYLAXIS; CARRIAGE; CARE	Objective To summarise the evidence for the role of antibiotics in preventing further cases of meningococcal disease through chemoprophylaxis given to the index patient, household contacts, and children in day care settings after a single case. Design Systematic review. Methods Studies were identified by searching Embase (1983-2003), Medline (1965-2003), and CAB Health (1973-2003) and by contacting the World Health Organization and the European meningococcal disease surveillance network and examining references of identified papers. The review included all studies with at least 10 cases in which outcomes were compared between treated and untreated groups. Main outcome measure Subsequent cases of meningococcal disease 1-30 days after onset of disease in the index patient. Results Four observational studies and one small trial met the inclusion criteria. Meta-analysis of studies on chemoprophylaxis given to household contacts showed a significant reduction in risk (risk ratio 0.11, 95% confidence interval 0.02 to 0.58). The number needed to treat to prevent a case was estimated as 218 (121 to 1135). Primary outcome data were not available in studies of chemoprophylaxis given to the index patient: when prophylaxis had not been given, rate of carriage after discharge from hospital was estimated as 3% (0 to 6), probably an underestimate of the true rate. No studies of chemoprophylaxis in day care settings were identified that met the inclusion criteria. Conclusion There have been no high quality experimental trials looking at control policies for meningococcal disease. The best available evidence is from retrospective studies. The risk of meningococcal disease in household contacts of a patient can be reduced by an estimated 89% if they take antibiotics known to eradicate meningococcal carriage. Chemoprophylaxis should be recommended for the index patient and A household contacts.	Ctr Communicable Dis Surveillance, Gloucester GL10 3RF, England; Statens Serum Inst, DK-2300 Copenhagen, Denmark; Ctr Communicable Dis Surveillance, Cardiff CF4 3QX, S Glam, Wales; Landesuntersuchungsanstalt Gesundheits & Vet Wese, D-01099 Dresden, Germany; Natl Reference Ctr Meningococci, A-8010 Graz, Austria; Publ Hlth Lab Serv, Stat Unit, London NW9 5EQ, England	Statens Serum Institut; Public Health England	Stuart, JM (corresponding author), Ctr Communicable Dis Surveillance, South West, Gloucester GL10 3RF, England.	jarnes.stuart@hpa.org.uk						ABRAMSON JS, 1985, J INFECT DIS, V151, P370, DOI 10.1093/infdis/151.2.370; ALVEZ F, 1991, PEDIATR INFECT DIS J, V10, P700, DOI 10.1097/00006454-199109000-00014; [Anonymous], 1976, J INFECT DIS, V134, P201, DOI 10.1093/infdis/134.2.201; BAND JD, 1984, JAMA-J AM MED ASSOC, V251, P2381, DOI 10.1001/jama.251.18.2381; Barroso D, 1999, TROP DOCT, V29, P108, DOI 10.1177/004947559902900217; Begg N, 1999, J EPIDEMIOL COMMUN H, V53, P516, DOI 10.1136/jech.53.9.516; BRADBURN MJ, 1998, STATA TECHNICAL B, V41, P4; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; COOKE RPD, 1989, BRIT MED J, V298, P555, DOI 10.1136/bmj.298.6673.555; CUEVAS LE, 1993, J ANTIMICROB CHEMOTH, V31, P79, DOI 10.1093/jac/31.suppl_B.79; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; *EUR CTR DIS PREV, 2003, STRENGTH EUR DEF HLT; HALL AP, 1993, J ANTIMICROB CHEMOTH, V31, P451, DOI 10.1093/jac/31.3.451; Jones IR, 1997, BRIT MED J, V314, P794, DOI 10.1136/bmj.314.7083.794; KAISER AB, 1974, J INFECT DIS, V130, P217, DOI 10.1093/infdis/130.3.217; KRISTIANSEN BE, 1992, SCAND J INFECT DIS, V24, P165, DOI 10.3109/00365549209052608; *MEN DIS SURV GROU, 1976, JAMA-J AM MED ASSOC, V235, P261; Pearson N, 1995, J PUBLIC HEALTH MED, V17, P455; Samuelsson S, 2000, EPIDEMIOL INFECT, V124, P433, DOI 10.1017/S0950268899003775; SAMUELSSON S, 1999, THESIS U SO DENMARK, P30; Scholten R J, 1993, Ned Tijdschr Geneeskd, V137, P1505; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; STUART JM, 1989, BRIT MED J, V298, P569, DOI 10.1136/bmj.298.6673.569; VAGUPSKY P, 1993, LANCET, V341, P11582; WEIS N, 1994, J MED MICROBIOL, V41, P339, DOI 10.1099/00222615-41-5-339; YAGUPSKY P, 1993, LANCET, V341, P1152, DOI 10.1016/0140-6736(93)93171-V; 1999, COMMUN DIS REP CDR W, V12, P98; 1999, COMMUN DIS REP CDR W, V12, P95	28	54	56	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1339	1342A		10.1136/bmj.328.7452.1339	http://dx.doi.org/10.1136/bmj.328.7452.1339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178612	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221952700015
J	To, MS; Alfirevic, Z; Heath, VCF; Cicero, S; Cacho, AM; Williamson, PR; Nicolaides, KH				To, MS; Alfirevic, Z; Heath, VCF; Cicero, S; Cacho, AM; Williamson, PR; Nicolaides, KH		Fetal Med Fdn Second Trimester Sc	Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial	LANCET			English	Article							GESTATION; LENGTH; RISK; PREDICTION	Background Cervical cerclage has been widely used in the past 50 years to prevent early preterm birth and its associated neonatal mortality and morbidity. Results of randomised trials have not generally lent support to this practice, but this absence of benefit may be due to suboptimum patient selection, which was essentially based on obstetric history. A more effective way of identifying the high-risk group for early preterm delivery might be by transvaginal sonographic measurement of cervical length. We undertook a multicentre randomised controlled trial to investigate whether, in women with a short cervix identified by routine transvaginal scanning at 22-24 weeks' gestation, the insertion of a Shirodkar suture reduces early preterm delivery. Methods Cervical length was measured in 47 123 women. The cervix was 15 mm or less in 470, and 253 (54%) of these women participated in the study and were randomised to cervical cerclage (127) or to expectant management (126). Primary outcome was the frequency of delivery before 33 completed weeks (231 days) of pregnancy. Findings The proportion of preterm delivery before 33 weeks was similar in both groups, 22% (28 of 127) in the cerclage group versus 26% (33 of 126) in the control group (relative risk=0.84, 95% Cl 0.54-1.31, p=0.44), with no significant differences in perinatal or maternal morbidity or mortality. Interpretation The insertion of a Shirodkar suture in women with a short cervix does not substantially reduce the risk of early preterm delivery. Routine sonographic measurement of cervical length at 22-24 weeks identifies a group at high risk of early preterm birth.	Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr Fetal Med, London SE5 8RX, England; Liverpool Womens Hosp, Univ Dept Obstet & Gynaecol, Liverpool, Merseyside, England; Univ Liverpool, Ctr Med Stat & Hlth Evaluat, Liverpool L69 3BX, Merseyside, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Liverpool; University of Liverpool	Nicolaides, KH (corresponding author), Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr Fetal Med, Denmark Hill, London SE5 8RX, England.	Kypros@fetalmedicine.com	Williamson, Paula R/B-6425-2016	Williamson, Paula R/0000-0001-9802-6636; Nicolaides, Kypros/0000-0003-1266-0711				Althuisius SM, 2001, AM J OBSTET GYNECOL, V185, P1106, DOI 10.1067/mob.2001.118655; *DEP HLTH STAT OFF, 2002, DAT OFF POP CENS SUR; Draper ES, 1999, BRIT MED J, V319, P1093, DOI 10.1136/bmj.319.7217.1093; Heath VCF, 1998, ULTRASOUND OBST GYN, V12, P304, DOI 10.1046/j.1469-0705.1998.12050304.x; Heath VCF, 1998, ULTRASOUND OBST GYN, V12, P312, DOI 10.1046/j.1469-0705.1998.12050312.x; Heath VCF, 1998, ULTRASOUND OBST GYN, V12, P318, DOI 10.1046/j.1469-0705.1998.12050318.x; Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; Koppe JGV-VP, 1998, TXB PERINATAL MED, P1362; LAZAR P, 1984, BRIT J OBSTET GYNAEC, V91, P731, DOI 10.1111/j.1471-0528.1984.tb04841.x; MACNAUGHTON MC, 1993, BRIT J OBSTET GYNAEC, V100, P516; Petrou S, 2003, BJOG-INT J OBSTET GY, V110, P17, DOI 10.1016/S1470-0328(03)00013-2; RUSH RW, 1984, BRIT J OBSTET GYNAEC, V91, P724, DOI 10.1111/j.1471-0528.1984.tb04840.x; Rust OA, 2000, AM J OBSTET GYNECOL, V183, P830, DOI 10.1067/mob.2000.109040; Shirodkar VN., 1955, ANTISEPTIC, V52, P299; Taipale P, 1998, OBSTET GYNECOL, V92, P902, DOI 10.1016/S0029-7844(98)00346-9; To MS, 2001, ULTRASOUND OBST GYN, V18, P200, DOI 10.1046/j.1469-0705.2001.00437.x	16	276	290	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1849	1853		10.1016/S0140-6736(04)16351-4	http://dx.doi.org/10.1016/S0140-6736(04)16351-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183621				2022-12-28	WOS:000221822300007
J	van Puijenbroek, E; Verhoef, E; de Graaf, L				van Puijenbroek, E; Verhoef, E; de Graaf, L			Drug points - Slipped capital femoral epiphyses associated with the withdrawal of a gonadotrophin releasing hormone	BRITISH MEDICAL JOURNAL			English	Article									Netherlands Pharmacovigliance, NL-5327 MH Shertogenbosch, Netherlands		van Puijenbroek, E (corresponding author), Netherlands Pharmacovigliance, Goudsbloemvallei 7, NL-5327 MH Shertogenbosch, Netherlands.	e.vanpuijenbroek@lareb.nl	van Puijenbroek, Eugene/AAI-3240-2020	van Puijenbroek, Eugene/0000-0002-2236-1398				Blethen SL, 1996, HORM RES, V46, P113, DOI 10.1159/000185006; Kempers MJE, 2001, J PEDIATR ENDOCR MET, V14, P729; SKINNER SR, 2003, RUDOLPHS PEDIAT, P2145	3	1	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 5	2004	328	7452					1353	1353		10.1136/bmj.328.7452.1353	http://dx.doi.org/10.1136/bmj.328.7452.1353			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178613	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221952700019
J	Hill, JP; Jin, WS; Kosaka, A; Fukushima, T; Ichihara, H; Shimomura, T; Ito, K; Hashizume, T; Ishii, N; Aida, T				Hill, JP; Jin, WS; Kosaka, A; Fukushima, T; Ichihara, H; Shimomura, T; Ito, K; Hashizume, T; Ishii, N; Aida, T			Self-assembled hexa-peri-hexabenzocoronene graphitic nanotube	SCIENCE			English	Article							ORGANIC NANOTUBES; MOBILITY; CARBON	An amphiphilic hexa-peri-hexabenzocoronene self-assembles to form a pi-electronic, discrete nanotubular object. The object is characterized by an aspect ratio greater than 1000 and has a uniform, 14-nanometer-wide, open-ended hollow space, which is an order of magnitude larger than those of carbon nanotubes. The wall is 3 nanometers thick and consists of helical arrays of the pi-stacked graphene molecule, whose exterior and interior surfaces are covered by hydrophilic triethylene glycol chains. The graphitic nanotube is redox active, and a single piece of the nanotube across 180-nanometer-gap electrodes shows, upon oxidation, an electrical conductivity of 2.5 megohms at 285 kelvin. This family of molecularly engineered graphite with a one-dimensional tubular shape and a chemically accessible surface constitutes an important step toward molecular electronics.	Japan Sci & Technol Agcy, Natl Museum Emerging Sci & Innovat, Aida Nanospace Project, Exploratory Res Adv Technol,Koto Ku, Tokyo 1350064, Japan; Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba 2778561, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba 3058566, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Hitachi Limited; National Institute of Advanced Industrial Science & Technology (AIST)	Fukushima, T (corresponding author), Japan Sci & Technol Agcy, Natl Museum Emerging Sci & Innovat, Aida Nanospace Project, Exploratory Res Adv Technol,Koto Ku, 2-41 Aomi, Tokyo 1350064, Japan.	fukushima@nanospace.miraikan.jst.go.jp; aida@macro.t.u-tokyo.ac.jp	Fukushima, Takanori/D-2474-2015; Hill, Jonathan P/B-9332-2011; Ishii, Noriyuki/E-5661-2011; Shimomura, Takeshi/B-9993-2013; Aida, Takuzo/I-9117-2012	Fukushima, Takanori/0000-0001-5586-9238; Hill, Jonathan P/0000-0002-4229-5842; Ishii, Noriyuki/0000-0002-4120-6203; Shimomura, Takeshi/0000-0001-9580-1019; 				Arikainen EO, 1995, J MATER CHEM, V5, P2161, DOI 10.1039/jm9950502161; Bong DT, 2001, ANGEW CHEM INT EDIT, V40, P988, DOI 10.1002/1521-3773(20010316)40:6<988::AID-ANIE9880>3.0.CO;2-N; Dresselhaus M. S., 2001, CARBON NANOTUBES SYN; Fleming AJ, 2003, J PHYS CHEM B, V107, P37, DOI 10.1021/jp0262618; Goldberger J, 2003, NATURE, V422, P599, DOI 10.1038/nature01551; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; John G, 2001, ADV MATER, V13, P715, DOI 10.1002/1521-4095(200105)13:10<715::AID-ADMA715>3.0.CO;2-Z; Kim Y, 2003, ANGEW CHEM INT EDIT, V42, P1121, DOI 10.1002/anie.200390295; Oda R, 1999, NATURE, V399, P566, DOI 10.1038/21154; Piris J, 2003, ADV MATER, V15, P1736, DOI 10.1002/adma.200305358; Rathore R, 2003, J ORG CHEM, V68, P4071, DOI 10.1021/jo034271e; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; Terech P, 2002, ADV MATER, V14, P495, DOI 10.1002/1521-4095(20020404)14:7<495::AID-ADMA495>3.0.CO;2-9; van de Craats AM, 1999, ADV MATER, V11, P1469, DOI 10.1002/(SICI)1521-4095(199912)11:17<1469::AID-ADMA1469>3.0.CO;2-K; van de Craats AM, 2003, ADV MATER, V15, P495, DOI 10.1002/adma.200390114; von Berlepsch H, 2000, LANGMUIR, V16, P5908, DOI 10.1021/la000014i; Watson MD, 2001, CHEM REV, V101, P1267, DOI 10.1021/cr990322p; Yamaguchi T, 2003, J AM CHEM SOC, V125, P13934, DOI 10.1021/ja038178j	19	913	924	8	402	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1481	1483		10.1126/science.1097789	http://dx.doi.org/10.1126/science.1097789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178796				2022-12-28	WOS:000221795800037
J	Sack, FD				Sack, FD			Plant sciences - YODA would be proud: Valves for land plants	SCIENCE			English	Editorial Material							STOMATAL DEVELOPMENT; ARABIDOPSIS		Ohio State Univ, Dept Plant Cellular & Mol Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Sack, FD (corresponding author), Ohio State Univ, Dept Plant Cellular & Mol Biol, Columbus, OH 43210 USA.	sack.1@osu.edu						Berger D, 2000, GENE DEV, V14, P1119; Bergmann DC, 2004, SCIENCE, V304, P1494, DOI 10.1126/science.1096014; Bergmann DC, 2004, CURR OPIN PLANT BIOL, V7, P26, DOI 10.1016/j.pbi.2003.10.001; Geisler M, 2000, PLANT CELL, V12, P2075, DOI 10.1105/tpc.12.11.2075; Lukowitz W, 2004, CELL, V116, P109, DOI 10.1016/S0092-8674(03)01067-5; Nadeau JA, 2002, SCIENCE, V296, P1697, DOI 10.1126/science.1069596; Nadeau JA, 2003, TRENDS PLANT SCI, V8, P294, DOI 10.1016/S1360-1385(03)00102-X; Nadeau JA, 2002, THE ARABIDOPSIS BOOK; von Groll U, 2002, PLANT CELL, V14, P1527, DOI 10.1105/tpc.001016	9	7	8	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1461	1462		10.1126/science.1099445	http://dx.doi.org/10.1126/science.1099445			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178791				2022-12-28	WOS:000221795800031
J	Bayliss, R				Bayliss, R			The arrogance of youth	LANCET			English	Editorial Material											Bayliss, R (corresponding author), 61 Onslow Sq, London SW7 3LS, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1793	1793		10.1016/S0140-6736(04)16306-X	http://dx.doi.org/10.1016/S0140-6736(04)16306-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172779				2022-12-28	WOS:000221705800022
J	Myles, PS; Leslie, K; McNeil, J; Forbes, A; Chan, MTV				Myles, PS; Leslie, K; McNeil, J; Forbes, A; Chan, MTV		B-Aware Trial Grp	Bispectral index monitoring to prevent awareness during anaesthesia: the B-Aware randomised controlled trial	LANCET			English	Article							AUDITORY EVOKED-RESPONSE; GENERAL-ANESTHESIA; INDUCED SEDATION; DEPTH; RECALL; PROPOFOL; ELECTROENCEPHALOGRAM; RECOVERY; ATTITUDES; SURGERY	Background Awareness is an uncommon complication of anaesthesia, affecting 0.1-0.2% of all surgical patients. Bispectral index (BIS) monitoring measures the depth of anaesthesia and facilitates anaesthetic titration. In this trial we determined whether BIS-guided anaesthesia reduced the incidence of awareness during surgery in adults. Methods We did a prospective, randomised, double-blind, multicentre trial. Adult patients at high risk of awareness were randomly allocated to BIS-guided anaesthesia or routine care. Patients were assessed by a blinded observer for awareness at 2-6 h, 24-36 h, and 30 days after surgery. An independent committee, blinded to group identity, assessed every report of awareness. The primary outcome measure was confirmed awareness under anaesthesia at any time. Findings Of 2463 eligible and consenting patients, 1225 were assigned to the BIS group and 1238 to the routine care group. There were two reports of awareness in the BIS-guided group and 11 reports in the routine care group (p=0.022). BIS-guided anaesthesia reduced the risk of awareness by 82% (95% Cl 17-98%). Interpretation BIS-guided anaesthesia reduces the risk of awareness in at-risk adult surgical patients undergoing relaxant general anaesthesia. With a cost of routine BIS monitoring at US$16 per use in Australia and a number needed to treat of 138, the cost of preventing one case of awareness in high-risk patients is about $2200.	Alfred Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic 3004, Australia; Monash Univ, Dept Anaesthesia, Melbourne, Vic 3004, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; Natl Hlth & Med Res Council Ctr Clin Res Excellen, Canberra, ACT, Australia; Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Royal Melbourne Hospital; University of Melbourne; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Myles, PS (corresponding author), Alfred Hosp, Dept Anaesthesia & Pain Management, POB 315, Melbourne, Vic 3004, Australia.	p.myles@alfred.org.au	Myles, Paul/AAU-9524-2020; Chan, Matthew/J-2884-2013; McNeil, John/L-6440-2019	Myles, Paul/0000-0002-3324-5456; Chan, Matthew/0000-0002-3574-7855; McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X; Leslie, Kate/0000-0001-8512-3517				ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; BOGETZ MS, 1984, ANESTHESIOLOGY, V61, P6, DOI 10.1097/00000542-198461010-00003; COBCROFT MD, 1993, ANAESTH INTENS CARE, V21, P837, DOI 10.1177/0310057X9302100616; DeMets DL, 1999, LANCET, V354, P1983, DOI 10.1016/S0140-6736(99)03464-9; Domino KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019; Dowd NP, 1998, ANESTHESIOLOGY, V89, P1068, DOI 10.1097/00000542-199811000-00006; DWYER RC, 1994, ANESTHESIOLOGY, V81, P403, DOI 10.1097/00000542-199408000-00019; EDMONDS HL, 1993, ACTA ANAESTHESI S100, V37, P102; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Ghoneim MM, 1997, ANESTHESIOLOGY, V87, P387, DOI 10.1097/00000542-199708000-00027; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; Lennmarken C, 2002, ACTA ANAESTH SCAND, V46, P229, DOI 10.1034/j.1399-6576.2002.t01-1-460301.x; LESLIE K, 1995, ANESTH ANALG, V81, P1269, DOI 10.1097/00000539-199512000-00025; Leslie K, 2003, ANAESTH INTENS CARE, V31, P63, DOI 10.1177/0310057X0303100113; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; LYONS G, 1991, ANAESTHESIA, V46, P62, DOI 10.1111/j.1365-2044.1991.tb09321.x; MOERMAN N, 1993, ANESTHESIOLOGY, V79, P454, DOI 10.1097/00000542-199309000-00007; Myles PS, 2003, ANAESTHESIA, V58, P11, DOI 10.1046/j.1365-2044.2003.02955.x; Myles PS, 2000, BRIT J ANAESTH, V84, P6, DOI 10.1093/oxfordjournals.bja.a013383; Myles PS, 1999, BRIT J ANAESTH, V83, P833, DOI 10.1093/bja/83.6.833; O'Connor MF, 2001, ANESTHESIOLOGY, V94, P520, DOI 10.1097/00000542-200103000-00025; Ostenfeld C. H., 1900, ZOOL ANZ, V23, P198; PHILLIPS AA, 1993, CAN J ANAESTH, V40, P922, DOI 10.1007/BF03010093; PRYSROBERTS C, 1987, BRIT J ANAESTH, V59, P1341, DOI 10.1093/bja/59.11.1341; Ranta SOV, 1998, ANESTH ANALG, V86, P1084, DOI 10.1097/00000539-199805000-00035; Reboussin DM, 2000, CONTROL CLIN TRIALS, V21, P190, DOI 10.1016/S0197-2456(00)00057-X; Rowan KJ, 2002, ANAESTH INTENS CARE, V30, P505, DOI 10.1177/0310057X0203000421; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; SHUSTER JJ, 1993, CONTROL CLIN TRIALS, V14, P198, DOI 10.1016/0197-2456(93)90003-V; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; THORNTON C, 1988, BRIT J ANAESTH, V60, P372, DOI 10.1093/bja/60.4.372; THORNTON C, 1989, BRIT J ANAESTH, V63, P411, DOI 10.1093/bja/63.4.411; Todd MM, 1998, ANESTHESIOLOGY, V89, P815, DOI 10.1097/00000542-199810000-00002; WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	750	800	6	54	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1757	1763		10.1016/S0140-6736(04)16300-9	http://dx.doi.org/10.1016/S0140-6736(04)16300-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172773				2022-12-28	WOS:000221705800008
J	Huber, R; Ghilardi, MF; Massimini, M; Tononi, G				Huber, R; Ghilardi, MF; Massimini, M; Tononi, G			Local sleep and learning	NATURE			English	Article							MEMORY; EEG; CONSOLIDATION; STIMULATION; TOPOGRAPHY; RESONANCE; STATES; SKILL; FORMS	Human sleep is a global state whose functions remain unclear. During much of sleep, cortical neurons undergo slow oscillations in membrane potential, which appear in electroencephalograms as slow wave activity (SWA) of < 4 Hz(1). The amount of SWA is homeostatically regulated, increasing after wakefulness and returning to baseline during sleep(2). It has been suggested that SWA homeostasis may reflect synaptic changes underlying a cellular need for sleep(3). If this were so, inducing local synaptic changes should induce local SWA changes, and these should benefit neural function. Here we show that sleep homeostasis indeed has a local component, which can be triggered by a learning task involving specific brain regions. Furthermore, we show that the local increase in SWA after learning correlates with improved performance of the task after sleep. Thus, sleep homeostasis can be induced on a local level and can benefit performance.	Univ Wisconsin, Dept Psychiat, Madison, WI 53719 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	University of Wisconsin System; University of Wisconsin Madison; Columbia University	Tononi, G (corresponding author), Univ Wisconsin, Dept Psychiat, Madison, WI 53719 USA.	gtononi@wisc.edu	Massimini, Marcello/T-8115-2017	Massimini, Marcello/0000-0003-2271-957X				Benington JH, 2003, PROG NEUROBIOL, V69, P71, DOI 10.1016/S0301-0082(03)00018-2; Borbely A. A., 2000, PRINCIPLES PRACTICE, P377; Cirelli C, 2004, NEURON, V41, P35, DOI 10.1016/S0896-6273(03)00814-6; Cohen YE, 2002, NAT REV NEUROSCI, V3, P553, DOI 10.1038/nrn873; Fenn KM, 2003, NATURE, V425, P614, DOI 10.1038/nature01951; Finelli LA, 2001, EUR J NEUROSCI, V13, P2282, DOI 10.1046/j.0953-816x.2001.01597.x; Fischer S, 2002, P NATL ACAD SCI USA, V99, P11987, DOI 10.1073/pnas.182178199; Gais S, 2000, NAT NEUROSCI, V3, P1335, DOI 10.1038/81881; Ghilardi MF, 2000, BRAIN RES, V871, P127, DOI 10.1016/S0006-8993(00)02365-9; Ghilardi MF, 2003, NEUROLOGY, V60, P1313, DOI 10.1212/01.WNL.0000059545.69089.EE; Hoffman KL, 2002, TRENDS NEUROSCI, V25, P1, DOI 10.1016/S0166-2236(00)02005-1; Huber R, 2000, J NEUROPHYSIOL, V84, P1888, DOI 10.1152/jn.2000.84.4.1888; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; KATTLER H, 1994, J SLEEP RES, V3, P159, DOI 10.1111/j.1365-2869.1994.tb00123.x; KRUEGER JM, 1993, J SLEEP RES, V2, P63, DOI 10.1111/j.1365-2869.1993.tb00064.x; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; Maquet P, 2003, J NEUROSCI, V23, P1432, DOI 10.1523/JNEUROSCI.23-04-01432.2003; Mednick SC, 2002, NAT NEUROSCI, V5, P677, DOI 10.1038/nn864; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; SMITH C, 1995, BEHAV BRAIN RES, V69, P137, DOI 10.1016/0166-4328(95)00024-N; Steriade M, 2003, NEURON, V37, P563, DOI 10.1016/S0896-6273(03)00065-5; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Stickgold R, 2000, NAT NEUROSCI, V3, P1237, DOI 10.1038/81756; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; Tononi G, 2001, ARCH ITAL BIOL, V139, P221; Vyazovskiy V, 2000, J SLEEP RES, V9, P367, DOI 10.1046/j.1365-2869.2000.00230.x; WALKER M, IN PRESS BEHAV BRAIN; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8	30	1213	1230	4	192	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					78	81		10.1038/nature02663	http://dx.doi.org/10.1038/nature02663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15184907				2022-12-28	WOS:000222356800046
J	Sui, GC; El Bachir, A; Shi, YJ; Brignone, C; Wall, NR; Yin, P; Donohoe, M; Luke, MP; Calvo, D; Grossman, SR; Shi, Y				Sui, GC; El Bachir, A; Shi, YJ; Brignone, C; Wall, NR; Yin, P; Donohoe, M; Luke, MP; Calvo, D; Grossman, SR; Shi, Y			Yin Yang 1 is a negative regulator of p53	CELL			English	Article							TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REPRESSION; ADENOVIRUS E1A; MDM2-DEFICIENT MICE; EMBRYONIC LETHALITY; TARGETED DISRUPTION; MAMMALIAN-CELLS; GENE-EXPRESSION; MDM2; YY1	Yin Yang 1 (YY1) is a transcription factor that plays an essential role in development. However, the full spectrum of YY1's functions and mechanism of action remains unclear. We find that YY1 ablation results in p53 accumulation due to a reduction of p53 ubiquitination in vivo. Conversely, YY1 overexpression stimulates p53 ubiquitination and degradation. Significantly, recombinant YY1 is sufficient to induce Hdm2-mediated p53 polyubiquitination in vitro, suggesting that this function of YY1 is independent of its transcriptional activity. We identify direct physical interactions of YY1 with Hdm2 and p53 and show that the basis for YY1-regulating p53 ubiquitination is its ability to facilitate Hdm2-p53 interaction. Importantly, the tumor suppressor p14(ARF) compromises the Hdm2-YY1 interaction, which is important for YY1 regulation of p53. Taken together, these findings identify YY1 as a potential cofactor for Hdm2 in the regulation of p53 homeostasis and suggest a possible role for YY1 in tumorigenesis.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	yang_shi@hms.harvard.edu	Wall, Nathan R./H-7368-2015	Wall, Nathan R./0000-0002-3235-4386; Sui, Guangchao/0000-0002-8164-5585	NCI NIH HHS [R01 CA107532-01, T32CA72320, F32CA097802, T32CA09031, R01 CA107532] Funding Source: Medline; NIGMS NIH HHS [GM53874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107532, F32CA097802, T32CA072320, T32CA009031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Cummins JM, 2004, NATURE, V416, P648; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; FIRE A, 1988, NATURE, V39, P806; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kessler BM, 2001, CHEM BIOL, V8, P913, DOI 10.1016/S1074-5521(01)00069-2; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; MIYASHITA T, 1995, CELL, V80, P293; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	335	359	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					859	872		10.1016/j.cell.2004.06.004	http://dx.doi.org/10.1016/j.cell.2004.06.004			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210108	Bronze			2022-12-28	WOS:000222300200005
J	Gustafsson, L; Leijonhufvud, I; Aronsson, A; Mossberg, A; Svanborg, C				Gustafsson, L; Leijonhufvud, I; Aronsson, A; Mossberg, A; Svanborg, C			Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APOPTOSIS-LIKE MECHANISM; TUMOR-CELLS; CANCER; IMMUNOSUPPRESSION; INFECTIONS; PROTEIN; WARTS	Background We studied the effect on skin papillomas of topical application of a complex of alpha-lactalbumin and oleic acid (often referred to as human alpha-lactalbumin made lethal to tumor cells [HAMLET]) to establish proof of the principle that alpha-lactalbumin-oleic acid kills transformed cells but not healthy, differentiated cells. Methods Forty patients with cutaneous papillomas that were resistant to conventional treatment were enrolled in a randomized, placebo-controlled, double-blind study, in which alpha-lactalbumin-oleic acid or saline placebo was applied daily for three weeks and the change in the volume of each lesion was recorded. After this first phase of the study, 34 patients participated in the second phase, an open-label trial of a three-week course of alpha-lactalbumin-oleic acid. Approximately two years after the end of the open-label phase of the study, 38 of the original 40 patients were examined, and long-term follow-up data were obtained. Results In the first phase of the study, the lesion volume was reduced by 75 percent or more in all 20 patients in the alpha-lactalbumin-oleic acid group, and in 88 of 92 papillomas; in the placebo group, a similar effect was evident in only 3 of 20 patients (15 of 74 papillomas) (P<0.001). After the patients in the initial placebo group had been treated with alpha-lactalbumin-oleic acid in the second phase of the study, a median reduction of 82 percent in lesion volume was observed. At follow-up two years after the end of the second phase, all lesions had completely resolved in 83 percent of the patients treated with alpha-lactalbumin-oleic acid, and the time to resolution was shorter in the group originally assigned to receive alpha-lactalbumin-oleic acid than among patients originally in the placebo group (2.4 vs. 9.9 months; P<0.01). No adverse reactions were reported, and there was no difference in the outcomes of treatment between immunocompetent and immunosuppressed patients. Conclusions Treatment with topical alpha-lactalbumin-oleic acid has a beneficial and lasting effect on skin papillomas.	Lund Univ, Dept Microbiol Immunol & Glycobiol, Inst Lab Med, S-22362 Lund, Sweden; Lund Univ, Dept Dermatol & Venereol, S-22362 Lund, Sweden	Lund University; Lund University	Svanborg, C (corresponding author), Lund Univ, Dept Microbiol Immunol & Glycobiol, Inst Lab Med, Solvegatan 23, S-22362 Lund, Sweden.	catharina.svanborg@mig.lu.se		Gustafsson, Lotta/0000-0002-9826-9133				Bavinck JNB, 1997, CLIN DERMATOL, V15, P427, DOI 10.1016/S0738-081X(96)00154-X; Bikle DD, 2003, J CELL BIOCHEM, V88, P290, DOI 10.1002/jcb.10339; deVilliers EM, 1997, CLIN DERMATOL, V15, P199, DOI 10.1016/S0738-081X(96)00164-2; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; Fischer W, 2004, CANCER RES, V64, P2105, DOI 10.1158/0008-5472.CAN-03-2661; Gibbs S, 2002, BMJ-BRIT MED J, V325, P461, DOI 10.1136/bmj.325.7362.461; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z; Kohler C, 1999, EXP CELL RES, V249, P260, DOI 10.1006/excr.1999.4472; Kohler C, 2001, EUR J BIOCHEM, V268, P186, DOI 10.1046/j.1432-1327.2001.01870.x; Leigh I M, 1995, Recent Results Cancer Res, V139, P69; Leman J A, 2000, Am J Clin Dermatol, V1, P143, DOI 10.2165/00128071-200001030-00001; LINDAHL L, 1984, ANAL BIOCHEM, V140, P394, DOI 10.1016/0003-2697(84)90184-2; STRAUSS MJ, 1949, P SOC EXP BIOL MED, V72, P46, DOI 10.3181/00379727-72-17328; Svanborg C, 2003, ADV CANCER RES, V88, P1; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; WALDER BK, 1971, LANCET, V2, P1282; WHO, 2003, WORLD HLTH REP; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 1974, Int J Cancer, V13, P650; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	21	157	171	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2663	2672		10.1056/NEJMoa032454	http://dx.doi.org/10.1056/NEJMoa032454			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215482	Green Published			2022-12-28	WOS:000222199000007
J	Lange, H; Suryapranata, H; De Luca, G; Borner, C; Dille, J; Kallmayer, K; Pasalary, MN; Scherer, E; Dambrink, JHE				Lange, H; Suryapranata, H; De Luca, G; Borner, C; Dille, J; Kallmayer, K; Pasalary, MN; Scherer, E; Dambrink, JHE			Folate therapy and in-stent restenosis after coronary stenting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAT CAROTID ARTERIES; PLASMA HOMOCYSTEINE; RISK-FACTOR; INTIMAL HYPERPLASIA; VASCULAR-DISEASE; TISSUE FACTOR; HYPERHOMOCYSTEINEMIA; SUPPLEMENTATION; PROLIFERATION; DEFICIENCY	Background Vitamin therapy to lower homocysteine levels has recently been recommended for the prevention of restenosis after coronary angioplasty. We tested the effect of a combination of folic acid, vitamin B-6 and vitamin B-6, and vitamin B-12 (referred to as folate therapy) on the risk of angiographic restenosis after coronary-stent placement in a double-blind, multicenter trial. Methods A total of 636 patients who had undergone successful coronary stenting were randomly assigned to receive 1 mg of folic acid, 5 mg of vitamin B-6, and 1 mg of vitamin B-12 intravenously, followed by daily oral doses of 1.2 mg of folic acid, 48 mg of vitamin B-6, and 60 mug of vitamin B-12 for six months, or to receive placebo. The angiographic end points (minimal luminal diameter, late loss, and restenosis rate) were assessed at six months by means of quantitative coronary angiography. Results At follow-up, the mean (+/-SD) minimal luminal diameter was significantly smaller in the folate group than in the placebo group (1.59+/-0.62 mm vs. 1.74+/-0.64 mm, P=0.008), and the extent of late luminal loss was greater (0.90+/-0.55 mm vs. 0.76+/-0.58 mm, P=0.004). The restenosis rate was higher in the folate group than in the placebo group (34.5 percent vs. 26.5 percent, P=0.05), and a higher percentage of patients in the folate group required repeated target-vessel revascularization (15.8 percent vs. 10.6 percent, P=0.05). Folate therapy had adverse effects on the risk of restenosis in all subgroups except for women, patients with diabetes, and patients with markedly elevated homocysteine levels (15 mumol per liter or more) at baseline. Conclusions Contrary to previous findings, the administration of folate, vitamin B-6, and vitamin B-12 after coronary stenting may increase the risk of in-stent restenosis and the need for target-vessel revascularization.	Hosp Weezenlanden, Isala Klin, Dept Cardiol, NL-8011 JW Zwolle, Netherlands; Klinikum Links Weser, Ctr Heart, Kardiol Praxis, Bremen, Germany; Diagram, Zwolle, Netherlands	Isala Clinics; University of Hamburg; University Medical Center Hamburg-Eppendorf	Suryapranata, H (corresponding author), Hosp Weezenlanden, Isala Klin, Dept Cardiol, Groot Wezeland 20, NL-8011 JW Zwolle, Netherlands.	h.suryapranata@diagram-zwolle.nl	Suryapranata, H./H-8095-2014					BAGGOTT JE, 1992, JNCI-J NATL CANCER I, V84, P1740, DOI 10.1093/jnci/84.22.1740; BAIM DS, 1994, CIRCULATION, V90, P2560, DOI 10.1161/01.CIR.90.5.2560; Benoit C, 1999, ARCH MAL COEUR VAISS, V92, P1457; BILLS ND, 1992, JNCI-J NATL CANCER I, V84, P332, DOI 10.1093/jnci/84.5.332; Buemi M, 2001, THROMB RES, V104, P207, DOI 10.1016/S0049-3848(01)00363-2; Bunch TJ, 2002, AM J CARDIOL, V90, P299, DOI 10.1016/S0002-9149(02)02467-0; Carmody BJ, 1999, J VASC SURG, V30, P1121, DOI 10.1016/S0741-5214(99)70053-4; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Cook JW, 2002, J VASC SURG, V35, P158, DOI 10.1067/mva.2002.118819; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; Genser D, 2002, AM J CARDIOL, V89, P495, DOI 10.1016/S0002-9149(01)02286-X; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Kosokabe T, 2001, CIRCULATION, V103, P2048; Kumbasar SD, 2001, J CARDIOVASC RISK, V8, P9, DOI 10.1097/00043798-200102000-00002; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; Marcucci R, 2000, THROMB HAEMOSTASIS, V83, P826; Miner SES, 2000, AM HEART J, V140, P272, DOI 10.1067/mhj.2000.107546; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Morita H, 2001, CIRCULATION, V103, P133; Morita H, 2000, THROMB HAEMOSTASIS, V84, P27; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; Schnyder G, 2002, EUR HEART J, V23, P726, DOI 10.1053/euhj.2001.2962; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Schomig A, 2002, J AM COLL CARDIOL, V40, P854, DOI 10.1016/S0735-1097(02)02053-3; SCOTT JM, 1981, LANCET, V2, P337; Seshadri N, 2000, MED CLIN N AM, V84, P215, DOI 10.1016/S0025-7125(05)70215-7; Smith TP, 2001, J VASC SURG, V34, P474, DOI 10.1067/mva.2001.117144; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499	34	254	262	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2673	2681		10.1056/NEJMoa032845	http://dx.doi.org/10.1056/NEJMoa032845			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215483				2022-12-28	WOS:000222199000008
J	Lindley-Jones, M; Lewis, D; Southgate, JL				Lindley-Jones, M; Lewis, D; Southgate, JL			Recurrent tetanus	LANCET			English	Editorial Material									Ipswich Hosp NHS Trust, Ipswich IP1 5PD, Suffolk, England	Ipswich Hospital NHS Trust; Ipswich Hospital	Lindley-Jones, M (corresponding author), Ipswich Hosp NHS Trust, Ipswich IP1 5PD, Suffolk, England.	mlj@doctors.org.uk						Attygalle D, 1997, ANAESTHESIA, V52, P956, DOI 10.1111/j.1365-2044.1997.206-az0340.x; BLECK TP, 1991, DIS MON, V37, P556; JACOBS RL, 1982, JAMA-J AM MED ASSOC, V247, P40, DOI 10.1001/jama.247.1.40; SALISBURY PM, 1996, IMMUNISATION INFECT	4	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2048	2048		10.1016/S0140-6736(04)16455-6	http://dx.doi.org/10.1016/S0140-6736(04)16455-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207956				2022-12-28	WOS:000222159800012
J	Seligman, SJ; Gould, EA				Seligman, SJ; Gould, EA			Live flavivirus vaccines: reasons for caution	LANCET			English	Review							VARICELLA-ZOSTER-VIRUS; WEST-NILE-VIRUS; FEVER; SAFETY; IMMUNOGENICITY; TRANSMISSION; TRANSFUSION; RECOMBINANT; VACCINATION; INFECTION	Context Dengue, Japanese encephalitis, tick-borne encephalitis, yellow fever, and West Nile viruses cause substantial morbidity and mortality each year. Modern transportation and the relaxation of mosquito-control measures are largely responsible for the increase of disease caused by flaviviruses. Without effective antiviral drugs, vaccination offers the best chance of decreasing the incidence of these diseases, and live virus vaccines are the most promising and cost effective. However, flaviviruses can recombine, which raises the possibility of recombination between a vaccine strain and wild-type virus resulting in a new virus with potentially undesirable properties. Starting point Recently, Arunee Sabchareon and colleagues reported up to 90% seroconversion rates in a phas I trial of live-attenuated dengue-virus vaccines in children (Pediatr Infect Dos J 2004; 23; 99-109). Other live flavivirus vaccines have also been tested against dengue, Japanese encephalitis, and West Nile viruses. Thus far, efficacy seems promising. Where next Safety issues with the live flavivirus vaccines need to be recognised and addressed. The theoretical possibility of untoward recombination events can never be entirely dismissed, but steps can be taken to minimise risk. The development of non-live flavivirus vaccines should be encouraged.	New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA; CEH Oxford, Inst Virol & Environm Microbiol, Oxford, England	New York Medical College; UK Centre for Ecology & Hydrology (UKCEH)	Seligman, SJ (corresponding author), New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.	stephen_seligman@nymc.edu						Adhiyaman V, 2001, LANCET, V358, P1907, DOI 10.1016/S0140-6736(01)06914-8; Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7; COETZER JAW, 1977, ONDERSTEPOORT J VET, V44, P205; Dodd RY, 2003, NEW ENGL J MED, V349, P1205, DOI 10.1056/NEJMp038138; Dumpis U, 1999, CLIN INFECT DIS, V28, P882, DOI 10.1086/515195; Edelman R, 2003, AM J TROP MED HYG, V69, P48, DOI 10.4269/ajtmh.2003.69.48; Ermolovich M. A., 2002, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P42; Gould EA, 2003, ADV VIRUS RES, V59, P277, DOI 10.1016/S0065-3527(03)59008-X; GOULD EA, 2004, ARCH VIROL, V18, P1; Gritsun TS, 2003, ANTIVIR RES, V57, P129, DOI 10.1016/S0166-3542(02)00206-1; HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997; Halstead SB, 2002, LANCET, V360, P1243, DOI 10.1016/S0140-6736(02)11276-1; Huang CYH, 2003, J VIROL, V77, P11436, DOI 10.1128/JVI.77.21.11436-11447.2003; Hunter P, 2002, ONDERSTEPOORT J VET, V69, P95; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; Johnson BW, 2002, AM J TROP MED HYG, V67, P260, DOI 10.4269/ajtmh.2002.67.260; Langevin SA, 2003, AM J TROP MED HYG, V69, P78, DOI 10.4269/ajtmh.2003.69.78; Levin MJ, 2003, J INFECT DIS, V188, P954, DOI 10.1086/378502; Levy O, 2003, J INFECT DIS, V188, P948, DOI 10.1086/378503; Marianneau P, 2001, LANCET, V358, P84, DOI 10.1016/S0140-6736(01)05374-0; Martin J, 2002, J VIROL, V76, P10921, DOI 10.1128/JVI.76.21.10921-10928.2002; Martin M, 2001, LANCET, V358, P98, DOI 10.1016/S0140-6736(01)05327-2; Monath TP, 2003, J INFECT DIS, V188, P1213, DOI 10.1086/378356; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Pletnev AG, 2003, VIROLOGY, V314, P190, DOI 10.1016/S0042-6822(03)00450-1; Sabchareon A, 2004, PEDIATR INFECT DIS J, V23, P99, DOI 10.1097/01.inf.0000109289.55856.27; Troillet N, 2001, LANCET, V358, P1908, DOI 10.1016/S0140-6736(01)06916-1; Twiddy SS, 2003, J GEN VIROL, V84, P429, DOI 10.1099/vir.0.18660-0; Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0; Weaver SC, 1997, J VIROL, V71, P613, DOI 10.1128/JVI.71.1.613-623.1997; Werfel U, 2001, LANCET, V358, P1909, DOI 10.1016/S0140-6736(01)06917-3; Whitehead SS, 2003, VACCINE, V21, P4307, DOI 10.1016/S0264-410X(03)00488-2; 2002, MMWR MORB MORTAL WKL, V51, P989	34	93	101	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2073	2075		10.1016/S0140-6736(04)16459-3	http://dx.doi.org/10.1016/S0140-6736(04)16459-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207960				2022-12-28	WOS:000222159800024
J	Carbotte, SM; Small, C; Donnelly, K				Carbotte, SM; Small, C; Donnelly, K			The influence of ridge migration on the magmatic segmentation of mid-ocean ridges	NATURE			English	Article							EAST PACIFIC RISE; JUAN-DE-FUCA; MELT REGION; GRAVITY-ANOMALIES; CRUSTAL THICKNESS; MANTLE FLOW; DEGREES N; BENEATH; ACCRETION	The Earth's mid-ocean ridges display systematic changes in depth and shape, which subdivide the ridges into discrete spreading segments bounded by transform faults and smaller non-transform offsets of the axis(1-3). These morphological changes have been attributed to spatial variations in the supply of magma from the mantle, although the origin of the variations is poorly understood(1,4,5). Here we show that magmatic segmentation of ridges with fast and intermediate spreading rates is directly related to the migration velocity of the spreading axis over the mantle. For over 9,500km of mid-ocean ridge examined, leading ridge segments in the 'hotspot' reference frame coincide with the shallow magmatically robust segments across 86 per cent of all transform faults and 73 per cent of all second-order discontinuities. We attribute this relationship to asymmetric mantle upwelling and melt production due to ridge migration, with focusing of melt towards ridge segments across discontinuities. The model is consistent with variations in crustal structure across discontinuities of the East Pacific Rise, and may explain variations in depth of melting and the distribution of enriched lavas.	Columbia Univ, Lamont Doherty Geol Observ, Palisades, NY 10964 USA	Columbia University	Carbotte, SM (corresponding author), Columbia Univ, Lamont Doherty Geol Observ, 61 Rte 9W, Palisades, NY 10964 USA.	carbotte@ldeo.columbia.edu						[Anonymous], [No title captured]; Canales JP, 2003, GEOPHYS J INT, V152, P766, DOI 10.1046/j.1365-246X.2003.01885.x; Cochran JR, 1997, J GEOPHYS RES-SOL EA, V102, P15463, DOI 10.1029/97JB00511; Conder JA, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000807; CORMIER MH, 1995, J GEOPHYS RES-SOL EA, V100, P8063, DOI 10.1029/95JB00243; DAVIS EE, 1986, EARTH PLANET SC LETT, V79, P385, DOI 10.1016/0012-821X(86)90194-9; DETRICK RS, 1987, NATURE, V326, P35, DOI 10.1038/326035a0; Donnelly K., 2002, GENESIS E MORB EXTEN; Forsyth DW, 1998, SCIENCE, V280, P1235, DOI 10.1126/science.280.5367.1235; Forsyth DW, 1998, SCIENCE, V280, P1215, DOI 10.1126/science.280.5367.1235; Gripp AE, 2002, GEOPHYS J INT, V150, P321, DOI 10.1046/j.1365-246X.2002.01627.x; Hirschmann MM, 1996, CONTRIB MINERAL PETR, V124, P185, DOI 10.1007/s004100050184; HOOFT EEE, 1995, J GEOPHYS RES-SOL EA, V100, P22499, DOI 10.1029/95JB02502; KATZ R, UNPUB GEOPHYS RES LE; Kent GM, 2000, NATURE, V406, P614, DOI 10.1038/35020543; LANGMUIR CH, 1986, NATURE, V322, P422, DOI 10.1038/322422a0; LIN J, 1992, GEOPHYS RES LETT, V19, P13, DOI 10.1029/91GL03041; LIN J, 1990, NATURE, V344, P627, DOI 10.1038/344627a0; MACDONALD KC, 1988, NATURE, V335, P217, DOI 10.1038/335217a0; MADGE LS, 1997, J GEOPHYS RES, V102, P20571; SCHEIRER DS, 1993, J GEOPHYS RES-SOL EA, V98, P7871, DOI 10.1029/93JB00015; SCHOUTEN H, 1987, NATURE, V326, P835, DOI 10.1038/326835a0; Small C, 2003, GEOLOGY, V31, P399, DOI 10.1130/0091-7613(2003)031<0399:PEFMDD>2.0.CO;2; STEIN S, 1977, EARTH PLANET SC LETT, V36, P51, DOI 10.1016/0012-821X(77)90187-X; Toomey DR, 1998, SCIENCE, V280, P1224, DOI 10.1126/science.280.5367.1224; Toomey DR, 2002, EARTH PLANET SC LETT, V200, P287, DOI 10.1016/S0012-821X(02)00655-6; Van Avendonk HJA, 2001, J GEOPHYS RES-SOL EA, V106, P10961, DOI 10.1029/2000JB900459; Wang XJ, 1996, J GEOPHYS RES-SOL EA, V101, P17927, DOI 10.1029/96JB00194; Weiland CM, 1996, J GEOPHYS RES-SOL EA, V101, P20257, DOI 10.1029/96JB01756; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230	30	45	47	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					743	746		10.1038/nature02652	http://dx.doi.org/10.1038/nature02652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201906				2022-12-28	WOS:000222059900034
J	Chan, MA; Beitler, B; Parry, WT; Ormo, J; Komatsu, G				Chan, MA; Beitler, B; Parry, WT; Ormo, J; Komatsu, G			A possible terrestrial analogue for haematite concretions on Mars	NATURE			English	Article							FLUID-FLOW	Recent exploration has revealed extensive geological evidence for a water-rich past in the shallow subsurface of Mars. Images of in situ and loose accumulations of abundant, haematite-rich spherical balls from the Mars Exploration Rover 'Opportunity' landing site at Meridiani Planum(1-3) bear a striking resemblance to diagenetic (post-depositional), haematite-cemented concretions found in the Jurassic Navajo Sandstone of southern Utah(4,5). Here we compare the spherical concretions imaged on Mars to these terrestrial concretions, and investigate the implications for analogous groundwater-related formation mechanisms. The morphology, character and distribution of Navajo haematite concretions allow us to infer host-rock properties and fluid processes necessary for similar features to develop on Mars. We conclude that the formation of such spherical haematite concretions requires the presence of a permeable host rock, groundwater flow and a chemical reaction front.	Univ Utah, Dept Geol & Geophys, Salt Lake City, UT 84112 USA; Inst Nacl Tecn Aeroespacial, CSIC, Ctr Astrobiol, Madrid 28850, Spain; Univ G DAnnunzio, Int Res Sch Planetary Sci, I-65127 Pescara, Italy	Utah System of Higher Education; University of Utah; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); G d'Annunzio University of Chieti-Pescara	Chan, MA (corresponding author), Univ Utah, Dept Geol & Geophys, 135 S 1460 E, Salt Lake City, UT 84112 USA.	machan@mines.utah.edu	Ormö, Jens/L-9058-2014; Komatsu, Goro/I-7822-2012	Ormö, Jens/0000-0002-5810-9442; Komatsu, Goro/0000-0003-4155-108X				ADAMOVIC J, 2002, IRONSTONES PSEUDOKAR, V2, P7; ANTONELLINI M, 1995, AAPG BULL, V79, P642; Beitler B, 2003, GEOLOGY, V31, P1041, DOI 10.1130/G19794.1; BEITLER B, 2002, GEOL SOC AM ABSTR, V34, P277; BEITLER B, 2004, LUNAR PLANET SCI C, V35; Catling DC, 2003, ICARUS, V165, P277, DOI 10.1016/S0019-1035(03)00173-8; Chan MA, 2000, AAPG BULL, V84, P1281; Chan MA, 2001, GEOLOGY, V29, P331, DOI 10.1130/0091-7613(2001)029<0331:AAAACO>2.0.CO;2; CHAN MA, 2002, RAINBOW ROCKS MYSTER; Christensen PR, 2001, J GEOPHYS RES-PLANET, V106, P23873, DOI 10.1029/2000JE001415; Cornell R.M., 1996, CORROS SCI, DOI [DOI 10.1016/S0010-938X(99)00005-0, DOI 10.1016/S0010-938X(97)00096-6]; Fernandez-Remolar D, 2004, PLANET SPACE SCI, V52, P239, DOI 10.1016/j.pss.2003.08.027; GLOTCH TD, 2004, LUNAR PLANET SCI C, V35; Hoffman N, 2000, ICARUS, V146, P326, DOI 10.1006/icar.2000.6398; HOOD JW, 1984, TECHNICAL PUBLICATIO, V78; Hynek BM, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2002JE001891; MINITTI ME, 2004, LUNAR PLANET SCI C, V35; MORGAN P, 1989, MEM GEOL SOC AM, V172, P493; *NASA JET PROP LAB, 2004, MARS EXPL ROV MISS; Newsom HE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001993; NUCCIO VF, 1996, US GEOL SURV B, V76, pO1; ORMO J, 2003, LUNAR PLANET SCI C, V34; Ortoleva P., 1994, GEOCHEMICAL SELF ORG; Parry WT, 2004, AAPG BULL, V88, P175, DOI 10.1306/09090303034; SQUYRES SW, 2004, LUNAR PLANET SCI C, V35	25	145	148	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					731	734		10.1038/nature02600	http://dx.doi.org/10.1038/nature02600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201902				2022-12-28	WOS:000222059900030
J	Kainer, MA; Linden, JV; Whaley, DN; Holmes, HT; Jarvis, WR; Jernigan, DB; Archibald, LK				Kainer, MA; Linden, JV; Whaley, DN; Holmes, HT; Jarvis, WR; Jernigan, DB; Archibald, LK			Clostridium infections associated with musculoskeletal-tissue allografts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TENDON-BONE ALLOGRAFTS; ANTERIOR CRUCIATE LIGAMENT; GAMMA-IRRADIATION; RECONSTRUCTION; TRANSMISSION; PROCUREMENT; VIRUS	Background: Allografts are commonly used in orthopedic reconstructive surgery. In 2001, approximately 875,000 musculoskeletal allografts were distributed by U.S. tissue banks. After the death from Clostridium sordellii sepsis of a 23-year-old man who had received a contaminated allograft from a tissue bank (Tissue Bank A), the Centers for Disease Control and Prevention initiated an investigation, including enhanced case finding, of the methods used for the recovery, processing, and testing of tissue. Methods: A case of allograft-associated clostridium infection was defined as a culture-proven infection of a surgical site within one year after allograft implantation, from January 1998 to March 2002. We traced tissues to tissue banks that recovered and processed these tissues. We also estimated the rates of and risk ratios for clostridium infections for tissues processed by the implicated tissue bank and reviewed processing and testing methods used by various tissue banks. Results: Fourteen patients were identified, all of whom had received allografts processed by Tissue Bank A. The rates of clostridium infection were 0.12 percent among patients who received sports-medicine tissues (i.e., tendons, femoral condyles, menisci) from Tissue Bank A and 0.36 percent among those who received femoral condyles in particular. The risk-ratio estimates for clostridium infections from tissues processed by Tissue Bank A, as compared with those from other tissue banks, were infinite (P<0.001) for musculoskeletal allografts, sports-medicine tissues, or tendons. Because Tissue Bank A cultured tissues only after treating them with a nonsporicidal antimicrobial solution, some test results were probably false negatives. Tissues from implicated donors were released despite the isolation of clostridium or bowel flora from other anatomical sites or reports of infections in other recipients. Conclusions: Clostridium infections were traced to allograft implantation. We provide interim recommendations to enhance tissue-transplantation safety. Tissue banks should validate processes and culture methods. Sterilization methods that do not adversely affect the functioning of transplanted tissue are needed to prevent allograft-related infections.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Monash University; State University of New York (SUNY) System; Wadsworth Center	Kainer, MA (corresponding author), Tennessee Dept Hlth, 4th Fl,Cordell Hull Bldg,425 5th Ave N, Nashville, TN 37247 USA.	marion.kainer@state.tn.us		Kainer, Marion/0000-0001-7678-8744				[Anonymous], 2002, STAT ABSTR US 2003, P113; BIANCHI JR, 1999, P BIOENG C BED NEW Y, V42, P407; BROOK I, 1989, J INFECT DIS, V160, P1071, DOI 10.1093/infdis/160.6.1071; CONRAD EU, 1995, J BONE JOINT SURG AM, V77A, P214, DOI 10.2106/00004623-199502000-00007; D'ANGELO G L, 1988, Arthroscopy, V4, P10, DOI 10.1016/S0749-8063(88)80004-5; Deijkers RLM, 1997, J BONE JOINT SURG BR, V79B, P161, DOI 10.1302/0301-620X.79B1.7137; EGGEN BM, 1992, NEW ENGL J MED, V326, P411; *FDA, 2001, FED REGISTER, V66, P1507; *FDA, 1997, FED REGISTER, V62, P40429; FIDELER BM, 1995, AM J SPORT MED, V23, P643, DOI 10.1177/036354659502300521; FINEGOLD SM, 1985, DM-DIS MON, V31, P1; FITZGERALD RH, 1982, CLIN ORTHOP RELAT R, P141; GIBBONS MJ, 1991, J ORTHOPAED RES, V9, P209, DOI 10.1002/jor.1100090209; Harner CD, 1996, CLIN ORTHOP RELAT R, P134; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; JACKSON DW, 1990, AM J SPORT MED, V18, P1, DOI 10.1177/036354659001800101; KAINER MA, 2002, P 40 ANN INF DIS SOC, P46; KETTERL R, 1989, Arthroscopy, V5, P79, DOI 10.1016/0749-8063(89)90098-4; LOTY B, 1990, INT ORTHOP, V14, P237; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; MARTINEZ OV, 1996, 96 GEN M AM SOC MICR, P16; Miller A.I., 2001, P49, DOI 10.1002/9780470999295.ch9; *PHARM CONV, 2001, US PHARM NAT FORM 20, P1878; RASMUSSEN TJ, 1994, ARTHROSCOPY, V10, P188, DOI 10.1016/S0749-8063(05)80092-1; ROBERTS TS, 1991, AM J SPORT MED, V19, P35, DOI 10.1177/036354659101900106; ROBERTS TS, 1991, AM J SPORTS MED, V19, P272; Ryan MJ, 1997, BRIT J RHEUMATOL, V36, P370; SHUTKIN NM, 1954, J BONE JOINT SURG AM, V36-A, P160, DOI 10.2106/00004623-195436010-00028; SIMONDS RJ, 1992, NEW ENGL J MED, V326, P726, DOI 10.1056/NEJM199203123261102; SMALL NC, 1993, ORTHOPEDICS, V16, P985; SUMMITT MC, 2001, P 25 ANN M AM ASS TI, P54; SUMMITT MC, 2001, P 25 ANN M AM ASS TI, P55; VEEN MR, 1994, CLIN ORTHOP RELAT R, P259; WHALEY DN, 2003, 103 GEN M AM SOC MIC, P117; Woll JE KD, 2001, STANDARDS TISSUE BAN; 2001, MMWR MORB MORTAL WKL, V50, P1081; 2003, MMWR MORB MORTAL WKL, V52, P273; 2003, MMWR MORB MORTAL WKL, V52, P276; 2002, MMWR MORB MORTAL WKL, V51, P207; 2001, MMWR MORB MORTAL WKL, V50, P1035; 2001, MMWR MORB MORTAL WKL, V50, P1080	41	179	185	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2564	2571		10.1056/NEJMoa023222	http://dx.doi.org/10.1056/NEJMoa023222			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201413	Bronze			2022-12-28	WOS:000222054700007
J	Ebbeling, CB; Sinclair, KB; Pereira, MA; Garcia-Lago, E; Feldman, HA; Ludwig, DS				Ebbeling, CB; Sinclair, KB; Pereira, MA; Garcia-Lago, E; Feldman, HA; Ludwig, DS			Compensation for energy intake from fast food among overweight and lean adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; RESTAURANT USE; PORTION SIZE; OBESE; DIETARY; CONSUMPTION; TRENDS; MEN	Context Fast food consumption has increased greatly among children in recent years, in tandem with the obesity epidemic. Fast food tends to promote a positive energy balance and, for this reason, may result in weight gain. However, if fast food and obesity are causally related, the question arises of why some children who frequently eat fast food do not become overweight. Objective To test the hypothesis that overweight adolescents are more susceptible to the adverse effects of fast food than lean adolescents. Design and Setting In study 1, we fed participants an "extra large" fast food meal in a naturalistic setting (a food court). The participants were instructed to eat as much or little as desired during this 1-hour meal. In study 2, we assessed energy intake under free-living conditions for 2 days when fast food was consumed and 2 days when it was not consumed. Data were collected in Boston, Mass, between July 2002 and March 2003. Participants Overweight (n=26) and lean (n=28) adolescents aged 13 to 17 years. Overweight was defined as a body mass index exceeding sex- and age-specific 85th percentiles based on the 2000 Centers for Disease Control and Prevention growth charts. Main Outcome Measures Energy intake determined by direct observation in study 1 and by unannounced 24-hour dietary recalls, administered by telephone, in study 2. Results In study 1, mean (SEM) energy intake from the fast food meal among all participants was extremely large (1652 [87] kcal), accounting for 61.6% (2.2%) of estimated daily energy requirements. Overweight participants ate more than lean participants whether energy was expressed in absolute terms (1860 [129] vs 1458 [107] kcal, P=.02) or relative to estimated daily energy requirements (66.5% [3.1%] vs 57.0% [2.9%], P=.03). In study 2, overweight participants consumed significantly more total energy on fast food days than non-fast food days (2703 [226] vs 2295 [162] kcal/d; +409 [142] kcal/d; P=.02), an effect that was not observed among lean participants (2575 [157] vs 2622 [191] kcal/d; -47 [173] kcal/d; P=.76). Conclusions In this study, adolescents overconsumed fast food regardless of body weight, although this phenomenon was especially pronounced in overweight participants. Moreover, overweight adolescents were less likely to compensate for the energy in fast food, by adjusting energy intake throughout the day, than their lean counterparts.	Childrens Hosp, Dept Med, Div Endocrinol, Boston, MA 02115 USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA	Harvard University; Boston Children's Hospital; University of Minnesota System; University of Minnesota Twin Cities	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu	Feldman, Henry/M-2302-2013	Ludwig, David/0000-0003-3307-8544; Pereira, Mark/0000-0002-6704-5276	NCRR NIH HHS [M01 RR02172] Funding Source: Medline; NIDDK NIH HHS [R01 DK59240, K01 DK62237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062237, R01DK059240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421; Bandini LG, 1999, OBES RES, V7, P438, DOI 10.1002/j.1550-8528.1999.tb00431.x; Binkley JK, 2000, INT J OBESITY, V24, P1032, DOI 10.1038/sj.ijo.0801356; Bowman SA, 2004, PEDIATRICS, V113, P112, DOI 10.1542/peds.113.1.112; Brownell K. D., 2004, FOOD FIGHT INSIDE ST; DIETZ WH, 1991, J PEDIATR-US, V118, P146, DOI 10.1016/S0022-3476(05)81870-0; Diliberti N, 2004, OBES RES, V12, P562, DOI 10.1038/oby.2004.64; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; EDELMAN B, 1986, APPETITE, V7, P71, DOI 10.1016/S0195-6663(86)80043-5; Fisher JO, 2003, AM J CLIN NUTR, V77, P1164, DOI 10.1093/ajcn/77.5.1164; Freeland-Graves J, 2002, J AM DIET ASSOC, V102, P100, DOI 10.1016/S0002-8223(02)90030-1; French SA, 2001, INT J OBESITY, V25, P1823, DOI 10.1038/sj.ijo.0801820; French SA, 2000, INT J OBESITY, V24, P1353, DOI 10.1038/sj.ijo.0801429; GAZZANIGA JM, 1993, AM J CLIN NUTR, V58, P21, DOI 10.1093/ajcn/58.1.21; Goris AHC, 2000, AM J CLIN NUTR, V71, P130; Guthrie JF, 2002, J NUTR EDUC BEHAV, V34, P140, DOI 10.1016/S1499-4046(06)60083-3; HEITMANN BL, 1995, BRIT MED J, V311, P986; Jeffery RW, 1998, AM J PUBLIC HEALTH, V88, P277, DOI 10.2105/AJPH.88.2.277; Johansson L, 1998, AM J CLIN NUTR, V68, P266, DOI 10.1093/ajcn/68.2.266; Krebs-Smith SM, 2000, EUR J CLIN NUTR, V54, P281, DOI 10.1038/sj.ejcn.1600936; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; McCrory MA, 2002, J NUTR, V132, p3830S, DOI 10.1093/jn/132.12.3830S; McNutt SW, 1997, J ADOLESCENT HEALTH, V20, P27, DOI 10.1016/S1054-139X(96)00176-0; Nielsen SJ, 2002, PREV MED, V35, P107, DOI 10.1006/pmed.2002.1037; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Pate RR, 2003, PEDIATR EXERC SCI, V15, P257, DOI 10.1123/pes.15.3.257; Pereira MA, 2003, CIRCULATION, V107, pE7008; Pereira MA, 2001, PEDIATR CLIN N AM, V48, P969, DOI 10.1016/S0031-3955(05)70351-5; Rolls BJ, 1999, AM J CLIN NUTR, V69, P863; Rolls BJ, 2004, APPETITE, V42, P63, DOI 10.1016/S0195-6663(03)00117-X; St-Onge MP, 2003, AM J CLIN NUTR, V78, P1068, DOI 10.1093/ajcn/78.6.1068; Story M, 2002, J AM DIET ASSOC, V102, pS40, DOI 10.1016/S0002-8223(02)90421-9; 1989, N ENGL J MED, V321, P752	35	140	146	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2828	2833		10.1001/jama.291.23.2828	http://dx.doi.org/10.1001/jama.291.23.2828			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199032	Bronze			2022-12-28	WOS:000221962500027
J	Paytan, A; Kastner, M; Campbell, D; Thiemens, MH				Paytan, A; Kastner, M; Campbell, D; Thiemens, MH			Seawater sulfur isotope fluctuations in the cretaceous	SCIENCE			English	Article							ATMOSPHERIC OXYGEN; PHANEROZOIC TIME; GEOCHEMICAL CYCLES; SULFATE; CARBON; OCEANS; O-2; FRACTIONATION; SEDIMENTS; BURIAL	The exogenic sulfur cycle is tightly coupled with the carbon and oxygen cycles, and therefore a central component of Earth's biogeochemistry. Here we present a high-resolution record of the sulfur isotopic composition of seawater sulfate for the Cretaceous. The general enrichment of isotopically light sulfur that prevailed during the Cretaceous may have been due to increased volcanic and hydrothermal activity. Two excursions toward isotopically lighter sulfur represent periods of lower rates of pyrite burial, implying a shift in the location of organic carbon burial to terrestrial or open-cean settings. The concurrent changes in seawater sulfur and inorganic carbon isotopic compositions imply short-term variability in atmospheric oxygen partial pressure.	Stanford Univ, Dept Geog & Environm Sci, Stanford, CA 94305 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	Stanford University; University of California System; University of California San Diego	Paytan, A (corresponding author), Stanford Univ, Dept Geog & Environm Sci, Stanford, CA 94305 USA.	apaytan@pangea.stanford.edu						[Anonymous], [No title captured]; ARTHUR MA, 1990, NATO ASI SER C-MATH, V304, P71; Arthur MA, 2000, ENCY VOLCANOES, P1045; Berner RA, 1999, P NATL ACAD SCI USA, V96, P10955, DOI 10.1073/pnas.96.20.10955; BERNER RA, 1983, GEOCHIM COSMOCHIM AC, V47, P855, DOI 10.1016/0016-7037(83)90151-5; BERNER RA, 1989, AM J SCI, V289, P333, DOI 10.2475/ajs.289.4.333; Berner RA, 2000, SCIENCE, V287, P1630, DOI 10.1126/science.287.5458.1630; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Canfield DE, 2001, GEOCHIM COSMOCHIM AC, V65, P1117, DOI 10.1016/S0016-7037(00)00584-6; Carpenter SJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4831, DOI 10.1016/S0016-7037(97)00361-X; CLAYPOOL GE, 1980, CHEM GEOL, V28, P199, DOI 10.1016/0009-2541(80)90047-9; Erbacher J, 2001, NATURE, V409, P325, DOI 10.1038/35053041; Haq B. U., 1988, SOC ECON PALEONT MIN, V42, P71, DOI DOI 10.2110/PEC.88.01.0071; HAYS JD, 1973, NATURE, V246, P18, DOI 10.1038/246018a0; HOLLAND HD, 1973, GEOCHIM COSMOCHIM AC, V37, P2605, DOI 10.1016/0016-7037(73)90268-8; Holser W. T., 1988, CHEM CYCLES EVOLUTIO, P105; Holser W.T., 1966, CHEM GEOL, V1, P93, DOI [10.1016/0009-2541(66)90011-8., DOI 10.1016/0009-2541(66)90011-8]; JENKYNS HC, 1980, J GEOL SOC LONDON, V137, P171, DOI 10.1144/gsjgs.137.2.0171; Kaplan I.R., 1983, STABLE ISOTOPES SEDI, P1; KATZ ME, IN PRESS MAR GEOL; Krouse H.R., 1980, SULFUR ISOTOPES OUR; KUMP LR, 1989, AM J SCI, V289, P390, DOI 10.2475/ajs.289.4.390; KUMP LR, 1986, AM J SCI, V286, P337, DOI 10.2475/ajs.286.5.337; KURTZ AC, 2003, PALEOCEANOGRAPHY, V12, P239; LARSON RL, 1991, GEOLOGY, V19, P547, DOI 10.1130/0091-7613(1991)019<0547:LPOEEF>2.3.CO;2; Lowenstein TK, 2001, SCIENCE, V294, P1086, DOI 10.1126/science.1064280; McArthur JM, 2001, J GEOL, V109, P155, DOI 10.1086/319243; Migdisov A.A., 1983, GLOBAL BIOGEOCHEMICA, P25; Paytan A, 1998, SCIENCE, V282, P1459, DOI 10.1126/science.282.5393.1459; Paytan A, 2000, INT GEOL REV, V42, P491, DOI 10.1080/00206810009465094; Petsch ST, 1998, AM J SCI, V298, P246, DOI 10.2475/ajs.298.3.246; Raiswell R, 1998, AM J SCI, V298, P219, DOI 10.2475/ajs.298.3.219; Ravizza G, 1999, GEOLOGY, V27, P971, DOI 10.1130/0091-7613(1999)027<0971:GOTMUC>2.3.CO;2; RICHTER FM, 1993, EARTH PLANET SC LETT, V119, P121, DOI 10.1016/0012-821X(93)90010-7; SCHIDLOWSKI M, 1981, GEOCHIM COSMOCHIM AC, V45, P89; SCHLANGER S O, 1976, Geologie en Mijnbouw, V55, P179; Scott R.W., 1993, CRETACEOUS CARBONATE, V56, P1; Strauss H, 1999, CHEM GEOL, V161, P89, DOI 10.1016/S0009-2541(99)00082-0; Taylor AS, 1999, CHEM GEOL, V161, P199, DOI 10.1016/S0009-2541(99)00087-X; VanCappellen P, 1996, SCIENCE, V271, P493, DOI 10.1126/science.271.5248.493; VEIZER J, 1980, GEOCHIM COSMOCHIM AC, V44, P579, DOI 10.1016/0016-7037(80)90250-1; Veizer J, 2000, NATURE, V408, P698, DOI 10.1038/35047044; WALKER JCG, 1986, MAR GEOL, V70, P259	43	175	180	3	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1663	1665		10.1126/science.1095258	http://dx.doi.org/10.1126/science.1095258			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192227				2022-12-28	WOS:000221934300048
J	White, JWC				White, JWC			Do I hear a million?	SCIENCE			English	Editorial Material									Univ Colorado, Environm Studies Program, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	White, JWC (corresponding author), Univ Colorado, Environm Studies Program, Boulder, CO 80309 USA.	james.white@colorado.edu	White, James W.C./A-7845-2009	White, James W.C./0000-0001-6041-4684				Berger A., 2003, GEOPHYS MONOGR SER, P17, DOI DOI 10.1029/137GM02); *EPICA COMM MEMB, 2004, NATURE, V0429; Intergovernmental Panel on Climate Change, 2001, 3 INT PAN CLIM CHANG; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P371, DOI 10.2973/odp.proc.sr.138.120.1995; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Ruddiman WF, 2001, QUATERNARY SCI REV, V20, P1769, DOI 10.1016/S0277-3791(01)00067-1	6	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1609	1610		10.1126/science.1100084	http://dx.doi.org/10.1126/science.1100084			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192208				2022-12-28	WOS:000221934300028
J	Chen, YH; Li, MH; Zhang, Y; He, LL; Yamada, Y; Fitzmaurice, A; Shen, Y; Zhang, HL; Tong, L; Yang, J				Chen, YH; Li, MH; Zhang, Y; He, LL; Yamada, Y; Fitzmaurice, A; Shen, Y; Zhang, HL; Tong, L; Yang, J			Structural basis of the alpha(1)-beta subunit interaction of voltage-gated Ca2+ channels	NATURE			English	Article							GUANYLATE KINASE; CALCIUM-CHANNELS; PROTEINS; IDENTIFICATION; ASSOCIATION; DIFFRACTION; DOMAINS; PROGRAM; PSD-95; MODELS	High-voltage-activated Ca2+ channels are essential for diverse biological processes. They are composed of four or five subunits, including alpha(1), alpha(2)-delta, beta and gamma ( ref. 1). Their expression and function are critically dependent on the beta-subunit, which transports alpha(1) to the surfacemembrane and regulates diverse channel properties(2-4). It is believed(3-6) that the beta-subunit interacts with alpha(1) primarily through the beta-interaction domain (BID), which binds directly to the alpha-interaction domain (AID) of alpha(1)(7); however, the molecular mechanism of the alpha(1)-beta interaction is largely unclear. Here we report the crystal structures of the conserved core region of b 3, alone and in complex with AID, and of b 4 alone. The structures show that the beta-subunit core contains two interacting domains: a Src homology 3 (SH3) domain and a guanylate kinase (GK) domain. The AID binds to a hydrophobic groove in the GK domain through extensive interactions, conferring extremely high affinity between alpha(1) and beta-subunits(4,8). The BID is essential both for the structural integrity of and for bridging the SH3 and GK domains, but it does not participate directly in binding alpha(1). The presence of multiple protein-interactingmodules in the beta-subunit opens a new dimension to its function as a multi-functional protein.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Yang, J (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jy160@columbia.edu	Tuluc, Petronel/C-2527-2011	Tong, Liang/0000-0002-0563-6468				Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Blaszczyk J, 2001, J MOL BIOL, V307, P247, DOI 10.1006/jmbi.2000.4427; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canti C, 2001, BIOPHYS J, V81, P1439, DOI 10.1016/S0006-3495(01)75799-2; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DOLPHIN AC, 2003, J BIOENERG BIOMEMBR, V55, P607; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	30	239	249	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					675	680		10.1038/nature02641	http://dx.doi.org/10.1038/nature02641			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15170217				2022-12-28	WOS:000221912600045
J	Lipton, SA				Lipton, SA			Erythropoietin for neurologic protection and diabetic neuropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BRAIN		Salk Inst Biol Studies, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA USA; Univ Calif San Diego, La Jolla, CA 92093 USA	Salk Institute; Scripps Research Institute; University of California System; University of California San Diego	Lipton, SA (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Lipton, Stuart/0000-0002-3490-1259				Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DIGICAYLIOGLU M, IN PRESS P NATL ACAD; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029	6	45	52	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2516	2517		10.1056/NEJMcibr041121	http://dx.doi.org/10.1056/NEJMcibr041121			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190146				2022-12-28	WOS:000221887200014
J	Roca, AL; Bar-Gal, GK; Eizirik, E; Helgen, KM; Maria, R; Springer, MS; O'Brien, SJ; Murphy, WJ				Roca, AL; Bar-Gal, GK; Eizirik, E; Helgen, KM; Maria, R; Springer, MS; O'Brien, SJ; Murphy, WJ			Mesozoic origin for West Indian insectivores	NATURE			English	Article							MOLECULAR EVIDENCE; BIOGEOGRAPHY; EVOLUTION; MAMMALS; VERTEBRATES; PHYLOGENY; ORDER	The highly endangered solenodons, endemic to Cuba ( Solenodon cubanus) and Hispaniola ( S. paradoxus), comprise the only two surviving species of West Indian insectivores(1,2). Combined gene sequences (13.9 kilobases) from S. paradoxus established that solenodons diverged from other eulipotyphlan insectivores 76 million years ago in the Cretaceous period, which is consistent with vicariance, though also compatible with dispersal. A sequence of 1.6 kilobases of mitochondrial DNA from S. cubanus indicated a deep divergence of 25 million years versus the congeneric S. paradoxus, which is consistent with vicariant origins as tectonic forces separated Cuba and Hispaniola(3,4). Efforts to prevent extinction of the two surviving solenodon species would conserve an entire lineage as old or older than many mammalian orders.	SAIC Frederick, Lab Genom Divers, Basic Res Program, Frederick, MD 21702 USA; NCI, Lab Genom Divers, Frederick, MD 21702 USA; Pontificia Univ Catolica Rio Grande do Sul, Ctr Biol Genom & Mol, Porto Alegre, RS, Brazil; Univ Adelaide, Sch Earth & Environm Sci, Adelaide, SA 5005, Australia; ZOODOM, Parque Zool Nacl, Santo Domingo, Dominican Rep; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pontificia Universidade Catolica Do Rio Grande Do Sul; University of Adelaide; University of California System; University of California Riverside	Roca, AL (corresponding author), SAIC Frederick, Lab Genom Divers, Basic Res Program, Frederick, MD 21702 USA.	roca@ncifcrf.gov; obrien@ncifcrf.gov; murphywi@ncifcrf.gov	Helgen, Kristofer M./AAB-8348-2019; Eizirik, Eduardo/K-8034-2012; OBRIEN, STEPHEN/ABD-1346-2020	Helgen, Kristofer M./0000-0002-8776-4040; Eizirik, Eduardo/0000-0002-9658-0999; OBRIEN, STEPHEN/0000-0001-7857-0757; Roca, Alfred/0000-0001-9217-5593				ACTON GD, 2000, P OCEAN DRILLING PRO, V165, P149; Asher RJ, 1999, CLADISTICS, V15, P231, DOI 10.1111/j.1096-0031.1999.tb00266.x; Asher RJ, 2002, B AM MUS NAT HIST, P1; BUTLER PM, 1988, PHYLOGENY CLASSIFICA, V2, P117; Cabrera A., 1925, GENERA MAMMALIUM INS; Donnelly Thomas W., 1992, P1; Eisenberg J.F., 1985, ACTA ZOOL FENN, V173, P275; Emerson GL, 1999, CLADISTICS, V15, P221, DOI 10.1111/j.1096-0031.1999.tb00265.x; HEDGES SB, 1992, P NATL ACAD SCI USA, V89, P1909, DOI 10.1073/pnas.89.5.1909; Hedges SB, 1996, ANNU REV ECOL SYST, V27, P163, DOI 10.1146/annurev.ecolsys.27.1.163; HEDGES SB, 1993, MOL PHYLOGENET EVOL, V2, P76, DOI 10.1006/mpev.1993.1008; Hershkovitz P., 1972, EVOLUTION MAMMALS SO, P311; *INT UN CONS NAT, 2003 IUCN RED LIST T; Iturralde-Vinent MA, 1999, B AM MUS NAT HIST, P1; Kishino H, 2001, MOL BIOL EVOL, V18, P352, DOI 10.1093/oxfordjournals.molbev.a003811; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LILLEGRAVEN J A, 1981, University of Wyoming Publications, V45, P1; MACFADDEN BJ, 1980, J BIOGEOGR, V7, P11, DOI 10.2307/2844544; MacPhee R.D.E., 1999, American Museum Novitates, V3261, P1; MACPHEE RDE, 1993, MAMMAL PHYLOGENY : PLACENTALS, P13; MCDOWELL SAMUEL BOOKER, 1958, BULL AMER MUS NAT HIST, V115, P113; McKenna MC, 1997, CLASSIFICATION MAMMA; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; OTTENWALDER JA, 1985, THESIS U FLORIDA GAI, P1; Ottenwalder Jose A., 2001, P253; Robertson DS, 2004, GEOL SOC AM BULL, V116, P760, DOI 10.1130/B25402.1; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892; Whidden Howard P., 2001, P237	30	106	110	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					649	651		10.1038/nature02597	http://dx.doi.org/10.1038/nature02597			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190349				2022-12-28	WOS:000221912600037
J	Wang, XL; Zhou, ZH				Wang, XL; Zhou, ZH			Palaeontology: Pterosaur embryo from the Early Cretaceous	NATURE			English	Editorial Material							CHINA		Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Wang, XL (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	xlinwang@263.net						BENNETT SC, 1993, PALEOBIOLOGY, V19, P92, DOI 10.1017/S0094837300012331; Chiappe LM, 1998, NATURE, V396, P258, DOI 10.1038/24370; Ji SA, 1999, NATURE, V398, P573, DOI 10.1038/19221; NORELL MA, 1994, SCIENCE, V266, P779, DOI 10.1126/science.266.5186.779; SMITH PE, 1995, CAN J EARTH SCI, V32, P1426, DOI 10.1139/e95-115; Unwin David M., 2003, Geological Society Special Publication, V217, P139, DOI 10.1144/GSL.SP.2003.217.01.11; Unwin David M., 2000, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V3, P181; Unwin David M., 2001, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V4, P189; Wang XL, 2001, CHINESE SCI BULL, V46, P1112; WANG XL, 2003, JEHOL BIOTA, P19; Wellnhofer P., 1991, P1	11	49	61	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					621	621		10.1038/429621a	http://dx.doi.org/10.1038/429621a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190343	Bronze			2022-12-28	WOS:000221912600029
J	Ferraroli, S; Georges, JY; Gaspar, P; Le Maho, Y				Ferraroli, S; Georges, JY; Gaspar, P; Le Maho, Y			Endangered species - Where leatherback turtles meet fisheries	NATURE			English	Editorial Material									Univ Strasbourg 1, F-67070 Strasbourg, France; Diren Guyane, Direct Reg Environm, F-97300 Cayenne, Guyane Francais, French Guiana; CLS, Direct Oceanog Spatiale, F-31526 Ramonville St Agne, France; CNRS, UPR 9010, CEPE, F-67087 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ferraroli, S (corresponding author), WWF France, F-97300 Cayenne, Guyane Francais, French Guiana.	jean-yves.georges@c-strasbourg.fr		GEORGES, Jean Yves/0000-0003-1161-2275				[Anonymous], [No title captured]; BLEAKNEY J. SHERMAN, 1965, CAN FIELD NATUR, V79, P120; FERRAROLI S, 2003, C R ACAD SCI PARIS R, V17, P319; Gueguen F, 2000, CR ACAD SCI III-VIE, V323, P775, DOI 10.1016/S0764-4469(00)01222-1; Hays GC, 2003, MAR ECOL PROG SER, V262, P305, DOI 10.3354/meps262305; LAURS RM, 1984, DEEP-SEA RES, V31, P1085, DOI 10.1016/0198-0149(84)90014-1; Lewison RL, 2004, ECOL LETT, V7, P221, DOI 10.1111/j.1461-0248.2004.00573.x; Morrisey J. K., 1996, Exotic Pet Practice, V1, P1; PODESTA GP, 1993, CONT SHELF RES, V13, P253, DOI 10.1016/0278-4343(93)90109-B; Spotila James R., 1996, Chelonian Conservation and Biology, V2, P209	10	118	131	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					521	522		10.1038/429521a	http://dx.doi.org/10.1038/429521a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175741	Green Submitted			2022-12-28	WOS:000221767700028
J	Svoboda, T; Henry, B; Shulman, L; Kennedy, E; Rea, E; Ng, W; Wallington, T; Yaffe, B; Gournis, E; Vicencio, E; Basrur, S; Glazier, RH				Svoboda, T; Henry, B; Shulman, L; Kennedy, E; Rea, E; Ng, W; Wallington, T; Yaffe, B; Gournis, E; Vicencio, E; Basrur, S; Glazier, RH			Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARS	Background: Toronto was the site of North America's largest outbreak of the severe acute respiratory syndrome (SARS). An understanding of the patterns of transmission and the effects on public health in relation to control measures that were taken will help health officials prepare for any future outbreaks. Methods: We analyzed SARS case, quarantine, and hotline records in relation to control measures. The two phases of the outbreak were compared. Results: Toronto Public Health investigated 2132 potential cases of SARS, identified 23,103 contacts of SARS patients as requiring quarantine, and logged 316,615 calls on its SARS hotline. In Toronto, 225 residents met the case definition of SARS, and all but 3 travel-related cases were linked to the index patient, from Hong Kong. SARS spread to 11 (58 percent) of Toronto's acute care hospitals. Unrecognized SARS among in-patients with underlying illness caused a resurgence, or a second phase, of the outbreak, which was finally controlled through active surveillance of hospitalized patients. In response to the control measures of Toronto Public Health, the number of persons who were exposed to SARS in nonhospital and nonhousehold settings dropped from 20 (13 percent) before the control measures were instituted (phase 1) to 0 afterward (phase 2). The number of patients who were exposed while in a hospital ward rose from 25 (17 percent) in phase 1 to 68 (88 percent) in phase 2, and the number exposed while in the intensive care unit dropped from 13 (9 percent) in phase 1 to 0 in phase 2. Community spread (the length of the chains of transmission outside of hospital settings) was significantly reduced in phase 2 of the outbreak (P<0.001). Conclusions: The transmission of SARS in Toronto was limited primarily to hospitals and to households that had had contact with patients. For every case of SARS, health authorities should expect to quarantine up to 100 contacts of the patients and to investigate 8 possible cases. During an outbreak, active in-hospital surveillance for SARS-like illnesses and heightened infection-control measures are essential.	Univ Toronto, Inner City Hlth Res Unit, Toronto Publ Hlth, Toronto, ON M5C 1N8, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5C 1N8, Canada; Univ Toronto, Dept Family & Community Med, Toronto, ON M5C 1N8, Canada; St Michaels Hosp, Inner City Hlth Res Unit, Toronto, ON M5B 1W8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Svoboda, T (corresponding author), Univ Toronto, Inner City Hlth Res Unit, Toronto Publ Hlth, 70 Richmond St E,4th Fl, Toronto, ON M5C 1N8, Canada.	tomislav.svoboda@utoronto.ca	Glazier, Richard H/E-5255-2012					Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Booth CM, 2003, JAMA-J AM MED ASSOC, V290, P334; Dyer O, 2003, BRIT MED J, V326, P999, DOI 10.1136/bmj.326.7397.999; *GREAT TOR AIRP AU, 2002, 6 YEARS ACC ANN REP; *HLTH CAN, 2003, OUTBR PER NAT CAS DE; Hoey J, 2003, CAN MED ASSOC J, V168, P1013; *KPMG CAN, 2003, TOR TOUR REV LOSS EX; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; National Instruments, 2003, LEARN SARS REN PUBL; Oyranoski D, 2003, NATURE, V423, P4, DOI 10.1038/423004a; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5; *TOR BOARD TRAD, 2003, IMP SARS TOR BUS COM; Varia M, 2003, CAN MED ASSOC J, V169, P285; *WHO, 2003, SEV AC RESP SYNDR VI; *WHO, MAN SEV AC RESP SYND; World Health Organization, CUM NUMB REP PROB CA; 2003, JAMA, V289, P2788; 2003, MMWR MORB MORTAL WKL, V52, P547	21	159	164	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2352	2361		10.1056/NEJMoa032111	http://dx.doi.org/10.1056/NEJMoa032111			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175437	Bronze			2022-12-28	WOS:000221754200006
J	Chichak, KS; Cantrill, SJ; Pease, AR; Chiu, SH; Cave, GWV; Atwood, JL; Stoddart, JF				Chichak, KS; Cantrill, SJ; Pease, AR; Chiu, SH; Cave, GWV; Atwood, JL; Stoddart, JF			Molecular Borromean rings	SCIENCE			English	Article							CHEMICAL TOPOLOGY; COMPLEXES; DEVICES; LINKS	The realization of the Borromean link in a wholly synthetic molecular form is reported. The self-assembly of this link, which is topologically achiral, from 18 components by the template-directed formation of 12 imine and 30 dative bonds, associated with the coordination of three interlocked macrocycles, each tetranucleating and decadentate overall, to a total of six zinc(II) ions, is near quantitative. Three macrocycles present diagonally in pairs, six exo-bidentate bipyridyl and six endo-diiminopyridyl ligands to the six zinc(II) ions. The use, in concert, of coordination, supramolecular, and dynamic covalent chemistry allowed the highly efficient construction, by multiple cooperative self-assembly processes, of a nanoscale dodecacation with an approximate diameter of 2.5 nanometers and an inner chamber of volume 250 Angstrom(3), lined with 12 oxygen atoms.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA; Univ Missouri, Dept Chem, Columbia, MO 65211 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Missouri System; University of Missouri Columbia	Stoddart, JF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	stoddart@chem.ucla.edu	Stoddart, James Fraser/H-1518-2011; Cantrill, Stuart J/B-6157-2008; atwood, jerry/ABA-8947-2021; Cave, Gareth WV/B-2187-2012	Stoddart, James Fraser/0000-0003-3161-3697; Cantrill, Stuart/0000-0002-3754-7902; CHIU, SHENG-HSIEN/0000-0002-0040-1555				Amabilino DB, 1995, CHEM REV, V95, P2725, DOI 10.1021/cr00040a005; AUSTIN SM, 1995, SCI AM, V272, P90, DOI 10.1038/scientificamerican0695-90; Blanco MJ, 2003, TOP STEREOCHEM, V23, P125; Carlucci L, 2003, CRYSTENGCOMM, V5, P269, DOI 10.1039/b305246j; Chiu SH, 2002, ANGEW CHEM INT EDIT, V41, P270, DOI 10.1002/1521-3773(20020118)41:2<270::AID-ANIE270>3.0.CO;2-5; CRAM DJ, 1994, CONTAINER MOL THEIR, P20; Cromwell P, 1998, MATH INTELL, V20, P53; Diederich F., 2000, TEMPLATED ORGANIC SY; Dolomanov OV, 2003, CHEM COMMUN, P682, DOI 10.1039/b300605k; FRISCH HL, 1961, J AM CHEM SOC, V83, P3789, DOI 10.1021/ja01479a015; Hoff L, 2001, ACOUSTIC CHARACTERIZ; Hubin TJ, 1999, ADV SUPR CH, V5, P237; KRAMER R, 1993, P NATL ACAD SCI USA, V90, P5394, DOI 10.1073/pnas.90.12.5394; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Leigh DA, 2001, ANGEW CHEM INT EDIT, V40, P1538, DOI 10.1002/1521-3773(20010417)40:8<1538::AID-ANIE1538>3.0.CO;2-F; LIANG CZ, 1994, J MATH CHEM, V16, P27, DOI 10.1007/BF01169193; LINDSEY JS, 1991, NEW J CHEM, V15, P153; Loren JC, 2003, ANGEW CHEM INT EDIT, V42, P5702, DOI 10.1002/anie.200352562; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; Mao CD, 1997, NATURE, V386, P137, DOI 10.1038/386137b0; Mislow K., 1999, TOPICS STEREOCHEMIST, P1, DOI DOI 10.1002/9780470147313.CH1; Rowan SJ, 2002, ANGEW CHEM INT EDIT, V41, P898, DOI 10.1002/1521-3773(20020315)41:6<898::AID-ANIE898>3.0.CO;2-E; Ruben M, 2003, CHEM-EUR J, V9, P4422, DOI 10.1002/chem.200304933; RUZMAIKIN A, 1994, PHYS PLASMAS, V1, P331, DOI 10.1063/1.870835; Sauvage, 1999, MOL CATENANES ROTAXA; Schill G., 1971, CATENANES ROTAXANES; Schmittel M, 2002, ORG LETT, V4, P2289, DOI 10.1021/ol025885t; SIMON J, 1992, P S APPL MATH, V45, P97; Sokolov V. I., 1973, RUSS CHEM REV, V42, P452, DOI DOI 10.1070/RC1973V042N06ABEH002636; TAUBER SJ, 1963, J RES NBS A PHYS CH, VA 67, P591, DOI 10.6028/jres.067A.058; VANGULICK N, 1993, NEW J CHEM, V17, P619; WALBA DM, 1985, TETRAHEDRON, V41, P3161, DOI 10.1016/S0040-4020(01)96671-2; WASSERMAN E, 1960, J AM CHEM SOC, V82, P4433, DOI 10.1021/ja01501a082; Wu H, 2000, J AM CHEM SOC, V122, P12691, DOI 10.1021/ja002687t	34	625	625	6	195	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1308	1312		10.1126/science.1096914	http://dx.doi.org/10.1126/science.1096914			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166376	Green Submitted			2022-12-28	WOS:000221669600050
J	Wolkers, MC; Brouwenstijn, N; Bakker, AH; Toebes, M; Schumacher, TNM				Wolkers, MC; Brouwenstijn, N; Bakker, AH; Toebes, M; Schumacher, TNM			Antigen bias in T cell cross-priming	SCIENCE			English	Article							DENDRITIC CELLS; LYMPHOCYTE EPITOPE; CD8(+); INDUCTION; SEQUENCES; MOUSE	Activated CD8(+) T cells detect virally infected cells and tumor cells by recognition of major histocompatibility complex class I-bound peptides derived from degraded, endogenously produced proteins. In contrast, CD8(+) T cell activation often occurs through interaction with specialized antigen-presenting cells displaying peptides acquired from an exogenous cellular source, a process termed cross-priming. Here, we observed a marked inefficiency in exogenous presentation of epitopes derived from signal sequences in mouse models. These data indicate that certain virus- and tumor-associated antigens may not be detected by CD8(+) T cells because of impaired cross-priming. Such differences in the ability to cross-present antigens should form important considerations in vaccine design.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Schumacher, TNM (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	t.schumacher@nki.nl	Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Wolkers, Monika/0000-0003-3242-1363; Bakker, Arne/0000-0003-1944-6515				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BACIK I, 1994, J IMMUNOL, V152, P381; Belz GT, 2000, J IMMUNOL, V165, P2404, DOI 10.4049/jimmunol.165.5.2404; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Chen W, 1996, J VIROL, V70, P7773, DOI 10.1128/JVI.70.11.7773-7782.1996; den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295; Haanen JBAG, 1999, EUR J IMMUNOL, V29, P1168, DOI 10.1002/(SICI)1521-4141(199904)29:04<1168::AID-IMMU1168>3.0.CO;2-J; HOMBACH J, 1995, J EXP MED, V182, P1615, DOI 10.1084/jem.182.5.1615; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MCCOY JL, 1967, CANCER RES, V27, P1743; Norbury CC, 2004, SCIENCE, V304, P1318, DOI 10.1126/science.1096378; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Shen LJ, 2004, P NATL ACAD SCI USA, V101, P3035, DOI 10.1073/pnas.0308345101; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; WOLFEL T, 1994, EUR J IMMUNOL, V24, P759, DOI 10.1002/eji.1830240340; Wolkers MC, 2001, J IMMUNOL, V167, P3577, DOI 10.4049/jimmunol.167.7.3577; WOLKERS MC, UNPUB; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; Zinkernagel RM, 2002, EUR J IMMUNOL, V32, P2385, DOI 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V	27	153	160	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1314	1317		10.1126/science.1096268	http://dx.doi.org/10.1126/science.1096268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166378				2022-12-28	WOS:000221669600052
J	Miyashita, M; Sasaki, M; Hattori, I; Sakai, M; Tanino, K				Miyashita, M; Sasaki, M; Hattori, I; Sakai, M; Tanino, K			Total synthesis of norzoanthamine	SCIENCE			English	Article							HETEROCYCLIC AMINAL CORE; ALPHA,BETA-UNSATURATED CARBONYL-COMPOUNDS; MIZOROKI-HECK REACTION; DIELS-ALDER REACTION; ABC RING-SYSTEM; ZOANTHAMINE ALKALOIDS; MARINE ZOANTHID; STEREOSELECTIVE-SYNTHESIS; ZOANTHAMINE/NORZOANTHAMINE ALKALOIDS; CDEFG RING	Norzoanthamine, an alkaloid isolated from Zoanthus sp., can suppress the loss of bone weight and strength in ovariectomized mice. Norzoanthamine derivatives can also strongly inhibit the growth of P-388 murine leukemia cell lines and human platelet aggregation. However, norzoanthamine's densely functionalized complex stereostructure and scarce availability from natural sources have proved a synthetic challenge. We report the stereoselective total synthesis of norzoanthamine in 41 steps, with an overall yield of 3.5% ( an average of 92% yield each step).	Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Miyashita, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan.	miyasita@sci.hokudai.ac.jp	Tanino, Keiji/M-3564-2019; Tanino, Keiji/D-8399-2012	Tanino, Keiji/0000-0002-0580-0125; Tanino, Keiji/0000-0002-0580-0125				CLIVE DLJ, 1994, J AM CHEM SOC, V116, P11275, DOI 10.1021/ja00104a009; CLIVE DLJ, 1993, TETRAHEDRON, V49, P7917, DOI 10.1016/S0040-4020(01)88016-9; Daranas AH, 1999, TETRAHEDRON, V55, P5539, DOI 10.1016/S0040-4020(99)00198-2; Daranas AH, 1998, TETRAHEDRON, V54, P7891, DOI 10.1016/S0040-4020(98)00423-2; Fukuzawa S., 1995, HETEROCYCL COMMUN, V1, P207, DOI DOI 10.1515/HC.1995.1.2-3.207; Ghosh S, 2004, ORG LETT, V6, P941, DOI 10.1021/ol036492c; Hikage N, 2000, CHEM PHARM BULL, V48, P1370; Hikage N, 1998, TETRAHEDRON LETT, V39, P6241, DOI 10.1016/S0040-4039(98)01285-4; Hikage N, 1998, TETRAHEDRON LETT, V39, P6237, DOI 10.1016/S0040-4039(98)01284-2; Hirai G, 2002, ORG LETT, V4, P1627, DOI 10.1021/ol025852d; Hirai G, 2001, TETRAHEDRON LETT, V42, P5783, DOI 10.1016/S0040-4039(01)01110-8; Hirai G, 1999, CHEM LETT, P141, DOI 10.1246/cl.1999.141; ITO Y, 1978, J ORG CHEM, V43, P1011, DOI 10.1021/jo00399a052; KATSUMURA S, 1985, TETRAHEDRON LETT, V26, P4625, DOI 10.1016/S0040-4039(00)98769-0; Kuramoto M, 1998, B CHEM SOC JPN, V71, P771, DOI 10.1246/bcsj.71.771; Kuramoto M, 1997, TETRAHEDRON LETT, V38, P5683, DOI 10.1016/S0040-4039(97)01238-0; Lebel H, 1999, TETRAHEDRON LETT, V40, P7303, DOI 10.1016/S0040-4039(99)01502-6; Moharram SM, 2000, TETRAHEDRON LETT, V41, P6669, DOI 10.1016/S0040-4039(00)01116-3; Mutti S, 1996, TETRAHEDRON LETT, V37, P3125, DOI 10.1016/0040-4039(96)00519-9; NAKAMURA E, 1986, TETRAHEDRON LETT, V27, P4029, DOI 10.1016/S0040-4039(00)84902-3; Nakamura H, 1998, B CHEM SOC JPN, V71, P781, DOI 10.1246/bcsj.71.781; Nielsen TE, 2002, J ORG CHEM, V67, P6366, DOI 10.1021/jo025902s; OJIMA I, 1982, ORGANOMETALLICS, V1, P1390, DOI 10.1021/om00070a024; Ooi T, 2001, HETEROCYCLES, V54, P593; RAHMAN AU, 1989, TETRAHEDRON LETT, V30, P6825; RAO CB, 1989, HETEROCYCLES, V28, P103; RAO CB, 1984, J AM CHEM SOC, V106, P7983, DOI 10.1021/ja00337a062; RAO CB, 1985, J ORG CHEM, V50, P3757, DOI 10.1021/jo00220a016; Sakai M, 2002, TETRAHEDRON LETT, V43, P1705, DOI 10.1016/S0040-4039(02)00079-5; TANNER D, 1994, TETRAHEDRON, V50, P9135, DOI 10.1016/S0040-4020(01)85379-5; Tanner D, 1997, ACTA CHEM SCAND, V51, P1217, DOI 10.3891/acta.chem.scand.51-1217; TROST BM, 1984, TETRAHEDRON LETT, V25, P173, DOI 10.1016/S0040-4039(00)99832-0; Vedejs E, 2002, J AM CHEM SOC, V124, P748, DOI 10.1021/ja0120835; Venkateswarlu Y, 1998, HETEROCYCL COMMUN, V4, P575; Villar RM, 2003, BIOORGAN MED CHEM, V11, P2301, DOI 10.1016/S0968-0896(03)00107-X; Williams DR, 1998, TETRAHEDRON LETT, V39, P2675, DOI 10.1016/S0040-4039(98)00369-4; Williams DR, 2000, ORG LETT, V2, P1023, DOI 10.1021/ol9904085; Yamaguchi K, 1999, BIOL PHARM BULL, V22, P920	38	169	173	0	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	2004	305	5683					495	499		10.1126/science.1098851	http://dx.doi.org/10.1126/science.1098851			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	840AH	15205476				2022-12-28	WOS:000222828900033
J	Boter, H; van Delden, JJM; de Haan, RJ; Rinkel, GJE				Boter, H; van Delden, JJM; de Haan, RJ; Rinkel, GJE		Home Evaluation Stroke Induced Aid	Patients' evaluation of informed consent to postponed information: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DD Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	Boter, H (corresponding author), Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, POB 85500, NL-3508 GA Utrecht, Netherlands.	h.boter@azu.nl						Boter H, 2003, BRIT MED J, V327, P284, DOI 10.1136/bmj.327.7409.284; Dennis M, 2003, BRIT MED J, V327, P286, DOI 10.1136/bmj.327.7409.286; Doyal L, 1997, BMJ-BRIT MED J, V314, P1107, DOI 10.1136/bmj.314.7087.1107; Lambert MF, 2000, J CLIN EPIDEMIOL, V53, P163, DOI 10.1016/S0895-4356(99)00146-8; McLean S, 1997, BRIT MED J, V314, P1076, DOI 10.1136/bmj.314.7087.1076	5	17	17	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	2004	329	7457					86	86		10.1136/bmj.38041.636250.EE	http://dx.doi.org/10.1136/bmj.38041.636250.EE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15210571	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222645000023
J	Case, RB; Chang, YP; Smith, SB; Gore, J; Cozzarelli, NR; Bustamante, C				Case, RB; Chang, YP; Smith, SB; Gore, J; Cozzarelli, NR; Bustamante, C			RETRACTED: The bacterial condensin MukBEF compacts DNA into a repetitive, stable structure (Retracted Article. See vol 307, pg 1409, 2005)	SCIENCE			English	Article; Retracted Publication							MITOTIC CHROMOSOME CONDENSATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; 13S CONDENSIN; COMPLEX; PROTEIN; SMC; YEAST; ARCHITECTURE; SEGREGATION	Condensins are conserved proteins containing SMC ( structural maintenance of chromosomes) moieties that organize and compact chromosomes in an unknown mechanism essential for faithful chromosome partitioning. We show that MukBEF, the condensin in Escherichia coli, cooperatively compacts a single DNA molecule into a. lament with an ordered, repetitive structure in an adenosine triphosphate (ATP) binding-dependent manner. When stretched to a tension of similar to17 pico-newtons, the. lament extended in a series of repetitive transitions in a broad distribution centered on 45 nanometers. A. lament so extended and held at a lower force recondensed in steps of 35 nanometers or its multiples; this cycle was repeatable even in the absence of ATP and free MukBEF. Remarkably, the pattern of transitions displayed by a given. lament during the initial extension was identical in every subsequent extension. Hence, after being deformed micrometers in length, each. lament returned to its original compact structure without the addition of energy. Incubation with topoisomerase I increased the rate of recondensation and allowed the structure to extend and reform almost reversibly, indicating that supercoiled DNA is trapped in the condensed structure. We suggest a new model for how MukBEF organizes the bacterial chromosome in vivo.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	ncozzare@socrates.berkeley.edu; carlos@alice.berkeley.edu		Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543, R01GM031655] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31655, GM32543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JD, 2002, MOL CELL BIOL, V22, P7147, DOI 10.1128/MCB.22.20.7147-7157.2002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Brower-Toland BD, 2002, P NATL ACAD SCI USA, V99, P1960, DOI 10.1073/pnas.022638399; BUSTAMANTE C, IN PRESS ANN REV BIO; Cui Y, 2000, P NATL ACAD SCI USA, V97, P127, DOI 10.1073/pnas.97.1.127; Graumann PL, 2001, J BACTERIOL, V183, P4052, DOI 10.1128/JB.183.13.4052-4060.2001; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hardy CD, 2004, PHILOS T R SOC B, V359, P39, DOI 10.1098/rstb.2003.1363; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HOWARD J, 2001, MECH MOTOR PROTEINS, P61; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lindow JC, 2002, J BACTERIOL, V184, P5317, DOI 10.1128/JB.184.19.5317-5322.2002; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; Ohsumi K, 2001, MOL MICROBIOL, V40, P835, DOI 10.1046/j.1365-2958.2001.02447.x; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Sherratt DJ, 2003, SCIENCE, V301, P780, DOI 10.1126/science.1084780; Smith SB, 2003, METHOD ENZYMOL, V361, P134; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Trun NJ, 1998, ASM NEWS, V64, P276; van den Ent F, 1999, STRUCTURE, V7, P1181, DOI 10.1016/S0969-2126(00)80052-0; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitao T, 2000, EMBO REP, V1, P494; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873	41	34	36	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					222	227		10.1126/science.1098225	http://dx.doi.org/10.1126/science.1098225			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15178751				2022-12-28	WOS:000222501000046
J	Nossal, GJV				Nossal, GJV			Mentors and manipulation - How Nobel assistance helped a young researcher test a crazy idea.	NATURE			English	Editorial Material									Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia	University of Melbourne	Nossal, GJV (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.							NOSSAL GJV, 1958, NATURE, V181, P1419, DOI 10.1038/1821383a0	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	2004	429	6994					811	811		10.1038/429811a	http://dx.doi.org/10.1038/429811a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215842	Bronze			2022-12-28	WOS:000222213000021
J	Julius, S; Kjeldsen, SE; Weber, M; Brunner, HR; Ekman, S; Hansson, L; Hua, TS; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Zanchetti, A				Julius, S; Kjeldsen, SE; Weber, M; Brunner, HR; Ekman, S; Hansson, L; Hua, TS; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Zanchetti, A		VALUE Trial Grp	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial	LANCET			English	Article							CALCIUM-CHANNEL BLOCKER; DOUBLE-BLIND; ANGIOTENSIN-II; BLOOD-PRESSURE; ELECTROCARDIOGRAPHIC IDENTIFICATION; ACTIVE TREATMENT; CORONARY RISK; BETA-BLOCKERS; MORBIDITY; MORTALITY	Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. Methods 15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4.2 years. Findings Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4.0/2.1 mm Hg lower in amlodipine than valsartan group after I month; 1.5/1.3 mm Hg after 1 year; p<0.001 between groups). The primary composite endpoint occurred in 810 patients in the valsartan group (10.6%, 25.5 per 1000 patient-years) and 789 in the amlodipine group (10.4%, 24.7 per 1000 patient-years; hazard ratio 1.04, 95% Cl 0.94-1.15, p=0.49). Interpretation The main outcome of cardiac disease did not differ between the treatment groups. Unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.	Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiovasc Med,TC 3918, Ann Arbor, MI 48109 USA; Ullevaal Univ Hosp, Oslo, Norway; SUNY, Brooklyn, NY USA; Univ Lausanne, Lausanne, Switzerland; Uppsala Univ, Uppsala, Sweden; Novartis Pharmaceut, Basel, Switzerland; Novartis Pharmaceut, E Hanover, NJ USA; Cornell Med Ctr, New York, NY USA; Univ Glasgow, Glasgow, Lanark, Scotland; Osped Maggiore, Ist Auxol Italiano, Milan, Italy; Univ Milan, Milan, Italy	University of Michigan System; University of Michigan; University of Oslo; State University of New York (SUNY) System; SUNY Maritime College; University of Lausanne; Uppsala University; Novartis; Novartis; Cornell University; University of Glasgow; IRCCS Istituto Auxologico Italiano; University of Milan	Julius, S (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiovasc Med,TC 3918, Ann Arbor, MI 48109 USA.	sjulius@med.umich.edu	Portaluppi, Francesco/H-2206-2012	Portaluppi, Francesco/0000-0002-2948-1579; da Silva Franco, Roberto Jorge/0000-0001-9787-4393; zanchetti, alberto/0000-0003-4796-7959				Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Brunner HR, 2001, AM J CARDIOL, V87, p3C; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Criscione L, 1995, CARDIOVASC DRUG REV, V13, P230, DOI 10.1111/j.1527-3466.1995.tb00305.x; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Fox KM, 2003, LANCET, V362, P782; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; JULIUS S, 1990, JAMA-J AM MED ASSOC, V264, P354; Julius S, 2003, AM J HYPERTENS, V16, P544, DOI 10.1016/S0895-7061(03)00904-X; Kjeldsen SE, 2001, BLOOD PRESSURE, V10, P83, DOI 10.1080/08037050152112069; Ligtenberg G, 1999, NEW ENGL J MED, V340, P1321, DOI 10.1056/NEJM199904293401704; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; Malacco E, 2003, BLOOD PRESSURE, V12, P160, DOI 10.1080/08037050310009545; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; Mann Jessica, 1998, Blood Pressure, V7, P176; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; OKIN PM, 1995, J AM COLL CARDIOL, V25, P417, DOI 10.1016/0735-1097(94)00371-V; Okin PM, 1996, J AM COLL CARDIOL, V27, P124, DOI 10.1016/0735-1097(95)00421-1; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pool JL, 1999, J HUM HYPERTENS, V13, P275, DOI 10.1038/sj.jhh.1000788; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Staessen JA, 2003, J HYPERTENS, V21, P1055, DOI 10.1097/00004872-200306000-00002; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Turnbull F, 2003, LANCET, V362, P1527; WEBER M, LANCET          0614; WHO, 1999, WHO LAB MAN EX HUM S, P1; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD	40	1963	2126	1	88	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2022	2031		10.1016/S0140-6736(04)16451-9	http://dx.doi.org/10.1016/S0140-6736(04)16451-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207952	Green Submitted			2022-12-28	WOS:000222159800008
J	Durst, AC; Girvin, SM				Durst, AC; Girvin, SM			Cooking a two-dimensional electron gas with microwaves	SCIENCE			English	Editorial Material							OSCILLATIONS		Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University	Durst, AC (corresponding author), Yale Univ, Dept Phys, POB 208120, New Haven, CT 06520 USA.	steven.girvin@yale.edu						Andreev AV, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.056803; Dorozhkin SI, 2003, JETP LETT+, V77, P577, DOI 10.1134/1.1595700; Durst AC, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.086803; KEAY BJ, 1995, PHYS REV LETT, V75, P4102, DOI 10.1103/PhysRevLett.75.4102; Mani RG, 2002, NATURE, V420, P646, DOI 10.1038/nature01277; Mani RG, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.146801; RYZHII VI, 1970, FIZ TVERD TELA+, V11, P2078; RYZHII VI, 1986, SOV PHYS SEMICOND, V20, P1289; Vavilov MG, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.035303; Zudov MA, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.046807; Zudov MA, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.201311	11	13	15	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1752	1753		10.1126/science.1099262	http://dx.doi.org/10.1126/science.1099262			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205518				2022-12-28	WOS:000222089500029
J	Kelley, DE				Kelley, DE			Thermodynamics, liposuction, and metbolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEPENDENT DIABETES-MELLITUS; WEIGHT-LOSS; RESTRICTION		Univ Pittsburgh, Med Ctr, Obes & Nutr Res Ctr, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kelley, DE (corresponding author), Univ Pittsburgh, Med Ctr, Obes & Nutr Res Ctr, Pittsburgh, PA 15260 USA.							Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; HENRY RR, 1985, J CLIN ENDOCR METAB, V61, P917, DOI 10.1210/jcem-61-5-917; KELLEY DE, 1993, J CLIN ENDOCR METAB, V77, P1287, DOI 10.1210/jc.77.5.1287; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Sjostrom CD, 2000, HYPERTENSION, V36, P20, DOI 10.1161/01.HYP.36.1.20	5	18	19	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2542	2544		10.1056/NEJMp048115	http://dx.doi.org/10.1056/NEJMp048115			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201408				2022-12-28	WOS:000222054700002
J	Stach, S; Benard, J; Giurfa, M				Stach, S; Benard, J; Giurfa, M			Local-feature assembling in visual pattern recognition and generalization in honeybees	NATURE			English	Article							EQUAL ORTHOGONAL BARS; APIS-MELLIFERA; SPECTRAL PROPERTIES; VISION; DISCRIMINATION; ORIENTATION; PERCEPTION; BEES; MEDULLA; INSECT	Generalization is a cognitive ability that allows similar stimuli along a given dimension to be treated as equivalents(1-3). Insects exhibit high levels of visual generalization(4-6). Honeybees trained to recognize complex visual stimuli on the basis of a single feature generalize their choice to novel stimuli sharing that common feature with the trained stimuli(7). The demonstration of this kind of performance has been limited to the use of a single visual feature, and the possibility that bees link different features in learning a visual pattern has been denied(8,9). Here we show that honeybees trained with a series of complex patterns sharing a common layout comprising four edge orientations remember these orientations simultaneously in their appropriate positions, and generalize their response to novel stimuli that preserve the trained layout. Honeybees also generalize their response to patterns with fewer correct orientations, depending on their match with the trained layout. Stimulation of the achromatic L-photoreceptor input is necessary for this task. The mini-brain of the honeybee can thus extract regularities in its environment and establish correspondences among correlated features. It can thus generate a large set of object descriptions from a finite set of elements.	Univ Toulouse 3, CNRS, Res Ctr Anim Cognit, F-31062 Toulouse 4, France; Free Univ Berlin, Inst Biol, D-14195 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Free University of Berlin	Giurfa, M (corresponding author), Univ Toulouse 3, CNRS, Res Ctr Anim Cognit, 118 Route Narbonne, F-31062 Toulouse 4, France.	giurfa@cict.fr	Giurfa, Martin/H-5140-2016; Giurfa, Martin MG/A-7322-2008; Giurfa, Martin/AAS-4945-2020	Giurfa, Martin/0000-0001-7173-769X; Giurfa, Martin/0000-0001-7173-769X				BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; Chen L, 2003, P NATL ACAD SCI USA, V100, P6884, DOI 10.1073/pnas.0732090100; DILL M, 1993, NATURE, V365, P751, DOI 10.1038/365751a0; Ghirlanda S, 2003, ANIM BEHAV, V66, P15, DOI 10.1006/anbe.2003.2174; Giger AD, 1996, J COMP PHYSIOL A, V178, P763; Giurfa M, 1997, CURR OPIN NEUROBIOL, V7, P505, DOI 10.1016/S0959-4388(97)80030-X; Giurfa M, 1999, ANIM BEHAV, V57, P315, DOI 10.1006/anbe.1998.0957; Giurfa M, 1996, NATURE, V382, P458, DOI 10.1038/382458a0; Giurfa M, 2003, CURR OPIN NEUROBIOL, V13, P726, DOI 10.1016/j.conb.2003.10.015; HORRIDGE GA, 1995, J INSECT PHYSIOL, V41, P681, DOI 10.1016/0022-1910(95)00021-L; Horridge GA, 1997, J INSECT PHYSIOL, V43, P741, DOI 10.1016/S0022-1910(97)00041-3; Horridge GA, 2003, J COMP PHYSIOL A, V189, P703, DOI 10.1007/s00359-003-0446-7; Horridge GA, 1996, J INSECT PHYSIOL, V42, P131, DOI 10.1016/0022-1910(95)00088-7; Horridge GA, 1997, J COMP PHYSIOL A, V181, P267, DOI 10.1007/s003590050113; James AC, 1996, J COMP PHYSIOL A, V178, P183, DOI 10.1007/BF00188161; Maurer D, 2002, TRENDS COGN SCI, V6, P255, DOI 10.1016/S1364-6613(02)01903-4; Menzel Randolf, 1991, P262; OSORIO D, 1987, J COMP PHYSIOL A, V161, P441, DOI 10.1007/BF00603969; RONACHER B, 1992, VISION RES, V32, P1837, DOI 10.1016/0042-6989(92)90045-K; Ronacher B, 1998, BIOL CYBERN, V79, P477, DOI 10.1007/s004220050497; SHEPARD RN, 1987, SCIENCE, V237, P1317, DOI 10.1126/science.3629243; Spence KW, 1937, PSYCHOL REV, V44, P430, DOI 10.1037/h0062885; SRINIVASAN MV, 1994, J INSECT PHYSIOL, V40, P183, DOI 10.1016/0022-1910(94)90041-8; SRINIVASAN MV, 1988, J COMP PHYSIOL A, V162, P159, DOI 10.1007/BF00606081; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VANHATEREN JH, 1990, J COMP PHYSIOL A, V167, P649, DOI 10.1007/BF00192658; von Frisch K., 1967, DANCE LANGUAGE ORIEN; Werner C. W., 1999, ANIM COGN, V2, P27	28	97	97	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					758	761		10.1038/nature02594	http://dx.doi.org/10.1038/nature02594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201910				2022-12-28	WOS:000222059900038
J	Pronovost, PJ; Wu, AW; Sexton, JB				Pronovost, PJ; Wu, AW; Sexton, JB			Acute decompensation after removing a central line: Practical approaches to increasing safety in the intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article							CRITICAL PATHWAYS; AIR-EMBOLISM; PREVENTION; RISK; QUALITY	Intensive care is one of the largest, most expensive, and complex components of U.S. health care. Errors and the resulting adverse events are, however, common in intensive care units (ICUs). Theories about errors in high-risk environments, developed by aviation and other industries, provide insight into why ICUs are prone to errors. Complex systems-of which ICUs are certainly an example-are breeding grounds for errors because interdependent components interact in unexpected ways. To achieve favorable outcomes, ICUs require that many processes occur in sequence. For example, patients are cared for by many providers with varying levels of expertise across several disciplines, and these providers use highly sensitive and potentially dangerous technologies and medications. Such complex systems require careful planning, excellent teamwork and communication, and designed redundancies to recheck for proper care processes. This paper provides a practical framework for improving patient safety.	Johns Hopkins Univ, Qual & Safety Res Grp, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Pronovost, PJ (corresponding author), Johns Hopkins Univ, Qual & Safety Res Grp, 901 S Bond St,Suite 318, Baltimore, MD 21231 USA.		Wu, Albert/AAJ-4780-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011902] Funding Source: NIH RePORTER; AHRQ HHS [U18 HS11902] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berenholtz S, 2001, INTENS CARE MED, V27, P1029, DOI 10.1007/s001340100952; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burgmeier Jean, 2002, Jt Comm J Qual Improv, V28, P331; Cook RI, 1994, HUMAN ERROR MED, P255; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; DeRosier Joseph, 2002, Jt Comm J Qual Improv, V28, P248; Dy SM, 2003, MED CARE, V41, P637; Ely EW, 1999, CRIT CARE MED, V27, P2113, DOI 10.1097/00003246-199910000-00006; Friedrich M. J., 2002, JAMA-J AM MED ASSOC, V288, P2811; Friedrich MJ, 2002, JAMA-J AM MED ASSOC, V288, P2808, DOI 10.1001/jama.288.22.2808; Gawande A., 2002, COMPLICATIONS SURG N; Hatala RM, 2003, ADV HEALTH SCI EDUC, V8, P17, DOI 10.1023/A:1022687404380; HELMREICH RL, 1998, CULTURE WORK AVIATIO, P176; HELMREICH RL, 2004, TEAMING COMPONENTS S; *JOINT COMM ACCR H, 2000, EV HOSP SHOULD KNOW; Klein G., 1999, SOURCES POWER; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; McGaghie WC, 2003, ADV HEALTH SCI EDUC, V8, P97, DOI 10.1023/A:1024936200782; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; Michie S, 2004, BRIT MED J, V328, P343, DOI 10.1136/bmj.328.7435.343; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pronovost P, 2003, J CRIT CARE, V18, P71, DOI 10.1053/jcrc.2003.50008; Pronovost Peter J, 2004, Jt Comm J Qual Saf, V30, P59; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; REASON JT, 1995, CLIN RISK MANAGEMENT, P9; Rubin HR, 2001, INT J QUAL HEALTH C, V13, P489, DOI 10.1093/intqhc/13.6.489; SEXTON JB, 2004, IN PRESS GOLDEN RULE; Shojania K G, 2001, Eff Clin Pract, V4, P82; Souders JE, 2000, J CLIN MONIT COMPUT, V16, P375, DOI 10.1023/A:1011455701892; SPATH P, 1997, INVESTIGATING SENTIN; Thomas EJ, 2003, CRIT CARE MED, V31, P956, DOI 10.1097/01.CCM.0000056183.89175.76; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; Vincent C, 1997, BRIT MED J, V314, P1775, DOI 10.1136/bmj.314.7097.1775; VINCENT C, 1995, CLIN RISK MANAGEMENT, P439; Wysoki MG, 2001, J VASC INTERV RADIOL, V12, P764, DOI 10.1016/S1051-0443(07)61451-1	44	67	67	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					1025	1033		10.7326/0003-4819-140-12-200406150-00013	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00013			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197020				2022-12-28	WOS:000222055500006
J	Waselenko, JK; MacVittie, TJ; Blakely, WF; Pesik, N; Wiley, AL; Dickerson, WE; Tsu, H; Confer, DL; Coleman, CN; Seed, T; Lowry, P; Armitage, JO; Dainiak, N				Waselenko, JK; MacVittie, TJ; Blakely, WF; Pesik, N; Wiley, AL; Dickerson, WE; Tsu, H; Confer, DL; Coleman, CN; Seed, T; Lowry, P; Armitage, JO; Dainiak, N			Medical management of the acute radiation syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group	ANNALS OF INTERNAL MEDICINE			English	Review							COLONY-STIMULATING FACTOR; BONE-MARROW-TRANSPLANTATION; IMPROVES NEUTROPHIL RECOVERY; PERIPHERAL-BLOOD LYMPHOCYTES; EARLY DOSE ASSESSMENT; FUNGAL-INFECTIONS; FLUCONAZOLE PROPHYLAXIS; HEMATOPOIETIC RECOVERY; G-CSF; BIOLOGICAL DOSIMETRY	Physicians, hospitals, and other health care facilities will assume the responsibility for aiding individuals injured by a terrorist act involving radioactive material. Scenarios have been developed for such acts that include a range of exposures resulting in few to many casualties. This consensus document was developed by the Strategic National Stockpile Radiation Working Group to provide a framework for physicians in internal medicine and the medical subspecialties to evaluate and manage large-scale radiation injuries. Individual radiation close is assessed by determining the time to onset and severity of nausea and vomiting, decline in absolute lymphocyte count over several hours or days after exposure, and appearance of chromosome aberrations (including dicentrics and ring forms) in peripheral blood lymphocytes. Documentation of clinical signs and symptoms (affecting the hematopoietic, gastrointestinal, cerebrovascular, and cutaneous systems) over time is essential for triage of victims, selection of therapy, and assignment of prognosis. Recommendations based on radiation dose and physiologic response are made for treatment of the hematopoietic syndrome. Therapy includes treatment with hematopoietic cytokines; blood transfusion; and, in selected cases, stem-cell transplantation. Additional medical management based on the evolution of clinical signs and symptoms includes the use of antimicrobial agents (quinolones, antiviral therapy, and antifungal agents), antiemetic agents, and analgesic agents. Because of the strong psychological impact of a possible radiation exposure, psychosocial support will be required for those exposed, regardless of the dose, as well as for family and friends. Treatment of pregnant women must account for risk to the fetus. For terrorist or accidental events involving exposure to radioicidines, prophylaxis against malignant disease of the thyroid is also recommended, particularly for children and adolescents.	Bridgeport Hosp, Dept Med, Bridgeport, CT USA; Walter Reed Army Med Ctr, Washington, DC USA; Catholic Univ Amer, Washington, DC USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD USA; Armed Forces Radiobiol Res Inst, Bethesda, MD USA; NIH, Bethesda, MD USA; Off Emergency Preparedness & Response, Ctr Dis Control & Prevent, Strateg Natl Stockpile Program, Atlanta, GA USA; Oak Ridge Associated Univ, Oak Ridge, TN USA; Natl Marrow Donor Program, Minneapolis, MN USA; Univ Nebraska, Omaha, NE 68182 USA; Yale New Haven Hlth Syst, New Haven, CT USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Catholic University of America; University System of Maryland; University of Maryland Baltimore; United States Department of Defense; National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA; United States Department of Energy (DOE); Oak Ridge National Laboratory; National Marrow Donor Program; University of Nebraska System; Yale University; Yale University	Dainiak, N (corresponding author), Bridgeport Hosp, Dept Med, 267 Grant St, Bridgeport, CT USA.	pndain@bpthosp.org						Abbott B, 1999, BONE MARROW TRANSPL, V23, P265, DOI 10.1038/sj.bmt.1701565; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 2001, RADIAT PROT DOSIM, V97, P11, DOI 10.1093/oxfordjournals.rpd.a006632; Anno GH, 2003, HEALTH PHYS, V84, P565, DOI 10.1097/00004032-200305000-00001; *ARM FORC RAD RES, 2003, MED MAN RAD CAS HDB; ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BAGDASAROV A, 1959, PROBL GEMAT, V4, P3; Barabanova AV, 2002, MEDICAL BASIS FOR RADIATION-ACCIDENT PREPAREDNESS, P217; BARANOV A, 1989, NEW ENGL J MED, V321, P205, DOI 10.1056/NEJM198907273210401; BARANOV AE, 1995, STEM CELLS, V13, P69; BARLOW Y, 1994, BURNS, V20, P487, DOI 10.1016/0305-4179(94)90002-7; Bedell C, 2003, CLIN J ONCOL NURS, V7, P63; Bence-Bruckler I, 1998, BONE MARROW TRANSPL, V22, P965, DOI 10.1038/sj.bmt.1701469; BENDER MA, 1966, RADIAT RES, V29, P568, DOI 10.2307/3572080; Blajchman Morris A, 2002, Am J Ther, V9, P389, DOI 10.1097/00045391-200209000-00005; BROOK I, 1994, J ANTIMICROB CHEMOTH, V33, P63, DOI 10.1093/jac/33.1.63; BROOK I, 1994, J ANTIMICROB CHEMOTH, V33, P777, DOI 10.1093/jac/33.4.777; BROOK I, 1990, RADIAT RES, V122, P215, DOI 10.2307/3577609; Brook Itzhak, 2002, Mil Med, V167, P105; Browne D, 1990, TREATMENT RAD INJURI; CHEADLE WG, 1993, J TRAUMA, V35, P844, DOI 10.1097/00005373-199312000-00007; Ciernik IF, 1999, BONE MARROW TRANSPL, V24, P147, DOI 10.1038/sj.bmt.1701872; COHEN AM, 1988, INFECT IMMUN, V56, P2861, DOI 10.1128/IAI.56.11.2861-2865.1988; Dainiak N, 2002, EXP HEMATOL, V30, P513, DOI 10.1016/S0301-472X(02)00802-0; DAINIAK N, 1997, RAD INJURY CHERNOBYL; Demirer T, 2002, BRIT J HAEMATOL, V118, P1104, DOI 10.1046/j.1365-2141.2002.03762.x; DENSOW D, 1997, RAD INJURY CHERNOBYL; DiGiovanni C, 1999, AM J PSYCHIAT, V156, P1500, DOI 10.1176/ajp.156.10.1500; Durante M, 1996, RADIAT RES, V145, P53, DOI 10.2307/3579195; Engels EA, 1999, CLIN INFECT DIS, V28, P256, DOI 10.1086/515103; Engels EA, 1998, J CLIN ONCOL, V16, P1179, DOI 10.1200/JCO.1998.16.3.1179; Epstein JB, 2002, ORAL SURG ORAL MED O, V94, P712, DOI 10.1067/moe.2002.127585; FARESE AM, 1993, BLOOD, V82, P3012; Farese AM, 1996, J CLIN INVEST, V97, P2145, DOI 10.1172/JCI118652; Farese AM, 2001, STEM CELLS, V19, P522, DOI 10.1634/stemcells.19-6-522; Farese AM, 2001, STEM CELLS, V19, P514, DOI 10.1634/stemcells.19-6-514; Farese AM, 1999, BLOOD, V94, p49A; Fliedner T.M., 1995, ASSESSMENT RAD EFFEC; Fliedner TM., 2001, MED MANAGEMENT RAD A; FLIEDNER TM, 2000, MED ASPECTS RAD EMER, P228; FLIEDNER TM, 2004, RAD INDUCED MULTI OR; Fullerton CS, 1997, PROG PSYCH, P3; FURTH FW, 1953, J LAB CLIN MED, V41, P918; Gale JD, 1995, J PEDIATR GASTR NUTR, V21, pS22, DOI 10.1097/00005176-199501001-00008; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; Goans RE, 2002, MEDICAL BASIS FOR RADIATION-ACCIDENT PREPAREDNESS, P11; Goans RE, 1997, HEALTH PHYS, V72, P513, DOI 10.1097/00004032-199704000-00001; Goans RE, 2001, HEALTH PHYS, V81, P446, DOI 10.1097/00004032-200110000-00009; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; Grace MB, 2002, INT J RADIAT BIOL, V78, P1011, DOI 10.1080/09553000210158056; Hall E, 2000, RADIOBIOLOGY RADIOLO, P124; Hebert PC, 2003, JAMA-J AM MED ASSOC, V289, P1941, DOI 10.1001/jama.289.15.1941; Hidalgo M, 1997, ANTIMICROB AGENTS CH, V41, P1175, DOI 10.1128/AAC.41.5.1175; Holmes FA, 2002, J CLIN ONCOL, V20, P727, DOI 10.1200/JCO.20.3.727; Hughes WT, 2002, MEDICAL BASIS FOR RADIATION-ACCIDENT PREPAREDNESS, P117; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; *I MED NAT RES COU, 1999, POT RAD EXP MIL OP P; INOUE T, 1995, EXP HEMATOL, V23, P1296; JACKSON DP, 1959, J CLIN INVEST, V38, P1689, DOI 10.1172/JCI103947; JAMMET H, 1959, REV FR ETUD CLIN BIO, V4, P210; Kanda R, 1999, INT J RADIAT BIOL, V75, P441, DOI 10.1080/095530099140366; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KLUMPP TR, 1995, J CLIN ONCOL, V13, P1323, DOI 10.1200/JCO.1995.13.6.1323; Kumar KS, 2002, J RADIAT RES, V43, P361, DOI 10.1269/jrr.43.361; MACVITTIE TJ, 1991, RADIAT RES, V128, pS29, DOI 10.2307/3577998; MacVittie TJ, 1996, BLOOD, V87, P4129, DOI 10.1182/blood.V87.10.4129.bloodjournal87104129; MACVITTIE TJ, 1990, INT J RADIAT BIOL, V57, P723, DOI 10.1080/09553009014550891; MACVITTIE TJ, 1996, P ADV TREATM RAD INJ; Maekawa K, 2002, MEDICAL BASIS FOR RADIATION-ACCIDENT PREPAREDNESS, P313; MALDONADO MD, 1991, BURNS, V17, P188, DOI 10.1016/0305-4179(91)90101-L; MATHE G, 1959, REV FR ETUD CLIN BIO, V4, P226; MAYER P, 1991, J INFECT DIS, V163, P584, DOI 10.1093/infdis/163.3.584; Meineke V, 2003, MIL MED, V168, P219, DOI 10.1093/milmed/168.3.219; Mettler FA, 2002, NEW ENGL J MED, V346, P1554, DOI 10.1056/NEJMra000365; Mettler FA, 1995, MED EFFECTS IONIZING; MISTRY S, 1986, BURNS, V12, P318, DOI 10.1016/0305-4179(86)90101-4; Murphy M, 1997, CLIN INFECT DIS, V25, P346, DOI 10.1086/516925; Narvios AB, 2001, HAEMATOLOGICA, V86, P749; *NCRP, 2001, 138 NCRP, P125; *NCRP, 2001, NCRP PUBL, V138, P54; Neelis KJ, 1997, BLOOD, V90, P2565, DOI 10.1182/blood.V90.7.2565.2565_2565_2573; Neelis KJ, 1997, EXP HEMATOL, V25, P1084; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; PERMAN V, 1962, BLOOD, V19, P724, DOI 10.1182/blood.V19.6.724.724; Peter RU, 2002, MEDICAL BASIS FOR RADIATION-ACCIDENT PREPAREDNESS, P225; PRASANNA PG, 2003, HLTH PHYS SOC MIDY T, P218; Prasanna PGS, 2000, MUTAT RES-GEN TOX EN, V466, P131, DOI 10.1016/S1383-5718(00)00011-5; Preiksaitis JK, 2000, TRANSFUS MED REV, V14, P112, DOI 10.1016/S0887-7963(00)80003-6; Priestman T J, 1993, Clin Oncol (R Coll Radiol), V5, P358, DOI 10.1016/S0936-6555(05)80086-X; PRIESTMAN TJ, 1989, EUR J CANCER CLIN ON, V25, pS29; Pynoos RS, 1998, CHILD ADOL PSYCH CL, V7, P195, DOI 10.1016/S1056-4993(18)30268-2; REDDING S W, 1990, NCI (National Cancer Institute) Monographs, P103; Ricks RC, 2002, MED BASIS RAD ACCIDE; RICKS RC, 1979, MED BASIS RAD ACCIDE; Rotstein C, 1999, CLIN INFECT DIS, V28, P331, DOI 10.1086/515128; SCHAFFNER A, 1995, J INFECT DIS, V172, P1035, DOI 10.1093/infdis/172.4.1035; Schiffer CA, 1996, BLOOD, V88, P3675, DOI 10.1182/blood.V88.10.3675.bloodjournal88103675; Schreyer S, 2002, BR J RADIOL S, V26, P129; SCHUENING FG, 1993, BLOOD, V81, P20; SCHUENING FG, 1989, BLOOD, V74, P1308; Schull W.J, 1996, EFFECTS ATOMIC RAD H; SHIGEMATSU I, 1993, BOMB RAD EFFECTS DIG; Sine R C, 2001, Mil Med, V166, P85; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; SORENSEN DK, 1960, RADIAT RES, V13, P669, DOI 10.2307/3571030; *US DHHS, 2001, GUID POT IOD THYR BL; VANBEKKUM DW, 1991, RADIAT RES, V128, pS4, DOI 10.2307/3577994; Voisin P, 2002, CELL MOL BIOL, V48, P501; Voisin P, 2001, CELL MOL BIOL, V47, P557; Vorobiev AI., 1997, RAD INJURY CHERNOBYL; WALKER RI, 1989, MED CONSEQUECES NUCL; WEISBART RH, 1989, ANN INTERN MED, V110, P297, DOI 10.7326/0003-4819-110-4-297; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; Yehezkelli Y, 2002, ISRAEL MED ASSOC J, V4, P530; ZINNER SH, 1994, JAMA-J AM MED ASSOC, V272, P1183, DOI 10.1001/jama.1994.03520150051036; 2004, HOSPITAL EMERGENCY I; [No title captured]	120	498	541	2	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					1037	1051		10.7326/0003-4819-140-12-200406150-00015	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00015			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197022				2022-12-28	WOS:000222055500008
J	English, M; Esamai, F; Wasunna, A; Were, F; Ogutu, B; Wamae, A; Snow, RW; Peshu, N				English, M; Esamai, F; Wasunna, A; Were, F; Ogutu, B; Wamae, A; Snow, RW; Peshu, N			Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya	LANCET			English	Article							BLOOD-TRANSFUSION; CHILDREN; SURVIVAL	Background The district hospital is considered essential for delivering basic, cost-effective health care to children in resource poor countries. We aimed to investigate the performance of these facilities in Kenya. Methods Government hospitals providing first referral level care were prospectively sampled from 13 Kenyan districts. Workload statistics and data documenting the management and care of admitted children were obtained by specially trained health workers. Findings Data from 14 hospitals were surveyed with routine statistics showing considerable variation in inpatient paediatric mortality (range 4-15%) and specific case fatality rates (eg, anaemia 3-46%). The value of these routine data is seriously undermined by missing data, apparent avoidance of a diagnosis of HIV/AIDS, and absence of standard definitions. Case management practices are often not in line with national or international guidelines. For malaria, signs defining severity such as the level of consciousness and degree of respiratory distress are often not documented (range per hospital 0-100% and 9-77%, respectively), loading doses of quinine are rarely given (3% of cases) and dose errors are not uncommon. Resource constraints such as a lack of nutritional supplements for malnourished children also restrict the provision of basic, effective care. Interpretation Even crude performance measures suggest there is a great need to improve care and data quality, and to identify and tackle key health system constraints at the first referral level in Kenya. Appropriate intervention might. lead to more effective use of health workers' efforts in such hospitals.	KEMRI Ctr Geog Med Res, Kilifi, Kenya; Univ Oxford, Dept Paediat, Oxford, England; John Radcliffe Hosp, Oxford OX3 9DU, England; Moi Univ, Coll Hlth Sci, Dept Paediat & Child Hlth, Eldoret, Kenya; Moi Teaching & Referral Hosp, Eldoret, Kenya; Univ Nairobi, Dept Paediat & Child Hlth, Kenyatta Natl Hosp, Nairobi, Kenya; KEMRI Ctr Clin Res, Kisumu, Kenya; Minist Hlth, Dept Prevent & Promot Hlth Serv, Div Child Hlth, Nairobi, Kenya; Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England; KEMRI Wellcome Trust Collaborat Programme, Nairobi, Kenya	University of Oxford; University of Oxford; Moi University; Kenyatta National Hospital; University of Nairobi; University of Oxford	English, M (corresponding author), KEMRI Wellcome Trust Collaborat Programme, POB 43640,00100 GPO, Nairobi, Kenya.	menglish@wtnairobi.mimcom.net	ESAMAI, FABIAN/AAI-3268-2020; Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; English, Michael/0000-0002-7427-0826				[Anonymous], MILL DEV GOALS; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 2002, COCHRANE LIB; English M, 2003, B WORLD HEALTH ORGAN, V81, P166; English M, 2002, LANCET, V359, P494, DOI 10.1016/S0140-6736(02)07666-3; Fisman DN, 2000, INFECT DIS CLIN N AM, V14, P475, DOI 10.1016/S0891-5520(05)70259-2; Global Forum for Health Research, 1999, 10 90 REP HLTH RES 1; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; Lee JW, 2003, LANCET, V362, P262, DOI 10.1016/S0140-6736(03)14006-8; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; *MIN HLTH NAT AIDS, 2001, AIDS KEN; *MIN HLTH REP KEN, 1994, CLIN GUID; *MIN HLTH REP KEN, 2001, HLTH MAN INF SYST RE; Moore A, 2001, LANCET, V358, P657, DOI 10.1016/S0140-6736(01)05783-X; *NAT MAL CONTR PRO, 1998, NAT GUID DIAGN TREAT; National Center for Health Statistics, 2000, 2000 CDC GROWTH CHAR; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Ross LM, 2000, ARCH DIS CHILD, V83, P492, DOI 10.1136/adc.83.6.492; WHO, 2000, WORLD HLTH REP HLTH; WHO, 1994, MOTH BAB PACK IMPL S; *WHO, 2002, IMPR QUAL PAED CAR A; World Health Organization, 2000, MAN CHILD SER INF SE; World Health Organization, INT MAN CHILDH ILLN; World Health Organization, 1990, AC RESP INF CHILDR C; World Health Organization, 1999, MAN SEV MALN MAN PHY	28	200	204	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1948	1953		10.1016/S0140-6736(04)16408-8	http://dx.doi.org/10.1016/S0140-6736(04)16408-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194254				2022-12-28	WOS:000221962800009
J	Marik, PE; Zaloga, GP				Marik, PE; Zaloga, GP			Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-MALFORMATIONS; CHILDHOOD-CANCER; RECORD-LINKAGE; BIRTH-DEFECTS; RISK; ROUTE; COMPLICATIONS; POPULATION; CHILDREN; INFANTS	Objective To compare the safety and clinical outcomes of enteral and parenteral nutrition in patients with acute pancreatitis. Data sources Medline, Embase, Cochrane controlled trials register, and citation review of relevant primary and review articles. Study selection Randomised controlled studies that compared enteral nutrition with parenteral nutrition in patients with acute pancreatitis. From 117 articles screened, six were identified as randomised controlled trials and were included for data extraction. Data extraction Six studies with 263 participants were analysed. Descriptive and outcome data were extracted. Main outcome measures were infections, complications other than infections, operative interventions, length of hospital stay, and mortality. The meta-analysis was performed with the random effects model. Data synthesis Enteral nutrition was associated with a significantly lower incidence of infections (relative risk 0.45; 95% confidence interval 0.26 to 0.78, P = 0.004), reduced surgical interventions to control pancreatitis (0.48, 0.22 to 1.0, P = 0.05), and a reduced length of hospital stay (mean reduction 2.9 days, 1.6 days to 4.3 days, P < 0.001). There were no significant differences in mortality (relative risk 0.66, 0.32 to 1.37, P = 0.3) or non-infectious complications (0.61, 0.31 to 1.22, P = 0.16) between the two groups of patients. Conclusions Enteral nutrition should be the preferred route of nutritional support in patients with acute pancreatitis.	Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Methodist Res Inst, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Indiana University System	Marik, PE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA.	maripe@ccm.upmc.edu	Marik, Paul E/U-9733-2019					Abou-Assi S, 2002, AM J GASTROENTEROL, V97, P2255, DOI 10.1111/j.1572-0241.2002.05979.x; [Anonymous], 1989, Ann Intern Med, V110, P734; Bistrian BR, 2001, AM J CLIN NUTR, V74, P153; Braga M, 1998, CRIT CARE MED, V26, P24, DOI 10.1097/00003246-199801000-00012; Christensen K, 1999, CLEFT PALATE-CRAN J, V36, P96, DOI 10.1597/1545-1569(1999)036<0096:TCDFCP>2.3.CO;2; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; Christensen K, 2002, CLEFT PALATE-CRAN J, V39, P392, DOI 10.1597/1545-1569(2002)039<0392:FCAPDA>2.0.CO;2; CHRISTENSEN K, 1994, CLIN GENET, V46, P329; Dominguez-Cherit Guillermo, 2002, Curr Opin Crit Care, V8, P285; Fogh-Andersen, 1942, INHERITANCE HARELIP; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; GOODGAME JT, 1977, ANN SURG, V186, P651, DOI 10.1097/00000658-197711000-00018; GRANT JP, 1984, ANN SURG, V200, P627, DOI 10.1097/00000658-198411000-00012; Gupta R, 2003, PANCREATOLOGY, V3, P406, DOI 10.1159/000073657; HUJOEL PP, 1992, CLEFT PALATE-CRAN J, V29, P451, DOI 10.1597/1545-1569(1992)029<0451:FYMAIW>2.3.CO;2; Hunt GM, 2003, BRIT MED J, V326, P1365, DOI 10.1136/bmj.326.7403.1365; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jeejeebhoy KN, 2001, AM J CLIN NUTR, V74, P160; Juel K, 1999, DAN MED BULL, V46, P354; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; KALFARENTZOS FE, 1991, J AM COLL NUTR, V10, P156; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Lin MT, 1996, ANN SURG, V223, P84, DOI 10.1097/00000658-199601000-00012; Lipman TO, 1998, JPEN-PARENTER ENTER, V22, P167, DOI 10.1177/0148607198022003167; Mackeprang M, 1972, Cleft Palate J, V9, P51; Marik PE, 2003, INTENS CARE MED, V29, P867, DOI 10.1007/s00134-003-1744-9; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; MILI F, 1993, AM J EPIDEMIOL, V137, P629, DOI 10.1093/oxfordjournals.aje.a116720; MILI F, 1993, AM J EPIDEMIOL, V137, P639, DOI 10.1093/oxfordjournals.aje.a116721; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; Nopoulos P, 2002, GENET MED, V4, P1, DOI 10.1097/00125817-200201000-00001; Olah A, 2002, NUTRITION, V18, P259, DOI 10.1016/S0899-9007(01)00755-9; Ramstad T, 1995, SCAND J PLAST RECONS, V29, P329, DOI 10.3109/02844319509008968; STRINGER MD, 1998, PEDIAT SURG UROLOGY; Varga P, 2003, INTENS CARE MED, V29, P1861, DOI 10.1007/s00134-003-2006-6; Vu MK, 1999, EUR J CLIN INVEST, V29, P1053; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WINDHAM GC, 1985, AM J EPIDEMIOL, V121, P49, DOI 10.1093/oxfordjournals.aje.a113982; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431; YEO CJ, 1997, TXB SURG BIOL BASIS, P1151; ZACK M, 1991, CANCER RES, V51, P3696; Zhu JL, 2002, BRIT J CANCER, V87, P524, DOI 10.1038/sj.bjc.6600488	42	285	319	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1407	1410		10.1136/bmj.38118.593900.55	http://dx.doi.org/10.1136/bmj.38118.593900.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15175229	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222114400017
J	Laland, KN; Odling-Smee, J; Feldman, MW				Laland, KN; Odling-Smee, J; Feldman, MW			Causing a commotion	NATURE			English	Editorial Material									Univ St Andrews, Sch Biol, St Andrews KY16 9AJ, Fife, Scotland; Univ Oxford, Inst Biol Anthropol, Oxford OX1 2JD, England; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of St Andrews; University of Oxford; Stanford University	Laland, KN (corresponding author), Univ St Andrews, Sch Biol, St Andrews KY16 9AJ, Fife, Scotland.		Laland, Kevin N/C-9482-2011					Feldman M. W., 2003, MONOGRAPHS POPULATIO, V37; Jones CG, 1997, ECOLOGY, V78, P1946, DOI 10.1890/0012-9658(1997)078[1946:PANEOO]2.0.CO;2; Keller L, 2003, NATURE, V425, P769, DOI 10.1038/425769a; Laland KN, 1999, P NATL ACAD SCI USA, V96, P10242, DOI 10.1073/pnas.96.18.10242; Vandermeer J, 2004, SCIENCE, V303, P472, DOI 10.1126/science.1091922	5	31	33	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					609	609		10.1038/429609a	http://dx.doi.org/10.1038/429609a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190333	Bronze			2022-12-28	WOS:000221912600021
J	Murthy, VH; Krumholz, HM; Gross, CP				Murthy, VH; Krumholz, HM; Gross, CP			Participation in cancer clinical trials - Race-, sex-, and age-based disparities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICANS; OLDER; WOMEN; RECRUITMENT; PREVENTION; ATTITUDES; PROSTATE; REPRESENTATION; ENROLLMENT; INSTITUTE	Context Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. Objective To characterize the representation of racial and ethnic minorities, the elderly, and women in cancer trials sponsored by the National Cancer Institute. Design, Setting, and Patients Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. In a separate analysis, the ethnic distribution of patients enrolled in 2000 through 2002 was compared with those enrolled in 1 996 through 1998, using logistic regression models to estimate the relative risk ratio of enrollment for racial and ethnic minorities to that of white patients during these time periods. Main Outcome Measure Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup. Results Cancer research participation varied significantly across racial/ethnic and age groups. Compared with a 1.8% enrollment fraction among white patients, lower enrollment fractions were noted in Hispanic (1.3 %; odds ratio [OR] vs whites, 0.72; 95% confidence interval [CI], 0.68-0.77; P<.001) and black (1.3%; OR, 0.71; 95% Cl, 0.68-0.74; P<001) patients. There was a strong relationship between age and enrollment fraction, with trial participants 30 to 64 years of age representing 3.0% of incident cancer patients in that age group, in comparison to 1.3% of 65- to 74-year-old patients and 0.5% of patients 75 years of age and older. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups. Although the total number of trial participants increased during our study period, the representation of racial and ethnic minorities decreased. in comparison to whites, after adjusting for age, cancer type, and sex, patients enrolled in 2000 through 2002 were 24% less likely to be black (adjusted relative risk ratio, 0.76; 95% Cl, 0.65-0.89; P<.001). Men were more likely than women to enroll in colorectal cancer trials (enrollment fractions: 2.1 % vs 1.6%, respectively; OR, 1.30; 95% Cl, 1.24-1,35; P<.001) and lung cancer trials (enrollment fractions: 0.9% vs 0.7%, respectively; OR, 1.23; 95% Cl, 1.16-1.31; P<001). Conclusions Enrollment in cancer trials is low for all patient groups. Racial and ethnic minorities, women, and the elderly were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively. The proportion of trial participants who are black has declined in recent years.	Yale Univ, Sch Med, Primary Care Ctr, Gen Internal Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale New Haven Hosp, Ctr Outcomes Res & Evaluat,Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Sect Hlth Policy & Adm, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, Gen Internal Med Sect, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	cary.gross@yale.edu	, Harlan/AAI-2875-2020		NCI NIH HHS [1K07CA-90402] Funding Source: Medline; NIA NIH HHS [P30AG21342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA090402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021342] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Cancer Society, 1999, CANC FACTS FIG 1999; Bach PB, 2002, MED CARE, V40, P19; Brown DR, 2000, ANN EPIDEMIOL, V10, pS13, DOI 10.1016/S1047-2797(00)00197-6; Chang SM, 2002, CANCER-AM CANCER SOC, V94, P2681, DOI 10.1002/cncr.10536; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; CRIVELLARI D, ADJUVANT TREATMENT E; Dignam JJ, 2003, J CLIN ONCOL, V21, P413, DOI 10.1200/JCO.2003.02.004; Farkas Andrew, 2000, Ethnicity and Disease, V10, P69; Ford ME, 2003, GERONTOLOGIST, V43, P27, DOI 10.1093/geront/43.1.27; Fowler JE, 1999, CANCER, V86, P836, DOI 10.1002/(SICI)1097-0142(19990901)86:5<836::AID-CNCR20>3.3.CO;2-G; FRELICK RW, 1994, J CLIN ONCOL, V12, P1718, DOI 10.1200/JCO.1994.12.8.1718; Gross CP, 2000, JAMA-J AM MED ASSOC, V284, P2886, DOI 10.1001/jama.284.22.2886; Harris DJ, 2000, NEW ENGL J MED, V343, P475, DOI 10.1056/NEJM200008173430706; Harris Y, 1996, J NATL MED ASSOC, V88, P630; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; INGRAM D, 2003, US CENSUS 2000 POP 2; Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010; Lyman GH, 1997, ANN SURG ONCOL, V4, P80, DOI 10.1007/BF02316814; Meinert CL, 2000, NEW ENGL J MED, V343, P1972; Mouton CP, 1997, J NATL MED ASSOC, V89, P721; *NAT CANC I, AR HLTH REL EXCL KEE; *NAT I AG NAT CANC, 2001, EXPL ROL CANC CTR IN; Paskett ED, 1996, PREV MED, V25, P547, DOI 10.1006/pmed.1996.0088; Ramasubbu K, 2001, J WOMEN HEALTH GEN-B, V10, P757, DOI 10.1089/15246090152636514; Rathore SS, 2003, BRIT MED J, V327, P763, DOI 10.1136/bmj.327.7418.763; Robinson SB, 1996, J COMMUN HEALTH, V21, P77, DOI 10.1007/BF01682300; Sateren WB, 2002, J CLIN ONCOL, V20, P2109, DOI 10.1200/JCO.2002.08.056; Shavers VL, 2002, ANN EPIDEMIOL, V12, P248, DOI 10.1016/S1047-2797(01)00265-4; Shavers-Hornaday V L, 1997, Ethn Health, V2, P31; SHIAO YH, 1995, CANCER RES, V55, P1485; Stallings FL, 2000, CONTROL CLIN TRIALS, V21, p379S, DOI 10.1016/S0197-2456(00)00093-3; *STATACORP, 2004, STAT REF MAN REL 8, V4; Surveillance Epidemiology and End Results (SEER) Program, SEER STAT DAT INC SE; SWANSON GM, 1995, J NATL CANCER I, V87, P1747, DOI 10.1093/jnci/87.23.1747; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; Unson CG, 2001, J NATL MED ASSOC, V93, P392; *US GEN ACC OFF, 1999, NIH CLIN TRIALS VAR; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Zhu KM, 2000, J NATL MED ASSOC, V92, P169; 1997, FED REG         1030	41	1420	1427	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2720	2726		10.1001/jama.291.22.2720	http://dx.doi.org/10.1001/jama.291.22.2720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826XH	15187053				2022-12-28	WOS:000221862300026
J	Roy, D; Liston, DR; Idone, VJ; Di, A; Nelson, DJ; Pujol, C; Bliska, JB; Chakrabarti, S; Andrews, NW				Roy, D; Liston, DR; Idone, VJ; Di, A; Nelson, DJ; Pujol, C; Bliska, JB; Chakrabarti, S; Andrews, NW			A process for controlling intracellular bacterial infections induced by membrane injury	SCIENCE			English	Article							PHAGOSOME-LYSOSOME FUSION; PORE FORMATION; SALMONELLA-TYPHIMURIUM; EPITHELIAL-CELLS; SYNAPTOTAGMIN; PHAGOCYTOSIS; MACROPHAGES; INHIBITION; EXOCYTOSIS	Strategies for inhibiting phagolysosome fusion are essential for the intracellular survival and replication of many pathogens. We found that the lysosomal synaptotagmin Syt VII is required for a mechanism that promotes phagolysosomal fusion and limits the intracellular growth of pathogenic bacteria. Syt VII was required for a form of Ca2+-dependent phagolysosome fusion that is analogous to Ca2+-regulated exocytosis of lysosomes, which can be triggered by membrane injury. Bacterial type III secretion systems, which permeabilize membranes and cause Ca2+ influx in mammalian cells, promote lysosomal exocytosis and inhibit intracellular survival in Syt VII +/+ but not -/- cells. Thus, the lysosomal repair response can also protect cells against pathogens that trigger membrane permeabilization.	Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Univ Chicago, Dept Physiol & Pharmacol, Chicago, IL 60637 USA; SUNY Stony Brook, Sch Med, Ctr Infect Dis, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Yale University; Yale University; University of Chicago; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Andrews, NW (corresponding author), Yale Univ, Sch Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06510 USA.			Idone, Vincent/0000-0002-5622-2011; Andrews, Norma/0000-0002-0611-2412	NIAID NIH HHS [AI43389, AI34867, AI48507] Funding Source: Medline; NIGMS NIH HHS [GM64625, R01 GM064625] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034867, R01AI048507, R56AI043389, R37AI034867, R01AI043389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064625] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beauregard KE, 1997, J EXP MED, V186, P1159, DOI 10.1084/jem.186.7.1159; BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232, DOI 10.1128/IAI.59.7.2232-2238.1991; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Holden DW, 2002, TRAFFIC, V3, P161, DOI 10.1034/j.1600-0854.2002.030301.x; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; Kubori T, 2003, CELL, V115, P333, DOI 10.1016/S0092-8674(03)00849-3; Malik ZA, 2000, J EXP MED, V191, P287, DOI 10.1084/jem.191.2.287; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Oh YK, 1996, INFECT IMMUN, V64, P3877, DOI 10.1128/IAI.64.9.3877-3883.1996; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Pujol C, 2003, INFECT IMMUN, V71, P5892, DOI 10.1128/IAI.71.10.5892-5899.2003; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Schoehn G, 2003, EMBO J, V22, P4957, DOI 10.1093/emboj/cdg499; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; Viboud GI, 2002, METHOD ENZYMOL, V358, P345; Viboud GI, 2001, EMBO J, V20, P5373, DOI 10.1093/emboj/20.19.5373; Waterman SR, 2003, CELL MICROBIOL, V5, P501, DOI 10.1046/j.1462-5822.2003.00294.x	22	122	125	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1515	1518		10.1126/science.1098371	http://dx.doi.org/10.1126/science.1098371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178804				2022-12-28	WOS:000221795800049
J	Weinstein, RA				Weinstein, RA			Planning for epidemics - The lessons of SARS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Rush Med Coll, John H Stroger Jr Cool Cty Hosp, Div Infect Dis, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; Rush University	Weinstein, RA (corresponding author), Rush Med Coll, John H Stroger Jr Cool Cty Hosp, Div Infect Dis, Chicago, IL 60612 USA.							*CDCP, 2003, RESP HYG COUGH ET HE	1	51	52	1	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2332	2334		10.1056/NEJMp048082	http://dx.doi.org/10.1056/NEJMp048082			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175434				2022-12-28	WOS:000221754200003
J	Collin, J; Lee, K; Gilmore, AB				Collin, J; Lee, K; Gilmore, AB			Unlocking the corporate documents of British American Tobacco: an invaluable global resource needs radically improved access	LANCET			English	Editorial Material							INDUSTRY		London Sch Hyg & Trop Med, Ctr Global Change & Hlth, London WC1, England; London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Collin, J (corresponding author), London Sch Hyg & Trop Med, Ctr Global Change & Hlth, London WC1, England.	jeff.collin@lshtm.ac.uk	gilmore, anna B/I-7130-2012	gilmore, anna B/0000-0003-0281-1248	NATIONAL CANCER INSTITUTE [R01CA091021] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bero L, 2003, ANNU REV PUBL HEALTH, V24, P267, DOI 10.1146/annurev.publhealth.24.100901.140813; Glantz S.A., 1996, CIGARETTE PAPERS; LOVELLS DD, 2000, 250 BRIT AM TOB; MOODY L, 1992, PGL POSITIONING STAT; Muggli ME, 2002, TOB CONTROL, V11, P201, DOI 10.1136/tc.11.3.201; Neuman M, 2002, LANCET, V359, P1323, DOI 10.1016/S0140-6736(02)08275-2; Pollay R., 2001, SMOKING TOBACCO CONT, P199; *SEL COMM HLTH, 2000, TOB IND HLTH RISKS S; *WHO COMM EXP, 2000, TOB CO STRAT UND TOB	9	33	33	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1746	1747		10.1016/S0140-6736(04)16334-4	http://dx.doi.org/10.1016/S0140-6736(04)16334-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824SD	15172767				2022-12-28	WOS:000221705800002
J	Guo, G; Wang, W; Bradley, A				Guo, G; Wang, W; Bradley, A			Mismatch repair genes identified using genetic screens in Blm-deficient embryonic stem cells	NATURE			English	Article							MUTATIONS; RECOMBINATION; DISRUPTION; EXPRESSION; BINDING; TUMORS; LEADS; GTBP; MSH2	Phenotype-driven recessive genetic screens in diploid organisms require a strategy to render the mutation homozygous. Although homozygous mutant mice can be generated by breeding, a reliable method to make homozygous mutations in cultured cells has not been available, limiting recessive screens in culture. Cultured embryonic stem (ES) cells(1) provide access to all of the genes required to elaborate the fundamental components and physiological systems of a mammalian cell. Here we have exploited the high rate of mitotic recombination in Bloom's syndrome protein (Blm)-deficient ES2 cells to generate a genome-wide library of homozygous mutant cells from heterozygous mutations induced with a revertible gene trap(3) retrovirus. We have screened this library for cells with defects in DNA mismatch repair (MMR), a system that detects and repairs base-base mismatches(4). We demonstrate the recovery of cells with homozygous mutations in known and novel MMR genes. We identified Dnmt1(ref. 5) as a novel MMR gene and confirmed that Dnmt1-deficient ES cells exhibit micro-satellite instability(6), providing a mechanistic explanation for the role of Dnmt1 in cancer. The combination of insertional mutagenesis in Blm-deficient ES cells establishes a new approach for phenotype-based recessive genetic screens in ES cells.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Bradley, A (corresponding author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.	abradley@sanger.ac.uk		Bradley, Allan/0000-0002-2349-8839				Abuin A, 2000, MOL CELL BIOL, V20, P149, DOI 10.1128/MCB.20.1.149-157.2000; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GRODEN J, 1990, P NATL ACAD SCI USA, V87, P4315, DOI 10.1073/pnas.87.11.4315; HOOPER ML, 1977, DEV BIOL, V55, P271, DOI 10.1016/0012-1606(77)90172-5; Ishida Y, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e35; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luria SE, 1943, GENETICS, V28, P491; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; STRAND M, 1994, NATURE, V368, P569, DOI 10.1038/368569a0; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	29	119	128	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					891	895		10.1038/nature02653	http://dx.doi.org/10.1038/nature02653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215866				2022-12-28	WOS:000222213000045
J	Kaneda, M; Okano, M; Hata, K; Sado, T; Tsujimoto, N; Li, E; Sasaki, H				Kaneda, M; Okano, M; Hata, K; Sado, T; Tsujimoto, N; Li, E; Sasaki, H			Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting	NATURE			English	Article							COMPLETE HYDATIDIFORM MOLES; OOCYTE GROWTH; METHYLATION; GENE; MOUSE; ESTABLISHMENT; LOCUS; MICE	Imprinted genes are epigenetically marked during gametogenesis so that they are exclusively expressed from either the paternal or the maternal allele in offspring(1). Imprinting prevents parthenogenesis in mammals and is often disrupted in congenital malformation syndromes, tumours and cloned animals(1). Although de novo DNA methyltransferases of the Dnmt3 family are implicated in maternal imprinting(2), the lethality of Dnmt3a and Dnmt3b knockout mice(3) has precluded further studies. We here report the disruption of Dnmt3a and Dnmt3b in germ cells, with their preservation in somatic cells, by conditional knockout technology(4). Offspring from Dnmt3a conditional mutant females die in utero and lack methylation and allele-specific expression at all maternally imprinted loci examined. Dnmt3a conditional mutant males show impaired spermatogenesis and lack methylation at two of three paternally imprinted loci examined in spermatogonia. By contrast, Dnmt3b conditional mutants and their offspring show no apparent phenotype. The phenotype of Dnmt3a conditional mutants is indistinguishable from that of Dnmt3L knockout mice2,5, except for the discrepancy in methylation at one locus. These results indicate that both Dnmt3a and Dnmt3L are required for methylation of most imprinted loci in germ cells, but also suggest the involvement of other factors.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Grad Univ Adv Studies Sokendai, Sch Adv Sci, Dept Biosyst Sci, Hayama 2400193, Japan; JST, PRESTO, Kawaguchi 3320012, Japan; Natl Inst Genet, Res Org Informat & Syst, Dept Integrat Genet, Div Human Genet, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies Sokendai, Sch Life Sci, Dept Genet, Mishima, Shizuoka 4118540, Japan; RIKEN, Ctr Dev Biol, Lab Mammalian Epigenet Studies, Kobe, Hyogo 6500047, Japan	Harvard University; Massachusetts General Hospital; Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; RIKEN	Sasaki, H (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	hisasaki@lab.nig.ac.jp	Kaneda, Masahiro/E-3117-2010; Sado, Takashi/AAI-1689-2019	Kaneda, Masahiro/0000-0003-0660-7156; Sado, Takashi/0000-0002-1232-0250				Bao SQ, 2000, BIOL REPROD, V62, P616, DOI 10.1095/biolreprod62.3.616; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Cerrato F, 2003, HUM MOL GENET, V12, P3123, DOI 10.1093/hmg/ddg338; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DAVID B V, 1985, Pesticides (Bombay), V19, P9; El-Maarri O, 2003, HUM MOL GENET, V12, P1405, DOI 10.1093/hmg/ddg152; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fisher RA, 2002, HUM MOL GENET, V11, P3267, DOI 10.1093/hmg/11.26.3267; HASHIMOTO N, 1990, J EXP ZOOL, V253, P61, DOI 10.1002/jez.1402530109; Hata K, 2002, DEVELOPMENT, V129, P1983; Hayward BE, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-2; Judson H, 2002, NATURE, V416, P539, DOI 10.1038/416539a; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Lucifero D, 2004, HUM MOL GENET, V13, P839, DOI 10.1093/hmg/ddh104; Obata Y, 2002, J BIOL CHEM, V277, P5285, DOI 10.1074/jbc.M108586200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Sado T, 2004, DEVELOPMENT, V131, P975, DOI 10.1242/dev.00995; Torres RM, 1997, LAB PROTOCOLS CONDIT; Ueda T, 2000, GENES CELLS, V5, P649, DOI 10.1046/j.1365-2443.2000.00351.x; Xu XL, 2001, GENESIS, V30, P1, DOI 10.1002/gene.1025	24	968	1012	2	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					900	903		10.1038/nature02633	http://dx.doi.org/10.1038/nature02633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215868				2022-12-28	WOS:000222213000047
J	Mohammed, MA; Rathbone, A; Myers, P; Patel, D; Onions, H; Stevens, A				Mohammed, MA; Rathbone, A; Myers, P; Patel, D; Onions, H; Stevens, A			An investigation into general practitioners associated with high patient mortality flagged up through the Shipman inquiry: retrospective analysis of routine data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRISTOL; RATES	Objective To identify a credible explanation for the excessively high mortality associated with general practitioners who were flagged up by the Shipman inquiry. Design Retrospective analysis of routine data. Setting Primary care. Participants Two general practitioners in the West Midlands who were associated with an unacceptably high mortality of patients during 1993-2000. Main outcome measures Observed and expected number of deaths and deaths in nursing homes. Results Preliminary discussions with the general practitioners highlighted deaths in nursing homes as a possible explanatory factor. No relation was found between the expected number of deaths and deaths in nursing homes in each year during 1993-2000 for either general practitioner. In contrast, the magnitude and shape of the curves of a cumulative sum plot for excess number of deaths (observed minus expected) in each year were closely mirrored by the magnitude and shape of the curves of the number of patients dying in nursing homes; and this was reflected in die high correlations (R-2 = 0.87 and 0.89) between excess mortality and the number of deaths in nursing homes in each year for the general practitioners. These findings were supported by administrative data. Conclusions The excessively high mortality associated with two general practitioners was credibly explained by a nursing home effect. General practitioners associated with high patient mortality, albeit after sophisticated statistical analysis, should not be labelled as having poor performance but instead should be considered as a signal meriting scientific investigation.	Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England; Telford & Wrekin Primary Care Trust, Telford TF1 5RY, England; Shopshire & Staffordshire Stateg Hlth Author, Stafford ST16 3SR, England; Shropshire Cty Primary Care Trust, Shrewsbury SY3 8XL, Salop, England	University of Birmingham	Mohammed, MA (corresponding author), Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England.	m.a.mohammed@bham.ac.uk		Stevens, Andrew/0000-0003-2079-3397				Aylin P, 2003, LANCET, V362, P485, DOI 10.1016/S0140-6736(03)14077-9; AYLIN P, 2003, ONITORING MORTALITY; Baker R, 2003, BRIT MED J, V326, P274, DOI 10.1136/bmj.326.7383.274; BAKER R, 2001, H SHIPMANS CLIN PRAC; BEBBINGTON A, LONGITUDINAL STUDY E; BILLETT J, 2003, PRIVATE CONFIDENTIAL; CONGDON P, 141 PUBL HLTH DIR BA; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; Lilford RJ, 2003, QUAL SAF HLTH CAR S2, V12, P118, DOI DOI 10.1136/QHC.12.SUPPL_2.II8; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; SHIPMAN INQUIRY INDE	12	42	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1474	1477		10.1136/bmj.328.7454.1474	http://dx.doi.org/10.1136/bmj.328.7454.1474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205291	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222244600017
J	Daw, ND; Dayan, P				Daw, ND; Dayan, P			Matchmaking	SCIENCE			English	Editorial Material							PARIETAL CORTEX; REWARD		UCL, Gatsby Computat Neurosci Unit, London WC1N 3AR, England	University of London; University College London	Daw, ND (corresponding author), UCL, Gatsby Computat Neurosci Unit, London WC1N 3AR, England.	dayan@gatsby.ucl.ac.uk		Dayan, Peter/0000-0003-3476-1839				DORRIS MC, 2003, SOC NEUR ABSTR, P767; HERRNSTEIN RJ, 1961, J EXP ANAL BEHAV, V4, P267, DOI 10.1901/jeab.1961.4-267; LAU B, 2003, SOC NEUR ABSTR; LAU B, COMMUNICATION; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Roitman JD, 2002, J NEUROSCI, V22, P9475; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765	10	6	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1753	1754		10.1126/science.1099898	http://dx.doi.org/10.1126/science.1099898			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205519				2022-12-28	WOS:000222089500030
J	Weaver, HA				Weaver, HA			Not a rubble pile?	SCIENCE			English	Editorial Material							CAMERA		Johns Hopkins Univ, Appl Phys Lab, Dept Space, Laurel, MD 20723 USA	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Weaver, HA (corresponding author), Johns Hopkins Univ, Appl Phys Lab, Dept Space, Johns Hopkins Rd, Laurel, MD 20723 USA.	hal.weaver@jhuapl.edu	Weaver, Harold A/D-9188-2016	Weaver, Harold A/0000-0003-0951-7762				Britt D. T., 2002, ASTEROIDS 3, VIII, P485; Brownlee DE, 2004, SCIENCE, V304, P1764, DOI 10.1126/science.1097899; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; Kissel J, 2004, SCIENCE, V304, P1774, DOI 10.1126/science.1098836; Levasseur-Regourd AC, 2004, SCIENCE, V304, P1762, DOI 10.1126/science.1100601; Newburn RL, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002081; RICHARDSON DC, 2002, ASTEROIDS, V3, P501; Sekanina Z, 2004, SCIENCE, V304, P1769, DOI 10.1126/science.1098388; Soderblom LA, 2002, SCIENCE, V296, P1087, DOI 10.1126/science.1069527; Tuzzolino AJ, 2004, SCIENCE, V304, P1776, DOI 10.1126/science.1098759; WEISSMAN PR, IN PRESS COMETS, V2; Yelle RV, 2004, ICARUS, V167, P30, DOI 10.1016/j.icarus.2003.08.020	12	18	18	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1760	1762						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205522				2022-12-28	WOS:000222089500033
J	Swaroop, VS; Chari, ST; Clain, JE				Swaroop, VS; Chari, ST; Clain, JE			Severe acute pancreatitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PARENTERAL-NUTRITION; NECROTIZING PANCREATITIS; APACHE-II; MANAGEMENT; CT; NECROSECTOMY		Mayo Clin & Mayo Fdn, Div Gen Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Gastroenterol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Swaroop, VS (corresponding author), Mayo Clin & Mayo Fdn, Div Gen Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	vege.santhi@mayo.edu	Chari, Suresh/K-9297-2015	Chari, Suresh/0000-0002-3924-0971				BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; Balthazar EJ, 2002, RADIOLOGY, V223, P603, DOI 10.1148/radiol.2233010680; Baron TH, 1996, GASTROENTEROLOGY, V111, P755, DOI 10.1053/gast.1996.v111.pm8780582; BLAMEY SL, 1984, GUT, V25, P1340, DOI 10.1136/gut.25.12.1340; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; Carter CR, 2000, ANN SURG, V232, P175, DOI 10.1097/00000658-200008000-00004; Dejong C H, 2001, Curr Opin Crit Care, V7, P251, DOI 10.1097/00075198-200108000-00007; Dervenis C, 1999, INT J PANCREATOL, V25, P195; Folsch UR, 1997, NEW ENGL J MED, V336, P237, DOI 10.1056/NEJM199701233360401; Glazer G, 1998, GUT, V42, pS1; Golub R, 1998, J Gastrointest Surg, V2, P496, DOI 10.1016/S1091-255X(98)80048-6; Isenmann R, 2004, GASTROENTEROLOGY, V126, P997, DOI 10.1053/j.gastro.2003.12.050; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lankisch PG, 2002, PANCREAS, V24, P217, DOI 10.1097/00006676-200204000-00002; Lankisch PG, 2001, AM J GASTROENTEROL, V96, P2081, DOI 10.1016/S0002-9270(01)02529-1; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; Mier J, 1997, AM J SURG, V173, P71, DOI 10.1016/S0002-9610(96)00425-4; Morgan DE, 1997, RADIOLOGY, V203, P773, DOI 10.1148/radiology.203.3.9169703; Mutinga M, 2000, INT J PANCREATOL, V28, P91, DOI 10.1385/IJGC:28:2:091; RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69; Russo MW, 2004, GASTROENTEROLOGY, V126, P1448, DOI 10.1053/j.gastro.2004.01.025; Sabater L, 2004, PANCREAS, V28, P65, DOI 10.1097/00006676-200401000-00010; Sharma VK, 1999, AM J GASTROENTEROL, V94, P3211, DOI 10.1111/j.1572-0241.1999.01520.x; TENNER S, 1994, AM J GASTROENTEROL, V89, P1863; Toouli J, 2002, J GASTROEN HEPATOL, V17, pS15, DOI 10.1046/j.1440-1746.17.s1.2.x; Uhl W, 2003, PANCREATOLOGY, V3, DOI 10.1159/000067684; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431; Yousaf M, 2003, BRIT J SURG, V90, P407, DOI 10.1002/bjs.4179	29	194	215	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2865	2868		10.1001/jama.291.23.2865	http://dx.doi.org/10.1001/jama.291.23.2865			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199038				2022-12-28	WOS:000221962500033
J	Verghese, A				Verghese, A			Resident redux	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Texas, Ctr Hlth Sci, Ctr Med Humanities & Eth, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio	Verghese, A (corresponding author), Univ Texas, Ctr Hlth Sci, Ctr Med Humanities & Eth, 7703 Floyd Curl Dr,Mail Code 7730, San Antonio, TX USA.							BERK SL, 1991, JAMA-J AM MED ASSOC, V266, P1760; BLOOM A, 1987, CLOSING AM MIND, P253; Ludmerer KM, 1999, TIME HEAL; Osler, 1932, AEQUANIMITAS OTHER A; Srivastava Ranjana, 2004, Ann Intern Med, V140, P1057	5	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					1034	1036		10.7326/0003-4819-140-12-200406150-00014	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197021				2022-12-28	WOS:000222055500007
J	Xue, LL; Gollapalli, DR; Maiti, P; Jahng, WJ; Rando, RR				Xue, LL; Gollapalli, DR; Maiti, P; Jahng, WJ; Rando, RR			A palmitoylation switch mechanism in the regulation of the visual cycle	CELL			English	Article							LECITHIN RETINOL ACYLTRANSFERASE; PIGMENT-EPITHELIUM; VITAMIN-A; PROTEIN PALMITOYLATION; BINDING-PROTEIN; ENERGY-SOURCE; RPE65; 11-CIS-RETINOL; PURIFICATION; ISOMERIZATION	RPE65 is essential for the biosynthesis of 11-cis-retinal, the chromophore of rhodopsin. Here, we show that the membrane-associated form (mRPE65) is triply palmitoylated and is a chaperone for all-trans-retinyl esters, allowing their entry into the visual cycle for processing into 11-cis-retinal. The soluble form of RPE65 (sRPE65) is not palmitoylated and is a chaperone for vitamin A, rather than all-trans-retinyl esters. Thus, the palmitoylation of RPE65 controls its ligand binding selectivity. The two chaperones are interconverted by lecithin retinol acyl transferase (LRAT) acting as a molecular switch. Here mRPE65 is a palmitoyl donor, revealing a new acyl carrier protein role for palmitoylated proteins. When chromophore synthesis is not required, mRPE65 is converted into sRPE65 by LRAT, and further chromophore synthesis is blocked. The studies reveal new roles for palmitoylated proteins as molecular switches and LRAT as a palmitoyl transferase whose role is to catalyze the mRPE65 to sRPE65 conversion.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Rando, RR (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 45 Shattuck St, Boston, MA 02115 USA.	robert_rando@hms.harvard.edu	Jahng, Wan Jin/C-1236-2018	Jahng, Wan Jin/0000-0001-8241-7739	NEI NIH HHS [EY-04096] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004096, R37EY004096] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Anantharaman V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r11; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bok D, 2003, BIOCHEMISTRY-US, V42, P6090, DOI 10.1021/bi0342416; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Gollapalli DR, 2004, BIOCHEMISTRY-US, V43, P7226, DOI 10.1021/bi040028d; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Hanna-Rose W, 2002, DEV BIOL, V241, P247, DOI 10.1006/dbio.2001.0514; HOUSLAY MD, 1996, CELL SIGNAL, V8, P403; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P12805, DOI 10.1021/bi035370p; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P6159, DOI 10.1021/bi034002i; Kammer B, 2003, MOL CELL NEUROSCI, V23, P333, DOI 10.1016/S1044-7431(03)00064-2; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Patterson SI, 2002, BIOL RES, V35, P139, DOI 10.4067/S0716-97602002000200005; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697; SEGAL I, 1993, ENZYME KINETICS; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P3077, DOI 10.1021/bi00063a019; STACIE RL, 1997, J NEUROCHEM, V69, P1864; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Thompson DA, 2003, DEV OPHTHALMOL, V37, P141; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; WALD G, 1953, ANNU REV BIOCHEM, V22, P497, DOI 10.1146/annurev.bi.22.070153.002433; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d	46	115	116	2	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					761	771		10.1016/j.cell.2004.05.016	http://dx.doi.org/10.1016/j.cell.2004.05.016			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186777	Bronze			2022-12-28	WOS:000222048400009
J	Esteban, A; Frutos-Vivar, F; Ferguson, ND; Arabi, Y; Apezteguia, C; Gonzalez, M; Epstein, SK; Hill, NS; Nava, S; Soares, MA; D'Empaire, G; Alia, I; Anzueto, A				Esteban, A; Frutos-Vivar, F; Ferguson, ND; Arabi, Y; Apezteguia, C; Gonzalez, M; Epstein, SK; Hill, NS; Nava, S; Soares, MA; D'Empaire, G; Alia, I; Anzueto, A			Noninvasive positive-pressure ventilation for respiratory failure after extubation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MECHANICAL VENTILATION; SUPPORT VENTILATION; COPD PATIENTS; CARE-UNIT; DURATION; TRIAL; MASK	BACKGROUND The need for reintubation after extubation and discontinuation of mechanical ventilation is not uncommon and is associated with increased mortality. Noninvasive positive-pressure ventilation has been suggested as a promising therapy for patients with respiratory failure after extubation, but a single-center, randomized trial recently found no benefit. We conducted a multicenter, randomized trial to evaluate the effect of noninvasive positive-pressure ventilation on mortality in this clinical setting. METHODS Patients in 37 centers in eight countries who were electively extubated after at least 48 hours of mechanical ventilation and who had respiratory failure within the subsequent 48 hours were randomly assigned to either noninvasive positive-pressure ventilation by face mask or standard medical therapy. RESULTS A total of 221 patients with similar baseline characteristics had been randomly assigned to either noninvasive ventilation ( 114 patients) or standard medical therapy ( 107 patients) when the trial was stopped early, after an interim analysis. There was no difference between the noninvasive-ventilation group and the standard-therapy group in the need for reintubation ( rate of reintubation, 48 percent in both groups; relative risk in the noninvasive-ventilation group, 0.99; 95 percent confidence interval, 0.76 to 1.30). The rate of death in the intensive care unit was higher in the noninvasive-ventilation group than in the standard-therapy group ( 25 percent vs. 14 percent; relative risk, 1.78; 95 percent confidence interval, 1.03 to 3.20; P= 0.048), and the median time from respiratory failure to reintubation was longer in the noninvasive-ventilation group ( 12 hours vs. 2 hours 30 minutes, P= 0.02). CONCLUSIONS Noninvasive positive-pressure ventilation does not prevent the need for reintubation or reduce mortality in unselected patients who have respiratory failure after extubation.	Hosp Univ Getafe, Unidad Cuidados Intens, Madrid 28905, Spain; Univ Toronto, Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada; Univ Toronto, Univ Hlth Network, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; King Fahad Natl Guard Hosp, Riyadh, Saudi Arabia; Hosp Prof Posadas, Buenos Aires, DF, Argentina; Hosp Gen Medellin, Medellin, Colombia; Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Pulm & Crit Care Div, Boston, MA 02111 USA; Fdn S Maugeri, Ist Sci Pavia, Resp Intens Care Unit, Pavia, Italy; Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil; Hosp Clin, Caracas, Venezuela; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA	Hospital Universitario de Getafe; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Tufts Medical Center; Tufts University; Istituti Clinici Scientifici Maugeri IRCCS; University of Texas System; University of Texas Health San Antonio	Esteban, A (corresponding author), Hosp Univ Getafe, Unidad Cuidados Intens, Carretera Toledo Km 12,500, Madrid 28905, Spain.	aesteban@ucigetafe.com	Ferguson, Niall/D-7619-2019; Arabi, Yaseen/ABF-3316-2020	Ferguson, Niall/0000-0002-6213-5264; Arabi, Yaseen/0000-0001-5735-6241; Frutos-Vivar, Fernando/0000-0002-4648-9636				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; Esteban, 1997, AM J RESP CRIT CARE, V156, P2028; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gil B, 2003, CLIN PULM MED, V10, P226; Girault C, 2002, JAMA-J AM MED ASSOC, V288, P2540, DOI 10.1001/jama.288.20.2540; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; *INT CONS C INT CA, 2001, AM J RESP CRIT CARE, V163, P283; Jiang J S, 1999, Respirology, V4, P161, DOI 10.1046/j.1440-1843.1999.00168.x; Keenan SP, 2002, JAMA-J AM MED ASSOC, V287, P3238, DOI 10.1001/jama.287.24.3238; Kilger E, 1999, INTENS CARE MED, V25, P1374, DOI 10.1007/s001340051084; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Manthous CA, 2002, CHEST, V121, P1738, DOI 10.1378/chest.121.6.1738; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; Munshi IA, 1999, CHEST, V116, P1025, DOI 10.1378/chest.116.4.1025; Peter JV, 2002, CRIT CARE MED, V30, P555, DOI 10.1097/00003246-200203000-00010; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PUTENSEN C, 1993, CRIT CARE MED, V21, P357, DOI 10.1097/00003246-199303000-00011; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	29	529	591	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2452	2460		10.1056/NEJMoa032736	http://dx.doi.org/10.1056/NEJMoa032736			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190137				2022-12-28	WOS:000221887200004
J	Luzuriaga, K; McManus, M; Mofenson, L; Britto, P; Graham, B; Sullivan, JL				Luzuriaga, K; McManus, M; Mofenson, L; Britto, P; Graham, B; Sullivan, JL		PACTG 356 Investigators	A trial of three antiretroviral regimens in HIV-1-infected children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE PROGRESSION; INFECTED CHILDREN; THERAPY; REPLICATION; DYNAMICS; INFANTS	BACKGROUND Depletion of CD4 T-cell counts or progression of human immunodeficiency virus (HIV) disease occurs rapidly in children, but few data address the efficacy of aggressive therapy for HIV-infected children. METHODS We evaluated the safety, tolerability, and activity of three regimens of antiretroviral therapy in a multicenter, open-label, phase 1 - 2 trial. Children infected with HIV type 1 (HIV-1) were stratified at entry according to age - three months or younger ( early therapy) or older than three months ( delayed therapy) - and assigned sequentially to one of three regimens. Children continued to receive treatment for up to 200 weeks if the plasma HIV-1 RNA level was less than 1000 copies per milliliter by 16 weeks. RESULTS Plasma HIV-1 RNA levels fell from a median of 5.3 log copies per milliliter ( range, 3.3 to 6.4 log copies per milliliter) at baseline to less than 1000 copies per milliliter at 16 weeks in 32 of 52 infants ( 62 percent). Plasma HIV-1 RNA levels were below 400 copies per milliliter at 48 weeks in 26 infants ( 50 percent) and at 200 weeks in 23 infants ( 44 percent). An intention-to-treat analysis revealed that significantly more children who received stavudine, lamivudine, nevirapine, and nelfinavir had plasma HIV-1 RNA levels of less than 400 copies per milliliter at 48 weeks ( 83 percent) and 200 weeks ( 72 percent) than children who received reverse-transcriptase inhibitors alone ( P=0.001 and P=0.01, respectively). Fewer infants in the delayed-therapy group than in the early-therapy group ( 30 percent vs. 60 percent) had plasma HIV-1 RNA levels of less than 400 copies per milliliter at 200 weeks ( P=0.03). Treatment-associated adverse effects were infrequent. CONCLUSIONS In this phase 1 - 2 trial involving HIV-1 - infected children, an age of three months or younger at the initiation of therapy and treatment with stavudine, lamivudine, nevirapine, and nelfinavir were associated with improved long-term viral suppression. Larger, randomized trials are required to define the optimal time to initiate therapy and the optimal regimen for these infants.	Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; NICHHD, NIH, Rockville, MD USA; Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA; Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard T.H. Chan School of Public Health; Frontier Science Foundation	Luzuriaga, K (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, 373 Plantat St,Suite 318,Biotech 2, Worcester, MA 01605 USA.	katherine.luzuriaga@umassmed.edu	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808	NIAID NIH HHS [AI32391, AI32907, AI4845] Funding Source: Medline; NICHD NIH HHS [HD01489] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032907, R01AI032391] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrams EJ, 2003, LANCET, V362, P1595, DOI 10.1016/S0140-6736(03)14837-4; Abrams EJ, 2003, AIDS, V17, P867, DOI 10.1097/00002030-200304110-00012; *AIDSINFO, 2003, GUID US ANT AG PED H; *AIDSINFO, 2002, GUID US ANT AG HIV I; Diaz C, 1998, J ACQ IMMUN DEF SYND, V18, P221, DOI 10.1097/00042560-199807010-00004; Dunn DT, 2003, LANCET, V362, P1605, DOI 10.1016/S0140-6736(03)14793-9; Gray L, 2001, PEDIATRICS, V108, P116, DOI 10.1542/peds.108.1.116; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; Hainaut M, 2000, EUR J PEDIATR, V159, P778, DOI 10.1007/PL00008346; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; Luzuriaga K, 1999, J VIROL, V73, P362, DOI 10.1128/JVI.73.1.362-367.1999; Sharland M, 2002, HIV Med, V3, P215, DOI 10.1046/j.1468-1293.2002.00120.x; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56	13	109	111	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2471	2480		10.1056/NEJMoa032706	http://dx.doi.org/10.1056/NEJMoa032706			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190139				2022-12-28	WOS:000221887200006
J	Siemers, BM; Schnitzler, HU				Siemers, BM; Schnitzler, HU			Echolocation signals reflect niche differentiation in five sympatric congeneric bat species	NATURE			English	Article							NOTCH-EARED BAT; FORAGING BEHAVIOR; MYOTIS-EMARGINATUS; FLIGHT PERFORMANCE; RHINOLOPHOID BATS; GENUS MYOTIS; EATING BATS; VESPERTILIONIDAE; PREY; CHIROPTERA	Echolocating bats can be divided into guilds according to their preferred habitat and foraging behaviour(1-4), which coincide with distinct adaptations in wing morphology(5) and structure of echolocation signals(6). Although coarse structuring of niche space between different guilds is generally accepted, it is not clear how niches differ within guilds(7-10), or whether there is fine-grained niche differentiation reflected in echolocation signal structure(11,12). Using a standardized performance test, here we show clutter-dependent differences in prey-capture success for bats from five species of European Myotis. These species are morphologically similar, sympatric(13), and all belong to the guild labelled "edge space aerial/trawling foragers"(4). We further demonstrate a strong correlation between the prey-detection ability of the species and the respective search-call bandwidth. Our findings indicate that differences in echolocation signals contribute to within-guild niche differentiation. This is the first study relating sensory abilities of a set of potentially competing animal species to a direct measure of their respective foraging performance, suggesting an important role of sensory ecology in the structuring of animal communities.	Univ Tubingen, Inst Zool, D-72706 Tubingen, Germany	Eberhard Karls University of Tubingen	Siemers, BM (corresponding author), Univ Tubingen, Inst Zool, Morgenstelle 28, D-72706 Tubingen, Germany.	bjoern.siemers@uni-tuebingen.de						ALDRIDGE HDJN, 1987, J ANIM ECOL, V56, P763, DOI 10.2307/4947; Arlettaz R, 2001, NATURE, V414, P742, DOI 10.1038/414742a; Britton ARC, 1997, J ZOOL, V241, P503, DOI 10.1111/j.1469-7998.1997.tb04842.x; CROME FHJ, 1988, ECOLOGY, V69, P1960, DOI 10.2307/1941173; FENTON MB, 1990, CAN J ZOOL, V68, P411, DOI 10.1139/z90-061; Fenton MB, 2002, CAN J ZOOL, V80, P1004, DOI 10.1139/Z02-083; FINDLEY JS, 1976, AM NAT, V110, P129, DOI 10.1086/283053; HELLER KG, 1989, OECOLOGIA, V80, P178, DOI 10.1007/BF00380148; JONES G, 1988, J ZOOL, V215, P113, DOI 10.1111/j.1469-7998.1988.tb04888.x; Kingston T, 1999, J ZOOL, V249, P359, DOI 10.1017/S0952836999009917; Kingston T, 2000, OECOLOGIA, V124, P332, DOI 10.1007/PL00008866; KRULL D, 1991, BEHAV ECOL SOCIOBIOL, V28, P247; MCKENZIE NL, 1986, J ANIM ECOL, V55, P401, DOI 10.2307/4727; Muller R, 2000, J ACOUST SOC AM, V108, P836, DOI 10.1121/1.429617; NEUWEILER G, 1990, PHYSIOL REV, V70, P615, DOI 10.1152/physrev.1990.70.3.615; NORBERG U M, 1987, Philosophical Transactions of the Royal Society of London B Biological Sciences, V316, P335, DOI 10.1098/rstb.1987.0030; Ruedi M, 2001, MOL PHYLOGENET EVOL, V21, P436, DOI 10.1006/mpev.2001.1017; Schmidt S, 2000, J COMP PHYSIOL A, V186, P975, DOI 10.1007/s003590000151; Schnitzler HU, 2003, TRENDS ECOL EVOL, V18, P386, DOI 10.1016/S0169-5347(03)00185-X; Schnitzler HU, 2001, BIOSCIENCE, V51, P557, DOI 10.1641/0006-3568(2001)051[0557:EBIEB]2.0.CO;2; SCHUMM A, 1991, BEHAV ECOL SOCIOBIOL, V28, P255; Siemers BM, 2001, J EXP BIOL, V204, P3843; Siemers BM, 2000, BEHAV ECOL SOCIOBIOL, V47, P400, DOI 10.1007/s002650050683; SIMMONS JA, 1980, J COMP PHYSIOL, V135, P61, DOI 10.1007/BF00660182; Sleep DJH, 2003, J MAMMAL, V84, P216, DOI 10.1644/1545-1542(2003)084<0216:AETOCT>2.0.CO;2; Swift SM, 2002, BEHAV ECOL SOCIOBIOL, V52, P408, DOI 10.1007/s00265-002-0531-x; von Helversen D, 1999, NATURE, V398, P759, DOI 10.1038/19648; [No title captured]; [No title captured]	29	261	283	0	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					657	661		10.1038/nature02547	http://dx.doi.org/10.1038/nature02547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190352				2022-12-28	WOS:000221912600040
J	Alloueche, A; Bailey, W; Barton, S; Bwika, J; Chimpeni, P; Falade, CO; Fehintola, FA; Horton, J; Jaffar, S; Kanyok, T; Kremsner, PG; Kublin, JG; Lang, T; Missinou, MA; Mkandala, C; Oduola, AMJ; Premji, Z; Robertson, L; Sowunmi, A; Ward, SA; Winstanley, PA				Alloueche, A; Bailey, W; Barton, S; Bwika, J; Chimpeni, P; Falade, CO; Fehintola, FA; Horton, J; Jaffar, S; Kanyok, T; Kremsner, PG; Kublin, JG; Lang, T; Missinou, MA; Mkandala, C; Oduola, AMJ; Premji, Z; Robertson, L; Sowunmi, A; Ward, SA; Winstanley, PA			Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial	LANCET			English	Article							ELIMINATION HALF-LIFE; PLASMODIUM-FALCIPARUM; SELECTIVE PRESSURE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; RESISTANCE; ARTESUNATE; SEQUENCE; COMBINATIONS; CHLOROQUINE; EVOLUTION	Background Increasing resistance to sulfadoxine-pyrimethamine is leading to a decline in its effectiveness. We aimed to assess the safety profile of chlorproguanil-dapsone (CD), and to compare the safety and efficacy of this drug with that of sulfadoxine-pyrimethamine (SP) as treatment for uncomplicated falciparum malaria. Methods We undertook a double-blind, randomised trial in 1850 consecutively recruited children with uncomplicated falciparum malaria, pooling data from five African countries. Analyses were based on all randomised patients with available data. Findings CD was significantly more efficacious than SP (odds ratio 3.1 [95% CI 2.0-4.8]); 1313 patients (96%) given CD and 306 (89%) given SP achieved acceptable clinical and parasitological response by day 14. Adverse events were reported in 46% and 50% of patients randomised to CD and SP, respectively (treatment difference -4.4%, [95% CI -10.1 to 1.3]). Haemoglobin in the CD group was significantly lower than in the SP group at day 7, a difference of -4 g/L (95% CI -6 to -2). Mean day 14 haemoglobin (measured only for the small number of patients whose day 7 data caused concern) was 94 g/L (92-96) and 97 g/L (92-102) after CD and SP, respectively. Glucose-6-phosphate dehydrogenase deficient patients on CD had greater odds than those on SP of having a fall of 20 g/dL or more in haemoglobin when baseline temperature was high. Methaemoglobinaemia was seen in the CD group (n=320, mean 0.4% [95% CI 0.4-0.4]) before treatment, 4.2% (95% CI 3.8-4.6) (n=301) at day 3, and 0.6% (0.6-0.7( (n=300) at day 7). Interpretation CD had greater efficacy than SP in Africa and was well tolerated. Haematological adverse effects were more common with CD than with SP and were reversible. CD is a useful alternative where SP is failing due to resistance.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England; Kenya Govt Med Res Ctr, Ctr Geog Med, Kilifi, Kenya; Malawi Liverpool Wellcome Trust Programme Trop Me, Blantyre, Malawi; Univ Ibadan, Coll Med, Malaria Res Labs, Ibadan, Nigeria; Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon; Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Muhimbili Med Ctr, Dar Es Salaam, Tanzania; Univ Maryland, Sch Med, Ctr Vaccine Dev, Malaria Sect, Baltimore, MD 21201 USA; London Sch Hyg & Trop Med, London WC1, England; WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland; GlaxoSmithKline, Dis Dev World Grp, GSK House, Brentford, Middx, England; Statwood, Hitchin, Herts, England; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	University of Liverpool; Kenya Medical Research Institute; University of Malawi; University of Ibadan; Eberhard Karls University of Tubingen; University System of Maryland; University of Maryland Baltimore; University of London; London School of Hygiene & Tropical Medicine; World Health Organization; GlaxoSmithKline; Wellcome Trust Sanger Institute; Liverpool School of Tropical Medicine; University of Liverpool	Winstanley, PA (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, POB 147, Liverpool L69 3BX, Merseyside, England.	p.a.winstanley@liverpool.ac.uk	Ward, Steve/G-6003-2015	Ward, Steve/0000-0003-2331-3192; Kublin, James/0000-0003-1279-3741; Jaffar, Shabbar/0000-0002-9615-1588; FEHINTOLA, Fatai/0000-0001-9454-0742				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2; Amukoye E, 1997, ANTIMICROB AGENTS CH, V41, P2261, DOI 10.1128/AAC.41.10.2261; Ansah EK, 2001, TROP MED INT HEALTH, V6, P496, DOI 10.1046/j.1365-3156.2001.00740.x; BEUTLER E, 1989, BLOOD, V74, P2550; Bradley D., 1996, OXFORD TXB MED, P835; Carrazza MZN, 2000, REV SAUDE PUBL, V34, P396, DOI 10.1590/S0034-89102000000400013; Curtis J, 2002, J INFECT DIS, V186, P1861, DOI 10.1086/345765; DOLLERY C, 1999, DAPSONE THERAPEUTIC, P13; Hastings IM, 2002, PHILOS T ROY SOC B, V357, P505, DOI 10.1098/rstb.2001.1036; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; Jollow DJ, 2001, ADV EXP MED BIOL, V500, P595; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; LUZATTO L, 1996, OXFORD TXB MED; *MMV, MMV ANN REP 2002, P17; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Ranford-Cartwright LC, 1997, T ROY SOC TROP MED H, V91, P719, DOI 10.1016/S0035-9203(97)90539-3; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Smith R.P., 1996, CASARETT DOULLS TOXI, Vfifth, P335; Snow RW, 2003, TRENDS PARASITOL, V19, P363, DOI 10.1016/S1471-4922(03)00168-5; Sulo J, 2002, LANCET, V360, P1136, DOI 10.1016/S0140-6736(02)11198-6; von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x; VULLIAMY TJ, 1991, P NATL ACAD SCI USA, V88, P8568, DOI 10.1073/pnas.88.19.8568; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; *WHO, 2000, WHOCDSRBM200133; *WHO, 2002, WHOCDSCSREPH200217MA; WHO, 1996, WHOMAL961077; Winstanley P, 1997, T ROY SOC TROP MED H, V91, P322, DOI 10.1016/S0035-9203(97)90093-6	30	86	86	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1843	1848		10.1016/S0140-6736(04)16350-2	http://dx.doi.org/10.1016/S0140-6736(04)16350-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183620				2022-12-28	WOS:000221822300006
J	Busza, A; Emery-Le, M; Rosbash, M; Emery, P				Busza, A; Emery-Le, M; Rosbash, M; Emery, P			Roles of the two Drosophila CRYPTOCHROME structural domains in circadian photoreception	SCIENCE			English	Article							LIGHT RESPONSE; S-PHASE; CLOCK; TIMELESS; ENTRAINMENT; PROTEIN; CRY; MECHANISM; SUGGESTS	CRYPTOCHROME ( CRY) is the primary circadian photoreceptor in Drosophila. We show that CRY binding to TIMELESS ( TIM) is light-dependent in flies and irreversibly commits TIM to proteasomal degradation. In contrast, CRY degradation is dependent on continuous light exposure, indicating that the CRY-TIM interaction is transient. A novel cry mutation (cry(m)) reveals that CRY's photolyase homology domain is sufficient for light detection and phototransduction, whereas the carboxyl-terminal domain regulates CRY stability, CRY-TIM interaction, and circadian photosensitivity. This contrasts with the function of Arabidopsis CRY domains and demonstrates that insect and plant cryptochromes use different mechanisms.	Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	University of Massachusetts System; University of Massachusetts Worcester; Brandeis University; Howard Hughes Medical Institute	Emery, P (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, 364 Plantat St, Worcester, MA 01605 USA.	patrick.emery@umassmed.edu		Busza, Ania/0000-0002-1761-088X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM033205, R01GM066777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044232, T32NS007366] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM33205, GM66777-01] Funding Source: Medline; NINDS NIH HHS [5 T32 NS07366-08, P01 NS44232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akten B, 2003, NAT NEUROSCI, V6, P251, DOI 10.1038/nn1007; Cashmore AR, 2003, CELL, V114, P537, DOI 10.1016/j.cell.2003.08.004; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Chan RC, 2003, NATURE, V423, P1002, DOI 10.1038/nature01697; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Foss EJ, 2001, GENETICS, V157, P567; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ivanchenko M, 2001, J BIOL RHYTHM, V16, P205, DOI 10.1177/074873001129001917; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; Krishnan B, 2001, NATURE, V411, P313, DOI 10.1038/35077094; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stanewsky R, 2002, CELL TISSUE RES, V309, P11, DOI 10.1007/s00441-002-0569-0; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	29	223	234	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1503	1506		10.1126/science.1096973	http://dx.doi.org/10.1126/science.1096973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178801				2022-12-28	WOS:000221795800045
J	Mittman, BS				Mittman, BS			Creating the evidence base for quality improvement collaboratives	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE; UNITED-STATES; FRAMEWORK; LESSONS	Intensive efforts are under way to improve health care quality and safety throughout the United States and abroad. Many of these efforts use the quality improvement collaborative method, an approach emphasizing collaborative learning and exchange of insights and support among a set of health care organizations. Unfortunately, the widespread acceptance and reliance on this approach are based not on solid evidence but on shared beliefs and anecdotal affirmations that may overstate the actual effectiveness of the method. More effective use of the collaborative method will require a commitment by users, researchers, and other stakeholders to rigorous, objective evaluation and the creation of a valid, useful knowledge and evidence base. Development of this evidence base will require improved conceptions of the nature of quality problems, quality improvement processes, and the types of research needed to elucidate these processes. Researchers, journal editors, and funding agencies must also cooperate to ensure that published evaluations are relevant, comprehensive, and cumulative.	Vet Affairs Greater Los Angeles Healthcare Syst 1, Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA; Vet Affairs Qual Enchancement Res Initiat, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Mittman, BS (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst 1, Ctr Study Healthcare Provider Behav, 16111 Plummer St, Sepulveda, CA 91343 USA.	Brian.Mittman@med.va.gov	Magee, Colin/E-7897-2010	Magee, Colin/0000-0002-5849-7836				Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; Cretin S, 2004, EVALUATION REV, V28, P28, DOI 10.1177/0193841X03256298; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Institute of Medicine, 2001, CROSSING QUALITY CHA; Landon BE, 2004, ANN INTERN MED, V140, P887, DOI 10.7326/0003-4819-140-11-200406010-00010; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Leatherman S, 2002, QUAL SAF HEALTH CARE, V11, P307, DOI 10.1136/qhc.11.4.307; Lomas J, 2003, BMJ-BRIT MED J, V327, P1301, DOI 10.1136/bmj.327.7427.1301; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MCKINLAY JB, 1981, MILBANK FUND Q, V59, P374, DOI 10.2307/3349685; Mills Peter D, 2004, Jt Comm J Qual Saf, V30, P152; Nisbett R. E., 1980, HUMAN INFERENCE STRA; Ovretveit J, 2002, QUAL SAF HEALTH CARE, V11, P345, DOI 10.1136/qhc.11.4.345; Weeks W B, 2001, Jt Comm J Qual Improv, V27, P243; Wilson Tim, 2003, Jt Comm J Qual Saf, V29, P85	16	204	204	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					897	901		10.7326/0003-4819-140-11-200406010-00011	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172904				2022-12-28	WOS:000221680600006
J	Giordano, M; Momigliano-Richiardi, P				Giordano, M; Momigliano-Richiardi, P			Maternal effect in multiple sclerosis	LANCET			English	Editorial Material							MITOCHONDRIAL-DNA; GENETIC-BASIS; RISKS; RELATIVES		Eastern Piedmont Univ, Dept Med Sci, I-28100 Novara, Italy; Eastern Piedmont Univ, Interdisciplinary Res Ctr Autoimmune Dis, I-28100 Novara, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro	Giordano, M (corresponding author), Eastern Piedmont Univ, Dept Med Sci, I-28100 Novara, Italy.	giordano@med.unipmn.it	GIORDANO, Mara/AAB-1379-2019	GIORDANO, Mara/0000-0001-6686-4600				Carton H, 1997, J NEUROL NEUROSUR PS, V62, P329, DOI 10.1136/jnnp.62.4.329; Chalmers RM, 1996, ANN NEUROL, V40, P239, DOI 10.1002/ana.410400216; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; Giordano Mara, 2002, Am J Pharmacogenomics, V2, P37, DOI 10.2165/00129785-200202010-00004; HARDING AE, 1995, MUSCLE NERVE, pS82; Herrera BM, 2003, CURR OPIN NEUROL, V16, P253, DOI 10.1097/00019052-200306000-00002; Kalman B, 1998, ACTA NEUROL SCAND, V98, P232, DOI 10.1111/j.1600-0404.1998.tb07301.x; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Morison IM, 2001, NUCLEIC ACIDS RES, V29, P275, DOI 10.1093/nar/29.1.275; Robertson NP, 1996, BRAIN, V119, P449, DOI 10.1093/brain/119.2.449; Sadovnick AD, 1999, CLIN GENET, V56, P118, DOI 10.1034/j.1399-0004.1999.560204.x; SADOVNICK AD, 1991, ANN NEUROL, V29, P252, DOI 10.1002/ana.410290304; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; Thorsby E, 1997, HUM IMMUNOL, V53, P1, DOI 10.1016/S0198-8859(97)00024-4	14	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1748	1749		10.1016/S0140-6736(04)16336-8	http://dx.doi.org/10.1016/S0140-6736(04)16336-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172769				2022-12-28	WOS:000221705800004
J	Mariathasan, S; Newton, K; Monack, DM; Vucic, D; French, DM; Lee, WP; Roose-Girma, M; Erickson, S; Dixit, VM				Mariathasan, S; Newton, K; Monack, DM; Vucic, D; French, DM; Lee, WP; Roose-Girma, M; Erickson, S; Dixit, VM			Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; KAPPA-B ACTIVATION; MACROPHAGE APOPTOSIS; RECRUITMENT DOMAIN; MICE DEFICIENT; PROTEIN; ICE; IDENTIFICATION; MONOCYTES; REGULATOR	Specific adaptors regulate the activation of initiator caspases; for example, FADD and Apaf-1 engage caspases 8 and 9, respectively(1). The adaptors ASC, Ipaf and RIP2 have each been proposed to regulate caspase-1 ( also called interleukin (IL)-1 converting enzyme), which is activated within the 'inflammasome', a complex comprising several adaptors(2). Here we show the impact of ASC-, Ipaf- or RIP2-deficiency on inflammasome function. ASC was essential for extracellular ATP-driven activation of caspase-1 in toll-like receptor (TLR)-stimulated macrophages. Accordingly, ASC- deficient macrophages exhibited defective maturation of IL-1beta and IL-18, and ASC-null mice were resistant to lipopoly-saccharide-induced endotoxic shock. Furthermore, activation of caspase-1 in response to an intracellular pathogen (Salmonella typhimurium) was abrogated severely in ASC- null macrophages. Unexpectedly, Ipaf- deficient macrophages activated caspase-1 in response to TLR plus ATP stimulation but not S. typhimurium. Caspase-1 activation was not compromised by loss of RIP2. These data show that whereas ASC is key to caspase-1 activation within the inflammasome, Ipaf provides a special conduit to the inflammasome for signals triggered by intracellular pathogens. Notably, cell death triggered by stimuli that engage caspase-1 was ablated in macrophages lacking either ASC or Ipaf, suggesting a coupling between the inflammatory and cell death pathways.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Stanford University	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Monack, Denise/0000-0003-3804-2209				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; Conway KE, 2000, CANCER RES, V60, P6236; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gumucio DL, 2002, CLIN EXP RHEUMATOL, V20, pS45; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Monack DM, 2000, J EXP MED, V192, P249, DOI 10.1084/jem.192.2.249; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; Srinivasula SM, 2002, J BIOL CHEM, V19, P19; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200	30	1359	1416	2	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					213	218		10.1038/nature02664	http://dx.doi.org/10.1038/nature02664			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15190255				2022-12-28	WOS:000222470600045
J	Doll, R; Peto, R; Boreham, J; Sutherland, I				Doll, R; Peto, R; Boreham, J; Sutherland, I			Mortality in relation to smoking: 50 years' observations on male British doctors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; TOBACCO; STATISTICS; COHORT; DEATHS; INDIA	Objective To compare the hazards of cigarette smoking in men who formed their habits at different periods, and the extent of the reduction in risk when cigarette smoking is stopped at different ages. Design Prospective study that has continued from 1951 to 2001. Setting United Kingdom. Participants 34 439 male British doctors. Information about their smoking habits was obtained in 1951, and periodically thereafter; cause specific mortality was monitored for 50 years. Main outcome measures Overall mortality by smoking habit, considering separately men born in different periods. Results The excess mortality associated with smoking chiefly involved vascular, neoplastic, and respiratory diseases that can be caused by smoking. Men born in 1900-1930 who smoked only cigarettes mid continued smoking died on average about 10 years younger than lifelong non-smokers. Cessation at age 60, 50, 40, or 30 years gained respectively, about 3, 6, 9, or 10 years of life expectancy. The excess mortality associated with cigarette smoking was less for men born in the 19th century and was greatest for men born in the 1920s. The cigarette smoker versus non-smoker probabilities of dying in middle age (35-69) were 42% v 24% (a twofold death rate ratio) for those born in 1900-1909, but were 43% v 15% (a threefold death rate ratio) for those born in the 1920s. At older acres, the cigarette smoker versus non-smoker probabilities Of surviving from age 70 to 90 were 10% v 12% at the death rates of the 1950s (that is, among men born around the 1870s) but were 7% v 33% (again a threefold death rate ratio) at the death rates of the 1990s (that is, among men born around the 1910s). Conclusion A substantial progressive decrease in the mortality rates among non-smokers over the past half century (due to prevention and improved treatment of disease) has been wholly outweighed, among cigarette smokers, by a progressive increase in the smoker v non-smoker death rate ratio due to earlier and more intensive use of cigarettes. Among the men born around 1920, prolonged cigarette smoking from early adult life tripled age specific mortality rates, but cessation at age 50 halved the hazard, and cessation at age 30 avoided almost all of it.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit CTSU, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Doll, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.	secretary@ctsu.ox.ac.uk						DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1964, BMJ-BRIT MED J, V1, P1460, DOI 10.1136/bmj.1.5396.1460; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Doll R, 1999, J URBAN HEALTH, V76, P289, DOI 10.1007/BF02345669; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Doll R, 1954, BRIT MED J, V228, P151; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1193; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; Gupta PC, 2000, B WORLD HEALTH ORGAN, V78, P877; Harris JE, 2004, BMJ-BRIT MED J, V328, P72, DOI 10.1136/bmj.37936.585382.44; International Agency for Research on Cancer, 2004, IARC MONOGRAPHS EVAL, V83, P33; LAM TH, 2001, BRIT MED J, V323, P1; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; LOPEZ A, 1997, TOBACCO HLTH GLOBAL; *MED RES COUNC, 1957, BMJ-BRIT MED J, V1, P1523; MILLS CA, 1950, CANCER RES, V10, P539; MULLER F. H., 1939, ZEITSCHR KREBSJORSCH, V49, P57; NICOLAIDESBOUMA.A, 1993, INT SMOKING STAT; Peto R, 1999, NAT MED, V5, P15, DOI 10.1038/4691; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Peto R, 1994, MORTALITY SMOKING DE; Peto R., 2001, CRITICAL ISSUES GLOB, P154, DOI DOI 10.4314/NMP.V55I6.45441; Royal College of Physicians, 1962, SMOK HLTH; SCHAIRER E, 1943, Z KREBSFORSCH, V54, P261; SHREK R, 1950, CANCER RES, V10, P49; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; *US DEP HHS, 1989, DHHS PUBL; VINEIS P, 2001, J NATL CANCER I, V96, P99; WASSINK W. F., 1948, NEDERLANDSCH TIJDSCHR GENEESK, V92, P3732; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74	38	2046	2099	7	158	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2004	328	7455					1519	1528		10.1136/bmj.38142.554479.AE	http://dx.doi.org/10.1136/bmj.38142.554479.AE			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15213107	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222392700015
J	Motose, H; Sugiyama, M; Fukuda, H				Motose, H; Sugiyama, M; Fukuda, H			A proteoglycan mediates inductive interaction during plant vascular development	NATURE			English	Article							LOCAL INTERCELLULAR COMMUNICATION; TRACHEARY ELEMENT DIFFERENTIATION; LIPID-TRANSFER PROTEINS; ARABINOGALACTAN-PROTEIN; MESOPHYLL-CELLS; MEMBRANE; ANCHOR	Inductive cell-cell interactions are essential for controlling cell fate determination in both plants and animals(1); however, the chemical basis of inductive signals in plants remains little understood. A proteoglycan-like factor named xylogen mediates local and inductive cell-cell interactions required for xylem differentiation in Zinnia cells cultured in vitro(2,)3. Here we describe the purification of xylogen and cloning of its complementary DNA, and present evidence for its role in planta. The polypeptide backbone of xylogen is a hybrid-type molecule with properties of both arabinogalactan proteins and nonspecific lipid-transfer proteins. Xylogen predominantly accumulates in the meristem, procambium and xylem. In the xylem, xylogen has a polar localization in the cell walls of differentiating tracheary elements. Double knockouts of Arabidopsis lacking both genes that encode xylogen proteins show defects in vascular development: discontinuous veins, improperly interconnected vessel elements and simplified venation. Our results suggest that the polar secretion of xylogen draws neighbouring cells into the pathway of vascular differentiation to direct continuous vascular development, thereby identifying a molecule that mediates an inductive cell cell interaction involved in plant tissue differentiation.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Bot Gardens, Bunkyo Ku, Tokyo 1120001, Japan; RIKEN, Plant Sci Ctr, Tsurumi Ku, Kanagawa 2300045, Japan	University of Tokyo; University of Tokyo; RIKEN	Motose, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	hmotose@ucdavis.edu	SUGIYAMA, MUNETAKA/G-4922-2014; MOTOSE, Hiroyasu/B-1474-2011	Motose, Hiroyasu/0000-0001-5038-6640				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ANDERSON RL, 1977, AUST J PLANT PHYSIOL, V4, P143, DOI 10.1071/PP9770143; Berleth T, 2000, CURR OPIN PLANT BIOL, V3, P406, DOI 10.1016/S1369-5266(00)00104-7; Carland FM, 2002, PLANT CELL, V14, P2045, DOI 10.1105/tpc.003939; FUKUDA H, 1980, PLANT PHYSIOL, V65, P57, DOI 10.1104/pp.65.1.57; Fukuda H, 1997, PLANT CELL, V9, P1147, DOI 10.1105/tpc.9.7.1147; Ito M, 1998, PLANT CELL, V10, P331; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Koizumi K, 2000, DEVELOPMENT, V127, P3197; KOMALAVILAS P, 1991, J BIOL CHEM, V266, P15956; Matsubayashi Y, 1996, P NATL ACAD SCI USA, V93, P7623, DOI 10.1073/pnas.93.15.7623; Motose H, 2001, PLANTA, V213, P121, DOI 10.1007/s004250000482; Motose H, 2001, PLANT CELL PHYSIOL, V42, P129, DOI 10.1093/pcp/pce014; Nishitani C, 2001, PLANT CELL PHYSIOL, V42, P1210, DOI 10.1093/pcp/pce156; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; Oxley D, 1999, P NATL ACAD SCI USA, V96, P14246, DOI 10.1073/pnas.96.25.14246; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Schindelman G, 2001, GENE DEV, V15, P1115, DOI 10.1101/gad.879101; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Svetek J, 1999, J BIOL CHEM, V274, P14724, DOI 10.1074/jbc.274.21.14724; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; YAMADA M, 1992, PLANT CELL PHYSIOL, V33, P1; Yates EA, 1996, GLYCOBIOLOGY, V6, P131, DOI 10.1093/glycob/6.2.131; Youl JJ, 1998, P NATL ACAD SCI USA, V95, P7921, DOI 10.1073/pnas.95.14.7921	25	248	262	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					873	878		10.1038/nature02613	http://dx.doi.org/10.1038/nature02613			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215864				2022-12-28	WOS:000222213000042
J	Fiala, SK				Fiala, SK			Normal is a place I visit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												suziviolet@aol.com						Office of the Surgeon General, 2019, SURG GEN ADV MAR US	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2924	2926		10.1001/jama.291.24.2924	http://dx.doi.org/10.1001/jama.291.24.2924			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213186				2022-12-28	WOS:000222184600001
J	Riebe, M; Haffner, H; Roos, CF; Hansel, W; Benhelm, J; Lancaster, GPT; Korber, TW; Becher, C; Schmidt-Kaler, F; James, DFV; Blatt, R				Riebe, M; Haffner, H; Roos, CF; Hansel, W; Benhelm, J; Lancaster, GPT; Korber, TW; Becher, C; Schmidt-Kaler, F; James, DFV; Blatt, R			Deterministic quantum teleportation with atoms	NATURE			English	Article							PODOLSKY-ROSEN CHANNELS; COMPUTER; STATE	Teleportation of a quantum state encompasses the complete transfer of information from one particle to another. The complete specification of the quantum state of a system generally requires an infinite amount of information, even for simple two-level systems (qubits). Moreover, the principles of quantum mechanics dictate that any measurement on a system immediately alters its state, while yielding at most one bit of information. The transfer of a state from one system to another ( by performing measurements on the first and operations on the second) might therefore appear impossible. However, it has been shown(1) that the entangling properties of quantum mechanics, in combination with classical communication, allow quantum-state teleportation to be performed. Teleportation using pairs of entangled photons has been demonstrated(2-6), but such techniques are probabilistic, requiring post-selection of measured photons. Here, we report deterministic quantum-state teleportation between a pair of trapped calcium ions. Following closely the original proposal(1), we create a highly entangled pair of ions and perform a complete Bell-state measurement involving one ion from this pair and a third source ion. State reconstruction conditioned on this measurement is then performed on the other half of the entangled pair. The measured fidelity is 75%, demonstrating unequivocally the quantum nature of the process.	Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria; Los Alamos Natl Lab, Div Theoret T 4, Los Alamos, NM 87545 USA; Austrian Acad Sci, Inst Quantenopt & Quanteninformat, A-6020 Innsbruck, Austria	University of Innsbruck; United States Department of Energy (DOE); Los Alamos National Laboratory; Austrian Academy of Sciences	Blatt, R (corresponding author), Univ Innsbruck, Inst Expt Phys, Tech Str 25, A-6020 Innsbruck, Austria.	Rainer.Blatt@uibk.ac.at	Becher, Christoph/AAE-8756-2020; James, Daniel/B-9805-2009; Becker, Jonas/GZG-4234-2022; Haeffner, Hartmut/D-8046-2012; Blatt, Rainer/H-9527-2014; Roos, Christian F/D-8475-2011; Schmidt-Kaler, Ferdinand/E-2151-2017	Becher, Christoph/0000-0003-4645-6882; James, Daniel/0000-0003-3981-4602; Haeffner, Hartmut/0000-0002-5113-9622; Roos, Christian F/0000-0001-7121-8259; Schmidt-Kaler, Ferdinand/0000-0002-5697-2568				BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Boschi D, 1998, PHYS REV LETT, V80, P1121, DOI 10.1103/PhysRevLett.80.1121; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Fattal D, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.037904; Furusawa A, 1998, SCIENCE, V282, P706, DOI 10.1126/science.282.5389.706; Gisin N, 1996, PHYS LETT A, V210, P157, DOI 10.1016/S0375-9601(96)80002-8; Gulde S, 2003, NATURE, V421, P48, DOI 10.1038/nature01336; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; Kielpinski D, 2002, NATURE, V417, P709, DOI 10.1038/nature00784; MASSAR S, 1995, PHYS REV LETT, V74, P1259, DOI 10.1103/PhysRevLett.74.1259; Nielsen MA, 1998, NATURE, V396, P52, DOI 10.1038/23891; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pan JW, 2001, PHYS REV LETT, V86, P4435, DOI 10.1103/PhysRevLett.86.4435; ROOS CF, 2003, IN PRESS PHYS REV LE; Schmidt-Kaler F, 2003, APPL PHYS B-LASERS O, V77, P789, DOI 10.1007/s00340-003-1346-9; WOOTTERS WK, 1982, NATURE, V299, P802, DOI 10.1038/299802a0	18	749	771	2	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	2004	429	6993					734	737		10.1038/nature02570	http://dx.doi.org/10.1038/nature02570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201903				2022-12-28	WOS:000222059900031
J	Feigin, V; Vander Hoorn, S				Feigin, V; Vander Hoorn, S			How to study stroke incidence	LANCET			English	Editorial Material							CASE-FATALITY; CARDIOVASCULAR-DISEASE; SECULAR TRENDS; POPULATION; PREVALENCE; AUCKLAND; RATES		Univ Auckland, Sch Populat Hlth, Clin Trials Res Unit, Auckland 1, New Zealand	University of Auckland	Feigin, V (corresponding author), Univ Auckland, Sch Populat Hlth, Clin Trials Res Unit, Auckland 1, New Zealand.	v.feigin@ctru.auckland.ac.nz	Feigin, Valery/AAF-2313-2019	Feigin, Valery L./0000-0002-6372-1740				BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; BONITA R, 1995, INT J EPIDEMIOL, V24, P535, DOI 10.1093/ije/24.3.535; BONITA R, 1995, STROKE, V26, P541, DOI 10.1161/01.STR.26.4.541; Brown RD, 1996, STROKE, V27, P373; Ezzati M, 2003, LANCET, V362, P271, DOI 10.1016/S0140-6736(03)13968-2; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; FEIGIN VL, 1995, STROKE, V26, P924, DOI 10.1161/01.STR.26.6.924; Jamrozik K, 1999, STROKE, V30, P2105, DOI 10.1161/01.STR.30.10.2105; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; MALMGREN R, 1987, LANCET, V2, P1196; Morikawa Y, 2000, STROKE, V31, P1583, DOI 10.1161/01.STR.31.7.1583; Numminen H, 1996, STROKE, V27, P1487, DOI 10.1161/01.STR.27.9.1487; Qizilbash N, 1995, LANCET, V346, P1647; Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550; Thorvaldsen P, 1999, STROKE, V30, P2529, DOI 10.1161/01.STR.30.12.2529; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; 1999, CARDIOVASC DIS PREV, V2, P281	17	78	78	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	2004	363	9425					1920	1921		10.1016/S0140-6736(04)16436-2	http://dx.doi.org/10.1016/S0140-6736(04)16436-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194247				2022-12-28	WOS:000221962800002
J	Vitousek, PM; Ladefoged, TN; Kirch, PV; Hartshorn, AS; Graves, MW; Hotchkiss, SC; Tuljapurkar, S; Chadwick, OA				Vitousek, PM; Ladefoged, TN; Kirch, PV; Hartshorn, AS; Graves, MW; Hotchkiss, SC; Tuljapurkar, S; Chadwick, OA			Soils, agriculture, and society in precontact Hawai	SCIENCE			English	Article							KOHALA; NUTRIENTS; ISLAND	Before European contact, Hawai` i supported large human populations in complex societies that were based on multiple pathways of intensive agriculture. We show that soils within a long-abandoned 60-square-kilometer dryland agricultural complex are substantially richer in bases and phosphorus than are those just outside it, and that this enrichment predated the establishment of intensive agriculture. Climate and soil fertility combined to constrain large dryland agricultural systems and the societies they supported to well-defined portions of just the younger islands within the Hawaiian archipelago; societies on the older islands were based on irrigated wetland agriculture. Similar processes may have influenced the dynamics of agricultural intensification across the tropics.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Auckland, Dept Anthropol, Auckland 1, New Zealand; Univ Calif Berkeley, Dept Anthropol, Berkeley, CA 94720 USA; Univ Calif Santa Barbara, Dept Geog, Santa Barbara, CA 93106 USA; Univ Hawaii Manoa, Dept Anthropol, Honolulu, HI 96822 USA; Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	Stanford University; University of Auckland; University of California System; University of California Berkeley; University of California System; University of California Santa Barbara; University of Hawaii System; University of Hawaii Manoa; University of Wisconsin System; University of Wisconsin Madison	Vitousek, PM (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	vitousek@stanford.edu		Hartshorn, Anthony/0000-0002-0004-5749; Tuljapurkar, Shripad/0000-0001-5549-4245; Ladefoged, Thegn/0000-0002-6950-9898				Allen J., 1991, ASIAN PERSPECT, V30, P117; Blaikie P M, 1987, LAND DEGRADATION SOC; Boserup Ester, 1981, POPULATION TECHNOLOG; Chadwick OA, 1999, NATURE, V397, P491, DOI 10.1038/17276; Chadwick OA, 2001, GEODERMA, V100, P321, DOI 10.1016/S0016-7061(01)00027-1; Chadwick OA, 2003, CHEM GEOL, V202, P195, DOI 10.1016/j.chemgeo.2002.09.001; CHADWICK OA, UNPUB; Clague David A., 1996, P35; Earle T., 1980, ARCHAEOL PHYS ANTHRO, V25, P1; EARLE TK, 1997, CHIEFS POWER POLITIC; Ewel JJ, 1999, AGROFOREST SYST, V45, P1, DOI 10.1023/A:1006219721151; Giambelluca TW, 1986, R76 STAT HAW DEP LAN; Handy Elizabeth Green, 1972, NATIVE PLANTERS OLD; Heckenberger MJ, 2003, SCIENCE, V301, P1710, DOI 10.1126/science.1086112; Jobbagy EG, 2001, BIOGEOCHEMISTRY, V53, P51, DOI 10.1023/A:1010760720215; Kirch P.V., 1984, EVOLUTION POLYNESIAN; Kirch Patrick, 1994, WET DRY IRRIGATION A; KIRCH PV, IN PRESS P NATL ACAD; KIRCH PV, 2000, ROAD WINDS ARCHAEOLO; Kurtz AC, 2000, GEOLOGY, V28, P683, DOI 10.1130/0091-7613(2000)28<683:REMIVS>2.0.CO;2; Ladefoged TN, 1996, ANTIQUITY, V70, P861, DOI 10.1017/S0003598X0008412X; Ladefoged TN, 2000, AM ANTIQUITY, V65, P423, DOI 10.2307/2694529; Ladefoged TN, 2003, J ARCHAEOL SCI, V30, P923, DOI 10.1016/S0305-4403(02)00271-6; MEGGERS B, 1996, AMAZONIA MAN NATURE; MOORE JG, 1992, GEOL SOC AM BULL, V104, P1471, DOI 10.1130/0016-7606(1992)104<1471:VGAEOT>2.3.CO;2; Morrison K.D., 1994, J ARCHAEOL METHOD TH, V1, P111, DOI [DOI 10.1007/BF02231414, 10.1007/BF02231414]; MURPHY PG, 1986, ANNU REV ECOL SYST, V17, P67, DOI 10.1146/annurev.es.17.110186.000435; Nagata K. M., 1985, HAWAIIAN J HIST, V19, P35; NEWMAN TS, 1970, HAWAIIAN FISHING FAR; NGEVE JM, 1992, TROP AGR, V69, P43; PURSEGLOVE JW, 1968, TROPICAL CROPS DICTO, V1; ROSENDAHL PH, 1994, HAWAIIAN ARCHAEOLOGY, V3, P14; Sanchez P. A., 1976, Properties and management of soils in the tropics.; Stewart BW, 2001, GEOCHIM COSMOCHIM AC, V65, P1087, DOI 10.1016/S0016-7037(00)00614-1; Tuggle H.D., 1980, J FIELD ARCHAEOL, V7, P297, DOI DOI 10.1179/009346980791505347; Vitousek, 2004, NUTR CYCLING LIMITAT; Willis KJ, 2004, SCIENCE, V304, P402, DOI 10.1126/science.1093991	37	132	135	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1665	1669		10.1126/science.1099619	http://dx.doi.org/10.1126/science.1099619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192228				2022-12-28	WOS:000221934300049
J	Knauth, DC; Andersson, BG; McCandliss, SR; Moos, HW				Knauth, DC; Andersson, BG; McCandliss, SR; Moos, HW			The interstellar N-2 abundance towards HD 124314 from far-ultraviolet observations	NATURE			English	Article							DENSE MOLECULAR CLOUDS; O-TYPE STARS; DIFFUSE; CHEMISTRY; MODEL; GAS; CO; WAVELENGTHS; TRANSITION; BANDS	The abundance of interstellar molecular nitrogen (N-2) is of considerable importance: models of steady-state gas-phase interstellar chemistry(1,2), together with millimetre- wavelength observations(3,4) of interstellar N2H+ in dense molecular clouds predict that N-2 should be the most abundant nitrogen-bearing molecule in the interstellar medium. Previous attempts to detect N2 absorption in the far-ultraviolet(5) or infrared(6) (ice features) have hitherto been unsuccessful. Here we report the detection of interstellar N-2 at far-ultraviolet wavelengths towards the moderately reddened star HD 124314 in the constellation of Centaurus. The N-2 column density is larger than expected from models of diffuse clouds and significantly smaller than expected for dense molecular clouds(1). Moreover, the N-2 abundance does not explain the observed variations(7) in the abundance of atomic nitrogen (N I) towards high-column-density sightlines, implying that the models of nitrogen chemistry in the interstellar medium are incomplete(8).	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Knauth, DC (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, 3400 N Charles St, Baltimore, MD 21218 USA.	dknauth@pha.jhu.edu						ABGRALL H, 1989, ASTRON ASTROPHYS SUP, V79, P313; Abgrall H., 1982, Astronomy & Astrophysics Supplement Series, V50, P505; Andre MK, 2003, ASTROPHYS J, V591, P1000, DOI 10.1086/375530; BERGIN EA, 1995, ASTROPHYS J, V441, P222, DOI 10.1086/175351; BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; Clayton RN, 2002, NATURE, V415, P860, DOI 10.1038/415860b; CONTI PS, 1977, ASTROPHYS J, V213, P438, DOI 10.1086/155173; Cruz-Gonzalez C., 1974, Revista Mexicana de Astronomia y Astrofisica, V1, P211; DIXON WV, 2003, ASP C SER, V295, P241; FEDERMAN SR, 1980, ASTROPHYS J, V242, P545, DOI 10.1086/158489; HEDIN AE, 1991, J GEOPHYS RES-SPACE, V96, P1159, DOI 10.1029/90JA02125; Knauth DC, 2003, ASTROPHYS J, V596, pL51, DOI 10.1086/379055; Knauth DC, 2003, ASTROPHYS J, V592, P964, DOI 10.1086/375767; Lanz T, 2003, ASTROPHYS J SUPPL S, V146, P417, DOI 10.1086/374373; Le Petit F, 2004, ASTRON ASTROPHYS, V417, P993, DOI 10.1051/0004-6361:20035629; LUTZ BL, 1979, ASTROPHYS J, V227, P159, DOI 10.1086/156715; Moos HW, 2000, ASTROPHYS J, V538, pL1, DOI 10.1086/312795; Morton DC, 2003, ASTROPHYS J SUPPL S, V149, P205, DOI 10.1086/377639; Perryman MAC, 1997, ASTRON ASTROPHYS, V323, pL49; Sahnow DJ, 2000, ASTROPHYS J, V538, pL7, DOI 10.1086/312794; Sandford SA, 2001, ASTROPHYS J, V548, P836, DOI 10.1086/319023; Sheffer Y, 2003, ASTROPHYS J, V597, pL29, DOI 10.1086/379699; SNEDEN C, 1978, ASTROPHYS J, V223, P168, DOI 10.1086/156247; Stark G, 2000, ASTROPHYS J, V531, P321, DOI 10.1086/308464; VANDISHOECK EF, 1988, ASTROPHYS J, V334, P771, DOI 10.1086/166877; VIALA YP, 1986, ASTRON ASTROPHYS SUP, V64, P391; WALBORN NR, 1973, ASTRON J, V78, P1067, DOI 10.1086/111509; WOMACK M, 1992, ASTROPHYS J, V393, P188, DOI 10.1086/171496; WOMACK M, 1992, ASTROPHYS J, V387, P417, DOI 10.1086/171094	29	97	98	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					636	638		10.1038/nature02614	http://dx.doi.org/10.1038/nature02614			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190346				2022-12-28	WOS:000221912600033
J	Green, PHR				Green, PHR			Missed diagnosis and repeat procedures	LANCET			English	News Item									Columbia Presbyterian Med Ctr, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital	Green, PHR (corresponding author), Columbia Presbyterian Med Ctr, New York, NY 10032 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1902	1902		10.1016/S0140-6736(04)16361-7	http://dx.doi.org/10.1016/S0140-6736(04)16361-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183631				2022-12-28	WOS:000221822300025
J	Mount, AM; Mwapasa, V; Elliott, SR; Beeson, JG; Tadesse, E; Lema, VM; Molyneux, ME; Meshnick, SR; Rogerson, SJ				Mount, AM; Mwapasa, V; Elliott, SR; Beeson, JG; Tadesse, E; Lema, VM; Molyneux, ME; Meshnick, SR; Rogerson, SJ			Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection	LANCET			English	Article							VARIANT SURFACE-ANTIGENS; PLACENTAL MALARIA; ACQUIRED-IMMUNITY; WOMEN; ANTIBODIES; ADULTS; ERYTHROCYTES; RESPONSES; ABNORMALITIES; DETERMINANTS	Background HIV infection increases the risk of malaria infection in pregnant women. Antibodies to variant surface antigens (VSA) on infected erythrocytes might protect against malaria in pregnancy. We postulated that HIV-induced impairment of humoral immunity to VSA mediates the increased susceptibility to malaria. Methods We compared serum concentrations of antibodies to VSA by flow cytometry or agglutination, and to merozoite proteins AMA-1 and MSP1(19), by ELISA, in 298 pregnant Malawian women, and related the findings to malaria and HIV infection, CD4-positive T-cell count, and HIV-1 viral load. Findings Concentrations of IgG to placental type VSA were lower in HIV-infected women than in HIV-uninfected women (median 8 units [IQR 4-23] vs 20 [12-30]; p<0.0001), among women with malaria (p=0.009) and those without malaria (p=0.0062). The impairment was greatest in first pregnancy. Agglutinating antibodies to placental VSA were present in a lower proportion of HIV-infected than HIV-uninfected women (58 [35.1%] of 165 vs 50 [53.8%] of 93, p<0.001). The degree of antibody binding by flow cytometry was correlated with CD4-positive T-cell count (r=0.16, p=0.019) and inversely with HIV-1 viral load (r=-0.16, p=0.030). Concentrations of antibodies to AMA-1 were lower in HIV infection (p<0.0001) but were not correlated with CD4-positive T-cell count or viral load. Responses to MSP1(19) were little affected by HIV infection. In multivariate analyses, HIV was negatively associated with amount of antibody to both VSA and AMA-1 (p<0.001 for each) but not MSP1(19). Interpretation HIV infection impairs antimalarial immunity, especially responses to placental type VSA. The impairment is greatest in the most immunosuppressed women and could explain the increased susceptibility to malaria seen in pregnant women with HIV infection.	Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Malawi, Coll Med, Dept Community Hlth, Blantyre, Malawi; Univ Malawi, Coll Med, Dept Obstet & Gynaecol, Blantyre, Malawi; Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; Univ Liverpool, Sch Trop Med, Liverpool L69 3BX, Merseyside, England; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA	Royal Melbourne Hospital; University of Melbourne; University of Michigan System; University of Michigan; University of Malawi; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rogerson, SJ (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.	sroger@unimelb.edu.au		Mwapasa, Victor/0000-0002-2748-8902; Rogerson, Stephen/0000-0003-4287-1982	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049084] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 49084] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayisi JG, 2003, J INFECTION, V46, P164, DOI 10.1053/jinf.2002.1088; Beeson JG, 2004, J INFECT DIS, V189, P540, DOI 10.1086/381186; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; BRABIN BJ, 1991, APPL FIELD RES MALAR, P1; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; French N, 2001, AIDS, V15, P899, DOI 10.1097/00002030-200105040-00010; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Guyatt HL, 2001, AM J TROP MED HYG, V64, P36, DOI 10.4269/ajtmh.2001.64.36; Kashamuka M, 2003, AM J TROP MED HYG, V68, P376, DOI 10.4269/ajtmh.2003.68.376; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; Kroon FP, 1998, AIDS, V12, pF217, DOI 10.1097/00002030-199817000-00002; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; Marshall VM, 1996, MOL BIOCHEM PARASIT, V77, P109, DOI 10.1016/0166-6851(96)02583-2; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; Migot F, 1996, PARASITE IMMUNOL, V18, P333, DOI 10.1046/j.1365-3024.1996.d01-116.x; Moore JM, 2000, J INFECT DIS, V182, P960, DOI 10.1086/315755; MWAPASA V, IN PRESS AIDS; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; Rogerson SJ, 2003, AM J TROP MED HYG, V68, P115, DOI 10.4269/ajtmh.2003.68.1.0680115; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; Van Eijk AM, 2001, AM J TROP MED HYG, V65, P623, DOI 10.4269/ajtmh.2001.65.623; WABWIREMANGEN F, 1989, AM J TROP MED HYG, V41, P504, DOI 10.4269/ajtmh.1989.41.504; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6	28	109	110	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1860	1867		10.1016/S0140-6736(04)16354-X	http://dx.doi.org/10.1016/S0140-6736(04)16354-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183624				2022-12-28	WOS:000221822300010
J	Bazykin, GA; Kondrashov, FA; Ogurtsov, AY; Sunyaev, S; Kondrashov, AS				Bazykin, GA; Kondrashov, FA; Ogurtsov, AY; Sunyaev, S; Kondrashov, AS			Positive selection at sites of multiple amino acid replacements since rat-mouse divergence	NATURE			English	Article							PROTEIN EVOLUTION; MAXIMUM-LIKELIHOOD; GENOME; NUCLEOTIDE; DROSOPHILA; SEQUENCE; HUMANS; GENES; MODEL	New alleles become fixed owing to random drift of nearly neutral mutations or to positive selection of substantially advantageous mutations(1-3). After decades of debate, the fraction of fixations driven by selection remains uncertain(4-9). Within 9,390 genes, we analysed 28,196 codons at which rat and mouse differ from each other at two nucleotide sites and 1,982 codons with three differences. At codons where rat-mouse divergence involved two non-synonymous substitutions, both of them occurred in the same lineage, either rat or mouse, in 64% of cases; however, independent substitutions would occur in the same lineage with a probability of only 50%. All three non-synonymous substitutions occurred in the same lineage for 46% of codons, instead of the 25% expected. Furthermore, comparison of 12 pairs of prokaryotic genomes also shows clumping of multiple nonsynonymous substitutions in the same lineage. This pattern cannot be explained by correlated mutation or episodes of relaxed negative selection, but instead indicates that positive selection acts at many sites of rapid, successive amino acid replacement.	Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA; Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA; NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, Boston, MA 02115 USA	Princeton University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bazykin, GA (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.	gbazykin@princeton.edu	Kondrashov, Fyodor Alexeevich/H-6331-2015; Bazykin, Georgii/E-4601-2012	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694; Bazykin, Georgii/0000-0003-2334-2751	NATIONAL LIBRARY OF MEDICINE [Z01LM000095] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anisimova M, 2003, GENETICS, V164, P1229; Bustamante CD, 2002, NATURE, V416, P531, DOI 10.1038/416531a; Bustamante CD, 2002, MOL BIOL EVOL, V19, P110, DOI 10.1093/oxfordjournals.molbev.a003975; Eyre-Walker A, 2002, GENETICS, V162, P2017; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; FITCH WM, 1970, BIOCHEM GENET, V4, P579, DOI 10.1007/BF00486096; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; Hellmann I, 2003, GENOME RES, V13, P831, DOI 10.1101/gr.944903; Huelsenbeck JP, 2002, MOL BIOL EVOL, V19, P698, DOI 10.1093/oxfordjournals.molbev.a004128; Kimura M., 1983, NEUTRAL THEORY MOL E; Kondrashov AS, 2003, HUM MUTAT, V21, P12, DOI 10.1002/humu.10147; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MIYATA T, 1979, J MOL EVOL, V12, P219, DOI 10.1007/BF01732340; Nachman MW, 2000, GENETICS, V156, P297; Ohta T, 2002, P NATL ACAD SCI USA, V99, P16134, DOI 10.1073/pnas.252626899; Smith NGC, 2002, NATURE, V415, P1022, DOI 10.1038/4151022a; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WILBUR WJ, 1985, MOL BIOL EVOL, V2, P434; Yang ZH, 2002, CURR OPIN GENET DEV, V12, P688, DOI 10.1016/S0959-437X(02)00348-9; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	25	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	2004	429	6991					558	562		10.1038/nature02601	http://dx.doi.org/10.1038/nature02601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175752				2022-12-28	WOS:000221767700039
J	Ellerin, TB; Walsh, SR; Hooper, DC				Ellerin, TB; Walsh, SR; Hooper, DC			Recurrent meningitis of unknown aetiology	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION; HERPES-SIMPLEX TYPE-2; MOLLARETS MENINGITIS		Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Ellerin, TB (corresponding author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.	tellerin@partners.org		Walsh, Stephen/0000-0002-0817-9370				COHEN BA, 1994, ANN NEUROL, V35, P112, DOI 10.1002/ana.410350118; Jensenius M, 1998, ACTA NEUROL SCAND, V98, P209, DOI 10.1111/j.1600-0404.1998.tb07296.x; Mollaret MP, 1944, REV NEUROL-FRANCE, V76, P57; PICARD FJ, 1993, NEUROLOGY, V43, P1722, DOI 10.1212/WNL.43.9.1722; Teot LA, 1996, DIAGN CYTOPATHOL, V15, P345, DOI 10.1002/(SICI)1097-0339(199611)15:4<345::AID-DC19>3.0.CO;2-O	5	8	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1772	1772		10.1016/S0140-6736(04)16303-4	http://dx.doi.org/10.1016/S0140-6736(04)16303-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172776				2022-12-28	WOS:000221705800011
J	Norbury, CC; Basta, S; Donohue, KB; Tscharke, DC; Princiotta, MF; Berglund, P; Gibbs, J; Bennink, JR; Yewdell, JW				Norbury, CC; Basta, S; Donohue, KB; Tscharke, DC; Princiotta, MF; Berglund, P; Gibbs, J; Bennink, JR; Yewdell, JW			CD8(+)T cell cross-priming via transfer of proteasome substrates	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; GENE-PRODUCTS; CTL RESPONSES; CUTTING EDGE; PEPTIDES; VIVO; GENERATION; MECHANISMS	"Cross-priming" describes the activation of naive CD8(+) T cells by professional antigen-presenting cells that have acquired viral or tumor antigens from "donor" cells. Antigen transfer is believed to be mediated by donor cell-derived molecular chaperones bearing short peptide ligands generated by proteasome degradation of protein antigens. We show here that cross-priming is based on the transfer of proteasome substrates rather than peptides. These findings are potentially important for the rational design of vaccines that elicit CD8(+) T cell responses.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Penn State Univ Huck Inst Life Sci, Integrat Biosci Grad Program, Hershey, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jyewdell@niaid.nih.gov	Tscharke, David/C-9133-2009; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Tscharke, David/0000-0001-6825-9172; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000814, R56AI056094, R01AI056094] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-056094-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Anton LC, 1997, J IMMUNOL, V158, P2535; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; Bellone M, 1997, J IMMUNOL, V159, P5391; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Clarke SRM, 2000, IMMUNOL CELL BIOL, V78, P110, DOI 10.1046/j.1440-1711.2000.00889.x; Day PM, 1997, P NATL ACAD SCI USA, V94, P8064, DOI 10.1073/pnas.94.15.8064; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; Hudrisier D, 2002, FASEB J, V16, P477, DOI 10.1096/fj.01-0933rev; Janeway Jr C.A., 2001, IMMUNOBIOLOGY IMMUNE, V5th; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; RESTIFO NP, 1995, J IMMUNOL, V154, P4414; Schoenberger SP, 1998, J IMMUNOL, V161, P3808; Serna A, 2003, J IMMUNOL, V171, P5668, DOI 10.4049/jimmunol.171.11.5668; Shen LJ, 2004, P NATL ACAD SCI USA, V101, P3035, DOI 10.1073/pnas.0308345101; Sigal LJ, 2000, J EXP MED, V192, P1143, DOI 10.1084/jem.192.8.1143; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Wolkers MC, 2004, SCIENCE, V304, P1314, DOI 10.1126/science.1096268; Yewdell J, 1999, IMMUNOL REV, V172, P97, DOI 10.1111/j.1600-065X.1999.tb01359.x; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860	22	238	241	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1318	1321		10.1126/science.1096378	http://dx.doi.org/10.1126/science.1096378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166379				2022-12-28	WOS:000221669600053
J	Adams, J; White, M; Forman, D				Adams, J; White, M; Forman, D			Are there socioeconomic gradients in stage and grade of breast cancer at diagnosis? Cross sectional analysis of UK cancer registry data	BRITISH MEDICAL JOURNAL			English	Article							PROGNOSTIC FACTORS; WOMEN; DEPRIVATION		Univ Newcastle Upon Tyne, Sch Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Leeds, Leeds LS2 9JT, W Yorkshire, England	Newcastle University - UK; University of Leeds	Adams, J (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.m.adams@ncl.ac.uk	Adams, Jean/G-2402-2010; White, Martin J. R./G-2410-2010	Adams, Jean/0000-0002-5733-7830; 				Brewster DH, 2001, BRIT MED J, V322, P830, DOI 10.1136/bmj.322.7290.830; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; Macleod U, 2000, ANN ONCOL, V11, P105, DOI 10.1023/A:1008385321476; SUTTON S, 1994, J EPIDEMIOL COMMUN H, V48, P65, DOI 10.1136/jech.48.1.65; Thomson CS, 2001, J EPIDEMIOL COMMUN H, V55, P308, DOI 10.1136/jech.55.5.308	5	45	45	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					142	143		10.1136/bmj.38114.679387.AE	http://dx.doi.org/10.1136/bmj.38114.679387.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15175228	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000222832300018
J	Maden, A; Scott, F; Burnett, R; Lewis, GH; Skapinakis, P				Maden, A; Scott, F; Burnett, R; Lewis, GH; Skapinakis, P			Offending in psychiatric patients after discharge from medium secure units: prospective national cohort study	BRITISH MEDICAL JOURNAL			English	Article									W London Mental Hlth NHS Trust Headquarters, Acad Ctr, Southall UB1 3EU, Middx, England; Inst Psychiat, London, England; Univ Bristol, Dept Psychiat, Bristol BS8 1TH, Avon, England	University of London; King's College London; University of Bristol	Maden, A (corresponding author), W London Mental Hlth NHS Trust Headquarters, Acad Ctr, Southall UB1 3EU, Middx, England.	a.maden@ic.ac.uk	Skapinakis, Petros/B-8718-2011; Lewis, Glyn/E-9944-2012	Skapinakis, Petros/0000-0003-1450-8051; Lewis, Glyn/0000-0001-5205-8245				Hart S.D., 1995, HARE PCL SV PSYCHOPA; *HOM OFF, 2001, STAT B STAT MENT DIS; Monahan J., 2001, RETHINKING RISK ASSE	3	58	58	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1534	1534		10.1136/bmj.38075.467569.EE	http://dx.doi.org/10.1136/bmj.38075.467569.EE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15169742	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000222392700018
J	Hallem, EA; Ho, MG; Carlson, JR				Hallem, EA; Ho, MG; Carlson, JR			The molecular basis of odor coding in the drosophila antenna	CELL			English	Article							OLFACTORY SENSORY MAP; RECEPTOR EXPRESSION; MAXILLARY PALP; TASTE NEURONS; FLY BRAIN; MELANOGASTER; INFORMATION; ORGANIZATION; RESPONSES; SYSTEM	We have undertaken a functional analysis of the odorant receptor repertoire in the Drosophila antenna. Each receptor was expressed in a mutant olfactory receptor neuron (ORN) used as a "decoder," and the odor response spectrum conferred by the receptor was determined in vivo by electrophysiological recordings. The spectra of these receptors were then matched to those of defined ORNs to establish a receptor-to-neuron map. In addition to the odor response spectrum, the receptors dictate the signaling mode, i.e., excitation or inhibition, and the response dynamics of the neuron. An individual receptor can mediate both excitatory and inhibitory responses to different odorants in the same cell, suggesting a model of odorant receptor transduction. Receptors vary widely in their breadth of tuning, and odorants vary widely in the number of receptors they activate. Together, these properties provide a molecular basis for odor coding by the receptor repertoire of an olfactory organ.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Carlson, JR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	john.carlson@yale.edu		Ho, Michael/0000-0002-4893-3016; Hallem, Elissa/0000-0003-0260-3174	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002174, R01DC004729] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC04729, DC02174] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AYER RK, 1992, J NEUROBIOL, V23, P965, DOI 10.1002/neu.480230804; Chyb S, 2003, P NATL ACAD SCI USA, V100, P14526, DOI 10.1073/pnas.2135339100; Clyne Peter, 1997, Invertebrate Neuroscience, V3, P127, DOI 10.1007/BF02480367; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; Dahanukar A, 2001, NAT NEUROSCI, V4, P1182, DOI 10.1038/nn765; de Bruyne M, 1999, J NEUROSCI, V19, P4520; de Bruyne M, 2001, NEURON, V30, P537, DOI 10.1016/S0896-6273(01)00289-6; Dobritsa AA, 2003, NEURON, V37, P827, DOI 10.1016/S0896-6273(03)00094-1; Duchamp-Viret P, 2000, J NEUROSCI, V20, P2383; Duchamp-Viret P, 1999, SCIENCE, V284, P2171, DOI 10.1126/science.284.5423.2171; Elmore T, 2003, J NEUROSCI, V23, P9906; Fiala A, 2002, CURR BIOL, V12, P1877, DOI 10.1016/S0960-9822(02)01239-3; Galizia CG, 1999, NAT NEUROSCI, V2, P473, DOI 10.1038/8144; Gao Q, 2000, NAT NEUROSCI, V3, P780, DOI 10.1038/77680; Gao Q, 1999, GENOMICS, V60, P31, DOI 10.1006/geno.1999.5894; Hallem EA, 2004, NATURE, V427, P212, DOI 10.1038/427212a; Heinbockel T, 1996, J INSECT PHYSIOL, V42, P565, DOI 10.1016/0022-1910(95)00133-6; Hildebrand JG, 1996, J COMP PHYSIOL A, V178, P5, DOI 10.1007/BF00189586; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; KAISSLING KE, 1989, J COMP PHYSIOL A, V165, P147, DOI 10.1007/BF00619189; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Laurent G, 2001, ANNU REV NEUROSCI, V24, P263, DOI 10.1146/annurev.neuro.24.1.263; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; Ng M, 2002, NEURON, V36, P463, DOI 10.1016/S0896-6273(02)00975-3; Nikonov AA, 2002, J CHEM ECOL, V28, P1075, DOI 10.1023/A:1015274104626; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Robertson HM, 2003, P NATL ACAD SCI USA, V100, P14537, DOI 10.1073/pnas.2335847100; Scott K, 2001, CELL, V104, P661, DOI 10.1016/S0092-8674(01)00263-X; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Shanbhag SR, 1999, INT J INSECT MORPHOL, V28, P377, DOI 10.1016/S0020-7322(99)00039-2; Shields VDC, 2001, J COMP PHYSIOL A, V186, P1135, DOI 10.1007/s003590000165; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; Stortkuhl KF, 2001, P NATL ACAD SCI USA, V98, P9381, DOI 10.1073/pnas.151105698; Strange PG, 2002, TRENDS PHARMACOL SCI, V23, P89, DOI 10.1016/S0165-6147(02)01993-4; *TNO, 2004, VOL COMP FOOD QUAL Q; UMANO K, 1992, J AGR FOOD CHEM, V40, P599, DOI 10.1021/jf00016a014; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vickers NJ, 2001, NATURE, V410, P466, DOI 10.1038/35068559; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Wetzel CH, 2001, P NATL ACAD SCI USA, V98, P9377, DOI 10.1073/pnas.151103998; Wilson RI, 2004, SCIENCE, V303, P366, DOI 10.1126/science.1090782	49	596	623	2	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					965	979		10.1016/j.cell.2004.05.012	http://dx.doi.org/10.1016/j.cell.2004.05.012			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210116	Bronze			2022-12-28	WOS:000222300200013
J	Cobb, JP; O'Keefe, GE				Cobb, JP; O'Keefe, GE			Injury research in the genomic era	LANCET			English	Review							TUMOR-NECROSIS-FACTOR; MULTIPLE ORGAN DYSFUNCTION; RESPIRATORY-DISTRESS-SYNDROME; GENE-EXPRESSION PROFILES; FACTOR-ALPHA; HUMAN ENDOTOXEMIA; SEVERE SEPSIS; SEPTIC SHOCK; L-SELECTIN; ANTIINFLAMMATORY CYTOKINE		Washington Univ, Dept Surg, Cellular Injury & Adaptat Lab, St Louis, MO 63110 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	Washington University (WUSTL); University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Cobb, JP (corresponding author), Washington Univ, Dept Surg, Cellular Injury & Adaptat Lab, St Louis, MO 63110 USA.	cobb@wustl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066946, R01GM059960] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066946, GM59960] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Buchman TG, 2002, NATURE, V420, P246, DOI 10.1038/nature01260; Buchman TG, 2001, SHOCK, V16, P248, DOI 10.1097/00024382-200116040-00002; BURTON JL, 1995, J LEUKOCYTE BIOL, V57, P317, DOI 10.1002/jlb.57.2.317; Callard R, 1999, IMMUNITY, V11, P507, DOI 10.1016/S1074-7613(00)80125-9; CALVANO SE, 2003, SHOCK, V19, P32; Chung TP, 2002, CRIT CARE MED, V30, pS51, DOI 10.1097/00003246-200201001-00007; CHUNG TP, 2003, SHOCK S1, V19, P33; Cobb J P, 2000, Surg Infect (Larchmt), V1, P207, DOI 10.1089/109629600750018132; Cobb JP, 2001, SHOCK, V15, P165; Cocks RA, 2000, RESUSCITATION, V45, P105, DOI 10.1016/S0300-9572(00)00176-3; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; DiSanto E, 1997, CYTOKINE, V9, P300, DOI 10.1006/cyto.1996.0169; Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465; Fernandez-Real JM, 2000, DIABETES, V49, P517, DOI 10.2337/diabetes.49.3.517; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Fitzwater J, 2003, J TRAUMA, V54, P959, DOI 10.1097/01.TA.0000029382.26295.AB; Freeman BD, 2001, AM J RESP CRIT CARE, V164, P190, DOI 10.1164/ajrccm.164.2.2011028; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guirao X, 1997, AM J PHYSIOL-ENDOC M, V273, pE1203, DOI 10.1152/ajpendo.1997.273.6.E1203; Hampton T, 2004, JAMA-J AM MED ASSOC, V291, P287, DOI 10.1001/jama.291.3.287; He YDD, 2001, NAT MED, V7, P658, DOI 10.1038/89022; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hughes MD, 2002, CONTROL CLIN TRIALS, V23, P703, DOI 10.1016/S0197-2456(02)00264-7; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; King RD, 2004, NATURE, V427, P247, DOI 10.1038/nature02236; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Laub MT, 2000, SCIENCE, V290, P2144, DOI 10.1126/science.290.5499.2144; Lawrie LC, 2001, LANCET ONCOL, V2, P270, DOI 10.1016/S1470-2045(00)00321-1; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584; Lin E, 1999, INTENS CARE MED, V25, P255, DOI 10.1007/s001340050832; Lin MT, 2004, CRIT CARE MED, V32, P569, DOI 10.1097/01.CCM.0000110878.49476.42; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Majetschak M, 1999, ANN SURG, V230, P207, DOI 10.1097/00000658-199908000-00011; Marshall JC, 2000, CRIT CARE MED, V28, P2646, DOI 10.1097/00003246-200007000-00080; Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086; Marx J, 2000, SCIENCE, V289, P1670, DOI 10.1126/science.289.5485.1670; Menges T, 2001, LANCET, V357, P1096, DOI 10.1016/S0140-6736(00)04311-7; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Mills PJ, 1997, BRAIN BEHAV IMMUN, V11, P333, DOI 10.1006/brbi.1997.0500; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Munford RS, 2001, AM J RESP CRIT CARE, V163, P316, DOI 10.1164/ajrccm.163.2.2007102; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; Nasraway SA, 1999, CRIT CARE MED, V27, P427, DOI 10.1097/00003246-199902000-00054; O'Keefe GE, 2002, J TRAUMA, V52, P817, DOI 10.1097/00005373-200205000-00001; OKeefe GE, 1997, ARCH SURG-CHICAGO, V132, P920; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIPER RD, 1997, SEPSIS MULTIORGAN FA, P189; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004; Rivera-Chavez FA, 2003, ANN SURG, V237, P408, DOI 10.1097/00000658-200303000-00016; Seely AJE, 2000, CRIT CARE MED, V28, P2193, DOI 10.1097/00003246-200007000-00003; Service RF, 2001, SCIENCE, V294, P2080, DOI 10.1126/science.294.5549.2080; Shannon MF, 2002, SCIENCE, V296, P666, DOI 10.1126/science.1062936; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Smirnova I, 2001, GENETICS, V158, P1657; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Spielmann S, 2001, ACTA ANAESTH SCAND, V45, P364, DOI 10.1034/j.1399-6576.2001.045003364.x; Stassen NA, 2002, SURGERY, V132, P289, DOI 10.1067/msy.2002.127167; Stephenson J, 1999, JAMA-J AM MED ASSOC, V282, P927, DOI 10.1001/jama.282.10.927; Strausbaugh HJ, 1999, NAT MED, V5, P1057, DOI 10.1038/12497; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200; TILG H, 1994, BLOOD, V83, P113; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Van den Berghe G, 2001, BEST PRACT RES CL EN, V15, P405, DOI 10.1053/beem.2001.0160; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vastag B, 2003, JAMA-J AM MED ASSOC, V289, P155, DOI 10.1001/jama.289.2.155; Waterer GW, 2001, AM J RESP CRIT CARE, V163, P1599, DOI 10.1164/ajrccm.163.7.2011088; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Witzmann FA, 2002, AM J PHYSIOL-GASTR L, V282, pG735, DOI 10.1152/ajpgi.00510.2001; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	104	72	80	2	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2076	2083		10.1016/S0140-6736(04)16460-X	http://dx.doi.org/10.1016/S0140-6736(04)16460-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207961				2022-12-28	WOS:000222159800025
J	Laffort, C; Le Deist, F; Favre, M; Caillat-Zucman, S; Radford-Weiss, I; Debre, M; Fraitag, S; Blanche, S; Cavazzana-Calvo, M; Saint Basile, GD; de Villartay, JP; Giliani, S; Orth, G; Casanova, JL; Bodemer, C; Fischer, A				Laffort, C; Le Deist, F; Favre, M; Caillat-Zucman, S; Radford-Weiss, I; Debre, M; Fraitag, S; Blanche, S; Cavazzana-Calvo, M; Saint Basile, GD; de Villartay, JP; Giliani, S; Orth, G; Casanova, JL; Bodemer, C; Fischer, A			Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gamma c cytokine receptor subunit or JAK-3 deficiency	LANCET			English	Article							COMBINED IMMUNODEFICIENCY; MUTATIONS	Haemopoietic stem-cell transplantation is a life-saving treatment for severe combined immune deficiency. However, there has been little long-term follow-up of this treatment. There is evidence for the persistance of partial immunodeficiency associated with significant infections, including severe human papillomavirus (HPV) disease. We did a retrospective analysis of severe HPV disease in a group of 41 patients with severe combined immune deficiency from one centre who were alive 10 years or longer after haemopoietic stem-cell transplantation. Nine of the 41 patients had extensive chronic HPV disease limited to the skin, with a median onset at 8 years after transplantation. Four had lesions typical of epidermodysplasia verruciformis, a rare genodermatosis. Transplant characteristics, immune status, and chimerism of these nine patients did not differ significantly from those of the other patients. The nine patients with HPV disease had severe combined immune deficiency associated with either common gammac receptor cytokine subunit or Janus kinase-3 (JAK-3) deficiency. By contrast, patients with other forms of severe combined immune deficiency did not have any signs of HPV disease. That genetic causes are the only predisposing factor to be identified for severe combined immune deficiency, suggests that natural-killer cells or gammac/JAK-3-dependent signalling in keratinocytes could have a role in anti-HPV immunity.	Hop Necker Enfants Malad, INSERM, U429, F-75743 Paris 15, France; Hop Necker Enfants Malad, Unite Immunol Hematol & Rhumatol Pediat, F-75743 Paris 15, France; Hop Necker Enfants Malad, CHU, INSERM, U550, F-75743 Paris 15, France; Hop Necker Enfants Malad, Serv Dermatol Pediat, F-75743 Paris 15, France; Hop Necker Enfants Malad, Immunol Lab, F-75743 Paris 15, France; Hop Necker Enfants Malad, Lab Cytogenet, F-75743 Paris 15, France; Hop Necker Enfants Malad, Lab Anatomopathol, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Biotherapie, F-75743 Paris 15, France; Univ Brescia, Inst Med Mol Angelo Nocivelli, I-25121 Brescia, Italy; Inst Pasteur, Unite Papillomavirus, Paris, France; Hop Necker Enfants Malad, Lab Immunol Pediat, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Brescia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Le Deist, F (corresponding author), Hop Necker Enfants Malad, INSERM, U429, 149 Rue Sevres, F-75743 Paris 15, France.	ledeist@necker.fr	ORTH, Gérard C/C-2518-2009; de Villartay, jean pierre/H-9353-2017; Giliani, Silvia/AAX-8843-2020; Casanova, Jean-Laurent/I-3418-2017; de Saint Basile, Genevieve/G-9731-2017	de Villartay, jean pierre/0000-0001-5987-0463; Giliani, Silvia/0000-0001-8137-4642; Casanova, Jean-Laurent/0000-0002-7782-4169; Caillat-Zucman, Sophie/0000-0002-4535-3550; de Saint Basile, Genevieve/0000-0002-1913-5269				Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Fischer A, 2001, LANCET, V357, P1863, DOI 10.1016/S0140-6736(00)04959-X; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Nishio H, 2001, J ANAT, V198, P581, DOI 10.1046/j.1469-7580.2001.19850581.x; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; Ruckert R, 2000, J IMMUNOL, V165, P2240, DOI 10.4049/jimmunol.165.4.2240	7	112	113	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2051	2054		10.1016/S0140-6736(04)16457-X	http://dx.doi.org/10.1016/S0140-6736(04)16457-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207958				2022-12-28	WOS:000222159800014
J	Tuzzolino, AJ; Economou, TE; Clark, BC; Tsou, P; Brownlee, DE; Green, SF; McDonnell, JAM; McBride, N; Colwell, MTSH				Tuzzolino, AJ; Economou, TE; Clark, BC; Tsou, P; Brownlee, DE; Green, SF; McDonnell, JAM; McBride, N; Colwell, MTSH			Dust measurements in the coma of comet 81P/Wild 2 by the Dust Flux Monitor Instrument	SCIENCE			English	Article							P/HALLEY; ENCOUNTER; NUCLEUS	We present measurements of the dust particle flux and mass distribution from the Stardust Dust Flux Monitor Instrument (DFMI) throughout the flyby of comet 81P/Wild 2. In the particle mass regime from 10(-14) to 10(-7) kilograms, the spacecraft encountered regions of intense swarms of particles, together with bursts of activity corresponding to clouds of particles only a few hundred meters across. This fine-scale structure can be explained by particle fragmentation. We estimate that 2800+/-500 particles of diameter 15 micrometers or larger impacted the aerogel collectors, the largest being similar to6x10(-7) kilograms, which dominates the total collected mass.	Univ Chicago, Enrico Fermi Inst, Lab Astrophys & Space Res, Chicago, IL 60637 USA; Lockheed Martin Astronaut, Denver, CO 80201 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Washington, Dept Astron & Astrophys, Seattle, WA 98195 USA; Open Univ, Planetary & Space Sci Res Inst, Milton Keynes MK7 6AA, Bucks, England	University of Chicago; Lockheed Martin; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Washington; University of Washington Seattle; Open University - UK	Economou, TE (corresponding author), Univ Chicago, Enrico Fermi Inst, Lab Astrophys & Space Res, 9333 E 56th St, Chicago, IL 60637 USA.	tecon@tecon.uchicago.edu	Green, Simon F/C-7408-2009	Green, Simon F/0000-0002-9153-9786				CLARK BC, UNPUB; Crifo JF, 2002, EARTH MOON PLANETS, V90, P227, DOI 10.1023/A:1021501509992; Crifo JF, 1999, ICARUS, V138, P85, DOI 10.1006/icar.1999.6051; Fulle M, 2000, ASTRON J, V119, P1968, DOI 10.1086/301285; HANNER M, COMMUNICATION; Levasseur-Regourd AC, 1999, ASTRON ASTROPHYS, V348, P636; MAZETS EP, 1987, ASTRON ASTROPHYS, V187, P699; MCDONNELL JAM, 1987, ASTRON ASTROPHYS, V187, P719; MCDONNELL JAM, 1991, COMETS POST HALLEY E, V2, P1043; NEWBURN RL, UNPUB; Rodionov AV, 2002, PLANET SPACE SCI, V50, P983, DOI 10.1016/S0032-0633(02)00047-8; Sekanina Z, 2004, SCIENCE, V304, P1769, DOI 10.1126/science.1098388; SIMKPSON JA, 1987, EUROPEAN SPACE AGENC, V278, P391; SIMPSON JA, 1986, NATURE, V321, P278, DOI 10.1038/321278a0; SIMPSON JA, 1987, ASTRON ASTROPHYS, V187, P742; Soderblom LA, 2004, ICARUS, V167, P4, DOI 10.1016/j.icarus.2003.07.008; THOMAS N, 1987, ASTRON ASTROPHYS, V187, P843; Tsou P, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002109; Tuzzolino AJ, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002086; VAISBERG OL, 1987, ASTRON ASTROPHYS, V187, P753	20	128	130	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1776	1780		10.1126/science.1098759	http://dx.doi.org/10.1126/science.1098759			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205527				2022-12-28	WOS:000222089500038
J	Boynton, PM; Wood, GW; Greenhalgh, T				Boynton, PM; Wood, GW; Greenhalgh, T			Hands-on guide to questionnaire research - Reaching beyond the white middle classes	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, Dept Primary Care & Populat, London N19 5LW, England; Univ Birmingham, Dept Educ, Birmingham B15 2TT, W Midlands, England	University of London; University College London; University of Birmingham	Boynton, PM (corresponding author), UCL, Dept Primary Care & Populat, London N19 5LW, England.	p.boynton@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Boynton, Petra/0000-0001-6699-2266				BELSON WA, 1981, DESIGN UNDERSTANDING; Boston NK, 2001, FAM PRACT, V18, P141, DOI 10.1093/fampra/18.2.141; Boynton PM, 2004, BMJ-BRIT MED J, V328, P1372, DOI 10.1136/bmj.328.7452.1372; Boynton PM, 2001, PSYCHOLOGIST, V14, P14; BOYNTON PM, IN PRESS RES COMPANI; Boynton PM, 2004, BMJ, V328; Bullinger M, 1998, J CLIN EPIDEMIOL, V51, P913, DOI 10.1016/S0895-4356(98)00082-1; Dumas JE, 1999, APPL PREV PSYCHOL, V8, P175, DOI 10.1016/S0962-1849(05)80076-9; Fish J, 1999, FEM PSYCHOL, V9, P229, DOI 10.1177/0959353599009002022; Greenhalgh T, 1998, BRIT MED J, V316, P978, DOI 10.1136/bmj.316.7136.978; Herpertz S, 1998, DIABETES CARE, V21, P1110, DOI 10.2337/diacare.21.7.1110; HoutkoopSteenstra H., 2000, INTERACTION STANDARD; LEUDAR I, 1997, CRITICAL SOCIAL PSYC; Mackenbach JP, 1996, AM J PUBLIC HEALTH, V86, P706, DOI 10.2105/AJPH.86.5.706; NAIK PC, 1994, BRIT MED J, V308, P248, DOI 10.1136/bmj.308.6923.248; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN; Osgood C.E., 1975, CROSS CULTURAL UNIVE; ROSNOW RL, 1999, PEOPLE STUDYING PEOP; Sapsford R, 1999, SURVEY RES; WADSWORTH J, 1993, J ROY STAT SOC A STA, V156, P407, DOI 10.2307/2983066; Wood Fiona, 2002, Health Expect, V5, P282, DOI 10.1046/j.1369-6513.2002.00186.x	21	43	44	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1433	1436		10.1136/bmj.328.7453.1433	http://dx.doi.org/10.1136/bmj.328.7453.1433			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	830IB	15191985	Green Published			2022-12-28	WOS:000222114400031
J	An, W; Kim, J; Roeder, RG				An, W; Kim, J; Roeder, RG			Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53	CELL			English	Article							HISTONE H3; PROTEIN METHYLTRANSFERASE; DNA-BINDING; METHYLATION; ACETYLATION; CHROMATIN; COACTIVATORS; PHOSPHORYLATION; RECRUITMENT; CBP	Transcriptional coactivators that modify histones represent an increasingly important group of regulatory factors, although their ability to modify other factors as well precludes common assumptions that they necessarily act by histone modification. In an extension of previous studies showing a role for acetyltransferase p300/CBP in p53 function, we have used systems reconstituted with recombinant chromatin templates and (co)activators to demonstrate (1) the additional involvement of protein arginine methyltransferases PRMT1 and CARM1 in p53 function; (2) both independent and ordered cooperative functions of p300, PRMT1, and CARM1; and (3) mechanisms that involve direct interactions with p53 and, most importantly, obligatory modifications of corresponding histone substrates. ChIP analyses have confirmed the ordered accumulation of these (and other) coactivators and cognate histone modifications on the GADD45 gene following ectopic p53 expression and/or UV irradiation. These studies thus define diverse cofactor functions, as well as underlying mechanisms involving distinct histone modifications, in p53-dependent gene activation.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA.	roeder@mail.rockefeller.edu	zhang, shijun/K-3688-2013; Kim, Jaehoon/G-2711-2011	Kim, Jaehoon/0000-0003-4035-0438				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; An WJ, 2004, METHOD ENZYMOL, V377, P460; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Scolnick DM, 1997, CANCER RES, V57, P3693; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	38	393	409	0	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					735	748		10.1016/j.cell.2004.05.009	http://dx.doi.org/10.1016/j.cell.2004.05.009			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186775	Bronze			2022-12-28	WOS:000222048400007
J	Lu, PJ				Lu, PJ			Early precision compound machine from ancient China	SCIENCE			English	Article									Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University	Lu, PJ (corresponding author), Harvard Univ, Dept Phys, 17 Oxford St, Cambridge, MA 02138 USA.	plu@fas.harvard.edu	Lu, Peter J/G-1971-2011	Lu, Peter J/0000-0003-1489-5725				[Anonymous], 1991, XICHUAN XIASI CHUNQI; GOLAS PJ, 2000, CHINA EMPIRE CIVILIZ, P178; GULLBERG J, 1997, MATH BIRTH NUMBERS, P57; HEATH TL, 2002, WORKS ARCHIMEDES, P151; HUMPHREY JW, 1998, GREEK ROMAN TECHNOLO, P46; JIA E, 1993, ZHONGGUO YUQI QUANJI, V3, P37; LI B, 1999, ZHONGHUA GUOBAO SHAA, P124; NEEDHAM J, 1962, SCI CIVILIZATION C 2, V4, P111; RAWSON J, 1995, CHINESE JADE NEOLITH, P20; SALMONY A, 1952, ARCHAIC CHINESE JADE, P204; SO J, 1995, E ZHOU RITUAL BRONZE, P423; YAO Q, 1996, WUGUO WANGSHI YUQI, P26; 1956, SHOUXIAN CAI HOU MU	13	4	5	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1638	1638		10.1126/science.1096588	http://dx.doi.org/10.1126/science.1096588			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192220				2022-12-28	WOS:000221934300040
J	Pierrehumbert, RT				Pierrehumbert, RT			High levels of atmospheric carbon dioxide necessary for the termination of global glaciation	NATURE			English	Article							EARTH; CYCLE	The possibility that the Earth suffered episodes of global glaciation as recently as the Neoproterozoic period, between about 900 and 543 million years ago, has been widely discussed(1-3). Termination of such 'hard snowball Earth' climate states has been proposed to proceed from accumulation of carbon dioxide in the atmosphere(4). Many salient aspects of the snowball scenario depend critically on the threshold of atmospheric carbon dioxide concentrations needed to trigger deglaciation(2,5). Here I present simulations with a general circulation model, using elevated carbon dioxide levels to estimate this deglaciation threshold. The model simulates several phenomena that are expected to be significant in a 'snowball Earth' scenario, but which have not been considered in previous studies with less sophisticated models, such as a reduction of vertical temperature gradients in winter, a reduction in summer tropopause height, the effect of snow cover and a reduction in cloud greenhouse effects. In my simulations, the system remains far short of deglaciation even at atmospheric carbon dioxide concentrations of 550 times the present levels (0.2 bar of CO2). I find that at much higher carbon dioxide levels, deglaciation is unlikely unless unknown feedback cycles that are not captured in the model come into effect.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Pierrehumbert, RT (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	rtp1@geosci.uchicago.edu		Pierrehumbert, Raymond/0000-0002-5887-1197				CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; Chandler MA, 2000, J GEOPHYS RES-ATMOS, V105, P20737, DOI 10.1029/2000JD900221; Donnadieu Y, 2003, EARTH PLANET SC LETT, V208, P101, DOI 10.1016/S0012-821X(02)01152-4; Forget F, 1997, SCIENCE, V278, P1273, DOI 10.1126/science.278.5341.1273; Goodman JC, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002073; Goodman JC, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001471; Higgins JA, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000403; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Jacob R. L., 1997, LOW FREQUENCY VARIAB; Jenkins GS, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD001582; KASTING JF, 1984, ICARUS, V57, P335, DOI 10.1016/0019-1035(84)90122-2; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; Kiehl JT, 1998, J CLIMATE, V11, P1131, DOI 10.1175/1520-0442(1998)011<1131:TNCFAR>2.0.CO;2; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; Pierrehumbert RT, 2002, NATURE, V419, P191, DOI 10.1038/nature01088; Poulsen CJ, 2001, GEOPHYS RES LETT, V28, P1575, DOI 10.1029/2000GL012058; Tajika E, 2003, EARTH PLANET SC LETT, V214, P443, DOI 10.1016/S0012-821X(03)00396-0; WALKER JCG, 2001, EARTH SYSTEM PROCESS, P110; WARREN SG, 2002, J GEOPHYS RES C, V107, DOI DOI 10.1029/2001/JC001123; ZHANG YX, 1993, EARTH PLANET SC LETT, V117, P331, DOI 10.1016/0012-821X(93)90088-Q	22	128	130	3	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					646	649		10.1038/nature02640	http://dx.doi.org/10.1038/nature02640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190348				2022-12-28	WOS:000221912600036
J	Dahal, K				Dahal, K			Legal abortion in Nepal and women in prison	LANCET			English	Editorial Material									Tribhuvan Univ, Inst Med, Kathmandu, Nepal	Tribhuvan University; Institute of Medicine (IoM) - Nepal	Dahal, K (corresponding author), Tribhuvan Univ, Inst Med, Kathmandu, Nepal.	khagenvikram@hotmail.com						*CRLP, 2002, CTR REPR LAW POL CRL, P9; *CTR RES ENV HLTH, 2003, REPR HLTH RES POL BR; *DHS, 20023 DHS MIN HLTH; *MAT HOSP, 2004, HOSP REC SAF AB CLIN; TAMANG A, 1994, DETERMINANTS ABORTIO	5	4	4	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1905	1905		10.1016/S0140-6736(04)16364-2	http://dx.doi.org/10.1016/S0140-6736(04)16364-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826IH	15185709				2022-12-28	WOS:000221822300028
J	Leibfried, D; Barrett, MD; Schaetz, T; Britton, J; Chiaverini, J; Itano, WM; Jost, JD; Langer, C; Wineland, DJ				Leibfried, D; Barrett, MD; Schaetz, T; Britton, J; Chiaverini, J; Itano, WM; Jost, JD; Langer, C; Wineland, DJ			Toward Heisenberg-limited spectroscopy with multiparticle entangled states	SCIENCE			English	Article							TRAPPED IONS; PROJECTION NOISE; ENSEMBLE; LIGHT; ATOMS	The precision in spectroscopy of any quantum system is fundamentally limited by the Heisenberg uncertainty relation for energy and time. For N systems, this limit requires that they be in a quantum-mechanically entangled state. We describe a scalable method of spectroscopy that can potentially take full advantage of entanglement to reach the Heisenberg limit and has the practical advantage that the spectroscopic information is transferred to states with optimal protection against readout noise. We demonstrate our method experimentally with three beryllium ions. The spectroscopic sensitivity attained is 1.45(2) times as high as that of a perfect experiment with three non-entangled particles.	Natl Inst Stand & Technol, Boulder, CO 80305 USA	National Institute of Standards & Technology (NIST) - USA	Leibfried, D (corresponding author), Natl Inst Stand & Technol, 325 Broadway, Boulder, CO 80305 USA.	dil@boulder.nist.gov	Barrett, Murray D/G-2732-2012; Itano, Wayne/AAV-8781-2020; Jost, John D/F-4701-2010	Barrett, Murray D/0000-0002-1483-8029; jost, john/0000-0002-1698-8602; Britton, Joe/0000-0001-8103-7347				ANDRE A, PREPRINT; Bollinger JJ, 1996, PHYS REV A, V54, pR4649, DOI 10.1103/PhysRevA.54.R4649; Bouyer P, 1997, PHYS REV A, V56, pR1083, DOI 10.1103/PhysRevA.56.R1083; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83, DOI 10.1109/TIM.1982.6312526; Geremia JM, 2004, SCIENCE, V304, P270, DOI 10.1126/science.1095374; Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319; Heisenberg W., 1927, Z PHYS J PHYS, V43, P172; HOLLAND MJ, 1993, PHYS REV LETT, V71, P1355, DOI 10.1103/PhysRevLett.71.1355; Huelga SF, 1997, PHYS REV LETT, V79, P3865, DOI 10.1103/PhysRevLett.79.3865; ITANO WM, 1993, PHYS REV A, V47, P3554, DOI 10.1103/PhysRevA.47.3554; King BE, 1998, PHYS REV LETT, V81, P1525, DOI 10.1103/PhysRevLett.81.1525; KITAGAWA M, 1993, PHYS REV A, V47, P5138, DOI 10.1103/PhysRevA.47.5138; Kuzmich A, 1997, PHYS REV LETT, V79, P4782, DOI 10.1103/PhysRevLett.79.4782; Leibfried D, 2003, NATURE, V422, P412, DOI 10.1038/nature01492; Meyer V, 2001, PHYS REV LETT, V86, P5870, DOI 10.1103/PhysRevLett.86.5870; MILBURN GJ, 2001, SCALABLE QUANTUM COM, P31; Molmer K, 1999, PHYS REV LETT, V82, P1835, DOI 10.1103/PhysRevLett.82.1835; Ramsey N. F., 1956, MOL BEAMS; Rowe MA, 2002, QUANTUM INF COMPUT, V2, P257; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Steane A, 1996, P ROY SOC A-MATH PHY, V452, P2551, DOI 10.1098/rspa.1996.0136; Wang XG, 2001, PHYS REV LETT, V86, P3907, DOI 10.1103/PhysRevLett.86.3907; Wineland DJ, 2003, PHILOS T R SOC A, V361, P1349, DOI 10.1098/rsta.2003.1205; WINELAND DJ, 1994, PHYS REV A, V50, P67, DOI 10.1103/PhysRevA.50.67; YURKE B, 1986, PHYS REV A, V33, P4033, DOI 10.1103/PhysRevA.33.4033	28	435	441	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1476	1478		10.1126/science.1097576	http://dx.doi.org/10.1126/science.1097576			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178794				2022-12-28	WOS:000221795800035
J	Forsgren, E; Amundsen, T; Borg, AA; Bjelvenmark, J				Forsgren, E; Amundsen, T; Borg, AA; Bjelvenmark, J			Unusually dynamic sex roles in a fish	NATURE			English	Article							POTENTIAL REPRODUCTIVE RATES; PARENTAL INVESTMENT; MATING SYSTEM; MATE CHOICE; SELECTION; COMPETITION; EVOLUTION; CARE; POPULATION; DIRECTION	Sex roles are typically thought of as being fixed for a given species. In most animals males compete for females, whereas the females are more reluctant to mate. Therefore sexual selection usually acts most strongly on males(1,2). This is explained by males having a higher potential reproductive rate than females, leading to more males being sexually active (a male-biased operational sex ratio)(3,4). However, what determines sex roles and the strength of sexual selection is a controversial and much debated question(3,5-10). In this large-scale field study, we show a striking temporal plasticity in the mating competition of a fish (two-spotted goby, Gobiusculus flavescens). Over the short breeding season fierce male-male competition and intensive courtship behaviour in males were replaced by female-female competition and actively courting females. Hence, sex role reversal occurred rapidly. This is the first time that a shift in sex roles has been shown in a vertebrate. The shift might be explained by a large decline in male abundance, strongly skewing the sex ratio towards females. Notably, the sex role reversal did not occur at an equal operational sex ratio, contrary to established sex role theory(3,4).	Univ Gothenburg, Dept Marine Ecol, Kristineberg Marine Res Stn, SE-45034 Fiskebackskil, Sweden; Norwegian Univ Sci & Technol, Dept Biol, NO-7491 Trondheim, Norway	University of Gothenburg; Norwegian University of Science & Technology (NTNU)	Forsgren, E (corresponding author), Univ Gothenburg, Dept Marine Ecol, Kristineberg Marine Res Stn, SE-45034 Fiskebackskil, Sweden.	elisabet.forsgren@bio.ntnu.no		Amundsen, Trond/0000-0003-4261-0555				AHNESJO I, 1995, BEHAV ECOL, V6, P229, DOI 10.1093/beheco/6.2.229; Ahnesjo I, 2001, BEHAV ECOL, V12, P397, DOI 10.1093/beheco/12.4.397; ALMADA VC, 1995, ANIM BEHAV, V49, P1125, DOI 10.1006/anbe.1995.0142; Amundsen T, 2001, P NATL ACAD SCI USA, V98, P13155, DOI 10.1073/pnas.211439298; Andersson Malte, 1994; Bjelvenmark J, 2003, BEHAVIOUR, V140, P55, DOI 10.1163/156853903763999890; Borg AA, 2002, OIKOS, V98, P105, DOI 10.1034/j.1600-0706.2002.980111.x; CLUTTONBROCK TH, 1992, Q REV BIOL, V67, P437, DOI 10.1086/417793; CLUTTONBROCK TH, 1991, NATURE, V351, P58; Darwin C., 1871, P475; EMLEN ST, 1977, SCIENCE, V197, P215, DOI 10.1126/science.327542; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; Garcia CM, 1998, J FISH BIOL, V53, P104, DOI 10.1111/j.1095-8649.1998.tb01021.x; Godwin J, 1995, B MAR SCI, V57, P637; GWYNNE DT, 1993, ECOLOGY, V74, P1406, DOI 10.2307/1940070; GWYNNE DT, 1990, NATURE, V346, P172, DOI 10.1038/346172a0; Gwynne DT, 1998, BEHAV ECOL SOCIOBIOL, V42, P157, DOI 10.1007/s002650050426; Kokita T, 1998, J ETHOL, V16, P81, DOI 10.1007/BF02769286; Kokko H, 2001, ECOL LETT, V4, P159, DOI 10.1046/j.1461-0248.2001.00212.x; Kokko H, 2002, PHILOS T R SOC B, V357, P319, DOI 10.1098/rstb.2001.0926; KVARNEMO C, 1994, P ROY SOC B-BIOL SCI, V256, P151, DOI 10.1098/rspb.1994.0063; Kvarnemo C, 1996, TRENDS ECOL EVOL, V11, P404, DOI 10.1016/0169-5347(96)10056-2; KYNARD BE, 1978, BEHAVIOUR, V67, P178, DOI 10.1163/156853978X00323; Lindstrom K, 2001, AM NAT, V158, P64, DOI 10.1086/320867; MARCONATO A, 1993, BEHAV ECOL SOCIOBIOL, V32, P229; Parker GA, 1996, P ROY SOC B-BIOL SCI, V263, P315, DOI 10.1098/rspb.1996.0048; Trivers R., 1972, SEXUAL SELECTION DES, P139; VINCENT A, 1992, TRENDS ECOL EVOL, V7, P237, DOI 10.1016/0169-5347(92)90052-D; Vincent A, 1998, BEHAVIORAL ECOLOGY AND CONSERVATION BIOLOGY, P209; Wade MJ, 2002, AM NAT, V160, P285, DOI 10.1086/341520	30	211	212	3	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					551	554		10.1038/nature02562	http://dx.doi.org/10.1038/nature02562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175750				2022-12-28	WOS:000221767700037
J	Vollaard, AM; Ali, S; van Asten, HAGH; Widjaja, S; Visser, LG; Surjadi, C; van Dissel, JT				Vollaard, AM; Ali, S; van Asten, HAGH; Widjaja, S; Visser, LG; Surjadi, C; van Dissel, JT			Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEKONG-DELTA; CHILDREN; VACCINE; IMMUNIZATION; COMMUNITY; EPIDEMIC; VIETNAM; INDIA	Context The proportion of paratyphoid fever cases to typhoid fever cases may change due to urbanization and increased dependency on food purchased from street vendors. For containment of paratyphoid a different strategy may be needed than for typhoid, because risk factors for disease may not coincide and current typhoid vaccines do not protect against paratyphoid fever. Objective To determine risk factors for typhoid and paratyphoid fever in an endemic area. Design, Setting, and Participants Community-based case-control study conducted from June 2001 to February 2003 in hospitals and outpatient health centers in Jatinegara district, Jakarta, Indonesia. Enrolled participants were 1019 consecutive patients with fever lasting 3 or more days, from which 69 blood culture-confirmed typhoid cases, 24 confirmed paratyphoid cases, and 289 control patients with fever but without Salmonella bacteremia were interviewed, plus 378 randomly selected community controls. Main Outcome Measures Blood culture-confirmed typhoid or paratyphoid fever; risk factors for both diseases. Results In 1019 fever patients we identified 88 (9%) Salmonella typhi and 26 (3%) Salmonella paratyphi A infections. Paratyphoid fever among cases was independently associated with consumption of food from street vendors (comparison with community controls: odds ratio [OR], 3.34; 95% confidence interval [CI], 1.41-7.91; with fever controls: OR, 5.17; 95% CI, 2.12-12.60) and flooding (comparison with community controls: OR, 4.52; 95% CI, 1.90-10.73; with fever controls: OR, 3.25; 95% CI, 1.31-8.02). By contrast, independent risk factors for typhoid fever using the community control group were mostly related to the household, ie, to recent typhoid fever in the household (OR, 2.38; 95% CI, 1.03-5.48); no use of soap for handwashing (OR, 1.91; 95% CI, 1.06-3.46); sharing food from the same plate (OR, 1.93; 95% CI, 1.10-3.37), and no toilet in the household (OR, 2.20; 95% CI, 1.06-4.55). Also, typhoid fever was associated with young age in years (OR, 0.96; 95% CI, 0.94-0.98). In comparison with fever controls; risk factors for typhoid fever were use of ice cubes (OR 2.27; 95% CI, 1.31-3.93) and female sex (OR, 1.79;95% CI, 1.04-3.06). Fecal contamination of drinking water was not associated with typhoid or paratyphoid fever. We did not detect fecal carriers among food handlers in the households. Conclusions In Jakarta, typhoid and paratyphoid fever are associated with distinct routes of transmission, with the risk factors for disease either mainly within the household (typhoid) or outside the household (paratyphoid).	Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Atma Jaya Catholic Univ, Fac Med, Dept Biol, Jakarta, Indonesia; Atma Jaya Catholic Univ, Ctr Hlth Res, Jakarta, Indonesia; Atma Jaya Catholic Univ, Dept Internal Med, Jakarta, Indonesia; Univ Med Ctr Nijmegen, Inst Int Hlth, Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University Katolik Indonesia Atma Jaya; University Katolik Indonesia Atma Jaya; University Katolik Indonesia Atma Jaya; Radboud University Nijmegen	van Dissel, JT (corresponding author), Leiden Univ, Med Ctr, Dept Infect Dis, C5-P,POB 9600, NL-2300 RC Leiden, Netherlands.	j.t.van_dissel@lumc.nl	van Asten, Henri/AID-4234-2022; Visser, Leo/AAH-5755-2021	Visser, Leo/0000-0002-3600-9782; Ali, Soegianto/0000-0002-9972-8696				Arya SC, 1995, VACCINE, V13, P1727, DOI 10.1016/0264-410X(96)81276-X; Bhan MK, 2002, J INFECT DIS, V186, P1857, DOI 10.1086/345762; BLACK RE, 1985, B WORLD HEALTH ORGAN, V63, P899; BODHIDATTA L, 1987, REV INFECT DIS, V9, P841; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Castillo M. T. G., 1995, SE ASIAN J TROP M S2, V26, P39; Christie AB, 1987, INFECT DIS EPIDEMIOL, V4th; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; DICKENS DL, 1985, JAMA-J AM MED ASSOC, V253, P3141, DOI 10.1001/jama.253.21.3141; Estrada-Garcia T, 2002, EPIDEMIOL INFECT, V129, P223, DOI 10.1017/S0950268802007070; FERRECCIO C, 1984, J PEDIATR-US, V104, P899, DOI 10.1016/S0022-3476(84)80492-8; Gasem MH, 2001, TROP MED INT HEALTH, V6, P484, DOI 10.1046/j.1365-3156.2001.00734.x; KING CC, 1989, INT J EPIDEMIOL, V18, P254, DOI 10.1093/ije/18.1.254; Koo D, 1996, EPIDEMIOL INFECT, V116, P121, DOI 10.1017/S0950268800052341; Lin FYC, 2000, AM J TROP MED HYG, V62, P644, DOI 10.4269/ajtmh.2000.62.644; Luby SP, 1998, EPIDEMIOL INFECT, V120, P129, DOI 10.1017/S0950268897008558; Luxemburger C, 2001, T ROY SOC TROP MED H, V95, P19, DOI 10.1016/S0035-9203(01)90318-9; Mermin JH, 1999, J INFECT DIS, V179, P1416, DOI 10.1086/314766; Pang T, 1998, TRENDS MICROBIOL, V6, P131, DOI 10.1016/S0966-842X(98)01236-0; Parry CM, 1999, J CLIN MICROBIOL, V37, P2882, DOI 10.1128/JCM.37.9.2882-2886.1999; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Saha MR, 2002, INDIAN J MED RES, V115, P46; Saha SK, 2001, PEDIATR INFECT DIS J, V20, P521, DOI 10.1097/00006454-200105000-00010; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; Sood S, 1999, EMERG INFECT DIS, V5, P483, DOI 10.3201/eid0503.990329; Sun GW, 1996, J CLIN EPIDEMIOL, V49, P907, DOI 10.1016/0895-4356(96)00025-X; Swaddiwudhipong Witaya, 2001, Journal of the Medical Association of Thailand, V84, P1513; Tankhiwale SS, 2003, INDIAN J MED RES, V117, P10; Velema JP, 1997, TROP MED INT HEALTH, V2, P1088, DOI 10.1046/j.1365-3156.1997.d01-179.x; Wain J, 2001, J CLIN MICROBIOL, V39, P1571, DOI 10.1128/JCM.39.4.1571-1576.2001; WHO (World Health Organisation), 1997, GUID DRINK WAT QUAL	32	184	201	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2607	2615		10.1001/jama.291.21.2607	http://dx.doi.org/10.1001/jama.291.21.2607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173152	Bronze			2022-12-28	WOS:000221738800024
J	Narayan, V; Benjamin, E; Gregg, EW; Norris, SL; Engelgau, MM				Narayan, V; Benjamin, E; Gregg, EW; Norris, SL; Engelgau, MM			Diabetes translation research: Where are we and where do we want to be?	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PHYSICIANS; HEALTH MAINTENANCE ORGANIZATION; IMPROVE GLYCEMIC CONTROL; QUALITY-OF-CARE; GENERAL-PRACTICE; COMPLEXITY SCIENCE; PRACTICE GUIDELINES; CLINICAL CARE; MANAGED CARE	Translation research transforms currently available knowledge into useful measures for everyday clinical and public health practice. We review the progress in diabetes translation research and identify future challenges and opportunities in this field. Several promising interventions to optimize implementation of efficacious diabetes treatments are available. Many of these interventions, singly or in combination, need to be more formally tested in larger randomized or quasi-experimental practical trials using outcomes of special interest to patients (for example, patient satisfaction and quality of life) and policymakers (for example, cost and cost-effectiveness). The long-term outcomes (such as morbidity, mortality, quality of life, and costs) of strategies aimed at improving diabetes care must be assessed. Translation research also needs to incorporate ways of studying complex systems of care. The challenges and opportunities offered by translation research are tremendous.	CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Narayan, V (corresponding author), CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Mailstop K-10,4770 Buford Highway NE, Atlanta, GA 30341 USA.			Gregg, Edward/0000-0003-2381-6822				ADELMAN AM, 1999, CLIN DIABETES, V16, P154; Anderson GM, 1996, CAN MED ASSOC J, V154, P1013; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P965; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Benjamin EM, 1999, DIABETES CARE, V22, P1672, DOI 10.2337/diacare.22.10.1672; Bernard AM, 1999, DIABETES CARE, V22, P661, DOI 10.2337/diacare.22.5.661; Branger PJ, 1999, INT J MED INFORM, V53, P133, DOI 10.1016/S1386-5056(98)00154-3; Chin MH, 1998, DIABETES CARE, V21, P1090, DOI 10.2337/diacare.21.7.1090; Curb JD, 2002, DIABETES CARE, V25, P386; Dalewitz J, 2000, AM J MED QUAL, V15, P16, DOI 10.1177/106286060001500104; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Dickey LL, 1996, ARCH FAM MED, V5, P399, DOI 10.1001/archfami.5.7.399; Drass J, 1998, DIABETES CARE, V21, P1282, DOI 10.2337/diacare.21.8.1282; Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035; Etzwiler DD, 1997, DIABETES EDUCATOR, V23, P569, DOI 10.1177/014572179702300509; FARMER A, 1990, BRIT J GEN PRACT, V40, P56; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; Fox C H, 1998, Fam Med, V30, P441; Fraser SW, 2001, BRIT MED J, V323, P799, DOI 10.1136/bmj.323.7316.799; Friedman N M, 1998, Eff Clin Pract, V1, P5; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Garfield SA, 2003, DIABETES CARE, V26, P2670, DOI 10.2337/diacare.26.9.2670; GLASGOW RE, 1992, PATIENT EDUC COUNS, V19, P61, DOI 10.1016/0738-3991(92)90102-O; Glasgow RE, 1997, PATIENT EDUC COUNS, V32, P175, DOI 10.1016/S0738-3991(97)00039-6; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Grol R, 2001, MED CARE, V39, pII46; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; Halbert RJ, 1999, DIABETES CARE, V22, P752, DOI 10.2337/diacare.22.5.752; Helseth LD, 1999, J FAM PRACTICE, V48, P37; Hiss RG, 1996, ANN INTERN MED, V124, P146, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00012; Hiss RG, 2001, DIABETES CARE, V24, P1293, DOI 10.2337/diacare.24.7.1293; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; Institute of Medicine, 2001, CROSSING QUALITY CHA; Jacques C H, 1993, Arch Fam Med, V2, P739, DOI 10.1001/archfami.2.7.739; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; Kleschen M Z, 2000, Jt Comm J Qual Improv, V26, P538; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Konen JC, 1996, ARCH FAM MED, V5, P135, DOI 10.1001/archfami.5.3.135; KOPERSKI M, 1992, BRIT J GEN PRACT, V42, P508; Larme AC, 1998, DIABETES CARE, V21, P1391, DOI 10.2337/diacare.21.9.1391; Latessa RA, 2000, FAM MED, V32, P196; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; Lobach DF, 1997, AM J MED, V102, P89, DOI 10.1016/S0002-9343(96)00382-8; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; MAZZE RS, 1994, DIABETES CARE, V17, P56; McFarlane SI, 2002, DIABETES CARE, V25, P718, DOI 10.2337/diacare.25.4.718; McVea K, 1996, J FAM PRACTICE, V43, P361; NAJI S, 1994, BRIT MED J, V308, P1208; Narayan KMV, 2000, DIABETES CARE, V23, P1794, DOI 10.2337/diacare.23.12.1794; Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77; Nilasena D S, 1995, Proc Annu Symp Comput Appl Med Care, P640; OConnor PJ, 1996, ARCH FAM MED, V5, P502, DOI 10.1001/archfami.5.9.502; Ornstein S M, 1998, Top Health Inf Manage, V19, P35; Peters AL, 1998, DIABETES CARE, V21, P1037, DOI 10.2337/diacare.21.7.1037; Peters AL, 1996, DIABETES CARE, V19, P601, DOI 10.2337/diacare.19.6.601; PIEBER TR, 1995, DIABETIC MED, V12, P349, DOI 10.1111/j.1464-5491.1995.tb00491.x; Plsek PE, 2001, BRIT MED J, V323, P625, DOI 10.1136/bmj.323.7313.625; Renders CM, 2001, DIABETES CARE, V24, P1821, DOI 10.2337/diacare.24.10.1821; Rith-Najarian S, 1998, J FAM PRACTICE, V47, P127; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; Sidorov J, 2000, AM J MANAG CARE, V6, P1217; Sperl-Hillen J, 2000, Jt Comm J Qual Improv, V26, P615; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Wagner E H, 1998, Eff Clin Pract, V1, P2; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; Zhang P, 2004, ANN INTERN MED, V140, P972, DOI 10.7326/0003-4819-140-11-200406010-00039	71	75	80	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					958	963		10.7326/0003-4819-140-11-200406010-00037	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00037			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172921				2022-12-28	WOS:000221680600027
J	Sankar, P; Cho, MK; Condit, CM; Hunt, LM; Koenig, B; Marshall, P; Lee, SSJ; Spicer, P				Sankar, P; Cho, MK; Condit, CM; Hunt, LM; Koenig, B; Marshall, P; Lee, SSJ; Spicer, P			Genetic research and health disparities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ENVIRONMENT INTERACTIONS; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; PROSTATE-CANCER; ASTHMA; CHILDREN; RACE; PHARMACOGENOMICS; DISCRIMINATION	Alleviating health disparities in the United States is a goal with broad support. Medical research undertaken to achieve this goal typically adopts the well-established perspective that racial discrimination and poverty are the major contributors to unequal health status. However, the suggestion is increasingly made that genetic research also has a significant role to play in alleviating this problem, which likely overstates the importance of genetics as a factor in health disparities. Overemphasis on genetics as a major explanatory factor in health disparities could lead researchers to miss factors that contribute to disparities more substantially and may also reinforce racial stereotyping, which may contribute to disparities in the first place. Arguments that promote genetics research as a way to help alleviate health disparities are augmented by several factors, including research funding initiatives and the distinct demographic patterns of health disparities in the United States.	Univ Penn, Ctr Bioeth, Sch Med, Philadelphia, PA 19104 USA; Stanford Univ, Ctr Biomed Eth, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; Univ Georgia, Dept Speech Commun, Athens, GA 30602 USA; Michigan State Univ, Dept Anthropol, E Lansing, MI 48824 USA; Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH USA; Univ Colorado, Sch Med, Denver, CO USA	University of Pennsylvania; Pennsylvania Medicine; Stanford University; University System of Georgia; University of Georgia; Michigan State University; Case Western Reserve University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sankar, P (corresponding author), Univ Penn, Ctr Bioeth, Sch Med, 3401 MArket St,Suite 320, Philadelphia, PA 19104 USA.	sankarp@mail.med.upenn.edu		Lee, Sandra Soo-Jin/0000-0002-2312-9814	NHGRI NIH HHS [R01 HG002189-03, R01 HG02189-03, R01-HG02207-01, 5R01HG002191-03, R01 HG002191, R01 HG002189-01, 1K01HG002883-01, K01 HG002299, R01 HG002189-02, K01 HG002883, R01 HG002207, 5K01HG002299-04] Funding Source: Medline; NIDA NIH HHS [R01 DA014577, R01 DA014577-01A1] Funding Source: Medline; NIEHS NIH HHS [5R01ES010830-03] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K01HG002883, R01HG002191, K01HG002299, R01HG002207, R01HG002189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014577] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alexander GR, 1999, PAEDIATR PERINAT EP, V13, P205; Andrews R M, 2000, Ethn Dis, V10, P384; Banini AE, 2003, NUTRITION, V19, P722, DOI 10.1016/S0899-9007(03)00108-4; Berkowitz GS, 2003, ENVIRON HEALTH PERSP, V111, P79, DOI 10.1289/ehp.5619; Bevan JL, 2003, GENET MED, V5, P393, DOI 10.1097/01.GIM.0000087989.12317.3F; Bowler RM, 2003, NEUROTOXICOLOGY, V24, P553, DOI 10.1016/S0161-813X(03)00027-5; Bratt O, 2002, J UROLOGY, V168, P906, DOI 10.1016/S0022-5347(05)64541-7; Bubela TM, 2004, CAN MED ASSOC J, V170, P1399, DOI 10.1503/cmaj.1030762; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Coleman AL, 1999, LANCET, V354, P1803, DOI 10.1016/S0140-6736(99)04240-3; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Condit C, 2003, GENET MED, V5, P385, DOI 10.1097/01.GIM.0000087990.30961.72; Conrad P, 1999, PUBLIC UNDERST SCI, V8, P285, DOI 10.1088/0963-6625/8/4/302; Cooper RS, 1999, SCI AM, V280, P56, DOI 10.1038/scientificamerican0299-56; Cooper RS, 1997, DIABETES CARE, V20, P343, DOI 10.2337/diacare.20.3.343; DANIEL H, 2003, ETHN DIS S2, V13, P553; DELAFUENTE A, 1998, GEORGETOWN U CUBA BR, P18; Doris PA, 2002, HYPERTENSION, V39, P323, DOI 10.1161/hy0202.104087; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Fernandez JR, 2003, OBES RES, V11, P904, DOI 10.1038/oby.2003.124; Forquera Ralph, 2001, PROMISES KEEP PUBLIC, P121; Forrester T, 2004, J NUTR, V134, P211, DOI 10.1093/jn/134.1.211; Fujimura J. H., 1996, CRAFTING SCI SOCIOHI; Gee GC, 2002, AM J PUBLIC HEALTH, V92, P615, DOI 10.2105/AJPH.92.4.615; Geiger H.J., 2003, UNEQUAL TREATMENT CO; Gibson PG, 2003, PEDIATR PULM, V36, P209, DOI 10.1002/ppul.10323; Glaser SL, 2002, LEUKEMIA RES, V26, P261, DOI 10.1016/S0145-2126(01)00126-6; Hakonarson H, 2001, CURR OPIN PEDIATR, V13, P267, DOI 10.1097/00008480-200106000-00010; HALPERN D, 1993, SOC SCI MED, V36, P597, DOI 10.1016/0277-9536(93)90056-A; Harris D. Robert, 1997, Ethnicity and Disease, V7, P91; HEALY M, 2004, RACE FACTOR THOUSAND; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; *HJ KAIS FAM FDN, 1999, SOURC FIN LEV HLTH S; *HJ KAIS FAM FDN, 2003, RAC ETHN IMM STAT LA; *I MED, 2003, UN TREATM CONFR RAC; Iacoviello L, 2001, HYPERTENSION, V38, P1199, DOI 10.1161/hy1101.099478; Istre GR, 2001, NEW ENGL J MED, V344, P1911, DOI 10.1056/NEJM200106213442506; KRIEGER N, 1990, SOC SCI MED, V30, P1273, DOI 10.1016/0277-9536(90)90307-E; Lee S S, 2001, Yale J Health Policy Law Ethics, V1, P33; Lewallen S, 2001, BRIT J OPHTHALMOL, V85, P897, DOI 10.1136/bjo.85.8.897; Mayes MD, 2003, RHEUM DIS CLIN N AM, V29, P239, DOI 10.1016/S0889-857X(03)00022-X; Merrill Ray M., 2000, Ethnicity and Disease, V10, P248; Miller RL, 1999, AM J PUBLIC HEALTH, V89, P819, DOI 10.2105/AJPH.89.6.819; *NAT EYE I, STRAT PLAN RED HLTH; *NAT LIB MED, NLM STRAT PLAN RED R; National Institute of Arthritis and Muswloskeletal and Skin Diseases, STRAT PLAN RED HLTH; National Institute of Health, STRAT RES PLAN BUDG; PARKER DJ, 1993, ANN EMERG MED, V22, P517, DOI 10.1016/S0196-0644(05)81935-3; Reynolds T, 2003, J NATL CANCER I, V95, P1356, DOI 10.1093/jnci/95.18.1356; Risch N., 2002, GENOME BIOL, V3, pcomm, DOI [10.1186/gb-2002-3-7-comment2007, 10.1186/GB-2002-3-7-COMMENT2007]; Rotimi Charles N., 1999, Ethnicity and Disease, V9, P190; Schecter AD, 1996, AM J CARDIOL, V78, P996, DOI 10.1016/S0002-9149(96)00523-1; Shalat SL, 2003, J EXPO ANAL ENV EPID, V13, P42, DOI 10.1038/sj.jea.7500249; Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309; Shkolnikov V, 2001, LANCET, V357, P917, DOI 10.1016/S0140-6736(00)04212-4; SOLIMAN MRI, 1993, TOXICOL IND HEALTH, V9, P901, DOI 10.1177/074823379300900511; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; U. S. Department of Health and Human Services, 2003, NAT HEALTHC DISP REP; *US HOUS REPR COMM, CHANG NAT HEALTHC DI; van Ryn M, 2002, MED CARE, V40, P140; *WHO, SEL HLTH IND CUB; Woodcock A, 2001, J ALLERGY CLIN IMMUN, V108, P463, DOI 10.1067/mai.2001.116859; Yancy CW, 2001, NEW ENGL J MED, V344, P1358, DOI 10.1056/NEJM200105033441803; 1996, OTOLARYNGOL HEAD NEC, V114, P256	67	182	183	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2985	2989		10.1001/jama.291.24.2985	http://dx.doi.org/10.1001/jama.291.24.2985			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213210	Green Accepted			2022-12-28	WOS:000222184600028
J	Jardine, AP; Dworski, S; Fouquet, P; Alexandrowicz, G; Riley, DJ; Lee, GYH; Ellis, J; Allison, W				Jardine, AP; Dworski, S; Fouquet, P; Alexandrowicz, G; Riley, DJ; Lee, GYH; Ellis, J; Allison, W			Ultrahigh-resolution spin-echo measurement of surface potential energy landscapes	SCIENCE			English	Article							HELIUM-ATOM SCATTERING; SELECTIVE-ADSORPTION; ELASTIC-SCATTERING; LINE-SHAPES; HE-4; LIF; DIFFUSION; PRINCIPLES; LIF(001); NAF	We demonstrate two approaches that use the recently developed helium spin-echo technique to measure surface potential energy landscapes. For helium-lithium fluoride (100), we use the selective adsorption phenomenon to obtain the complete experimental band structure of atoms in a corrugated surface potential. For carbon monoxide-copper (001), we measure the diffusion-induced energy broadening in the scattered helium beam and extract properties of the adsorbate-substrate potential. The measurements are made possible by the resolution of our new spectrometer, which improves on existing resolution by three orders of magnitude. We show that it is possible to produce benchmark energy landscapes to assist evaluation and development of first-principles theory in the problematic van der Waals/weak chemisorption regime.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	University of Cambridge	Jardine, AP (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.	apj24@cam.ac.uk	Fouquet, Peter/P-7723-2019; Fouquet, Peter/B-5212-2008	Fouquet, Peter/0000-0002-5542-0059; Fouquet, Peter/0000-0002-5542-0059; Alexandrowicz, Gil/0000-0003-3203-5577				ARMAND G, 1989, PHYS REV B, V39, P10514, DOI 10.1103/PhysRevB.39.10514; Barth JV, 2000, SURF SCI REP, V40, P75, DOI 10.1016/S0167-5729(00)00002-9; BRUSDEYLINS G, 1983, PHYS REV B, V27, P3662, DOI 10.1103/PhysRevB.27.3662; CARLOS WE, 1979, PHYS REV B, V19, P3258, DOI 10.1103/PhysRevB.19.3258; CELLI V, 1985, J CHEM PHYS, V83, P2504, DOI 10.1063/1.449297; DEKEVIET M, 1995, PHYS REV LETT, V75, P1919; DEKEVIET M, 1997, SURF SCI, V337, P1112; DERRY G, 1978, SURF SCI, V74, P245, DOI 10.1016/0039-6028(78)90284-4; Dworski S, 2004, REV SCI INSTRUM, V75, P1963, DOI 10.1063/1.1753093; Estermann I, 1930, Z PHYS, V61, P95, DOI 10.1007/BF01340293; Farias D, 1998, REP PROG PHYS, V61, P1575, DOI 10.1088/0034-4885/61/12/001; Fouquet P, 2003, J CHEM PHYS, V119, P509, DOI 10.1063/1.1578054; FRANKL DR, 1978, PHYS REV LETT, V41, P60, DOI 10.1103/PhysRevLett.41.60; Frisch R, 1933, Z PHYS, V84, P430, DOI 10.1007/BF01342223; Ge Q, 1999, J CHEM PHYS, V111, P9461, DOI 10.1063/1.480275; Ge Q, 2001, J CHEM PHYS, V114, P1053, DOI 10.1063/1.1328039; Graham AP, 1998, J CHEM PHYS, V108, P7825, DOI 10.1063/1.476219; Gross A, 2002, SURF SCI, V500, P347, DOI 10.1016/S0039-6028(01)01526-6; HOINKES H, 1992, HELIUM ATOM SCATTERI; HOUSTON DE, 1973, PHYS REV LETT, V31, P298, DOI 10.1103/PhysRevLett.31.298; Hulpke E, 1992, SPRINGER SERIES SURF; HUTCHISON JS, 1980, PHYS REV B, V22, P5671, DOI 10.1103/PhysRevB.22.5671; Jardine AP, 2004, J CHEM PHYS, V120, P8724, DOI 10.1063/1.1695320; Jardine AP, 2002, J PHYS-CONDENS MAT, V14, P6173, DOI 10.1088/0953-8984/14/24/315; Jardine AP, 2001, REV SCI INSTRUM, V72, P3834, DOI 10.1063/1.1405794; LENNARDJONES JE, 1936, NATURE, V137, P1069; MEZEI F, 1972, Z PHYS, V255, P146, DOI 10.1007/BF01394523; MILLER DR, 1998, ATOMIC MOL BEAM METH; WESNER DA, 1981, PHYS REV B, V24, P1798, DOI 10.1103/PhysRevB.24.1798; WOLKEN G, 1973, J CHEM PHYS, V58, P3047, DOI 10.1063/1.1679617	30	78	78	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1790	1793		10.1126/science.1098490	http://dx.doi.org/10.1126/science.1098490			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205531				2022-12-28	WOS:000222089500042
J	Wardle, DA; Bardgett, RD; Klironomos, JN; Setala, H; van der Putten, WH; Wall, DH				Wardle, DA; Bardgett, RD; Klironomos, JN; Setala, H; van der Putten, WH; Wall, DH			Ecological linkages between aboveground and belowground biota	SCIENCE			English	Review							ARBUSCULAR MYCORRHIZAL FUNGI; PLANT COMMUNITY STRUCTURE; SOIL BIOTA; SPECIES-DIVERSITY; NITROGEN; GRASSLAND; CARBON; PATTERNS; RHIZOSPHERE; EARTHWORMS	All terrestrial ecosystems consist of aboveground and belowground components that interact to influence community- and ecosystem-level processes and properties. Here we show how these components are closely interlinked at the community level, reinforced by a greater degree of specificity between plants and soil organisms than has been previously supposed. As such, aboveground and belowground communities can be powerful mutual drivers, with both positive and negative feedbacks. A combined aboveground-belowground approach to community and ecosystem ecology is enhancing our understanding of the regulation and functional significance of biodiversity and of the environmental impacts of human-induced global change phenomena.	Landcare Res, Lincoln, New Zealand; Swedish Univ Agr Sci, Dept Forest Vegetat Ecol, SE-90183 Umea, Sweden; Univ Lancaster, Inst Environm & Nat Sci, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Guelph, Dept Bot, Guelph, ON N1G 2W1, Canada; Univ Helsinki, Dept Ecol & Environm Sci, FIN-15140 Lahti, Finland; Netherlands Inst Ecol, Dept Multitroph Interact, Heteren, Netherlands; Colorado State Univ, Nat Resource Ecol Lab, Ft Collins, CO 80523 USA	Landcare Research - New Zealand; Swedish University of Agricultural Sciences; Lancaster University; University of Guelph; University of Helsinki; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Colorado State University	Wardle, DA (corresponding author), Landcare Res, POB 69, Lincoln, New Zealand.	david.wardle@svek.slu.se	Setälä, Heikki M/P-7354-2015; van der Putten, Wim H/C-3707-2011; Wardle, David A./F-6031-2011; Wall, Diana H/F-5491-2011; Kapitel, Kristina/AAR-5818-2021	van der Putten, Wim H/0000-0002-9341-4442; Wardle, David A./0000-0002-0476-7335; 				ALMUFTI MM, 1977, J ECOL, V65, P759, DOI 10.2307/2259378; Alphei J, 1996, OECOLOGIA, V106, P111, DOI 10.1007/BF00334413; Bardgett RD, 1999, FUNCT ECOL, V13, P650, DOI 10.1046/j.1365-2435.1999.00362.x; Bardgett RD, 2003, ECOLOGY, V84, P2258, DOI 10.1890/02-0274; Bever JD, 1997, J ECOL, V85, P561, DOI 10.2307/2960528; Bezemer TM, 2003, OIKOS, V101, P555, DOI 10.1034/j.1600-0706.2003.12424.x; Boag B., 2000, Aspects of Applied Biology, V62, P79; Bonkowski M, 2001, OIKOS, V95, P441, DOI 10.1034/j.1600-0706.2001.950309.x; Bradford MA, 2002, SCIENCE, V298, P615, DOI 10.1126/science.1075805; BROWN VK, 1992, VEGETATIO, V101, P3, DOI 10.1007/BF00031910; Cebrian J, 1999, AM NAT, V154, P449, DOI 10.1086/303244; COLEMAN DC, 1983, ADV ECOL RES, V13, P1, DOI 10.1016/S0065-2504(08)60107-5; Cornelissen JHC, 2001, OECOLOGIA, V129, P611, DOI 10.1007/s004420100752; Couteaux MM, 1999, TREE PHYSIOL, V19, P301; De Deyn GB, 2003, NATURE, V422, P711, DOI 10.1038/nature01548; DEROOIJVANDERGOES PCEM, 1995, NEW PHYTOL, V129, P661, DOI 10.1111/j.1469-8137.1995.tb03035.x; DERUITER PC, 1995, SCIENCE, V269, P1257, DOI 10.1126/science.269.5228.1257; DIAZ S, 1993, NATURE, V364, P616, DOI 10.1038/364616a0; Ehrenfeld JG, 2003, ECOSYSTEMS, V6, P503, DOI 10.1007/s10021-002-0151-3; Eviner VT, 2003, SCOPE SER, V61, P151; Eviner VT, 2003, ECOLOGY, V84, P120, DOI 10.1890/0012-9658(2003)084[0120:GPFIAE]2.0.CO;2; Gange AC, 2003, ECOL LETT, V6, P1051, DOI 10.1046/j.1461-0248.2003.00540.x; Gange AC, 1997, NEW PHYTOL, V137, P335, DOI 10.1046/j.1469-8137.1997.00813.x; GEHRING CA, 1994, TRENDS ECOL EVOL, V9, P251, DOI 10.1016/0169-5347(94)90290-9; Goverde M, 2000, OECOLOGIA, V125, P362, DOI 10.1007/s004420000465; GRIFFITHS BS, 1992, OECOLOGIA, V91, P253, DOI 10.1007/BF00317793; Grime J. P., 2001, PLANT STRATEGIES VEG; GRIME JP, 1987, NATURE, V328, P420, DOI 10.1038/328420a0; Hamilton EW, 2001, ECOLOGY, V82, P2397, DOI 10.1890/0012-9658(2001)082[2397:CPSSMA]2.0.CO;2; Hartnett DC, 1999, ECOLOGY, V80, P1187, DOI 10.1890/0012-9658(1999)080[1187:MIPCSA]2.0.CO;2; Hedlund K, 2003, OIKOS, V103, P45, DOI 10.1034/j.1600-0706.2003.12511.x; Hendrix PF, 2002, BIOSCIENCE, V52, P801, DOI 10.1641/0006-3568(2002)052[0801:EEIINA]2.0.CO;2; HOBBS RJ, 1995, ECOLOGY, V72, P1374; Hu S, 2001, NATURE, V409, P188, DOI 10.1038/35051576; Jackson RB, 2002, NATURE, V418, P623, DOI 10.1038/nature00910; Jones JA, 1998, SCIENCE, V280, P229, DOI 10.1126/science.280.5361.229; Jonsson LM, 2001, OIKOS, V93, P353, DOI 10.1034/j.1600-0706.2001.930301.x; Klironomos JN, 2002, NATURE, V417, P67, DOI 10.1038/417067a; Klironomos JN, 2003, ECOLOGY, V84, P2292, DOI 10.1890/02-0413; Korner C, 2000, ECOL APPL, V10, P1590, DOI 10.2307/2641226; Kowalchuk GA, 2002, ANTON LEEUW INT J G, V81, P509, DOI 10.1023/A:1020565523615; Laakso J, 1999, OIKOS, V87, P57, DOI 10.2307/3546996; LAWTON JH, 1994, OIKOS, V71, P367, DOI 10.2307/3545824; Liiri M, 2002, OIKOS, V96, P137, DOI 10.1034/j.1600-0706.2002.960115.x; Masters GJ, 2001, OECOLOGIA, V127, P246, DOI 10.1007/s004420000569; Mikola J, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P169; Moore JC, 2003, ECOLOGY, V84, P846, DOI 10.1890/0012-9658(2003)084[0846:TIBDPI]2.0.CO;2; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; PASTOR J, 1993, ECOLOGY, V74, P467, DOI 10.2307/1939308; Porazinska DL, 2003, ECOL MONOGR, V73, P377, DOI 10.1890/0012-9615(2003)073[0377:RATAIP]2.0.CO;2; Reinhart KO, 2003, ECOL LETT, V6, P1046, DOI 10.1046/j.1461-0248.2003.00539.x; Rillig MC, 1999, NATURE, V400, P628, DOI 10.1038/23168; Saetre P, 2000, SOIL BIOL BIOCHEM, V32, P909, DOI 10.1016/S0038-0717(99)00215-1; Scheu S, 1999, OECOLOGIA, V119, P541, DOI 10.1007/s004420050817; SETALA H, 1991, ECOLOGY, V72, P665, DOI 10.2307/2937206; SETALA H, 2004, IN PRESS SOIL BIODIV; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; Stampe ED, 2003, OIKOS, V100, P362, DOI 10.1034/j.1600-0706.2003.12006.x; Stark S, 2003, ECOGRAPHY, V26, P51, DOI 10.1034/j.1600-0587.2003.03336.x; Swift M.J., 1979, DECOMPOSITION TERRES, V5; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P776, DOI 10.1128/AEM.56.3.776-781.1990; TOYOTA K, 1994, BIOL FERT SOILS, V18, P32, DOI 10.1007/BF00336441; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Van der Putten WH, 2001, TRENDS ECOL EVOL, V16, P547, DOI 10.1016/S0169-5347(01)02265-0; Van Der Putten WH, 2003, ECOLOGY, V84, P2269, DOI 10.1890/02-0284; VANDERPUTTEN WH, 1993, NATURE, V362, P53; Vicari M, 2002, ECOLOGY, V83, P2452, DOI 10.1890/0012-9658(2002)083[2452:CEOFAM]2.0.CO;2; VIRGINIA RA, 1992, BIOL FERT SOILS, V14, P90, DOI 10.1007/BF00336256; VITOUSEK PM, 1989, ECOL MONOGR, V59, P247, DOI 10.2307/1942601; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Wall DH, 2001, ECOL STU AN, V152, P47; Wardle D., 2002, COMMUNITIES ECOSYSTE; Wardle DA, 1999, ECOL MONOGR, V69, P535, DOI 10.1890/0012-9615(1999)069[0535:PRIPGV]2.0.CO;2; Wardle DA, 2003, SCIENCE, V300, P972, DOI 10.1126/science.1082709; Wardle DA, 2001, ECOL MONOGR, V71, P587, DOI 10.1890/0012-9615(2001)071[0587:IBMINZ]2.0.CO;2; Yeates GW, 1999, ANNU REV PHYTOPATHOL, V37, P127, DOI 10.1146/annurev.phyto.37.1.127; Yeates GW, 2003, BIOL FERT SOILS, V38, P319, DOI 10.1007/s00374-003-0659-5; Zavaleta ES, 2003, P NATL ACAD SCI USA, V100, P7650, DOI 10.1073/pnas.0932734100	78	2770	3184	269	2655	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1629	1633		10.1126/science.1094875	http://dx.doi.org/10.1126/science.1094875			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192218				2022-12-28	WOS:000221934300038
J	Zakany, J; Kmita, M; Duboule, D				Zakany, J; Kmita, M; Duboule, D			A dual role for Hox genes in limb anterior-posterior asymmetry	SCIENCE			English	Article							SONIC-HEDGEHOG; POLARIZING ACTIVITY; VERTEBRATE LIMB; SHORT-RANGE; EXPRESSION; BUD; GLI3; ESTABLISHMENT; REGION; TRANSCRIPTION	Anterior-to-posterior patterning, the process whereby our digits are differently shaped, is a key aspect of limb development. It depends on the localized expression in posterior limb bud of Sonic hedgehog (Shh) and the morphogenetic potential of its diffusing product. By using an inversion of and a large deficiency in the mouse HoxD cluster, we found that a perturbation in the early collinear expression of Hoxd11, Hoxd12, and Hoxd13 in limb buds led to a loss of asymmetry. Ectopic Hox gene expression triggered abnormal Shh transcription, which in turn induced symmetrical expression of Hox genes in digits, thereby generating double posterior limbs. We conclude that early posterior restriction of Hox gene products sets up an anterior-posterior prepattern, which determines the localized activation of Shh. This signal is subsequently translated into digit morphological asymmetry by promoting the late expression of Hoxd genes, two collinear processes relying on opposite genomic topographies, upstream and downstream Shh signaling.	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Natl Program Frontiers Genet, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	Denis.Duboule@zoo.unige.ch		duboule, denis/0000-0001-9961-2960; Kmita, Marie/0000-0003-4021-0478				Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Charite J, 2000, DEVELOPMENT, V127, P2461; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; Dillon R, 2003, P NATL ACAD SCI USA, V100, P10152, DOI 10.1073/pnas.1830500100; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; Drossopoulou G, 2000, DEVELOPMENT, V127, P1337; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Grieshammer U, 1996, DEVELOPMENT, V122, P3851; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Kmita M, 2002, NATURE, V420, P145, DOI 10.1038/nature01189; Knezevic V, 1997, DEVELOPMENT, V124, P4523; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; Mackem S, 1999, CELL TISSUE RES, V296, P27, DOI 10.1007/s004410051263; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Neumann CJ, 1999, DEVELOPMENT, V126, P4817; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Ros MA, 2003, DEVELOPMENT, V130, P527, DOI 10.1242/dev.00245; Sharpe J, 1999, CURR BIOL, V9, P97, DOI 10.1016/S0960-9822(99)80022-0; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Tickle C, 2002, INT J DEV BIOL, V46, P847; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Vidal F, 1998, MOL REPROD DEV, V51, P274, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;274::AID-MRD6&gt;3.0.CO;2-M; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393; Zakany J, 2001, CELL, V106, P207, DOI 10.1016/S0092-8674(01)00436-6; Zuniga A, 1999, DEVELOPMENT, V126, P13	32	223	228	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1669	1672		10.1126/science.1096049	http://dx.doi.org/10.1126/science.1096049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192229				2022-12-28	WOS:000221934300050
J	May, T				May, T			Isolation is not the answer	NATURE			English	Editorial Material									Med Coll Wisconsin, Milwaukee, WI 53226 USA	Medical College of Wisconsin	May, T (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.							ALIBEK K, 1999, BIOHAZARD, pCH20; CLARKE R, 2004, ALL ENEMIES INSIDE A, pCH7; RUDMAN W, 2003, EMERGENCY RESPONDERS; US Department of State, 2003, NAT STRAT COMB TERR	4	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					603	603		10.1038/429603a	http://dx.doi.org/10.1038/429603a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190328	Green Published, Bronze			2022-12-28	WOS:000221912600017
J	Blau, WJ; Fleming, AJ				Blau, WJ; Fleming, AJ			Materials science - Designer nanotubes by molecular self-assembly	SCIENCE			English	Editorial Material									Univ Dublin Trinity Coll, Dept Phys, Dublin 2, Ireland	Trinity College Dublin	Blau, WJ (corresponding author), Univ Dublin Trinity Coll, Dept Phys, Dublin 2, Ireland.	wblau@tcd.ie	Blau, Werner/A-4440-2008	Blau, Werner/0000-0002-9666-7058				Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Cacialli F, 2004, MATER TODAY, V7, P24, DOI 10.1016/S1369-7021(04)00186-5; Hill JP, 2004, SCIENCE, V304, P1481, DOI 10.1126/science.1097789; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; Wu JH, 2003, ANGEW CHEM INT EDIT, V42, P5329, DOI 10.1002/anie.200352047	5	46	46	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1457	1458		10.1126/science.1099568	http://dx.doi.org/10.1126/science.1099568			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178789				2022-12-28	WOS:000221795800029
J	Zhang, RY; Suh, I; Zhao, J; Zhang, D; Fortner, EC; Tie, XX; Molina, LT; Molina, MJ				Zhang, RY; Suh, I; Zhao, J; Zhang, D; Fortner, EC; Tie, XX; Molina, LT; Molina, MJ			Atmospheric new particle formation enhanced by organic acids	SCIENCE			English	Article							AEROSOL FORMATION; TROPOSPHERE; NUCLEATION; PHOTOOXIDATION; TOLUENE; NOX	Atmospheric aerosols often contain a substantial fraction of organic matter, but the role of organic compounds in new nanometer-sized particle formation is highly uncertain. Laboratory experiments show that nucleation of sulfuric acid is considerably enhanced in the presence of aromatic acids. Theoretical calculations identify the formation of an unusually stable aromatic acid - sulfuric acid complex, which likely leads to a reduced nucleation barrier. The results imply that the interaction between organic and sulfuric acids promotes efficient formation of organic and sulfate aerosols in the polluted atmosphere because of emissions from burning of fossil fuels, which strongly affect human health and global climate.	Texas A&M Univ, Dept Atmospher Sci, College Stn, TX 77843 USA; Natl Ctr Atmospher Res, Div Atmospher Chem, Boulder, CO 80307 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Texas A&M University System; Texas A&M University College Station; National Center Atmospheric Research (NCAR) - USA; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Zhang, RY (corresponding author), Texas A&M Univ, Dept Atmospher Sci, College Stn, TX 77843 USA.	zhang@ariel.met.tamu.edu	Zhao, Jun/C-8565-2009; Zhang, Renyi/A-2942-2011	Zhao, Jun/0000-0002-3340-4816; Zhang, Renyi/0000-0001-8708-3862				Ball SM, 1999, J GEOPHYS RES-ATMOS, V104, P23709, DOI 10.1029/1999JD900411; Boy M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003838; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Chebbi A, 1996, ATMOS ENVIRON, V30, P4233, DOI 10.1016/1352-2310(96)00102-1; EPA, 1996, EPA600P95001CF; Forstner HJL, 1997, ENVIRON SCI TECHNOL, V31, P1345, DOI 10.1021/es9605376; GASPARINI R, IN PRESS ATMOS ENV; Hoffmann T, 1998, J GEOPHYS RES-ATMOS, V103, P25569, DOI 10.1029/98JD01816; Houghton J. T., 2001, CLIMATE CHANGE 2001; Jang MS, 2002, SCIENCE, V298, P814, DOI 10.1126/science.1075798; Jang MS, 2001, ENVIRON SCI TECHNOL, V35, P3626, DOI 10.1021/es010676+; Kathmann SM, 2002, J CHEM PHYS, V116, P5046, DOI 10.1063/1.1451059; Kavouras IG, 1998, NATURE, V395, P683, DOI 10.1038/27179; Kolb CE, 2002, NATURE, V417, P597, DOI 10.1038/417597a; Kulmala M, 2003, SCIENCE, V302, P1000, DOI 10.1126/science.1090848; Larson LJ, 1999, J PHYS CHEM A, V103, P6786, DOI 10.1021/jp991529p; Laskin A, 2003, SCIENCE, V301, P340, DOI 10.1126/science.1085374; Lee SH, 2003, SCIENCE, V301, P1886, DOI 10.1126/science.1087236; Marti JJ, 1997, J GEOPHYS RES-ATMOS, V102, P6331, DOI 10.1029/96JD02545; O'Dowd CD, 2002, NATURE, V416, P497, DOI 10.1038/416497a; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Odum JR, 1996, ENVIRON SCI TECHNOL, V30, P2580, DOI 10.1021/es950943+; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; Orville RE, 2001, GEOPHYS RES LETT, V28, P2597, DOI 10.1029/2001GL012990; PANKOW JF, 1994, ATMOS ENVIRON, V28, P185, DOI 10.1016/1352-2310(94)90093-0; Pitts Jr J. N., 2000, CHEM UPPER LOWER ATM; Re S, 1999, J PHYS CHEM A, V103, P3535, DOI 10.1021/jp984759x; Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY; Suh I, 2003, J AM CHEM SOC, V125, P12655, DOI 10.1021/ja0350280; Tie XX, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003659; Weber RJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003112; Weber RJ, 1999, GEOPHYS RES LETT, V26, P307, DOI 10.1029/1998GL900308; YU F, 2001, J GEOPHYS RES, V106, P4767; Zhang RY, 2000, J GEOPHYS RES-ATMOS, V105, P24627, DOI 10.1029/2000JD900330; Zhang RY, 2003, P NATL ACAD SCI USA, V100, P1505, DOI 10.1073/pnas.252763799; Zhao J, 2004, J AM CHEM SOC, V126, P2686, DOI 10.1021/ja0386391	36	602	633	17	440	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1487	1490		10.1126/science.1095139	http://dx.doi.org/10.1126/science.1095139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178797				2022-12-28	WOS:000221795800039
J	Gupta, PC; Sreevidya, S				Gupta, PC; Sreevidya, S			Smokeless tobacco use, birth weight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To study the effect of using smokeless tobacco during pregnancy on babies' birth weight and gestational age at birth. Design Population based, prospective cohort study using a house to house approach. Setting Eight primary health post areas in the city of Mumbai (Bombay), India. Participants 1217 women who were three to seven months pregnant and planning to deliver in the study area. 1167 women (96%) were followed up. Main outcome measures Birth weight and gestational age in singleton births. Results Smokeless tobacco use was associated with an average reduction of 105 g in birth weight (95% confidence interval 30 g to 181 g) and a reduction in gestational age of 6.2 (3.0 to 9.4) days. The odds ratio for low birth weight was 1.6 (1.1 to 2.4), adjusted by logistic regression for maternal age, education, socioeconomic status, weight, anaemia, antenatal care, and gestational age. The adjusted odds ratio for preterm delivery (< 37 weeks) was 1.4 (1.0 to 2.1); for delivery before 32 weeks it was 4.9 (2.1 to 11.8) and before 28 weeks was 8.0 (2.6 to 27.2). Conclusions Consumption of smokeless tobacco during pregnancy decreases gestational age at birth and birth weight independent of gestational age. It should receive specific attention as a part of routine prenatal care.	Tata Mem Hosp, Epidemiol Res Unit, Bombay 400012, Maharashtra, India; Tata Inst Fundamental Res, Epidemiol Res Unit, Bombay 400005, Maharashtra, India	Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Institute of Fundamental Research (TIFR)	Sreevidya, S (corresponding author), Tata Mem Hosp, Epidemiol Res Unit, Dr Ernest Borges Marg, Bombay 400012, Maharashtra, India.	sona917@hotmail.com						Global Youth Tobacco Survey Collabor, 2003, J SCHOOL HEALTH, V73, P207; Gupta P C, 1996, Tob Control, V5, P114, DOI 10.1136/tc.5.2.114; International Agency for Research on Cancer, 1984, IARC MON EV CARC RIS, V37; KRISHNA K, 1978, BRIT J OBSTET GYNAEC, V85, P726, DOI 10.1111/j.1471-0528.1978.tb15591.x; KRISHNAMURTHY S, 1993, J TROP PEDIATRICS, V39, P253, DOI 10.1093/tropej/39.4.253; Mehta A, 1990, J OBSTET GYNAECOL IN, V40, P156; *NAT CTR CHRON DIS, 2001, WOM SMOK REP SURG GE, P113; PINDBORG JJ, 1990, CONTROL TOBACCO RELA, P13; SARKAR S, 1991, NITROSO COMPOUNDS BI; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; *US DEP HHS, 1979, DHHS PUBL, P72; *US DEP HHS, 1980, HLTH CONS SMOK WOM R, P217; Verma R C, 1983, Indian Pediatr, V20, P105; Yach D, 2002, TOB CONTROL, V11, P252, DOI 10.1136/tc.11.3.252	14	133	135	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2004	328	7455					1538	1540B		10.1136/bmj.38113.687882.EB	http://dx.doi.org/10.1136/bmj.38113.687882.EB			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15198947	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222392700022
J	Ye, YH; Shibata, Y; Yun, C; Ron, D; Rapoport, TA				Ye, YH; Shibata, Y; Yun, C; Ron, D; Rapoport, TA			A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol	NATURE			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; I HEAVY-CHAINS; AAA-ATPASE; DISULFIDE-ISOMERASE; MISFOLDED GLYCOPROTEINS; CAENORHABDITIS-ELEGANS; QUALITY-CONTROL; RETROTRANSLOCATION; DISLOCATION; RECOGNITION	Elimination of misfolded proteins from the endoplasmic reticulum (ER) by retro-translocation is an important physiological adaptation to ER stress. This process requires recognition of a substrate in the ER lumen and its subsequent movement through the membrane by the cytosolic p97 ATPase. Here we identify a p97-interacting membrane protein complex in the mammalian ER that links these two events. The central component of the complex, Derlin-1, is a homologue of Der1, a yeast protein whose inactivation prevents the elimination of misfolded luminal ER proteins. Derlin-1 associates with different substrates as they move through the membrane, and inactivation of Derlin-1 in C. elegans causes ER stress. Derlin-1 interacts with US11, a virally encoded ER protein that specifically targets MHC class I heavy chains for export from the ER, as well as with VIMP, a novel membrane protein that recruits the p97 ATPase and its cofactor.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; New York University	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA.	tom_rapoport@hms.harvard.edu		Ron, David/0000-0002-3014-5636	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK033008, ZIADK033008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama Y, 2003, J BIOL CHEM, V278, P18146, DOI 10.1074/jbc.M302152200; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; FRANKS CM, 1970, BEHAV THER, V1, P1, DOI 10.1016/S0005-7894(70)80053-3; Gao Y, 2004, FEBS LETT, V563, P185, DOI 10.1016/S0014-5793(04)00296-0; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hitt R, 2004, FEMS YEAST RES, V4, P721, DOI 10.1016/j.femsyr.2004.02.003; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lilley BN, 2003, MOL BIOL CELL, V14, P3690, DOI 10.1091/mbc.E03-03-0192; LILLEY BN, NATURE; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Plemper RK, 1999, J CELL SCI, V112, P4123; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Urano F, 2002, J CELL BIOL, V158, P639, DOI 10.1083/jcb.200203086; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Wang QQ, 2003, EMBO J, V22, P3792, DOI 10.1093/emboj/cdg378; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	40	754	782	4	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					841	847		10.1038/nature02656	http://dx.doi.org/10.1038/nature02656			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215856				2022-12-28	WOS:000222213000033
J	Esposito, K; Giugliano, F; Di Palo, C; Giugliano, G; Marfella, R; D'Andrea, F; D'Armiento, M; Giugliano, D				Esposito, K; Giugliano, F; Di Palo, C; Giugliano, G; Marfella, R; D'Andrea, F; D'Armiento, M; Giugliano, D			Effect of lifestyle changes on erectile dysfunction in obese men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; QUALITY-OF-LIFE; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; VASCULAR-DISEASE; ADIPOSE-TISSUE; RISK-FACTORS; WEIGHT-LOSS; HEALTH	Context Healthy lifestyle factors are associated with maintenance of erectile function in men. Objective To determine the effect of weight loss and increased physical activity on erectile and endothelial functions in obese men. Design, Setting, and Patients Randomized, single-blind trial of 110 obese men (body mass index greater than or equal to30) aged 35 to 55 years, without diabetes, hypertension, or hyperlipidemia, who had erectile dysfunction that was determined by having a score of 21 or less on the International Index of Erectile Function (IIEF). The study was conducted from October 2000 to October 2003 at a university hospital in Italy. Interventions The 55 men randomly assigned to the intervention group received detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity. Men in the control group (n=55) were given general information about healthy food choices and exercise. Main Outcomes Measures Erectile function score, levels of cholesterol and tryglycerides, circulating levels of interleukin 6, interleukin 8, and C-reactive protein, and endothelial function as assessed by vascular responses to L-arginine. Results After 2 years, body mass index decreased more in the intervention group (from a mean [SD] of 36.9 [2.5] to 31.2 [2.1]) than in the control group (from 36.4 [2.3] to 35.7 [2.5]) (P<.001), as did serum concentrations of interleukin 6 (P=.03), and C-reactive protein (P=.02). The mean (SD) level of physical activity increased more in the intervention group (from 48 [10] to 195 [36] min/wk; P<.001)than in the control group (from 51 [9] to 84 [28] min/wk; P<.001). The mean (SD) IIEF score improved in the intervention group (from 13.9 [4.0] to 17 [5]; P<.001), but remained stable in the control group (from 13.5 [4.0] to 13.6 [4.1]; P=.89). Seventeen men in the intervention group and 3 in the control group (P=.001) reported an IIEF score of 22 or higher. In multivariate analyses, changes in body mass index (P=.02), physical activity (P=.02), and C-reactive protein (P=.03) were independently associated with changes in IIEF score. Conclusion Lifestyle changes are associated with improvement in sexual function in about one third of obese men with erectile dysfunction at baseline.	Univ Naples 2, Div Metab Dis, Naples, Italy; Univ Naples 2, Dept Urol, Naples, Italy; Univ Naples 2, Dept Plast & Reconstruct Surg, Naples, Italy; Univ Naples 2, Ctr Excellence Cardiol, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Esposito, K (corresponding author), Policlin Univ, Dept Geriatr & Metab Dis, Ctr Obes Management, Piazza L Miraglia, I-80138 Naples, Italy.	katherine.esposito@unina2.it	Maiorino, Maria Ida/AHE-9986-2022; Marfella, Raffaele/C-6899-2012; Esposito, Katherine/AHE-2564-2022	Maiorino, Maria Ida/0000-0003-4659-7546; Marfella, Raffaele/0000-0003-3960-9270; Esposito, Katherine/0000-0002-3652-5154; D'andrea, Francesco/0000-0002-3518-0406; Giugliano, Dario/0000-0002-9377-873X				Bacon CG, 2003, ANN INTERN MED, V139, P161, DOI 10.7326/0003-4819-139-3-200308050-00005; Bank AJ, 2003, INT J IMPOT RES, V15, P231, DOI 10.1038/sj.ijir.3901012; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Blake GJ, 2001, CIRC RES, V89, P763, DOI 10.1161/hh2101.099270; Chung WS, 1999, EUR UROL, V36, P68, DOI 10.1159/000019929; De Angelis L, 2001, DIABETOLOGIA, V44, P1155, DOI 10.1007/s001250100616; Derby CA, 2000, UROLOGY, V56, P302, DOI 10.1016/S0090-4295(00)00614-2; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Giugliano D, 1997, AM J PHYSIOL-ENDOC M, V273, pE606, DOI 10.1152/ajpendo.1997.273.3.E606; Higdon JV, 2003, ARTERIOSCL THROM VAS, V23, P365, DOI 10.1161/01.ATV.0000063608.43095.E2; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; KRANE RJ, 1989, NEW ENGL J MED, V321, P1648, DOI 10.1056/NEJM198912143212406; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; Litwin MS, 1998, J GEN INTERN MED, V13, P159, DOI 10.1046/j.1525-1497.1998.00050.x; Nappo F, 1999, JAMA-J AM MED ASSOC, V281, P2113, DOI 10.1001/jama.281.22.2113; Pasceri V, 2000, CIRCULATION, V102, P2165; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Roberts CK, 2002, CIRCULATION, V106, P2530, DOI 10.1161/01.CIR.0000040584.91836.0D; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Straczkowski M, 2002, J CLIN ENDOCR METAB, V87, P4602, DOI 10.1210/jc.2002-020135; Sullivan ME, 1999, CARDIOVASC RES, V43, P658, DOI 10.1016/S0008-6363(99)00135-2; TIEFER L, 1995, UROL CLIN N AM, V22, P767; Ventegodt S, 1998, ARCH SEX BEHAV, V27, P295, DOI 10.1023/A:1018655219133; Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E; Vita JA, 2000, NEW ENGL J MED, V342, P503, DOI 10.1056/NEJM200002173420710; Walczak Monika K, 2002, J Gend Specif Med, V5, P19; Yeh ETH, 2001, CIRCULATION, V104, P974, DOI 10.1161/01.CIR.104.9.974; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	30	543	571	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2978	2984		10.1001/jama.291.24.2978	http://dx.doi.org/10.1001/jama.291.24.2978			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213209				2022-12-28	WOS:000222184600027
J	Xiang, JH; George, SL; Wunschmann, S; Chang, Q; Klinzman, D; Stapleton, JT				Xiang, JH; George, SL; Wunschmann, S; Chang, Q; Klinzman, D; Stapleton, JT			Inhibition of HIV-1 veplication by GB virus C infection through increases in RANTES, MIP-1 alpha, MIP-1 beta, and SDF-1	LANCET			English	Article							HEPATITIS-G VIRUS; C/HEPATITIS-G VIRUS; CHEMOKINE RECEPTORS; INCUBATION PERIOD; T-LYMPHOCYTES; SUPPRESSION; CELLS; IDENTIFICATION; REPLICATION; PROGRESSION	Background People coinfected with HIV and GB virus C (GBV-C) have lower mortality than HIV-positive individuals without GBV-C infection. HIV uses either of the chemokine receptors CCR5 and CXCR4 for entry into CD4-positive cells. Longer survival in HIV-positive individuals is associated with high serum concentrations of ligands for CCR5 (RANTES [regulated on activation, normal T-cell expressed and secreted] and macrophage inflammatory proteins [MIP] 1alpha and 1beta) and CXCR4 (stromal-derived factor [SDF-1]), and with decreased expression of CCR5 on lymphocytes. Methods Peripheral-blood mononuclear cells were coinfected with GBV-C and HIV, and HIV replication was monitored by measuring infectivity and HIV p24 antigen production. Chemokine secretion was measured by ELISA, chemokine-receptor expression by flow cytometry, and cellular chemokine mRNA expression by differential hybridisation. Findings GBV-C infection of peripheral-blood mononuclear cells resulted in decreased replication of both clinical and laboratory HIV strains that use either CCR5 or CXCR4 as their coreceptor. Inhibition was related to the dose and timing of the GBV-C infection. Expression of mRNA for RANTES, MIP-1alpha, MIP-1beta, and SDF-1 and secretion of the chemokines into culture supernatants were higher in GBV-C-infected cells than in mock-infected cells. The inhibitory effect of GBV-C on HIV replication was blocked by incubation with neutralising antibodies against the relevant chemokines, and surface expression of CCR5 was significantly lower in GBV-C-infected cells than in mock-infected cells. Interpretation GBV-C induces HIV-inhibitory chemokines and reduces expression of the HIV coreceptor CCR5 in vitro. This study provides insight into the epidemiological association between GBV-C infection and longer survival in HIV-infected individuals.	Iowa City VA Med Ctr, Res Serv, Iowa City, IA USA; Iowa City VA Med Ctr, Dept Internal Med, Iowa City, IA USA; Univ Iowa, Iowa City, IA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa	Stapleton, JT (corresponding author), UIHC Iowa City, Dept Internal Med, SW34-P,GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	jack-stapleton@uiowa.edu		Stapleton, Jack/0000-0002-2302-9055; George, Sarah/0000-0002-9699-1042	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI050478, U01AI027661, R01AI058740] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27661, AI058740, AI50478] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cook RT, 1997, J INVEST MED, V45, P265; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Fogeda M, 2000, J VIROL, V74, P7936, DOI 10.1128/JVI.74.17.7936-7942.2000; Fogeda M, 1999, J VIROL, V73, P4052, DOI 10.1128/JVI.73.5.4052-4061.1999; George SL, 2003, VIROLOGY, V316, P191, DOI 10.1016/S0042-6822(03)00585-3; Grivel JC, 2001, NAT MED, V7, P1232, DOI 10.1038/nm1101-1232; Kalinkovich A, 1999, IMMUNOL LETT, V68, P281, DOI 10.1016/S0165-2478(99)00059-0; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Lin YL, 2002, P NATL ACAD SCI USA, V99, P15590, DOI 10.1073/pnas.242134499; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; Pinto LA, 2000, J VIROL, V74, P4505, DOI 10.1128/JVI.74.10.4505-4511.2000; Rowland-Jones S, 1999, J INFECTION, V38, P67, DOI 10.1016/S0163-4453(99)90070-1; Rowland-Jones S, 1999, SEX TRANSM INFECT, V75, P148, DOI 10.1136/sti.75.3.148; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741; Stapleton JT, 2003, SEMIN LIVER DIS, V23, P137; Tacke M, 1997, HEPATOLOGY, V26, P1626, DOI 10.1002/hep.510260635; Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245; Watt G, 2000, LANCET, V356, P475, DOI 10.1016/S0140-6736(00)02557-5; Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107; Wunschmann S, 2000, J CLIN MICROBIOL, V38, P3055; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364; Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000	30	162	171	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2040	2046		10.1016/S0140-6736(04)16453-2	http://dx.doi.org/10.1016/S0140-6736(04)16453-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207954				2022-12-28	WOS:000222159800010
J	Schuske, K; Jorgensen, EM				Schuske, K; Jorgensen, EM			Vesicular glutamate transporter - Shooting blanks	SCIENCE			English	Editorial Material							INORGANIC-PHOSPHATE COTRANSPORTER; MOLECULAR-CLONING; IDENTIFICATION; NEURONS; EXPRESSION; DEFINES		Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Jorgensen, EM (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.	jorgensen@biology.utah.edu						Aihara Y, 2000, J NEUROCHEM, V74, P2622, DOI 10.1046/j.1471-4159.2000.0742622.x; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Fremeau RT, 2001, NEURON, V31, P247, DOI 10.1016/S0896-6273(01)00344-0; Fremeau RT, 2004, SCIENCE, V304, P1815, DOI 10.1126/science.1097468; Fremeau RT, 2002, P NATL ACAD SCI USA, V99, P14488, DOI 10.1073/pnas.222546799; Gras C, 2002, J NEUROSCI, V22, P5442; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; Schafer MKH, 2002, J BIOL CHEM, V277, P50734, DOI 10.1074/jbc.M206738200; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Takamori S, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-22-j0002.2001; Takamori S, 2002, EMBO REP, V3, P798, DOI 10.1093/embo-reports/kvf159; Varoqui H, 2002, J NEUROSCI, V22, P142, DOI 10.1523/JNEUROSCI.22-01-00142.2002; Wojcik SM, 2004, P NATL ACAD SCI USA, V101, P7158, DOI 10.1073/pnas.0401764101; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	15	27	28	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1750	1752		10.1126/science.1100475	http://dx.doi.org/10.1126/science.1100475			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205517				2022-12-28	WOS:000222089500028
J	Bowcock, SJ; Shee, CD; Rassam, SMB; Harper, PG				Bowcock, SJ; Shee, CD; Rassam, SMB; Harper, PG			Chemotherapy for cancer patients who present late	BRITISH MEDICAL JOURNAL			English	Article							CELL LUNG-CANCER; DEATH; TUMORS; RISK		Queen Marys Sidcup NHS Trust, Sidcup DA14 6LT, Kent, England; Guys & St Thomas Hosp NHS Trust, Dept Med Oncol, London SE1 9RT, England		Bowcock, SJ (corresponding author), Queen Marys Sidcup NHS Trust, Sidcup DA14 6LT, Kent, England.	stella.bowcock@qms.nhs.uk						Agra Y, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001990; Archer V R, 1999, Oncologist, V4, P470; Buckman R, 1998, OXFORD TXB PALLIATIV, P145; Burnett AK, 1997, LANCET, V349, P270, DOI 10.1016/S0140-6736(96)08086-5; Cottin V, 1999, ANN ONCOL, V10, P809, DOI 10.1023/A:1008399831512; EARL HM, 1991, BRIT J CANCER, V64, P566, DOI 10.1038/bjc.1991.351; ELLIS PA, 1995, BRIT J CANCER, V71, P366, DOI 10.1038/bjc.1995.74; Gomez H, 1998, J CLIN ONCOL, V16, P2065, DOI 10.1200/JCO.1998.16.6.2065; HEIM ME, 1983, RECENT RES CANCER, V86, P37; Hickish TF, 1998, BRIT J CANCER, V78, P28, DOI 10.1038/bjc.1998.437; Miller R J, 1989, Am J Hosp Care, V6, P19, DOI 10.1177/104990918900600317; Muss HB, 2001, NEW ENGL J MED, V345, P1128, DOI 10.1056/NEJM200110113451512; Osoba D, 1998, OXFORD TXB PALLIATIV, P255; PARKES CM, 1983, RECOVERY BEREAVEMENT, P57; RADFORD JA, 1993, EUR J CANCER, V29A, P81, DOI 10.1016/0959-8049(93)90581-Y; Ray-Coquard I, 2001, BRIT J CANCER, V85, P816, DOI 10.1054/bjoc.2001.2011; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Smith R, 2000, BMJ-BRIT MED J, V320, P129, DOI 10.1136/bmj.320.7228.129	19	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1430	1432		10.1136/bmj.328.7453.1430	http://dx.doi.org/10.1136/bmj.328.7453.1430			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15191983	Green Published			2022-12-28	WOS:000222114400029
J	Bloom, P				Bloom, P			Can a dog learn a word?	SCIENCE			English	Editorial Material									Yale Univ, Dept Psychol, New Haven, CT 06520 USA	Yale University	Bloom, P (corresponding author), Yale Univ, Dept Psychol, POB 208205, New Haven, CT 06520 USA.	paul.bloom@yale.edu						CAREY S, 1978, CHILD LANG DEV, V15, P29; Hare B, 2002, SCIENCE, V298, P1634, DOI 10.1126/science.1072702; Kaminski J, 2004, SCIENCE, V304, P1682, DOI 10.1126/science.1097859; Macnamara J., 1982, NAMES THINGS; Markson L, 1997, NATURE, V385, P813, DOI 10.1038/385813a0; SEIDENBERG MS, 1987, J EXP PSYCHOL GEN, V116, P279, DOI 10.1037/0096-3445.116.3.279	7	43	44	3	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1605	1606		10.1126/science.1099899	http://dx.doi.org/10.1126/science.1099899			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192205				2022-12-28	WOS:000221934300025
J	Green, MT; Dawson, JH; Gray, HB				Green, MT; Dawson, JH; Gray, HB			Oxoiron(IV) in chloroperoxidase compound II is basic: Implications for P450 chemistry	SCIENCE			English	Article							CYTOCHROME-C PEROXIDASE; NITRIC-OXIDE SYNTHASE; X-RAY-ABSORPTION; RESONANCE RAMAN-SPECTRA; HORSERADISH-PEROXIDASE; MICE LACKING; BIOINORGANIC CHEMISTRY; HIGH-RESOLUTION; AXIAL LIGAND; SPECTROSCOPY	With the use of x-ray absorption spectroscopy, we have found that the Fe-O bond in chloroperoxidase compound II (CPO-II) is much longer than expected for an oxoiron(IV) (ferryl) unit; notably, the experimentally determined bond length of 1.82(1)Angstrom accords closely with density functional calculations on a protonated ferryl (Fe-IV- OH, 1.81 Angstrom). The basicity of the CPO-II ferryl [pK(a) > 8.2 (where K-a is the acid dissociation constant)] is attributable to strong electron donation by the axial thiolate. We suggest that the CPO-II protonated ferryl is a good model for the rebound intermediate in the P450 oxygenation cycle; with elevated pK(a) values after one-electron reduction, thiolate-ligated ferryl radicals are competent to oxygenate saturated hydrocarbons at potentials that can be tolerated by folded polypeptide hosts.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; California Institute of Technology	Green, MT (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	mtg10@psu.edu	Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019038, R37DK019038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19038] Funding Source: Medline; NIGMS NIH HHS [GM26730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Antony J, 1997, J PHYS CHEM A, V101, P2692, DOI 10.1021/jp9632955; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Bonagura CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/bi034058c; BORDWELL FG, 1991, J AM CHEM SOC, V113, P9790, DOI 10.1021/ja00026a012; CHANCE B, 1984, ARCH BIOCHEM BIOPHYS, V235, P596, DOI 10.1016/0003-9861(84)90234-0; CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1266, DOI 10.1021/bi00354a011; Daborn PJ, 2002, SCIENCE, V297, P2253, DOI 10.1126/science.1074170; Dunford H. B., 1999, HEME PEROXIDASES; Egawa T, 2001, J BIOL INORG CHEM, V6, P46, DOI 10.1007/s007750000181; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Green MT, 1999, J AM CHEM SOC, V121, P7939, DOI 10.1021/ja991541v; Green MT, 2001, J AM CHEM SOC, V123, P9218, DOI 10.1021/ja010105h; Groves JT, 2003, P NATL ACAD SCI USA, V100, P3569, DOI 10.1073/pnas.0830019100; HAYASHI Y, 1979, J BIOL CHEM, V254, P9101; Hersleth HP, 2002, J BIOL INORG CHEM, V7, P299, DOI 10.1007/s007750100296; Hoffman BM, 2003, P NATL ACAD SCI USA, V100, P3575, DOI 10.1073/pnas.0636464100; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Kincaid JR, 1996, J BIOL CHEM, V271, P28805, DOI 10.1074/jbc.271.46.28805; LAMBEIR AM, 1987, EUR J BIOCHEM, V163, P123, DOI 10.1111/j.1432-1033.1987.tb10744.x; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; Mayer JM, 1998, ACCOUNTS CHEM RES, V31, P441, DOI 10.1021/ar970171h; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; RECZEK CM, 1989, J MOL STRUCT, V214, P27, DOI 10.1016/0022-2860(89)80004-3; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; Schoneboom JC, 2002, J AM CHEM SOC, V124, P8142, DOI 10.1021/ja026279w; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; van Rantwijk F, 2000, CURR OPIN BIOTECH, V11, P554, DOI 10.1016/S0958-1669(00)00143-9; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wolter T, 2000, J INORG BIOCHEM, V78, P117, DOI 10.1016/S0162-0134(99)00217-2	33	416	421	3	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1653	1656		10.1126/science.1096897	http://dx.doi.org/10.1126/science.1096897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192224				2022-12-28	WOS:000221934300045
J	Herrgard, MJ; Palsson, BO				Herrgard, MJ; Palsson, BO			Flagellar biosynthesis in silico: Building quantitative models of regulatory networks	CELL			English	Editorial Material							EXPRESSION KINETICS; ESCHERICHIA-COLI; GENES	In this issue of Cell, Kalir and Alon (2004) describe the construction of an in silico model for the regulatory network responsible for the control of flagellar biosynthesis in E. coli based on quantitative gene expression data. They show how the model can be used as a quantitative blueprint to design genetic modifications with predictable influence on the dynamics of the system. The work by Kalir and Alon (2004) provides a general approach for building detailed models of transcriptional regulatory networks.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Herrgard, MJ (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Palsson, Bernhard/0000-0003-2357-6785				Aldridge P, 2002, CURR OPIN MICROBIOL, V5, P160, DOI 10.1016/S1369-5274(02)00302-8; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Kalir S, 2004, CELL, V117, P713, DOI 10.1016/j.cell.2004.05.010; Kalir S, 2001, SCIENCE, V292, P2080, DOI 10.1126/science.1058758; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lehnen D, 2002, MOL MICROBIOL, V45, P521, DOI 10.1046/j.1365-2958.2002.03032.x; NEIDHARDT FC, 1996, CELLULAR MOL BIOL; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Setty Y, 2003, P NATL ACAD SCI USA, V100, P7702, DOI 10.1073/pnas.1230759100; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881	10	3	4	1	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	2004	117	6					689	690		10.1016/j.cell.2004.05.020	http://dx.doi.org/10.1016/j.cell.2004.05.020			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186769	Bronze			2022-12-28	WOS:000222048400001
J	McMahon, GT				McMahon, GT			Coming to America - International medical graduates in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EDUCATION		Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	McMahon, GT (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA.		McMahon, Graham/D-3740-2009	McMahon, Graham/0000-0003-4288-6535				*COUNC GRAD MED ED, 2003, M SEPT 17 2003; Whelan GP, 2002, JAMA-J AM MED ASSOC, V288, P1079, DOI 10.1001/jama.288.9.1079; WHITCOMB ME, 1995, JAMA-J AM MED ASSOC, V274, P696, DOI 10.1001/jama.274.9.696; 2003, PHYS CHARACTERISTICS	4	52	52	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2435	2437		10.1056/NEJMp038221	http://dx.doi.org/10.1056/NEJMp038221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190134				2022-12-28	WOS:000221887200001
J	Busza, J; Castle, S; Diarra, A				Busza, J; Castle, S; Diarra, A			Trafficking and health	BMJ-BRITISH MEDICAL JOURNAL			English	Article									London Sch Hyg & Trop Med, Ctr Populat Studies, London WC1B 3DP, England	University of London; London School of Hygiene & Tropical Medicine	Busza, J (corresponding author), London Sch Hyg & Trop Med, Ctr Populat Studies, London WC1B 3DP, England.	joanna.busza@lshtm.ac.uk		Busza, Joanna/0000-0001-6334-0318				BOBAK L, 1996, OTTAWA SUN      1024; Busza J, 2001, REPROD HEALTH MATTER, V9, P72, DOI 10.1016/S0968-8080(01)90010-2; Butcher K, 2003, LANCET, V361, P1983, DOI 10.1016/S0140-6736(03)13596-9; Castle S., 2003, INT MIGRATION YOUNG; COOMARASWAMY R, 2000, INTEGRATION HUMAN RI; Jones M., 2003, MOTHER JONES NOV; MARSHALL P, 2001, 1 UN INT PROJ TRAFF; PHAL S, 2002, SURVEY POLICE HUMAN; SUTEES R, 2003, RES SEX WORK, V6, P5; TARAN PA, 2002, UN INTERAGENCY PROJE, V7, P1; UN, 2000, PROT PREV SUPPR PUN; *UN, UN SUPP NAT SEM HUM; *US AG INT DEV, 2001, TRAFF PERS USAIDS RE, P10; Zimmerman C., 2003, HLTH RISKS CONSEQUEN; 2001, CNN             0417; 2001, DAILY TELEGRAPH 0424	16	41	41	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1369	1371		10.1136/bmj.328.7452.1369	http://dx.doi.org/10.1136/bmj.328.7452.1369			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178619	Green Published, Green Accepted			2022-12-28	WOS:000221952700026
J	Raine, R; Carter, S; Sensky, T; Black, N				Raine, R; Carter, S; Sensky, T; Black, N			General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CFS	Objectives To compare general practitioners' perceptions of chronic fatigue syndrome and irritable bowel syndrome and to consider the implications of their perceptions for treatment. Design Qualitative analysis of transcripts of group discussions. Participants and setting A randomly selected sample of 46 general practitioners in England. Results The participants tended to stereotype patients with chronic fatigue syndrome as having certain undesirable traits. This stereotyping was due to the lack of a precise bodily location; the reclassification of the syndrome over time; transgression of social roles, with patients seen as failing to conform to the work ethic and "sick role"; and conflict between doctor and patient over causes and management. These factors led to difficulties for many general practitioners in managing patients with chronic fatigue syndrome. For both conditions many participants would not consider referral for mental health interventions, even though the doctors recognised social and psychological factors, because they were not familiar with the interventions or thought them unavailable or unnecessary. Conclusions Barriers to the effective clinical management of patients with irritable bowel syndrome and chronic fatigue syndrome are partly due to doctors' beliefs, which result in negative stereotyping of patients with chronic fatigue syndrome and the use of management strategies for both syndromes that may not take into account the best available evidence.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; Univ London Imperial Coll Sci Technol & Med, W Middlesex Univ Hosp, Isleworth TW7 6AF, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Raine, R (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.	rosalind.raine@lshtm.ac.uk		Raine, Rosalind/0000-0003-0904-749X; Carter, Simon/0000-0003-1838-3479				Asbring P, 2002, QUAL HEALTH RES, V12, P148, DOI 10.1177/104973202129119801; Asbring P, 2003, SOC SCI MED, V57, P711, DOI 10.1016/S0277-9536(02)00420-3; Ax S, 1997, J ROY SOC MED, V90, P250, DOI 10.1177/014107689709000505; Banks J, 2001, SOC SCI MED, V52, P11, DOI 10.1016/S0277-9536(00)00117-9; Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; CFS/ME Working Group, 2002, REP CFS ME WORK GROU; Deale A, 2001, SOC SCI MED, V52, P1859, DOI 10.1016/S0277-9536(00)00302-6; Dixon-Woods M, 2000, FAM PRACT, V17, P108, DOI 10.1093/fampra/17.2.108; Downes-Grainger E, 1998, PSYCHOL MED, V28, P703, DOI 10.1017/S0033291798006552; FRANK A, 1991, THEORIES MODERNITY; FUAT A, 2003, BRIT MED J, V326, P883; Green J, 1998, BMJ-BRIT MED J, V316, P1064; Green J, 1999, BRIT MED J, V319, P421; Guthrie E, 2002, BMJ-BRIT MED J, V325, P701, DOI 10.1136/bmj.325.7366.701; Heitkemper Margaret, 2002, Gastroenterol Nurs, V25, P192, DOI 10.1097/00001610-200209000-00004; HOYEN DO, 1991, BRIT J GEN PRACT, V41, P324; Michael M, 1997, PUBLIC UNDERST SCI, V6, P1, DOI 10.1088/0963-6625/6/1/001; NAJMAN JM, 1982, SOC SCI MED, V16, P1781, DOI 10.1016/0277-9536(82)90272-6; PARSNS T, 1951, SOCIAL SYSTEM; Raine R, 2002, BMJ-BRIT MED J, V325, P1082, DOI 10.1136/bmj.325.7372.1082; Shilling C, 2002, BRIT J SOCIOL, V53, P621, DOI 10.1080/0007131022000021515; *SPSS, 1999, SPSS BAS 10 0 WIND U; Talley NJ, 2002, LANCET, V360, P555, DOI 10.1016/S0140-6736(02)09712-X; Thompson WG, 1997, EUR J GASTROEN HEPAT, V9, P689; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2	25	85	86	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1354	1256B		10.1136/bmj.38078.503819.EE	http://dx.doi.org/10.1136/bmj.38078.503819.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15169743	Green Published, Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000221952700020
J	Goroll, AH; Sirio, C; Duffy, FD; LeBlond, RF; Alguire, P; Blackwell, TA; Rodak, WE; Nasca, T				Goroll, AH; Sirio, C; Duffy, FD; LeBlond, RF; Alguire, P; Blackwell, TA; Rodak, WE; Nasca, T		Residency Review Comm Internal Med	A new model for accreditation of residency programs in internal medicine	ANNALS OF INTERNAL MEDICINE			English	Article							OUTCOME-BASED EDUCATION; GUIDE NO. 14; COMPETENCE; QUALITY	A renewed emphasis on clinical competence and its assessment has grown out of public concerns about the safety, efficacy, and accountability of health care in the United States. Medical schools and residency training programs are paying increased attention to teaching and evaluating basic clinical skills, stimulated in part by these concerns and the responding initiatives of accrediting, certifying, and licensing bodies. This paper, from the Residency Review Committee for Internal Medicine of the Accreditation Council for Graduate Medical Education, proposes a new outcomes-based accreditation strategy for residency training programs in internal medicine. It shifts residency program accreditation from external audit of educational process to continuous assessment and improvement of trainee clinical competence.	Massachusetts Gen Hosp, Ctr Ambulatory Care, Boston, MA 02114 USA; Accreditat Council Grad Med Educ, Chicago, IL USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Univ Iowa, Sch Med, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Sch Med, Philadelphia, PA 19107 USA; Amer Coll Physicians, Amer Board Internal Med, Philadelphia, PA USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; University of Texas System; University of Texas Medical Branch Galveston; University of Iowa; Jefferson University; American Board of Internal Medicine; American College of Physicians; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School	Goroll, AH (corresponding author), Massachusetts Gen Hosp, Ctr Ambulatory Care, Suite 645,15 Parkman St, Boston, MA 02114 USA.	ahgoroll@partners.org						*ACCR COUNC GRAD M, 2001, PROGR REQ INT MED; *ACCR COUNC GRAD M, 2002, 2001 ANN REP, P1; *AM BOARD MED SPEC, 2002, AM BOARD MED SPEC C; [Anonymous], 2001, CROSSING QUALITY CHA; Bell H S, 1997, Fam Med, V29, P701; Block James H., 1971, MASTERY LEARNING THE; Bowen JL, 1999, AM J MED, V106, P493; *COUNC MED SPEC SO, 2003, REP FUT CONT MED ED; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; FEDERMAN DD, 1998, GUIDE EVALUATION RES; *GEN ACC OFF, 1994, REP CARD; Harden RM, 1999, MED TEACH, V21, P7, DOI 10.1080/01421599979969; Holmboe ES, 1998, ANN INTERN MED, V129, P42, DOI 10.7326/0003-4819-129-1-199807010-00011; Klessig JM, 2000, ACAD MED, V75, P71, DOI 10.1097/00001888-200001000-00018; MARKSON LE, 1995, ACCOUNTABILITY QUALI; Nasca TJ, 2001, ARCH INTERN MED, V161, P760, DOI 10.1001/archinte.161.5.760; *NAT BOARD EX FED, 2002, SERV PRACT PHYS NBME; Smith SR, 1999, MED TEACH, V21, P15, DOI 10.1080/01421599979978; SPADY WG, 1993, J CURRICULUM SUPERVI, V8, P354; Swing SR, 2002, ACAD EMERG MED, V9, P1278, DOI 10.1111/j.1553-2712.2002.tb01588.x; Wasserman SI, 2000, ANN INTERN MED, V133, P202, DOI 10.7326/0003-4819-133-3-200008010-00012; Whitcomb ME, 2003, ACAD MED, V78, P112; 2002, CLIN SKILLS ASSE FAL	24	76	79	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					902	909		10.7326/0003-4819-140-11-200406010-00012	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172905				2022-12-28	WOS:000221680600007
J	Holmboe, ES; Hawkins, RE; Huot, SJ				Holmboe, ES; Hawkins, RE; Huot, SJ			Effects of training in direct observation of medical residents' clinical competence - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-EXAMINATION SKILLS; INTERNAL-MEDICINE; STANDARDIZED PATIENTS; EVALUATION FORM; AMERICAN BOARD; PERFORMANCE; STUDENTS; COMMUNICATION; RELIABILITY; DIAGNOSIS	Background: Faculty observation of residents and students performing clinical skills is essential for reliable and valid evaluation of trainees. Objective: To evaluate the efficacy of a new multifaceted method of faculty development called direct observation of competence training. Design: Controlled trial of faculty from 16 internal medicine residency programs using a cluster randomization design. Setting: Academic medical centers. Participants: 40 internal medicine teaching faculty members: 17 in the intervention group and 23 in the control group. Measurements: Changes in faculty comfort performing direct observation, faculty satisfaction with workshop, and changes in faculty rating behaviors 8 months after completing the training. Intervention: The direct observation of competence workshop combines didactic mini-lectures, interactive small group and videotape evaluation exercises, and evaluation skill practice with standardized residents and patients. Results: 37 faculty members (16 in the intervention group and 21 in the control group) completed the study. Most of the faculty in the intervention group (14 [88%]) reported that they felt significantly more comfortable performing direct observation compared with control group faculty (4 [19%]) (P = 0.04), and all intervention faculty rated the training as outstanding. For 9 videotaped clinical encounters, intervention group faculty were more stringent than controls in their evaluations of medical interviewing, physical examination, and counseling; differences in ratings for medical interviewing and physical examination remained statistically significant even after adjustment for baseline rating behavior. Limitations: The study involved a limited number of residency programs, and faculty did not rate the performance of actual residents. Conclusion: Direct observation of competence training, a new multifaceted approach to faculty development, leads to meaningful changes in rating behaviors and in faculty comfort with evaluation of clinical skills.	Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Yale Univ, New Haven, CT USA	Uniformed Services University of the Health Sciences - USA; Yale University	Holmboe, ES (corresponding author), Waterbury Hosp & Hlth Ctr, Dept Med, Pomeroy 6,64 Robbins St, Waterbury, CT 06721 USA.							*ACCR COUNC GRAD M, 2003, ACGMA OUTC PROJ GEN; *AM BOARD INT MED, 2001, PORT INT MED RES PRO; ANDERSON MB, 1994, TEACH LEARN MED, V6, P15, DOI DOI 10.1080/10401339409539637; [Anonymous], 2002, INT HDB RES MED ED; BARROWS HS, 1993, ACAD MED, V68, P443, DOI 10.1097/00001888-199306000-00002; BEAUMIER A, 1992, CAN MED ASSOC J, V146, P489; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; BUTTERWORTH JS, 1960, JAMA-J AM MED ASSOC, V174, P32, DOI 10.1001/jama.1960.03030010034009; DUPRAS DM, 1995, ACAD MED, V70, P1029, DOI 10.1097/00001888-199511000-00022; ELLIOT DL, 1987, JAMA-J AM MED ASSOC, V258, P3405, DOI 10.1001/jama.258.23.3405; Fox RA, 2000, MED EDUC, V34, P1007, DOI 10.1046/j.1365-2923.2000.00729.x; HABER RJ, 1994, J GEN INTERN MED, V9, P140, DOI 10.1007/BF02600028; Hauenstein NMA., 1998, PERFORMANCE APPRAISA, P404, DOI 10.1007/s003300050383; HERBERS JE, 1989, J GEN INTERN MED, V4, P202, DOI 10.1007/BF02599524; Homboe ES, 2001, J GEN INTERN MED, V16, P427, DOI 10.1046/j.1525-1497.2001.016007427.x; JOHNSON JE, 1986, ARCH INTERN MED, V146, P937, DOI 10.1001/archinte.146.5.937; KALET A, 1992, J GEN INTERN MED, V7, P499, DOI 10.1007/BF02599452; Kassebaum DG, 1999, ACAD MED, V74, P842, DOI 10.1097/00001888-199907000-00020; Katz J., 1984, SILENT WORLD DOCTOR; Knowles M. S, 1984, ADULT LEARNER NEGLEC; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; KROBOTH FJ, 1992, J GEN INTERN MED, V7, P174, DOI 10.1007/BF02598008; LI JTC, 1994, ACAD MED, V69, P296, DOI 10.1097/00001888-199404000-00013; Lockyer J M, 2001, J Contin Educ Health Prof, V21, P82, DOI 10.1002/chp.1340210204; MANGIONE S, 1995, ACAD EMERG MED, V2, P622, DOI 10.1111/j.1553-2712.1995.tb03601.x; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; MEULEMAN JR, 1989, ACAD MED, V64, P277, DOI 10.1097/00001888-198905000-00018; Murphy K.R., 1991, PERFORMANCE APPRAISA; NOEL GL, 1992, ANN INTERN MED, V117, P757, DOI 10.7326/0003-4819-117-9-757; Pfeiffer C, 1998, MED EDUC, V32, P283, DOI 10.1046/j.1365-2923.1998.00222.x; PLATT FW, 1979, ANN INTERN MED, V91, P898, DOI 10.7326/0003-4819-91-6-898; RAFTERY EB, 1967, AM J EPIDEMIOL, V85, P438, DOI 10.1093/oxfordjournals.aje.a120705; Ram P, 1999, ACAD MED, V74, P62, DOI 10.1097/00001888-199901000-00020; Ramsey PG, 1998, AM J MED, V104, P152, DOI 10.1016/S0002-9343(97)00310-0; RETHANS JJ, 1991, BRIT MED J, V303, P1377, DOI 10.1136/bmj.303.6814.1377; RICHARDS T, 1990, BRIT MED J, V301, P1407, DOI 10.1136/bmj.301.6766.1407; SACHDEVA AK, 1995, SURGERY, V118, P300, DOI 10.1016/S0039-6060(05)80338-1; SCOLES PV, 2002, J MED LICENSURE DISC, V88, P66; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SKEFF KM, 1992, ARCH INTERN MED, V152, P1156, DOI 10.1001/archinte.1992.00400180028004; STAMOULIS DT, 1993, J APPL PSYCHOL, V78, P994, DOI 10.1037/0021-9010.78.6.994; Stewart M A, 1979, J R Coll Gen Pract, V29, P77; Szenas P., 1997, CONT ISSUES MED ED, V1, P1; THOMPSON WG, 1990, J GEN INTERN MED, V5, P214, DOI 10.1007/BF02600537; Todd IK, 2000, ACAD MED, V75, P50, DOI 10.1097/00001888-200001000-00011; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852; WOEHR DJ, 1994, J OCCUP ORGAN PSYCH, V67, P189, DOI 10.1111/j.2044-8325.1994.tb00562.x; WRAY NP, 1983, JAMA-J AM MED ASSOC, V249, P1035, DOI 10.1001/jama.249.8.1035	49	186	191	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					874	881		10.7326/0003-4819-140-11-200406010-00008	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172901	Green Published			2022-12-28	WOS:000221680600003
J	Jack, L; Liburd, L; Spencer, T; Airhihenbuwa, CO				Jack, L; Liburd, L; Spencer, T; Airhihenbuwa, CO			Understanding the environmental issues in diabetes self-management education research: A reexamination of 8 studies in community-based settings	ANNALS OF INTERNAL MEDICINE			English	Article							MEXICAN-AMERICANS; HEALTH-PROMOTION; INTERVENTIONS; OUTCOMES; NIDDM; INITIATIVES; FRAMEWORK; FAMILIES; EXERCISE; PROGRAM	Eight studies included in a recent systematic review of the efficacy of diabetes self-management education were qualitatively reexamined to determine the presence of theoretical frameworks, methods used to ensure cultural appropriateness, and the quality of the instrument. Theoretical frameworks that help to explain complex pathways that produce health outcomes were lacking; culture indices were not incorporated into diabetes self-management education; and the instruments used to measure outcomes were inadequate. We provide recommendations to improve research on diabetes self-management education in community settings through use of a contextual framework that encourages targeting multiple levels of influence-individual, family, organizational, community, and policy.	CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA; Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; Penn State Univ, University Pk, PA 16802 USA	Centers for Disease Control & Prevention - USA; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Jack, L (corresponding author), CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Mailstop K-10,4770 Buford Highway NE, Atlanta, GA 30341 USA.	ljack@cdc.gov						Airhihenbuwa C. O., 1995, HLTH CULTURE W PARAD; [Anonymous], 1991, NURSING CONCEPTS PRA; BARNARD RJ, 1994, DIABETES CARE, V17, P1469, DOI 10.2337/diacare.17.12.1469; BARRERA M, 1981, SOCIAL NETWORKS SOCI; Brody GH, 1998, CHILD DEV, V69, P803, DOI 10.1111/j.1467-8624.1998.tb06244.x; Brody GH, 2001, DIABETES EDUCATOR, V27, P685, DOI 10.1177/014572170102700509; BROWN SA, 1995, DIABETES EDUCATOR, V21, P203, DOI 10.1177/014572179502100307; Brown SA, 1998, DIABETES EDUCATOR, V24, P331, DOI 10.1177/014572179802400308; Brown SA, 1999, DIABETES EDUCATOR, V25, P52, DOI 10.1177/014572179902500623; CAMPBELL T, 1994, FAMILIES CHANGE COPI; DeBourdeaudhuij I, 1997, HEALTH EDUC RES, V12, P77, DOI 10.1093/her/12.1.77; ELSHAWS EB, 1994, DIABETES EDUCATOR, V20, P228, DOI 10.1177/014572179402000309; Fisher L, 2000, J FAM PRACTICE, V49, P561; Flores E T, 1995, J Natl Cancer Inst Monogr, P101; GLASGOW RE, 1988, DIABETES CARE, V11, P377, DOI 10.2337/diacare.11.5.377; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Goodman R M, 1998, J Public Health Manag Pract, V4, P37; GOODMAN RM, 1994, J COMMUNITY PSYCHOL, P6; Hahn JM, 1998, DIABETES EDUCATOR, V24, P153, DOI 10.1177/014572179802400204; HEATH GW, 1987, DIABETES CARE, V10, P579, DOI 10.2337/diacare.10.5.579; Hepworth J, 1997, HEALTH PROMOT INT, V12, P233, DOI 10.1093/heapro/12.3.233; Jack L, 1999, DIABETES EDUCATOR, V25, P775, DOI 10.1177/014572179902500510; JACK L, 2002, DIABETES EDUCATOR, V28, P922; Kumanyika S. K., 1997, Overweight and weight management: the health professional's guide to understanding and practice., P69; Nader P.R., 1988, HLTH BEHAV, P107; Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77; NOBLES WW, 1978, J MARRIAGE FAM, V40, P679, DOI 10.2307/351188; Norris SL, 2002, AM J PREV MED, V22, P39, DOI 10.1016/S0749-3797(02)00424-5; Petersen DM, 2002, AM J EVAL, V23, P55, DOI 10.1177/109821400202300106; Resnicow Ken, 1999, Ethnicity and Disease, V9, P10; Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119; Shiell A, 1996, HEALTH ECON, V5, P241, DOI 10.1002/(SICI)1099-1050(199605)5:3<241::AID-HEC197>3.3.CO;2-7; Sorensen G, 1998, ANNU REV PUBL HEALTH, V19, P379, DOI 10.1146/annurev.publhealth.19.1.379; Wang CY, 1998, PUBLIC HEALTH NURS, V15, P406, DOI 10.1111/j.1525-1446.1998.tb00367.x; WILSON W, 1987, AM J PUBLIC HEALTH, V77, P634, DOI 10.2105/AJPH.77.5.634	36	27	27	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					964	971		10.7326/0003-4819-140-11-200406010-00038	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00038			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824IS	15172922				2022-12-28	WOS:000221680600028
J	Murphy, D; Chapel, T; Clark, C				Murphy, D; Chapel, T; Clark, C			Moving diabetes care from science to practice: The evolution of the national diabetes prevention and control program	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH; MANAGEMENT; REDUCTION; MELLITUS; PEOPLE; RISK; US	The National Diabetes Prevention and Control Program has a dynamic and evolving scientific foundation. This article describes this program and how seminal research studies provide an impetus for its public health policy and programs. The charge and challenges of integrating science into past, current, and future program designs are detailed, as are the program's accomplishments. Areas requiring new science are explored, including better research to translate new findings into clinical and public health practice and models to evaluate the effect of public health on improved outcomes. The epidemic of diabetes and its increasing burden on public health demands a better understanding of existing science and its limitations and informed public dialogue and policy responses.	Ctr Dis Control & Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Murphy, D (corresponding author), MPH, 4770 Buford Highway NE,MSK-10, Atlanta, GA 30341 USA.							Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P965; BOUFFORD JI, 2001, HLTH POLITICS 21 CEN; Bowman Barbara A, 2003, J Public Health Manag Pract, VSuppl, pS8; *CDCP, 2003, STAT DIAB CONTR PROG; *CDCP, 1983, DIAB PROGR HDB; *CDCP, 2003, PROM PRACT CHRON DIS; *CDCP, 1980, CDC STAT DIAB PROGR; Centre for Disease Control and Prevention, 2002, NAT DIAB FACT SHEET; Clark N, 2003, DIABETES CARE, V26, P3333; Damond Marietta, 2003, J Public Health Manag Pract, VSuppl, pS15; Davidoff F, 1996, ANN INTERN MED, V124, P65, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00011; DESAI J, 2003, J PUBLIC HLTH MANA S, pS44; Desai Jay, 2003, J Public Health Manag Pract, VSuppl, pS36; Etheridge E.W, 1992, SENTINEL HLTH HIST C, P36; Glasgow RE, 2003, AM J PUBLIC HEALTH, V93, P1261, DOI 10.2105/AJPH.93.8.1261; HARRIS MI, 1995, NIH PUBL; HECLO H, 1995, HEALTH AFFAIR, V14, P86, DOI 10.1377/hlthaff.14.1.86; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Institute of Medicine, 2001, CROSSING QUALITY CHA; Institute of Medicine Committee on Assuring the Health of the Public in the 21st C, 2002, FUT PUBL HLTH 21 CEN; Jack L, 1999, DIABETES EDUCATOR, V25, P775, DOI 10.1177/014572179902500510; JACK L, 2003, J PUBLIC HLTH MANA S, pD64; Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Liburd LC, 1999, DIABETES EDUCATOR, V25, P382, DOI 10.1177/014572179902500309; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; McGinnis JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/hlthaff.21.2.78; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Narayan KMV, 2002, BMJ-BRIT MED J, V325, P403, DOI 10.1136/bmj.325.7361.403; *NIH, 1976, NIH PUBL; REIBER GE, 1992, DIABETES CARE, V15, P29, DOI 10.2337/diacare.15.1.S29; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; ROSE G, 1989, ANN MED, V21, P409, DOI 10.3109/07853898909149231; Safran Marc A, 2003, J Public Health Manag Pract, V9, P58; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shiell A, 1996, HEALTH ECON, V5, P241, DOI 10.1002/(SICI)1099-1050(199605)5:3<241::AID-HEC197>3.3.CO;2-7; Simmons D, 1997, DIABETIC MED, V14, P519, DOI 10.1002/(SICI)1096-9136(199707)14:7<519::AID-DIA414>3.0.CO;2-K; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Valdez R, 1999, AM J PUBLIC HEALTH, V89, P1715, DOI 10.2105/AJPH.89.11.1715; Vinicor F, 2000, DIABETES CARE, V23, P853, DOI 10.2337/diacare.23.6.853; 1981, OPHTHALMOLOGY, V88, P5583; 2000, MMWR MORB MORTAL WKL, V49, P954; 1994, MMWR MORB MORTAL WKL, V43, P798	47	14	14	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					978	984		10.7326/0003-4819-140-11-200406010-00040	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00040			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172924				2022-12-28	WOS:000221680600030
J	Nordentoft, M; Laursen, TM; Agerbo, E; Qin, P; Hoyer, EH; Mortensen, PB				Nordentoft, M; Laursen, TM; Agerbo, E; Qin, P; Hoyer, EH; Mortensen, PB			Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MENTAL-ILLNESS; MORTALITY; REGISTER; PEOPLE	Objective To study the change in risk of suicide among patients with schizophrenia and related disorders. Design Nested case-control design with linked data. Setting Four longitudinal Danish registers. Participants 18 744 people aged Lip to 75 years who committed suicide in 1981-97 individually matched with 20 controls. Results Over the time studied the reduction in suicide rate among patients with schizophrenia and schizophrenia spectrum disorder was similar to that seen in the general population (incidence rate ratio 1.00, 95% confidence interval 0.98 to 1.03). The reduction among patients with other psychosis in the schizophrenia spectrum was faster than the reduction seen in the general population. Among people admitted to hospital with schizophrenia the risk of suicide was highest in the first year after first admission, and the excess risk was largest in the younger age groups-that is, the risk decreased per year for every additional year of age. Conclusion he suicide rate among patients with a diagnosis of schizophrenia and related disorders has fallen. This may be due to better psychiatric treatment, reduced access to means of suicide, or improvements in treatment after suicide attempts.	Bispebjerg Hosp, Dept Psychiat, DK-2400 Copenhagen NV, Denmark; Univ Aarhus, Natl Ctr Register Based Res, DK-8200 Aarhus, Denmark	University of Copenhagen; Bispebjerg Hospital; Aarhus University	Nordentoft, M (corresponding author), Bispebjerg Hosp, Dept Psychiat, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	merete.nordentoft@dadlnet.dk	Laursen, Thomas Munk/AFQ-8066-2022; Nordentoft, Merete/AAH-3253-2019; Mortensen, Preben B/D-2358-2015; Agerbo, Esben/A-2645-2012	Mortensen, Preben B/0000-0002-5230-9865; Agerbo, Esben/0000-0002-2849-524X; Nordentoft, Merete/0000-0003-4895-7023; Laursen, Thomas Munk/0000-0001-6934-1784				Agerbo E, 2001, BRIT MED J, V322, P334, DOI 10.1136/bmj.322.7282.334; Appleby L, 1999, LANCET, V353, P1397, DOI 10.1016/S0140-6736(98)10014-4; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P71; COPAS JB, 1982, BRIT J PSYCHIAT, V141, P503, DOI 10.1192/bjp.141.5.503; *DANM STAT, 1991, IDA INT DAT ARB; Hills, 1993, STAT MODELS EPIDEMIO; Malig C., 1996, CIVIL REGISTRATION S; *MIN SOC AFF MOTIA, 2002, GOV STAT REP SERV ME; MORTENSEN PB, 1993, BRIT J PSYCHIAT, V163, P183, DOI 10.1192/bjp.163.2.183; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; Munk-Jorgensen P, 1999, EUR ARCH PSY CLIN N, V249, P136, DOI 10.1007/s004060050078; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Osby U, 2000, BRIT MED J, V321, P483, DOI 10.1136/bmj.321.7259.483; PALMER BA, IN PRESS AM J PSYCHI; Qin P, 2003, AM J PSYCHIAT, V160, P765, DOI 10.1176/appi.ajp.160.4.765; Qin P, 2000, BRIT J PSYCHIAT, V177, P546, DOI 10.1192/bjp.177.6.546; Rossau CD, 1997, BRIT J PSYCHIAT, V171, P355, DOI 10.1192/bjp.171.4.355; Rossing W, 1997, COMPUT ELECTRON AGR, V17, P1, DOI 10.1016/S0168-1699(96)01229-X; ROY A, 1982, BRIT J PSYCHIAT, V141, P171, DOI 10.1192/bjp.141.2.171; *SUNDH, 1982, CAUS DEATH DENM 1980; *SUNDH, 1998, FORSL NAT HAND FOR S; [No title captured]	22	97	99	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 31	2004	329	7460					261	264B		10.1136/bmj.38133.622488.63	http://dx.doi.org/10.1136/bmj.38133.622488.63			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844BY	15213108	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223133300016
J	Margolin, W				Margolin, W			Catching some Zs: A new protein for spatial regulation of bacterial cytokinesis	CELL			English	Editorial Material							CELL DIVISION; BACILLUS-SUBTILIS; MIN SYSTEM; Z-RING; FTSZ; LOCALIZATION; PLACEMENT	Prior to its duplication, the bacterial nucleoid exerts local negative control over assembly of the cytokinetic Z ring to prevent potential cuffing of the chromosome. In this issue of Cell, Wu and Errington show that a specific nucleoid-associated protein mediates this nucleoid occlusion effect, providing the first mechanistic insight into this key spatial regulatory system.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System	Margolin, W (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, 6431 Fannin St, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061074] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061074] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Harry EJ, 2001, MOL MICROBIOL, V40, P795, DOI 10.1046/j.1365-2958.2001.02370.x; Margolin W, 2001, CURR OPIN MICROBIOL, V4, P647, DOI 10.1016/S1369-5274(01)00264-8; Marston AL, 1998, GENE DEV, V12, P3419, DOI 10.1101/gad.12.21.3419; Migocki MD, 2002, EMBO REP, V3, P1163, DOI 10.1093/embo-reports/kvf233; Quardokus EM, 2002, MOL MICROBIOL, V45, P605, DOI 10.1046/j.1365-2958.2002.03040.x; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; WOLDRINGH CL, 1990, RES MICROBIOL, V141, P39, DOI 10.1016/0923-2508(90)90096-9; Wu LJ, 2004, CELL, V117, P915, DOI 10.1016/j.cell.2004.06.002; Yu XC, 2000, J BACTERIOL, V182, P6203, DOI 10.1128/JB.182.21.6203-6213.2000; Yu XC, 1999, MOL MICROBIOL, V32, P315, DOI 10.1046/j.1365-2958.1999.01351.x	10	3	3	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	2004	117	7					850	851		10.1016/j.cell.2004.06.005	http://dx.doi.org/10.1016/j.cell.2004.06.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210105	Bronze			2022-12-28	WOS:000222300200002
J	Berkowitz, LR				Berkowitz, LR			A 46-year-old woman with pelvic-floor relaxation after a second vaginal delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							URINARY-INCONTINENCE; STRESS-INCONTINENCE; ORGAN PROLAPSE; CESAREAN-SECTION; VAGINAL DELIVERY; FOLLOW-UP; WOMEN; PREVALENCE; PREGNANCY; CHILDBIRTH		Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University	Berkowitz, LR (corresponding author), Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA.							Abrams P, 1988, Scand J Urol Nephrol Suppl, V114, P5; ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; BUCHSBAUM GM, 1997, OBSTET GYNECOL, V76, P324; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; Cammu H, 2000, BJU INT, V85, P655, DOI 10.1046/j.1464-410x.2000.00506.x; Chaliha C, 2000, BRIT J OBSTET GYNAEC, V107, P1354, DOI 10.1111/j.1471-0528.2000.tb11647.x; Chaliha C, 1999, OBSTET GYNECOL, V94, P689, DOI 10.1016/S0029-7844(99)00364-6; Chen BH, 2002, INT UROGYNECOL J, V13, P80, DOI 10.1007/s001920200020; COMBS CA, 1990, AM J OBSTET GYNECOL, V163, P100, DOI 10.1016/S0002-9378(11)90678-4; Davila GW, 2002, INT UROGYNECOL J, V13, P319, DOI 10.1007/s001920200069; Dietz HP, 2002, INT UROGYNECOL J PEL, V13, P284, DOI 10.1007/s001920200062; Eason E, 2000, OBSTET GYNECOL, V95, P464, DOI 10.1016/S0029-7844(99)00560-8; Faltin DL, 2001, INT UROGYNECOL J, V12, P117, DOI 10.1007/PL00004031; Faundes A, 2001, INT J GYNECOL OBSTET, V72, P41, DOI 10.1016/S0020-7292(00)00327-1; Foldspang A, 1999, AM J PUBLIC HEALTH, V89, P209, DOI 10.2105/AJPH.89.2.209; FOLDSPANG A, 1992, J EPIDEMIOL COMMUN H, V46, P595, DOI 10.1136/jech.46.6.595; GILPIN SA, 1989, BRIT J OBSTET GYNAEC, V96, P15, DOI 10.1111/j.1471-0528.1989.tb01570.x; Goh JTW, 2002, INT UROGYNECOL J PEL, V13, P76, DOI 10.1007/s001920200019; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; IOSIF CS, 1982, INT J GYNECOL OBSTET, V20, P87, DOI 10.1016/0020-7292(82)90017-0; Kammerer-Doak DN, 1999, AM J OBSTET GYNECOL, V181, P1317, DOI 10.1016/S0002-9378(99)70370-4; Lovatsis D, 2002, INT UROGYNECOL J PEL, V13, P308, DOI 10.1007/s001920200067; MacLennan AH, 2000, BRIT J OBSTET GYNAEC, V107, P1460, DOI 10.1111/j.1471-0528.2000.tb11669.x; Meyer S, 2001, OBSTET GYNECOL, V97, P673, DOI 10.1016/S0029-7844(00)01101-7; Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6; Peschers UM, 1997, BRIT J OBSTET GYNAEC, V104, P1004, DOI 10.1111/j.1471-0528.1997.tb12057.x; Rockner G, 1991, ACTA OBSTET GYN SCAN, V70, P51, DOI 10.3109/00016349109006178; Rortveit G, 2003, NEW ENGL J MED, V348, P900, DOI 10.1056/NEJMoa021788; Sampselle CM, 2002, OBSTET GYNECOL, V100, P1230, DOI 10.1016/S0029-7844(02)02241-X; Sampselle CM, 1998, OBSTET GYNECOL, V91, P406, DOI 10.1016/S0029-7844(97)00672-8; SHIONO P, 1990, OBSTET GYNECOL, V75, P765; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; Subak LL, 2002, OBSTET GYNECOL, V100, P72, DOI 10.1016/S0029-7844(02)01993-2; Swift SE, 2000, AM J OBSTET GYNECOL, V183, P277, DOI 10.1067/mob.2000.107583; Sze EHM, 1997, OBSTET GYNECOL, V89, P466, DOI 10.1016/S0029-7844(96)00337-7; Sze EHM, 2002, OBSTET GYNECOL, V100, P981, DOI 10.1016/S0029-7844(02)02246-9; Tetzschner T, 1997, ACTA OBSTET GYN SCAN, V76, P324, DOI 10.1111/j.1600-0412.1997.tb07986.x; Thorp JM, 1999, AM J OBSTET GYNECOL, V181, P266, DOI 10.1016/S0002-9378(99)70546-6; VELPEAU A, 1831, ELEMENTARY TREATISE; VIKTRUP L, 1992, OBSTET GYNECOL, V79, P945; Wilson PD, 1996, BRIT J OBSTET GYNAEC, V103, P154, DOI 10.1111/j.1471-0528.1996.tb09668.x	43	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2699	2706		10.1056/NEJMcpc049011	http://dx.doi.org/10.1056/NEJMcpc049011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215487				2022-12-28	WOS:000222199000013
J	Provenzano, V; Shapiro, AJ; Shull, RD				Provenzano, V; Shapiro, AJ; Shull, RD			Reduction of hysteresis losses in the magnetic refrigerant Gd5Ge2Si2 by the addition of iron	NATURE			English	Article							TRANSITION	The magnetocaloric effect is the change in temperature of a material as a result of the alignment of its magnetic spins that occurs on exposure to an external magnetic field. The phenomenon forms the basis for magnetic refrigeration, a concept purported to be more efficient and environmentally friendly than conventional refrigeration systems(1-5). In 1997, a 'giant' magnetocaloric effect, between 270 K and 300 K, was reported in Gd5Ge2Si2, demonstrating its potential as a near-room-temperature magnetic refrigerant(6-8). However, large hysteretic losses ( which make magnetic refrigeration less efficient) occur in the same temperature range(8,9). Here we report the reduction (by more than 90 per cent) of these hysteretic losses by alloying the compound with a small amount of iron. This has the additional benefit of shifting the magnetic entropy change peak ( a measure of the refrigerator's optimal operating temperature) from 275 K to 305 K, and broadening its width. Although the addition of iron does not significantly affect the refrigerant capacity of the material, a greater net capacity is obtained for the iron-containing alloy when the hysteresis losses are accounted for. The iron-containing alloy is thus a much-improved magnetic refrigerant for near-room-temperature applications.	NIST, Magnet Mat Grp, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Provenzano, V (corresponding author), NIST, Magnet Mat Grp, 100 Bur Dr,MS-8552, Gaithersburg, MD 20899 USA.	virgil12@nist.gov	Shull, Robert/F-5971-2013					Choe W, 2000, PHYS REV LETT, V84, P4617, DOI 10.1103/PhysRevLett.84.4617; Fujita A, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.104416; Giguere A, 1999, PHYS REV LETT, V83, P2262, DOI 10.1103/PhysRevLett.83.2262; Glanz J, 1998, SCIENCE, V279, P2045, DOI 10.1126/science.279.5359.2045; Gschneidner KA, 1999, MATER SCI FORUM, V315-3, P69, DOI 10.4028/www.scientific.net/MSF.315-317.69; Levin EM, 2000, PHYS REV B, V62, P14625, DOI 10.1103/PhysRevB.62.R14625; MCMICHAEL RD, 1992, J MAGN MAGN MATER, V111, P29, DOI 10.1016/0304-8853(92)91049-Y; MCMICHAEL RD, 1993, J APPL PHYS, V73, P6946, DOI 10.1063/1.352443; Meyers J, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.012106; Morellon L, 1998, PHYS REV B, V58, pR14721, DOI 10.1103/PhysRevB.58.R14721; Pecharsky VK, 1997, PHYS REV LETT, V78, P4494, DOI 10.1103/PhysRevLett.78.4494; Pecharsky VK, 1997, J ALLOY COMPD, V260, P98, DOI 10.1016/S0925-8388(97)00143-6; Percharsky A O, 2003, J APPL PHYS, V93, P4722; SHULL RD, 1991, P 6 INT CRYOC C ANN, P231; Tegus O, 2002, NATURE, V415, P150, DOI 10.1038/415150a; Tegus O, 2002, PHYSICA B, V319, P174, DOI 10.1016/S0921-4526(02)01119-5; TISHIN AM, 1990, J APPL PHYS, V68, P6480, DOI 10.1063/1.347186; von Ranke PJ, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.024422; WOOD ME, 1985, CRYOGENICS, V25, P667, DOI 10.1016/0011-2275(85)90187-0	19	703	725	3	195	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					853	857		10.1038/nature02657	http://dx.doi.org/10.1038/nature02657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215859				2022-12-28	WOS:000222213000036
J	Kissel, J; Krueger, FR; Silen, J; Clark, BC				Kissel, J; Krueger, FR; Silen, J; Clark, BC			The Cometary and Interstellar Dust Analyzer at Comet 81P/Wild 2	SCIENCE			English	Article							ION FORMATION; HALLEY; PARTICLES; WILD-2; IMPACT	The CIDA (Cometary and Interstellar Dust Analyzer) instrument on the Stardust spacecraft is a time-of-flight mass spectrometer used to analyze ions formed when fast dust particles strike the instrument's target. In the spectra of 45 presumably interstellar particles, quinone derivates were identified as constituents in the organic component. The 29 spectra obtained during the flyby of Comet 81P/Wild 2 confirm the predominance of organic matter. In moving from interstellar to cometary dust, the organic material seems to lose most of its hydrogen and oxygen as water and carbon monoxide. These are now present in the comet as gas phases, whereas the dust is rich in nitrogen-containing species. No traces of amino acids were found. We detected sulfur ions in one spectrum, which suggests that sulfur species are important in cometary organics.	Max Planck Inst Aeron, D-37191 Katlenburg, Germany; Finnish Meteorol Inst, SF-00101 Helsinki, Finland; Lockheed Martin Aerosp, Denver, CO 80201 USA; Ingn Bur Krueger, D-64291 Darmstadt, Germany	Max Planck Society; Finnish Meteorological Institute; Lockheed Martin	Kissel, J (corresponding author), Max Planck Inst Aeron, Max Planck Str 2, D-37191 Katlenburg, Germany.							Caro GMM, 2002, NATURE, V416, P403, DOI 10.1038/416403a; CLARK BC, 1987, ASTRON ASTROPHYS, V187, P779; GREENBERG JM, 1984, SCI AM, V250, P124, DOI 10.1038/scientificamerican0684-124; KISSEL J, 1987, NATURE, V326, P755, DOI 10.1038/326755a0; Kissel J, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002091; KISSEL J, 1986, NATURE, V321, P280, DOI 10.1038/321280a0; Kissel J, 2001, RAPID COMMUN MASS SP, V15, P1713, DOI 10.1002/rcm.431; KISSEL J, 1987, APPL PHYS A-MATER, V42, P69, DOI 10.1007/BF00618161; KISSEL J, 1986, NATURE, V321, P336, DOI 10.1038/321336a0; KISSEL J, UNPUB; Krueger FR, 2004, RAPID COMMUN MASS SP, V18, P103, DOI 10.1002/rcm.1291; MCLAFFERTY FW, 1980, INTERPRETATION MASS, P3; SCHULZE H, 1992, METEORITICS, V27, P286; Tuzzolino AJ, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002086	14	116	117	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1774	1776		10.1126/science.1098836	http://dx.doi.org/10.1126/science.1098836			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205526				2022-12-28	WOS:000222089500037
J	Sekanina, Z; Brownlee, DE; Economou, TE; Tuzzolino, AJ; Green, SF				Sekanina, Z; Brownlee, DE; Economou, TE; Tuzzolino, AJ; Green, SF			Modeling the nucleus and jets of comet 81 P/Wild 2 based on the Stardust encounter data	SCIENCE			English	Article							ROTATION; COMA	We interpret the nucleus properties and jet activity from the Stardust spacecraft imaging and the onboard dust monitoring system data. Triangulation of 20 jets shows that 2 emanate from the nucleus dark side and 16 emanate from sources that are on slopes where the Sun's elevation is greater than predicted from the fitted triaxial ellipsoid. Seven sources, including five in the Mayo depression, coincide with relatively bright surface spots. Fitting the imaged jets, the spikelike temporal distribution of dust impacts indicates that the spacecraft crossed thin, densely populated sheets of particulate ejecta extending from small sources on the rotating nucleus, consistent with an emission cone model.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Washington, Dept Astron, Seattle, WA 98195 USA; Univ Chicago, Enrico Fermi Inst, Lab Astrophys & Space Res, Chicago, IL 60637 USA; Open Univ, Planetary & Space Sci Res Inst, Milton Keynes MK7 6AA, Bucks, England	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Washington; University of Washington Seattle; University of Chicago; Open University - UK	Sekanina, Z (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	zs@sek.jpl.nasa.gov	Green, Simon F/C-7408-2009	Green, Simon F/0000-0002-9153-9786				Brownlee DE, 2004, SCIENCE, V304, P1764, DOI 10.1126/science.1097899; FARNHAM TL, 2003, B AM ASTRON SOC, V35, P971; Ishiguro M, 2003, ASTROPHYS J, V589, pL101, DOI 10.1086/376440; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; LARSON S, 1978, B AM ASTRON SOC, V10, P589; McBride N, 1997, MON NOT R ASTRON SOC, V289, P535, DOI 10.1093/mnras/289.3.535; Sekanina Z, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002093; SEKANINA Z, 1979, ICARUS, V37, P420, DOI 10.1016/0019-1035(79)90006-X; Sekanina Z, 1998, ASTROPHYS J, V494, pL121, DOI 10.1086/311147; SEKANINA Z, 1981, ANNU REV EARTH PL SC, V9, P113, DOI 10.1146/annurev.ea.09.050181.000553; SEKANINA Z, 1982, COMETS, P251; Sekanina Z, 1987, ESA SP, V278, P315; Soderblom LA, 2004, ICARUS, V167, P4, DOI 10.1016/j.icarus.2003.07.008; Tuzzolino AJ, 2004, SCIENCE, V304, P1776, DOI 10.1126/science.1098759; VASUNDHARA R, COMMUNICATION; WHIPPLE FL, 1978, NATURE, V273, P134, DOI 10.1038/273134a0	16	92	92	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1769	1774		10.1126/science.1098388	http://dx.doi.org/10.1126/science.1098388			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205525				2022-12-28	WOS:000222089500036
J	Sugrue, LP; Corrado, GS; Newsome, WT				Sugrue, LP; Corrado, GS; Newsome, WT			Matching behavior and the representation of value in the parietal cortex	SCIENCE			English	Article							LATERAL INTRAPARIETAL AREA; DECISION; ATTENTION; REWARD; CHOICE; SPACE; LAW	Psychologists and economists have long appreciated the contribution of reward history and expectation to decision-making. Yet we know little about how specific histories of choice and reward lead to an internal representation of the "value" of possible actions. We approached this problem through an integrated application of behavioral, computational, and physiological techniques. Monkeys were placed in a dynamic foraging environment in which they had to track the changing values of alternative choices through time. In this context, the monkeys' foraging behavior provided a window into their subjective valuation. We found that a simple model based on reward history can duplicate this behavior and that neurons in the parietal cortex represent the relative value of competing actions predicted by this model.	Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Sugrue, LP (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	leo@monkeybiz.stanford.edu	Newsome, William T./W-7171-2019					Barraclough DJ, 2004, NAT NEUROSCI, V7, P404, DOI 10.1038/nn1209; BAUM WM, 1981, J EXP ANAL BEHAV, V36, P387, DOI 10.1901/jeab.1981.36-387; Bisley JW, 2003, SCIENCE, V299, P81, DOI 10.1126/science.1077395; Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; Davison M, 2000, J EXP ANAL BEHAV, V74, P1, DOI 10.1901/jeab.2000.74-1; Davison M., 1988, ERLBAUM; DEVILLIERS PA, 1976, PSYCHOL BULL, V83, P1131, DOI DOI 10.1037/0033-2909.83.6.1131; DORRIS MC, 2003, SOC NEUR ABSTR, V767, P1; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Gallistel CR, 2001, J EXP PSYCHOL ANIM B, V27, P354, DOI 10.1037//0097-7403.27.4.354; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Gold JI, 2001, TRENDS COGN SCI, V5, P10, DOI 10.1016/S1364-6613(00)01567-9; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; HARLEY CB, 1981, J THEOR BIOL, V89, P611, DOI 10.1016/0022-5193(81)90032-1; HERRNSTEIN RJ, 1961, J EXP ANAL BEHAV, V4, P267, DOI 10.1901/jeab.1961.4-267; HERRNSTEIN RJ, 1991, J ECON PERSPECT, V5, P137, DOI 10.1257/jep.5.3.137; Herrnstein RJ, 1980, LIMITS ACTION ALLOCA, P143, DOI DOI 10.1016/B978-0-12-662650-6.50011-8; HEYMAN GM, 1979, J EXP ANAL BEHAV, V31, P41, DOI 10.1901/jeab.1979.31-41; Itti L, 2001, NAT REV NEUROSCI, V2, P194, DOI 10.1038/35058500; Kahneman D, 2000, CHOICES VALUES FRAME; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Krebs JR., 1997, BEHAV ECOLOGY EVOLUT; Maynard Smith J., 1982, pi; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Rachlin H., 1997, RJ HERRNSTEIN MATCHI; Roitman JD, 2002, J NEUROSCI, V22, P9475; Schultz W, 2004, CURR OPIN NEUROBIOL, V14, P139, DOI 10.1016/j.conb.2004.03.017; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; STADDON JER, 1978, PSYCHOL REV, V85, P436, DOI 10.1037/0033-295X.85.5.436; Stephens D.W., 1986, pi	31	705	716	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1782	1787		10.1126/science.1094765	http://dx.doi.org/10.1126/science.1094765			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205529				2022-12-28	WOS:000222089500040
J	Steinbrook, R				Steinbrook, R			The cost of admission - Tiered copayments for hospital use	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Gabel J, 2003, HEALTH AFFAIR, V22, P117, DOI 10.1377/hlthaff.22.5.117; Kindig DA, 2004, HLTH LITERACY PRESCR; Lee TH, 2004, NEW ENGL J MED, V350, P2409, DOI 10.1056/NEJMsb041193; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; Newhouse JP, 1993, FREE ALL LESSONS RAN	5	11	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2539	2542		10.1056/NEJMp048107	http://dx.doi.org/10.1056/NEJMp048107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201407				2022-12-28	WOS:000222054700001
J	Hayashi, T; Boyko, EJ; Leonetti, DL; McNeely, MJ; Newell-Morris, L; Kahn, SE; Fujimoto, WY				Hayashi, T; Boyko, EJ; Leonetti, DL; McNeely, MJ; Newell-Morris, L; Kahn, SE; Fujimoto, WY			Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-FAT DISTRIBUTION; FASTING PLASMA-INSULIN; BLOOD-PRESSURE; ABDOMINAL OBESITY; HEART-DISEASE; PREVALENCE; RISK; MEN; TISSUE; HYPERINSULINEMIA	Background: Visceral adiposity is generally considered to play a key role in the metabolic syndrome. Objective: To examine the relationship between directly measured visceral adiposity and the risk for incident hypertension, independent of other adipose depots and fasting plasma insulin levels. Design: Community-based prospective cohort study with 10- to 11-year follow-up. Setting: King County, Washington. Participants: 300 Japanese Americans with a systolic blood pressure less than 140 mm Hg and a diastolic blood pressure less than 90 mm Hg who were not taking anti hypertensive medications, oral hypoglycemic medications, or insulin at study entry. Measurements: Abdominal, thoracic, and thigh fat areas were measured by using computed tomography. Total subcutaneous fat area was calculated as the sum of these fat areas excluding the intra-abdominal fat area. Hypertension during follow-up was defined as having a systolic blood pressure of 140 mm Hg or greater, having a diastolic blood pressure of 90 mm Hg or greater, or taking anti hypertensive medications. Results: There were 92 incident cases of hypertension during the follow-up period. The intra-abdominal fat area was associated with an increased risk for hypertension. Multiple-adjusted odds ratios of hypertension for quartiles of intra-abdominal fat area (1 = lowest; 4 = highest) were 5.07 (95% CI, 1.75 to 14.73) for quartile 3 and 3.48 (CI, 1.01 to 11.99) for quartile 4 compared with quartile 1 after adjustment for age, sex, fasting plasma insulin level, 2-hour plasma glucose level, body mass index, systolic blood pressure, alcohol consumption, smoking status, and energy expenditure through exercise (P = 0.003 for quadratic trend). The intra-abdominal fat area remained a significant risk factor for hypertension, even after adjustment for total subcutaneous fat area, abdominal subcutaneous fat area, or waist circumference; however, no measure of these fat areas was associated with risk for hypertension in models that contained the intra-abdominal fat area. Limitations: It is not known whether these results pertain to other ethnic groups. Conclusions: Greater visceral adiposity increases the risk for hypertension in Japanese Americans.	Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA; Univ Washington, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Boyko, EJ (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, S-152E,1660 S Columbian Way, Seattle, WA 98108 USA.	eboyko@u.washington.edu	Hayashi, Tomoshige/N-8508-2015; Boyko, Edward J/G-2484-2017	Boyko, Edward J/0000-0002-3695-192X; Kahn, Steven/0000-0001-7307-9002	NCRR NIH HHS [RR-00037] Funding Source: Medline; NHLBI NIH HHS [HL-49293] Funding Source: Medline; NIDDK NIH HHS [DK-17047, DK-02654, DK-31170, DK-35816] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031170, R22DK031170, P30DK035816, P30DK017047, K24DK002654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; Boyko EJ, 1996, INT J OBESITY, V20, P801; BOYKO EJ, 1995, DIABETES CARE, V18, P174, DOI 10.2337/diacare.18.2.174; Boyko EJ, 2000, DIABETES CARE, V23, P465, DOI 10.2337/diacare.23.4.465; Cardillo C, 1999, CIRCULATION, V100, P820, DOI 10.1161/01.CIR.100.8.820; Cassano Patricia A., 1990, Annals of Epidemiology, V1, P33; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; FOLSOM AR, 1989, INT J EPIDEMIOL, V18, P361, DOI 10.1093/ije/18.2.361; FUJIMOTO WY, 1994, DIABETOLOGIA, V37, P524, DOI 10.1007/s001250050142; Fujimoto WY, 1999, DIABETES CARE, V22, P1808, DOI 10.2337/diacare.22.11.1808; FUJIMOTO WY, 1987, DIABETES, V36, P730, DOI 10.2337/diabetes.36.6.730; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gillum RF, 1998, INT J OBESITY, V22, P127, DOI 10.1038/sj.ijo.0800554; Glantz SA., 1990, PRIMER APPL REGRESSI, P181; GUPTA AK, 1992, HYPERTENSION, V19, pI78, DOI 10.1161/01.HYP.19.1_Suppl.I78; HAFFNER SM, 1992, DIABETES CARE, V15, P1277, DOI 10.2337/diacare.15.10.1277; Haffner SM, 1996, ARCH INTERN MED, V156, P1994, DOI 10.1001/archinte.156.17.1994; Han TS, 1997, INT J OBESITY, V21, P1161, DOI 10.1038/sj.ijo.0800530; Hayashi T, 2003, CIRCULATION, V108, P1718, DOI 10.1161/01.CIR.0000087597.59169.8D; HOSMER DW, 2000, WILEY PS TX, P1; JOHNSON D, 1992, INT J OBESITY, V16, P881; KANAI H, 1990, HYPERTENSION, V16, P484, DOI 10.1161/01.HYP.16.5.484; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; Katz MH, 2003, ANN INTERN MED, V138, P644, DOI 10.7326/0003-4819-138-8-200304150-00012; Kazumi T, 2002, DIABETES CARE, V25, P971, DOI 10.2337/diacare.25.6.971; KLEINBAUM DG, 1994, LOGISTIC REGRESSION, P191; Landsberg L, 2001, J HYPERTENS, V19, P523, DOI 10.1097/00004872-200103001-00001; Leonetti Donna L., 1992, Ethnicity and Disease, V2, P326; McNeely MJ, 2004, DIABETES CARE, V27, P66, DOI 10.2337/diacare.27.1.66; McNeely MJ, 1999, OBES RES S1, V7, p47S; Motoshima H, 2002, J CLIN ENDOCR METAB, V87, P5662, DOI 10.1210/JC.2002-020635; Okosun IS, 1999, J HUM HYPERTENS, V13, P425, DOI 10.1038/sj.jhh.1000862; Poli KA, 2000, CIRCULATION, V101, P264, DOI 10.1161/01.CIR.101.3.264; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P29; Schoen RE, 1998, INT J OBESITY, V22, P338, DOI 10.1038/sj.ijo.0800591; SHETTERLY SM, 1994, J HYPERTENS, V12, P1095; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; SHUMAN WP, 1986, INVEST RADIOL, V21, P483, DOI 10.1097/00004424-198606000-00007; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; WANG J, 1994, AM J CLIN NUTR, V60, P23, DOI 10.1093/ajcn/60.1.23; Wannamethee SG, 2003, ARCH INTERN MED, V163, P1329, DOI 10.1001/archinte.163.11.1329; Warnick G R, 1986, Methods Enzymol, V129, P101	44	205	216	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					992	1000		10.7326/0003-4819-140-12-200406150-00008	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197016				2022-12-28	WOS:000222055500002
J	Moore, FA; McKinley, BA; Moore, EE				Moore, FA; McKinley, BA; Moore, EE			The next generation in shock resuscitation	LANCET			English	Review							HUMAN POLYMERIZED HEMOGLOBIN; MULTIPLE ORGAN FAILURE; ABDOMINAL COMPARTMENT SYNDROME; INDEPENDENT RISK-FACTOR; ACTIVATED FACTOR-VII; FLUID RESUSCITATION; HYPERTONIC SALINE; HEMORRHAGIC-SHOCK; BLOOD-TRANSFUSION; LACTATED RINGERS	Resuscitation of the severely injured patient who presents in shock has improved greatly, following focused wartime experience and insight from laboratory and clinical studies. Further benefit is probable from technologies that are being brought into clinical use, especially hypertonic saline dextran, haemoglobin-based oxygen carriers, less invasive early monitors, and medical informatics. These technologies could improve the potential of prehospital and early hospital care to pre-empt or more rapidly reverse hypoxaemia, hypovolaemia, and onset of shock. Damage control surgery and definitive interventional radiology will probably combine with more real-time detection and intervention for hypothermia, coagulopathy, and acidosis, to avoid extreme pathophysiology and the "bloody vicious cycle". Although now widely practised as standard of care in the USA and Europe, shock resuscitation strategies involving haemoglobin replacement and fluid volume loading to regain tissue perfusion and oxygenation vary between trauma centres. One of the difficulties is the scarcity of published evidence for or against seemingly basic intervention strategies, such as early or large-volume fluid loading. Standardised protocols for resuscitation, representing the best and most current knowledge of the clinical process, could be devised and widely implemented as interactive computerised applications among trauma centres in the USA and Europe. Prevention of injury is preferable and feasible, but early care of the severely injured patient and modulation of exaggerated systemic inflammatory response due to transfusion and other complications of traditional strategies will probably provide the next generation of improvements in shock resuscitation.	Univ Texas, Houston Med Sch, Dept Surg, Houston, TX 77030 USA; Univ Colorado, Denver Hlth Med Ctr, Dept Surg, Denver, CO 80202 USA	University of Texas System; University of Texas Health Science Center Houston; Denver Health Medical Center; University of Colorado System; University of Colorado Denver	Moore, FA (corresponding author), Univ Texas, Houston Med Sch, Dept Surg, 6431 Fannin St,Suite 4-264, Houston, TX 77030 USA.	Frederick.A.Moore@uth.tmc.edu			NIGMS NIH HHS [P50-GM4922, P50 GM38529, U54 GM62119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062119, P50GM038529] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Siaidy W, 1979, Birth Defects Orig Artic Ser, V15, P149; AMBERSON WR, 1949, J APPL PHYSIOL, V1, P469, DOI 10.1152/jappl.1949.1.7.469; Amberson WR, 1933, SCIENCE, V78, P106, DOI 10.1126/science.78.2014.106; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Arvieux C, 2003, ANN CHIR, V128, P150, DOI 10.1016/S0003-3944(02)00029-9; Balogh Z, 2003, J TRAUMA, V54, P848, DOI 10.1097/01.TA.0000070166.29649.F3; Balogh Z, 2003, ARCH SURG-CHICAGO, V138, P637, DOI 10.1001/archsurg.138.6.637; Berezina TL, 2002, J SURG RES, V102, P6, DOI 10.1006/jsre.2001.6306; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Biffl WL, 1999, SURGERY, V126, P198, DOI 10.1067/msy.1999.98738; Biffl WL, 2001, J TRAUMA, V50, P426, DOI 10.1097/00005373-200103000-00005; BOEKSTEGERS P, 1994, CRIT CARE MED, V22, P640, DOI 10.1097/00003246-199404000-00021; BOTHA AJ, 1995, SURGERY, V118, P358, DOI 10.1016/S0039-6060(05)80345-9; BOTHA AJ, 1995, SHOCK, V3, P157, DOI 10.1097/00024382-199503000-00001; Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003; BURROWS L, 1982, LANCET, V2, P662; Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023; Carmichael FJL, 2000, CRIT CARE MED, V28, P2283, DOI 10.1097/00003246-200007000-00017; CARRY LC, 1971, CURR PROB SURG, P3; CERVERA AL, 1975, AM J SURG, V129, P670, DOI 10.1016/0002-9610(75)90343-8; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; Clemmer TP, 1998, NEW HORIZ-SCI PRACT, V6, P12; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; Conhaim RL, 1999, J TRAUMA, V46, P800, DOI 10.1097/00005373-199905000-00007; Cope JT, 1997, ANN THORAC SURG, V63, P78; CORAN AG, 1971, SURGERY, V69, P874; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; CROWELL JW, 1959, AM J PHYSIOL, V196, P1033, DOI 10.1152/ajplegacy.1959.196.5.1033; CZER LSC, 1978, SURG GYN OBS, V147, P262; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Durham RM, 1996, J TRAUMA, V41, P32, DOI 10.1097/00005373-199607000-00007; Fowler R, 2002, EMERG MED CLIN N AM, V20, P953, DOI 10.1016/S0733-8627(02)00038-X; Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Gore DC, 1996, ANN SURG, V224, P97, DOI 10.1097/00000658-199607000-00015; Gould SA, 1997, J TRAUMA, V43, P325, DOI 10.1097/00005373-199708000-00019; Gould SA, 1998, J AM COLL SURGEONS, V187, P113, DOI 10.1016/S1072-7515(98)00095-7; Gould SA, 2002, J AM COLL SURGEONS, V195, P445, DOI 10.1016/S1072-7515(02)01335-2; Harkins HN, 1941, ANN SURG, V114, P891, DOI 10.1097/00000658-194111000-00010; Healey MA, 1998, J TRAUMA, V45, P894, DOI 10.1097/00005373-199811000-00010; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; HIRSHBERG A, 1995, J TRAUMA, V39, P225, DOI 10.1097/00005373-199508000-00007; HOLCOMB JB, IN PRESS MIL MED; HOLCROFT JW, 1974, ANN SURG, V180, P408; James JH, 1999, LANCET, V354, P505, DOI 10.1016/S0140-6736(98)91132-1; Kao KJ, 2000, TRANSFUS MED REV, V14, P12, DOI 10.1016/S0887-7963(00)80112-1; Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002; Kirkley SA, 1999, CLIN DIAGN LAB IMMUN, V6, P652, DOI 10.1128/CDLI.6.5.652-657.1999; Koustova E, 2002, J TRAUMA, V52, P872, DOI 10.1097/00005373-200205000-00009; Krausz MM, 2003, J TRAUMA, V54, pS39, DOI 10.1097/01.TA.0000064506.47688.51; KRAUSZ MM, 1992, SURG GYNECOL OBSTET, V174, P363; KWAN I, 2003, COCHRANE DATABASE SY, V0003, DOI DOI 10.1002/14651858; LANDRO L, 2001, WALL STREET J    JUN; Ley K, 2001, NAT MED, V7, P1105, DOI 10.1038/nm1001-1105; Ligtenberg JJM, 2002, J TRAUMA, V53, P1196, DOI 10.1097/00005373-200212000-00036; LOFGREN O, 1979, ACTA ANAESTH SCAND, V23, P534; LUCAS CE, 1980, J TRAUMA, V20, P446, DOI 10.1097/00005373-198006000-00002; Lucas CE, 2001, J AM COLL SURGEONS, V192, P86, DOI 10.1016/S1072-7515(00)00761-4; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Mann DV, 1997, ANN SURG, V226, P653, DOI 10.1097/00000658-199711000-00010; Martinowitz U, 2001, J TRAUMA, V50, P721, DOI 10.1097/00005373-200104000-00021; Martinowitz U, 2001, J TRAUMA, V51, P431, DOI 10.1097/00005373-200109000-00002; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1989, CIRC SHOCK, V29, P27; McKinley BA, 2002, J TRAUMA, V53, P825, DOI 10.1097/00005373-200211000-00004; McKinley BA, 1998, J TRAUMA, V45, P633, DOI 10.1097/00005373-199809000-00043; McKinley BA, 2000, J TRAUMA, V48, P637, DOI 10.1097/00005373-200004000-00009; MILLER JH, 1951, J CLIN INVEST, V30, P1033, DOI 10.1172/JCI102522; Moore EE, 2003, J AM COLL SURGEONS, V196, P1, DOI 10.1016/S1072-7515(02)01704-0; MOORE EE, 1991, AUST NZ J SURG, V61, P732, DOI 10.1111/j.1445-2197.1991.tb00141.x; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; MOORE FA, 1991, SURG CLIN N AM, V71, P699; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; MOORE FA, 2002, AM COLL SURG ACS SUR, P31; MOORE FA, 1998, CONTEMP SURG, V53, P213; MOSS GS, 1984, SURGERY, V95, P249; Nielsen HJ, 1996, TRANSFUSION, V36, P960, DOI 10.1046/j.1537-2995.1996.36111297091738.x; O'Neill PA, 2002, J TRAUMA, V52, P400, DOI 10.1097/00005373-200202000-00034; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; OPELZ G, 1973, TRANSPLANT P, V5, P253; PARTHASARATHI K, 1999, AM J PHYSIOL, V277, pY2145; RABINER SF, 1967, J EXP MED, V126, P1127, DOI 10.1084/jem.126.6.1127; RABINOVICI R, 1989, SURG GYNECOL OBSTET, V169, P137; Revell M, 2003, J TRAUMA, V54, pS63, DOI 10.1097/01.TA.0000056157.94970.FA; Rezende-Neto JB, 2003, SHOCK, V20, P303, DOI 10.1097/01.shk.0000082487.34705.d3; Rhee P, 2003, J TRAUMA, V54, pS52, DOI 10.1097/01.TA.0000064507.80390.10; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; ROOTH G, 1976, CRIT CARE MED, V4, P162, DOI 10.1097/00003246-197605000-00009; Rotstein OD, 2000, J TRAUMA, V49, P580, DOI 10.1097/00005373-200010000-00002; Sailors RM, 2000, J AM MED INFORM ASSN, P1127; Sauaia A, 1998, J TRAUMA, V45, P291, DOI 10.1097/00005373-199808000-00014; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; Schreiber MA, 2002, J TRAUMA, V53, P252, DOI 10.1097/00005373-200208000-00011; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHAH DM, 1982, J TRAUMA, V22, P741, DOI 10.1097/00005373-198209000-00004; Shanwell A, 1997, TRANSFUSION, V37, P678, DOI 10.1046/j.1537-2995.1997.37797369441.x; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841; SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684; SIMCHON S, 1987, AM J PHYSIOL, V253, pH898, DOI 10.1152/ajpheart.1987.253.4.H898; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; SKILLMAN JJ, 1975, SURGERY, V78, P291; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; SMITH GJ, 1985, J SURG RES, V39, P517, DOI 10.1016/0022-4804(85)90120-9; Soucy DM, 1999, J TRAUMA, V46, P209, DOI 10.1097/00005373-199902000-00001; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TREMPER KK, 1981, CRIT CARE MED, V9, P706, DOI 10.1097/00003246-198110000-00007; TREMPER KK, 1980, CRIT CARE MED, V8, P608, DOI 10.1097/00003246-198011000-00002; Vamvakas EC, 2000, TRANSFUS MED REV, V14, P23, DOI 10.1016/S0887-7963(00)80113-3; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VELANOVICH V, 1989, SURGERY, V105, P65; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; Velmahos GC, 2000, ANN SURG, V232, P409, DOI 10.1097/00000658-200009000-00013; Vlahakes G J, 1989, Eur J Cardiothorac Surg, V3, P353, DOI 10.1016/1010-7940(89)90034-1; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WAXMAN K, 1983, AM J SURG, V146, P35, DOI 10.1016/0002-9610(83)90255-6; Weil MH, 1999, CRIT CARE MED, V27, P1225, DOI 10.1097/00003246-199907000-00001; Weiskopf RB, 1998, JAMA-J AM MED ASSOC, V279, P217, DOI 10.1001/jama.279.3.217; Wiggers CJ, 1942, PHYSIOL REV, V22, P74, DOI 10.1152/physrev.1942.22.1.74; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1; Zallen G, 2000, J TRAUMA, V48, P45, DOI 10.1097/00005373-200001000-00008; ZALLEN G, 1998, SURG FORUM, V49, P100; [No title captured]	135	206	227	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1988	1996		10.1016/S0140-6736(04)16415-5	http://dx.doi.org/10.1016/S0140-6736(04)16415-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194260				2022-12-28	WOS:000221962800021
J	Papp, B; Pal, C; Hurst, LD				Papp, B; Pal, C; Hurst, LD			Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast	NATURE			English	Article							ESCHERICHIA-COLI MG1655; POST-GENOME ERA; SACCHAROMYCES-CEREVISIAE; GENETIC ROBUSTNESS; DUPLICATE GENES; NULL MUTATIONS; PATHWAYS; DATABASE	Under laboratory conditions 80% of yeast genes seem not to be essential for viability(1). This raises the question of what the mechanistic basis for dispensability is, and whether it is the result of selection for buffering or an incidental side product. Here we analyse these issues using an in silico flux model(2-5) of the yeast metabolic network. The model correctly predicts the knockout fitness effects in 88% of the genes studied(4) and in vivo fluxes. Dispensable genes might be important, but under conditions not yet examined in the laboratory. Our model indicates that this is the dominant explanation for apparent dispensability, accounting for 37 - 68% of dispensable genes, whereas 15 - 28% of them are compensated by a duplicate, and only 4 - 17% are buffered by metabolic network flux reorganization. For over one-half of those not important under nutrient-rich conditions, we can predict conditions when they will be important. As expected, such condition-specific genes have a more restricted phylogenetic distribution. Gene duplicates catalysing the same reaction are not more common for indispensable reactions, suggesting that the reason for their retention is not to provide compensation. Instead their presence is better explained by selection for high enzymatic flux.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Coll Budapest, Inst Adv Study, H-1014 Budapest, Hungary; Eotvos Lorand Univ, MTA, Ecol & Theoret Biol Res Grp, H-1117 Budapest, Hungary	University of Bath; Eotvos Lorand University	Hurst, LD (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	l.d.hurst@bath.ac.uk	; Hurst, Laurence/F-9215-2010	Papp, Balazs/0000-0003-3093-8852; Hurst, Laurence/0000-0002-1002-1054				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Daran-Lapujade P, 2004, J BIOL CHEM, V279, P9125, DOI 10.1074/jbc.M309578200; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Famili I, 2003, P NATL ACAD SCI USA, V100, P13134, DOI 10.1073/pnas.2235812100; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Forster Jochen, 2003, OMICS A Journal of Integrative Biology, V7, P193, DOI 10.1089/153623103322246584; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Glasner JD, 2003, NUCLEIC ACIDS RES, V31, P147, DOI 10.1093/nar/gkg125; Gu X, 2003, TRENDS GENET, V19, P354, DOI 10.1016/S0168-9525(03)00139-2; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kitami T, 2002, NAT GENET, V32, P191, DOI 10.1038/ng945; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Nakao, 1999, Genome Inform Ser Workshop Genome Inform, V10, P94; Pal C, 2003, NATURE, V421, P496, DOI 10.1038/421496b; Papin JA, 2003, TRENDS BIOCHEM SCI, V28, P250, DOI 10.1016/S0968-0004(03)00064-1; Papp B, 2003, NATURE, V424, P194, DOI 10.1038/nature01771; Schilling CH, 2000, BIOTECHNOL BIOENG, V71, P286, DOI 10.1002/1097-0290(2000)71:4<286::AID-BIT1018>3.0.CO;2-R; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Seoighe C, 1999, CURR OPIN MICROBIOL, V2, P548, DOI 10.1016/S1369-5274(99)00015-6; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Thatcher JW, 1998, P NATL ACAD SCI USA, V95, P253, DOI 10.1073/pnas.95.1.253; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]	29	273	279	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					661	664		10.1038/nature02636	http://dx.doi.org/10.1038/nature02636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190353				2022-12-28	WOS:000221912600041
J	Doran, M; Rassam, SS; Jones, LM; Underhill, S				Doran, M; Rassam, SS; Jones, LM; Underhill, S			Lesson of the week - Toxicity after intermittent inhalation of nitrous oxide for analgesia	BRITISH MEDICAL JOURNAL			English	Review							VITAMIN-B12		Wrexham Maelor Hosp, Wrexham LL13 7TD, Wales		Doran, M (corresponding author), Wrexham Maelor Hosp, Wrexham LL13 7TD, Wales.	mark.doran@thewaltoncentre.nhs.uk						ABDULKAREEM HS, 1991, TOXICOL IND HEALTH, V7, P97, DOI 10.1177/074823379100700107; FILIPPO TS, 1993, ARCH SURG-CHICAGO, V128, P1391; Ilniczky S, 2002, EUR J NEUROL, V9, P101, DOI 10.1046/j.1468-1331.2002.00336.x; Iwata K, 2001, AM J MED SCI, V322, P173, DOI 10.1097/00000441-200109000-00014; KOBLIN DD, 1991, ALCOHOL CLIN EXP RES, V15, P543, DOI 10.1111/j.1530-0277.1991.tb00557.x; LOUISFERDINAND RT, 1994, ADVERSE DRUG REACT T, V13, P193; SCHILLING RF, 1986, JAMA-J AM MED ASSOC, V255, P1605, DOI 10.1001/jama.255.12.1605; SMALL DH, 1980, P AUST BIOCHEM SOC, V13, P113	8	25	28	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 5	2004	328	7452					1364	1365		10.1136/bmj.328.7452.1364	http://dx.doi.org/10.1136/bmj.328.7452.1364			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178617	Green Published			2022-12-28	WOS:000221952700024
J	Buller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Piovella, F; Prins, MH; Raskob, G; Segers, AEM; Cariou, R; Leeuwenkamp, O; Lensing, AWA				Buller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Piovella, F; Prins, MH; Raskob, G; Segers, AEM; Cariou, R; Leeuwenkamp, O; Lensing, AWA		Matisse Investigators	Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; PROXIMAL-VEIN THROMBOSIS; INTRAVENOUS UNFRACTIONATED HEPARIN; INDUCED THROMBOCYTOPENIA; THROMBOEMBOLIC DISEASE; PENTASACCHARIDE	Background: The current standard initial therapies for deep venous thrombosis are low-molecular-weight heparin and unfractionated heparin. In a dose-ranging study of patients with symptomatic deep venous thrombosis, fondaparinux had efficacy and a safety profile similar to those of low-molecular-weight heparin (dalteparin). Objective: To evaluate whether fondaparinux has efficacy and safety similar to those of enoxaparin in patients with deep venous thrombosis. Design: Randomized, double-blind study. Setting: 154 centers worldwide. Patients: 2205 patients with acute symptomatic deep venous thrombosis. Intervention: Fondaparinux, 7.5 mg (5.0 mg in patients weighing <50 kg and 10.0 mg in patients weighing >100 kg) subcutaneously once daily, or enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily for at least 5 days and until vitamin K antagonists induced an international normalized ratio greater than 2.0. Measurements: The primary efficacy outcome was the 3-month incidence of symptomatic recurrent venous thromboembolic complications. The main safety outcomes were major bleeding during initial treatment and death. An independent, blinded committee adjudicated all outcomes. Results: 43 (3.9%) of 1098 patients randomly assigned to fondaparinux had recurrent thromboembolic events compared with 45 (4.1%) of 1107 patients randomly assigned to enoxaparin (absolute difference, -0.15 percentage point [95% Cl, -1.8 to 1.5 percentage points]). Major bleeding occurred in 1.1% of patients receiving fondaparinux and 1.2% of patients receiving enoxaparin. Mortality rates were 3.8% and 3.0%, respectively. Limitations: Follow-up was incomplete in 0.4% of fondaparinux-treated patients and 1.0% of enoxaparin-treated patients. Conclusions: Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis.	NV Organon, NL-5340 BH Oss, Netherlands; Sanofi Synthelabo, Paris, France; Univ Hos Maastricht, Maastricht, Netherlands; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Univ Pavia, Policlin San Matteo, Ist Clin Med, I-27100 Pavia, Italy; Hamilton Civ Hosp, Res Ctr, Hamilton, ON, Canada; Flinders Med Ctr, Bedford Pk, SA, Australia; Univ St Etienne, Hosp Bellevue, St Etienne, France; Univ Washington, Sch Med, Swedish Med Ctr, Seattle, WA USA	Sanofi-Aventis; Sanofi France; Maastricht University; Maastricht University Medical Centre (MUMC); University of Oklahoma System; University of Oklahoma Health Sciences Center; IRCCS Fondazione San Matteo; University of Pavia; McMaster University; Flinders Medical Centre; CHU de St Etienne; Universite Jean Monnet; Swedish Medical Center; University of Washington; University of Washington Seattle	Buller, HR (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, F4-211,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Piovella, Franco/AAM-8305-2020	Gallus, Alexander/0000-0001-7347-9989				Amiral J, 1997, BLOOD COAGUL FIBRIN, V8, P114, DOI 10.1097/00001721-199703000-00005; Bijsterveld NR, 2002, CIRCULATION, V106, P2550, DOI 10.1161/01.CIR.0000038501.87442.02; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902; Buller HR, 2000, CIRCULATION, V102, P2726; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Collet JP, 2001, INT J CARDIOL, V80, P81, DOI 10.1016/S0167-5273(01)00455-7; Davidson BL, 1999, AM J RESP CRIT CARE, V159, pA358; Groce James B. III, 1998, Pharmacotherapy, V18, p175S; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; McKenzie CR, 1996, ARTERIOSCL THROM VAS, V16, P1285, DOI 10.1161/01.ATV.16.10.1285; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 2002, THROMB HAEMOSTASIS, V88, P402; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; Sanderink GJCM, 2002, THROMB RES, V105, P225, DOI 10.1016/S0049-3848(02)00031-2; tenCate JW, 1997, NEW ENGL J MED, V337, P657; VANDENBELT AG, 2000, COCHRANE DATABASE SY; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003	21	425	439	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					867	873		10.7326/0003-4819-140-11-200406010-00007	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172900				2022-12-28	WOS:000221680600002
J	Hefler, L; Grimm, C; Leodolter, S; Tempfer, C				Hefler, L; Grimm, C; Leodolter, S; Tempfer, C			To butterfly or to needle: The pilot phase	ANNALS OF INTERNAL MEDICINE			English	Letter							PAIN; TRIAL		Med Univ Vienna, A-1090 Vienna, Austria	Medical University of Vienna	Hefler, L (corresponding author), Med Univ Vienna, A-1090 Vienna, Austria.			Grimm, Christoph/0000-0003-2948-8129				Carley SD, 2000, BMJ-BRIT MED J, V321, P20, DOI 10.1136/bmj.321.7252.20; Eichenfield LF, 2002, PEDIATRICS, V109, P1093, DOI 10.1542/peds.109.6.1093; Grant Marian Sue, 2003, J Emerg Nurs, V29, P116, DOI 10.1067/men.2003.66; Loveland ME, 1999, LANCET, V354, P921, DOI 10.1016/S0140-6736(99)02902-5; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857	5	6	6	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					935	936		10.7326/0003-4819-140-11-200406010-00027	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00027			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172916				2022-12-28	WOS:000221680600021
J	Hogg, JC; Chu, F; Utokaparch, S; Woods, R; Elliott, WM; Buzatu, L; Cherniack, RM; Rogers, RM; Sciurba, FC; Coxson, HO; Pare, PD				Hogg, JC; Chu, F; Utokaparch, S; Woods, R; Elliott, WM; Buzatu, L; Cherniack, RM; Rogers, RM; Sciurba, FC; Coxson, HO; Pare, PD			The nature of small-airway obstruction in chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC-BRONCHITIS; SMOKERS; INFLAMMATION; DIMENSIONS; FIBROSIS; SITE	Background Chronic obstructive pulmonary disease (COPD) is a major public health problem associated with long-term exposure to toxic gases and particles. We examined the evolution of the pathological effects of airway obstruction in patients with COPD. Methods The small airways were assessed in surgically resected lung tissue from 159 patients -39 with stage 0 (at risk), 39 with stage 1, 22 with stage 2, 16 with stage 3, and 43 with stage 4 (very severe) COPD, according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Results The progression of COPD was strongly associated with an increase in the volume of tissue in the wall (P<0.001) and the accumulation of inflammatory mucous exudates in the lumen (P<0.001) of the small airways. The percentage of the airways that contained polymorphonuclear neutrophils (P<0.001), macrophages (P<0.001), CD4 cells (P=0.02), CD8 cells (P=0.038), B cells (P<0.001), and lymphoid aggregates containing follicles (P=0.003) and the absolute volume of B cells (P=0.03) and CD8 cells (P=0.02) also increased as COPD progressed. Conclusions Progression of COPD is associated with the accumulation of inflammatory mucous exudates in the lumen and infiltration of the wall by innate and adaptive inflammatory immune cells that form lymphoid follicles. These changes are coupled to a repair or remodeling process that thickens the walls of these airways.	St Pauls Hosp, McDonald Res Wing, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Ctr Cardiovasc & Pulm Res, Vancouver, BC, Canada; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	St. Paul's Hospital; University of Saskatchewan; University of British Columbia; National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hogg, JC (corresponding author), St Pauls Hosp, McDonald Res Wing, Rm 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jhogg@mrl.ubc.ca	Coxson, Harvey O/A-9861-2017; Sciurba, Frank/AAZ-9339-2021; Pare, Peter D/C-7425-2011	Coxson, Harvey O/0000-0001-5750-9711; sciurba, frank/0000-0001-7468-2225; Woods, Ryan/0000-0002-9520-2128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063117] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63117] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas A. K., 2000, CELLULAR MOL IMMUNOL, P270; Abbas AK, 2000, CELLULAR MOL IMMUNOL, P125; [Anonymous], 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3_10; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; BOSKEN CH, 1992, AM REV RESPIR DIS, V145, P911, DOI 10.1164/ajrccm/145.4_Pt_1.911; Coxson HO, 1997, AM J RESP CRIT CARE, V155, P1649, DOI 10.1164/ajrccm.155.5.9154871; CRUZORIVE LM, 1981, J MICROSC-OXFORD, V122, P235, DOI 10.1111/j.1365-2818.1981.tb01265.x; DiStefano A, 1996, AM J RESP CRIT CARE, V153, P629, DOI 10.1164/ajrccm.153.2.8564109; Dobson AJ., 2008, INTRO GEN LINEAR MOD, DOI 10.1201/9780367807849; Espada R, 1999, CHEST, V116, P1750; FIHSER LD, 1993, BIOSTATISTICS METHOD; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; FLETCHER C, 1976, NATURAL HIST CHRONIC, P93; *GOLD, 2003, NIH PUBL, V2701; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOGG JC, 1994, THORAX, V49, P473, DOI 10.1136/thx.49.5.473; JAMES AL, 1988, AM REV RESPIR DIS, V138, P136, DOI 10.1164/ajrccm/138.1.136; JONES JG, 1980, LANCET, V1, P66; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; MATSUBA K, 1972, AM J PATHOL, V67, P265; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; MOVAT HZ, 1955, ARCH PATHOL, V60, P289; MULLEN JBM, 1985, BMJ-BRIT MED J, V291, P1235, DOI 10.1136/bmj.291.6504.1235; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469, DOI 10.1164/ajrccm.164.3.2007149; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633, DOI 10.1164/ajrccm.156.5.9701081; Sethi S, 2001, CLIN MICROBIOL REV, V14, P336, DOI 10.1128/CMR.14.2.336-363.2001; SIMANI AS, 1974, LAB INVEST, V31, P75; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; VANBRABANDT H, 1983, J APPL PHYSIOL, V55, P1733, DOI 10.1152/jappl.1983.55.6.1733; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849, DOI 10.1152/jappl.1990.69.3.849; WRIGHT JL, 1984, AM REV RESPIR DIS, V129, P989; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016	40	2529	2651	3	237	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2645	2653		10.1056/NEJMoa032158	http://dx.doi.org/10.1056/NEJMoa032158			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215480				2022-12-28	WOS:000222199000005
J	Lu, T; Pan, Y; Kao, SY; Li, C; Kohane, I; Chan, J; Yankner, BA				Lu, T; Pan, Y; Kao, SY; Li, C; Kohane, I; Chan, J; Yankner, BA			Gene regulation and DNA damage in the ageing human brain	NATURE			English	Article							EXPRESSION; REPAIR; TRAFFICKING; MICROARRAYS; PROTEIN; PROFILE	The ageing of the human brain is a cause of cognitive decline in the elderly and the major risk factor for Alzheimer's disease1. The time in life when brain ageing begins is undefined(2-4). Here we show that transcriptional profiling of the human frontal cortex from individuals ranging from 26 to 106 years of age defines a set of genes with reduced expression after age 40. These genes play central roles in synaptic plasticity, vesicular transport and mitochondrial function. This is followed by induction of stress response, antioxidant and DNA repair genes. DNA damage is markedly increased in the promoters of genes with reduced expression in the aged cortex. Moreover, these gene promoters are selectively damaged by oxidative stress in cultured human neurons, and show reduced base-excision DNA repair. Thus, DNA damage may reduce the expression of selectively vulnerable genes involved in learning, memory and neuronal survival, initiating a programme of brain ageing that starts early in adult life.	Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Yankner, BA (corresponding author), Childrens Hosp, Dept Neurol, Enders 260,300 Longwood Ave, Boston, MA 02115 USA.	Bruce.Yankner@childrens.harvard.edu	Duarte, Graziela Biude Silva/Q-7728-2016; Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160				ATHAS WF, 1991, CANCER RES, V51, P5786; Blalock EM, 2003, J NEUROSCI, V23, P3807; Bruner SD, 2000, COLD SPRING HARB SYM, V65, P103, DOI 10.1101/sqb.2000.65.103; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Jiang CH, 2001, P NATL ACAD SCI USA, V98, P1930, DOI 10.1073/pnas.98.4.1930; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; LANDFIELD PW, 1984, SCIENCE, V226, P1089, DOI 10.1126/science.6494926; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Smith DS, 2002, TRENDS CELL BIOL, V12, P28, DOI 10.1016/S0962-8924(01)02181-X; TCHOU J, 1994, J BIOL CHEM, V269, P15318; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yankner BA, 2000, NATURE, V404, P125, DOI 10.1038/35004673	25	1322	1370	2	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					883	891		10.1038/nature02661	http://dx.doi.org/10.1038/nature02661			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15190254				2022-12-28	WOS:000222213000044
J	Wootten, A; Audisio, RA; Harris, O; Gradwell, E				Wootten, A; Audisio, RA; Harris, O; Gradwell, E			An unusual breast lump	LANCET			English	Editorial Material									Whiston Hosp, Dept Gen Surg, Prescot L35 5DR, Merseyside, England; Whiston Hosp, Dept Radiol, Prescot L35 5DR, Merseyside, England; Whiston Hosp, Dept Pathol, Prescot L35 5DR, Merseyside, England	Whiston Hospital; Whiston Hospital; Whiston Hospital	Wootten, A (corresponding author), Whiston Hosp, Dept Gen Surg, Prescot L35 5DR, Merseyside, England.			Audisio, Riccardo A./0000-0002-7538-4809					0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2047	2047		10.1016/S0140-6736(04)16454-4	http://dx.doi.org/10.1016/S0140-6736(04)16454-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207955				2022-12-28	WOS:000222159800011
J	Brownlee, DE; Horz, F; Newburn, RL; Zolensky, M; Duxbury, TC; Sandford, S; Sekanina, Z; Tsou, P; Hanner, MS; Clark, BC; Green, SF; Kissel, J				Brownlee, DE; Horz, F; Newburn, RL; Zolensky, M; Duxbury, TC; Sandford, S; Sekanina, Z; Tsou, P; Hanner, MS; Clark, BC; Green, SF; Kissel, J			Surface of young Jupiter family comet 81 P/Wild 2: View from the Stardust spacecraft	SCIENCE			English	Article							NUCLEUS; MORPHOLOGY; JETS	Images taken by the Stardust mission during its flyby of 81P/Wild 2 show the comet to be a 5-kilometer oblate body covered with remarkable topographic features, including unusual circular features that appear to be impact craters. The presence of high-angle slopes shows that the surface is cohesive and self-supporting. The comet does not appear to be a rubble pile, and its rounded shape is not directly consistent with the comet being a fragment of a larger body. The surface is active and yet it retains ancient terrain. Wild 2 appears to be in the early stages of its degradation phase as a small volatile-rich body in the inner solar system.	Univ Washington, Dept Astron, Seattle, WA 98195 USA; NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Univ Massachusetts, Amherst, MA 01003 USA; Lockheed Martin Astronaut, Denver, CO 80201 USA; Open Univ, Planetary & Space Sci Res Inst, Milton Keynes MK7 6AA, Bucks, England; Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany	University of Washington; University of Washington Seattle; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Massachusetts System; University of Massachusetts Amherst; Lockheed Martin; Open University - UK; Max Planck Society	Brownlee, DE (corresponding author), Univ Washington, Dept Astron, Seattle, WA 98195 USA.	brownlee@astro.washington.edu	Green, Simon F/C-7408-2009	Green, Simon F/0000-0002-9153-9786; Zolensky, Michael/0000-0002-3181-1303				Britt DT, 2004, ICARUS, V167, P45, DOI 10.1016/j.icarus.2003.09.004; Buratti BJ, 2004, ICARUS, V167, P16, DOI 10.1016/j.icarus.2003.05.002; DUXBURY TC, UNPUB; GRUN E, 1993, J GEOPHYS RES-PLANET, V98, P15091, DOI 10.1029/93JE01134; HORZ F, 1975, PLANET SPACE SCI, V23, P151, DOI 10.1016/0032-0633(75)90076-8; Housen KR, 2003, ICARUS, V163, P102, DOI 10.1016/S0019-1035(03)00024-1; HUGHES DW, 1975, Q J ROY ASTRON SOC, V16, P410; KELLER HU, 1990, COMET HALLEY INVESTI, V2, P133; KELLER HU, 2002, CENTURY SCI, P1323; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; Newburn RL, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002081; OBERBECK VR, 1968, ICARUS, V9, P446, DOI 10.1016/0019-1035(68)90039-0; Oberst J, 2004, ICARUS, V167, P70, DOI 10.1016/j.icarus.2003.05.001; Samarasinha NH, 2001, ICARUS, V154, P540, DOI 10.1006/icar.2001.6685; SEARS DWG, 1999, METEORIT PLANET SCI, V34, P105; Sekanina Z, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002093; Sekanina Z, 2004, SCIENCE, V304, P1769, DOI 10.1126/science.1098388; SEKANINA Z, 1985, ASTRON J, V90, P2335, DOI 10.1086/113939; Soderblom LA, 2004, ICARUS, V167, P4, DOI 10.1016/j.icarus.2003.07.008; Yelle RV, 2004, ICARUS, V167, P30, DOI 10.1016/j.icarus.2003.08.020	20	252	254	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1764	1769		10.1126/science.1097899	http://dx.doi.org/10.1126/science.1097899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205524				2022-12-28	WOS:000222089500035
J	Hansen, H				Hansen, H			Faith-based treatment for addiction in Puerto Rico	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Hansen, H (corresponding author), Yale Univ, Sch Med, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM07205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alegria M, 2001, INQUIRY-J HEALTH CAR, V38, P381, DOI 10.5034/inquiryjrnl_38.4.381; ALEGRIA M, 1998, DRUG ADDICTION RES H, P123; Brusco Elizabeth., 1995, REFORMATION MACHISMO; *CENTR INT AG, WORLD FACTB 2003; Cleary Edward L., 1997, POWER POLITICS PENTE; *COL U CASA NAT CT, SHOV IMP SUBST AB ST; *COL U NAT CTR ADD, SO HELP ME GOD SUBST; COLON H, 1998, HOUSEHOLD STUDY NEED; De la Rosa MR, 2001, J PSYCHOACTIVE DRUGS, V33, P233, DOI 10.1080/02791072.2001.10400570; GOODNOUGH A, 2003, NY TIMES        1228, P20; HOFFMAN F, 1994, INT J ADDICT, V29, P445, DOI 10.3109/10826089409047392; Martin D., 2001, PENTECOSTALISM WORLD; Melendez I., 1998, PUERTO RICO SUBSTANC; *NAT DRUG INT CTR, 2003, PUERT RIC US VIRG IS	14	8	9	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2882	2882		10.1001/jama.291.23.2882	http://dx.doi.org/10.1001/jama.291.23.2882			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199043				2022-12-28	WOS:000221962500038
J	Peterson, S; Nsungwa-Sabiiti, J; Were, W; Nsabagasani, X; Magumba, G; Nambooze, J; Mukasa, G				Peterson, S; Nsungwa-Sabiiti, J; Were, W; Nsabagasani, X; Magumba, G; Nambooze, J; Mukasa, G			Coping with paediatric referral - Ugandan parents' experience	LANCET			English	Article							SEVERELY ILL CHILDREN; MANAGEMENT	Referral of severely ill children to hospital is key in the Integrated Management of Childhood Illness (IMCI). In rural Uganda, we documented the caretakers' ability to complete referral to hospital from 12 health facilities. Of 227 children, only 63 (28%) had completed referral after 2 weeks, at a median cost of US$8-85 (range 0.40-89.00). Failure to attend hospital resulted from lack of money (139 children, 90%), transport problems (39, 26%), and responsibilities at home (26, 17%). Children with incomplete referral continued treatment at referring health centres (87, 54%) or in the private sector (45, 28%). Our results show that cost of referral must decrease to make paediatric referral realistic. When referral is difficult, more specific IMCI referral criteria should be used and first-level health workers should be empowered to manage severely ill children.	Minist Hlth, Child Hlth Div, Kampala, Uganda; Rubaga Hosp, Kampala, Uganda; Makerere Univ, Makerere Inst Social Res, Kampala, Uganda; USAID, UPHOLD Program, Kampala, Uganda; Makerere Univ, Sch Med, Dept Paediat & Child Hlth, Kampala, Uganda	Makerere University; United States Agency for International Development (USAID); Makerere University	Peterson, S (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, S-17176 Stockholm, Sweden.	stefan.peterson@phs.ki.se		Peterson, Stefan/0000-0001-7203-3096				Font Fidel, 2002, BMC Int Health Hum Rights, V2, P4, DOI 10.1186/1472-698X-2-4; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P119; Kalter HD, 2003, ACTA PAEDIATR, V92, P103; Macintyre K, 1999, SOC SCI MED, V49, P1473, DOI 10.1016/S0277-9536(99)00201-4; Simoes EAF, 2003, B WORLD HEALTH ORGAN, V81, P522	5	85	85	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1955	1956		10.1016/S0140-6736(04)16411-8	http://dx.doi.org/10.1016/S0140-6736(04)16411-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194257				2022-12-28	WOS:000221962800011
J	Kurdistani, SK; Tavazoie, S; Grunstein, M				Kurdistani, SK; Tavazoie, S; Grunstein, M			Mapping global histone acetylation patterns to gene expression	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; H4; HETEROCHROMATIN; DEACETYLASE; CHROMATIN; H3; TRANSCRIPTION; BROMODOMAIN; DEPOSITION	Histone acetyltransferases and deacetylases with specificities for different sites of acetylation affect common chromatin regions. This could generate unique patterns of acetylation that may specify downstream biological processes. To search for existence of these patterns and their relationship to gene activity, we analyzed the genome-wide acetylation profiles for eleven lysines in the four core histones of Saccharomyces cerevisiae. We find that both hyper- and hypoacetylation of individual lysines are associated with transcription, generating distinct patterns of acetylation that define groups of biologically related genes. The genes within these groups are significantly coexpressed, mediate similar physiological processes, share unique cis-regulatory DNA motifs, and are enriched for binding of specific transcription factors. Our data also indicate that the in vivo binding of the transcription factor Bdf1 is associated with acetylation on most lysines but relative deacetylation on H4 lysine 16. Thus, certain acetylation patterns may be used as surfaces for specific protein-histone interactions, providing one mechanism for coordinate regulation of chromatin processes that are biologically related.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	Princeton University; Princeton University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tavazoie, S (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	mg@mbi.ucla.edu; tavazoie@molbio.princeton.edu		Kurdistani, Siavash/0000-0003-3295-3511				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Beer MA, 2004, CELL, V117, P185, DOI 10.1016/S0092-8674(04)00304-6; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Hartigan J., 1975, CLUSTERING ALGORITHM; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; WANG H, 1990, MOL CELL BIOL, V10, P17443; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	34	485	504	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					721	733		10.1016/j.cell.2004.05.023	http://dx.doi.org/10.1016/j.cell.2004.05.023			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186774	Bronze			2022-12-28	WOS:000222048400006
J	Barwell, JR; Davies, CE; Deacon, J; Harvey, K; Minor, J; Sassano, A; Taylor, M; Usher, J; Wakely, C; Earnshaw, JJ; Heather, BP; Mitchell, DC; Whyman, MR; Poskitt, KR				Barwell, JR; Davies, CE; Deacon, J; Harvey, K; Minor, J; Sassano, A; Taylor, M; Usher, J; Wakely, C; Earnshaw, JJ; Heather, BP; Mitchell, DC; Whyman, MR; Poskitt, KR			Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial	LANCET			English	Article							ENDOSCOPIC PERFORATOR SURGERY; LEG ULCERS; VEIN INCOMPETENCE; VARICOSE-VEINS; RISK-FACTORS; REFLUX; MANAGEMENT; INSUFFICIENCY; RECURRENCE; ABLATION	Background Chronic venous leg ulceration can be managed by compression treatment, elevation of the leg, and exercise. The addition of ablative superficial venous surgery to this strategy has not been shown to affect ulcer healing, but does reduce ulcer recurrence. We aimed to assess healing and recurrence rates after treatment with compression with or without surgery in people with leg ulceration. Methods We did venous duplex imaging of ulcerated or recently healed legs in 500 consecutive patients from three centres. We randomly allocated those with isolated superficial venous reflux and mixed superficial and deep reflux either compression treatment alone or in combination with superficial venous surgery. Compression consisted of multilayer compression bandaging every week until healing then class 2 below-knee stockings. Primary endpoints were 24-week healing rates and 12-month recurrence rates. Analysis was by intention to treat. Findings 40 patients were lost to follow-up and were censored. Overall 24-week healing rates were similar in the compression and surgery and compression alone groups (65% vs 65%, hazard 0.84 [95% Cl 0.77 to 1.24]; p=0.85) but 12-month ulcer recurrence rates were significantly reduced in the compression and surgery group (12% vs 28%, hazard -2.76 [95% Cl -1.78 to -4.27]; p<0.0001). Adverse events were minimal and about equal in each group. Interpretation Surgical correction of superficial venous reflux reduces 12-month ulcer recurrence. Most patients with chronic venous; ulceration will benefit from the addition of simple venous surgery.	Cheltenham Gen Hosp, Dept Vasc Surg, Cheltenham GL53 7AN, Glos, England; Gloucester Royal Hosp, Gloucester GL1 3NN, England; Southmead Gen Hosp, Bristol BS10 5NB, Avon, England	Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Southmead Hospital	Poskitt, KR (corresponding author), Cheltenham Gen Hosp, Dept Vasc Surg, Cheltenham GL53 7AN, Glos, England.	poskitt@egnhst.org.uk						Abida A, 2000, SURG DEEP VENOUS INC; Adam DJ, 2003, EUR J VASC ENDOVASC, V25, P469, DOI 10.1053/ejvs.2002.1894; Barwell JR, 2000, EUR J VASC ENDOVASC, V20, P363, DOI 10.1053/ejvs.2000.1196; Barwell JR, 2000, PHLEBOLOGY, V15, P49, DOI 10.1007/s005230070021; Bello M, 1999, BRIT J SURG, V86, P755, DOI 10.1046/j.1365-2168.1999.01155.x; DARKE SG, 1992, EUR J VASCULAR SURG, V6, P4, DOI 10.1016/S0950-821X(05)80086-6; Dwerryhouse S, 1999, J VASC SURG, V29, P589, DOI 10.1016/S0741-5214(99)70302-2; Franks P, 1995, AGE AGEING, V240, P440; Ghauri ASK, 1998, EUR J VASC ENDOVASC, V16, P238, DOI 10.1016/S1078-5884(98)80226-8; Ghauri ASK, 2000, BRIT J SURG, V87, P1048, DOI 10.1046/j.1365-2168.2000.01491.x; Gloviczki P, 1999, J VASC SURG, V29, P489, DOI 10.1016/S0741-5214(99)70278-8; Grabs AJ, 1996, BRIT J SURG, V83, P1380, DOI 10.1002/bjs.1800831016; Iafrati MD, 2002, J VASC SURG, V36, P1167, DOI 10.1067/mva.2002.129642; IAFRATI MD, 1994, PHLEBOLOGY, V9, P114, DOI 10.1177/026835559400900306; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Labropoulos N, 1997, VASCULAR SURG, V31, P242, DOI 10.1177/153857449703100316; LABROPOULOS N, 1995, AM J SURG, V169, P572, DOI 10.1016/S0002-9610(99)80223-2; Labropoulos N, 2000, J VASC SURG, V32, P663, DOI 10.1067/mva.2000.110050; MACIN DCM, 1998, STAT TABLES DESIGN C; Margolis DJ, 1999, ARCH DERMATOL, V135, P920, DOI 10.1001/archderm.135.8.920; MOFFATT CJ, 1992, BRIT MED J, V305, P1389, DOI 10.1136/bmj.305.6866.1389; MONK BE, 1982, CLIN EXP DERMATOL, V7, P397, DOI 10.1111/j.1365-2230.1982.tb02447.x; Nachbur B, 1994, Wien Med Wochenschr, V144, P264; Nelzen O, 2000, BRIT J SURG, V87, P86, DOI 10.1046/j.1365-2168.2000.01305.x; Nelzen O, 2000, PHLEBOLOGY, V15, P110, DOI 10.1007/s005230070005; Padberg FT, 1996, J VASC SURG, V24, P711, DOI 10.1016/S0741-5214(96)70002-2; Sales CM, 1996, ANN VASC SURG, V10, P186, DOI 10.1007/BF02000764; Stuart WP, 1998, J VASC SURG, V28, P834, DOI 10.1016/S0741-5214(98)70058-8; Walsh J C, 1994, Ann Vasc Surg, V8, P566, DOI 10.1007/BF02017413; Zamboni P, 2003, EUR J VASC ENDOVASC, V25, P313, DOI 10.1053/ejvs.2002.1871	30	378	390	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1854	1859		10.1016/S0140-6736(04)16353-8	http://dx.doi.org/10.1016/S0140-6736(04)16353-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183623				2022-12-28	WOS:000221822300009
J	Bogaert, D; van Belkum, A; Sluijter, M; Luijendijk, A; de Groot, R; Rumke, HC; Verbrugh, HA; Hermans, PWM				Bogaert, D; van Belkum, A; Sluijter, M; Luijendijk, A; de Groot, R; Rumke, HC; Verbrugh, HA; Hermans, PWM			Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children	LANCET			English	Article							CONJUGATE VACCINE; DISEASE	A trial with a 7-valent pneumococcal-conjugate vaccine in children with recurrent acute otitis media showed a shift in pneumococcal colonisation towards non-vaccine serotypes and an increase in Staphylococcus aureus-related acute otitis media after vaccination. We investigated prevalence and determinants of nasopharyngeal carriage of Streptococcus pneumoniae and S aureus in 3198 healthy children aged 1-19 years. Nasopharyngeal carriage of S pneumoniae was detected in 598 (19%) children, and was affected by age (peak incidence at 3 years) and day-care attendance (odds ratio [OR] 2.14, 95% CI 1.44-3.18). S aureus carriage was affected by age (peak incidence at 10 years) and male sex (OR 1.46, 1.25-1.70). Serotyping showed 42% vaccine type pneumococci. We noted a negative correlation for co-colonisation of S aureus and vaccine-type pneumococci (OR 0.68, 0.48-0.94), but not for S aureus and non-vaccine serotypes. These findings suggest a natural competition between colonisation with vaccine-type pneumococci and S aureus, aureus, which might explain the increase in S aureus-related otitis media after vaccination.	Erasmus Med Ctr Sophia, Dept Paediat, Rotterdam, Netherlands; Erasmus Med Ctr Sophia, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands; Vaxinostics, Rotterdam, Netherlands; Erasmus Univ, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam	Hermans, PWM (corresponding author), Erasmus Med Ctr Sophia, Dept Paediat, Rotterdam, Netherlands.	p.hermans@erasmusmc.nl	Hermans, Peter W.M./H-8042-2014; Hermans, Peter P.W.M./F-4655-2010	Bogaert, Debby/0000-0003-2651-7000				[Anonymous], MMWR RECOMM REP; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; de Greeff S C, 2003, Ned Tijdschr Geneeskd, V147, P1132; Ghaffar F, 1999, PEDIATR INFECT DIS J, V18, P638, DOI 10.1097/00006454-199907000-00016; HOSMER DW, 1989, APPL LOGISTIC REGRES; Leiberman A, 1999, INT J PEDIATR OTORHI, V49, pS151; LENETTE EH, 1985, MANUAL CLIN MICROBIO; Veenhoven R, 2003, LANCET, V361, P2189, DOI 10.1016/S0140-6736(03)13772-5; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	9	425	444	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1871	1872		10.1016/S0140-6736(04)16357-5	http://dx.doi.org/10.1016/S0140-6736(04)16357-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183627				2022-12-28	WOS:000221822300013
J	Bergmann, DC; Lukowitz, W; Somerville, CR				Bergmann, DC; Lukowitz, W; Somerville, CR			Stomatal development and pattern controlled by a MAPKK kinase	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; CASCADE; PLANTS; MOUTHS; LEAVES; CO2; TOO	Stomata are epidermal structures that modulate gas exchange between a plant and its environment. During development, stomata are specified and positioned nonrandomly by the integration of asymmetric cell divisions and intercellular signaling. The Arabidopsis mitogen-activated protein kinase kinase kinase gene, YODA, acts as part of a molecular switch controlling cell identities in the epidermis. Null mutations in YODA lead to excess stomata, whereas constitutive activation of YODA eliminated stomata. Transcriptome analysis of seedlings with altered YODA activity was used to identify potential stomatal regulatory genes. A putative transcription factor from this set was shown to regulate the developmental behavior of stomatal precursors.	Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Carnegie Institution for Science; Stanford University	Somerville, CR (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.	crs@stanford.edu	Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Bergmann, Dominique/0000-0003-0873-3543	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064273] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 F32GM064273-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Berger D, 2000, GENE DEV, V14, P1119; BERGMANN DJ, UNPUB; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Geisler M, 2000, PLANT CELL, V12, P2075, DOI 10.1105/tpc.12.11.2075; Gray JE, 2000, NATURE, V408, P713, DOI 10.1038/35047071; Innes RW, 2001, TRENDS PLANT SCI, V6, P392, DOI 10.1016/S1360-1385(01)02058-1; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Lake JA, 2001, NATURE, V411, P154, DOI 10.1038/35075660; Lukowitz W, 2004, CELL, V116, P109, DOI 10.1016/S0092-8674(03)01067-5; MELARAGNO JE, 1993, PLANT CELL, V5, P1661, DOI 10.1105/tpc.5.11.1661; Nadeau JA, 2002, SCIENCE, V296, P1697, DOI 10.1126/science.1069596; Nadeau JA, 2003, TRENDS PLANT SCI, V8, P294, DOI 10.1016/S1360-1385(03)00102-X; Nadeau JA, 2002, THE ARABIDOPSIS BOOK; O'Rourke SM, 2002, TRENDS GENET, V18, P405, DOI 10.1016/S0168-9525(02)02723-3; Ouaked F, 2003, EMBO J, V22, P1282, DOI 10.1093/emboj/cdg131; Rhee SY, 2003, PLANT PHYSIOL, V133, P1170, DOI 10.1104/pp.103.028266; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; von Groll U, 2002, PLANT CELL, V14, P1527, DOI 10.1105/tpc.001016; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woodward FI, 2002, NEW PHYTOL, V153, P477, DOI 10.1046/j.0028-646X.2001.00338.x; Yang M, 1995, PLANT CELL, V7, P2227, DOI 10.1105/tpc.7.12.2227; Zhao LM, 1999, AM J BOT, V86, P929, DOI 10.2307/2656609	25	389	429	3	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1494	1497		10.1126/science.1096014	http://dx.doi.org/10.1126/science.1096014			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178800				2022-12-28	WOS:000221795800042
J	Canter, RJ; Greelish, JP				Canter, RJ; Greelish, JP			Paraesophageal hernia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Canter, RJ (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.			Canter, Robert/0000-0002-3331-5418					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2398	2398		10.1056/NEJMicm970888	http://dx.doi.org/10.1056/NEJMicm970888			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175441				2022-12-28	WOS:000221754200010
J	Lee, TH; Meyer, GS; Brennan, TA				Lee, TH; Meyer, GS; Brennan, TA			A middle ground on public accountability	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE; MORTALITY		Partners Healthcare Syst, Boston, MA 02199 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Partners Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Lee, TH (corresponding author), Partners Healthcare Syst, Prudential tower,11th Fl,800 Boylston St, Boston, MA 02199 USA.	thlee@partners.org						Dranove D, 2003, J POLIT ECON, V111, P555, DOI 10.1086/374180; Galvin R, 2002, NEW ENGL J MED, V347, P939, DOI 10.1056/NEJMsb012850; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; Krumholz HM, 2002, JAMA-J AM MED ASSOC, V287, P1277, DOI 10.1001/jama.287.10.1277; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638	8	55	55	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2409	2412		10.1056/NEJMsb041193	http://dx.doi.org/10.1056/NEJMsb041193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175444				2022-12-28	WOS:000221754200014
J	Schaefer, JB; Breeden, LL				Schaefer, JB; Breeden, LL			RB from a bud's eye view	CELL			English	Editorial Material							TRANSCRIPTION; ACTIVATION	RB and related proteins block transcriptional activation of genes critical to initiation of the cell cycle and suppress unwanted cell division. The circuitry controlling this response is generally conserved from humans to yeast, but no negative regulator like RB has been found in yeast. In this issue of Cell, two studies (Costanzo et al., 2004; de Bruin et al., 2004) reveal that Whi5 appears to play the role of RB in preventing precocious cell cycle entry in budding yeast.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Schaefer, JB (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Breeden, Linda/0000-0001-7337-5434				Breeden LL, 2003, CURR BIOL, V13, pR31, DOI 10.1016/S0960-9822(02)01386-6; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2	9	16	16	1	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	2004	117	7					849	850		10.1016/j.cell.2004.06.008	http://dx.doi.org/10.1016/j.cell.2004.06.008			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210104	Bronze			2022-12-28	WOS:000222300200001
J	McDonald, SP; Craig, JC				McDonald, SP; Craig, JC		Australian New Zealand Paediat Nep	Long-term survival of children with end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; DIALYSIS; MORTALITY; INFANTS; TRANSPLANTATION; RECIPIENTS; FAILURE; COHORT	Background Although renal-replacement therapy for children with end-stage renal disease has been used for several decades, data on patients' long-term survival are sparse. Methods We examined the long-term survival of all children and adolescents who were under 20 years of age when renal-replacement therapy commenced (study period, April 1963 through March 2002), using data from the Australia and New Zealand Dialysis and Transplant Registry. Survival was analyzed with the use of Kaplan-Meier methods and age-standardized mortality rates. Risk factors for death were analyzed with the use of Cox regression analysis with time-dependent covariates. Results A total of 1634 children and adolescents were followed for a median of 9.7 years. The long-term survival rate among children requiring renal-replacement therapy was 79 percent at 10 years and 66 percent at 20 years. Mortality rates were 30 times as high as for children without end-stage renal disease. Risk factors for death were a young age at the time renal-replacement therapy was initiated (especially for children under 1 year of age, among whom the risk was four times as high as for children 15 to 19 years of age) and treatment with dialysis (which was associated with a risk more than four times as high as for renal transplantation). Overall, a trend toward improved survival was observed over the four decades of the study. Conclusions Despite improvement in long-term survival, mortality rates among children requiring renal-replacement therapy remain substantially higher than those among children without end-stage renal disease. Increasing the proportion of children treated with renal transplantation rather than with dialysis can improve survival further.	Queen Elizabeth Hosp, ANZDATA Registry, Adelaide, SA, Australia; Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia; Childrens Hosp Westmead, Natl Hlth & Med Res Council Ctr Clin Res Excellen, Sydney, NSW, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney	McDonald, SP (corresponding author), Queen Elizabeth Hosp, ANZDATA Registry, 28 Woodville Rd, Woodville S, SA 5011, Australia.	stephenm@anzdata.org.au	Craig, Jonathan/E-2813-2013	Craig, Jonathan/0000-0002-2548-4035				[Anonymous], 2003, USRDS 2003 ANN DAT R; *AUSTR BUR STAT, 2001, 33020 ABS; Bakkaloglu SA, 2000, PERITON DIALYSIS INT, V20, P568; Coulthard MG, 2002, ARCH DIS CHILD, V87, P511, DOI 10.1136/adc.87.6.511; EHRICH JHH, 1992, NEPHROL DIAL TRANSPL, V7, P1171, DOI 10.1093/ndt/7.12.1171; Geary DF, 1998, J PEDIATR-US, V133, P154, DOI 10.1016/S0022-3476(98)70199-4; Groothoff JW, 2002, KIDNEY INT, V61, P621, DOI 10.1046/j.1523-1755.2002.00156.x; HELD PJ, 1992, CLIN TRANSPLANTS 199, P71; HENNING P, 1988, ARCH DIS CHILD, V63, P35, DOI 10.1136/adc.63.1.35; Ledermann SE, 2000, J PEDIATR-US, V136, P24, DOI 10.1016/S0022-3476(00)90044-1; Leonard MB, 2003, KIDNEY INT, V63, P744, DOI 10.1046/j.1523-1755.2003.00788.x; Li SQ, 2003, AUST NZ J PUBL HEAL, V27, P419, DOI 10.1111/j.1467-842X.2003.tb00420.x; McDonald SP, 2002, NEPHROL DIAL TRANSPL, V17, P2212, DOI 10.1093/ndt/17.12.2212; Mitsnefes MM, 2000, PEDIATR NEPHROL, V14, P898, DOI 10.1007/s004670000303; *NAPRTCS, 2003, 2003 ANN REP REN TRA; Parekh RS, 2002, J PEDIATR-US, V141, P191, DOI 10.1067/mpd.2002.125910; RUSS GR, 2002, AUSTR NZ DIALYSIS TR; Silverstein DM, 2000, PEDIATR NEPHROL, V14, P105, DOI 10.1007/s004670050022; Vats AN, 2000, TRANSPLANTATION, V69, P1414, DOI 10.1097/00007890-200004150-00035; WLAKER RG, 1999, 22 REPORT AUSTR NZ D, P90; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Wood EG, 2001, AM J KIDNEY DIS, V37, P573, DOI 10.1053/ajkd.2001.22083	22	535	556	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2654	2662		10.1056/NEJMoa031643	http://dx.doi.org/10.1056/NEJMoa031643			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215481				2022-12-28	WOS:000222199000006
J	Dattani, M; Preece, M				Dattani, M; Preece, M			Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment	LANCET			English	Review							HYPERSENSITIVE SITES I; LOCUS-CONTROL REGION; CHILDHOOD-ONSET; SHORT STATURE; BODY-COMPOSITION; MOLECULAR-BASIS; ADULT PATIENTS; SHORT CHILDREN; FINAL HEIGHT; GH TREATMENT	Advances in molecular biology have led to the identification of mutations within several novel genes associated with the phenotype of isolated growth hormone deficiency, combined pituitary hormone deficiency, and syndromes such as septo-optic dysplasia. Progress has also been made in terms of the optimum diagnosis of disorders of stature and their treatment. The use of growth hormone for the treatment of adults with growth hormone deficiency and conditions such as Turner's syndrome, Prader-Willi syndrome, intrauterine growth restriction, and chronic renal failure has changed the practice of endocrinology, although cost-benefit implications remain to be established.	UCL, Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Preece, M (corresponding author), UCL, Inst Child Hlth, London WC1N 1EH, England.	mpreece@ich.ucl.ac.uk	DATTANI, MEHUL/C-5401-2008					Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; Adan L, 1997, J CLIN ENDOCR METAB, V82, P229, DOI 10.1210/jc.82.1.229; Aimaretti G, 2000, CLIN ENDOCRINOL, V52, P287, DOI 10.1046/j.1365-2265.2000.00957.x; Allen DB, 1999, PEDIATRICS, V104, P1004; AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; Amselem S, 1996, BAILLIERE CLIN ENDOC, V10, P353, DOI 10.1016/S0950-351X(96)80485-X; ARIAS AMP, 2003, P ENDOCR SOC, P393; Arslanoglu I, 2001, J PEDIATR ENDOCR MET, V14, P517; Arvat E, 2001, J CLIN ENDOCR METAB, V86, P1169, DOI 10.1210/jc.86.3.1169; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Ayling RM, 1997, NAT GENET, V16, P13, DOI 10.1038/ng0597-13; Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; Baumann G, 2002, Minerva Endocrinol, V27, P265; Bengtsson BA, 2000, J CLIN ENDOCR METAB, V85, P933, DOI 10.1210/jc.85.3.933; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Bennani-Baiti IM, 1998, P NATL ACAD SCI USA, V95, P10655, DOI 10.1073/pnas.95.18.10655; BERCU BB, 1986, J CLIN ENDOCR METAB, V63, P709, DOI 10.1210/jcem-63-3-709; Blethen Sandra L., 1995, Current Opinion in Pediatrics, V7, P466, DOI 10.1097/00008480-199508000-00020; Blethen SL, 1996, J CLIN ENDOCR METAB, V81, P1704, DOI 10.1210/jc.81.5.1704; Bulow B, 2000, J CLIN ENDOCR METAB, V85, P574, DOI 10.1210/jc.85.2.574; Cacciari E, 1999, CLIN ENDOCRINOL, V51, P733, DOI 10.1046/j.1365-2265.1999.00875.x; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Carvalho LR, 2003, J CLIN INVEST, V112, P1192, DOI 10.1172/JCI200318589; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; Cohen LE, 2002, ENDOCR REV, V23, P431, DOI 10.1210/er.2001-0030; Cohen RN, 2003, J CLIN ENDOCR METAB, V88, P4832, DOI 10.1210/jc.2002-021868; Cuneo RC, 1998, J CLIN ENDOCR METAB, V83, P107, DOI 10.1210/jc.83.1.107; Cutfield W, 1999, ACTA PAEDIATR, V88, P72, DOI 10.1111/j.1651-2227.1999.tb14356.x; Cutfield WS, 2000, LANCET, V355, P610, DOI 10.1016/S0140-6736(99)04055-6; Dasen JS, 2001, ANNU REV NEUROSCI, V24, P327, DOI 10.1146/annurev.neuro.24.1.327; Date Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/en.141.11.4255; Dattani MT, 2000, CLIN GENET, V57, P337, DOI 10.1034/j.1399-0004.2000.570503.x; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; deBoer H, 1997, J CLIN ENDOCR METAB, V82, P2032, DOI 10.1210/jc.82.7.2032; DeVile CJ, 1996, ARCH DIS CHILD, V75, P108, DOI 10.1136/adc.75.2.108; Donaubauer J, 2003, CLIN ENDOCRINOL, V58, P456, DOI 10.1046/j.1365-2265.2003.01739.x; Ericson J, 1998, DEVELOPMENT, V125, P1005; FRADKIN JE, 1993, JAMA-J AM MED ASSOC, V270, P2829, DOI 10.1001/jama.270.23.2829; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; GLUCKMAN PD, 1981, CIBA F SYMP, V86, P5; GLUCKMAN PD, 1992, J PEDIATR-US, V121, P920, DOI 10.1016/S0022-3476(05)80342-7; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Goddard AD, 1997, J PEDIATR-US, V131, pS51, DOI 10.1016/S0022-3476(97)70012-X; Guyda HJ, 1999, J CLIN ENDOCR METAB, V84, P4307, DOI 10.1210/jc.84.12.4307; Hamilton J, 1998, AM J MED GENET, V80, P128, DOI 10.1002/(SICI)1096-8628(19981102)80:2<128::AID-AJMG7>3.3.CO;2-3; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hansen TB, 1996, J CLIN ENDOCR METAB, V81, P3352, DOI 10.1210/jc.81.9.3352; HERNANDEZ M, 1991, HORM RES, V35, P13, DOI 10.1159/000181869; Hilken J, 2001, ARCH DIS CHILD, V84, P387, DOI 10.1136/adc.84.5.387; HINDMARSH PC, 1995, ARCH DIS CHILD, V72, P362, DOI 10.1136/adc.72.4.362; HINDMARSH PC, 1988, CLIN ENDOCRINOL, V29, P35, DOI 10.1111/j.1365-2265.1988.tb00247.x; Hintz RL, 1999, NEW ENGL J MED, V340, P502, DOI 10.1056/NEJM199902183400702; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; Jaffe CA, 1998, J CLIN INVEST, V102, P153, DOI 10.1172/JCI2908; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; JORGENSEN JOL, 1991, ENDOCR REV, V12, P189, DOI 10.1210/edrv-12-3-189; JORGENSEN JOL, 1989, LANCET, V1, P1221; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; Juul A, 2002, HORM RES, V58, P233, DOI 10.1159/000066265; KARLBERG J, 1988, ACTA PAEDIATR SCAND, V77, P385, DOI 10.1111/j.1651-2227.1988.tb10665.x; KARLBERG J, 1987, STAT MED, V6, P185, DOI 10.1002/sim.4780060210; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LINDSAY R, 1994, J PEDIATR-US, V125, P29, DOI 10.1016/S0022-3476(94)70117-2; Loche S, 2002, J PEDIATR-US, V140, P445, DOI 10.1067/mpd.2002.122729; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MALOZOWSKI S, 1995, J PEDIATR-US, V126, P996, DOI 10.1016/S0022-3476(95)70232-6; McGauley G, 1996, HORM RES, V45, P34, DOI 10.1159/000184756; McGauley G, 2000, GROWTH HORM IGF RES, V10, P63, DOI 10.1016/S1096-6374(00)80012-X; McGuinness L, 2003, ENDOCRINOLOGY, V144, P720, DOI 10.1210/en.2002-220847; Mendonca BB, 1999, J CLIN ENDOCR METAB, V84, P942, DOI 10.1210/jc.84.3.942; Mitchell H, 1999, ARCH DIS CHILD, V80, P443, DOI 10.1136/adc.80.5.443; Monson JP, 2000, CLIN ENDOCRINOL, V53, P545, DOI 10.1046/j.1365-2265.2000.01043.x; Moseley CT, 2002, J CLIN ENDOCR METAB, V87, P847, DOI 10.1210/jc.87.2.847; Muccioli G, 2000, ANN ENDOCRINOL-PARIS, V61, P27; Nanduri VR, 2000, CLIN ENDOCRINOL, V53, P509, DOI 10.1046/j.1365-2265.2000.01125.x; Noeker M, 2000, J PEDIATR ENDOCR MET, V13, P1585; Norrelund H, 2000, J CLIN ENDOCR METAB, V85, P1912, DOI 10.1210/jc.85.5.1912; OGILVYSTUART AL, 1992, BRIT MED J, V304, P1601, DOI 10.1136/bmj.304.6842.1601; OGILVYSTUART AL, 1992, ARCH DIS CHILD, V67, P1107, DOI 10.1136/adc.67.9.1107; Osorio MGF, 2002, J CLIN ENDOCR METAB, V87, P5076, DOI 10.1210/jc.2001-011936; Palmqvist R, 2002, GUT, V50, P642, DOI 10.1136/gut.50.5.642; Papotti M, 2000, J CLIN ENDOCR METAB, V85, P3803, DOI 10.1210/jc.85.10.3803; Pinto G, 1999, ANN ENDOCRINOL-PARIS, V60, P224; PREECE MA, 2002, OXFORD TXB ENDOCRINO, P943; Ranke MB, 1999, HORM RES, V51, P70, DOI 10.1159/000053165; Ranke MB, 1996, BAILLIERE CLIN ENDOC, V10, P401, DOI 10.1016/S0950-351X(96)80530-1; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; RAPAPORT R, 1995, J PEDIATR-US, V126, P759, DOI 10.1016/S0022-3476(95)70407-8; ROCHICCIOLI P, 1990, HORM RES, V33, P97, DOI 10.1159/000181592; ROSEN T, 1993, ACTA ENDOCRINOL-COP, V129, P201, DOI 10.1530/acta.0.1290201; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; ROSEN T, 1993, CLIN ENDOCRINOL, V38, P63, DOI 10.1111/j.1365-2265.1993.tb00974.x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Rosenfeld MG, 2000, RECENT PROG HORM RES, V55, P1; Rosenfeld RG, 2002, J PEDIATR ENDOCR MET, V15, P1361; Rosenfeld RG, 1998, J PEDIATR-US, V132, P319, DOI 10.1016/S0022-3476(98)70452-4; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; Saenger P, 2002, BMJ-BRIT MED J, V325, P58, DOI 10.1136/bmj.325.7355.58; Saenger P, 2001, J CLIN ENDOCR METAB, V86, P3061, DOI 10.1210/jc.86.7.3061; Saggese G, 1996, J CLIN ENDOCR METAB, V81, P3077, DOI 10.1210/jc.81.8.3077; Saggese G., 1998, Hormone Research (Basel), V50, P320; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Sanchez JE, 1998, J CLIN ENDOCR METAB, V83, P4079, DOI 10.1210/jc.83.11.4079; Sandberg DE, 2002, BEST PRACT RES CL EN, V16, P449, DOI 10.1053/beem.2002.0211; SARGENT JD, 1994, ARCH PEDIAT ADOL MED, V148, P681, DOI 10.1001/archpedi.1994.02170070019003; Seminara S, 1998, CLIN ENDOCRINOL, V49, P125, DOI 10.1046/j.1365-2265.1998.00502.x; SHAH A, 1992, BRIT MED J, V304, P173, DOI 10.1136/bmj.304.6820.173; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Sheng HZ, 1999, TRENDS GENET, V15, P236, DOI 10.1016/S0168-9525(99)01742-4; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Shewchuk BM, 1999, J BIOL CHEM, V274, P35725, DOI 10.1074/jbc.274.50.35725; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Sizonenko PC, 2001, GROWTH HORM IGF RES, V11, P137, DOI 10.1054/ghir.2001.0203; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smith RG, 1999, HORM RES, V51, P1; Sobrier ML, 1997, J CLIN ENDOCR METAB, V82, P435, DOI 10.1210/jc.82.2.435; Sperling MA, 2002, J CLIN ENDOCR METAB, V87, P5351, DOI 10.1210/jc.2002-021467; Stavrou S, 2001, ENDOCRIN METAB CLIN, V30, P545, DOI 10.1016/S0889-8529(05)70201-2; Swerdlow AJ, 2002, LANCET, V360, P273, DOI 10.1016/S0140-6736(02)09519-3; Takahashi Y, 1999, GROWTH HORM IGF RES, V9, P37, DOI 10.1016/S1096-6374(99)80079-3; Takaya K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/jc.85.12.4908; Takuma N, 1998, DEVELOPMENT, V125, P4835; Tanaka T, 2002, GROWTH HORM IGF RES, V12, P323, DOI 10.1016/S1096-6374(02)00045-X; Tanaka T, 1997, J PEDIATR ENDOCR MET, V10, P623; Thomas M, 2001, HORM RES, V55, P88, DOI 10.1159/000049976; Tillmann V, 1997, J CLIN ENDOCR METAB, V82, P531, DOI 10.1210/jc.82.2.531; Tillmann V, 2000, J PEDIATR ENDOCR MET, V13, P1577; Tiulpakov AN, 1998, CLIN ENDOCRINOL, V49, P733, DOI 10.1046/j.1365-2265.1998.00590.x; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; TUFFLI GA, 1995, J CLIN ENDOCR METAB, V80, P1416, DOI 10.1210/jc.80.4.1416; Ulph F, 2004, ARCH DIS CHILD, V89, P17, DOI 10.1136/adc.2002.010694; Vahl N, 2000, J CLIN ENDOCR METAB, V85, P1874, DOI 10.1210/jc.85.5.1874; VIMPANI GV, 1981, ARCH DIS CHILD, V56, P922, DOI 10.1136/adc.56.12.922; Voss LD, 2000, J PEDIATR-US, V136, P103, DOI 10.1016/S0022-3476(00)90058-1; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400; Watkins-Chow DE, 1998, TRENDS GENET, V14, P284, DOI 10.1016/S0168-9525(98)01476-0; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; Wilson TA, 2003, J PEDIATR-US, V143, P415, DOI 10.1067/S0022-3476(03)00246-4; WILTON P, 1999, GROWTH HORMONE THERA, P349; WIT JM, 1992, ARCH DIS CHILD, V67, P920, DOI 10.1136/adc.67.7.920; Wit JM, 1996, PEDIATR RES, V39, P295, DOI 10.1203/00006450-199602000-00018; Wit JM, 2003, PEDIATR RES, V53, p154A; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Woods KA, 1997, J CLIN ENDOCR METAB, V82, P3529, DOI 10.1210/jc.82.11.3529; Woods KA, 1996, BAILLIERE CLIN ENDOC, V10, P371, DOI 10.1016/S0950-351X(96)80500-3; Wright CM, 1999, ARCH DIS CHILD, V81, P257, DOI 10.1136/adc.81.3.257; GUIDANCE USE HUMAN G	155	57	61	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1977	1987		10.1016/S0140-6736(04)16413-1	http://dx.doi.org/10.1016/S0140-6736(04)16413-1			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194259				2022-12-28	WOS:000221962800020
J	Bohannon, J				Bohannon, J			Roger Payne profile: A toxic odyssey	SCIENCE			English	News Item																			0	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1584	1586		10.1126/science.304.5677.1584	http://dx.doi.org/10.1126/science.304.5677.1584			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192192				2022-12-28	WOS:000221934300009
J	Feinstein, P; Bozza, T; Rodriguez, I; Vassalli, A; Mombaerts, P				Feinstein, P; Bozza, T; Rodriguez, I; Vassalli, A; Mombaerts, P			Axon guidance of mouse olfactory sensory neurons by odorant receptors and the beta 2 adrenergic receptor	CELL			English	Article							EXPRESSION; GENES; VOMERONASAL; PROJECTIONS; SYSTEM; FAMILY; BULB; TRAFFICKING; MICE; MAP	Odorant receptors (ORs) provide the core determinant of identity for axons of olfactory sensory neurons (OSNs) to coalesce into glomeruli in the olfactory bulb. Here, using gene targeting in mice, we examine how the OR protein determines axonal identity. An OR::GFP fusion protein is present in axons, consistent with a direct function of ORs in axon guidance. When the OR coding region is deleted, we observe OSNs that coexpress other ORs that function in odorant reception and axonal identity. It remains unclear if such coexpression is normally prevented by negative feedback on OR gene choice. A drastic reduction in OR protein level produces axonal coalescence into novel, remote glomeruli. By contrast, chimeric ORs and ORs with minor mutations perturb axon outgrowth. Strikingly, the beta2 adrenergic receptor can substitute for an OR in glomerular formation when expressed from an OR locus. Thus, ORs have not evolved a unique function in axon guidance.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Feinstein, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	feinstp@rockefeller.edu; peter@rockefeller.edu	Vassalli, Anne/M-7866-2016	Vassalli, Anne/0000-0002-5314-5620; rodriguez, ivan/0000-0002-6468-0565				Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Cho JY, 1996, J COMP NEUROL, V369, P264; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Ebrahimi FAW, 2000, CURR BIOL, V10, P219, DOI 10.1016/S0960-9822(00)00342-0; Feinstein P, 2004, CELL, V117, P817, DOI 10.1016/j.cell.2004.05.011; Hennecke M, 2001, NUCLEIC ACIDS RES, V29, P3327, DOI 10.1093/nar/29.16.3327; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Ivic L, 2002, J NEUROBIOL, V50, P56, DOI 10.1002/neu.10016; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Lewcock JW, 2004, P NATL ACAD SCI USA, V101, P1069, DOI 10.1073/pnas.0307986100; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; Menco BPM, 1997, J NEUROCYTOL, V26, P691, DOI 10.1023/A:1018554029186; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 2004, CURR OPIN NEUROBIOL, V14, P31, DOI 10.1016/j.conb.2004.01.014; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 2001, NAT NEUROSCI, V4, P1192, DOI 10.1038/nn751; Potter SM, 2001, J NEUROSCI, V21, P9713, DOI 10.1523/JNEUROSCI.21-24-09713.2001; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; RANDS E, 1990, J BIOL CHEM, V265, P10759; Reed RR, 2003, CURR OPIN NEUROBIOL, V13, P482, DOI 10.1016/S0959-4388(03)00104-1; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Xie SY, 2000, MAMM GENOME, V11, P1070, DOI 10.1007/s003350010217; Zhang XM, 2004, GENOMICS, V83, P802, DOI 10.1016/j.ygeno.2003.10.009; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X; Zylka MJ, 2003, P NATL ACAD SCI USA, V100, P10043, DOI 10.1073/pnas.1732949100	35	229	231	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					833	846		10.1016/j.cell.2004.05.013	http://dx.doi.org/10.1016/j.cell.2004.05.013			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186782	Bronze			2022-12-28	WOS:000222048400014
J	Lal, R				Lal, R			Soil carbon sequestration impacts on global climate change and food security	SCIENCE			English	Article							ORGANIC-MATTER; AGRICULTURAL ECOSYSTEMS; ATMOSPHERIC CARBON; CROPLAND SOILS; TILLAGE; PRODUCTIVITY; MANAGEMENT; FERTILITY; EROSION; FERTILIZATION	The carbon sink capacity of the world's agricultural and degraded soils is 50 to 66% of the historic carbon loss of 42 to 78 gigatons of carbon. The rate of soil organic carbon sequestration with adoption of recommended technologies depends on soil texture and structure, rainfall, temperature, farming system, and soil management. Strategies to increase the soil carbon pool include soil restoration and woodland regeneration, no-till farming, cover crops, nutrient management, manuring and sludge application, improved grazing, water conservation and harvesting, efficient irrigation, agroforestry practices, and growing energy crops on spare lands. An increase of 1 ton of soil carbon pool of degraded cropland soils may increase crop yield by 20 to 40 kilograms per hectare (kg/ha) for wheat, 10 to 20 kg/ha for maize, and 0.5 to 1 kg/ha for cowpeas. As well as enhancing food security, carbon sequestration has the potential to offset fossil-fuel emissions by 0.4 to 1.2 gigatons of carbon per year, or 5 to 15% of the global fossil-fuel emissions.	Ohio State Univ, Carbon Management & Sequestrat Ctr, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Lal, R (corresponding author), Ohio State Univ, Carbon Management & Sequestrat Ctr, Columbus, OH 43210 USA.	lal.1@osu.edu	Lal, Rattan/D-2505-2013					Armstrong RD, 2003, AUST J EXP AGR, V43, P141, DOI 10.1071/EA01175; Aune JB, 1997, TROP AGR, V74, P96; BAUER A, 1994, SOIL SCI SOC AM J, V58, P185, DOI 10.2136/sssaj1994.03615995005800010027x; Campbell CA, 2000, CAN J SOIL SCI, V80, P193, DOI 10.4141/S99-045; Diaz-Zorita M, 2002, SOIL TILL RES, V65, P1, DOI 10.1016/S0167-1987(01)00274-4; Follett RF, 2001, SOIL TILL RES, V61, P77, DOI 10.1016/S0167-1987(01)00180-5; Grace PR, 1995, AUST J EXP AGR, V35, P857, DOI 10.1071/EA9950857; Johnson E, 2004, ENVIRON INT, V30, P279, DOI 10.1016/j.envint.2003.09.001; JOHNSTON AE, 1986, SOIL USE MANAGE, V2, P97, DOI 10.1111/j.1475-2743.1986.tb00690.x; Kanchikerimath M, 2001, AGR ECOSYST ENVIRON, V86, P155, DOI 10.1016/S0167-8809(00)00280-2; Kapkiyai JJ, 1999, SOIL BIOL BIOCHEM, V31, P1773, DOI 10.1016/S0038-0717(99)00088-7; Lal R, 2003, SOIL SCI, V168, P827, DOI 10.1097/01.ss.0000106407.84926.6b; Lal R, 2004, SCIENCE, V304, P393, DOI 10.1126/science.1093079; Lal R, 2003, CRIT REV PLANT SCI, V22, P151, DOI 10.1080/713610854; Lal R, 2003, ENVIRON INT, V29, P437, DOI 10.1016/S0160-4120(02)00192-7; Lal R, 2001, ADV AGRON, V71, P145, DOI 10.1016/S0065-2113(01)71014-0; LAL R, 1981, GEODERMA, V25, P215, DOI 10.1016/0016-7061(81)90037-9; Levy R., 1984, CHEM IRRIGATED SOILS, P182; Manlay RJ, 2002, AGR ECOSYST ENVIRON, V88, P215, DOI 10.1016/S0167-8809(01)00218-3; PETCHAWEE S, 1995, ORGANIC MATTER MANAG, P21; PIERI C, 1986, AGRON TROP, V41, P1; Rosegrant MW, 2003, SCIENCE, V302, P1917, DOI 10.1126/science.1092958; Ruddiman WF, 2003, CLIMATIC CHANGE, V61, P261, DOI 10.1023/B:CLIM.0000004577.17928.fa; Sa JCD, 2001, SOIL SCI SOC AM J, V65, P1486, DOI 10.2136/sssaj2001.6551486x; Sanchez PA, 2002, SCIENCE, V295, P2019, DOI 10.1126/science.1065256; Sauerbeck DR, 2001, NUTR CYCL AGROECOSYS, V60, P253, DOI 10.1023/A:1012617516477; Silver WL, 2000, RESTOR ECOL, V8, P394, DOI 10.1046/j.1526-100x.2000.80054.x; Six J, 2002, AGRONOMIE, V22, P755, DOI 10.1051/agro:2002043; Smith P, 2001, NUTR CYCL AGROECOSYS, V60, P237, DOI 10.1023/A:1012617517839; Smith SV, 2001, GLOBAL BIOGEOCHEM CY, V15, P697, DOI 10.1029/2000GB001341; West TO, 2002, SOIL SCI SOC AM J, V66, P1930, DOI 10.2136/sssaj2002.1930; West TO, 2002, ENVIRON POLLUT, V116, P439, DOI 10.1016/S0269-7491(01)00221-4; Wright DG, 2001, COMMUN SOIL SCI PLAN, V32, P1803, DOI 10.1081/CSS-120000251; Yamoah CF, 2002, FIELD CROP RES, V75, P53, DOI 10.1016/S0378-4290(02)00008-4; [No title captured]; [No title captured]	36	4011	4800	382	4421	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1623	1627		10.1126/science.1097396	http://dx.doi.org/10.1126/science.1097396			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192216				2022-12-28	WOS:000221934300036
J	Williams, HM; McCammon, CA; Peslier, AH; Halliday, AN; Teutsch, N; Levasseur, S; Burg, JP				Williams, HM; McCammon, CA; Peslier, AH; Halliday, AN; Teutsch, N; Levasseur, S; Burg, JP			Iron isotope fractionation and the oxygen fugacity of the mantle	SCIENCE			English	Article							OXIDATION-STATE; SUBDUCTION ZONES; REDOX; GEOBAROMETER; OLIVINE; SPINEL; SPECTROSCOPY; PERIDOTITES; XENOLITHS; PRESSURE	The oxygen fugacity of the mantle exerts a fundamental influence on mantle melting, volatile speciation, and the development of the atmosphere. However, its evolution through time is poorly understood. Changes in mantle oxidation state should be reflected in the Fe3+/Fe2+ of mantle minerals, and hence in stable iron isotope fractionation. Here it is shown that there are substantial (1.7 per mil) systematic variations in the iron isotope compositions (delta(57/54)Fe) of mantle spinels. Spinel delta(57/54)Fe values correlate with relative oxygen fugacity, Fe3+/SigmaFe, and chromium number, and provide a proxy of changes in mantle oxidation state, melting, and volatile recycling.	ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany; Univ Houston, Texas Ctr Superconduct, Houston, TX 77204 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bayreuth; University of Houston System; University of Houston	Williams, HM (corresponding author), ETH, Dept Earth Sci, Sonneggstr 5, CH-8092 Zurich, Switzerland.	williams@erdw.ethz.ch	Peslier, Anne/F-3956-2010; Burg, Jean-Pierre/A-7640-2008	Burg, Jean-Pierre/0000-0002-4927-4729				ARCULUS RJ, 1994, LITHOS, V33, P189, DOI 10.1016/0024-4937(94)90060-4; BALLHAUS C, 1993, CONTRIB MINERAL PETR, V114, P331, DOI 10.1007/BF01046536; BALLHAUS C, 1991, CONTRIB MINERAL PETR, V107, P27, DOI 10.1007/BF00311183; Beard BL, 2003, CHEM GEOL, V195, P87, DOI 10.1016/S0009-2541(02)00390-X; Brandon AD, 1996, GEOCHIM COSMOCHIM AC, V60, P1739, DOI 10.1016/0016-7037(96)00056-7; BREY GP, 1990, J PETROL, V31, P1353, DOI 10.1093/petrology/31.6.1353; Canil D, 2002, EARTH PLANET SC LETT, V195, P75, DOI 10.1016/S0012-821X(01)00582-9; CHRISTIE DM, 1986, EARTH PLANET SC LETT, V79, P397, DOI 10.1016/0012-821X(86)90195-0; Delano JW, 2001, ORIGINS LIFE EVOL B, V31, P311, DOI 10.1023/A:1011895600380; Kamenetsky VS, 2001, J PETROL, V42, P655, DOI 10.1093/petrology/42.4.655; KELEMEN PB, 1990, J PETROL, V31, P51, DOI 10.1093/petrology/31.1.51; KILINC A, 1983, CONTRIB MINERAL PETR, V83, P136, DOI 10.1007/BF00373086; Lee DC, 1996, J PETROL, V37, P415, DOI 10.1093/petrology/37.2.415; Luhr JF, 1997, J PETROL, V38, P1075, DOI 10.1093/petrology/38.8.1075; MERCIER JCC, 1980, TECTONOPHYSICS, V70, P1, DOI 10.1016/0040-1951(80)90019-0; Nimis P, 1998, CONTRIB MINERAL PETR, V133, P122, DOI 10.1007/s004100050442; ONEILL HS, 1987, J PETROL, V28, P1169, DOI 10.1093/petrology/28.6.1169; Parkinson IJ, 1999, CHEM GEOL, V160, P409, DOI 10.1016/S0009-2541(99)00110-2; Polyakov VB, 2000, GEOCHIM COSMOCHIM AC, V64, P849, DOI 10.1016/S0016-7037(99)00329-4; Schauble EA, 2001, GEOCHIM COSMOCHIM AC, V65, P2487, DOI 10.1016/S0016-7037(01)00600-7; WELLS PRA, 1977, CONTRIB MINERAL PETR, V62, P129, DOI 10.1007/BF00372872; WOOD BJ, 1990, SCIENCE, V248, P337, DOI 10.1126/science.248.4953.337; Woodland AB, 2003, EARTH PLANET SC LETT, V214, P295, DOI 10.1016/S0012-821X(03)00379-0; Zhu XK, 2002, EARTH PLANET SC LETT, V200, P47, DOI 10.1016/S0012-821X(02)00615-5	24	152	160	3	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1656	1659		10.1126/science.1095679	http://dx.doi.org/10.1126/science.1095679			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192225				2022-12-28	WOS:000221934300046
J	Minna, JD; Gazdar, AF; Sprang, SR; Herz, J				Minna, JD; Gazdar, AF; Sprang, SR; Herz, J			Cancer - A bull's eye for targeted lung cancer therapy	SCIENCE			English	Editorial Material							MUTATIONS		Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.	john.minna@utsouthwestern.edu			NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907] Funding Source: Medline; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ciardiello F, 2004, CURR OPIN ONCOL, V16, P130, DOI 10.1097/00001622-200403000-00008; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Frederick L, 2000, CANCER RES, V60, P1383; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel JD, 2004, JAMA-J AM MED ASSOC, V291, P1763, DOI 10.1001/jama.291.14.1763	6	58	62	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1458	+		10.1126/science.1099578	http://dx.doi.org/10.1126/science.1099578			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178790				2022-12-28	WOS:000221795800030
J	Rosch, J; Caparon, M				Rosch, J; Caparon, M			A Microdomain for protein secretion in Gram-positive bacteria	SCIENCE			English	Article							STREPTOCOCCUS-PYOGENES; CELL-WALL; CYSTEINE PROTEINASE; BACILLUS-SUBTILIS; TRIGGER FACTOR; TRANSLOCATION; TRANSCRIPTION; GROWTH	Gram-positive bacteria face unique challenges in generating biologically active conformations for their exported proteins because they lack a dedicated compartment for folding secreted polypeptides. We have discovered that protein secretion by way of the general secretory ( Sec) pathway in the important human pathogen Streptococcus pyogenes proceeds through a single microdomain. Unlike other mechanisms for asymmetry involving the Sec pathway, proteins destined for secretion are targeted to a single locus distal to either cell pole that has specialized to contain the Sec translocons. This subcellular organization may represent a paradigm for secretion common to other Gram-positive pathogens with profound implications for pathogenesis.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Caparon, M (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Box 8230, St Louis, MO 63110 USA.	caparon@borcim.wustl.edu	Rosch, Jason W/N-8106-2018	Rosch, Jason W/0000-0002-1798-1760	NIAID NIH HHS [AI46433] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046433] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brandon LD, 2003, MOL MICROBIOL, V50, P45, DOI 10.1046/j.1365-2958.2003.03674.x; COLE RM, 1962, SCIENCE, V135, P722, DOI 10.1126/science.135.3505.722; Collin M, 2000, MOL MICROBIOL, V36, P1306, DOI 10.1046/j.1365-2958.2000.01942.x; Demchick P, 1996, J BACTERIOL, V178, P768, DOI 10.1128/jb.178.3.768-773.1996; Gauthier A, 2003, J BIOL CHEM, V278, P25273, DOI 10.1074/jbc.R300012200; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Lyon WR, 1998, EMBO J, V17, P6263, DOI 10.1093/emboj/17.21.6263; Lyon WR, 2004, INFECT IMMUN, V72, P1618, DOI 10.1128/IAI.72.3.1618-1625.2004; Lyon WR, 2003, J BACTERIOL, V185, P3661, DOI 10.1128/JB.185.12.3661-3667.2003; Lyon WR, 2001, MOL MICROBIOL, V42, P145, DOI 10.1046/j.1365-2958.2001.02616.x; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Mascarenhas J, 2001, EMBO REP, V2, P685, DOI 10.1093/embo-reports/kve160; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Scott ME, 2001, P NATL ACAD SCI USA, V98, P13978, DOI 10.1073/pnas.241411198; Shapiro L, 2002, SCIENCE, V298, P1942, DOI 10.1126/science.1072163; Snyder A, 2003, J BACTERIOL, V185, P5953, DOI 10.1128/JB.185.20.5953-5958.2003; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6	18	120	128	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1513	1515		10.1126/science.1097404	http://dx.doi.org/10.1126/science.1097404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178803				2022-12-28	WOS:000221795800048
J	Engelgau, MM; Geiss, LS; Saaddine, JB; Boyle, JP; Benjamin, SM; Gregg, EW; Tierney, EF; Rios-Burrows, N; Mokdad, AH; Ford, ES; Imperatore, G; Narayan, KMV				Engelgau, MM; Geiss, LS; Saaddine, JB; Boyle, JP; Benjamin, SM; Gregg, EW; Tierney, EF; Rios-Burrows, N; Mokdad, AH; Ford, ES; Imperatore, G; Narayan, KMV			The evolving diabetes burden in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							VISUAL IMPAIRMENT; HEART-DISEASE; RISK-FACTORS; US ADULTS; MORTALITY; PREVALENCE; MELLITUS; POPULATION; HEALTH; CLASSIFICATION	A diabetes epidemic emerged during the 20th century and continues unchecked into the 21st century. it has already taken an extraordinary toll on the U.S. population through its acute and chronic complications, disability, and premature death. Trend data suggest that the burden will continue to increase. Efforts to prevent or delay the complications of diabetes or, better yet, to prevent or delay the development of diabetes itself are urgently needed.	CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Engelgau, MM (corresponding author), CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-10,4770 Buford Highway NE, Atlanta, GA 30341 USA.	mxe1@cdc.gov	Narayan, K.M. Venkat/J-9819-2012	Narayan, K.M. Venkat/0000-0001-8621-5405; Gregg, Edward/0000-0003-2381-6822				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Anderson R N, 2001, Natl Vital Stat Rep, V49, P1; [Anonymous], 1995, DIABETES AM; APELQVIST J, 1989, DIABETIC MED, V6, P526, DOI 10.1111/j.1464-5491.1989.tb01221.x; Barzilay JI, 2001, DIABETES CARE, V24, P1233, DOI 10.2337/diacare.24.7.1233; BILD DE, 1992, J CLIN EPIDEMIOL, V45, P275, DOI 10.1016/0895-4356(92)90087-4; *CDCP, 2003, DIAB SURV SYST; EDERER F, 1981, AM J OPHTHALMOL, V91, P381, DOI 10.1016/0002-9394(81)90293-2; Evans JMM, 2002, BRIT MED J, V324, P939, DOI 10.1136/bmj.324.7343.939; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gregg E, 2003, DIABETES, V52, pA62; Gregg EW, 2002, BRIT MED J, V325, P916, DOI 10.1136/bmj.325.7370.916; Gregg EW, 2002, DIABETES CARE, V25, P61, DOI 10.2337/diacare.25.1.61; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HARRIS M, 1979, DIABETES, V28, P1039; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HAZZLETT BE, 2000, CLIN DIABETES MELLIT, P3; Honeycutt Amanda A, 2003, Health Care Manag Sci, V6, P155, DOI 10.1023/A:1024467522972; Kenny S. J., 1995, DIABETES AM, P47; Klein B E, 1995, Ophthalmic Epidemiol, V2, P49, DOI 10.3109/09286589509071451; KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lee WL, 2000, DIABETES CARE, V23, P962, DOI 10.2337/diacare.23.7.962; MANUEL DG, 2003, DIABETES ONTARIO; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1884, DOI 10.1001/jama.290.14.1884; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; PALUMBO PJ, 1985, NIH PUBLICATION; Qiao Q, 2003, DIABETES CARE, V26, P688; Ryerson B, 2003, DIABETES CARE, V26, P206, DOI 10.2337/diacare.26.1.206; Saaddine JB, 1999, AM J PUBLIC HEALTH, V89, P1200, DOI 10.2105/AJPH.89.8.1200; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Tavani A, 2002, J CLIN EPIDEMIOL, V55, P1082, DOI 10.1016/S0895-4356(02)00486-9; Thomas RJ, 2003, ARCH INTERN MED, V163, P445, DOI 10.1001/archinte.163.4.445; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; U.M. Office, 2012, NAT MET LIBR ARCH FA; Wingard DL., 1995, DIABETES AM, P429; World Health Organization Expert Committee on Diabetes Mellitus, 1980, WHO TECHN REP SER, V646; 1990, N ENGL J MED, V323, P613	47	489	508	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					945	950		10.7326/0003-4819-140-11-200406010-00035	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00035			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172919				2022-12-28	WOS:000221680600025
J	Nathens, AB; Brunet, FP; Maier, RV				Nathens, AB; Brunet, FP; Maier, RV			Development of trauma systems and effect on outcomes after injury	LANCET			English	Article							ADVANCED LIFE-SUPPORT; MAJOR TRAUMA; UNITED-STATES; CENTER VOLUME; CARE; MORTALITY; CENTERS; EXPERIENCE; SURVIVAL; IMPACT	The ideal system for management of trauma remains controversial, especially in respect of prehospital care and regionalisation of trauma-care delivery. To explore these issues, we compare two differing trauma systems-in the USA the focus is on the trauma centre, with a lesser emphasis on prehospital care, whereas in France there is more emphasis on prehospital care coordinated by the Service d'Aide Medicale Urgente. We describe the historical developments, current structure, and major controversies with regard to trauma-care delivery in the two countries. Comparative evidence on the effectiveness of the two systems was obtained through a structured review of databases, but very little evidence permits direct comparison of outcomes across the two systems. Crude injury mortality rates and fatality rates from motor-vehicle accidents (crashes in US usage) are higher in France than in the USA, although adjustment for potential confounders is difficult. Adjusted mortality rates suggest equivalent outcomes among patients who survive to hospital, although these data are confounded by the lack of a contemporaneous comparator population. There are differences in the American and French trauma systems that might translate into measurable differences in trauma-related mortality. However, the lack of data to allow comparison of outcomes between countries significantly impedes the identification and implementation of components of a trauma system that are effective and the discarding of those that offer little benefit.	Univ Washington, Harborview Med Ctr, Dept Surg, Div Gen & Trauma Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; St Michaels Hosp, Dept Crit Care Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Nathens, AB (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Div Gen & Trauma Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	anathens@u.washington.edu						Abbott D, 1998, Air Med J, V17, P94, DOI 10.1016/S1067-991X(98)90102-X; ALEXANDER RH, 1993, ADV TRAUMA LIFE SUPP, P317; American Trauma Society, 2002, TRAUM SYST AG FUT; [Anonymous], 1976, Bull Am Coll Surg, V61, P15; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; Bass RR, 1999, J TRAUMA, V47, pS15, DOI 10.1097/00005373-199909001-00005; BAZZOLI GJ, 1995, JAMA-J AM MED ASSOC, V273, P395; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BOURRET P, 1977, REV SAMU, V2, P112; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Carli P, 1998, Rev Med Suisse Romande, V118, P411; CARLI PA, 1995, NEW ENGL J MED, V332, P682; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; CLAY MN, 2001, MED CARE, V39, P643; Cooper A, 2000, J TRAUMA, V48, P16, DOI 10.1097/00005373-200001000-00004; Croser JL, 2003, INJURY, V34, P649, DOI 10.1016/S0020-1383(03)00157-8; Dick Wolfgang F, 2003, Prehosp Disaster Med, V18, P29; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Fingerhut L A, 1998, Adv Data, P1; Grossman DC, 1997, J TRAUMA, V42, P723, DOI 10.1097/00005373-199704000-00024; GROSSMAN DC, 1995, J TRAUMA, V38, P14, DOI 10.1097/00005373-199501000-00006; Kennedy Robert H., 1966, EMERGENCY CARE SICK, pvi; KONVOLINKA CW, 1995, AM J SURG, V170, P333, DOI 10.1016/S0002-9610(99)80299-2; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; London JA, 2003, J TRAUMA, V54, P16, DOI 10.1097/00005373-200301000-00003; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Mann NC, 1997, ACAD EMERG MED, V4, P764, DOI 10.1111/j.1553-2712.1997.tb03781.x; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Narad R A, 1996, Prehosp Disaster Med, V11, P134; *NAT COMM TRAUM CO, 1966, ACC DEATH DIS NEGL D; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Neel S, 1968, JAMA-J AM MED ASSOC, V204, P99; O'Keefe GE, 1999, ANN SURG, V229, P409, DOI 10.1097/00000658-199903000-00015; *ORG EC COOP DEV, INT ROAD TRAFF ACC D; Orliaguet G, 2001, INTENS CARE MED, V27, P743, DOI 10.1007/s001340100905; Peitzman AB, 1999, ANN SURG, V230, P87, DOI 10.1097/00000658-199907000-00013; Petri R W, 1995, Prehosp Disaster Med, V10, P24; PLAISANCE P, 1997, CIRCULATION, V95, P961; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; Riou B, 2001, ANESTHESIOLOGY, V95, P56, DOI 10.1097/00000542-200107000-00014; Rogers FB, 1999, J TRAUMA, V47, P802, DOI 10.1097/00005373-199910000-00038; RUTLEDGE R, 1993, ANN SURG, V218, P512, DOI 10.1097/00000658-199310000-00011; Sampalis JS, 1995, J TRAUMA, V39, P1029, DOI 10.1097/00005373-199512000-00002; SANCTON TA, 1998, DEATH PRINCESS INVES; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; Spaite D, 1998, ANN EMERG MED, V32, P480, DOI 10.1016/S0196-0644(98)70178-7; SPAITE DW, 1991, ANN EMERG MED, V20, P1299, DOI 10.1016/S0196-0644(05)81070-4; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Tepas JJ, 1998, J TRAUMA, V44, P827, DOI 10.1097/00005373-199805000-00014; WEST JG, 1988, JAMA-J AM MED ASSOC, V259, P3597, DOI 10.1001/jama.259.24.3597; WEST JG, 1983, ARCH SURG-CHICAGO, V118, P740; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455	59	150	160	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1794	1801		10.1016/S0140-6736(04)16307-1	http://dx.doi.org/10.1016/S0140-6736(04)16307-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172780				2022-12-28	WOS:000221705800023
J	Verhelst, D; Rossert, J; Casadevall, N; Kruger, A; Eckardt, KU; Macdougall, LC				Verhelst, D; Rossert, J; Casadevall, N; Kruger, A; Eckardt, KU; Macdougall, LC		Pure Red Cell Aplasia Study Grp	Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study	LANCET			English	Article							ANTIERYTHROPOIETIN ANTIBODIES	Background Recombinant human erythropoietin is the standard treatment for anaemia related to chronic kidney disease, and its widespread use has been favoured by a very high therapeutic index. However, since 1998, more than 200 patients worldwide with chronic kidney disease treated in this way have developed neutralising antibodies to erythropoietin, causing pure red cell aplasia. We aimed to collate clinical and pathological features in patients unequivocally shown to have erythropoietin-induced pure red cell aplasia. Methods We retrospectively obtained data from the files of 47 patients with pure red cell aplasia. We assessed treatment and outcome of patients and defined recovery from pure red cell aplasia as an increase in reticulocyte counts to more than 20 000 per muL in patients who were no longer transfusion-dependent. Findings When patients developed pure red cell aplasia, all were receiving erythropoietin subcutaneously, and the product most typically prescribed was epoetin alfa (Eprex, Ortho Biotech). The median delay between start of erythropoietin treatment and occurrence of pure red cell aplasia was 11 months (IQR 7.5-14). Nine patients received no immunosuppressive treatment, and none of these recovered. Of 37 patients who received immunosuppressive therapy, 29 (78%) recovered. All six patients who received a kidney transplant recovered within 1 month, and recovery rates were between 56% and 88% in patients treated with corticosteroids, corticosteroids plus cyclophosphamide, or ciclosporin. No relapse of pure red cell aplasia happened after stopping immunosuppressive treatment, but no patient was rechallenged with erythropoietin. Interpretation Immunosuppressive treatment accelerates recovery from erythropoietin-induced pure red cell aplasia.	Assistance Publ Hop Paris, Tenon Hosp, Dept Nephrol, F-75020 Paris, France; Univ Paris 06, Paris, France; Assistance Publ Hop Paris, Hotel Dieu, Dept Haematol, Paris, France; INSERM, U362, Paris, France; Univ Erlangen Nurnberg, Div Nephrol & Hypertens, Nurnberg, Germany; Kings Coll Hosp London, Dept Renal Med, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Erlangen Nuremberg; King's College Hospital NHS Foundation Trust; King's College Hospital	Rossert, J (corresponding author), Assistance Publ Hop Paris, Tenon Hosp, Dept Nephrol, 4 Rue Chine, F-75020 Paris, France.	jerome.rossert@tnn.ap-hop-paris.fr						Bunn HF, 2002, NEW ENGL J MED, V346, P522, DOI 10.1056/NEJM200202143460711; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; Casadevall N, 2002, NEPHROL DIAL TRANSPL, V17, P42, DOI 10.1093/ndt/17.suppl_5.42; Cavill I, 2002, LANCET, V360, P1606, DOI 10.1016/S0140-6736(02)11544-3; Chng WJ, 2003, AM J KIDNEY DIS, V41, P692, DOI 10.1053/ajkd.2003.50132; Eckardt KU, 2003, NEPHROL DIAL TRANSPL, V18, P865, DOI 10.1093/ndt/gfg182; Macdougall LC, 2004, CURR MED RES OPIN, V20, P83, DOI [10.1185/030079903125002702, 10.1185/030079904125003520]; Rossert J, 2004, J AM SOC NEPHROL, V15, P398, DOI 10.1097/01.ASN.0000107561.59698.42; Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3; Tong EM, 2001, SEMIN NEPHROL, V21, P190, DOI 10.1053/snep.2001.20939	10	107	120	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1768	1771		10.1016/S0140-6736(04)16302-2	http://dx.doi.org/10.1016/S0140-6736(04)16302-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172775				2022-12-28	WOS:000221705800010
J	Silvarolla, MB; Mazzafera, P; Fazuoli, LC				Silvarolla, MB; Mazzafera, P; Fazuoli, LC			Plant biochemistry - A naturally decaffeinated arabica coffee	NATURE			English	Editorial Material							CAFFEINE		IAC APTA, Ctr Anal & Pesquisa Tecnol Agronegocio Cafe Alcid, BR-13001970 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Fisiol Vegetal, BR-13083862 Campinas, Brazil	Instituto Agronomico de Campinas (IAC); Universidade de Sao Paulo; Universidade Estadual de Campinas	Silvarolla, MB (corresponding author), IAC APTA, Ctr Anal & Pesquisa Tecnol Agronegocio Cafe Alcid, CP 28, BR-13001970 Campinas, SP, Brazil.	pmazza@unicamp.br	Silvarolla, Maria Bernadete/AAD-8237-2020; Mazzafera, Paulo/D-4766-2012	Mazzafera, Paulo/0000-0001-9073-4056				Ashihara H, 2004, FRONT BIOSCI-LANDMRK, V9, P1864, DOI 10.2741/1367; Charrier A, 1978, STRUCTURE GENETIQUE; Evans W.C., 1996, TREASE EVANS PHARMAC; *FAO, 1968, FAO REP COFF MISS ET; JAMES JE, 1991, CAFFEINE HLTH; Kato M, 2004, FRONT BIOSCI-LANDMRK, V9, P1833, DOI 10.2741/1364; MAZZAFERA P, 1994, J AGR FOOD CHEM, V42, P1423, DOI 10.1021/jf00043a007; Mazzafera P., 1992, Euphytica, V59, P55; Ogita S, 2003, NATURE, V423, P823, DOI 10.1038/423823a; Silvarolla MB, 2000, GENET MOL BIOL, V23, P213, DOI 10.1590/S1415-47572000000100036; Vossen H. A. M. van der, 1985, Coffee: botany, biochemistry and production of beans and beverage., P48	11	78	88	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					826	826		10.1038/429826a	http://dx.doi.org/10.1038/429826a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215853	Bronze			2022-12-28	WOS:000222213000030
J	Sutherland, ER; Cherniack, RM				Sutherland, ER; Cherniack, RM			Current concepts - Management of chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LONG-TERM TREATMENT; IPRATROPIUM BROMIDE; LUNG-FUNCTION; INFLUENZA VACCINATION; INHALED BUDESONIDE; MEDICAL PROGRESS; DOUBLE-BLIND; SALMETEROL; THERAPY; SMOKING		Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cherniack, RM (corresponding author), 1400 Jackson St,J-208, Denver, CO 80206 USA.				NHLBI NIH HHS [K23 HL04385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aalbers R, 2002, EUR RESPIR J, V20, P245, DOI 10.1183/09031936.02.0024502; Aalbers R, 2002, EUR RESPIR J, V19, P936, DOI 10.1183/09031936.02.00240902; Altose MD, 2000, NEW ENGL J MED, V343, P1902; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Belman MJ, 1996, AM J RESP CRIT CARE, V153, P967, DOI 10.1164/ajrccm.153.3.8630581; BONE R, 1994, CHEST, V105, P1411; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Burge PS, 2003, THORAX, V58, P654, DOI 10.1136/thorax.58.8.654; Calverley P, 2003, LANCET, V361, P1660; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Clini E, 2002, EUR RESPIR J, V20, P1617, DOI 10.1183/09031936.02.00000002; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; Cook D, 2001, AM J RESP CRIT CARE, V163, P85, DOI 10.1164/ajrccm.163.1.2004214; Dahl R, 2001, AM J RESP CRIT CARE, V164, P778, DOI 10.1164/ajrccm.164.5.2007006; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Emtner M, 2003, AM J RESP CRIT CARE, V168, P1034, DOI 10.1164/rccm.200212-1525OC; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; Fabbri LM, 2003, EUR RESPIR J, V22, P1, DOI 10.1183/09031936.03.00063703; FERREIRA IM, 2003, COCHRANE DB SYST REV, V1; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; GrayDonald K, 1996, AM J RESP CRIT CARE, V153, P961, DOI 10.1164/ajrccm.153.3.8630580; Griffiths TL, 2000, LANCET, V355, P1280; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; GROSS NJ, 1989, AM REV RESPIR DIS, V139, P1188, DOI 10.1164/ajrccm/139.5.1188; HIGGINS BG, 1991, EUR RESPIR J, V4, P415; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Johnson AOC, 2003, THORAX, V58, P729, DOI 10.1136/thorax.58.8.729; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; Lacasse Y, 1996, LANCET, V348, P1115, DOI 10.1016/S0140-6736(96)04201-8; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; MCKAY SE, 1993, THORAX, V48, P227, DOI 10.1136/thx.48.3.227; Morgan MDL, 2001, THORAX, V56, P827; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542, DOI 10.1164/ajrccm.160.2.9901038; O'Donoghue FJ, 2002, THORAX, V57, P533, DOI 10.1136/thorax.57.6.533; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pearson MG, 1997, THORAX, V52, pS1; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608; PETRIE GR, 1975, BRIT MED J, V1, P430, DOI 10.1136/bmj.1.5955.430; Ram FSF, 2003, THORAX, V58, P580, DOI 10.1136/thorax.58.7.580; Rennard SI, 2001, AM J RESP CRIT CARE, V163, P1087, DOI 10.1164/ajrccm.163.5.9903053; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Spencer S, 2001, AM J RESP CRIT CARE, V163, P122, DOI 10.1164/ajrccm.163.1.2005009; Sutherland ER, 2003, THORAX, V58, P937, DOI 10.1136/thorax.58.11.937; Sutherland ER, 2003, J ALLERGY CLIN IMMUN, V112, P819, DOI 10.1016/S0091-6749(03)02011-6; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; Tashkin DP, 2001, LANCET, V357, P1571, DOI 10.1016/S0140-6736(00)04724-3; Tata LJ, 2003, THORAX, V58, P835, DOI 10.1136/thorax.58.10.835; van Noord JA, 2000, EUR RESPIR J, V15, P878, DOI 10.1034/j.1399-3003.2000.15e11.x; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Wadbo M, 2002, EUR RESPIR J, V20, P1138, DOI 10.1183/09031936.02.00301702; ZuWallack RL, 2001, CHEST, V119, P1661, DOI 10.1378/chest.119.6.1661	69	151	195	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2689	2697		10.1056/NEJMra030415	http://dx.doi.org/10.1056/NEJMra030415			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215485				2022-12-28	WOS:000222199000010
J	Beja-Pereira, A; England, PR; Ferrand, N; Jordan, S; Bakhiet, AO; Abdalla, MA; Mashkour, M; Jordana, J; Taberlet, P; Luikart, G				Beja-Pereira, A; England, PR; Ferrand, N; Jordan, S; Bakhiet, AO; Abdalla, MA; Mashkour, M; Jordana, J; Taberlet, P; Luikart, G			African origins of the domestic donkey	SCIENCE			English	Article									CNRS, Lab Ecol Alpine, UMR UJF 5553, F-38041 Grenoble, France; Univ Porto, Ctr Invest Biodiversidade & Recursos Genet, P-44485 Vairao, Portugal; Univ Porto, SAECA, Fac Ciencias, P-44485 Vairao, Portugal; Fac Ciencias, P-4099 Oporto, Portugal; Bucknell Univ, Dept Biol, Lewisburg, PA 17837 USA; Sudan Univ Sci & Technol, Coll Vet Med, Khartoum, Sudan; Museum Natl Hist Nat, CNRS, UMR 5197, F-75005 Paris, France; UAB, Dept Ciencia Anim Aliments, Fac Vet, Bellaterra 8193, Spain	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Savoie; Universidade do Porto; Universidade do Porto; Universidade do Porto; Bucknell University; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Autonomous University of Barcelona	Beja-Pereira, A (corresponding author), CNRS, Lab Ecol Alpine, UMR UJF 5553, F-38041 Grenoble, France.	albano.beja-pereira@ujf-grenoble.fr	Taberlet, Pierre/D-1178-2010; Jordana, Jordi/T-6986-2017; Bakhiet, Amel O/P-6642-2014; Beja-Pereira, Albano/B-3681-2008; abdalla, mohamed/AAB-6069-2020; Ferrand, Nuno/E-6085-2014; Mashkour, Marjan/B-5724-2018	Taberlet, Pierre/0000-0002-3554-5954; Jordana, Jordi/0000-0002-7789-2989; Bakhiet, Amel O/0000-0003-2386-2458; Beja-Pereira, Albano/0000-0002-1607-7382; Ferrand, Nuno/0000-0002-2408-4195; Mashkour, Marjan/0000-0003-3630-9459; Luikart, Gordon/0000-0001-8697-0582				Clutton-Brock J., 1999, NATURAL HIST DOMESTI; Marshall F., 2000, ORIGIN DEV AFRICAN L, P191; Peters J., 1986, THESIS RIJKSUNIVERSI	3	156	171	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1781	1781		10.1126/science.1096008	http://dx.doi.org/10.1126/science.1096008			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205528				2022-12-28	WOS:000222089500039
J	Hernandez, LD; Hueffer, K; Wenk, MR; Galan, JE				Hernandez, LD; Hueffer, K; Wenk, MR; Galan, JE			Salmonella modulates vesicular traffic by altering phosphoinositide metabolism	SCIENCE			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; TYPHIMURIUM-CONTAINING VACUOLES; III SECRETION SYSTEM; EPITHELIAL-CELLS; HOST-CELL; FILAMENTOUS STRUCTURES; ACTIN CYTOSKELETON; INVASION; PHOSPHATASE; PROTEIN	Salmonella enterica, the cause of food poisoning and typhoid fever, induces actin cytoskeleton rearrangements and membrane ruffling to gain access into nonphagocytic cells, where it can replicate and avoid innate immune defenses. Here, we found that SopB, a phosphoinositide phosphatase that is delivered into host cells by a type III secretion system, was essential for the establishment of Salmonella's intracellular replicative niche. SopB mediated the formation of spacious phagosomes following bacterial entry and was responsible for maintaining high levels of phosphatidylinositol-three-phosphate [PtdIns(3)P] in the membrane of the bacteria-containing vacuoles. Absence of SopB caused a significant defect in the maturation of the Salmonella-containing vacuole and impaired bacterial intracellular growth.	Yale Univ, Sch Microbial Pathogenesis, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Yale University; Yale University	Galan, JE (corresponding author), Yale Univ, Sch Microbial Pathogenesis, New Haven, CT 06536 USA.	jorge.galan@yale.edu	Wenk, Markus Rene/D-1441-2014	Hueffer, Karsten/0000-0001-7154-9066	NIAID NIH HHS [AI055472] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055472] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Galyov E. E., 1997, MOL MICROBIOL, V25, P1903; GARCIADELPORTILLO F, 1993, INFECT AGENT DIS, V2, P227; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; Gary JD, 2002, MOL BIOL CELL, V13, P1238, DOI 10.1091/mbc.01-10-0498; Gorvel JP, 2001, MICROBES INFECT, V3, P1299, DOI 10.1016/S1286-4579(01)01490-3; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hernandez L., UNPUB; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Knodler LA, 2003, TRAFFIC, V4, P587, DOI 10.1034/j.1600-0854.2003.00118.x; Marcus SL, 2001, FEBS LETT, V494, P201, DOI 10.1016/S0014-5793(01)02356-0; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Rudge SA, 2004, MOL BIOL CELL, V15, P24, DOI 10.1091/mbc.E03-05-0297; Saxena A, 2002, J BIOL CHEM, V277, P49935, DOI 10.1074/jbc.M206497200; Scott CC, 2002, J BIOL CHEM, V277, P12770, DOI 10.1074/jbc.M110399200; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sorensen M, 2003, FEBS LETT, V552, P110, DOI 10.1016/S0014-5793(03)00856-1; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Waterman SR, 2003, CELL MICROBIOL, V5, P501, DOI 10.1046/j.1462-5822.2003.00294.x; Wenk MR, 2003, NAT BIOTECHNOL, V21, P813, DOI 10.1038/nbt837; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	37	237	244	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1805	1807		10.1126/science.1098188	http://dx.doi.org/10.1126/science.1098188			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205533				2022-12-28	WOS:000222089500046
J	Matsuzaki, M; Honkura, N; Ellis-Davies, GCR; Kasai, H				Matsuzaki, M; Honkura, N; Ellis-Davies, GCR; Kasai, H			Structural basis of long-term potentiation in single dendritic spines	NATURE			English	Article							SYNAPTIC PLASTICITY; SILENT SYNAPSES; AMPA RECEPTORS; ADULT CORTEX; LTP; CA1; EXPRESSION; CAMKII; TRANSMISSION; STIMULATION	Dendritic spines of pyramidal neurons in the cerebral cortex undergo activity-dependent structural remodelling(1-5) that has been proposed to be a cellular basis of learning and memory(6). How structural remodelling supports synaptic plasticity(4),5, such as long-term potentiation(7), and whether such plasticity is input-specific at the level of the individual spine has remained unknown. We investigated the structural basis of long-term potentiation using two-photon photolysis of caged glutamate at single spines of hippocampal CA1 pyramidal neurons(8). Here we show that repetitive quantum-like photorelease (uncaging) of glutamate induces a rapid and selective enlargement of stimulated spines that is transient in large mushroom spines but persistent in small spines. Spine enlargement is associated with an increase in AMPA-receptor-mediated currents at the stimulated synapse and is dependent on NMDA receptors, calmodulin and actin polymerization. Long-lasting spine enlargement also requires Ca2+/calmodulin-dependent protein kinase II. Our results thus indicate that spines individually follow Hebb's postulate for learning. They further suggest that small spines are preferential sites for long-term potentiation induction, whereas large spines might represent physical traces of long-term memory.	Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies Sokendai, Okazaki, Aichi, Japan; Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Drexel University	Kasai, H (corresponding author), Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448787, Japan.	hkasai@nips.ac.jp	Honkura, Naoki/N-5521-2017	Honkura, Naoki/0000-0002-6018-867X; Kasai, Haruo/0000-0003-2327-9027; Matsuzaki, Masanori/0000-0003-3872-4322	NIGMS NIH HHS [R01 GM053395, R01 GM053395-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053395] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; GUSTAFSSON B, 1990, PROG BRAIN RES, V83, P223; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hebb Donald O., 1949, ORG BEHAV; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kasai H, 2003, TRENDS NEUROSCI, V26, P360, DOI 10.1016/S0166-2236(03)00162-0; KATO K, 1993, NEUROSCIENCE, V53, P39, DOI 10.1016/0306-4522(93)90282-K; Kim CH, 1999, J NEUROSCI, V19, P4314; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Rumbaugh G, 2003, J NEUROSCI, V23, P4567; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; VANHARREVELD A, 1975, EXP NEUROL, V49, P736, DOI 10.1016/0014-4886(75)90055-2; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071	30	1677	1713	5	246	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					761	766		10.1038/nature02617	http://dx.doi.org/10.1038/nature02617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15190253	Green Accepted			2022-12-28	WOS:000222059900039
J	Liu, EHC; Sia, ATH				Liu, EHC; Sia, ATH			Rates of caesarean section and instrumental vaginal delivery in nulliparous women after low concentration epidural infusions or opioid analgesia: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; UTERINE ACTIVITY; 2ND STAGE; INTRAVENOUS MEPERIDINE; ACTIVE LABOR; ANESTHESIA; PETHIDINE; BUPIVACAINE; PROGRESS; IMPACT	Objective To compare the effects of low concentration epidural infusions of bupivacaine with parenteral opioid analgesia on rates of caesarean section and instrumental vaginal delivery in nulliparous women. Data sources Medline, Embase, the Cochrane controlled trials register, and handsearching of the International Journal of Obstetric Anesthesia. Study selection Randomised controlled trials comparing low concentration epidural infusions with parenteral opioids. Data synthesis Seven trials fulfilled the inclusion criteria for meta-analysis. Epidural analgesia does not seem to be associated with an increased risk of caesarean section (odds ratio 1.03, 95% confidence interval 0.71 to 1.48) but may be associated with an increased risk of instrumental vaginal delivery (2.11, 0.95 to 4.65). Epidural analgesia was associated with a longer second stage of labour (weighted mean difference 15.2 minutes, 2.1 to 28.2 minutes). More women randomised to receive epidural analgesia had adequate pain relief, with fewer changing to parenteral opioids than vice versa (odds ratio 0.1, 0.05 to 0.22). Conclusions Epidural analgesia using low concentration infusions of bupivacaine is unlikely to increase the risk of caesarean section but may increase the risk of instrumental vaginal delivery. Although women receiving epidural analgesia had a longer second stage of labour, they had better pain relief.	Natl Univ Singapore Hosp, Dept Anaesthesia, Singapore 119074, Singapore; KK Womens & Childrens Hosp, Dept Obstet Anaesthesia, Singapore, Singapore	National University of Singapore; KK Women's & Children's Hospital	Liu, EHC (corresponding author), Natl Univ Singapore Hosp, Dept Anaesthesia, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.	analiue@nus.edu.sg	Sia, Alex/ABB-3299-2021					BATES RG, 1985, BRIT J OBSTET GYNAEC, V92, P1246, DOI 10.1111/j.1471-0528.1985.tb04870.x; Bofill JA, 1997, AM J OBSTET GYNECOL, V177, P1465, DOI 10.1016/S0002-9378(97)70092-9; Cheek TG, 1996, BRIT J ANAESTH, V77, P632, DOI 10.1093/bja/77.5.632; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; Chestnut DH, 1997, ANESTHESIOLOGY, V86, P273, DOI 10.1097/00000542-199702000-00001; CHESTNUT DH, 1987, OBSTET GYNECOL, V69, P323; CHESTNUT DH, 1987, ANESTHESIOLOGY, V66, P774, DOI 10.1097/00000542-198706000-00011; Clark A, 1998, AM J OBSTET GYNECOL, V179, P1527, DOI 10.1016/S0002-9378(98)70019-5; Dickinson JE, 2002, AUST NZ J OBSTET GYN, V42, P59; Findley I, 1999, BRIT MED J, V318, P927, DOI 10.1136/bmj.318.7188.927; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; GOODFELLOW CF, 1983, BRIT J OBSTET GYNAEC, V90, P214, DOI 10.1111/j.1471-0528.1983.tb08611.x; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Hawkins JL, 1997, ANESTHESIOLOGY, V87, P135, DOI 10.1097/00000542-199707000-00018; Hawkins JL, 1997, ANESTHESIOLOGY, V86, P277, DOI 10.1097/00000542-199702000-00002; Howell C.J, 2000, COCHRANE DB SYST REV; Howell CJ, 2001, BRIT J OBSTET GYNAEC, V108, P27, DOI 10.1016/S0306-5456(00)00012-7; Loughnan BA, 2000, BRIT J ANAESTH, V84, P715, DOI 10.1093/oxfordjournals.bja.a013580; MacArthur C, 2001, LANCET, V358, P19; Miller AC, 1997, INT J OBSTET ANESTH, V6, P2, DOI 10.1016/S0959-289X(97)80046-5; NEWTON ER, 1995, OBSTET GYNECOL, V85, P749, DOI 10.1016/0029-7844(95)00046-T; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; NOBLE AD, 1971, J OBSTET GYN BR COMM, V78, P559; PHILIPSEN T, 1989, EUR J OBSTET GYN R B, V30, P27, DOI 10.1016/0028-2243(89)90090-7; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Roberts CL, 2002, AUST NZ J OBSTET GYN, V42, P176, DOI 10.1111/j.0004-8666.2002.00176.x; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x; *SCOTT INT GUID NE, METH CHECKL 2 RAND C; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; Sharma SK, 1997, ANESTHESIOLOGY, V87, P487, DOI 10.1097/00000542-199709000-00006; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Zhang J, 1999, AM J OBSTET GYNECOL, V180, P970, DOI 10.1016/S0002-9378(99)70669-1	32	94	104	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1410	1412B		10.1136/bmj.38097.590810.7C	http://dx.doi.org/10.1136/bmj.38097.590810.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15169744	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222114400018
J	Rothwell, PM; Coull, AJ; Giles, MF; Howard, SC; Silver, LE; Bull, LM; Gutnikov, SA; Edwards, P; Mant, D; Sackley, CM; Farmer, A; Sandercock, PAG; Dennis, MS; Warlow, CP; Bamford, JM; Anslow, P				Rothwell, PM; Coull, AJ; Giles, MF; Howard, SC; Silver, LE; Bull, LM; Gutnikov, SA; Edwards, P; Mant, D; Sackley, CM; Farmer, A; Sandercock, PAG; Dennis, MS; Warlow, CP; Bamford, JM; Anslow, P		Oxford Vascular Study	Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)	LANCET			English	Article							TRANSIENT ISCHEMIC ATTACKS; SECULAR TRENDS; CARDIOVASCULAR-DISEASE; CAPTURE-RECAPTURE; NORTHERN SWEDEN; BLOOD-PRESSURE; EPIDEMIOLOGY; POPULATION; RATES; CHOLESTEROL	Background The incidence of stroke is predicted to rise because of the rapidly ageing population. However, over the past two decades, findings of randomised trials have identified several interventions that are effective in prevention of stroke. Reliable data on time-trends in stroke incidence, major risk factors, and use of preventive treatments in an ageing population are required to ascertain whether implementation of preventive strategies can offset the predicted rise in stroke incidence. We aimed to obtain these data. Methods We ascertained changes in incidence of transient ischaemic attack and stroke, risk factors, and premorbid use of preventive treatments from 1981-84 (Oxford Community Stroke Project; OCSP) to 2002-04 (Oxford Vascular Study; OXVASC). Findings Of 476 patients with transient ischaemic attacks or strokes in OXVASC, 262 strokes and 93 transient ischaemic attacks were incident events. Despite more complete case-ascertainment than in OCSP, age-adjusted and sex-adjusted incidence of first-ever stroke fell by 29% (relative incidence 0.71, 95% Cl 0.61-0.83, p=0.0002). Incidence declined by more than 50% for primary intracerebral haemorrhage (0.47, 0.27-0.83, p=0.01) but was unchanged for subarachnoid haemorrhage (0.83, 0.44-1.57, p=0.57). Thus, although 28% more incident strokes (366 vs 286) were expected in OXVASC due to demographic change alone (33% increase in those aged 75 or older), the observed number fell (262 vs 286). Major reductions were recorded in mortality rates for incident stroke (0.63, 0.44-0.90, p=0.02) and in incidence of disabling or fatal stroke (0.60, 0.50-0.73, p<0.0001), but no change was seen in case-fatality due to incident stroke (17.2% vs 17.8%; age and sex adjusted relative risk 0.85, 95% Cl 0.57-1.28, p=0-45). Comparison of premorbid risk factors revealed substantial reductions in the proportion of smokers, mean total cholesterol, and mean systolic and diastolic blood pressures and major increases in premorbid treatment with antiplatelet, lipid-lowering, and blood pressure lowering drugs (all p<0.0001). Interpretation The age-specific incidence of major stroke in Oxfordshire has fallen by 40% over the past 20 years in association with increased use of preventive treatments and major reductions in premorbid risk factors.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Care, Oxford, England; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland; St James Hosp, Dept Neurol, Leeds LS9 7TF, W Yorkshire, England; Radcliffe Infirm, Dept Neuroradiol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; University of Oxford; University of Edinburgh; Saint James's University Hospital; Radcliffe Infirmary	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Woodstock Rd, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Bamford, John/ABE-6218-2021; Rothwell, Peter/ABE-5913-2020; Mant, David CA/C-7763-2009	Rothwell, Peter/0000-0001-9739-9211; sackley, catherine/0000-0002-8580-6622; Edwards, Phil/0000-0003-4431-8822	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Acheson E.D., 1967, MED RECORD LINKAGE; [Anonymous], 2001, 2001 CENSUS AREA STA; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; Broderick J P, 1993, Ann Epidemiol, V3, P476; Brown RD, 1996, STROKE, V27, P373; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cormack RM, 1999, J CLIN EPIDEMIOL, V52, P909, DOI 10.1016/S0895-4356(99)00058-X; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; Department of the Environment, 2000, IND DEPR; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; FEIGIN VL, 1995, STROKE, V26, P924, DOI 10.1161/01.STR.26.6.924; Gillum RF, 1997, STROKE, V28, P1527, DOI 10.1161/01.STR.28.8.1527; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Jamrozik K, 1999, STROKE, V30, P2105, DOI 10.1161/01.STR.30.10.2105; Johansson B, 2000, STROKE, V31, P481, DOI 10.1161/01.STR.31.2.481; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; Kodama K, 1993, Ann Epidemiol, V3, P524; Lawlor DA, 2002, LANCET, V360, P1818, DOI 10.1016/S0140-6736(02)11769-7; Lemesle M, 1999, STROKE, V30, P371, DOI 10.1161/01.STR.30.2.371; MCGOVERN PG, 1992, JAMA-J AM MED ASSOC, V268, P753; Medin J, 2004, STROKE, V35, P1047, DOI 10.1161/01.STR.0000125866.78674.96; Morris RW, 2003, STROKE, V34, P2604, DOI 10.1161/01.STR.0000092489.98235.1D; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Neal B, 2000, LANCET, V356, P1955; Numminen H, 1996, STROKE, V27, P1487, DOI 10.1161/01.STR.27.9.1487; Papoz L, 1996, INT J EPIDEMIOL, V25, P474, DOI 10.1093/ije/25.3.474; Rastenyte D, 1996, CEREBROVASC DIS, V6, P13, DOI 10.1159/000107986; Reitsma JB, 1998, NEUROEPIDEMIOLOGY, V17, P121, DOI 10.1159/000026163; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHOUTEN LJ, 1994, INT J EPIDEMIOL, V23, P1111, DOI 10.1093/ije/23.6.1111; STEGMAYR B, 1994, STROKE, V25, P1738, DOI 10.1161/01.STR.25.9.1738; Stegmayr B, 1996, J INTERN MED, V240, P143, DOI 10.1046/j.1365-2796.1996.519857000.x; Terent A, 2003, STROKE, V34, P1353, DOI 10.1161/01.STR.0000074038.71700.1C; TERENT A, 1988, STROKE, V19, P598, DOI 10.1161/01.STR.19.5.598; Thom T J, 1993, Ann Epidemiol, V3, P509; Tuomilehto J, 1993, Ann Epidemiol, V3, P519; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; WOLF PA, 1992, STROKE, V23, P1551, DOI 10.1161/01.STR.23.11.1551; Wolfe CDA, 2000, BRIT MED BULL, V56, P275, DOI 10.1258/0007142001903120	47	785	799	2	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1925	1933		10.1016/S0140-6736(04)16405-2	http://dx.doi.org/10.1016/S0140-6736(04)16405-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194251				2022-12-28	WOS:000221962800006
J	Ricci, JE; Munoz-Pinedo, C; Fitzgerald, P; Bailly-Maitre, B; Perkins, GA; Yadava, N; Scheffler, IE; Ellisman, MH; Green, DR				Ricci, JE; Munoz-Pinedo, C; Fitzgerald, P; Bailly-Maitre, B; Perkins, GA; Yadava, N; Scheffler, IE; Ellisman, MH; Green, DR			Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain	CELL			English	Article							PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; BOVINE HEART-MITOCHONDRIA; PROGRAMMED CELL-DEATH; PHOSPHATIDYLSERINE EXPOSURE; DEPENDENT FORMATION; HL-60 CELLS; MEMBRANE; GENERATION; ACTIVATION	Mitochondrial outer membrane permeabilization and cytochrome c release promote caspase activation and execution of apoptosis through cleavage of specific caspase substrates in the cell. Among the first targets of activated caspases are the permeabilized mitochondria themselves, leading to disruption of electron transport, loss of mitochondrial transmembrane potential (Deltapsim), decline in ATP levels, production of reactive oxygen species (ROS), and loss of mitochondrial structural integrity. Here, we identify NDUFS1, the 75 kDa subunit of respiratory complex 1, as a critical caspase substrate in the mitochondria. Cells expressing a noncleavable mutant of p75 sustain Deltapsim and ATP levels during apoptosis, and ROS production in response to apoptotic stimuli is dampened. While cytochrome c release and DNA fragmentation are unaffected by the noncleavable p75 mutant, mitochondrial morphology of dying cells is maintained, and loss of plasma membrane integrity is delayed. Therefore, caspase cleavage of NDUFS1 is required for several mitochondrial changes associated with apoptosis.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, Mol Biol Sect, La Jolla, CA 92093 USA	La Jolla Institute for Immunology; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	doug@liai.org	Green, Douglas R/N-8083-2018; RICCI, Jean Ehrland/AAS-4379-2020; Munoz-Pinedo, Cristina/B-6118-2008; Ricci, Jean Ehrland/I-7117-2016	Green, Douglas R/0000-0002-7332-1417; RICCI, Jean Ehrland/0000-0003-1585-8117; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Ricci, Jean Ehrland/0000-0003-1585-8117; Perkins, Guy/0000-0002-1834-6646; Bailly-Maitre, Beatrice/0000-0002-8389-8498	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646, R01AI047891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014718] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NCRR NIH HHS [P41 RR04050] Funding Source: Medline; NIAID NIH HHS [AI40646, AI47891] Funding Source: Medline; NIGMS NIH HHS [GM52735] Funding Source: Medline; NINDS NIH HHS [R01 NS14718] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Arroyo A, 2002, J BIOL CHEM, V277, P49965, DOI 10.1074/jbc.M204513200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Benit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Dinsdale D, 1999, AM J PATHOL, V155, P607, DOI 10.1016/S0002-9440(10)65156-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsura T, 2002, FEBS LETT, V524, P25, DOI 10.1016/S0014-5793(02)02990-3; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Rudel T, 1998, J IMMUNOL, V160, P7; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SMITH S, 1980, BIOCHEM J, V185, P315, DOI 10.1042/bj1850315; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Uthaisang W, 2003, FEBS LETT, V545, P110, DOI 10.1016/S0014-5793(03)00508-8; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068; [No title captured]	50	449	463	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					773	786		10.1016/j.cell.2004.05.008	http://dx.doi.org/10.1016/j.cell.2004.05.008			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186778	Bronze			2022-12-28	WOS:000222048400010
J	Giles, J				Giles, J			Nanotech takes small step towards burying 'grey goo'	NATURE			English	News Item																		Phoenix C, 2004, NANOTECHNOLOGY, V15, P869, DOI 10.1088/0957-4484/15/8/001	1	8	8	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					591	591		10.1038/429591b	http://dx.doi.org/10.1038/429591b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190320	Bronze			2022-12-28	WOS:000221912600010
J	Huxman, TE; Smith, MD; Fay, PA; Knapp, AK; Shaw, MR; Loik, ME; Smith, SD; Tissue, DT; Zak, JC; Weltzin, JF; Pockman, WT; Sala, OE; Haddad, BM; Harte, J; Koch, GW; Schwinning, S; Small, EE; Williams, DG				Huxman, TE; Smith, MD; Fay, PA; Knapp, AK; Shaw, MR; Loik, ME; Smith, SD; Tissue, DT; Zak, JC; Weltzin, JF; Pockman, WT; Sala, OE; Haddad, BM; Harte, J; Koch, GW; Schwinning, S; Small, EE; Williams, DG			Convergence across biomes to a common rain-use efficiency	NATURE			English	Article							UNITED-STATES; ELEVATED CO2; ECOSYSTEMS; PRODUCTIVITY; DYNAMICS; GRADIENT; SHRUBS; STEPPE	Water availability limits plant growth and production in almost all terrestrial ecosystems(1-5). However, biomes differ substantially in sensitivity of aboveground net primary production ( ANPP) to between-year variation in precipitation(6-8). Average rain-use efficiency ( RUE; ANPP/precipitation) also varies between biomes, supposedly because of differences in vegetation structure and/or biogeochemical constraints(8). Here we show that RUE decreases across biomes as mean annual precipitation increases. However, during the driest years at each site, there is convergence to a common maximum RUE (RUEmax) that is typical of arid ecosystems. RUEmax was also identified by experimentally altering the degree of limitation by water and other resources. Thus, in years when water is most limiting, deserts, grasslands and forests all exhibit the same rate of biomass production per unit rainfall, despite differences in physiognomy and site-level RUE. Global climate models(9,10) predict increased between-year variability in precipitation, more frequent extreme drought events, and changes in temperature. Forecasts of future ecosystem behaviour should take into account this convergent feature of terrestrial biomes.	Univ Arizona, Tucson, AZ 85721 USA; Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; Yale Univ, Dept Ecol & Evolut Biol, New Haven, CT 06511 USA; Nat Resources Res Inst, Duluth, MN 55811 USA; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Carnegie Inst Sci, Dept Global Ecol, Stanford, CA 94305 USA; Univ Calif Santa Cruz, Dept Environm Studies, Santa Cruz, CA 95064 USA; Univ Nevada, Dept Biol Sci, Las Vegas, NV 89154 USA; Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA; Univ Tennessee, Knoxville, TN 37919 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Univ Buenos Aires, Fac Agron, Dept Ecol, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Agron, IFEVA, Buenos Aires, DF, Argentina; Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA; No Arizona Univ, Merriam Powell Ctr Environm Res, Flagstaff, AZ 86011 USA; Columbia Univ, Biosphere Ctr 2, Oracle, AZ 85623 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Wyoming, Laramie, WY 82071 USA	University of Arizona; National Center for Ecological Analysis & Synthesis; Yale University; Colorado State University; Carnegie Institution for Science; University of California System; University of California Santa Cruz; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Texas Tech University System; Texas Tech University; University of Tennessee System; University of Tennessee Knoxville; University of New Mexico; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of California System; University of California Berkeley; Northern Arizona University; Columbia University; University of Colorado System; University of Colorado Boulder; University of Wyoming	Huxman, TE (corresponding author), Univ Arizona, Tucson, AZ 85721 USA.	huxman@email.arizona.edu; melinda.smith@yale.edu	small, eric/B-4939-2011; Knapp, Alan K/A-2931-2008; Fay, Philip A./I-1853-2012; Tissue, David T/H-6596-2015; Williams, David G/A-6407-2014; Schwinning, Susanne/G-6412-2015; Smith, Melinda D/J-8987-2014; Tissue, David T/N-1710-2019; Small, eric/K-6007-2015; Pockman, William T/D-4086-2014; Tissue, David/AAA-8829-2019	Fay, Philip A./0000-0002-8291-6316; Tissue, David T/0000-0002-8497-2047; Williams, David G/0000-0003-3627-5260; Schwinning, Susanne/0000-0002-9740-0291; Pockman, William T/0000-0002-3286-0457; Tissue, David/0000-0002-8497-2047; Sala, Osvaldo/0000-0003-0142-9450; Small, ERIC/0000-0002-5010-4954				Aber J, 1998, BIOSCIENCE, V48, P921, DOI 10.2307/1313296; [Anonymous], 2001, CLIMATE CHANGE 2001; Austin AT, 1998, OECOLOGIA, V113, P519, DOI 10.1007/s004420050405; Chapin F.S., 2002, PRINCIPLES TERRESTRI, DOI 10.1007/978-1-4419-9504-9; Easterling DR, 2000, SCIENCE, V289, P2068, DOI 10.1126/science.289.5487.2068; Ehleringer JR, 2001, TERRESTRIAL GLOBAL P, P345, DOI [10.1016/B978-0-12-505290-0.X5000-5, DOI 10.1016/B978-012505290-0/50016-8]; Ehleringer JR, 1983, ENCY PLANT PHYSL D, V12D, P205; GRIME JP, 1977, AM NAT, V111, P1169, DOI 10.1086/283244; Jobbagy EG, 2000, ECOL APPL, V10, P541, DOI 10.1890/1051-0761(2000)010[0541:COGASA]2.0.CO;2; Knapp AK, 2001, SCIENCE, V291, P481, DOI 10.1126/science.291.5503.481; Knapp AK, 2002, SCIENCE, V298, P2202, DOI 10.1126/science.1076347; LAUENROTH WK, 1992, ECOL APPL, V2, P397, DOI 10.2307/1941874; LEHOUEROU HN, 1998, J ARID ENVIRON, V15, P1; Lieth H., 1975, PRIMARY PRODUCTIVITY, V14, P237, DOI [10.1007/978-3-642-80913-2_12, DOI 10.1007/978-3-642-80913-2_12]; NOYMEIR I, 1973, ANNU REV ECOL SYST, V4, P51; Paruelo JM, 1999, ECOSYSTEMS, V2, P64, DOI 10.1007/s100219900058; Reynolds JF, 1999, ECOL MONOGR, V69, P69, DOI 10.1890/0012-9615(1999)069[0069:IODODS]2.0.CO;2; ROSENZWEIG ML, 1968, AM NAT, V102, P67, DOI 10.1086/282523; SALA OE, 1988, ECOLOGY, V69, P40, DOI 10.2307/1943158; Schimel DS, 2001, NATURE, V414, P169, DOI 10.1038/35102500; SCHLESINGER WH, 1990, SCIENCE, V247, P1043, DOI 10.1126/science.247.4946.1043; Schlesinger WH., 1997, BIOGEOCHEMISTRY; SEASTEDT TR, 1993, AM NAT, V141, P421; Shaw MR, 2002, SCIENCE, V298, P1987, DOI 10.1126/science.1075312; Smith S.D., 1997, PHYSIOLOGICAL ECOLOG; Smith SD, 2000, NATURE, V408, P79, DOI 10.1038/35040544; TURNER FB, 1989, J ARID ENVIRON, V17, P23, DOI 10.1016/S0140-1963(18)30921-2; Veron SR, 2002, ECOSYSTEMS, V5, P625, DOI 10.1007/s10021-002-0145-1; WALTER HEINRICH, 1939, JAHRB WISS BOT, V87, P750; WEBB WL, 1983, ECOLOGY, V64, P134, DOI 10.2307/1937336	30	811	882	24	560	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					651	654		10.1038/nature02561	http://dx.doi.org/10.1038/nature02561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190350				2022-12-28	WOS:000221912600038
J	Cory, DG; Havel, TF				Cory, DG; Havel, TF			Physics - Ion entanglement in quantum information processing	SCIENCE			English	Editorial Material									MIT, Dept Nucl Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Cory, DG (corresponding author), MIT, Dept Nucl Engn, Cambridge, MA 02139 USA.	dcory@mit.edu						Cirac JI, 2004, PHYS TODAY, V57, P38, DOI 10.1063/1.1712500; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; Garisto R, 1999, PHYS REV A, V60, P827, DOI 10.1103/PhysRevA.60.827; Kielpinski D, 2001, SCIENCE, V291, P1013, DOI 10.1126/science.1057357; Knill E, 2000, NATURE, V404, P368, DOI 10.1038/35006012; Leibfried D, 2004, SCIENCE, V304, P1476, DOI 10.1126/science.1097576; MERMIN ND, 1990, AM J PHYS, V58, P731, DOI 10.1119/1.16503; Nielson M. A, 2000, QUANTUM COMPUTATION; Roos CF, 2004, SCIENCE, V304, P1478, DOI 10.1126/science.1097522; Terhal BM, 2003, PHYS TODAY, V56, P46, DOI 10.1063/1.1580049	11	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1456	1457		10.1126/science.1099639	http://dx.doi.org/10.1126/science.1099639			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178788				2022-12-28	WOS:000221795800028
J	Gostin, LO				Gostin, LO			International Infectious Disease Law - Revision of the World Health Organization's International Health Regulations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The International Health Regulations (IHR), the only global regulations for infectious disease control, have not been significantly changed since they were first issued in 1951. The World Health Organization (WHO) is currently engaged in a process to modernize the IHR. This article reviews WHO's draft revised IHR and recommends new reforms to improve global health; which include (1) a robust mission, emphasizing the WHO's core public health purposes, functions, and essential services; (2) broad scope, flexibly covering diverse health threats; (3) global surveillance, developing informational networks of official and unofficial data sources; (4) national public health systems, setting performance criteria, measuring outcomes, and holding states accountable; (5) human rights protection; setting science-based standards and fair procedures; and (6) good governance, adopting the principles of fairness, objectivity, and transparency. The WHO should ensure state compliance with health norms and generous economic and technical assistance to poorer countries. An important issue for the international community is how sovereign countries can join together to make global health work for everyone, the poor and the wealthy alike.	Georgetown Univ, Ctr Law & Publ Hlth, Washington, DC 20001 USA; Johns Hopkins Univ, Baltimore, MD USA	Georgetown University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						Arai-Takahashi Y, 2001, LAW PUBLIC DIMENSION, P113; Ashraf H, 1999, LANCET, V354, P2062, DOI 10.1016/S0140-6736(05)76812-4; Fidler D. P, 1999, INT LAW INFECT DIS; Fidler DP, 2003, J LAW MED ETHICS, V31, P485, DOI 10.1111/j.1748-720X.2003.tb00117.x; Gostin LO, 2003, JAMA-J AM MED ASSOC, V290, P3229, DOI 10.1001/jama.290.24.3229; Gostin LO, 2000, PUBLIC HLTH LAW POWE; GOSTIN LO, 2003, FLORIDA LAW REV, V52, P1; Grad FP, 2002, B WORLD HEALTH ORGAN, V80, P981; HEYMANN D, 2002, OXFORD TXB PUBLIC HL, P171; *I MED, 2003, MICR TRHEATS HLTH EM; *INT WORK GROUP RE, 2003, 12 IGWGIHR WHO; Klempner MS, 2004, NEW ENGL J MED, V350, P1171, DOI 10.1056/NEJMp048039; Koh H. H., 1997, YALE L J, V106, P2599, DOI DOI 10.2307/797228; Koh Harold Hongju, 1996, NEBR LAW REV, V75, P181; Slaughter Anne-Marie., 2004, NEW WORLD ORDER; TAYLOR AL, 2002, OXFORD TXB PUBLIC HL, P359; *URB MORG I, 1985, HUM RIGHTS Q, V7, P3; WHO, 1997, MID IMP US ANT FOOD; WHO, 2002, WHOCDSCSRGAR20024, P6; *WHO, 1995, PUBL WHO; *WHO, 1999, WKLY EPIDEMIOL REC, V74, P193; *WHO, 2000, GLOB DAT BLOOD SAF 1; *WHO, 2003, PUBL WHO; *WHO, 2003, WHO BAS DOC; *WHO SECR, 2004, PUBL WHO; *WHO SECR, 2003, PUBL WHO; *WHO SECR, 2002, PUBL WHO	27	54	54	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2623	2627		10.1001/jama.291.21.2623	http://dx.doi.org/10.1001/jama.291.21.2623			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173154				2022-12-28	WOS:000221738800026
J	Yach, D; Hawkes, C; Gould, CL; Hofman, KJ				Yach, D; Hawkes, C; Gould, CL; Hofman, KJ			The global burden of chronic diseases - Overcoming impediments to prevention and control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; CHALLENGES; DEATHS	Chronic diseases are the largest cause of death in the world. In 2002, the leading chronic diseases-cardiovascular disease, cancer, chronic respiratory disease, and diabetes-caused 29 million deaths worldwide. Despite growing evidence of epidemiological and economic impact, the global response to the problem remains inadequate. Stakeholders include governments, the World Health Organization and other United Nations bodies, academic and research groups, nongovernmental organizations, and the private sector. Lack of financial support retards capacity development for prevention, treatment, and research in most developing countries. Reasons for this include that up-to-date evidence related to the nature of the burden of chronic diseases is not in the hands of decision makers and strong beliefs persist that chronic diseases afflict only the affluent and the elderly, that they arise solely from freely acquired risks, and that their control is ineffective and too expensive and should wait until infectious diseases are addressed. The influence of global economic factors on chronic disease risks impedes progress, as does the orientation of health systems toward acute care. We identify 3 policy levers to address these impediments: elevating chronic diseases on the health agenda of key policymakers, providing them with better evidence about risk factor control, and persuading them of the need for health systems change. A more concerted, strategic, and multisectoral policy approach, underpinned by solid research, is essential to help reverse the negative trends in the global incidence of chronic disease.	WHO, CH-1211 Geneva 27, Switzerland; US Natl Inst Hlth, Fogarty Int Ctr, Washington, DC USA	World Health Organization; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Yach, D (corresponding author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	yachd@who.int	Stockwell, Tim/B-6662-2012	HOFMAN, KAREN/0000-0001-9512-7220				ALANO BP, 2003, GLOB FOR HLTH RES FO; [Anonymous], 2001, ASSESSMENT NATL CAPA; [Anonymous], 2003, WHO FRAM CONV TOB CO; [Anonymous], 2003, TOBACCO CONTROL POLI; *AS DEV BANK, 1999, POL HLTH SECT; *B M GAT FDN, 2004, GLOB HLTH PROGR FACT; Babor TF, 2003, ALCOHOL NO ORDINARY; Basnyat B, 2004, BMJ-BRIT MED J, V328, P781, DOI 10.1136/bmj.328.7443.781; Beaglehole R, 2003, LANCET, V362, P903, DOI 10.1016/S0140-6736(03)14335-8; Beaglehole R., 2003, WORLD HLTH REPORT 20; Bettcher DW, 2000, B WORLD HEALTH ORGAN, V78, P521; Brownell K. D., 2004, FOOD FIGHT INSIDE ST; BUMGARNER R, IN PRESS SOC PREV ME; Dodd R, 2002, POVERTY REDUCTION ST; FLECK R, 2004, BRIT MED J, V328, P730; Frenk J., 1989, Health Policy and Planning, V4, P29, DOI 10.1093/heapol/4.1.29; Fries JF, 2003, ANN INTERN MED, V139, P455, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00015; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; *GLOB FOR HLTH RES, 2002, 10 99 REP HLTH RES 2, P89; *GLOB FOR HLTH RES, 2002, MONT FIN FLOWS HLTH; Guindon GE, 2002, TOB CONTROL, V11, P35, DOI 10.1136/tc.11.1.35; Hawkes C., 2002, GLOBALIZATION DIETS; *IND COUNC MED RES, NONC DIS WEB PAG; Jha P., 2000, TOBACCO CONTROL DEV; Jha P., 1999, CURBING EPIDEMIC GOV; Leeder S, 2004, RACE TIME CHALLENGE; Mann J, 2004, LANCET, V363, P1068, DOI 10.1016/S0140-6736(04)15844-3; Marmot MG, 2004, BRIT MED J, V328, P906, DOI 10.1136/bmj.328.7445.906; McKeown T., 1988, ORIGINS HUMAN DIS; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Nchinda TC, 2002, SOC SCI MED, V54, P1699, DOI 10.1016/S0277-9536(01)00338-0; Organization WH, 2003, INT PREV NONC DIS DR; PENA M, 2000, PAN AM HLTH ORG SCI, V576, P3; Popkin BM, 1998, NUTR REV, V56, P106; RAMESH A, 1999, EC ANAL HLTH SECTOR, P8; *ROCK FDN, 2000, ROCK FDN LAUNCH NEW; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Sklar P, 2003, NEW ENGL J MED, V349, P2065, DOI 10.1056/NEJMe038158; Stewart B.W., 2003, WORLD CANC REPORT; STEYN K, 2003, DETERMINANTS TREATME; Thompson D, 2001, Obes Rev, V2, P189, DOI 10.1046/j.1467-789x.2001.00037.x; Tsalikian E, 2004, DIABETES CARE, V27, P722; *UN GLOB COMP, 2001, GUID GLOB COMP PRACT; *UN POP FUND, SUMM ICPD PROGR ACT; UNCTAD, 2003, WORLD INVESTMENT REP, P114; *UNDP, IMPL MILL DECL GOAL; Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769; Wakefield M, 2003, ADDICTION, V98, P79, DOI 10.1046/j.1360-0443.98.s1.6.x; Wanless, 2002, SECURING OUR FUTURE; *WHO, 2000, TOB CO STRAT UND TOB, V46, P116; *WHO, 1956, 9 WORLD HLTH ASS GEN; *WHO, 2000, 53 WORLD HLTH ASS MA; *WHO, 1999, UN FDN PROJ BUILD AL; WHO, 2002, INNOVATIVE CARE CHRO; *WHO, 2003, FIN MAN REP EXP IMPL; *WHO DEP GOV PRIV, 2003, BIL AID GUID; WHO/UNAIDS, 2003, TREAT 3 MILL 2005 MA; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Wilkinson RG, 2003, SOCIAL DETERMINANTS; World Bank, 1997, HLTH NUTR POP SECT S; World Health Organization, 2002, WHO STRAT PREV CONTR; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; YACH D, 1990, INT J EPIDEMIOL, V19, P1122, DOI 10.1093/ije/19.4.1122; Yach D, 2003, J PUBLIC HEALTH POL, V24, P274, DOI 10.2307/3343374; YACH D, IN PRESS SOCIAL JUST; 2000, LANCET, V355, P1923; 2000, G8 COMMUNIQUE; 2004, MANDAG MORGEN   0209	68	855	897	1	81	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2616	2622		10.1001/jama.291.21.2616	http://dx.doi.org/10.1001/jama.291.21.2616			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173153				2022-12-28	WOS:000221738800025
J	George, S; Rochford, JJ; Wolfrum, C; Gray, SL; Schinner, S; Wilson, JC; Soos, MA; Murgatroyd, PR; Williams, RM; Acerini, CL; Dunger, DB; Barford, D; Umpleby, AM; Wareham, NJ; Davies, HA; Schafer, AJ; Stoffel, M; O'Rahilly, S; Barroso, I				George, S; Rochford, JJ; Wolfrum, C; Gray, SL; Schinner, S; Wilson, JC; Soos, MA; Murgatroyd, PR; Williams, RM; Acerini, CL; Dunger, DB; Barford, D; Umpleby, AM; Wareham, NJ; Davies, HA; Schafer, AJ; Stoffel, M; O'Rahilly, S; Barroso, I			A family with severe insulin resistance and diabetes due to a mutation in AKT2	SCIENCE			English	Article							STRUCTURAL BASIS; MICE LACKING; KINASE; HYPERTENSION; GENETICS; MELLITUS; BETA; PKB	Inherited defects in signaling pathways downstream of the insulin receptor have long been suggested to contribute to human type 2 diabetes mellitus. Here we describe a mutation in the gene encoding the protein kinase AKT2/PKBbeta in a family that shows autosomal dominant inheritance of severe insulin resistance and diabetes mellitus. Expression of the mutant kinase in cultured cells disrupted insulin signaling to metabolic end points and inhibited the function of coexpressed, wild-type AKT. These findings demonstrate the central importance of AKT signaling to insulin sensitivity in humans.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England; Guys Kings & St Thomas Sch Med, Dept Diabet Endocrinol & Internal Med, London, England; MRC, Epidemiol Unit, Strangeways Res Lab, Cambridge CB1 8RN, England; Darent Valley Hosp, Dartford DA2 8DA, Kent, England; Incyte, Palo Alto, CA 94304 USA; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Rockefeller University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; Incyte; Wellcome Trust Sanger Institute	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd, Cambridge CB2 2QQ, England.	sorahill@hgmp.mrc.ac.uk	O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Acerini, Carlo/0000-0003-2121-5871; Barroso, Ines/0000-0001-5800-4520; Stoffel, Markus/0000-0003-1304-5817; Wolfrum, Christian/0000-0002-3862-6805; Dunger, Professor David/0000-0002-2566-9304; Rochford, Justin/0000-0002-5020-4939	Wellcome Trust [078986] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Baynes KCR, 1997, QJM-MON J ASSOC PHYS, V90, P557, DOI 10.1093/qjmed/90.9.557; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gloyn AL, 2001, BEST PRACT RES CL EN, V15, P293, DOI 10.1053/beem.2001.0147; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; McCarthy M I, 2001, Expert Rev Mol Diagn, V1, P403, DOI 10.1586/14737159.1.4.403; Pedersen O, 1999, EXP CLIN ENDOCR DIAB, V107, P113, DOI 10.1055/s-0029-1212085; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vihinen M, 2000, CLIN IMMUNOL, V96, P108, DOI 10.1006/clim.2000.4880; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870	18	399	423	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1325	1328		10.1126/science.1096706	http://dx.doi.org/10.1126/science.1096706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166380	Green Accepted			2022-12-28	WOS:000221669600055
J	Tamkins, T				Tamkins, T			South Koreans create human stem cell line using nuclear transfer	LANCET			English	News Item																			0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					623	623		10.1016/S0140-6736(04)15628-6	http://dx.doi.org/10.1016/S0140-6736(04)15628-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	15202474				2022-12-28	WOS:000189104900014
J	Bakolitsa, C; Cohen, DM; Bankston, LA; Bobkov, AA; Cadwell, GW; Jennings, L; Critchley, DR; Craig, SW; Liddington, RC				Bakolitsa, C; Cohen, DM; Bankston, LA; Bobkov, AA; Cadwell, GW; Jennings, L; Critchley, DR; Craig, SW; Liddington, RC			Structural basis for vinculin activation at sites of cell adhesion	NATURE			English	Article							ALPHA-CATENIN; INTRAMOLECULAR ASSOCIATION; CRYSTAL-STRUCTURE; TALIN-BINDING; TAIL DOMAINS; ACTIN; PROTEINS; VASP; HEAD	Vinculin is a highly conserved intracellular protein with a crucial role in the maintenance and regulation of cell adhesion and migration(1-3). In the cytosol, vinculin adopts a default autoinhibited conformation(4,5). On recruitment to cell - cell and cell - matrix adherens-type junctions, vinculin becomes activated and mediates various protein - protein interactions that regulate the links between F-actin and the cadherin and integrin families of cell-adhesion molecules. Here we describe the crystal structure of the full-length vinculin molecule ( 1,066 amino acids), which shows a five-domain autoinhibited conformation in which the carboxyterminal tail domain is held pincer-like by the vinculin head, and ligand binding is regulated both sterically and allosterically. We show that conformational changes in the head, tail and proline-rich domains are linked structurally and thermodynamically, and propose a combinatorial pathway to activation that ensures that vinculin is activated only at sites of cell adhesion when two or more of its binding partners are brought into apposition.	Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Sanford Burnham Prebys Medical Discovery Institute; Johns Hopkins University; University of Leicester	Liddington, RC (corresponding author), Burnham Inst, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org	Ladoux, Benoit/A-9879-2013	Cohen, Daniel/0000-0002-7963-668X; Bakolitsa, Constantina/0000-0002-6980-9831				Adey NB, 1997, BIOCHEM J, V324, P523, DOI 10.1042/bj3240523; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; JANSSEN MEW, UNPUB J CELL BIOL; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Liddington RC, 2000, EXP CELL RES, V261, P37, DOI 10.1006/excr.2000.5058; Lim WA, 2002, CURR OPIN STRUC BIOL, V12, P61, DOI 10.1016/S0959-440X(02)00290-7; Miller GJ, 2001, J BIOL CHEM, V276, P28829, DOI 10.1074/jbc.M102561200; OHALLORAN T, 1986, METHOD ENZYMOL, V134, P69; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; VOLBERG T, 1995, J CELL SCI, V108, P2253; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Xu WM, 1998, DEVELOPMENT, V125, P327; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645	30	269	276	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	2004	430	6999					583	586		10.1038/nature02610	http://dx.doi.org/10.1038/nature02610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841QI	15195105				2022-12-28	WOS:000222946100053
J	Rietveld, RP; ter Riet, G; Bindels, PJE; Sloos, JH; van Weert, HCPM				Rietveld, RP; ter Riet, G; Bindels, PJE; Sloos, JH; van Weert, HCPM			Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms	BRITISH MEDICAL JOURNAL			English	Article							TOPICAL LOMEFLOXACIN; RESISTANCE; CHLORAMPHENICOL	Objective To find an efficient set of diagnostic indicators that are optimally informative in. the diagnosis of a bacterial origin of acute infectious conjunctivitis. Design Cohort study involving consecutive patients. Results of index tests and reference standard were collected independently from each other. Setting 25 Dutch health centres. Participants 184 adults presenting with a red eye and either (muco)purulent discharge or glued eyelid(s), not wearing contact lenses. Main outcome measures Probability of a positive bacterial culture, given different combinations of index test results; area under receiver operating characteristics curve. Results Logistic regression analysis showed optimal diagnostic discrimination for the combination of early morning glued eye(s), itch, and a history of conjunctivitis. The first of these indicators increased the likelihood of a bacterial cause, whereas the other two decreased it. The area under the receiver operating characteristics curve for this combination of symptoms was 0.74 (95% confidence interval 0.63 to 0.80). The overall prevalence of bacterial involvement of 32% could be lowered to 4% or raised to 77%, depending on the pattern of index test results. Conclusion A bacterial origin of complaints indicative of acute infectious conjunctivitis can be made much more likely or unlikely by the answers to three simple questions posed during clinical history taking (possibly by telephone). These results may have consequences for more targeted prescription of ocular antibiotics.	Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Div Clin Methods & Publ Hlth, NL-1105 AZ Amsterdam, Netherlands; Horten Zentrum, Zurich, Switzerland; Med Ctr Alkmaar, Alkmaar, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Medical Center Of Alkmaar	Rietveld, RP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Div Clin Methods & Publ Hlth, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	r.p.rietveld@amc.uva.nl	Riet, Gerben ter/A-6943-2011	Riet, Gerben ter/0000-0002-2231-7637				Agius-Fernandez A, 1998, CLIN DRUG INVEST, V15, P263, DOI 10.2165/00044011-199815040-00001; Brown EM, 2002, LANCET, V359, P803, DOI 10.1016/S0140-6736(02)07869-8; CALLENGA PE, 1999, OPHTHALMOLOGICA, V213, P350; Chang SD, 2001, DUANES OPHTHALMOLOGY, V4; *DEP HLTH, 1998, PRESCR COST AN DAT; Everitt H, 2002, FAM PRACT, V19, P658, DOI 10.1093/fampra/19.6.658; Gallenga PE, 1999, OPHTHALMOLOGICA, V213, P250, DOI 10.1159/000027430; *GEN HULPM INF PRO, 2001, ANN REP PRESCR DAT; Goldstein MH, 1999, OPHTHALMOLOGY, V106, P1313, DOI 10.1016/S0161-6420(99)00716-2; Hall GS, 1995, CLIN MICROBIOLOGY PR; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HORVEN I, 1993, ACTA OPHTHALMOL, V71, P165; HOSMER DW, 1989, APPL LOGISTIC REGRES; KANSKI JJ, 1999, CLIN OPHTHALMOLOGY S; KIERVELD RP, 2003, BRIT MED J, V327, P789; Krachmer JH, 1997, CORNEA; Miller I M, 1992, Eur J Ophthalmol, V2, P58; Mills O, 2002, ACTA DERM-VENEREOL, V82, P260, DOI 10.1080/000155502320323216; OKKES IM, 1998, KLACHT NAAR DIAGNOSE; OKKES IM, 1998, KLACHT DIAGNOSE EPIS; Sheikh A, 2001, BRIT J GEN PRACT, V51, P473; Van-der-Werf GT, 1998, SPIEGEL HUISARTS REG; VANDELISDONK EH, 1999, CONTINUE MORBIDITEIT; VANDERWERF GT, 1998, SPIEGEL HUISARTSE RE	24	77	79	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 24	2004	329	7459					206	208B		10.1136/bmj.38128.631319.AE	http://dx.doi.org/10.1136/bmj.38128.631319.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840NW	15201195	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222866900019
J	Ogawa, SP; Imada, M; Yoshimoto, S; Okano, M; Noda, S				Ogawa, SP; Imada, M; Yoshimoto, S; Okano, M; Noda, S			Control of light emission by 3D photonic crystals	SCIENCE			English	Article							NEAR-INFRARED WAVELENGTHS; WAVE-GUIDES; DEFECT; BAND	Three-dimensional (3D) photonic crystals containing artificial point defects have been fabricated to emit light at optical communications wavelengths. They were constructed by stacking 0.7-micrometer-period gallium arsenide striped layers, resulting in a 3D "woodpile" photonic crystal. Indium-gallium arsenide-phosphide quantum-well layers emitting at a wavelength of 1.55 micrometers were incorporated in the center of the crystal. Samples having up to nine stacked layers were constructed, and artificial point-defect cavities of different sizes were formed in the light-emitting layer. Light emission was suppressed in the photonic crystal regions, whereas cavity modes were successfully observed at the point defects and were size dependent.	Kyoto Univ, Dept Elect Sci & Engn, Kyoto 6158510, Japan	Kyoto University	Noda, S (corresponding author), Kyoto Univ, Dept Elect Sci & Engn, Kyoto 6158510, Japan.	snoda@kuee.kyoto-u.ac.jp	Okano, Makoto/L-1997-2018; Ogawa, Shinpei/G-2029-2017	Okano, Makoto/0000-0002-5483-3425; Ogawa, Shinpei/0000-0002-9310-9026				Akahane Y, 2003, NATURE, V425, P944, DOI 10.1038/nature02063; Baba T, 1999, ELECTRON LETT, V35, P654, DOI 10.1049/el:19990438; Benisty H, 1999, J LIGHTWAVE TECHNOL, V17, P2063, DOI 10.1109/50.802996; Bulu I, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.205103; Fleming JG, 1999, OPT LETT, V24, P49, DOI 10.1364/OL.24.000049; Happ TD, 2001, OPT LETT, V26, P1102, DOI 10.1364/OL.26.001102; HO KM, 1994, SOLID STATE COMMUN, V89, P413, DOI 10.1016/0038-1098(94)90202-X; JOHN S, 1991, PHYS TODAY, V44, P32, DOI 10.1063/1.881300; Kramper P, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.113903; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; McNab SJ, 2003, OPT EXPRESS, V11, P2927, DOI 10.1364/OE.11.002927; Megens M, 1999, PHYS REV A, V59, P4727, DOI 10.1103/PhysRevA.59.4727; Noda S, 2000, NATURE, V407, P608, DOI 10.1038/35036532; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Noda S, 2002, IEEE J QUANTUM ELECT, V38, P726, DOI 10.1109/JQE.2002.1017582; Notomi M, 2002, IEEE J QUANTUM ELECT, V38, P736, DOI 10.1109/JQE.2002.1017583; Ogawa S, 2003, APPL PHYS LETT, V82, P3406, DOI 10.1063/1.1576911; Okano M., UNPUB; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Romanov SG, 2002, J APPL PHYS, V91, P9426, DOI 10.1063/1.1469688; SOGN B, 2003, SCIENCE, V300, P1537; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	22	333	339	3	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					227	229		10.1126/science.1097968	http://dx.doi.org/10.1126/science.1097968			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15178750				2022-12-28	WOS:000222501000047
J	Kanagawa, M; Saito, F; Kunz, S; Yoshida-Moriguchi, T; Barresi, R; Kobayashi, YM; Muschler, J; Dumanski, JP; Michele, DE; Oldstone, MBA; Campbell, KP				Kanagawa, M; Saito, F; Kunz, S; Yoshida-Moriguchi, T; Barresi, R; Kobayashi, YM; Muschler, J; Dumanski, JP; Michele, DE; Oldstone, MBA; Campbell, KP			Molecular recognition by LARGE is essential for expression of functional dystroglycan	CELL			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; HUMAN LARGE GENE; ALPHA-DYSTROGLYCAN; MUSCULAR-DYSTROPHY; SARCOGLYCAN COMPLEX; BETA-SARCOGLYCAN; LAMININ; DISRUPTION; DEFICIENCY; RECEPTOR	Reduced ligand binding activity of alpha-dystroglycan is associated with muscle and central nervous system pathogenesis in a growing number of muscular dystrophies. Posttranslational processing of alpha-dystroglycan is generally accepted to be critical for the expression of functional dystroglycan. Here we show that both the N-terminal domain and a portion of the mucin-like domain of alpha-dystroglycan are essential for high-affinity laminin-receptor function. Posttranslational modification of alpha-dystroglycan by glycosyltransferase, LARGE, occurs within the mucin-like domain, but the N-terminal domain interacts with LARGE, defining an intracellular enzyme-substrate recognition motif necessary to initiate functional glycosylation. Gene replacement in dystroglycan-deficient muscle demonstrates that the dystroglycan C-terminal domain is sufficient only for dystrophin-glycoprotein complex assembly, but to prevent muscle degeneration the expression of a functional dystroglycan through LARGE recognition and glycosylation is required. Therefore, molecular recognition of dystroglycan by LARGE is a key determinant in the biosynthetic pathway to produce mature and functional dystroglycan.	Univ Iowa, Royal J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Royal J & Lucille A Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Scripps Res Inst, Div Virol, Dept Neuropharmacol, La Jolla, CA 92037 USA; Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA; Uppsala Univ, Dept Genet & Pathol, S-75185 Uppsala, Sweden	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Scripps Research Institute; California Pacific Medical Center; California Pacific Medical Center Research Institute; Uppsala University	Campbell, KP (corresponding author), Univ Iowa, Royal J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022; Kunz, Stefan/K-5840-2017	Barresi, Rita/0000-0001-7351-959X; Muschler, John/0000-0001-9916-5937; Dumanski, Jan Piotr/0000-0002-1489-1452; Campbell, Kevin/0000-0003-2066-5889; Kanagawa, Motoi/0000-0003-0984-6398; Kunz, Stefan/0000-0001-6030-9550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45927] Funding Source: Medline; NIDDK NIH HHS [P30 DK54759] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRESI R, NAT MED; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Brancaccio A, 1997, EUR J BIOCHEM, V246, P166, DOI 10.1111/j.1432-1033.1997.00166.x; Burton EA, 2002, CELL, V108, P5, DOI 10.1016/S0092-8674(01)00626-2; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Duclos F, 1998, NEUROMUSCULAR DISORD, V8, P30, DOI 10.1016/S0960-8966(97)00135-1; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Esapa CT, 2002, HUM MOL GENET, V11, P3319, DOI 10.1093/hmg/11.26.3319; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Hall H, 2003, MOL CELL NEUROSCI, V24, P1062, DOI 10.1016/j.mcn.2003.08.007; Hayashi YK, 2001, NEUROLOGY, V57, P115, DOI 10.1212/WNL.57.1.115; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Kano H, 2002, BIOCHEM BIOPH RES CO, V291, P1283, DOI 10.1006/bbrc.2002.6608; Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103; Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Matsumura K, 2003, NEUROMUSCULAR DISORD, V13, P796, DOI 10.1016/S0960-8966(03)00139-1; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Muntoni F, 2004, CURR OPIN NEUROL, V17, P205, DOI 10.1097/00019052-200404000-00020; Noguchi S, 2000, EUR J BIOCHEM, V267, P640, DOI 10.1046/j.1432-1327.2000.00998.x; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Saito F, 2003, NEURON, V38, P747, DOI 10.1016/S0896-6273(03)00301-5; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Tome FMS, 1999, NEUROPEDIATRICS, V30, P55, DOI 10.1055/s-2007-973461; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Yamada H, 1996, J NEUROCHEM, V66, P1518	46	204	208	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					953	964		10.1016/j.cell.2004.06.003	http://dx.doi.org/10.1016/j.cell.2004.06.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210115	Bronze			2022-12-28	WOS:000222300200012
J	Yang, J; Mani, SA; Donaher, JL; Ramaswamy, S; Itzykson, RA; Come, C; Savagner, P; Gitelman, I; Richardson, A; Weinberg, RA				Yang, J; Mani, SA; Donaher, JL; Ramaswamy, S; Itzykson, RA; Come, C; Savagner, P; Gitelman, I; Richardson, A; Weinberg, RA			Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis	CELL			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; DROSOPHILA MESODERM DEVELOPMENT; BREAST-CANCER METASTASIS; E-CADHERIN EXPRESSION; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; NEURAL-TUBE; CARCINOMA; SNAIL; CELLS	Metastasis is a multistep process during which cancer cells disseminate from the site of primary tumors and establish secondary tumors in distant organs. In a search for key regulators of metastasis in a murine breast tumor model, we have found that the transcription factor Twist, a master regulator of embryonic morphogenesis, plays an essential role in metastasis. Suppression of Twist expression in highly metastatic mammary carcinoma cells specifically inhibits their ability to metastasize from the mammary gland to the lung. Ectopic expression of Twist results in loss of E-cadherin-mediated cell-cell adhesion, activation of mesenchymal markers, and induction of cell motility, suggesting that Twist contributes to metastasis by promoting an epithelial-mesenchymal transition (EMT). In human breast cancers, high level of Twist expression is correlated with invasive lobular carcinoma, a highly infiltrating tumor type associated with loss of E-cadherin expression. These results establish a mechanistic link between Twist, EMT, and tumor metastasis.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Broad Inst, Canc Genom Program, Cambridge, MA 02141 USA; MGH Ctr Canc Res, Charlestown, MA 02129 USA; Ecole Normale Super, F-75230 Paris 05, France; INSERM, EMI 0229, CRLC Val Aurelle Paul Lamarque, F-34298 Montpellier 5, France; Ben Gurion Univ Negev, Dept Mol Genet & Dev, IL-84105 Beer Sheva, Israel; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Ben Gurion University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu	Savagner, Pierre/AAD-9357-2020; Côme, Christophe/E-8395-2016; Gitelman, Inna/F-1338-2012; Mani, Sendurai A./A-7244-2009; Itzykson, Raphael/M-8517-2018	Côme, Christophe/0000-0001-5229-4440; Mani, Sendurai A./0000-0002-5918-4276; Itzykson, Raphael/0000-0003-2139-6262; Savagner, Pierre/0000-0002-8287-2229	NATIONAL CANCER INSTITUTE [F32CA101507, P01CA080111, R21CA096689] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA096689, P01-CA80111, 1 F32 CA101507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs G, 2001, AM J CLIN PATHOL, V115, P85; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Berx G, 1996, ONCOGENE, V13, P1919; BOYER B, 1993, APMIS, V101, P257, DOI 10.1111/j.1699-0463.1993.tb00109.x; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Furlong EEM, 2001, SCIENCE, V293, P1629, DOI 10.1126/science.1062660; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; Gohji K, 1997, AM J PATHOL, V151, P1655; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; MILLER FR, 1993, CRIT REV ONCOGENESIS, V4, P293; MOLL R, 1993, AM J PATHOL, V143, P1731; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Soo K, 2002, DEV BIOL, V247, P251, DOI 10.1006/dbio.2002.0699; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a	36	2918	3143	1	356	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					927	939		10.1016/j.cell.2004.06.006	http://dx.doi.org/10.1016/j.cell.2004.06.006			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210113	Bronze			2022-12-28	WOS:000222300200010
J	Bellwood, DR; Hughes, TP; Folke, C; Nystrom, M				Bellwood, DR; Hughes, TP; Folke, C; Nystrom, M			Confronting the coral reef crisis	NATURE			English	Review							GREAT-BARRIER-REEF; LONG-TERM DECLINE; DIADEMA-ANTILLARUM; BIODIVERSITY HOTSPOTS; PHASE-SHIFTS; GENOTYPIC DIVERSITY; JUVENILE CORALS; MASS MORTALITY; CLIMATE-CHANGE; GENE FLOW	The worldwide decline of coral reefs calls for an urgent reassessment of current management practices. confronting large-scale crises requires a major scaling-up of management efforts based on an improved understanding of the ecological processes that underlie reef resilience. Managing for improved resilience, incorporating the role of human activity in shaping ecosystems, provides a basis for coping with uncertainty, future changes and ecological surprises. Here we review the ecological roles of critical functional groups (for both corals and reef fishes) that are fundamental to understanding resilience and avoiding phase shifts from coral dominance to less desirable, degraded ecosystems. We identify striking biogeographic differences in the species richness and composition of functional groups, which highlight the vulnerability of Caribbean reef ecosystems. These findings have profound implications for restoration of degraded reefs, management of fisheries, and the focus on marine protected areas and biodiversity hotspots as priorities for conservation.	James Cook Univ N Queensland, Dept Marine Biol, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia; Univ Perpignan, Ecole Prat Hautes Etud, CNRS, UMR 8046, F-66860 Perpignan, France; Stockholm Univ, Dept Syst Ecol, SE-10691 Stockholm, Sweden; Royal Swedish Acad Sci, Beijer Int Inst Ecol Econ, Stockholm, Sweden	James Cook University; Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; Stockholm University; Royal Swedish Academy of Sciences; Beijer Institute of Ecological Economics	Bellwood, DR (corresponding author), James Cook Univ N Queensland, Dept Marine Biol, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia.	david.bellwood@jcu.edu.au	Bellwood, David/E-2497-2011; Folke, Carl/Z-1545-2019; Hughes, Terry P/L-4721-2013	Hughes, Terry P/0000-0002-5257-5063; Nystrom, Magnus/0000-0003-3608-2426; Folke, Carl/0000-0002-4050-3281				*AIMS, REEF MON; Aronson RB, 2002, ECOL MONOGR, V72, P233, DOI 10.1890/0012-9615(2002)072[0233:TESOST]2.0.CO;2; Ayre DJ, 2004, ECOL LETT, V7, P273, DOI 10.1111/j.1461-0248.2004.00585.x; Ayre DJ, 2000, EVOLUTION, V54, P1590; Bell R, 2002, J SCI MED SPORT, V5, P32, DOI 10.1016/S1440-2440(02)80295-X; Bellwood DR, 2003, ECOL LETT, V6, P281, DOI 10.1046/j.1461-0248.2003.00432.x; BELLWOOD DR, 1990, ENVIRON BIOL FISH, V28, P189, DOI 10.1007/BF00751035; Bellwood DR, 2001, SCIENCE, V292, P1532, DOI 10.1126/science.1058635; Birkeland C, 1997, TRENDS ECOL EVOL, V12, P364, DOI 10.1016/S0169-5347(97)01099-9; Bohnsack James A., 2003, Gulf and Caribbean Research, V14, P1; Connell JH, 1997, ECOL MONOGR, V67, P461, DOI 10.1890/0012-9615(1997)067[0461:AYSOCA]2.0.CO;2; Dietz T, 2003, SCIENCE, V302, P1907, DOI 10.1126/science.1091015; DONE TJ, 1992, HYDROBIOLOGIA, V247, P121, DOI 10.1007/BF00008211; DONE TJ, 1996, FUNCTIONAL ROLES BIO, P393; Eakin CM, 1996, CORAL REEFS, V15, P109; Edmunds PJ, 2001, P NATL ACAD SCI USA, V98, P5067, DOI 10.1073/pnas.071524598; Elmqvist T, 2003, FRONT ECOL ENVIRON, V1, P488, DOI 10.1890/1540-9295(2003)001[0488:RDECAR]2.0.CO;2; Folke C, 1996, ECOL APPL, V6, P1018, DOI 10.2307/2269584; FOLKE C, IN PRESS ANN REV ECO; Gardner TA, 2003, SCIENCE, V301, P958, DOI 10.1126/science.1086050; GLYNN P W, 1988, Galaxea, V7, P129; Glynn PW, 2000, CORAL REEFS, V19, P1, DOI 10.1007/s003380050220; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; Graham NAJ, 2003, ENVIRON CONSERV, V30, P200, DOI 10.1017/S0376892903000195; *GREAT BARR REEF M, OV CURR STAT GREAT B; Halpern BS, 2002, ECOL LETT, V5, P361, DOI 10.1046/j.1461-0248.2002.00326.x; Harvell CD, 2002, SCIENCE, V296, P2158, DOI 10.1126/science.1063699; HAY ME, 1984, ECOLOGY, V65, P446, DOI 10.2307/1941407; Heppell SS, 1996, WILDLIFE RES, V23, P143, DOI 10.1071/WR9960143; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Hughes TP, 2002, ECOL LETT, V5, P775, DOI 10.1046/j.1461-0248.2002.00383.x; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; Hughes TP, 1999, LIMNOL OCEANOGR, V44, P932, DOI 10.4319/lo.1999.44.3_part_2.0932; Hughes TP, 2000, ECOLOGY, V81, P2250, DOI 10.1890/0012-9658(2000)081[2250:RFLHAL]2.0.CO;2; HUNTE W, 1992, MAR BIOL, V114, P625, DOI 10.1007/BF00357259; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jennings S, 1997, CORAL REEFS, V16, P71, DOI 10.1007/s003380050061; JOHNSON KG, 1995, PALEOBIOLOGY, V21, P52, DOI 10.1017/S0094837300013075; Kareiva P, 2003, AM SCI, V91, P344, DOI 10.1511/2003.26.869; Kinzig AP, 2003, AMBIO, V32, P330, DOI 10.1639/0044-7447(2003)032[0330:CWUACF]2.0.CO;2; KNOWLTON N, 1992, AM ZOOL, V32, P674; LESSIOS HA, 1984, SCIENCE, V226, P335, DOI 10.1126/science.226.4672.335; LESSIOS HA, 1988, ANNU REV ECOL SYST, V19, P371, DOI 10.1146/annurev.es.19.110188.002103; LEVITAN DR, 1988, OECOLOGIA, V76, P627, DOI 10.1007/BF00397880; McCook LJ, 2001, CORAL REEFS, V19, P400, DOI 10.1007/s003380000129; McCulloch M, 2003, NATURE, V421, P727, DOI 10.1038/nature01361; McGilvray F., 2002, AQUACULTURE ASIA, V7, P21; Moberg F, 1999, ECOL ECON, V29, P215, DOI 10.1016/S0921-8009(99)00009-9; Munro JL., 1983, CARIBBEAN CORAL REEF, V2, P1; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Naeem S, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P3; *NOAA FISH, CAND COR ACR PALM EL; Nystrom M, 2001, ECOSYSTEMS, V4, P406, DOI 10.1007/s10021-001-0019-y; Nystrom M, 2000, TRENDS ECOL EVOL, V15, P413, DOI 10.1016/S0169-5347(00)01948-0; Ogden J, 1977, STUD GEOL POLONICA, V4, P281; OGDEN JC, 1973, SCIENCE, V182, P715, DOI 10.1126/science.182.4113.715; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; PAULY D, 1995, TRENDS ECOL EVOL, V10, P430, DOI 10.1016/S0169-5347(00)89171-5; Pauly D, 2002, NATURE, V418, P689, DOI 10.1038/nature01017; RICHMOND RH, 1993, AM ZOOL, V33, P524; Roberts CM, 2002, SCIENCE, V295, P1280, DOI 10.1126/science.1067728; Russ Garry R., 2002, P421, DOI 10.1016/B978-012615185-5/50024-4; Sadovy Yvonne J., 2002, P391, DOI 10.1016/B978-012615185-5/50023-2; SAMMARCO PW, 1980, J EXP MAR BIOL ECOL, V45, P245, DOI 10.1016/0022-0981(80)90061-1; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Scheffer M, 2003, TRENDS ECOL EVOL, V18, P648, DOI 10.1016/j.tree.2003.09.002; Scully EP, 2001, TRENDS ECOL EVOL, V16, P126, DOI 10.1016/S0169-5347(00)02088-7; Spalding M. D., 2001, WORLD ATLAS CORAL RE; Staneck RS, 1998, TRENDS ECOL EVOL, V13, P429, DOI 10.1016/S0169-5347(98)01494-3; Steneck R.S., 1988, P 6 INT COR REEF S A, P37; STENECK RS, 1994, OIKOS, V69, P476, DOI 10.2307/3545860; *USCRTF, 2000, NAT ACT PLAN CONS CO; Walker B. H., 1997, PLANT FUNCTIONAL TYP, P91; WILKINSON C, 2002, STATUS COREL REEFS W; WILLIAMS DM, 2002, CURRENT LEVEL SCI UN; 2003, GREAT BARRIER REEF M	76	2161	2265	86	2460	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					827	833		10.1038/nature02691	http://dx.doi.org/10.1038/nature02691			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215854				2022-12-28	WOS:000222213000031
J	Priola, SA; Vorberg, I				Priola, SA; Vorberg, I			Identification of possible animal origins of prion disease in human beings	LANCET			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; SINGLE AMINO-ACID; SPONGIFORM ENCEPHALOPATHY; VARIANT CJD; INCUBATION-TIME; BSE AGENT; SCRAPIE; PROTEIN; MICE; PHENOTYPES		NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Tech Univ Munich, Inst Virol, D-8000 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Technical University of Munich	Priola, SA (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	spriola@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Belay ED, 2001, ARCH NEUROL-CHICAGO, V58, P1673, DOI 10.1001/archneur.58.10.1673; Biacabe AG, 2004, EMBO REP, V5, P110, DOI 10.1038/sj.embor.7400054; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Bruce Moira E., 1996, P223; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Vorberg I, 2002, J BIOL CHEM, V277, P36775, DOI 10.1074/jbc.M206865200; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Yamakawa Y, 2003, JPN J INFECT DIS, V56, P221	17	7	7	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2013	2014		10.1016/S0140-6736(04)16487-8	http://dx.doi.org/10.1016/S0140-6736(04)16487-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207949				2022-12-28	WOS:000222159800005
J	Valent, F; Little, D; Bertollini, R; Nemer, LE; Barbone, F; Tamburlini, G				Valent, F; Little, D; Bertollini, R; Nemer, LE; Barbone, F; Tamburlini, G			Burden of disease attributable to selected environmental factors and injury among children and adolescents in Europe	LANCET			English	Article							AIR-POLLUTION; LEAD-EXPOSURE; TIME-SERIES; SAO-PAULO; HEALTH; MORTALITY; BRAZIL; LEVEL; WATER	Background Environmental exposures contribute to the global burden of disease. We have estimated the burden of disease attributable to outdoor and indoor air pollution, inadequate water and sanitation, lead exposure, and injury among European children and adolescents. Methods Published studies and reports from international agencies were reviewed for calculation of risk-factor exposure in Europe. Disability-adjusted life years (DALYs) or deaths attributable to each factor, or both, were estimated by application of the potential impact fraction to the estimates of mortality and burden of disease from the WHO global database of burden of disease. Findings Among children aged 0-4 years, between 1.8% and 6.4% of deaths from all causes were attributable to outdoor air pollution; acute lower-respiratory-tract infections attributable to indoor air pollution accounted for 4.6% of all deaths and 3.1% of DALYs; and mild mental retardation resulting from lead exposure accounted for 4.4% of DALYs. In the age-group 0-14 years, diarrhoea attributable to inadequate water and sanitation accounted for 5.3% of deaths and 3.5% of DALYs. In the age-group 0-19 years, injuries were the cause of 22.6% of all deaths and 19.0% of DALYs. The burden of disease was much higher in European subregions B and C than subregion A. There was substantial uncertainty around some of the estimates, especially for outdoor air pollution. Interpretation Large proportions of deaths and DALYs in European children are attributable to outdoor and indoor air pollution, inadequate water and sanitation, lead exposure, and injuries. Interventions aimed at reducing children's exposure to environmental factors and injuries could result in substantial gains. The pronounced differences by subregion and age indicate the need for targeted action.	Univ Udine, Univ Hosp, DPMSC, Inst Hyg & Epidemiol, I-33100 Udine, Italy; WHO, Reg Off Europe, Div Hlth Determinants, DK-2100 Copenhagen, Denmark; WHO, European Ctr Environm & Hlth, Rome, Italy; Inst Child Hlth IRCCS Burlo Garofolo, Unit Hlth Serv Res & Int Hlth, Trieste, Italy	University of Udine; World Health Organization; World Health Organization; IRCCS Burlo Garofolo	Valent, F (corresponding author), Policlin Univ, Ist Igiene & Epidemiol, Via Colugna 40, I-33100 Udine, Italy.	francesca.valent@uniud.it	Valent, Francesca/J-4759-2016; Barbone, Fabio/K-1755-2014	Valent, Francesca/0000-0002-4071-0897; Barbone, Fabio/0000-0001-8795-9959; Barbone, Fabio/0000-0003-1337-5111				[Anonymous], 2002, CHILDRENS HLTH ENV R; Bonnefoy XR, 2003, AM J PUBLIC HEALTH, V93, P1559, DOI 10.2105/AJPH.93.9.1559; Bruckner JV, 2000, REGUL TOXICOL PHARM, V31, P280, DOI 10.1006/rtph.2000.1393; Conceicao GMS, 2001, ENVIRON HEALTH PERSP, V109, P347, DOI 10.2307/3434781; Desai MA, 2004, WHO ENV BURDEN DIS S, V4; Dowd MD, 2002, CRIT CARE MED, V30, pS385, DOI 10.1097/00003246-200211001-00002; ESREY SA, 1985, B WORLD HEALTH ORGAN, V63, P757; *EUR ENV AG, AIR POLL EUR 1990 20; Ezzati M, 2003, LANCET, V362, P271, DOI 10.1016/S0140-6736(03)13968-2; Fewtrell L., 2003, WHO ENV BURDEN DIS S, V2; FISCHER AB, 2002, INT J HYG ENVIR HEAL, V205, P1; Gouveia N, 2000, OCCUP ENVIRON MED, V57, P477, DOI 10.1136/oem.57.7.477; HUTTLY SRA, 1997, B WORLD HEALTH ORGAN, V75, P165; KAY D, 2000, WHOSDRWSH007; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; LOVEI M, 1997, PHASING OUT LEAD GAS, P35; LYONS RA, 1982, INJURY PREV, V9, P33; Murray, 2002, SUMMARY MEASURES POP, P205; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1996, GLOBAL HLTH STAT; OSTRO B, 2003, IN PRESS WHO ENV BUR, V5; OSTRO B, 1998, FINE PARTICLE STANDA, V2, P939; Pruss A, 2002, ENVIRON HEALTH PERSP, V110, P537, DOI 10.1289/ehp.02110537; Pruss-Ustun A, 2003, WHO ENV BURDEN DIS S, V1; SALDIVA PHN, 1995, AIR POLLUTION MORTAL, P1; SCHWARTZ J, 1994, ENVIRON RES, V65, P42, DOI 10.1006/enrs.1994.1020; SMITH K, IN PRESS INDOOR SMOK; Smith KR, 1999, EPIDEMIOLOGY, V10, P573, DOI 10.1097/00001648-199909000-00027; Stromberg U, 2003, OCCUP ENVIRON MED, V60, P370, DOI 10.1136/oem.60.5.370; Thomas VM, 1999, ENVIRON SCI TECHNOL, V33, P3942, DOI 10.1021/es990231+; Tong S, 2000, B WORLD HEALTH ORGAN, V78, P1068; *UNICEF, 2004, STAT WORLDS CHILDR; *US EPA, 2003, AM CHILDR ENV MEAS C; Von Schirnding Y, ADDRESSING IMPACT HO; WALSH M, DRAFT MEMO PHASEOUT; *WHO, 2003, BURD DIS PROJ 2001 M; *WHO, 1999, DECL 3 MIN C ENV HLT; *WHO CHOICE, LIST MEMB STAT WHO R; WHO/UNICEF, 2000, GLOB WAT SUPPL SAN A; *WORLD BANK, AIR POLL DAT REG COU; 1908, 4 MIN C ENV HLTH BUD	41	84	91	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2032	2039		10.1016/S0140-6736(04)16452-0	http://dx.doi.org/10.1016/S0140-6736(04)16452-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207953				2022-12-28	WOS:000222159800009
J	Cohen-Armon, M; Visochek, L; Katzoff, A; Levitan, D; Susswein, AJ; Klein, R; Valbrun, M; Schwartz, JH				Cohen-Armon, M; Visochek, L; Katzoff, A; Levitan, D; Susswein, AJ; Klein, R; Valbrun, M; Schwartz, JH			Long-term memory requires polyADP-ribosylation	SCIENCE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; ADP-RIBOSYLATION; FEEDING-BEHAVIOR; SENSORY NEURONS; APLYSIA; SENSITIZATION; CHROMATIN; PARP; FACILITATION; INHIBITION	PolyADP-ribose-polymerase 1 is activated in neurons that mediate several forms of long-term memory in Aplysia. Because polyADP-ribosylation of nuclear proteins is a response to DNA damage in virtually all eukaryotic cells, it is surprising that activation of the polymerase occurs during learning and is required for long-term memory. We suggest that fast and transient decondensation of chromatin structure by polyADP-ribosylation enables the transcription needed to form long-term memory without strand breaks in DNA.	Tel Aviv Univ, Sackler Sch Med, Neufeld Cardiac Res Inst, Sheba Med Ctr, IL-69978 Tel Aviv, Israel; Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diagnost Res Ctr, IL-52900 Ramat Gan, Israel; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Bar Ilan University; Columbia University	Cohen-Armon, M (corresponding author), Tel Aviv Univ, Sackler Sch Med, Neufeld Cardiac Res Inst, Sheba Med Ctr, IL-69978 Tel Aviv, Israel.	marmon@post.tau.ac.3l; jhs6@columbia.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Susswein, Abraham J./0000-0001-6107-5901	NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR010294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER; NCRR NIH HHS [RR10294] Funding Source: Medline; NIMH NIH HHS [MH48850] Funding Source: Medline; NINDS NIH HHS [NS29832] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnold J, 2002, BIOESSAYS, V24, P1060, DOI 10.1002/bies.10179; Botzer D, 1998, LEARN MEMORY, V5, P204; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; BOULIKAS T, 1990, J BIOL CHEM, V24, P46381; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Byrne JH, 1996, J NEUROSCI, V16, P425; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Cleary LJ, 1998, J NEUROSCI, V18, P5988; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Guan ZH, 2003, J NEUROSCI, V23, P7317; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; JEANCHRISTOPHE A, 2000, DNA DAMAGE STRESS SI, P14; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Katzoff A, 2002, J NEUROSCI, V22, P9581; KATZOFF A, 2001, SOC NEUR ABSTR, V27; KUPFERMANN I, 1974, BEHAV BIOL, V10, P89, DOI 10.1016/S0091-6773(74)91694-0; MACKEY SL, 1987, P NATL ACAD SCI USA, V84, P8730, DOI 10.1073/pnas.84.23.8730; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; Morton DB, 2004, MOL NEUROBIOL, V29, P97, DOI 10.1385/MN:29:2:097; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; Richardson DS, 1999, ADV EXP MED BIOL, V457, P267; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SUSSWEIN AJ, 1986, J NEUROSCI, V6, P1513; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; UDEA K, 1990, ADP RIBOSYLATING TOX, P530; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WALTERS ET, 1995, TRENDS NEUROSCI, V18, P137, DOI 10.1016/0166-2236(95)93891-Z; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	33	136	141	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1820	1822		10.1126/science.1096775	http://dx.doi.org/10.1126/science.1096775			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205535				2022-12-28	WOS:000222089500050
J	McNeill, JR; Winiwarter, A				McNeill, JR; Winiwarter, A			Breaking the sod: Humankind, history, and soil	SCIENCE			English	Article							SCIENCE	For most of history, few things have mattered more to human communities than their relations with soil, because soil provided most of their food and nutrients. Accordingly, some of the earliest written documents were agricultural manuals intended to organize, preserve, and impart soil knowledge. Indeed, ancient civilizations often worshipped the soil as the foundry of life itself. For the past century or two, nothing has mattered more for soils than their relations with human communities, because human action inadvertently ratcheted up rates of soil erosion and, both intentionally and unintentionally, rerouted nutrient flows.	Georgetown Univ, Edmund A Walsh Sch Foreign Serv, Int Ctr 600, Washington, DC 20057 USA; Univ Nat Resources & Appl Life Sci, Inst Soil Res, A-180 Vienna, Austria; Inst Interdisciplinary Studies, A-1070 Vienna, Austria	Georgetown University; University of Natural Resources & Life Sciences, Vienna	McNeill, JR (corresponding author), Georgetown Univ, Edmund A Walsh Sch Foreign Serv, Int Ctr 600, Box 571035,3700 O St NW, Washington, DC 20057 USA.	mcneillj@georgetown.edu	Winiwarter, Verena/G-1599-2015	Winiwarter, Verena/0000-0002-6033-4219				Beach T, 2002, GEOGR REV, V92, P372, DOI 10.2307/4140916; Bray Francesca, 1984, SCI CIVILISATION C 2, V6; Dregne H. E., 1982, ASA [American Society of Agronomy] Special Publication, P1; Gong ZT, 2003, GEODERMA, V115, P3, DOI 10.1016/S0016-7061(03)00071-5; McNeill J. R., 1992, MOUNTAINS MEDITERRAN; McNeill J. R., 2000, SOMETHING NEW UNDER; Ren M. E, 1994, Holocene, V4, P314, DOI 10.1177/095968369400400311; Smil V., 2001, ENRICHING THE EARTH; WASSON R, IN PRESS WORLD ENV H; Winiwarter V., 2000, SHIFTING BOUNDARIES, P137; Yaalon DH, 2000, NATURE, V407, P301, DOI 10.1038/35030260	11	107	111	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1627	1629		10.1126/science.1099893	http://dx.doi.org/10.1126/science.1099893			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192217				2022-12-28	WOS:000221934300037
J	Mathur, SK; Grodinsky, D				Mathur, SK; Grodinsky, D			Dislocation of the lenses	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Loyola Univ, Med Ctr, Maywood, IL 60153 USA; US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Mathur, SK (corresponding author), Loyola Univ, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					E22	E22		10.1056/NEJMicm030131	http://dx.doi.org/10.1056/NEJMicm030131			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190155				2022-12-28	WOS:000221887200010
J	Mitchell, SL; Kiely, DK; Hamel, MB; Park, PS; Morris, JN; Fries, BE				Mitchell, SL; Kiely, DK; Hamel, MB; Park, PS; Morris, JN; Fries, BE			Estimating prognosis for nursing home residents with advanced dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PREDICTION RULES; MINIMUM DATA SET; SURVIVAL; CARE; MORTALITY; CRITERIA	Context Survival varies for patients with advanced dementia, and accurate prognostic tools have not been developed. A small proportion of patients admitted to hospice have dementia, in part because of the difficulty in predicting survival. Objectives To identify factors associated with 6-month mortality in newly admitted nursing home residents with advanced dementia and to create a practical risk score to predict 6-month mortality in this population. Design, Setting, and Participants This was a retrospective cohort study of data from the Minimum Data Set (MDS). All Medicare or Medicaid licensed nursing homes in New York and Michigan were included. Participants had advanced dementia and were admitted to New York nursing homes between June 1, 1994, and December 30, 1998 (derivation cohort, n=6799), and to Michigan nursing homes from October 1, 1998, through July 30, 2000 (validation cohort, n=4631). Main Outcome Measures MDS factors associated with 6-month mortality were determined in the derivation group, and the resulting mortality risk score was evaluated in the validation cohort. Risk score performance was compared with the cut point of 7c on the Functional Assessment Staging (FAST) scale. Results Among residents with advanced dementia, 28.3% (n = 1922) died within 6 months of nursing home admission in the derivation cohort; 35.1% (n = 1626) died in the validation cohort. The 6-month mortality rate increased across risk scores (possible range, 0-19): 0 points, 8.9% mortality; 1 to 2, 10.8%; 3 to 5, 23.2%; 6 to 8, 40.4%; 9 to 11, 57.0%; and at least 12, 70.0% in the validation cohort. The, area under the receiver operating characteristic (AUROC) curve for predicting 6-month mortality was 0.74 and 0.70 in the derivation and validation cohorts, respectively. Our risk score demonstrated better discrimination to predict 6-month mortality (AUROC, 0.64 for a cutoff of greater than or equal to6 points vs 0.51 for FAST stage 7c). Conclusion A risk score based on 12 variables from the MDS estimates 6-month mortality for nursing home residents with advanced dementia with greater accuracy than existing prognostic guidelines.	Hebrew Rehabil Ctr Aged, Res & Training Inst, Boston, MA 02131 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Ann Arbor, MI 48105 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mitchell, SL (corresponding author), Hebrew Rehabil Ctr Aged, Res & Training Inst, 1200 Ctr St, Boston, MA 02131 USA.	smitchell@mail.hrca.harvard.edu			NIA NIH HHS [AG04390, AG08812, K23AG20054] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG004390, P60AG008812, K23AG020054, P30AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguero-Torres H, 1998, J AM GERIATR SOC, V46, P444, DOI 10.1111/j.1532-5415.1998.tb02464.x; Berger A, 2001, J AM GERIATR SOC, V49, P1570, DOI 10.1046/j.1532-5415.2001.4911257.x; BILGRAD R, 2000, NATL DEATH INDEX USE; Carlson MC, 2001, J GERONTOL A-BIOL, V56, pM567, DOI 10.1093/gerona/56.9.M567; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; *COMM DIET HLTH FO, 1989, IMPL RED CHRON DIS R; FABISZEWSKI KJ, 1990, JAMA-J AM MED ASSOC, V263, P3168, DOI 10.1001/jama.263.23.3168; Flacker JM, 2003, J AM GERIATR SOC, V51, P213, DOI 10.1046/j.1532-5415.2003.51060.x; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Gambassi G, 1999, J NEUROL NEUROSUR PS, V67, P59, DOI 10.1136/jnnp.67.1.59; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANRAHAN P, 1995, J AM GERIATR SOC, V43, P56, DOI 10.1111/j.1532-5415.1995.tb06243.x; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LUCHINS DJ, 1993, J AM GERIATR SOC, V41, P25; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; Mitchell SL, 2004, ARCH INTERN MED, V164, P321, DOI 10.1001/archinte.164.3.321; MOR V, INTERRATER RELIABILI; Morris JN, 1997, J AM GERIATR SOC, V45, P1011, DOI 10.1111/j.1532-5415.1997.tb02974.x; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; National Hospice Organization, 1996, MED GUID DET PROGN S; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; VANDIJK PTM, 1991, J AM GERIATR SOC, V39, P603, DOI 10.1111/j.1532-5415.1991.tb03602.x; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x; Volicer L, 1997, J AM GERIATR SOC, V45, P1147, DOI 10.1111/j.1532-5415.1997.tb05982.x; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501	33	167	167	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2734	2740		10.1001/jama.291.22.2734	http://dx.doi.org/10.1001/jama.291.22.2734			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826XH	15187055				2022-12-28	WOS:000221862300028
J	Luscombe, CJ; Cooke, PW				Luscombe, CJ; Cooke, PW			Pain during prostate biopsy	LANCET			English	Editorial Material							ULTRASOUND-GUIDED BIOPSY; PERIPROSTATIC NERVE BLOCK; LOCAL-ANESTHESIA; TRIAL; LIDOCAINE; INJECTION		Royal Shrewsbury Hosp NHS Trust, Dept Urol, Shrewsbury SY3 8XQ, Shrops, England; New Cross Hosp, Dept Urol, Wolverhampton, W Midlands, England	New Cross Hospital	Luscombe, CJ (corresponding author), Royal Shrewsbury Hosp NHS Trust, Dept Urol, Shrewsbury SY3 8XQ, Shrops, England.	chrisluscombe@hotmail.com						ADAMAKIS I, 2003, WORLD J UROL; Crundwell MC, 1999, BJU INT, V83, P792; Davis M, 2002, J UROLOGY, V167, P566, DOI 10.1016/S0022-5347(01)69087-6; Jones JS, 2003, J UROLOGY, V170, P2316, DOI 10.1097/01.ju.0000095792.42718.83; Jones JS, 2003, PROSTATE CANCER P D, V6, P53, DOI 10.1038/sj.pcan.4500630; Lee-Elliott CE, 2004, J UROLOGY, V171, P247, DOI 10.1097/01.ju.0000098688.12631.a0; Lynn NNK, 2002, BJU INT, V90, P424, DOI 10.1046/j.1464-410X.2002.02902.x; Mallick S, 2004, J UROLOGY, V171, P730, DOI 10.1097/01.ju.0000108125.96072.ff; Manikandan R, 2003, J UROLOGY, V170, P1881, DOI 10.1097/01.ju.0000092501.40772.28; Ozden E, 2003, J UROLOGY, V170, P2319, DOI 10.1097/01.ju.0000095760.29931.f7; Schroder FH, 2003, BJU INT, V92, P1, DOI 10.1111/j.1464-410X.2003.04389.x	11	32	33	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1840	1841		10.1016/S0140-6736(04)16392-7	http://dx.doi.org/10.1016/S0140-6736(04)16392-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183618				2022-12-28	WOS:000221822300004
J	deYoung, B; Heath, M; Werner, F; Chai, F; Megrey, B; Monfray, P				deYoung, B; Heath, M; Werner, F; Chai, F; Megrey, B; Monfray, P			Challenges of Modeling ocean basin ecosystems	SCIENCE			English	Review							CALANUS-FINMARCHICUS; NORTH-ATLANTIC; MARINE COPEPOD; EL-NINO; VARIABILITY; PACIFIC; POPULATIONS; DYNAMICS; CLIMATE	With increasing pressure for a more ecological approach to marine fisheries and environmental management, there is a growing need to understand and predict changes in marine ecosystems. Biogeochemical and physical oceanographic models are well developed, but extending these further up the food web to include zooplankton and fish is a major challenge. The difficulty arises because organisms at higher trophic levels are longer lived, with important variability in abundance and distribution at basin and decadal scales. Those organisms at higher trophic levels also have complex life histories compared to microbes, further complicating their coupling to lower trophic levels and the physical system. We discuss a strategy that builds on recent advances in modeling and observations and suggest a way forward that includes approaches to coupling across trophic levels and the inclusion of uncertainty.	Mem Univ Newfoundland, St Johns, NF, Canada; Fisheries Res Serv, Marine Ecosyst Program, Aberdeen, Scotland; Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27599 USA; Univ Maine, Sch Marine Sci, Orono, ME 04469 USA; NOAA, Natl Marine Fisheries Serv, Alaska Fisheries Sci Ctr, Seattle, WA 98115 USA; Lab Etud Geophys & Oceanog Spatiales, Toulouse, France	Memorial University Newfoundland; University of North Carolina; University of North Carolina Chapel Hill; University of Maine System; University of Maine Orono; National Oceanic Atmospheric Admin (NOAA) - USA; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Laboratoire d'Etudes en Geophysique et oceanographie spatiales	deYoung, B (corresponding author), Mem Univ Newfoundland, St Johns, NF, Canada.	bdeyoung@physics.mun.ca	MONFRAY, Patrick/AAB-8665-2020; Megrey, Bernard/A-7065-2009; Heath, Michael R/D-5765-2013	MONFRAY, Patrick/0000-0002-3028-5591; 				BARBER RT, 1986, NATURE, V319, P279, DOI 10.1038/319279a0; Beaugrand G, 2002, SCIENCE, V296, P1692, DOI 10.1126/science.1071329; BROEKHUIZEN N, 1995, NETH J SEA RES, V33, P381, DOI 10.1016/0077-7579(95)90054-3; Chavez FP, 2003, SCIENCE, V299, P217, DOI 10.1126/science.1075880; Clark JS, 2001, SCIENCE, V293, P657, DOI 10.1126/science.293.5530.657; CONKRIGHT ME, 2002, NOAA ATLAS NATL ENV, V42; Cowen RK, 2000, SCIENCE, V287, P857, DOI 10.1126/science.287.5454.857; Ebenhoh W, 1997, J SEA RES, V38, P173, DOI 10.1016/S1385-1101(97)00043-9; Garcon VC, 2001, DEEP-SEA RES PT II, V48, P2199, DOI 10.1016/S0967-0645(00)00183-1; Gurney WSC, 2001, J ANIM ECOL, V70, P881, DOI 10.1046/j.0021-8790.2001.00549.x; Hare SR, 2000, PROG OCEANOGR, V47, P103, DOI 10.1016/S0079-6611(00)00033-1; Hind A, 2000, MAR ECOL PROG SER, V193, P95, DOI 10.3354/meps193095; Hirche HJ, 1996, OPHELIA, V44, P129, DOI 10.1080/00785326.1995.10429843; Le Quere C, 2003, TELLUS B, V55, P649, DOI 10.1034/j.1600-0889.2003.00043.x; Lehodey P, 1997, NATURE, V389, P715, DOI 10.1038/39575; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; Planque B, 1998, J MAR BIOL ASSOC UK, V78, P1015, DOI 10.1017/S0025315400044969; RILEY GA, 1946, J MAR RES, V6, P54; Schneider N, 2002, J CLIMATE, V15, P586, DOI 10.1175/1520-0442(2002)015<0586:AONPDV>2.0.CO;2; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; Willebrand J, 2001, PROG OCEANOGR, V48, P123, DOI 10.1016/S0079-6611(01)00003-9; Wood SN, 2001, ECOL MONOGR, V71, P1, DOI 10.1890/0012-9615(2001)071[0001:PSEM]2.0.CO;2	22	162	166	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1463	1466		10.1126/science.1094858	http://dx.doi.org/10.1126/science.1094858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178792				2022-12-28	WOS:000221795800032
J	Ellwood, MDF; Foster, WA				Ellwood, MDF; Foster, WA			Doubling the estimate of invertebrate biomass in a rainforest canopy	NATURE			English	Article							ABUNDANCE; INSECTS; WEIGHT	Forest canopies represent the functional interface between 90% of the Earth's terrestrial biomass and the atmosphere(1) and include some of the most threatened of all terrestrial ecosystems(2). However, we lack even a basic understanding of how the biomass of plants and animals is distributed throughout forest canopies, even though this information is vital for estimating energy flow, carbon cycling, resource use and the transfer of materials within this ecosystem(3,4). Here we measure the biomass of invertebrates living in a common rainforest epiphyte, describe a striking relationship between fern size and the biomass of animals within the ferns, and reveal that one large epiphyte may contain an invertebrate biomass similar to that found in the whole of the rest of the tree crown on which it is growing. Using these data, we show that including the fauna of these epiphytes-a neglected component in rainforest ecosystems-can more than double our estimate of the total invertebrate biomass in an entire rainforest canopy.	Univ Cambridge, Dept Zool, Univ Museum Zool, Cambridge CB2 3EJ, England	University of Cambridge	Ellwood, MDF (corresponding author), Univ Cambridge, Dept Zool, Univ Museum Zool, Downing St, Cambridge CB2 3EJ, England.	mdfe2@cam.ac.uk						Adis Joachim, 1998, Ecotropica, V4, P93; Basset Y, 2001, PLANT ECOL, V153, P87, DOI 10.1023/A:1017581406101; Benzing DH, 1990, VASCULAR EPIPHYTES G, DOI [10.1017/CBO9780511525438, DOI 10.1017/CBO9780511525438]; BESUCHET C, 1987, Coleopterists Bulletin, V41, P392; BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; ELLWOOD M. D. F., 2002, GLOBAL CANOPY HDB TE, P115; Ellwood Martin D. F., 2001, Selbyana, V22, P97; Ellwood MDF, 2002, BIOTROPICA, V34, P575, DOI 10.1111/j.1744-7429.2002.tb00576.x; Guerrero JCH, 2003, ARTHROPODS OF TROPICAL FORESTS, P170; NADKARNI NM, 1990, BIOTROPICA, V22, P286, DOI 10.2307/2388539; Ozanne CMP, 2003, SCIENCE, V301, P183, DOI 10.1126/science.1084507; PAGEL MD, 1991, AM NAT, V138, P836, DOI 10.1086/285255; Parris B. S., 1997, SANDAKANIA, V9, P77; POCS T, 1980, ACTA BOT HUNG, V26, P143; Richardson BA, 2000, J TROP ECOL, V16, P167, DOI 10.1017/S0266467400001346; ROGERS LE, 1976, ANN ENTOMOL SOC AM, V69, P387, DOI 10.1093/aesa/69.2.387; SCHOENER TW, 1980, ANN ENTOMOL SOC AM, V73, P106, DOI 10.1093/aesa/73.1.106; Stork N.E., 1990, P173; STORK NE, 1988, BIOL J LINN SOC, V35, P321, DOI 10.1111/j.1095-8312.1988.tb00474.x; STORK NE, 1991, J TROP ECOL, V7, P161, DOI 10.1017/S0266467400005319; Stork Nigel E., 1993, P115	21	166	181	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	2004	429	6991					549	551		10.1038/nature02560	http://dx.doi.org/10.1038/nature02560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175749				2022-12-28	WOS:000221767700036
J	Munekaga, Y; Hashimoto, M; Miyaka, C; Tomizawa, KI; Endo, T; Tasaka, M; Shikanai, T				Munekaga, Y; Hashimoto, M; Miyaka, C; Tomizawa, KI; Endo, T; Tasaka, M; Shikanai, T			Cyclic electron flow around photosystem I is essential for photosynthesis	NATURE			English	Article							NAD(P)H DEHYDROGENASE; NADH DEHYDROGENASE; NDHB GENE; TRANSPORT; TOBACCO; CHLOROPLASTS; FERREDOXIN; PHOTOPHOSPHORYLATION; COMPONENTS; COMPLEX	Photosynthesis provides at least two routes through which light energy can be used to generate a proton gradient across the thylakoid membrane of chloroplasts, which is subsequently used to synthesize ATP. In the first route, electrons released from water in photosystem II (PSII) are eventually transferred to NADP(+) by way of photosystem I (PSI)(1). This linear electron flow is driven by two photochemical reactions that function in series. The cytochrome b(6)f complex mediates electron transport between the two photosystems and generates the proton gradient (DeltapH). In the second route, driven solely by PSI, electrons can be recycled from either reduced ferredoxin or NADPH to plastoquinone, and subsequently to the cytochrome b(6)f complex(2-5). Such cyclic flow generates DeltapH and thus ATP without the accumulation of reduced species. Whereas linear flow from water to NADP 1 is commonly used to explain the function of the light-dependent reactions of photosynthesis, the role of cyclic flow is less clear. In higher plants cyclic flow consists of two partially redundant pathways. Here we have constructed mutants in Arabidopsis thaliana in which both PSI cyclic pathways are impaired, and present evidence that cyclic flow is essential for efficient photosynthesis.	Res Inst Innovat Technol Earth, Plant Res Grp, Kyoto 6190225, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Research Institute of Innovative Technology for the Earth; Kyoto University; Nara Institute of Science & Technology	Shikanai, T (corresponding author), CEA Cadarache, Dept Plant Ecophysiol & Microbiol, F-13108 St Paul Les Durance, France.	shikanai@agr.kyushu-u.ac.jp	Shikanai, Toshiharu/AAK-9112-2020					Allen JF, 2002, CELL, V110, P273, DOI 10.1016/S0092-8674(02)00870-X; ARNON DI, 1954, NATURE, V174, P394, DOI 10.1038/174394a0; ARNON DI, 1967, NATURE, V214, P562, DOI 10.1038/214562a0; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Backhausen JE, 2000, PHOTOSYNTH RES, V64, P1, DOI 10.1023/A:1026523809147; BENDALL DS, 1995, BBA-BIOENERGETICS, V1229, P23, DOI 10.1016/0005-2728(94)00195-B; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Endo T, 1999, FEBS LETT, V457, P5, DOI 10.1016/S0014-5793(99)00989-8; Endo T, 1998, PLANT CELL PHYSIOL, V39, P1226, DOI 10.1093/oxfordjournals.pcp.a029324; FORK DC, 1993, PHOTOSYNTH RES, V36, P149, DOI 10.1007/BF00033035; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; HEBER U, 1992, PLANT PHYSIOL, V100, P1621, DOI 10.1104/pp.100.4.1621; Heber U, 2002, PHOTOSYNTH RES, V73, P223, DOI 10.1023/A:1020459416987; HILL R, 1960, NATURE, V186, P136, DOI 10.1038/186136a0; Horvath EM, 2000, PLANT PHYSIOL, V123, P1337, DOI 10.1104/pp.123.4.1337; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; Kofer W, 1998, MOL GEN GENET, V258, P166, DOI 10.1007/s004380050719; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MI HL, 1995, PLANT CELL PHYSIOL, V36, P661; MIYAKE C, 1994, PLANT CELL PHYSIOL, V35, P539, DOI 10.1093/oxfordjournals.pcp.a078628; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; op den Camp RGL, 2003, PLANT CELL, V15, P2320, DOI 10.1105/tpc.014662; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; SCHREIBER U, 1988, Z NATURFORSCH C, V43, P686; Shikanai T, 1998, P NATL ACAD SCI USA, V95, P9705, DOI 10.1073/pnas.95.16.9705; TAGAWA K, 1963, P NATL ACAD SCI USA, V49, P567, DOI 10.1073/pnas.49.4.567	30	650	692	9	203	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					579	582		10.1038/nature02598	http://dx.doi.org/10.1038/nature02598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175756				2022-12-28	WOS:000221767700044
J	Duggan, C; Fontaine, O; Pierce, NF; Glass, RI; Mahalanabis, D; Alam, NH; Bhan, MK; Santosham, M				Duggan, C; Fontaine, O; Pierce, NF; Glass, RI; Mahalanabis, D; Alam, NH; Bhan, MK; Santosham, M			Scientific rationale for a change in the composition of oral rehydration solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE DIARRHEA; REDUCED OSMOLARITY; DOUBLE-BLIND; CLINICAL-TRIAL; SALT-SOLUTION; THERAPY; CHILDREN; GLUCOSE; CHOLERA; DISEASE		Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA 02115 USA; WHO, Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Soc Appl Studies, Kolkata, India; ICDDR B, Div Clin Sci, Ctr Hlth & Populat Res B, Dhaka, Bangladesh; All India Inst Med Sci, Dept Pediat, New Delhi, India	Harvard University; Boston Children's Hospital; World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Centers for Disease Control & Prevention - USA; International Centre for Diarrhoeal Disease Research (ICDDR); All India Institute of Medical Sciences (AIIMS) New Delhi	Duggan, C (corresponding author), Childrens Hosp Boston, Div Gastroenterol & Nutr, 300 Longwood Ave, Boston, MA 02115 USA.	christopher.duggan@childrens.harvard.edu						Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Alam S, 2000, Indian Pediatr, V37, P952; [Anonymous], 1978, LANCET, V2, P300; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BHAN MK, 1994, B WORLD HEALTH ORGAN, V72, P945; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BROWN KH, 1988, J PEDIATR-US, V112, P191, DOI 10.1016/S0022-3476(88)80055-6; Cash R, 1999, LANCET, V354, P1733, DOI 10.1016/S0140-6736(05)76725-8; Duggan C, 1997, J PEDIATR-US, V131, P801, DOI 10.1016/S0022-3476(97)70024-6; Dutta D, 2000, ACTA PAEDIATR, V89, P787, DOI 10.1080/080352500750043657; Dutta P, 2001, ARCH DIS CHILD, V84, P237, DOI 10.1136/adc.84.3.237; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Farthing M J, 1989, Acta Paediatr Scand Suppl, V364, P23; FAYAD IM, 1992, LANCET, V339, P389, DOI 10.1016/0140-6736(92)90079-I; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; Fontaine O, 2000, COCHRANE DB SYST REV; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; Hirschhorn N, 2002, PEDIATRICS, V109, P713, DOI 10.1542/peds.109.4.713-a; Hirschhorn N, 2002, LANCET, V360, P340, DOI 10.1016/S0140-6736(02)09528-4; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; HIRSCHHORN N, 1972, Lancet, V2, P15; HIRSCHHORN N, 1991, SCI AM, V264, P50, DOI 10.1038/scientificamerican0591-50; HUNT JB, 1994, GUT, V35, P211, DOI 10.1136/gut.35.2.211; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MOLLA AM, 1989, LANCET, V2, P429; MOLLA AM, 1981, J PEDIATR-US, V98, P835, DOI 10.1016/S0022-3476(81)80863-3; NALIN DR, 1970, GUT, V11, P768, DOI 10.1136/gut.11.9.768; Nazarian LF, 1996, PEDIATRICS, V97, P424; NICHOLS BL, 1977, AM J CLIN NUTR, V30, P1457, DOI 10.1093/ajcn/30.9.1457; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; Penny M. E., 2003, Nutrition in pediatrics: basic science and clinical applications, P174; PIERCE NF, 1968, GASTROENTEROLOGY, V55, P333; RIBEIRO H, 1994, J AM COLL NUTR, V13, P251, DOI 10.1080/07315724.1994.10718405; SANTOSHAM M, 1986, J PEDIATR-US, V109, P795, DOI 10.1016/S0022-3476(86)80696-5; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; SANTOSHAM M, 1985, PEDIATRICS, V76, P292; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; Sarker SA, 2001, J PEDIATR-US, V138, P532, DOI 10.1067/mpd.2001.112161; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; Thillainayagam AV, 1998, GASTROENTEROLOGY, V114, P197, DOI 10.1016/S0016-5085(98)70647-X; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; *WHO, 2001, WHOFCHCAH0122 UNICEF	46	40	48	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2628	2631		10.1001/jama.291.21.2628	http://dx.doi.org/10.1001/jama.291.21.2628			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173155				2022-12-28	WOS:000221738800027
J	Sharp, D				Sharp, D			Five sides of trauma	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Dick Wolfgang F, 2003, Prehosp Disaster Med, V18, P29; Maier RV, 2003, J TRAUMA, V54, P803, DOI 10.1097/01.TA.0000033769.65011.31	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1750	1750		10.1016/S0140-6736(04)16338-1	http://dx.doi.org/10.1016/S0140-6736(04)16338-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172771				2022-12-28	WOS:000221705800006
J	Collins, CT; Ryan, P; Crowther, CA; McPhee, AJ; Paterson, S; Hiller, JE				Collins, CT; Ryan, P; Crowther, CA; McPhee, AJ; Paterson, S; Hiller, JE			Effect of bottles, cups, and dummies on breast feeding in preterm infants: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; MOTHERS	Objective To determine the effect of artificial teats (bottle and dummy) and cups on breast feeding in preterm infants. Design Randomised controlled trial. Setting Two large tertiary hospitals, 54 peripheral hospitals. Participants 319 preterm infants (born at 23-33 weeks' gestation) randomly assigned to one of four groups: cup/no dummy (n=89), cup/dummy (n=72), bottle/no dummy (n=73), bottle/dummy (n=85). Women with singleton or twin infants <34 weeks' gestation who wanted to breastfeed were eligible to participate. Interventions Cup or bottle feeding occurred when the mother was unable to be present to breast feed. Infants randomised to the dummy groups received a dummy on entry into the trial. Main outcome measures Full breast feeding (compared with partial and non) and any breast feeding (compared with none) on discharge home. Secondary outcomes: prevalence of breast feeding at three and six months after discharge and length of hospital stay. Results 303 infants and (278 mothers) were included in the intention to treat analysis. There were no significant differences for any of the study outcomes according to use of a dummy. Infants randomised to cup feeds were more likely to be fully breast fed on discharge home (odds ration 1.73, 95% confidence interval 1.04 to 2.88, P=0.03), but had a longer length of stay (hazard ratio 0.71, 0.55 to 0.92, P=0.01). Conclusions Dummies do not affect breast feeding in preterm infants. Cup feeding significantly increases the likelihood that the baby will be fully breast fed at discharge home, but has no effect on any breast feeding and increases the length of hospital stay.	Womens & Childrens Hosp, Dept Nursing & Midwifery Res & Practice Dev, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Publ Hlth, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Obstet & Gynaecol, Adelaide, SA 5005, Australia; Womens & Childrens Hosp, Dept Neonatol Med, Adelaide, SA 5006, Australia; Mercy Hosp Women, Dept Neonatal Serv, Melbourne, Vic 3002, Australia	Womens & Childrens Hospital Australia; University of Adelaide; University of Adelaide; Womens & Childrens Hospital Australia	Collins, CT (corresponding author), Womens & Childrens Hosp, Dept Nursing & Midwifery Res & Practice Dev, 72 King William Rd, Adelaide, SA 5006, Australia.	collinsct@mail.wch.sa.gov.au	Hiller, Janet E./A-5633-2008	Hiller, Janet E./0000-0002-8532-4033				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Boo NY, 1999, J TROP PEDIATRICS, V45, P195, DOI 10.1093/tropej/45.4.195; BULOCK F, 1990, DEV MED CHILD NEUROL, V32, P669; Furman L, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e57; Hill P D, 1994, J Hum Lact, V10, P169, DOI 10.1177/089033449401000313; KAUFMAN KJ, 1989, RES NURS HEALTH, V12, P149, DOI 10.1002/nur.4770120305; Killersreiter B, 2001, EARLY HUM DEV, V60, P193, DOI 10.1016/S0378-3782(00)00116-X; Kliethermes P A, 1999, J Obstet Gynecol Neonatal Nurs, V28, P264; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; Lang S, 1994, Midwives Chron, V107, P171; LANG S, 1994, ARCH DIS CHILD, V71, P365, DOI 10.1136/adc.71.4.365; Lang S., 1997, BREASTFEEDING SPECIA; NEIFERT M, 1995, J PEDIATR-US, V126, pS125, DOI 10.1016/S0022-3476(95)90252-X; Nyqvist KH, 1999, ACTA PAEDIATR, V88, P1194, DOI 10.1080/080352599750030284; PINELLI J, 2004, COCHRANE DATABASE SY; Prescott RJ, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI DOI 10.3310/hta3200; Rocha Neide M N, 2002, J Hum Lact, V18, P132; Stine M J, 1990, J Hum Lact, V6, P167, DOI 10.1177/089033449000600413; World Health Organization, 1991, IND ASS BREAST FEED; Yip E, 1996, J PAEDIATR CHILD H, V32, P296, DOI 10.1111/j.1440-1754.1996.tb02556.x	20	80	88	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	2004	329	7459					193	196		10.1136/bmj.38131.675914.55	http://dx.doi.org/10.1136/bmj.38131.675914.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840NW	15208209	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000222866900014
J	Nakayama, K; Frew, IJ; Hagensen, M; Skals, M; Habelhah, H; Bhoumik, A; Kadoya, T; Erdjument-Bromage, H; Tempst, P; Frappell, PB; Bowtell, DD; Ronai, Z				Nakayama, K; Frew, IJ; Hagensen, M; Skals, M; Habelhah, H; Bhoumik, A; Kadoya, T; Erdjument-Bromage, H; Tempst, P; Frappell, PB; Bowtell, DD; Ronai, Z			Siah2 regulates stability of prolyl-hydroxylases, controls HIF1 alpha abundance, and modulates physiological responses to hypoxia	CELL			English	Article							INDUCIBLE FACTOR-I; MICE PARTIALLY DEFICIENT; TUMOR-SUPPRESSOR; MAMMALIAN HOMOLOGS; FACTOR 1-ALPHA; GROWTH-FACTOR; HIF-ALPHA; HIF-1-ALPHA; VHL; DEGRADATION	Hypoxia-inducible factor-1alpha (HIF1alpha) is a central regulator of the cellular response to hypoxia. Prolyl-hydroxylation of HIF1alpha by PHD enzymes is prerequisite for HIF1alpha degradation. Here, we demonstrate that the abundance of PHD1 and PHD3 are regulated via their targeting for proteasome-dependent degradation by the E3 ubiquitin ligases Siah1a/2, under hypoxia conditions. Siah2 null fibroblasts exhibit prolonged PHD3 half-life, resulting in lower levels of HIF1alpha expression during hypoxia. Significantly, hypoxia-induced HIF1alpha expression was completely inhibited in Siah1a/2 null cells, yet could be rescued upon inhibition of PHD3 by RNAi. Siah2 targeting of PHD3 for degradation increases upon exposure to even mild hypoxic conditions, which coincides with increased Siah2 transcription. Siah2 null mice subjected to hypoxia displayed an impaired hyperpneic respiratory response and reduced levels of hemoglobin. Thus, the control of PHD1/3 by Siah1a/2 constitutes another level of complexity in the regulation of HIF1alpha during hypoxia.	CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia; La Trobe Univ, Dept Zool, Melbourne, Vic 3086, Australia; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Peter Maccallum Cancer Center; La Trobe University; Memorial Sloan Kettering Cancer Center	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Hagensen, Mette Kallestrup K/I-6409-2018; Nakayama, Koh/U-9232-2019; Bowtell, David/H-1007-2016	Hagensen, Mette Kallestrup K/0000-0001-6728-8342; Bowtell, David/0000-0001-9089-7525; Habelhah, Hasem/0000-0003-4097-1007; Tempst, Paul/0000-0002-6680-3987; RONAI, ZEEV/0000-0002-3859-0400; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Frew, Ian/0000-0003-2735-5509	NCI NIH HHS [P30 CA08748, CA80058, CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; FRAPPELL P, 1992, AM J PHYSIOL, V262, pR1040, DOI 10.1152/ajpregu.1992.262.6.R1040; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Gebb SA, 2003, ADV EXP MED BIOL, V543, P117; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hevehan DL, 2000, EXP HEMATOL, V28, P267, DOI 10.1016/S0301-472X(99)00150-2; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; LaIuppa JA, 1998, EXP HEMATOL, V26, P835; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Mortola JP, 1998, CAN J PHYSIOL PHARM, V76, P937, DOI 10.1139/cjpp-76-10-11-937; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; VANZETTI G, 1966, J LAB CLIN MED, V67, P116; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wenger RH, 2000, J EXP BIOL, V203, P1253; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	44	328	354	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					941	952		10.1016/j.cell.2004.06.001	http://dx.doi.org/10.1016/j.cell.2004.06.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210114	Bronze			2022-12-28	WOS:000222300200011
J	Correia, ACM; Laskar, J				Correia, ACM; Laskar, J			Mercury's capture into the 3/2 spin-orbit resonance as a result of its chaotic dynamics	NATURE			English	Article							SOLAR-SYSTEM; PLANET MERCURY; ROTATION; EVOLUTION; PERIOD; VENUS	Mercury is locked into a 3/2 spin-orbit resonance where it rotates three times on its axis for every two orbits around the sun(1-3). The stability of this equilibrium state is well established(4-6), but our understanding of how this state initially arose remains unsatisfactory. Unless one uses an unrealistic tidal model with constant torques ( which cannot account for the observed damping of the libration of the planet) the computed probability of capture into 3/2 resonance is very low (about 7 per cent)(5). This led to the proposal that core-mantle friction may have increased the capture probability, but such a process requires very specific values of the core viscosity(7,8). Here we show that the chaotic evolution of Mercury's orbit can drive its eccentricity beyond 0.325 during the planet's history, which very efficiently leads to its capture into the 3/2 resonance. In our numerical integrations of 1,000 orbits of Mercury over 4 Gyr, capture into the 3/2 spin-orbit resonant state was the most probable final outcome of the planet's evolution, occurring 55.4 per cent of the time.	Observ Paris, IMCCE, CNRS,UMR 8028, F-75014 Paris, France; Univ Aveiro, Dept Fis, P-3810193 Aveiro, Portugal	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Universidade de Aveiro	Laskar, J (corresponding author), Observ Paris, IMCCE, CNRS,UMR 8028, 77 Ave Denfert Rochereau, F-75014 Paris, France.	Laskar@imcce.fr	Laskar, Jacques/E-1098-2011; Correia, Alexandre C. M./J-4315-2013	Laskar, Jacques/0000-0003-2634-789X; Correia, Alexandre C. M./0000-0002-8946-8579				ANDERSON JD, 1987, ICARUS, V71, P337, DOI 10.1016/0019-1035(87)90033-9; BRETAGNON P, 1974, ASTRON ASTROPHYS, V30, P141; Brouwer D, 1950, ASTRON PAP AM EPHERM, V13, P81; COLOMBO G, 1965, NATURE, V208, P575, DOI 10.1038/208575a0; COLOMBO G, 1966, ASTROPHYS J, V145, P296, DOI 10.1086/148762; Correia ACM, 2003, ICARUS, V163, P1, DOI 10.1016/S0019-1035(03)00042-3; COUNSELMAN CC, 1970, S MATH, V3, P121; GOLDREICH P, 1967, ASTRON J, V72, P662, DOI 10.1086/110289; GOLDREICH P, 1966, ASTRON J, V71, P425, DOI 10.1086/109947; Hansen P. A., 1855, AKHANDL K S GES WISS, VIV, P182; KAULA WM, 1964, REV GEOPHYS, V2, P661, DOI 10.1029/RG002i004p00661; LASKAR J, 1994, ASTRON ASTROPHYS, V287, pL9; LASKAR J, IN PRESS ICARUS; MCGOVERN WE, 1965, NATURE, V208, P375, DOI 10.1038/208375a0; Munk W. H., 1960, ROTATION EARTH GEOPH; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; PEALE SJ, 1977, J GEOPHYS RES, V82, P743, DOI 10.1029/JB082i005p00743; PETTENGI.GH, 1965, NATURE, V206, P1240, DOI 10.1038/2061240a0; Spohn T, 2001, PLANET SPACE SCI, V49, P1561, DOI 10.1016/S0032-0633(01)00093-9; Yoder C., 1995, GLOBAL EARTH PHYS HD, V1, P1	21	115	117	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					848	850		10.1038/nature02609	http://dx.doi.org/10.1038/nature02609			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215857				2022-12-28	WOS:000222213000034
J	Chasman, DI; Posada, D; Subrahmanyan, L; Cook, NR; Stanton, VP; Ridker, PM				Chasman, DI; Posada, D; Subrahmanyan, L; Cook, NR; Stanton, VP; Ridker, PM			Pharmacogenetic study of statin therapy and cholesterol reduction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E; GENE; PRAVASTATIN	Context Polymorphisms in genes involved in cholesterol synthesis, absorption, and transport may affect statin efficacy. Objective To evaluate systematically whether genetic variation influences response to pravastatin therapy. Design, Setting, and Population The DNA of 1536 individuals treated with pravastatin, 40 mg/d, was analyzed for 148 single-nucleotide polymorphisms (SNPs) within 10 candidate genes related to lipid metabolism. Variation within these genes was then examined for associations with changes in lipid levels observed with pravastatin therapy during a 24-week period. Main Outcome Measure Changes in lipid levels in response to pravastatin therapy. Results Two common and tightly linked SNPs (linkage disequilibrium r(2) = 0.90; heterozygote prevalence = 6.7% for both) were significantly associated with reduced efficacy of pravastatin therapy. Both of these SNPs were in the gene coding for 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase, the target enzyme that is inhibited by pravastatin. For example, compared with individuals homozygous for the major allele of one of the SNPs, individuals with a single copy of the minor allele had a 22% smaller reduction in total cholesterol (-32.8 vs -42.0 mg/dL [-0.85 vs -1.09 mmol/L]; P = .001; absolute difference, 9.2 mg/dL [95% confidence interval {Cl}, 3.8-14.6 mg/dL]) and a 19% smaller reduction in low-density lipoprotein (LDL) cholesterol (-27.7 vs -34.1 mg/dL [-0.72 vs -0.88 mmol/L]; P = .005; absolute difference, 6.4 mg/dL [95% Cl, 2.2-10.6 mg/dL]). The association for total cholesterol reduction persisted even after adjusting for multiple tests on all 33 SNPs evaluated in the HMG-CoA reductase gene as well as for all 148 SNPs evaluated was similar in magnitude and direction among men and women and was present in the ethnically diverse total cohort as well as in the majority subgroup of white participants. No association for either SNP was observed for the change in high-density lipoprotein (HDL) cholesterol (P > .80) and neither was associated with baseline lipid levels among those actively treated or among those who did not receive the drug. Among the remaining genes, less robust associations were found for squalene synthase and change in total cholesterol, apolipoprotein E and change in LDL cholesterol, and cholesteryl ester transfer protein and change in HDL cholesterol, although none of these met our conservative criteria for purely pharmacogenetic effects. Conclusion Individuals heterozygous for a genetic variant in the HMG-CoA reductase gene may experience significantly smaller reductions in cholesterol when treated with pravastatin.	Harvard Univ, Brigham & Womens Hosp,Sch Med, Donald W Reynolds Ctr Cardiovasc Res, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Leducq Ctr Mol & Genet Epidemiol, Boston, MA 02215 USA; Variagen Inc, Cambridge, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ridker, PM (corresponding author), Harvard Univ, Brigham & Womens Hosp,Sch Med, Donald W Reynolds Ctr Cardiovasc Res, Ctr Cardiovasc Dis Prevent, 900 Commonwealth Ave E, Boston, MA 02215 USA.	pridker@partners.org	Posada, David/C-4502-2008	Posada, David/0000-0003-1407-3406; Stanton, Vincent/0000-0002-2205-6000				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; [Anonymous], ONLINE MENDELIAN INH; Brorholt-Petersen JU, 2001, CLIN GENET, V59, P397, DOI 10.1034/j.1399-0004.2001.590604.x; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; GOTTO AM, 2002, DYSLIPOPROTEINEMIAS; HANSEN PS, 1994, CLIN INVESTIGATOR, V72, P1065, DOI 10.1007/BF00577757; Kokoris M, 2000, MOL DIAGN, V5, P329; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; ORDOVAS JM, 1995, ATHEROSCLEROSIS, V113, P157, DOI 10.1016/0021-9150(94)05439-P; Ordovas JM, 2002, CURR OPIN LIPIDOL, V13, P113, DOI 10.1097/00041433-200204000-00001; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Roses AD, 2002, NAT REV DRUG DISCOV, V1, P541, DOI 10.1038/nrd840; Schmitz G, 2003, CLIN CHEM LAB MED, V41, P581, DOI 10.1515/CCLM.2003.088; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; TEMPLETON AR, 1987, GENETICS, V117, P343; TSIMIKAS S, 2002, MOL BIOL LIPOPROTEIN; WATANABE J, 1993, DIABETES RES CLIN PR, V20, P21, DOI 10.1016/0168-8227(93)90018-Z; Westfall P.H., 1993, RESAMPLING BASED MUL	20	334	358	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2821	2827		10.1001/jama.291.23.2821	http://dx.doi.org/10.1001/jama.291.23.2821			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199031				2022-12-28	WOS:000221962500026
J	Holdgate, A; Pollock, T				Holdgate, A; Pollock, T			Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic	BRITISH MEDICAL JOURNAL			English	Review							DICLOFENAC SODIUM; INTRAVENOUS INDOMETHACIN; KETOROLAC TROMETHAMINE; PAIN SEVERITY; PETHIDINE; ANALGESIA; MEPERIDINE; SURGERY; MULTICENTER; MORPHINE	Objective To examine the relative benefits and disadvantages of non-steroidal anti-inflammatory drugs (NSAIDs) mid opioids for the management of acute renal colic. Data sources Cochrane Renal Group's specialised register, Cochrane central register of controlled trials, Medline, Embase, and reference lists of retrieved articles. Review methods Randomised controlled trials comparing any opioid with any NSAID in acute renal colic if they reported any of the following outcomes: patient rated pain, time to pain relief, need for rescue analgesia, rate of recurrence of pain, and adverse events. Results 20 trials totalling 1613 participants were identified. Both NSAIDs and opioids led to clinically important reductions in patient reported pain scores. Pooled analysis of six trials showed a greater reduction in pain scores for patients treated with NSAIDs than with opioids. Patients treated with NSAIDs were significantly less likely to require rescue analgesia (relative risk 0.75, 95% confidence interval 0.61 to 0.93). Most trials showed a higher incidence of adverse events in patients treated with opioids. Compared with patients treated with opioids, those treated with NSAIDs had significantly less vomiting (0.35, 0.23 to 0.53). Pethidine was associated with a higher rate of vomiting. Conclusions Patients receiving NSAIDs achieve greater reductions in pain scores and are less likely to require further analgesia in die short term than those receiving opioids. Opioids, particularly pethidine, are associated with a higher rate of vomiting.	St George Hosp, Dept Emergency Med, Kogarah, NSW 2217, Australia	St George Hospital	Holdgate, A (corresponding author), St George Hosp, Dept Emergency Med, Gray St, Kogarah, NSW 2217, Australia.	Holdgatean@sesahs.nsw.gov.au						al-Sahlawi K S, 1996, Eur J Emerg Med, V3, P183, DOI 10.1097/00063110-199609000-00008; Arnau J.M., 1991, EUR J CLIN PHARMACOL, V40, P543; Cordell WH, 1996, ANN EMERG MED, V28, P151, DOI 10.1016/S0196-0644(96)70055-0; CORDELL WH, 1994, ANN EMERG MED, V23, P262, DOI 10.1016/S0196-0644(94)70038-9; CURRY C, 1995, NEW ZEAL MED J, V108, P229; DeAndrade JR, 1996, CLIN ORTHOP RELAT R, P302; Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863; HETHERINGTON JW, 1986, BRIT MED J, V292, P237, DOI 10.1136/bmj.292.6515.237; Holdgate A, 1999, EMERGEN MED, V11, P9; INDUDHARA R, 1990, CLIN TRIALS J, V27, P295; JONSSON PE, 1987, BRIT J UROL, V59, P396, DOI 10.1111/j.1464-410X.1987.tb04833.x; Larkin GL, 1999, AM J EMERG MED, V17, P6, DOI 10.1016/S0735-6757(99)90003-7; LEHTONEN T, 1983, ANN CLIN RES, V15, P197; LUNDSTAM SOA, 1982, LANCET, V1, P1096; MARTHAK KV, 1991, CURR MED RES OPIN, V12, P366, DOI 10.1185/03007999109111506; McEvoy A, 1996, ANN ROY COLL SURG, V78, P363; MOLL J, 1999, EMERGENCY MED COMPRE, P640; Nicholson F., 2000, TXB ADULT EMERGENCY, P372; Nicolas Torralba J A, 1999, Arch Esp Urol, V52, P435; OOSTERLINCK W, 1990, J CLIN PHARMACOL, V30, P336, DOI 10.1002/j.1552-4604.1990.tb03603.x; PERSSON NH, 1985, ACTA CHIR SCAND, V151, P105; QUILEZ C, 1984, MED CLIN-BARCELONA, V82, P754; Reich JD, 1997, UROLOGY, V50, P858, DOI 10.1016/S0090-4295(97)00410-X; SANDHU DPS, 1994, BRIT J UROL, V74, P690, DOI 10.1111/j.1464-410X.1994.tb07107.x; Shende D, 1999, ACTA ANAESTH SCAND, V43, P265, DOI 10.1034/j.1399-6576.1999.430305.x; Smally AJ, 1997, ANN EMERG MED, V29, P296; Smith LA, 2000, BRIT J ANAESTH, V84, P48, DOI 10.1093/oxfordjournals.bja.a013381; SOMMER P, 1989, BRIT J UROL, V63, P4, DOI 10.1111/j.1464-410X.1989.tb05112.x; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; THOMPSON JF, 1989, BRIT MED J, V299, P1140, DOI 10.1136/bmj.299.6708.1140; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Tramer MR, 1998, ACTA ANAESTH SCAND, V42, P71; UDEN P, 1983, ACTA CHIR SCAND, V149, P497; Willis NS, 2003, COCHRANE LIB; Zackova M, 2001, Minerva Anestesiol, V67, P641	35	143	148	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1401	1404		10.1136/bmj.38119.581991.55	http://dx.doi.org/10.1136/bmj.38119.581991.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15178585	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222114400015
J	Eagle, KA; Lim, MJ; Dabbous, OH; Pieper, KS; Goldberg, RJ; Van de Werf, F; Goodman, SG; Granger, CB; Steg, PG; Gore, JM; Budaj, A; Avezum, A; Flather, MD; Fox, KAA				Eagle, KA; Lim, MJ; Dabbous, OH; Pieper, KS; Goldberg, RJ; Van de Werf, F; Goodman, SG; Granger, CB; Steg, PG; Gore, JM; Budaj, A; Avezum, A; Flather, MD; Fox, KAA		GRACE Investigators	A validated prediction model for all forms of acute coronary syndrome - Estimating the risk of 6-month postdischarge death in an international registry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELEVATION MYOCARDIAL-INFARCTION; ST-SEGMENT-ELEVATION; THERAPEUTIC DECISION-MAKING; GLOBAL REGISTRY; HOSPITAL MORTALITY; EVENTS GRACE; TRIAL; INTERVENTIONS; REPERFUSION; MANAGEMENT	Context Accurate estimation of risk for untoward outcomes after patients have been hospitalized for an acute coronary syndrome (ACS) may help clinicians guide the type and intensity of therapy. Objective To develop a simple decision tool for bedside risk estimation of 6-month mortality in patients surviving admission for an ACS. Design, Setting, and Patients A multinational registry, involving 94 hospitals in 14 countries, that used data from the Global Registry of Acute Coronary Events (GRACE) to develop and validate a multivariable stepwise regression model for death during 6 months postdischarge. From 17142 patients presenting with an ACS from April 1, 1999, to March 31, 2002, and discharged alive, 15007 (87.5%) had complete 6-month follow-up and represented the development cohort for a model that was subsequently tested on a validation cohort of 7638 patients admitted from April 1, 2002, to December 31, 2003. Main Outcome Measure All-cause mortality during 6 months postdischarge after admission for an ACS. Results The 6-month mortality rates were similar in the development (n=717; 4.8%) and validation cohorts (n=331; 4.7%). The risk-prediction tool for all forms of ACS identified 9 variables predictive of 6-month mortality: older age, history of myocardial infarction, history of heart failure, increased pulse rate at presentation, lower systolic blood pressure at presentation, elevated initial serum creatinine level, elevated initial serum cardiac biomarker levels, ST-segment depression on presenting electiocardiogram, and not having a percutaneous coronary intervention performed in hospital. The c statistics for the development and validation cohorts were 0.81 and 0.75, respectively. Conclusions The GRACE 6-month postdischarge prediction model is a simple, robust tool for predicting mortality in patients with ACS. Clinicians may find it simple to use and applicable to clinical practice.	Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Ziekenhuis Gasthuisberg, Dept Cardiol, Louvain, Belgium; Univ Toronto, St Michaels Hosp, Canadian Heart Res Ctr, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Terrence Donnelly Heart Ctr, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada; Hop Bichat, F-75877 Paris, France; Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; Educ & Res Inst Hosp Albert Einstein, Clin Res Ctr, Sao Paulo, Brazil; Royal Brompton & Harefield NHS Trust, London, England; Univ Edinburgh, Edinburgh, Midlothian, Scotland; Royal Infirm, Edinburgh, Midlothian, Scotland	University of Michigan System; University of Michigan; University of Massachusetts System; University of Massachusetts Worcester; Duke University; KU Leuven; University Hospital Leuven; Canadian Heart Research Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Centre of Postgraduate Medical Education - Poland; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; University of Edinburgh; Royal Infirmary of Edinburgh	Eagle, KA (corresponding author), Univ Michigan, Ctr Cardiovasc, Dept Internal Med, 300 N Ingalls,8B02, Ann Arbor, MI 48109 USA.	keagle@umich.edu	Fox, keith A A/I-3742-2013; Avezum, Alvaro/AAP-7687-2020; Avezum, Alvaro AA/K-6137-2016; Granger, Christopher B/D-3458-2014; STEG, Philippe Gabriel/Z-1567-2019	Avezum, Alvaro AA/0000-0002-3073-6890; Granger, Christopher B/0000-0002-0045-3291; Budaj, Andrzej/0000-0002-6395-2098; STEG, Philippe Gabriel/0000-0001-6896-2941; Van de Werf, Frans/0000-0001-9479-7767; Fox, Keith/0000-0002-0140-2752				Agnelli G, 2001, AM HEART J, V141, P190, DOI 10.1067/mhj.2001.112404; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Boersma E, 2000, CIRCULATION, V101, P2557, DOI 10.1161/01.CIR.101.22.2557; Braunwald E, 2002, J AM COLL CARDIOL, V40, P1366, DOI 10.1016/S0735-1097(02)02336-7; BRIEGER D, IN PRESS EUR HEART J; Budaj A, 2003, AM HEART J, V146, P999, DOI 10.1016/S0002-8703(03)00509-X; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; Granger CB, 2003, ARCH INTERN MED, V163, P2345, DOI 10.1001/archinte.163.19.2345; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Morrow DA, 2001, LANCET, V358, P1571, DOI 10.1016/S0140-6736(01)06649-1; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Moscucci M, 2001, J AM COLL CARDIOL, V37, p502A; Moscucci M, 2001, CIRCULATION, V104, P263, DOI 10.1161/01.CIR.104.3.263; Ohman EM, 2000, JAMA-J AM MED ASSOC, V284, P876, DOI 10.1001/jama.284.7.876; Rathore SS, 2003, CIRCULATION, V107, P811, DOI 10.1161/01.CIR.0000049743.45748.02; *SAS I INC, 1999, SAS STAT US GUID VER, P2571	19	1127	1190	0	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2727	2733		10.1001/jama.291.22.2727	http://dx.doi.org/10.1001/jama.291.22.2727			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826XH	15187054	Bronze			2022-12-28	WOS:000221862300027
J	Navas-Acien, A; Peruga, A; Breysse, P; Zavaleta, A; Blanco-Marquizo, A; Pitarque, R; Acuna, M; Jimenez-Reyes, K; Colombo, VL; Gamarra, G; Stillman, FA; Samet, J				Navas-Acien, A; Peruga, A; Breysse, P; Zavaleta, A; Blanco-Marquizo, A; Pitarque, R; Acuna, M; Jimenez-Reyes, K; Colombo, VL; Gamarra, G; Stillman, FA; Samet, J			Secondhand tobacco smoke in public places in Latin America, 2002-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	12th World Conference on Tobacco or Health	AUG 03-08, 2003	Helsinki, FINLAND				EXPOSURE; SCIENCE; HEALTH	Context The success of measures to restrict smoking in indoor environments and the intensity of enforcement vary among countries around the world. In 2001, the Pan American Health Organization (PAHO) launched the Smoke-Free Americas Initiative to build capacity to achieve smoke-free environments in Latin America and the Caribbean. Objective To assess secondhand smoke concentrations in public places in the capital cities of Argentina, Brazil, Chile, Costa Rica, Paraguay, Peru, and Uruguay in conjunction with the Smoke-Free Americas Initiative. Design and Setting Multicountry assessment of vapor-phase nicotine concentrations using a common protocol in all 7 Latin American countries. A total of 633 sampling devices were placed for 7 to 14 days in 1 hospital, 2 secondary schools, 1 city government building, 1 airport (2 in Argentina), and restaurants and bars in each country. Main Outcome Measure Concentrations of airborne nicotine. Results Airborne nicotine was detected in most (94%) of the locations surveyed. By country, Argentina and Uruguay had the highest median concentrations in most environments (eg, in hospitals: 1.33 [interquartile range {IQR), 0.51-3.12] mug/m(3) and 0.8 [IQR, 0.30-1.69] mug/m(3), respectively). Overall, bars and restaurants had the highest median concentrations (3.65 [IQR, 1.55-5.121 mug/m(3) and 1.24 [IQR, 0.41-2.48] mug/m(3), respectively). Nicotine concentrations were also found in a number of key, sentinel buildings, including 95% (155/163) of hospital samples (in the physicians' and nurses' stations the median was 0.27 [IQR, 0.02-1.94] mug/m(3)), schools, government buildings, and/or airports in most countries. Conclusions The finding of airborne nicotine in critical locations in Latin America provides a basis for enforcing smoke-free initiatives and for strengthening the protection of the public from unwanted exposure to secondhand smoke.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Inst Global Tobacco Control, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Pan Amer Hlth Org, Washington, DC USA; Univ Peruana Cayetano Heredia, Dept Biochem Mol Biol & Pharmacol, Lima, Peru; CEDRO, Lima, Peru; Intendencia Municipal, Montevideo, Uruguay; Minist Hlth, Buenos Aires, DF, Argentina; Minist Salud, Tobacco Unit, Santiago, Chile; IAFA, San Jose, Costa Rica; INCA, Rio De Janeiro, Brazil; Minist Hlth, Tobacco Unit, Asuncion, Paraguay	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pan American Health Organization; Universidad Peruana Cayetano Heredia; National Cancer Institute (Inca)	Navas-Acien, A (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Inst Global Tobacco Control, 615 N Wolfe St,Room W6027, Baltimore, MD 21205 USA.	anavasac@jhsph.edu	Peruga, Armando/G-9739-2019; ZAVALETA, ALFONSO/AAS-9595-2020; Peruga, Armando/M-5455-2017	Peruga, Armando/0000-0002-1138-3292				AGUINAGABIALOUS S, 2002, PROFITS PEOPLE TOBAC; Akbar-Khanzadeh F, 2003, ARCH ENVIRON HEALTH, V58, P97, DOI 10.3200/AEOH.58.2.97-103; *CDCP, 1986, HLTH CONS INV SMOK R; *CDCP WHO, GLOB YOUTH TOB SURV; Cook DG, 1999, THORAX, V54, P357, DOI 10.1136/thx.54.4.357; HAMMOND SK, 1987, ENVIRON SCI TECHNOL, V21, P494, DOI 10.1021/es00159a012; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; Hammond SK, 1999, ENVIRON HEALTH PERSP, V107, P329, DOI 10.2307/3434425; HAMMOND SK, 1993, SAMPLING ANAL AIRBOR, P319; Jane M, 2002, TOB CONTROL, V11, P83, DOI 10.1136/tc.11.1.83; Jenkins R.A., 2000, CHEM ENV TOBACCO SMO; LAMBERT WE, 1993, AM J PUBLIC HEALTH, V83, P1339, DOI 10.2105/AJPH.83.9.1339; Muggli ME, 2003, NICOTINE TOB RES, V5, P303, DOI 10.1080/1462220031000094169; OEI TPS, 1992, J DRUG EDUC, V22, P155, DOI 10.2190/DWLW-UGVB-R1Y4-DQA4; Ong EK, 2001, AM J PUBLIC HEALTH, V91, P1749, DOI 10.2105/AJPH.91.11.1749; Samet J. M., 2000, Environmental toxicants: human exposures and their health effects., P319; Schorp MK, 2002, ENVIRON INT, V27, P567, DOI 10.1016/S0160-4120(01)00110-6; Shafey O, 2003, TOBACCO CONTROL COUN; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yach D, 2002, TOB CONTROL, V11, P252, DOI 10.1136/tc.11.3.252	22	93	104	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2741	2745		10.1001/jama.291.22.2741	http://dx.doi.org/10.1001/jama.291.22.2741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	826XH	15187056				2022-12-28	WOS:000221862300029
J	Singer, R				Singer, R			Asylum seekers: an ethical response to their plight	LANCET			English	Editorial Material																		*GREAT LOND ASS, 2004, DEST DES WITHDR SUPP; *MED PRACT UN, 2004, UK PLAC REF; *UN HIGH COMM REF, 2003, REF NUMB; 2004, GUARDIAN        0318	4	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1904	1904		10.1016/S0140-6736(04)16363-0	http://dx.doi.org/10.1016/S0140-6736(04)16363-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826IH	15185708				2022-12-28	WOS:000221822300027
J	Little, AF; van Oppen, MJH; Willis, BL				Little, AF; van Oppen, MJH; Willis, BL			Flexibility in algal endosymbioses shapes growth in reef corals	SCIENCE			English	Article							MONTASTRAEA-ANNULARIS; ZOOXANTHELLAE; SYMBIODINIUM; DIVERSITY; ECOLOGY; SPECIFICITY; SYMBIOSIS; ACROPORA; PATTERNS	The relation between corals and their algal endosymbionts has been a key to the success of scleractinian (stony) corals as modern reef-builders, but little is known about early stages in the establishment of the symbiosis. Here, we show that initial uptake of zooxanthellae by juvenile corals during natural infection is nonspecific (a potentially adaptive trait); the association is flexible and characterized by a change in ( dominant) zooxanthella strains over time; and growth rates of experimentally infected coral holobionts are partly contingent on the zooxanthella strain harbored, with clade C - infected juveniles growing two to three times as fast as those infected with clade D.	James Cook Univ N Queensland, Sch Marine Biol & Aquaculture, Townsville, Qld 4811, Australia; Australian Inst Marine Sci, Townsville, Qld 4810, Australia	James Cook University; Australian Institute of Marine Science	Willis, BL (corresponding author), James Cook Univ N Queensland, Sch Marine Biol & Aquaculture, Townsville, Qld 4811, Australia.	Bette.Willis@jcu.edu.au	van Oppen, Madeleine JH/C-3261-2008	van Oppen, Madeleine/0000-0003-4607-0744				Baker AC, 2001, NATURE, V411, P765, DOI 10.1038/35081151; Baker AC, 2003, ANNU REV ECOL EVOL S, V34, P661, DOI 10.1146/annurev.ecolsys.34.011802.132417; BUDDEMEIER RW, 1993, BIOSCIENCE, V43, P320, DOI 10.2307/1312064; Carlos AA, 2000, MAR ECOL PROG SER, V195, P93, DOI 10.3354/meps195093; Fitt W.K., 1985, PROC 5 TH INT CORAL, V6, P131; Harrison P.L., 1990, ECOSYSTEMS WORLD, V25, P133; LaJeunesse TC, 2002, MAR BIOL, V141, P387, DOI 10.1007/s00227-002-0829-2; LaJeunesse TC, 2001, J PHYCOL, V37, P866, DOI 10.1046/j.1529-8817.2001.01031.x; LOH W, 1997, P ACRS 17 ANN C HER, P87; Rodriguez-Lanetty M, 2001, MAR BIOL, V138, P1175; ROWAN R, 1992, P NATL ACAD SCI USA, V89, P3639, DOI 10.1073/pnas.89.8.3639; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; ROWAN R, 1995, P NATL ACAD SCI USA, V92, P2850, DOI 10.1073/pnas.92.7.2850; Rowan R, 1997, NATURE, V388, P265, DOI 10.1038/40843; Santos SR, 2001, J PHYCOL, V37, P900, DOI 10.1046/j.1529-8817.2001.00194.x; Toller WW, 2001, BIOL BULL-US, V201, P360, DOI 10.2307/1543614; Toller WW, 2001, BIOL BULL, V201, P348, DOI 10.2307/1543613; Ulstrup KE, 2003, MOL ECOL, V12, P3477, DOI 10.1046/j.1365-294X.2003.01988.x; van Oppen MJH, 2001, P ROY SOC B-BIOL SCI, V268, P1759, DOI 10.1098/rspb.2001.1733; VANOPPEN M, UNPUB; WILLIS BL, 1997, CORAL REEFS S, V16, P53	21	412	423	3	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1492	1494		10.1126/science.1095733	http://dx.doi.org/10.1126/science.1095733			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178799				2022-12-28	WOS:000221795800041
J	Levy, BD; O'Connell, JJ				Levy, BD; O'Connell, JJ			Health care for homeless persons	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Levy, BD (corresponding author), Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02115 USA.							BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; OCONNELL J, 1997, INCREASED DEMAND DEC; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406	4	58	58	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2329	2332		10.1056/NEJMp038222	http://dx.doi.org/10.1056/NEJMp038222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175433				2022-12-28	WOS:000221754200002
J	Vinicor, F; Jack, L				Vinicor, F; Jack, L			25 years and counting: Centers for Disease Control and Prevention identifies opportunities and challenges for diabetes prevention and control	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT		CDCP, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Vinicor, F (corresponding author), CDCP, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Woodcock Blvd,Room 2044, Atlanta, GA 30341 USA.	FVinicor@cdc.gov						Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Egede LE, 2004, DIABETES CARE, V27, P421, DOI 10.2337/diacare.27.2.421; Feudtner C., 2003, BITTER SWEET DIABETE; Fisher L, 2000, J FAM PRACTICE, V49, P561; Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226; Glasgow RE, 1999, ANN BEHAV MED, V21, P159, DOI 10.1007/BF02908297; Hirsch IB, 2003, PRIMARY CARE, V30, P499, DOI 10.1016/S0095-4543(03)00031-9; Institute of Medicine, 2001, CROSSING QUALITY CHA; JACK L, 2003, J PUBLIC HLTH MANA S, pS64; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Larme AC, 2001, DIABETES CARE, V24, P1728, DOI 10.2337/diacare.24.10.1728; LEONARD J, 2003, J PUBLIC HLTH MANA S, pS5; Lteif Amale A, 2003, Cardiol Rev, V11, P262, DOI 10.1097/01.crd.0000086892.07437.05; Nathan DM, 2002, AM J MED, V113, P339, DOI 10.1016/S0002-9343(02)01219-6; Piette JD, 2004, DIABETES CARE, V27, P384, DOI 10.2337/diacare.27.2.384; Pretty J, 2003, SCIENCE, V302, P1912, DOI 10.1126/science.1090847; Safran Marc A, 2003, J Public Health Manag Pract, V9, P58; Schroeder SA, 2001, NEW ENGL J MED, V344, P847, DOI 10.1056/NEJM200103153441113; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Soltesz G, 2003, DIABETOLOGIA, V46, P447, DOI 10.1007/s00125-003-1101-0; Taylor R, 2004, NEW ENGL J MED, V350, P639, DOI 10.1056/NEJMp038239; VALK GD, 2001, COCHRANE DB SYST REV; Vinicor F, 2003, LANCET, V361, P544, DOI 10.1016/S0140-6736(03)12561-5; Zimmet P, 2000, J INTERN MED, V247, P301, DOI 10.1046/j.1365-2796.2000.00625.x	24	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					943	944		10.7326/0003-4819-140-11-200406010-00034	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00034			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172918				2022-12-28	WOS:000221680600024
J	Fazel, M; Stein, A				Fazel, M; Stein, A			UK immigration law disregards the best interests of children	LANCET			English	Editorial Material									Univ Oxford, Warneford Hosp, Dept Psychiat, Sect Child & Adolescent Psychiat, Oxford OX3 7JX, England	University of Oxford	Fazel, M (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Sect Child & Adolescent Psychiat, Oxford OX3 7JX, England.	mina.fazel@psych.ox.ac.uk		Fazel, Mina/0000-0001-9342-2365; Stein, Alan/0000-0001-8207-2822				[Anonymous], UNIPOLAR DEPRESSION; Friedman RJ, 2002, CHILD ADOLESCENT PSY, P261; HEATH T, 2003, ASYLUM STAT UK 2002; *HOM OFF LORD CHAN, 2002, ACH BEST EV CRIM P G; *HOUS COMM HOM AFF, 2003, AS REM 4 REP SESS 20; House of Lords House of Commons Joint Committee on Human Rights, 2003, UN CONV RIGHTS CHILD; Mares S., 2002, AUSTRALAS PSYCHIATRY, V10, P91, DOI [DOI 10.1046/J.1440-1665.2002, DOI 10.1046/j.1440-1665.2002.00414.x]; Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236; Rutter M, 2002, CHILD DEV, V73, DOI 10.1111/1467-8624.00388; SANDBERG S, 2002, CHILD ADOLESCENT PSY, P287; Silove D, 2001, LANCET, V357, P1436, DOI 10.1016/S0140-6736(00)04575-X	11	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1749	1750		10.1016/S0140-6736(04)16337-X	http://dx.doi.org/10.1016/S0140-6736(04)16337-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824SD	15172770				2022-12-28	WOS:000221705800005
J	Giannakou, ME; Goss, M; Junger, MA; Hafen, E; Leevers, SJ; Partridge, L				Giannakou, ME; Goss, M; Junger, MA; Hafen, E; Leevers, SJ; Partridge, L			Long-lived Drosophila with overexpressed dFOXO in adult fat body	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTOR; INSULIN-RECEPTOR; C-ELEGANS; LIFE-SPAN; DAF-16; LONGEVITY; TISSUE		UCL, Dept Biol, London WC1E 6BT, England; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; London Res Inst, Growth Regulat Lab, Canc Res UK, London WC2A 3PX, England	University of London; University College London; University of Zurich; Cancer Research UK	Partridge, L (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	L.Partridge@ucl.ac.uk	southall, Maria/ABA-4608-2021; Jünger, Martin A./A-8010-2011; Partridge, Linda/E-7342-2015; Partridge, Linda/A-5501-2010	southall, Maria/0000-0002-7935-6231; Partridge, Linda/0000-0001-9615-0094	Biotechnology and Biological Sciences Research Council [SF19106] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; GIANNAKOU M, UNPUB; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Roman G, 2001, P NATL ACAD SCI USA, V98, P12602, DOI 10.1073/pnas.221303998	9	425	445	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	2004	305	5682					361	361		10.1126/science.1098219	http://dx.doi.org/10.1126/science.1098219			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15192154				2022-12-28	WOS:000222662400028
J	Dausmann, KH; Glos, J; Ganzhorn, JU; Heldmaier, G				Dausmann, KH; Glos, J; Ganzhorn, JU; Heldmaier, G			Physiology: Hibernation in a tropical primate - Even in the wound-down hibernating state, this lemur can warm up without waking up.	NATURE			English	Editorial Material							ENERGETIC CONSEQUENCES; MAMMALIAN HIBERNATION		Univ Marburg, Dept Anim Physiol, D-35043 Marburg, Germany; Univ Wurzburg, Dept Anim Ecol & Trop Biol, D-97074 Wurzburg, Germany; Univ Hamburg, Dept Anim Ecol & Conservat, D-20146 Hamburg, Germany	Philipps University Marburg; University of Wurzburg; University of Hamburg	Heldmaier, G (corresponding author), Univ Marburg, Dept Anim Physiol, D-35043 Marburg, Germany.	dausmann@staff.uni-marburg.de	Dausmann, Kathrin/E-9270-2017; Heldmaier, Gerhard/AAI-3286-2020; Ganzhorn, Joerg/AAO-6955-2020	Ganzhorn, Joerg/0000-0003-1395-9758				ARNOLD W, 1991, J THERM BIOL, V16, P223, DOI 10.1016/0306-4565(91)90029-2; Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003; Heldmaier Gerhard, 1993, P175; Humphries MM, 2003, PHYSIOL BIOCHEM ZOOL, V76, P165, DOI 10.1086/367950; Schmid J, 1998, INT J PRIMATOL, V19, P797, DOI 10.1023/A:1020389228665; WANG LCH, 1979, CAN J ZOOL, V57, P149, DOI 10.1139/z79-012	6	200	204	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	2004	429	6994					825	826		10.1038/429825a	http://dx.doi.org/10.1038/429825a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215852				2022-12-28	WOS:000222213000029
J	Du, JL; Poo, MM				Du, JL; Poo, MM			Rapid BDNF-induced retrograde synaptic modification in a developing retinotectal system	NATURE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; RETINAL GANGLION-CELLS; VISUAL-SYSTEM; NEUROTROPHIC FACTOR; NEURAL-NETWORKS; RECEPTOR; SYNAPSES; CONDUCTANCE; PROPAGATION	In cultures of hippocampal neurons, induction of long-term synaptic potentiation or depression by repetitive synaptic activity is accompanied by a retrograde spread of potentiation or depression, respectively, from the site of induction at the axonal outputs to the input synapses on the dendrites of the presynaptic neuron(1,2). We report here that rapid retrograde synaptic modification also exists in an intact developing retinotectal system. Local application of brain-derived neurotrophic factor ( BDNF) to the Xenopus laevis optic tectum, which induced persistent potentiation of retinotectal synapses, led to a rapid modification of synaptic inputs at the dendrites of retinal ganglion cells (RGCs), as shown by a persistent enhancement of light-evoked excitatory synaptic currents and spiking activity of RGCs. This retrograde effect required TrkB receptor activation, phospholipase Cgamma activity and Ca2+ elevation in RGCs, and was accounted for by a selective increase in the number of postsynaptic AMPA-subtype glutamate receptors at RGC dendrites. Such retrograde information flow in the neuron allows rapid regulation of synaptic inputs at the dendrite in accordance to signals received at axon terminals, a process reminiscent of back-propagation algorithm for learning in neural networks(3).	Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Poo, MM (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.	mpoo@uclink.berkeley.edu						Balkowiec A, 2002, J NEUROSCI, V22, P10399; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; CHURCHLAND PS, 1992, COMPUTATIONAL BRAIN; Chytrova G, 2004, MOL CELL NEUROSCI, V25, P549, DOI 10.1016/j.mcn.2003.11.009; COHENCORY S, 1994, NEURON, V12, P747, DOI 10.1016/0896-6273(94)90328-X; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Ginty DD, 2002, CURR OPIN NEUROBIOL, V12, P268, DOI 10.1016/S0959-4388(02)00326-4; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; LESSMANN V, 1994, NEUROREPORT, V6, P21; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; Lom B, 2002, J NEUROSCI, V22, P7639; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; PURVES D, 1976, NATURE, V260, P535, DOI 10.1038/260535a0; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Schinder AF, 2000, NEURON, V25, P151, DOI 10.1016/S0896-6273(00)80879-X; Tao HZW, 2000, J NEUROSCI, V20, P3233, DOI 10.1523/JNEUROSCI.20-09-03233.2000; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; Watson FL, 1999, J NEUROSCI, V19, P7889; WINGATE RJT, 1994, J NEUROSCI, V14, P6621; Wong WT, 2000, J NEUROSCI, V20, P5024; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	30	88	92	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					878	883		10.1038/nature02618	http://dx.doi.org/10.1038/nature02618			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215865				2022-12-28	WOS:000222213000043
J	Lane, D				Lane, D			Curing cancer with p53	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Dundee, Dept Surg & Mol Oncol, Dundee, Scotland	University of Dundee	Lane, D (corresponding author), Univ Dundee, Dept Surg & Mol Oncol, Dundee, Scotland.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996	4	23	24	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2711	2712		10.1056/NEJMcibr041288	http://dx.doi.org/10.1056/NEJMcibr041288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215489				2022-12-28	WOS:000222199000015
J	Mueser, KT; McGurk, SR				Mueser, KT; McGurk, SR			Schizophrenia	LANCET			English	Review							SEVERE MENTAL-ILLNESS; RANDOMIZED CONTROLLED TRIAL; QUALITY-OF-LIFE; EPIDEMIOLOGIC CATCHMENT-AREA; 1ST-EPISODE PSYCHOSIS; NEGATIVE SYMPTOMS; FOLLOW-UP; OBSTETRIC COMPLICATIONS; MEDICATION COMPLIANCE; ANTIPSYCHOTIC-DRUGS	Schizophrenia is a mental illness that is among the world's top ten causes of long-term disability. The symptoms of schizophrenia include psychosis, apathy and withdrawal, and cognitive impairment, which lead to problems in social and occupational functioning, and self-care. About 1% of the population is affected by schizophrenia, with similar rates across different countries, cultural groups, and sexes. The illness tends to develop between the ages of 16 and 30 years, and mostly persists throughout the patient's lifetime. The cause of schizophrenia is unknown, but evidence suggests that genetic factors, early environmental influences (eg, obstetric complications), and social factors (eg, poverty) contribute. No biological alterations are pathognomonic of schizophrenia, although several pathophysiological differences exist in a wide range of brain structures. Antipsychotic medications are the mainstay for managing schizophrenia. A range of psychosocial treatments are also helpful, including family intervention, supported employment, cognitive-behaviour therapy for psychosis, social skills training, teaching illness self-management skills, assertive community treatment, and integrated treatment for co-occurring substance misuse.	Dartmouth Coll Sch Med, Dept Psychiat, New Hampshire Dartmouth Psychiat Res Ctr, Concord, NH 03301 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA	Dartmouth College; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mueser, KT (corresponding author), Dartmouth Coll Sch Med, Dept Psychiat, New Hampshire Dartmouth Psychiat Res Ctr, Main Bldg,105 Pleasant St, Concord, NH 03301 USA.	kim.t.mueser@dartmouth.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062324, R01MH062629, R21MH062270, R01MH064662, R01MH063463] Funding Source: NIH RePORTER; NIMH NIH HHS [MH63463, MH62324, MH62629, MH62270, MH64662, MH56083] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Addington D, 1998, BRIT J PSYCHIAT, V172, P90, DOI 10.1192/S0007125000297729; AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P178; Allin M, 2002, CURR OPIN PSYCHIATR, V15, P9, DOI 10.1097/00001504-200201000-00003; ALMEIDA OP, 1995, BRIT J PSYCHIAT, V166, P205, DOI 10.1192/bjp.166.2.205; ALVIR JMJ, 1995, PSYCHOPHARMACOL BULL, V31, P311; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andreasen NC, 1997, SCIENCE, V275, P1586, DOI 10.1126/science.275.5306.1586; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANGERMEYER MC, 1990, SCHIZOPHRENIA BULL, V16, P293, DOI 10.1093/schbul/16.2.293; [Anonymous], 1998, HDB SOCIAL FUNCTIONI; [Anonymous], J MENT HLTH, DOI DOI 10.1080/0963823031000118230; [Anonymous], [No title captured]; Atkinson Jacqueline M., 1996, British Journal of Psychiatry, V168, P199, DOI 10.1192/bjp.168.2.199; Azrin NH, 1998, BEHAV RES THER, V36, P849, DOI 10.1016/S0005-7967(98)00036-9; BARTELS SJ, 1991, SCHIZOPHRENIA BULL, V17, P163, DOI 10.1093/schbul/17.1.163; Becker D., 2003, WORKING LIFE PEOPLE; Bellack A. S., 2004, SOCIAL SKILLS TRAINI, V2nd; BIRCHWOOD M, 1989, PSYCHOL MED, V19, P649, DOI 10.1017/S0033291700024247; Birchwood M, 1998, BRIT J PSYCHIAT, V172, P53, DOI 10.1192/S0007125000297663; Bleuler E., 1950, DEMENTIA PRAECOX GRO; Bond GR, 2001, DIS MANAG HEALTH OUT, V9, P141, DOI 10.2165/00115677-200109030-00003; Bond GR, 2001, PSYCHIATR SERV, V52, P313, DOI 10.1176/appi.ps.52.3.313; Boydell J, 2001, BMJ-BRIT MED J, V323, P1336, DOI 10.1136/bmj.323.7325.1336; Brown S, 1997, BRIT J PSYCHIAT, V171, P502, DOI 10.1192/bjp.171.6.502; BRUCE ML, 1991, ARCH GEN PSYCHIAT, V48, P470; Buchsbaum MS, 1996, AM J PSYCHIAT, V153, P191; Burns J, 2003, BRIT J PSYCHIAT, V182, P439, DOI 10.1192/bjp.182.5.439; Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; Butzlaff RL, 1998, ARCH GEN PSYCHIAT, V55, P547, DOI 10.1001/archpsyc.55.6.547; Byne W, 2002, AM J PSYCHIAT, V159, P59, DOI 10.1176/appi.ajp.159.1.59; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Cannon TD, 2000, SCHIZOPHRENIA BULL, V26, P351, DOI 10.1093/oxfordjournals.schbul.a033458; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Corrigan PW, 2002, SCHIZOPHRENIA BULL, V28, P293, DOI 10.1093/oxfordjournals.schbul.a006939; Corrigan PW, 1999, AM PSYCHOL, V54, P765, DOI 10.1037/0003-066X.54.9.765; Couture Shannon M., 2003, J MENTAL HLTH, V12, P291, DOI [10.1080/09638231000118276, DOI 10.1080/09638231000118276]; Covell NH, 2002, SCHIZOPHRENIA BULL, V28, P17, DOI 10.1093/oxfordjournals.schbul.a006920; Craig TJ, 1997, BRIT J PSYCHIAT, V170, P229, DOI 10.1192/bjp.170.3.229; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; Cullberg J, 2002, ACTA PSYCHIAT SCAND, V106, P276, DOI 10.1034/j.1600-0447.2002.02376.x; CURSON DA, 1988, BMJ-BRIT MED J, V297, P819, DOI 10.1136/bmj.297.6652.819; Davis JM, 2003, ARCH GEN PSYCHIAT, V60, P553, DOI 10.1001/archpsyc.60.6.553; DELEON J, 1995, AM J PSYCHIAT, V152, P453; Dohrenwend BP, 1998, ADVERSITY, STRESS AND PSYCHOPATHOLOGY, P285; DRAKE RE, IN PRESS PSYCHIAT RE; ERICKSON DH, 1989, AM J PSYCHIAT, V146, P1456; Fannon D, 2000, AM J PSYCHIAT, V157, P1829, DOI 10.1176/appi.ajp.157.11.1829; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; Fenton WS, 1997, SCHIZOPHRENIA BULL, V23, P637, DOI 10.1093/schbul/23.4.637; FENTON WS, 1991, ARCH GEN PSYCHIAT, V48, P978; FISHER WH, 1992, AM J PSYCHIAT, V149, P385; Fowler D, 1995, COGNITIVE BEHAV THER; FOX JW, 1990, J HEALTH SOC BEHAV, V31, P344, DOI 10.2307/2136818; Freudenreich O, 2002, ACTA PSYCHIAT SCAND, V106, P323, DOI 10.1034/j.1600-0447.2002.01331.x; GELLER JL, 1992, AM J PSYCHIAT, V149, P1526; Gingerich S, 2002, ILLNESS MANAGEMENT R; Glynn SM, 2002, AM J PSYCHIAT, V159, P829, DOI 10.1176/appi.ajp.159.5.829; Goeree R, 1999, CAN J PSYCHIAT, V44, P464, DOI 10.1177/070674379904400506; Gould RA, 2001, SCHIZOPHR RES, V48, P335, DOI 10.1016/S0920-9964(00)00145-6; GREDEN JF, 1991, NEGATIVE SCHIZOPHREN; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; Hafner H, 2000, ACTA PSYCHIAT SCAND, V102, P44, DOI 10.1034/j.1600-0447.2000.00008.x; Hafner H, 1999, ACTA PSYCHIAT SCAND, V100, P105, DOI 10.1111/j.1600-0447.1999.tb10831.x; Hafner H, 2003, SCHIZOPHRENIA BULL, V29, P325, DOI 10.1093/oxfordjournals.schbul.a007008; HAFNER H, 2003, SCHIZOPHRENIA, P101; Haghighat R, 2001, BRIT J PSYCHIAT, V178, P207, DOI 10.1192/bjp.178.3.207; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Harvey PD, 2001, AM J PSYCHIAT, V158, P176, DOI 10.1176/appi.ajp.158.2.176; HEATON R, 1994, ARCH GEN PSYCHIAT, V51, P469; Heinssen RK, 2000, SCHIZOPHRENIA BULL, V26, P21, DOI 10.1093/oxfordjournals.schbul.a033441; HERZ MI, 2002, SCHIZOPHRENIA COMPRE; Hogarty G.E., 2002, PERSONAL THERAPY SCH; Honey GD, 1999, P NATL ACAD SCI USA, V96, P13432, DOI 10.1073/pnas.96.23.13432; Huppert JD, 2001, J NERV MENT DIS, V189, P669, DOI 10.1097/00005053-200110000-00003; HYDE TM, 1992, ARCH NEUROL-CHICAGO, V49, P401, DOI 10.1001/archneur.1992.00530280095028; Innocenti GM, 2003, MOL PSYCHIATR, V8, P261, DOI 10.1038/sj.mp.4001205; Inskip HM, 1998, BRIT J PSYCHIAT, V172, P35, DOI 10.1192/bjp.172.1.35; Jablensky A, 1992, Psychol Med Monogr Suppl, V20, P1; Jablensky A, 1997, SCHIZOPHR RES, V28, P111, DOI 10.1016/S0920-9964(97)85354-6; Jablensky A, 1999, CURR OPIN PSYCHIATR, V12, P19, DOI 10.1097/00001504-199901000-00013; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; KESHAVAN MS, 1994, J PSYCHIATR RES, V28, P239, DOI 10.1016/0022-3956(94)90009-4; Kim T, 2003, DHA GUIDE EFFECTIVE; Kleinman A., 1988, RETHINKING PSYCHIAT; Knapp M, 1997, BRIT J PSYCHIAT, V171, P509, DOI 10.1192/bjp.171.6.509; Kraepelin E, 1919, DEMENTIA PRAECOX PAR; Lawrie SM, 1998, BRIT J PSYCHIAT, V172, P110, DOI 10.1192/bjp.172.2.110; Lefley HP, 1996, FAMILY CAREGIVING ME; Lewis S, 2002, BRIT J PSYCHIAT, V181, pS91, DOI 10.1192/bjp.181.43.s91; LIDDLE PF, 1987, BRIT J PSYCHIAT, V151, P145, DOI 10.1192/bjp.151.2.145; Lieberman JA, 2003, AM J PSYCHIAT, V160, P1396, DOI 10.1176/appi.ajp.160.8.1396; Lieberman JA, 2001, BIOL PSYCHIAT, V50, P884, DOI 10.1016/S0006-3223(01)01303-8; Lim KO, 1998, BIOL PSYCHIAT, V43, p11S, DOI 10.1016/S0006-3223(98)90485-1; LINK BG, 1987, AM J SOCIOL, V92, P1461, DOI 10.1086/228672; Malla AK, 2002, PSYCHIATR SERV, V53, P458, DOI 10.1176/appi.ps.53.4.458; Marshall M, 1999, BRIT J PSYCHIAT, V175, P501, DOI 10.1192/bjp.175.6.501; Mathalon DH, 2003, ARCH GEN PSYCHIAT, V60, P846, DOI 10.1001/archpsyc.60.8.846; Maurer K, 1996, Gesundheitswesen, V58, P79; McDonald C, 2002, AM J MED GENET, V114, P616, DOI 10.1002/ajmg.10604; MCGLASHAN TH, 1992, ARCH GEN PSYCHIAT, V49, P63; McGorry PD, 2002, ARCH GEN PSYCHIAT, V59, P921, DOI 10.1001/archpsyc.59.10.921; MCGUFFIN P, 1995, LANCET, V346, P678, DOI 10.1016/S0140-6736(95)92285-7; MECHANIC D, 1994, SOC SCI MED, V39, P155, DOI 10.1016/0277-9536(94)90324-7; Meltzer HY, 2003, ARCH GEN PSYCHIAT, V60, P82, DOI 10.1001/archpsyc.60.1.82; MUESER KT, 1991, SCHIZOPHRENIA BULL, V17, P565, DOI 10.1093/schbul/17.4.565; Mueser KT, 2002, PSYCHIAT SERV, V53, P1272, DOI 10.1176/appi.ps.53.10.1272; Mueser KT, 2002, SCHIZOPHR RES, V53, P123, DOI 10.1016/S0920-9964(01)00173-6; Mueser KT, 2001, SCHIZOPHRENIA BULL, V27, P281, DOI 10.1093/oxfordjournals.schbul.a006874; MUIJEN M, 1994, BRIT J PSYCHIAT, V165, P211, DOI 10.1192/bjp.165.2.211; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; Murray RM, 1998, J CLIN PSYCHOPHARM, V18, p2S, DOI 10.1097/00004714-199804001-00002; Narr KL, 2001, BIOL PSYCHIAT, V50, P84, DOI 10.1016/S0006-3223(00)01120-3; Nordentoft M, 2002, BRIT J PSYCHIAT, V181, pS98, DOI 10.1192/bjp.181.43.s98; NUECHTERLEIN KH, 1984, SCHIZOPHRENIA BULL, V10, P300, DOI 10.1093/schbul/10.2.300; Page S, 1995, J Health Soc Policy, V7, P61; Peen J, 1997, ACTA PSYCHIAT SCAND, V96, P301, DOI 10.1111/j.1600-0447.1997.tb10167.x; Penn D., 2003, J MENTAL HLTH, V12, P332; Penn DL, 1997, PSYCHOL BULL, V121, P114, DOI 10.1037/0033-2909.121.1.114; Peralta V, 2003, SCHIZOPHRENIA BULL, V29, P413, DOI 10.1093/oxfordjournals.schbul.a007016; Pinfold V, 2003, BRIT J PSYCHIAT, V182, P342, DOI 10.1192/bjp.182.4.342; Pinkham AE, 2003, AM J PSYCHIAT, V160, P815, DOI 10.1176/appi.ajp.160.5.815; Pitschel-Walz G, 2001, SCHIZOPHRENIA BULL, V27, P73, DOI 10.1093/oxfordjournals.schbul.a006861; RABKIN JG, 1979, AM J PSYCHIAT, V136, P1562; Racenstein JM, 2002, SCHIZOPHR RES, V56, P95, DOI 10.1016/S0920-9964(01)00273-0; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; REISCHIES FM, 1988, ARCH NEUROL-CHICAGO, V45, P1114, DOI 10.1001/archneur.1988.00520340068014; Rice DP, 1999, EC NEUROSCIENCE, V1, P40; RIDGELY MS, 1990, SCHIZOPHRENIA BULL, V16, P123, DOI 10.1093/schbul/16.1.123; Rosenberg SD, 2001, AM J PUBLIC HEALTH, V91, P31, DOI 10.2105/AJPH.91.1.31; Sartorius N, 1997, BRIT J PSYCHIAT, V170, P297, DOI 10.1192/bjp.170.4.297; Sayers SL, 1996, PSYCHOL ASSESSMENT, V8, P269, DOI 10.1037/1040-3590.8.3.269; SCHULSINGER F, 1991, ACTA PSYCHIAT SCAND, V83, P4; Schultz SK, 1999, LANCET, V353, P1425, DOI 10.1016/S0140-6736(98)07549-7; Selten JP, 1997, PSYCHOL MED, V27, P807, DOI 10.1017/S0033291797005199; Sharma T, 1999, SCHIZOPHR RES, V40, P111, DOI 10.1016/S0920-9964(99)00143-7; STEIN LI, 1998, ASSERTIVE COMMUNITY; SUSSER E, 1989, ARCH GEN PSYCHIAT, V46, P845; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; Takei N, 1996, BIOL PSYCHIAT, V40, P817, DOI 10.1016/0006-3223(95)00592-7; TERKELSEN KG, 1995, PHARMACOECONOMICS, V8, P199, DOI 10.2165/00019053-199508030-00004; Thaker GK, 2001, NAT MED, V7, P667, DOI 10.1038/89040; THARA R, 1994, ACTA PSYCHIAT SCAND, V90, P329, DOI 10.1111/j.1600-0447.1994.tb01602.x; Thomas HV, 2001, BRIT J PSYCHIAT, V179, P409, DOI 10.1192/bjp.179.5.409; Thornicroft G, 1998, BRIT J PSYCHIAT, V173, P363, DOI 10.1192/bjp.173.5.363; *US I MED, NEUR PSYCH DEV DIS M; van Os J, 1998, SCHIZOPHR RES, V32, P127, DOI 10.1016/S0920-9964(98)00049-8; Wahl O.F., 1995, MEDIA MADNESS PUBLIC; Wahlbeck K, 1999, AM J PSYCHIAT, V156, P990; Walsh E, 2003, BRIT J PSYCHIAT, V183, P233, DOI 10.1192/bjp.183.3.233; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; Weinberger DR, 2003, SCHIZOPHRENIA NEUROD, P326; WEINER B, 1995, JUDGMENTS RESPONSILI; Weisman AG, 1998, J ABNORM PSYCHOL, V107, P355, DOI 10.1037/0021-843X.107.2.355; Woods SW, 2003, BIOL PSYCHIAT, V54, P453, DOI 10.1016/S0006-3223(03)00321-4; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1979, SCHIZ INT FOLL STUD; Wright IC, 2000, AM J PSYCHIAT, V157, P16, DOI 10.1176/ajp.157.1.16; Yung AR, 2003, SCHIZOPHR RES, V60, P21, DOI 10.1016/S0920-9964(02)00167-6; YurgelunTodd DA, 1996, AM J PSYCHIAT, V153, P200; Zhang MY, 1998, PSYCHIAT CLIN NEUROS, V52, pS344, DOI 10.1111/j.1440-1819.1998.tb03264.x	160	663	687	4	145	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2063	2072		10.1016/S0140-6736(04)16458-1	http://dx.doi.org/10.1016/S0140-6736(04)16458-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	830YJ	15207959				2022-12-28	WOS:000222159800023
J	Morrison, RS; Meier, DE				Morrison, RS; Meier, DE			Palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-LIFE CARE; ALL-INCLUSIVE CARE; ELDERLY PACE; HEALTH-CARE; END; MANAGEMENT; PROGRAM; OUTCOMES; HOSPICE; IMPACT		Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Morrison, RS (corresponding author), Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave L Levy Pl, New York, NY 10029 USA.	sean.morrison@mssm.edu			NATIONAL INSTITUTE ON AGING [K24AG022345, K07AG000903] Funding Source: NIH RePORTER; NIA NIH HHS [K24AG022345, K07AG00903] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM AC PHYS PAT, UPC COURS M; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Bernabei R, 1999, JAMA-J AM MED ASSOC, V281, P136; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; BUCKMAN R, 2000, JAMA-J AM MED ASSOC, V283, P909; Casarett DJ, 2001, ANN INTERN MED, V135, P32, DOI 10.7326/0003-4819-135-1-200107030-00011; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Dowsett SM, 2000, PSYCHO-ONCOL, V9, P147, DOI 10.1002/(SICI)1099-1611(200003/04)9:2<147::AID-PON443>3.0.CO;2-X; Doyle D., 2004, OXFORD TXB PALLIATIV; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Elkan R, 2001, BMJ-BRIT MED J, V323, P719, DOI 10.1136/bmj.323.7315.719; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; *EPEC PROJ, ED PALL END OF LIF C; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Field MJ, 1997, APPROACHING DEATH IM; Finlay IG, 2002, ANN ONCOL, V13, P257, DOI 10.1093/annonc/mdf668; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Foley KM, 1999, ARCH NEUROL-CHICAGO, V56, P413, DOI 10.1001/archneur.56.4.413; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; *HARV MED SCH CTR, PRACT ASP PALL MED I; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Manfredi PL, 2000, J PAIN SYMPTOM MANAG, V20, P166, DOI 10.1016/S0885-3924(00)00163-9; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; MITTELMAN MS, 1995, GERONTOLOGIST, V35, P792, DOI 10.1093/geront/35.6.792; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Morrison RS., 2003, GERIATRIC PALLIATIVE, V1st; MORRISON RS, IN PRESS ARCH INTERN; Mukamel DB, 2002, MED CARE, V40, P1136, DOI 10.1097/00005650-200212000-00002; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; REGNARD C, 1992, Palliative Medicine, V6, P146, DOI 10.1177/026921639200600209; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Strasser F, 2002, HEMATOL ONCOL CLIN N, V16, P589, DOI 10.1016/S0889-8588(02)00011-4; Stroebe M.S., 1993, HDB BEREAVEMENT THEO; Stroebe Margaret S., 1993, P175, DOI 10.1017/CBO9780511664076.013; Sullivan AM, 2003, J GEN INTERN MED, V18, P685, DOI 10.1046/j.1525-1497.2003.21215.x; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; TULSKY JA, 2003, GERIATRIC PALLIATIVE, P314; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5; Wieland D, 2000, J AM GERIATR SOC, V48, P1373, DOI 10.1111/j.1532-5415.2000.tb02625.x; Wieland D, 2001, J AM GERIATR SOC, V49, P835, DOI 10.1046/j.1532-5415.2001.49166.x	60	357	362	4	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2582	2590		10.1056/NEJMcp035232	http://dx.doi.org/10.1056/NEJMcp035232			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	829NE	15201415				2022-12-28	WOS:000222054700009
J	Leith, W				Leith, W			Geology - Building for earthquakes	SCIENCE			English	Editorial Material									US Geol Survey, Reston, VA 20192 USA	United States Department of the Interior; United States Geological Survey	Leith, W (corresponding author), US Geol Survey, Reston, VA 20192 USA.	wleith@usgs.gov						*ADV NAT SEISM SYS, 1188 USGS ADV NAT SE; Earthquake Engineering Research Institute [EERI], 2003, SEC SOC CAT EARTHQ L; *FEMA, 1996, 277 EMA; *NAT RES COUNC, 2003, PREV EARTHQ DIS GRAN; SHAH HC, 1995, DISASTER RES; Somerville P., 1995, EOS T AM GEOPHYS UNI, V76, P49; *WORK GROUP EARTHQ, 2003, 03214 USGS WORK GROU	7	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	2004	304	5677					1604	1604						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192204				2022-12-28	WOS:000221934300024
J	Achermann, M; Petruska, MA; Kos, S; Smith, DL; Koleske, DD; Klimov, VI				Achermann, M; Petruska, MA; Kos, S; Smith, DL; Koleske, DD; Klimov, VI			Energy-transfer pumping of semiconductor nanocrystals using an epitaxial quantum well	NATURE			English	Article							LIGHT-EMITTING-DIODES; STIMULATED-EMISSION; DOTS; RELAXATION; POLYMER	As a result of quantum-confinement effects, the emission colour of semiconductor nanocrystals can be modified dramatically by simply changing their size(1,2). Such spectral tunability, together with large photoluminescence quantum yields and high photostability, make nanocrystals attractive for use in a variety of light-emitting technologies - for example, displays, fluorescence tagging(3), solid-state lighting and lasers(4). An important limitation for such applications, however, is the difficulty of achieving electrical pumping, largely due to the presence of an insulating organic capping layer on the nanocrystals. Here, we describe an approach for indirect injection of electron - hole pairs ( the electron - hole radiative recombination gives rise to light emission) into nanocrystals by non-contact, non-radiative energy transfer from a proximal quantum well that can in principle be pumped either electrically or optically. Our theoretical and experimental results indicate that this transfer is fast enough to compete with electron - hole recombination in the quantum well, and results in greater than 50 per cent energy-transfer efficiencies in the tested structures. Furthermore, the measured energy-transfer rates are sufficiently large to provide pumping in the stimulated emission regime, indicating the feasibility of nanocrystal-based optical amplifiers and lasers based on this approach.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Sandia Natl Labs, Albuquerque, NM 87185 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Sandia National Laboratories	Klimov, VI (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	achermann@lanl.gov; klimov@lanl.gov	Kos, Simon/G-3289-2016; Klimov, Victor/Y-2823-2019; Achermann, Marc/A-1849-2011	Kos, Simon/0000-0003-1657-9793; Klimov, Victor/0000-0003-1158-3179; Achermann, Marc/0000-0002-3939-9309				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Basko D, 1999, EUR PHYS J B, V8, P353, DOI 10.1007/s100510050700; Bidnyk S, 1998, APPL PHYS LETT, V72, P1623, DOI 10.1063/1.121133; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Coe S, 2002, NATURE, V420, P800, DOI 10.1038/nature01217; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Klimov VI, 2000, SCIENCE, V290, P314, DOI 10.1126/science.290.5490.314; Klimov VI, 2000, SCIENCE, V287, P1011, DOI 10.1126/science.287.5455.1011; Klimov VI, 1998, PHYS REV LETT, V80, P4028, DOI 10.1103/PhysRevLett.80.4028; Klimov VI, 2000, J PHYS CHEM B, V104, P6112, DOI 10.1021/jp9944132; Koleske DD, 2002, APPL PHYS LETT, V81, P1940, DOI 10.1063/1.1506793; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Nakamura S., 1997, BLUE LASER DIODE GAN; Schlamp MC, 1997, J APPL PHYS, V82, P5837, DOI 10.1063/1.366452; Wu LW, 2002, IEEE J QUANTUM ELECT, V38, P446, DOI 10.1109/3.998615; Xu S, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.045319; NEXT GENERATION LIGH	18	517	527	1	173	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					642	646		10.1038/nature02571	http://dx.doi.org/10.1038/nature02571			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190347				2022-12-28	WOS:000221912600035
J	Thomas, CF; Limper, AH				Thomas, CF; Limper, AH			Pneumocystis pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACTIVATED PROTEIN-KINASE; DIHYDROPTEROATE SYNTHASE GENE; MAJOR SURFACE GLYCOPROTEIN; ALVEOLAR EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; CARINII-PNEUMONIA; OPPORTUNISTIC INFECTIONS; BRONCHOALVEOLAR LAVAGE; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION		Mayo Clin, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med,Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Limper, AH (corresponding author), Mayo Clin, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med,Thorac Dis Res Unit, 8-24 Stabile Bldg, Rochester, MN 55905 USA.	limper.andrew@mayo.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055934, R01HL062150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048409] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 55934, R01 HL 62150] Funding Source: Medline; NIAID NIH HHS [R01 AI-48409] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afessa B, 1998, CHEST, V113, P1225, DOI 10.1378/chest.113.5.1225; ARMBRUSTER C, 1995, ACTA CYTOL, V39, P1089; Beck J M, 1998, Semin Respir Infect, V13, P330; BECK JM, 1991, INFECT IMMUN, V59, P3859, DOI 10.1128/IAI.59.11.3859-3862.1991; BECK JM, 1991, AM J RESP CELL MOL, V5, P186, DOI 10.1165/ajrcmb/5.2.186; Beck JM, 1998, AM J PHYSIOL-LUNG C, V275, pL118, DOI 10.1152/ajplung.1998.275.1.L118; Beers MF, 1999, J LAB CLIN MED, V133, P423, DOI 10.1016/S0022-2143(99)90019-7; Benfield TL, 1997, CHEST, V111, P1193, DOI 10.1378/chest.111.5.1193; BENFIELD TL, 1995, AM J RESP CRIT CARE, V151, P1058; BIGBY TD, 1994, CHEST, V105, P650, DOI 10.1378/chest.105.3.650; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Carinii A., 1910, COMMUN SOC MED SAO P, V16, P204; *CDCP, 2003, HIV AIDS SURVEILLANC, V9, P20; Chagas C, 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008; CHEN WX, 1992, INFECT IMMUN, V60, P1279, DOI 10.1128/IAI.60.4.1279-1284.1992; Curtis JR, 2000, AM J RESP CRIT CARE, V162, P393, DOI 10.1164/ajrccm.162.2.9909014; Cushion M T, 2001, J Eukaryot Microbiol, VSuppl, p101S, DOI 10.1111/j.1550-7408.2001.tb00470.x; Delanoe P, 1912, CR HEBD ACAD SCI, V155, P658; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; Douglas CM, 2001, MED MYCOL, V39, P55, DOI 10.1080/mmy.39.1.55.66; Downing JF, 1999, INFECT IMMUN, V67, P1347, DOI 10.1128/IAI.67.3.1347-1352.1999; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; Fox D, 1999, MOL MICROBIOL, V34, P451, DOI 10.1046/j.1365-2958.1999.01606.x; Fox D, 2000, CELL SIGNAL, V12, P381, DOI 10.1016/S0898-6568(00)00076-0; GIGLIOTTI F, 1986, J INFECT DIS, V154, P315, DOI 10.1093/infdis/154.2.315; GIGLIOTTI F, 1992, J INFECT DIS, V165, P329, DOI 10.1093/infdis/165.2.329; GIGLIOTTI F, 1993, INFECT IMMUN, V61, P2886, DOI 10.1128/IAI.61.7.2886-2890.1993; GIGLIOTTI F, 1988, J INFECT DIS, V158, P848, DOI 10.1093/infdis/158.4.848; Gruden JF, 1997, AM J ROENTGENOL, V169, P967, DOI 10.2214/ajr.169.4.9308446; Gustafson MP, 2001, J BIOL CHEM, V276, P835, DOI 10.1074/jbc.M007814200; Hahn PY, 2003, J BIOL CHEM, V278, P2043, DOI 10.1074/jbc.M209715200; HAIDARIS PJ, 1993, MOL MICROBIOL, V7, P647, DOI 10.1111/j.1365-2958.1993.tb01156.x; HARMSEN AG, 1990, J EXP MED, V172, P937, DOI 10.1084/jem.172.3.937; Helweg-Larsen J, 1999, LANCET, V354, P1347, DOI 10.1016/S0140-6736(99)03320-6; HOFFMAN OA, 1993, J IMMUNOL, V150, P3932; HUGHES WT, 1982, J INFECT DIS, V145, P842, DOI 10.1093/infdis/145.6.842; Hughes WT, 2003, EMERG INFECT DIS, V9, P276; ITATANI CA, 1988, J PARASITOL, V74, P700, DOI 10.2307/3282193; Kaneshiro ES, 2002, MOL MICROBIOL, V44, P989, DOI 10.1046/j.1365-2958.2002.02932.x; Kolls JK, 1997, AM J RESP CELL MOL, V16, P112, DOI 10.1165/ajrcmb.16.2.9032117; Kottom TJ, 2003, INFECT IMMUN, V71, P6463, DOI 10.1128/IAI.71.11.6463-6471.2003; Kottom TJ, 2000, J BIOL CHEM, V275, P40628, DOI 10.1074/jbc.M002103200; Kottom TJ, 2000, AM J RESP CELL MOL, V22, P722, DOI 10.1165/ajrcmb.22.6.3838; KOVACS JA, 1993, J BIOL CHEM, V268, P6034; KOVACS JA, 1989, J INFECT DIS, V159, P60, DOI 10.1093/infdis/159.1.60; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; Koziel H, 1998, J CLIN INVEST, V102, P1332, DOI 10.1172/JCI560; Koziel H, 1998, AM J RESP CELL MOL, V18, P834, DOI 10.1165/ajrcmb.18.6.3059; Langford CA, 2003, AM J MED, V114, P463, DOI 10.1016/S0002-9343(03)00077-9; LIMPER AH, 1993, INFECT IMMUN, V61, P4302, DOI 10.1128/IAI.61.10.4302-4309.1993; Limper AH, 1997, J CLIN INVEST, V99, P2110, DOI 10.1172/JCI119384; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Limper AH, 1998, J CLIN INVEST, V101, P1148, DOI 10.1172/JCI659; LINKE MJ, 1989, INFECT IMMUN, V57, P1547, DOI 10.1128/IAI.57.5.1547-1555.1989; Lundgren B, 1997, THORAX, V52, P422, DOI 10.1136/thx.52.5.422; LUNDGREN B, 1993, APMIS, V101, P194, DOI 10.1111/j.1699-0463.1993.tb00101.x; Ma L, 2002, ANTIMICROB AGENTS CH, V46, P3101, DOI 10.1128/AAC.46.9.3101-3103.2002; Manoloff ES, 2003, EMERG INFECT DIS, V9, P132, DOI 10.3201/eid0901.020141; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; Masur H, 2002, ANN INTERN MED, V137, P435, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00002; MATSUMOTO Y, 1984, J PROTOZOOL, V31, P420, DOI 10.1111/j.1550-7408.1984.tb02989.x; Miller RF, 2001, J CLIN MICROBIOL, V39, P3877, DOI 10.1128/JCM.39.11.3877-3882.2001; Morales IJ, 2003, AM J RESP CELL MOL, V29, P232, DOI 10.1165/rcmb.2003-0012OC; Morris A, 2002, MICROBES INFECT, V4, P95, DOI 10.1016/S1286-4579(01)01514-3; Nahimana A, 2003, EMERG INFECT DIS, V9, P864; Navin TR, 2001, LANCET, V358, P545, DOI 10.1016/S0140-6736(01)05705-1; ORIORDAN DM, 1995, INFECT IMMUN, V63, P779, DOI 10.1128/IAI.63.3.779-784.1995; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Ortona E, 1996, MOL CELL PROBE, V10, P187, DOI 10.1006/mcpr.1996.0026; Pareja JG, 1998, CHEST, V113, P1215, DOI 10.1378/chest.113.5.1215; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Powles MA, 1998, ANTIMICROB AGENTS CH, V42, P1985, DOI 10.1128/AAC.42.8.1985; QUIST J, 1995, CHEST, V108, P415, DOI 10.1378/chest.108.2.415; Ribes JA, 1997, J CLIN MICROBIOL, V35, P830, DOI 10.1128/JCM.35.4.830-835.1997; ROTHS JB, 1990, AM J PATHOL, V136, P1173; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; Sepkowitz KA, 2002, CLIN INFECT DIS, V34, P1098, DOI 10.1086/339548; SEPKOWITZ KA, 1992, JAMA-J AM MED ASSOC, V267, P832, DOI 10.1001/jama.267.6.832; Sepkowitz KA, 2002, CLIN INFECT DIS, V34, P1293; SEPKOWITZ KA, 1993, CLIN INFECT DIS, V17, pS416, DOI 10.1093/clinids/17.Supplement_2.S416; Shelhamer JH, 1996, ANN INTERN MED, V124, P585, DOI 10.7326/0003-4819-124-6-199603150-00008; SHELLITO J, 1990, J CLIN INVEST, V85, P1686, DOI 10.1172/JCI114621; Skelly M, 2003, LANCET, V361, P1267, DOI 10.1016/S0140-6736(03)12984-4; Smulian AG, 1996, INFECT IMMUN, V64, P691, DOI 10.1128/IAI.64.3.691-701.1996; Smulian AG, 2001, GENETICS, V157, P991; Stringer JR, 2002, EMERG INFECT DIS, V8, P891, DOI 10.3201/eid0809.020096; Stringer JR, 2001, INFECT IMMUN, V69, P627, DOI 10.1128/IAI.69.2.627-639.2001; Takahashi T, 2000, J CLIN MICROBIOL, V38, P3161, DOI 10.1128/JCM.38.9.3161-3164.2000; Tamburrini E, 1996, J CLIN MICROBIOL, V34, P1586, DOI 10.1128/JCM.34.6.1586-1588.1996; Thomas CF, 2003, FEBS LETT, V548, P59, DOI 10.1016/S0014-5793(03)00730-0; Thomas CF, 1998, AM J PHYSIOL-LUNG C, V275, pL193, DOI 10.1152/ajplung.1998.275.1.L193; Thomas CF, 1998, AM J RESP CELL MOL, V18, P297, DOI 10.1165/ajrcmb.18.3.3122; Vargas SL, 2000, J CLIN MICROBIOL, V38, P1536, DOI 10.1128/JCM.38.4.1536-1538.2000; Vargas SL, 2001, CLIN INFECT DIS, V32, P855, DOI 10.1086/319340; Vassallo R, 2001, AM J RESP CELL MOL, V25, P203, DOI 10.1165/ajrcmb.25.2.4427; Vassallo R, 2000, J IMMUNOL, V164, P3755, DOI 10.4049/jimmunol.164.7.3755; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; Vohra PK, 2003, FEBS LETT, V551, P139, DOI 10.1016/S0014-5793(03)00914-1; Vohra PK, 2003, GENE, V312, P173, DOI 10.1016/S0378-1119(03)00614-0; Vuk-Pavlovic Z, 2001, AM J RESP CELL MOL, V24, P475, DOI 10.1165/ajrcmb.24.4.3504; Wakefield AE, 2003, J INFECT DIS, V187, P901, DOI 10.1086/368165; WAKEFIELD AE, 1991, LANCET, V337, P1378, DOI 10.1016/0140-6736(91)93062-E; WALZER PD, 1986, LAB INVEST, V54, P589; Williams MD, 1996, AM J RESP CELL MOL, V14, P232, DOI 10.1165/ajrcmb.14.3.8845173; Wright TW, 1999, INFECT IMMUN, V67, P3452, DOI 10.1128/IAI.67.7.3452-3460.1999; Wright TW, 2001, INFECT IMMUN, V69, P758, DOI 10.1128/IAI.69.2.758-764.2001; Wright TW, 1999, J CLIN INVEST, V104, P1307, DOI 10.1172/JCI6688; Wyder MA, 1998, J EUKARYOT MICROBIOL, V45, P233, DOI 10.1111/j.1550-7408.1998.tb04531.x; Yale SH, 1996, MAYO CLIN PROC, V71, P5, DOI 10.4065/71.1.5; Ye DJ, 2001, GENE, V263, P151, DOI 10.1016/S0378-1119(00)00577-1; Yong SJ, 2003, INFECT IMMUN, V71, P1662, DOI 10.1128/IAI.71.4.1662-1671.2003; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	113	672	702	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2487	2498		10.1056/NEJMra032588	http://dx.doi.org/10.1056/NEJMra032588			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190141				2022-12-28	WOS:000221887200008
J	Boynton, PM				Boynton, PM			Hands-on guide to questionnaire research - Administering, analysing, and reporting your questionnaire	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPONSE RATES; MAIL		UCL, Dept Primary Care & Populat sci, London N19 5LW, England	University of London; University College London	Boynton, PM (corresponding author), UCL, Dept Primary Care & Populat sci, London N19 5LW, England.	p.boynton@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Boynton, Petra/0000-0001-6699-2266				Boynton PM, 2004, BRIT MED J, V328, P1312, DOI 10.1136/bmj.328.7451.1312; BOYNTON PM, IN PRESS RES COMPANI; BOYNTON PM, IN PRESS BMJ; Brogger J, 2003, AM J EPIDEMIOL, V157, P558, DOI 10.1093/aje/kwg003; Dallosso HM, 2003, BJU INT, V91, P631, DOI 10.1046/j.1464-410X.2003.04172.x; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Gill R., 1996, HDB QUALITATIVE RES, P141; GILLHAM B, 2000, DEV QUESTIONAIRE REA; Gueguen N, 2003, CAN J BEHAV SCI, V35, P84, DOI 10.1037/h0087191; Halpern SD, 2002, MED CARE, V40, P834, DOI 10.1097/00005650-200209000-00012; HOWITT D, 2000, 1 STEPS RES STAT; Keeter S, 2001, J SOC SERV RES, V28, P69, DOI 10.1300/J079v28n01_04; MCCOLL E, 2001, HEALTH TECHNOL ASSES, P5; Meadows K A, 1998, J Eval Clin Pract, V4, P243, DOI 10.1046/j.1365-2753.1998.00008.x; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN; Puleo E, 2002, EVAL HEALTH PROF, V25, P169, DOI 10.1177/016327870202500203; Sapsford R, 1999, SURVEY RES; Shannon DM, 2002, J EXP EDUC, V70, P179, DOI 10.1080/00220970209599505; WALL CR, 2002, J FAM PRACTICE, V51, P21	19	146	151	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1372	1375		10.1136/bmj.328.7452.1372	http://dx.doi.org/10.1136/bmj.328.7452.1372			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178620	Green Published, Green Submitted			2022-12-28	WOS:000221952700027
J	Simon, DA; Dix, FP; McCollum, CN				Simon, DA; Dix, FP; McCollum, CN			Management of venous leg ulcers	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED-TRIAL; GROWTH-FACTOR; RECURRENCE; ULCERATION; SURGERY; CLINICS; INSUFFICIENCY; COMPRESSION; IMPACT		Wythenshawe Hosp, Acad Dept Surg, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	McCollum, CN (corresponding author), Wythenshawe Hosp, Acad Dept Surg, Manchester M23 9LT, Lancs, England.	cnmcc@man.ac.uk						ABUOWN A, 1994, J VASC SURG, V20, P705, DOI 10.1016/S0741-5214(94)70157-1; Adam DJ, 2003, EUR J VASC ENDOVASC, V25, P469, DOI 10.1053/ejvs.2002.1894; BAKER SR, 1992, EUR J VASCULAR SURG, V6, P245, DOI 10.1016/S0950-821X(05)80313-5; Barwell JR, 2000, EUR J VASC ENDOVASC, V20, P363, DOI 10.1053/ejvs.2000.1196; Bello M, 1999, BRIT J SURG, V86, P755, DOI 10.1046/j.1365-2168.1999.01155.x; BLAIR SD, 1988, BRIT MED J, V297, P1159, DOI 10.1136/bmj.297.6657.1159; BOURNE IHJ, 1974, BRIT MED J, V2, P581, DOI 10.1136/bmj.2.5919.581; CALLUM M, 1992, PHLEBOLOGY, V1, P287; Campbell B, 2001, ANN ROY COLL SURG, V83, P287; Campbell WB, 1996, ANN ROY COLL SURG, V78, P490; CHEATLE TR, 1991, J ROY SOC MED, V84, P354, DOI 10.1177/014107689108400616; CULLUM N, 2004, COCHRANE DB SYST REV; De Sanctis MT, 2002, ANGIOLOGY, V53, pS49; Dormandy JA, 1995, J CARDIOVASC PHARM, V25, pS61, DOI 10.1097/00005344-199500252-00013; Eich D, 1999, VASA-J VASCULAR DIS, V28, P3, DOI 10.1024/0301-1526.28.1.3; Ellison D A, 2002, J Wound Care, V11, P47; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; FRANKS PJ, 1995, AGE AGEING, V24, P490, DOI 10.1093/ageing/24.6.490; Glinski W, 1999, PHLEBOLOGY, V14, P151, DOI 10.1007/s005239970005; Grabs AJ, 1996, BRIT J SURG, V83, P1380, DOI 10.1002/bjs.1800831016; Greenwood JE, 1995, WOUNDS, V7, P211; Harrison-Balestra C, 2002, DERMATOL SURG, V28, P755, DOI 10.1046/j.1524-4725.2002.02004.x; HERRICK SE, 1992, AM J PATHOL, V141, P1085; LAYTON AM, 1994, LANCET, V344, P164, DOI 10.1016/S0140-6736(94)92759-6; LEES TA, 1992, BRIT J SURG, V79, P1032, DOI 10.1002/bjs.1800791015; MANN RJ, 1981, BRIT J CLIN PRACT, V35, P79; MOFFATT C, 1989, PRIMARY HLTH CAR JUL, P18; MOFFATT CJ, 1992, BRIT MED J, V305, P1389, DOI 10.1136/bmj.305.6866.1389; Morrell CJ, 1998, BMJ-BRIT MED J, V316, P1487, DOI 10.1136/bmj.316.7143.1487; Nanninga PB, 1990, WOUNDS, V2, P205; Nayeri F, 2002, J DERMATOL TREAT, V13, P81, DOI 10.1080/095466302317584449; Nelson E A, 1997, Prof Nurse, V12, pS7; NELSON EA, 2004, COCHRANE DATABASE SY; Payne SPK, 1996, EUR J VASC ENDOVASC, V11, P195, DOI 10.1016/S1078-5884(96)80051-7; Robson MC, 2001, WOUND REPAIR REGEN, V9, P347, DOI 10.1046/j.1524-475x.2001.00347.x; Ruckley CV, 1997, ANGIOLOGY, V48, P67, DOI 10.1177/000331979704800111; Schonfeld WH, 2000, WOUND REPAIR REGEN, V8, P251, DOI 10.1046/j.1524-475x.2000.00251.x; Scondotto G, 1999, ANGIOLOGY, V50, P883, DOI 10.1177/000331979905001102; Scriven JM, 1998, BRIT J SURG, V85, P781; Simon D A, 1996, Ostomy Wound Manage, V42, P34; Simon DA, 1996, BRIT MED J, V312, P1648, DOI 10.1136/bmj.312.7047.1648; STEMMER R, 1980, DERMATOLOGIST, V31, P355; Trengove NJ, 2000, WOUND REPAIR REGEN, V8, P13, DOI 10.1046/j.1524-475x.2000.00013.x; WILSON CL, 1991, CLIN EXP DERMATOL, V16, P250, DOI 10.1111/j.1365-2230.1991.tb00368.x; WRIGHT DDI, 1991, BRIT J SURG, V78, P1269, DOI 10.1002/bjs.1800781039; Zamboni P, 2003, EUR J VASC ENDOVASC, V25, P313, DOI 10.1053/ejvs.2002.1871	46	112	116	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1358	1362		10.1136/bmj.328.7452.1358	http://dx.doi.org/10.1136/bmj.328.7452.1358			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178615	Green Published			2022-12-28	WOS:000221952700022
J	Hayden, SM; Mook, HA; Dai, PC; Perring, TG; Dogan, F				Hayden, SM; Mook, HA; Dai, PC; Perring, TG; Dogan, F			The structure of the high-energy spin excitations in a high-transition-temperature superconductor	NATURE			English	Article							NEUTRON-SCATTERING; MAGNETIC EXCITATIONS; FLUCTUATIONS; SPECTRUM; STRIPES	In conventional superconductors, lattice vibrations (phonons) mediate the attraction between electrons that is responsible for superconductivity(1). The high transition temperatures (high-T-c) of the copper oxide superconductors has led to collective spin excitations being proposed as the mediating excitations in these materials(2). The mediating excitations must be strongly coupled to the conduction electrons, have energy greater than the pairing energy, and be present at T-c. The most obvious feature in the magnetic excitations of high-T-c superconductors such as YBa2Cu3O6+x is the so-called 'resonance'(3-6). Although the resonance may be strongly coupled to the superconductivity(3-8), it is unlikely to be the main cause, because it has not been found in the La2-x(Ba,Sr)(x)CuO4 family and is not universally present in Bi2Sr2CaCu2O8+delta (ref. 9). Here we use inelastic neutron scattering to characterize possible mediating excitations at higher energies in YBa2Cu3O6.6. We observe a square-shaped continuum of excitations peaked at incommensurate positions. These excitations have energies greater than the superconducting pairing energy, are present at T-c, and have spectral weight far exceeding that of the 'resonance'. The discovery of similar excitations in La2-xBaxCuO4 (ref. 10) suggests that they are a general property of the copper oxides, and a candidate for mediating the electron pairing.	Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA; Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA; Rutherford Appleton Lab, ISIS Facil, Didcot OX11 0QX, Oxon, England; Univ Missouri, Dept Ceram Engn, Rolla, MO 65409 USA	University of Bristol; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; University of Missouri System; Missouri University of Science & Technology	Hayden, SM (corresponding author), Univ Bristol, HH Wills Phys Lab, Tyndall Ave, Bristol BS8 1TL, Avon, England.	S.Hayden@bristol.ac.uk	spectrometer, MAPS/AAA-5554-2020; Hayden, Stephen M/F-4162-2011; Dai, Pengcheng/C-9171-2012	Hayden, Stephen M/0000-0002-3209-027X; Dai, Pengcheng/0000-0002-6088-3170				Arai M, 1999, PHYS REV LETT, V83, P608, DOI 10.1103/PhysRevLett.83.608; AXE JD, 1973, PHYS REV LETT, V30, P214, DOI 10.1103/PhysRevLett.30.214; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Bourges P, 2000, SCIENCE, V288, P1234, DOI 10.1126/science.288.5469.1234; Bourges P, 1997, PHYS REV B, V56, P11439, DOI 10.1103/PhysRevB.56.R11439; BULUT N, 1990, PHYS REV LETT, V64, P2723, DOI 10.1103/PhysRevLett.64.2723; CHRISTENSEN NB, 2004, UNIVERSAL DISPERSIVE; Chubukov AV, 2003, PHYSICS OF SUPERCONDUCTORS, VOL I, P495; Dai PC, 1999, SCIENCE, V284, P1344, DOI 10.1126/science.284.5418.1344; Dai PC, 1998, PHYS REV LETT, V80, P1738, DOI 10.1103/PhysRevLett.80.1738; Damascelli A, 2003, REV MOD PHYS, V75, P473, DOI 10.1103/RevModPhys.75.473; Demler E, 1998, NATURE, V396, P733, DOI 10.1038/25482; Fong HF, 2000, PHYS REV B, V61, P14773, DOI 10.1103/PhysRevB.61.14773; Haworth C, 1998, PHYSICA B, V246, P73, DOI 10.1016/S0921-4526(98)00028-3; Hussey NE, 2003, NATURE, V425, P814, DOI 10.1038/nature01981; Hwang J, 2004, NATURE, V427, P714, DOI 10.1038/nature02347; MOOK HA, 1993, PHYS REV LETT, V70, P3490, DOI 10.1103/PhysRevLett.70.3490; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; Norman MR, 2000, PHYS REV B, V61, P14751, DOI 10.1103/PhysRevB.61.14751; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; Scalapino DJ, 1998, PHYS REV B, V58, P8222, DOI 10.1103/PhysRevB.58.8222; SHAMOTO S, 1993, PHYS REV B, V48, P13817, DOI 10.1103/PhysRevB.48.13817; Stock C, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.014502; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; Tranquada JM, 2004, NATURE, V429, P534, DOI 10.1038/nature02574	26	326	331	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					531	534		10.1038/nature02576	http://dx.doi.org/10.1038/nature02576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175744				2022-12-28	WOS:000221767700031
J	Lee, K; Walt, G; Haines, A				Lee, K; Walt, G; Haines, A			The challenge to improve global health - Financing the millennium development goals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Lee, K (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	kelley.lee@lshtm.ac.uk		Haines, Andy/0000-0002-8053-4605				Beaglehole R., 2003, WORLD HLTH REPORT 20; BROWN G, 2004, GUARDIAN        0216; Brown G., 2004, COMMUNICATION   0216; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Killick Tony, 2004, DEV POLICY REV, V22, P5, DOI DOI 10.1111/DPR.2004.22.ISSUE-1; Lee K., 2003, HLTH FOREIGN POLICY; McDonnell I, 2003, PUBLIC OPINION FIGHT; *WHO COMM MACR HLT, 2002, IMPR HLTH OUTC POOR; WOLFENSOHN J, 2004, COMMUNICATION   0216; *WORLD BANK, 2003, MILL DEV GOALS HLTH; WRAY R, 2003, GUARDIAN        0923; WYSS K, 2003, J INT DEV, V15, P87, DOI DOI 10.1002/JID.967	12	23	23	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2636	2638		10.1001/jama.291.21.2636	http://dx.doi.org/10.1001/jama.291.21.2636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173157	Green Accepted			2022-12-28	WOS:000221738800029
J	Landon, BE; Wilson, IB; McInnes, K; Landrum, MB; Hirschhorn, L; Marsden, PV; Gustafson, D; Cleary, PD				Landon, BE; Wilson, IB; McInnes, K; Landrum, MB; Hirschhorn, L; Marsden, PV; Gustafson, D; Cleary, PD			Effects of a quality improvement collaborative on the outcome of care of patients with HIV infection: The EQHIV study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE; UPDATED RECOMMENDATIONS; CLINICAL-PRACTICE; IMPACT; ADULTS; INTERVENTION; PUBLICATION; PHYSICIANS; MORTALITY	Background: Multi-institution collaborative quality improvement programs are a well-established and broadly applicable quality improvement strategy, but there is little systematic assessment their effectiveness. Objective: To evaluate the effectiveness of a quality improvement collaborative in improving the quality of care for HIV-infected patients. Design: Controlled pre- and postintervention study. Setting: Clinics receiving funding from the Ryan White Comprehensive AIDS Resources Emergency Act. Participants: 44 intervention clinics and 25 control clinics matched by location (urban or rural), region, size, and clinic type. Measurements: Changes in quality-of-care measures abstracted from medical records of pre- and postintervention samples of patients at each study clinic. Measures examined included use and effectiveness of antiretroviral therapy, screening and prophylaxis, and access to care. Intervention: A multi-institutional quality improvement collaborative (the "Breakthrough Series"). Results: 9986 patients were studied. Clinical and sociodemographic characteristics of the intervention and control patients were similar (P > 0.05). Differences in changes in the quality of care were not statistically significant. The proportion of patients with a suppressed viral load increased by 11 percentage points (from 40.1% to 51.1%) in the intervention group compared with 5.3 percentage points (from 43.6% to 48.8%) in the control group, but this difference was not statistically significant (P = 0.18). In addition, rates of appropriate screening tests and prophylaxis did not differ between intervention and control sites. Limitations: It was not possible to perform a pure randomized trial of the intervention or to assess other measures of quality, such as adherence and satisfaction. Conclusions: This prospective, matched study of almost 10 000 patients found that a quality improvement collaborative did not significantly affect the quality of care. Additional research is needed to improve methods of teaching and implementing quality improvement programs to achieve better results.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Univ Wisconsin, Madison, WI 53706 USA; Dimock Community Hlth Ctr, Boston, MA USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Beth Israel Deaconess Med Ctr, Boston, MA USA; Harvard Univ, Boston, MA 02115 USA	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; Tufts Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	landon@hcp.med.harvard.edu	Wilson, Ira/F-9190-2016; Cleary, Paul/AAF-7048-2019	Wilson, Ira/0000-0002-0246-738X; Hirschhorn, Lisa/0000-0002-4355-7437	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010227] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Agema WRP, 2002, AM HEART J, V144, P760, DOI 10.1067/mhj.2002.125509; BATE P, 2002, 42 U BIRM; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Blumenthal D, 1998, MILBANK Q, V76, P625, DOI 10.1111/1468-0009.00108; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; DEMMING EW, 2000, OUT CRISIS; DIVINE GW, 1992, J GEN INTERN MED, V7, P623, DOI 10.1007/BF02599201; Flamm BL, 1998, BIRTH-ISS PERINAT C, V25, P117, DOI 10.1046/j.1523-536x.1998.00117.x; Holman WL, 2001, JAMA-J AM MED ASSOC, V285, P3003, DOI 10.1001/jama.285.23.3003; Horbar JD, 2001, PEDIATRICS, V107, P14, DOI 10.1542/peds.107.1.14; Kerr D, 2002, BMJ-BRIT MED J, V324, P164, DOI 10.1136/bmj.324.7330.164; Kilo C M, 1998, Qual Manag Health Care, V6, P1; Kohn KT, 2000, ERR IS HUMAN BUILDIN; LANGLEY GJ, 1997, IMPROVEMENT GUIDE PR; Leape L L, 2000, Jt Comm J Qual Improv, V26, P321; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mehta RH, 2002, JAMA-J AM MED ASSOC, V287, P1269, DOI 10.1001/jama.287.10.1269; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pronovost Peter J, 2002, Jt Comm J Qual Improv, V28, P595; Shafer MAB, 2002, JAMA-J AM MED ASSOC, V288, P2846, DOI 10.1001/jama.288.22.2846; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; SHORTELL SM, 1995, HEALTH SERV RES, V30, P377; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; Wilson Tim, 2003, Jt Comm J Qual Saf, V29, P85; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	34	135	137	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					887	896		10.7326/0003-4819-140-11-200406010-00010	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824IS	15172903				2022-12-28	WOS:000221680600005
J	Spencer, FA; Allegrone, J; Goldberg, RJ; Gore, JM; Fox, KAA; Granger, CB; Mehta, RH; Brieger, D				Spencer, FA; Allegrone, J; Goldberg, RJ; Gore, JM; Fox, KAA; Granger, CB; Mehta, RH; Brieger, D		GRACE Investigators	Association of statin therapy with outcomes of acute coronary syndromes: The GRACE Study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; NITRIC-OXIDE SYNTHASE; REDUCTASE INHIBITORS; HOSPITAL OUTCOMES; COLLAGEN CONTENT; GLOBAL REGISTRY; EVENTS GRACE; ATORVASTATIN; SIMVASTATIN; MANAGEMENT	Background: Statins administered early in patients with acute coronary syndromes may lead to modest reductions in recurrent ischemic events. Objective: To examine the association between previous and early in-hospital statin therapy and the presentation and outcomes of an acute coronary syndrome. Design: Cohort study. Setting: 94 hospitals in 14 countries participating in the Global Registry of Acute Coronary Events (GRACE). Patients: 19 537 patients with an acute coronary syndrome who were enrolled from April 1999 to September 2002. Measurements: Statin use before and after presentation with an acute coronary syndrome and associated rates of myocardial infarction, hospital complications, and hospital mortality. The composite end point included death, in-hospital myocardial infarction, and stroke. Results: Patients who were already taking statins when they presented to the hospital were less likely to have ST-segment elevation (odds ratio [OR], 0.79 [95% Cl, 0.71 to 0.88]) or myocardial infarction (OR, 0.78 [Cl, 0.70 to 0.86]). Patients who continued to take statins in the hospital were less likely to experience complications or die than patients who never received statins (OR, 0.66 [Cl, 0.56 to 0.77]). Patients not previously taking statins who began statin therapy in the hospital were less likely to die than patients who never received statin therapy (OR, 0.38 [Cl, 0.30 to 0.48]). However, adjustment for the hospital of admission attenuated the association between initiation of statin therapy and the composite end point (OR, 0.84 [Cl, 0.65 to 1.10]). Limitations: This observational study cannot exclude confounding by clinical and hospital factors. Conclusions: These data support the hypothesis that statin therapy can modulate early pathophysiologic processes in patients with acute coronary syndromes. A randomized trial of statin therapy in acute myocardial infarction is warranted.	Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA 01655 USA; Concord Hosp, Sydney, NSW, Australia; Univ Michigan, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Durham, NC USA; Royal Infirm, Edinburgh, Midlothian, Scotland	University of Massachusetts System; University of Massachusetts Worcester; Concord Repatriation General Hospital; University of Michigan System; University of Michigan; Duke University; Royal Infirmary of Edinburgh	Spencer, FA (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, 55 Lake Ave N, Worcester, MA 01655 USA.	spencerf@ummhc.org	Granger, Christopher B/D-3458-2014; Fox, keith A A/I-3742-2013	Granger, Christopher B/0000-0002-0045-3291; Fox, Keith/0000-0002-0140-2752				Agnelli G, 2001, AM HEART J, V141, P190, DOI 10.1067/mhj.2001.112404; Borzak S, 1998, AM J CARDIOL, V81, P678, DOI 10.1016/S0002-9149(97)01006-0; COL NF, 1995, ARCH INTERN MED, V155, P1386, DOI 10.1001/archinte.155.13.1386; Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fonarow GC, 2001, AM J CARDIOL, V87, P819, DOI 10.1016/S0002-9149(00)01519-8; Fox KAA, 2002, EUR HEART J, V23, P1177, DOI 10.1053/euhj.2001.3081; Fukumoto Y, 2001, CIRCULATION, V103, P993; Hayashidani S, 2002, CIRCULATION, V105, P868, DOI 10.1161/hc0702.104164; Heeschen C, 2002, CIRCULATION, V105, P1446, DOI 10.1161/01.CIR.0000012530.68333.C8; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 2001, AM J CARDIOL, V88, P1306, DOI 10.1016/S0002-9149(01)02095-1; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; PEDERSEN TR, 1994, LANCET, V344, P1383; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Spencer FA, 2002, AM J CARDIOL, V90, P1056, DOI 10.1016/S0002-9149(02)02769-8; Steg PG, 2002, AM J CARDIOL, V90, P358, DOI 10.1016/S0002-9149(02)02489-X; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; 1998, N ENGL J  MED, V339, P1349	23	154	181	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					857	866		10.7326/0003-4819-140-11-200406010-00006	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172899				2022-12-28	WOS:000221680600001
J	Brouwer, AE; Rajanuwong, A; Chierakul, W; Griffin, GE; Larsen, RA; White, NJ; Harrison, TS				Brouwer, AE; Rajanuwong, A; Chierakul, W; Griffin, GE; Larsen, RA; White, NJ; Harrison, TS			Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial	LANCET			English	Article							AMPHOTERICIN-B; FLUCONAZOLE; THAILAND	Background It frequently takes more than 2 weeks for drug treatments for cryptococcal meningitis to sterilise cerebrospinal fluid (CSF). In-vitro and animal studies lend support to the use of combinations of amphotericin B, flucytosine, and fluconazole for treatment of cryptococcosis. We compared the fungicidal activity of combinations of these drugs for initial treatment of patients with cryptococcal meningitis. Methods 64 patients with a first episode of HIV-associated cryptococcal meningitis were randomised to initial treatment with: amphotericin B (0.7 mg/kg daily); amphotericin B plus flucytosine (100 mg/kg daily); amphotericin B plus fluconazole (400 mg daily); or triple therapy with amphotericin B, flucytosine, and fluconazole. Our primary endpoint was fungicidal activity, measured by the rate of reduction in CSF cryptococcal colony-forming units (CFU) from serial quantitative CSF cultures on days 3, 7, and 14 of treatment. Findings Baseline CSF CFU counts were an important prognostic factor. Clearance of cryptococci from the CSF was exponential and was significantly faster with amphotericin B plus flucytosine than with amphotericin B alone (p=0.0006), amphotericin B plus fluconazole (p=0.02), or triple therapy (p=0.02). Interpretation At these doses, amphotericin B plus flucytosine is the most rapidly fungicidal regimen. Quantification of CSF cultures provides a powerful new means to accurately assess the fungicidal activity of new treatment regimens for cryptococcal meningitis.	St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; Mahidol Univ, Fac Trop Med, Bangkok, Thailand; Univ Med Ctr Nijmegen, Dept Internal Med & Infect Dis, Nijmegen, Netherlands; Sappasitprasong Hosp, Dept Med, Ubon Ratchathani, Thailand; Univ So Calif, Dept Med Infect Dis, Los Angeles, CA USA; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England	St Georges University London; Mahidol University; Radboud University Nijmegen; University of Southern California; University of Oxford	Harrison, TS (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.	tharriso@sghms.ac.uk	White, Nicholas J/I-4629-2012; Chierakul, Wirongrong/AAC-3226-2020; White, Nick/AAC-6527-2019	Chierakul, Wirongrong/0000-0003-2103-9425; White, Nick/0000-0002-1897-1978; Harrison, Thomas/0000-0003-3619-4348				Chariyalertsak S, 2001, CLIN INFECT DIS, V32, P955, DOI 10.1086/319348; Diamond DM, 1998, ANTIMICROB AGENTS CH, V42, P528, DOI 10.1128/AAC.42.3.528; Dorsthorst DTAT, 2002, ANTIMICROB AGENTS CH, V46, P2982, DOI 10.1128/AAC.46.9.2982-2989.2002; Imwidthaya P, 2000, POSTGRAD MED J, V76, P85, DOI 10.1136/pmj.76.892.85; Larsen RA, 2004, ANTIMICROB AGENTS CH, V48, P985, DOI 10.1128/AAC.48.3.985-991.2004; Pitisuttithum P, 2001, J INFECTION, V43, P226, DOI 10.1053/jinf.2001.0916; Robinson PA, 1999, CLIN INFECT DIS, V28, P82, DOI 10.1086/515074; vanderHorst CM, 1997, NEW ENGL J MED, V337, P15, DOI 10.1056/NEJM199707033370103	8	315	339	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1764	1767		10.1016/S0140-6736(04)16301-0	http://dx.doi.org/10.1016/S0140-6736(04)16301-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172774				2022-12-28	WOS:000221705800009
J	Mamdani, M; Juurlink, DN; Lee, DS; Rochon, PA; Kopp, A; Naglie, G; Austin, PC; Laupacis, A; Stukel, TA				Mamdani, M; Juurlink, DN; Lee, DS; Rochon, PA; Kopp, A; Naglie, G; Austin, PC; Laupacis, A; Stukel, TA			Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study	LANCET			English	Article							GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; BLOOD-PRESSURE; RISK; CYCLOOXYGENASE-2; ROFECOXIB; CELECOXIB; NAPROXEN; OSTEOARTHRITIS; NSAIDS	Background Non-selective, non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of congestive heart failure, but little is known about the cardiovascular effects of a newer group of NSAIDS called selective cyclo-oxygenase (COX)-2 inhibitors. We aimed to compare rates of admission for congestive heart failure in elderly patients who were newly dispensed COX-2 inhibitors or non-selective NSAIDs. Methods In this population-based retrospective cohort study we identified NSAID-naive individuals aged 66 years or older, who were started on rofecoxib (n=14,583), celecoxib (n=18,908), and non-selective NSAIDs (n=5,391), and randomly selected non-NSAID users as controls (n=100,000). Findings Relative to non-NSAID users, patients on rofecoxib and non-selective NSAIDS had an increased risk of admission for congestive heart failure (adjusted rate ratio 1.8, 95% Cl 1.5-2.2, and 1.4, 1.0-1.9, respectively), but not celecoxib (1.0, 0.8-1.3). Compared with celecoxib users, admission was significantly more likely in users of nonselective NSAIDs (1.4, 1.0-1.9) and rofecoxib (1.8, 1.4-2.4). Risk of admission for rofecoxib users was higher than that for non-selective NSAID users (1.5, 1.1-2.1). Of patients with no admission in the past 3 years, only rofecoxib users were at increased risk of subsequent admission relative to controls (1.8, 1.4-2.3). Interpretation These findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to nonNSAID controls.	Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, Fac Pharm, Toronto, ON, Canada; Univ Toronto, Fac Med, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada; Univ Hlth Network, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University Toronto Affiliates; Baycrest	Mamdani, M (corresponding author), Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada.	muhammad.mamdani@ices.on.ca	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151; Austin, Peter/0000-0003-3337-233X; Lee, Douglas/0000-0001-7078-745X; Stukel, Therese/0000-0002-2951-1360; Naglie, Gary/0000-0002-6274-0894				Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Feenstra J, 2002, ARCH INTERN MED, V162, P265, DOI 10.1001/archinte.162.3.265; Feldman DE, 2001, CAN MED ASSOC J, V165, P1033; Frishman WH, 2002, AM J CARDIOL, V89, p18D; Geba GP, 2002, JAMA-J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64; Heerdink ER, 1998, ARCH INTERN MED, V158, P1108, DOI 10.1001/archinte.158.10.1108; *IMS HLTH CAN, NEW ARTHR MED ACH FA; Jong P, 2003, CIRCULATION, V108, P184, DOI 10.1161/01.CIR.0000080290.39027.48; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Mamdani M, 2002, BRIT MED J, V325, P624, DOI 10.1136/bmj.325.7365.624; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Rodriguez LAG, 2003, EPIDEMIOLOGY, V14, P240; Rossat J, 1999, CLIN PHARMACOL THER, V66, P76, DOI 10.1016/S0009-9236(99)70056-1; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schwartz JI, 2002, CLIN PHARMACOL THER, V72, P50, DOI 10.1067/mcp.2002.126182; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; TOWNEND JN, 1995, BRIT HEART J, V73, P434; *VIOXX ROF, 2003, US PROD INF; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9; Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391-200103000-00003; 2001, FDA ARTHR ADV COMM M	26	325	340	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1751	1756		10.1016/S0140-6736(04)16299-5	http://dx.doi.org/10.1016/S0140-6736(04)16299-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172772				2022-12-28	WOS:000221705800007
J	Lopriore, E; van Burk, GF; Walther, FJ; de Beaufort, AJ				Lopriore, E; van Burk, GF; Walther, FJ; de Beaufort, AJ			Correct use of the Apgar score for resuscitated and intubated newborn babies: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									Leiden Univ, Med Ctr, Dept Paediat, Div Neonatol, NL-2300 RC Leiden, Netherlands; Juliana Childrens Hosp, Dept Paediat, Div Neonatol, The Hague, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Lopriore, E (corresponding author), Leiden Univ, Med Ctr, Dept Paediat, Div Neonatol, POB 9600, NL-2300 RC Leiden, Netherlands.	e.lopriore@lumc.nl	Lopriore, Enrico/ABE-3576-2021	Lopriore, Enrico/0000-0002-3513-5066; Walther, Frans/0000-0003-1931-159X; de Beaufort, Arnout Jan/0000-0003-1990-2672				APGAR V, 1966, PEDIATR CLIN N AM, V13, P645; APGAR V, 1958, JAMA-J AM MED ASSOC, V168, P1985, DOI 10.1001/jama.1958.03000150027007; APGAR V, 1953, ANESTH ANALG CLEVE, V32, P260, DOI DOI 10.1213/00000539-195301000-00041; CLARK DA, 1998, J PERINATOL, V8, P203	4	29	29	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					143	144		10.1136/bmj.38117.665197.F7	http://dx.doi.org/10.1136/bmj.38117.665197.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15208208	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222832300019
J	Liao, EH; Hung, W; Abrams, B; Zhen, M				Liao, EH; Hung, W; Abrams, B; Zhen, M			An SCF-like ubiquitin ligase complex that controls presynaptic differentiation	NATURE			English	Article							RECEPTOR TYROSINE KINASE; C-ELEGANS; SYNAPTIC GROWTH; CAENORHABDITIS-ELEGANS; PROTEIN; DROSOPHILA; ALK; SYNAPTOGENESIS; DEGRADATION; GENE	During synapse formation, specialized subcellular structures develop at synaptic junctions in a tightly regulated fashion. Cross-signalling initiated by ephrins, Wnts and transforming growth factor-beta family members between presynaptic and postsynaptic termini are proposed to govern synapse formation(1-3). It is not well understood how multiple signals are integrated and regulated by developing synaptic termini to control synaptic differentiation. Here we report the identification of FSN-1, a novel F-box protein that is required in presynaptic neurons for the restriction and/or maturation of synapses in Caenorhabditis elegans. Many F-box proteins are target recognition subunits of SCF (Skp, Cullin, F-box) ubiquitin-ligase complexes(4-7). fsn-1 functions in the same pathway as rpm-1, a gene encoding a large protein with RING finger domains(8,9). FSN-1 physically associates with RPM-1 and the C. elegans homologues of SKP1 and Cullin to form a new type of SCF complex at presynaptic periactive zones. We provide evidence that T10H9.2, which encodes the C. elegans receptor tyrosine kinase ALK ( anaplastic lymphoma kinase(10)), may be a target or a downstream effector through which FSN-1 stabilizes synapse formation. This neuron-specific, SCF-like complex therefore provides a localized signal to attenuate presynaptic differentiation.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med Genet & Microbiol, Toronto, ON M5G 1X5, Canada; Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Santa Cruz	Zhen, M (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med Genet & Microbiol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	zhen@mshri.on.ca	Zhen, Mei/A-4967-2012	Zhen, Mei/0000-0003-0086-9622; Liao, Edward/0000-0002-4955-6881; Abrams, Benjamin/0000-0002-8164-2675; Hung, Wesley/0000-0001-8488-7638				Broadie KS, 2002, CURR OPIN NEUROBIOL, V12, P491, DOI 10.1016/S0959-4388(02)00359-8; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jin YS, 2002, CURR OPIN NEUROBIOL, V12, P71, DOI 10.1016/S0959-4388(02)00292-1; Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; McCabe BD, 2004, NEURON, V41, P891, DOI 10.1016/S0896-6273(04)00073-X; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nonet ML, 1999, J NEUROSCI METH, V89, P33, DOI 10.1016/S0165-0270(99)00031-X; Packard M, 2003, NAT REV NEUROSCI, V4, P113, DOI 10.1038/nrn1036; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schaefer AM, 2000, NEURON, V26, P345, DOI 10.1016/S0896-6273(00)81168-X; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sone M, 2000, DEVELOPMENT, V127, P4157; Speese SD, 2003, CURR BIOL, V13, P899, DOI 10.1016/S0960-9822(03)00338-5; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Yamanaka A, 2002, CURR BIOL, V12, P267, DOI 10.1016/S0960-9822(02)00657-7; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	30	172	190	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	2004	430	6997					345	350		10.1038/nature02647	http://dx.doi.org/10.1038/nature02647			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15208641				2022-12-28	WOS:000222631200040
J	de Bruin, RAM; McDonald, WH; Kalashnikova, TI; Yates, J; Wittenberg, C				de Bruin, RAM; McDonald, WH; Kalashnikova, TI; Yates, J; Wittenberg, C			Cln3 activates G1-specific transcription via phosphorylation of the SBF transcription bound repressor Whi5	CELL			English	Article							G(1) CYCLIN CLN3; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEXES; SYSTEMATIC IDENTIFICATION; YEAST; GENE; SWI4; SIZE; G1	G1-specific transcriptional activation by Cln3/CDK initiates the budding yeast cell cycle. To identify targets of Cln3/CDK, we analyzed the SBF and MBF transcription factor complexes by multidimensional protein interaction technology [MudPIT). Whi5 was identified as a stably bound component of SBF but not MBF. Inactivation of Whi5 leads to premature expression of G1-specific genes and budding, whereas overexpression retards those processes. Whi5 inactivation bypasses the requirement for Cln3 both for transcriptional activation and cell cycle initiation. Whi5 associates with G1-specific promoters via SBF during early G1 phase, then dissociates coincident with transcriptional activation. Dissociation of Whi5 is promoted by Cln3 in vivo. Cln/CDK phosphorylation of Whi5 in vitro promotes its dissociation from SBF complexes. Mutation of putative CDK phosphorylation sites, at least five of which are phosphorylated in vivo, strongly reduces SBF-dependent transcription and delays cell cycle initiation. Like mammalian Rb, Whi5 is a G1-specific transcriptional repressor antagonized by CDK.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wittenberg, C (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	curtw@scripps.edu	McDonald, W. Hayes/B-4109-2016	McDonald, W. Hayes/0000-0002-3510-426X	NIGMS NIH HHS [GM59941] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Breeden LL, 2003, CURR BIOL, V13, pR31, DOI 10.1016/S0960-9822(02)01386-6; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EPSTEIN CB, 1994, MOL CELL BIOL, V14, P2041, DOI 10.1128/MCB.14.3.2041; Flick K, 1998, MOL CELL BIOL, V18, P2492, DOI 10.1128/MCB.18.5.2492; Flick KM, 2003, MOL BIOL CELL, V14, P3230, DOI 10.1091/mbc.E03-03-0135; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gavin AC, 2003, CURR OPIN CHEM BIOL, V7, P21, DOI 10.1016/S1367-5931(02)00007-8; Harrington LA, 1996, NUCLEIC ACIDS RES, V24, P558, DOI 10.1093/nar/24.4.558; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kesti T, 2004, J BIOL CHEM, V279, P14245, DOI 10.1074/jbc.M313289200; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; MARINI NJ, 1992, GENE DEV, V6, P557, DOI 10.1101/gad.6.4.557; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Partridge JF, 1997, J BIOL CHEM, V272, P9071; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Reid RJD, 2002, YEAST, V19, P319, DOI 10.1002/yea.817; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wijnen H, 2002, MOL CELL BIOL, V22, P4402, DOI 10.1128/MCB.22.12.4402-4418.2002; Wijnen H, 1999, GENETICS, V153, P1131; Wittenberg C, 2003, MOL B INT U, P14; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2	54	290	294	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					887	898		10.1016/j.cell.2004.05.025	http://dx.doi.org/10.1016/j.cell.2004.05.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210110	Bronze			2022-12-28	WOS:000222300200007
J	Shi, YG				Shi, YG			Caspase activation: Revisiting the induced proximity model	CELL			English	Review							OLIGOMERIZATION; APOPTOSIS; PROCASPASE-7; MECHANISMS; INHIBITION; SUBSTRATE	Caspases execute cell death. The mechanism of effector caspase activation primarily involves reorganization of active site loops following the activation cleavage. The Induced Proximity hypothesis, originally proposed to explain the activation of initiator caspases, has recently been reinterpreted to be proximity-driven dimerization of initiator caspases, and consequently their activation. The evidence supporting these models is critically evaluated and other possible mechanisms for initiator caspase activation are discussed.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	yshi@moibio.princeton.edu		Shi, Yigong/0000-0003-2030-168X				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355	19	255	275	3	48	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	2004	117	7					855	858		10.1016/j.cell.2004.06.007	http://dx.doi.org/10.1016/j.cell.2004.06.007			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210107	Bronze			2022-12-28	WOS:000222300200004
J	McNally, EM				McNally, EM			Powerful genes - Myostatin regulation of human muscle mass	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICE		Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.		McNally, Elizabeth/W-4909-2019	McNally, Elizabeth/0000-0002-1221-719X				Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Dickman S, 1997, SCIENCE, V277, P1922, DOI 10.1126/science.277.5334.1922; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	4	50	83	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2642	2644		10.1056/NEJMp048124	http://dx.doi.org/10.1056/NEJMp048124			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215479				2022-12-28	WOS:000222199000004
J	Sirovich, BE; Welch, HG				Sirovich, BE; Welch, HG			Cervical cancer screening among women without a cervix	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAPANICOLAOU SMEARS; UNITED-STATES; PAP-SMEAR; HYSTERECTOMY; ACCURACY; DISEASE; POPULATION	Context Most US women who have undergone hysterectomy are not at risk of cervical cancer-they underwent the procedure for benign disease and they no longer have a cervix. In 1996, the US Preventive Services Task Force recommended that routine Papanicolaou (Pap) smear screening is unnecessary for these women. Objective To determine whether Pap smear screening among women who have undergone hysterectomy has decreased following the recommendation. Design We used data from the Behavioral Risk Factor Surveillance System (1992-2002), an annual, population-based telephone survey of US adults conducted by the Centers for Disease Control and Prevention. Data about timing, type, and indication for hysterectomies were obtained from the Nationwide Inpatient Sample and other sources. Study Participants in each year of the survey, a representative sample of US women 18 years and older who had undergone hysterectomy (combined n=188390) was studied. Main Outcome Measure The main outcome was the proportion of women with a history of hysterectomy who reported a current Pap smear (within 3 years). Overall proportions are age adjusted to the 2002 US female population. Results Twenty-two million US women 18 years and older have undergone hysterectomy, representing 21% of the population. The proportion of these women who reported a current Pap smear did not change during the 10-year study period. In 1992 (before the US Preventive Services Task Force recommendations), 68.5% of women who had undergone hysterectomy reported having had a Pap smear in the past 3 years; in 2002 (6 years after the recommendation), 69.1% had had a Pap smear during the same period (P value for the comparison=.22). After accounting for Pap smears that may have preceded a recent hysterectomy and hysterectomies that spared the cervix or were performed for cervical neoplasia, we estimate that almost 10 million women, or half of all women who have undergone hysterectomy, are being screened unnecessarily. Conclusions Many US women are undergoing Pap smear screening even though they are not at risk of cervical cancer. The US Preventive Services Task Force recommendations either have not been heard or have been ignored.	Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, White River Jct, VT 05009 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA	VA Outcomes Group; Dartmouth College	Sirovich, BE (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, White River Jct, VT 05009 USA.	brenda.sirovich@dartmouth.edu						ACOG committee opinion, 1995, INT J GYNECOL OBSTET, V49, P210; *AG HEALTHC RES QU, 2003, NAT INP SAMPL NIS HE; Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; Agency for Healthcare Research and Quality, 2003, AHRQ PUBL; *AM CANC SOC, 1988, SUMM CURR GUID CANC; [Anonymous], BEH RISK FACT SURV S; Bowman JA, 1997, SOC SCI MED, V44, P969, DOI 10.1016/S0277-9536(96)00222-5; Eaker ED, 1998, OBSTET GYNECOL, V91, P551, DOI 10.1016/S0029-7844(98)00020-9; Fetters MD, 1996, JAMA-J AM MED ASSOC, V275, P940, DOI 10.1001/jama.275.12.940; Gimbel H, 2001, ACTA OBSTET GYN SCAN, V80, P267, DOI 10.1034/j.1600-0412.2001.080003267.x; HCUP Cost to Charge Ratio Files (CCR), 2000, HEALTHC COST UT PROJ; Keshavarz Homa, 2002, Morbidity and Mortality Weekly Report, V51, P1; McGovern PG, 1998, AM J PREV MED, V14, P201, DOI 10.1016/S0749-3797(97)00076-7; National Center for Health Statistics, 2000, DAT FIL DOC NAT HLTH; Newell SA, 1999, AM J PREV MED, V17, P211, DOI 10.1016/S0749-3797(99)00069-0; Pearce KF, 1996, NEW ENGL J MED, V335, P1559, DOI 10.1056/NEJM199611213352103; Saraiya M, 2001, OBSTET GYNECOL, V98, P269, DOI 10.1016/S0029-7844(01)01447-8; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Schwartz LM, 2004, JAMA-J AM MED ASSOC, V291, P71, DOI 10.1001/jama.291.1.71; *US DEP HHS, 2003, 2002 BEH RISK FACT S; *US DEP HHS, 2001, 2000 BEH RISK FACT S; *US DEP HHS, 1999, 1998 BEH RISK FACT S; *US DEP HHS, 1995, 1994 BEH RISK FACT S; *US DEP HHS, 2000, 1999 BEH RISK FACT S; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P105; *US PREV SERV TASK, 1989, GUID CLIN PREV SERV, P57	26	62	64	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2990	2993		10.1001/jama.291.24.2990	http://dx.doi.org/10.1001/jama.291.24.2990			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213211	Bronze			2022-12-28	WOS:000222184600029
J	Lim, MM; Wang, ZX; Olazabal, DE; Ren, XH; Terwilliger, EF; Young, LJ				Lim, MM; Wang, ZX; Olazabal, DE; Ren, XH; Terwilliger, EF; Young, LJ			Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene	NATURE			English	Article							VOLES MICROTUS-OCHROGASTER; MONOGAMOUS PRAIRIE VOLE; PAIR-BOND FORMATION; VASOPRESSIN RECEPTOR; PATERNAL BEHAVIOR; SOCIAL-BEHAVIOR; NUCLEUS-ACCUMBENS; V-1A RECEPTOR; DOPAMINE; PENNSYLVANICUS	The molecular mechanisms underlying the evolution of complex behaviour are poorly understood. The mammalian genus Microtus provides an excellent model for investigating the evolution of social behaviour. Prairie voles (Microtus ochrogaster) exhibit a monogamous social structure in nature, whereas closely related meadow voles (Microtus pennsylvanicus) are solitary and polygamous(1). In male prairie voles, both vasopressin and dopamine act in the ventral forebrain to regulate selective affiliation between adult mates, known as pair bond formation, as assessed by partner preference in the laboratory(2-4). The vasopressin V1a receptor (V1aR) is expressed at higher levels in the ventral forebrain of monogamous than in promiscuous vole species(5), whereas dopamine receptor distribution is relatively conserved between species. Here we substantially increase partner preference formation in the socially promiscuous meadow vole by using viral vector V1aR gene transfer into the ventral forebrain. We show that a change in the expression of a single gene in the larger context of pre-existing genetic and neural circuits can profoundly alter social behaviour, providing a potential molecular mechanism for the rapid evolution of complex social behaviour.	Emory Univ, Ctr Behav Neurosci, Atlanta, GA 30322 USA; Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA; Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA; Harvard Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Emory University; Emory University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Young, LJ (corresponding author), Emory Univ, Ctr Behav Neurosci, Atlanta, GA 30322 USA.	lyoun03@emory.edu	Young, Larry/HGE-5031-2022					Aragona BJ, 2003, J NEUROSCI, V23, P3483, DOI 10.1523/jneurosci.23-08-03483.2003; Aragona BJ, 2003, HORM BEHAV, V44, P37; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; Bester-Meredith JK, 1999, HORM BEHAV, V36, P25, DOI 10.1006/hbeh.1999.1522; Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360; Gingrich B, 2000, BEHAV NEUROSCI, V114, P173, DOI 10.1037/0735-7044.114.1.173; GRUDERADAMS S, 1985, J MAMMAL, V66, P165, DOI 10.2307/1380976; Hammock EAD, 2002, EUR J NEUROSCI, V16, P399, DOI 10.1046/j.1460-9568.2002.02083.x; HAMMOCK EAD, IN PRESS MOL BIOL EV; INSEL TR, 1994, J NEUROSCI, V14, P5381; Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125; KLEIMAN DG, 1977, Q REV BIOL, V52, P39, DOI 10.1086/409721; Landgraf R, 2003, EUR J NEUROSCI, V18, P403, DOI 10.1046/j.1460-9568.2003.02750.x; Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008; Lim MM, 2004, J COMP NEUROL, V468, P555, DOI 10.1002/cne.10973; Parker KJ, 2001, ANIM BEHAV, V61, P1217, DOI 10.1006/anbe.2000.1707; Phelps SM, 2003, J COMP NEUROL, V466, P564, DOI 10.1002/cne.10902; Pitkow LJ, 2001, J NEUROSCI, V21, P7392, DOI 10.1523/JNEUROSCI.21-18-07392.2001; Roberts RL, 1998, ANIM BEHAV, V55, P1131, DOI 10.1006/anbe.1997.0659; Robinson GE, 2002, GENES BRAIN BEHAV, V1, P197, DOI 10.1034/j.1601-183X.2002.10401.x; Wang ZX, 1999, BEHAV NEUROSCI, V113, P602, DOI 10.1037/0735-7044.113.3.602; Wang ZX, 1997, BRAIN RES, V768, P147, DOI 10.1016/S0006-8993(97)00636-7; WANG ZX, 1994, P NATL ACAD SCI USA, V91, P400, DOI 10.1073/pnas.91.1.400; WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475; Young LJ, 1999, J NEUROENDOCRINOL, V11, P291; Young LJ, 1997, BEHAV NEUROSCI, V111, P599, DOI 10.1037/0735-7044.111.3.599; Young LJ, 1999, HORM BEHAV, V36, P212, DOI 10.1006/hbeh.1999.1548	28	426	436	2	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					754	757		10.1038/nature02539	http://dx.doi.org/10.1038/nature02539			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201909				2022-12-28	WOS:000222059900037
J	Rauramaa, R; Halonen, P; Vaisanen, SB; Lakka, TA; Schmidt-Trucksass, A; Berg, A; Penttila, IM; Rankinen, T; Bouchard, C				Rauramaa, R; Halonen, P; Vaisanen, SB; Lakka, TA; Schmidt-Trucksass, A; Berg, A; Penttila, IM; Rankinen, T; Bouchard, C			Effects of aerobic physical exercise on inflammation and atherosclerosis in men: The DNASCO study - A six-year randomized controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR-DISEASE; CAROTID ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; MEDIA THICKNESS; RISK-FACTORS; ALL-CAUSE; MORTALITY	Background: Although regular physical activity is recommended for prevention of cardiovascular diseases, no data are available on its antiatherosclerotic effects in the general population. Objective: To determine whether progressive aerobic exercise compared with usual activity slows progression of atherosclerosis in men. Design: A 6-year randomized, controlled trial. Setting: Eastern Finland. Participants: 140 middle-aged men randomly selected from the population registry. Intervention: Low- to moderate-intensity aerobic exercise. Measurements: Atherosclerosis was quantitated ultrasonographically as the mean intima-media thickness in the carotid artery at baseline and at years 2 through 6. Results: On the basis of intention-to-treat analyses, a 19.5% net increase (P < 0.001) in ventilatory aerobic threshold was evident in the exercise group after 6 years. High-sensitivity C-reactive protein levels were statistically nonsignificantly lower in the exercise group than in the control group (P > 0.2). The progression of intima-media thickness in the carotid artery did not differ between the study groups (P > 0.2). A subgroup analysis that excluded men taking statins showed that the 6-year progression of intima-media thickness, adjusted for smoking and annual measures of low-density lipoprotein cholesterol level, systolic blood pressure, and waist circumference, was 40% less in the exercise group (0.12 mm [95% CI, -0.010 to 0.26 mm]) than in the control group (0.20 mm [CI, 0.05 to 0.35 mm]). Limitations: only middle-aged white men were included. The intervention included mainly aerobic exercises. Conclusions: Aerobic physical exercise did not attenuate progression of atherosclerosis, except in a subgroup of men not taking statins.	Kuopio Res Inst Exercise Med, FIN-70100 Kuopio, Finland		Rauramaa, R (corresponding author), Kuopio Res Inst Exercise Med, Haapaniementie 16, FIN-70100 Kuopio, Finland.	rainer.rauramaa@uku.fi	Rankinen, Tuomo/N-1984-2017; Bouchard, Claude/AAE-2035-2019; Schmidt-Trucksäss, Arno/I-7673-2015; Bouchard, Claude/A-7637-2009	Schmidt-Trucksäss, Arno/0000-0002-4662-3911; Bouchard, Claude/0000-0002-0048-491X; Berg, Aloys/0000-0002-6794-9494; Lakka, Timo/0000-0002-9199-2871				Balk EM, 2003, ANN INTERN MED, V139, P670, DOI 10.7326/0003-4819-139-8-200310210-00011; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Cheng DC, 2002, COMPUT METH PROG BIO, V67, P27, DOI 10.1016/S0169-2607(00)00149-8; Crowder M.J., 1990, ANAL REPEATED MEASUR; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Erikssen G, 1998, LANCET, V352, P759, DOI 10.1016/S0140-6736(98)02268-5; Friedman L, 1985, FUNDAMENTALS CLIN TR, P83; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Hambrecht R, 2000, NEW ENGL J MED, V342, P454, DOI 10.1056/NEJM200002173420702; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; Lakka TA, 2001, ANN INTERN MED, V134, P12, DOI 10.7326/0003-4819-134-1-200101020-00008; Laukkanen JA, 2001, ARCH INTERN MED, V161, P825, DOI 10.1001/archinte.161.6.825; Lee CD, 1999, AM J CLIN NUTR, V69, P373; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Rastas M., 1990, NUTR COMPOSITION FOO, V3; RAURAMAA R, 1995, ATHEROSCLEROSIS, V112, P213, DOI 10.1016/0021-9150(94)05416-G; RAURAMAA R, 1994, EUR HEART J, V15, P1020, DOI 10.1093/oxfordjournals.eurheartj.a060623; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Schimert J, 2001, ANAL DATA MISSING VA; SHAPER AG, 1991, BRIT HEART J, V66, P384; Smith JK, 1999, JAMA-J AM MED ASSOC, V281, P1722, DOI 10.1001/jama.281.18.1722; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU	34	107	111	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					1007	1014		10.7326/0003-4819-140-12-200406150-00010	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197018				2022-12-28	WOS:000222055500004
J	Parmar, MS				Parmar, MS			Kidney stones	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RISK-FACTORS; MEDICAL-MANAGEMENT; URETERAL CALCULI; URINARY OXALATE; UNITED-STATES; NEPHROLITHIASIS; UROLITHIASIS; HISTORY; PREVALENCE; EXCRETION		Timmins & Dist Hosp, Med Program Internal Med, Timmins, ON P4N 8R1, Canada		Parmar, MS (corresponding author), Suite 108,707 Ross Ave E, Timmins, ON P4N 8R1, Canada.	atbeat@ntl.sympatico.ca	Parmar, Malvinder S/Q-1532-2019	Parmar, Malvinder S/0000-0003-3182-0530				Asplin J.R., 1996, BRENNER RECTORS KIDN, V5th ed., P1893; Assimos DG, 1999, J ENDOUROL, V13, P665, DOI 10.1089/end.1999.13.665; Auge BK, 2002, ENDOCRIN METAB CLIN, V31, P1065, DOI 10.1016/S0889-8529(02)00033-6; Baldwin DN, 2003, J PAEDIATR CHILD H, V39, P381, DOI 10.1046/j.1440-1754.2003.00159.x; Baxmann AC, 2003, KIDNEY INT, V63, P1066, DOI 10.1046/j.1523-1755.2003.00815.x; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; Cappuccio FP, 1999, J HYPERTENS, V17, P1017, DOI 10.1097/00004872-199917070-00019; Chandhoke PS, 2002, J UROLOGY, V168, P937, DOI 10.1016/S0022-5347(05)64546-6; Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x; Cooper JT, 2000, UROLOGY, V56, P575, DOI 10.1016/S0090-4295(00)00658-0; Curhan GC, 1997, J AM SOC NEPHROL, V8, P1568; Delvecchio FC, 2003, CURR OPIN UROL, V13, P229, DOI 10.1097/00042307-200305000-00011; Dey J, 2002, J UROLOGY, V167, P169, DOI 10.1016/S0022-5347(05)65405-5; Duncan SH, 2002, APPL ENVIRON MICROB, V68, P3841, DOI 10.1128/AEM.68.8.3841-3847.2002; Eskelinen M, 1998, EUR UROL, V34, P467, DOI 10.1159/000019785; GLOWACKI LS, 1992, J UROLOGY, V147, P319, DOI 10.1016/S0022-5347(17)37225-7; Goldfarb DS, 2001, J UROLOGY, V166, P263, DOI 10.1016/S0022-5347(05)66142-3; Grentz L., 2002, Topics in Clinical Nutrition, V17, P60; Hall WD, 2001, AM J MED SCI, V322, P12, DOI 10.1097/00000441-200107000-00003; Hoffman N, 2003, UROLOGY, V61, DOI 10.1016/S0090-4295(02)02593-1; Holmes RP, 2001, KIDNEY INT, V59, P270, DOI 10.1046/j.1523-1755.2001.00488.x; Kober A, 2003, J UROLOGY, V170, P741, DOI 10.1097/01.ju.0000080570.83834.ad; Kramer HJ, 2003, KIDNEY INT, V64, P1022, DOI 10.1046/j.1523-1755.2003.t01-2-00171.x; Kramer HJM, 2003, J AM SOC NEPHROL, V14, P1272, DOI 10.1097/01.ASN.0000060682.25472.C3; Kubota M, 2000, BRAIN DEV-JPN, V22, P230, DOI 10.1016/S0387-7604(00)00118-2; Lopes T, 2001, BJU INT, V87, P322, DOI 10.1046/j.1464-410x.2001.00068.x; McHarg T, 2003, BJU INT, V92, P765, DOI 10.1046/j.1464-410X.2003.04472.x; Mollerup CL, 2002, BMJ-BRIT MED J, V325, P807, DOI 10.1136/bmj.325.7368.807; Parks JH, 2003, J UROLOGY, V170, P384, DOI 10.1097/01.ju.0000071721.91229.27; Parks JH, 2003, J UROLOGY, V169, P863, DOI 10.1097/01.ju.0000044922.22478.32; Sakhaee K, 2002, KIDNEY INT, V62, P971, DOI 10.1046/j.1523-1755.2002.00508.x; Saltel E, 2000, J UROLOGY, V164, P1895, DOI 10.1016/S0022-5347(05)66911-X; Schaller J L, 2001, MedGenMed, V3, P24; Segura JW, 1997, J UROLOGY, V158, P1915, DOI 10.1016/S0022-5347(01)64173-9; Sidhu H, 2001, J UROLOGY, V166, P1487, DOI 10.1016/S0022-5347(05)65817-X; Sofer M, 2002, J UROLOGY, V167, P31, DOI 10.1016/S0022-5347(05)65376-1; Sparagana SP, 2001, EPILEPSIA, V42, P682, DOI 10.1046/j.1528-1157.2001.32500.x; Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x; Yagisawa T, 2001, J UROLOGY, V166, P1078, DOI 10.1016/S0022-5347(05)65925-3	39	145	153	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1420	1424		10.1136/bmj.328.7453.1420	http://dx.doi.org/10.1136/bmj.328.7453.1420			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15191979	Green Published			2022-12-28	WOS:000222114400025
J	Lee, H; Habas, R; Abate-Shen, C				Lee, H; Habas, R; Abate-Shen, C			Msx1 cooperates with histone H1b for inhibition of transcription and myogenesis	SCIENCE			English	Article							IN-VIVO; DLX HOMEOPROTEINS; LINKER HISTONES; GENE; EXPRESSION; MYOD; DIFFERENTIATION; ORGANIZATION; INVOLVEMENT; HOMEODOMAIN	During embryogenesis, differentiation of skeletal muscle is regulated by transcription factors that include members of the Msx homeoprotein family. By investigating Msx1 function in repression of myogenic gene expression, we identified a physical interaction between Msx1 and H1b, a specific isoform of mouse histone H1. We found that Msx1 and H1b bind to a key regulatory element of MyoD, a central regulator of skeletal muscle differentiation, where they induce repressed chromatin. Moreover, Msx1 and H1b cooperate to inhibit muscle differentiation in cell culture and in Xenopus animal caps. Our findings define a previously unknown function for "linker" histones in gene-specific transcriptional regulation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Abate-Shen, C (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.	abate@cabm.rutgers.edu	Abate-Shen, Cory/O-2520-2014	Abate-Shen, Cory/0000-0002-5021-0570	NICHD NIH HHS [HD29446] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029446] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bendall AJ, 1999, DEVELOPMENT, V126, P4965; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Downs JA, 2003, MOL CELL, V11, P1685, DOI 10.1016/S1097-2765(03)00197-7; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Houzelstein D, 1999, DEVELOPMENT, V126, P2689; Hu GZ, 2001, DEVELOPMENT, V128, P2373; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Kucharczuk KL, 1999, DEVELOPMENT, V126, P1957; LEE HM, UNPUB; LENNOX RW, 1988, BIOCHEM CELL BIOL, V66, P636, DOI 10.1139/o88-073; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; ZLATANOVA J, 1992, J CELL SCI, V103, P889	25	188	205	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1675	1678		10.1126/science.1098096	http://dx.doi.org/10.1126/science.1098096			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192231				2022-12-28	WOS:000221934300052
J	Rak, A; Pylypenko, O; Niculae, A; Pyatkov, K; Goody, RS; Alexandrov, K				Rak, A; Pylypenko, O; Niculae, A; Pyatkov, K; Goody, RS; Alexandrov, K			Structure of the Rab7 : REP-1 complex: Insights into the mechanism of rab prenylation and choroideremia disease	CELL			English	Article							GERANYLGERANYLTRANSFERASE TYPE-II; GDP-DISSOCIATION INHIBITOR; ESCORT PROTEIN; SMALL GTPASES; IN-VITRO; BINDING; SUPERFAMILY; TRANSFERASE; EXPRESSION; FAMILY	Members of the RabGDI/REP family serve as multifunctional regulators of the Rab family of GTP binding proteins. Mutations in members of this family, such as REP-1, lead to abnormalities, including progressive retinal degradation (choroideremia) in humans. The crystal structures of the REP-1 protein in complex with monoprenylated or C-terminally truncated Rab7 proteins revealed that Rab7 interacts with the Rab binding platform of REP-1 via an extended interface involving the Switch 1 and 2 regions. The C terminus of the REP-1 molecule functions as a mobile lid covering a conserved hydrophobic patch on the surface of REP-1 that in the complex coordinates the C terminus of Rab proteins. Using semisynthetic fluorescent Rab27A, we demonstrate that although Rab27A can be prenylated by REP-2, this reaction can be effectively inhibited by other Rab proteins, providing a possible explanation for the accumulation of unprenylated Rab27A in choroideremia.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA	Max Planck Society; California Institute of Technology	Alexandrov, K (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	kirill.alexandrov@mpi-dortmund.mpg.de	Goody, Roger S/J-8845-2014; Alexandrov, Kirill/A-5830-2013	Goody, Roger S/0000-0002-0772-0444; Alexandrov, Kirill/0000-0002-0957-6511; Pylypenko, Olena/0000-0001-7073-5238				Alexandrov K, 1999, EUR J BIOCHEM, V265, P160, DOI 10.1046/j.1432-1327.1999.00699.x; Alexandrov K, 2001, METHOD ENZYMOL, V329, P14; Alory C, 2001, TRAFFIC, V2, P532, DOI 10.1034/j.1600-0854.2001.20803.x; Alory C, 2000, J CELL BIOL, V150, P89, DOI 10.1083/jcb.150.1.89; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Iakovenko A, 2000, FEBS LETT, V468, P155, DOI 10.1016/S0014-5793(00)01143-1; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kalinin A, 2001, PROTEIN EXPRES PURIF, V22, P84, DOI 10.1006/prep.2001.1423; Larijani B, 2003, J BIOL CHEM, V278, P46798, DOI 10.1074/jbc.M307799200; Miaczynska M, 1997, J BIOL CHEM, V272, P16972, DOI 10.1074/jbc.272.27.16972; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pylypenko O, 2003, MOL CELL, V11, P483, DOI 10.1016/S1097-2765(03)00044-3; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; Rak A, 2003, J STRUCT BIOL, V141, P93, DOI 10.1016/S1047-8477(02)00634-2; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Seabra MC, 1996, OPHTHALMIC GENET, V17, P43, DOI 10.3109/13816819609057869; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Sidorovitch V, 2002, PROTEIN EXPRES PURIF, V26, P50, DOI 10.1016/S1046-5928(02)00506-5; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Thoma NH, 2001, BIOCHEMISTRY-US, V40, P268, DOI 10.1021/bi002034p; WILSON AL, 1993, J BIOL CHEM, V268, P14561; Wu SK, 1998, J BIOL CHEM, V273, P26931, DOI 10.1074/jbc.273.41.26931	33	125	135	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					749	760		10.1016/j.cell.2004.05.017	http://dx.doi.org/10.1016/j.cell.2004.05.017			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186776	Bronze			2022-12-28	WOS:000222048400008
J	Looareesuwan, S; Imwong, M; Wilairatana, P				Looareesuwan, S; Imwong, M; Wilairatana, P			Chlorproguanil-dapsone for malaria in Africa	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA; SELECTIVE PRESSURE; RESISTANCE; COMBINATIONS; EFFICACY		Mahidol Univ, Fac Trop Med, Dept Clin Trop Med, Bangkok 10400, Thailand	Mahidol University	Looareesuwan, S (corresponding author), Mahidol Univ, Fac Trop Med, Dept Clin Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	trns1r@mahcol.ac.th	Imwong, Mallika/ABE-6493-2020					Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0; WATKINS WM, 1988, T ROY SOC TROP MED H, V82, P398, DOI 10.1016/0035-9203(88)90133-2; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; White NJ, 2002, TRENDS PARASITOL, V18, P458, DOI 10.1016/S1471-4922(02)02373-5; Wilairatana P, 1997, ANN TROP MED PARASIT, V91, P125, DOI 10.1080/00034989761454	9	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1838	1839		10.1016/S0140-6736(04)16390-3	http://dx.doi.org/10.1016/S0140-6736(04)16390-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183616				2022-12-28	WOS:000221822300002
J	Barnea, G; O'Donnell, S; Mancia, F; Sun, X; Nemes, A; Mendelsohn, M; Axel, R				Barnea, G; O'Donnell, S; Mancia, F; Sun, X; Nemes, A; Mendelsohn, M; Axel, R			Odorant receptors on axon termini in the brain	SCIENCE			English	Article							ORGANIZATION; GENE; MAP		Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Axel, R (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, 701 W 168th St, New York, NY 10032 USA.	ra27@columbia.edu		Mancia, Filippo/0000-0003-3293-2200; Axel, Richard/0000-0002-3141-4076				BARNEA G, UNPUB; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Ishii T, 2001, GENES CELLS, V6, P71, DOI 10.1046/j.1365-2443.2001.00398.x; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9	7	140	145	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1468	1468		10.1126/science.1096146	http://dx.doi.org/10.1126/science.1096146			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178793				2022-12-28	WOS:000221795800033
J	Prewitt, K				Prewitt, K			Sociology - What if we give a census and no one comes?	SCIENCE			English	Editorial Material									Columbia Univ, New York, NY 10027 USA; US Bur Census, Washington, DC 20233 USA	Columbia University	Prewitt, K (corresponding author), Columbia Univ, New York, NY 10027 USA.							CITRO CF, 2004, 2000 CENSUS COUNTING; COHN D, 2000, WASHINGTON POST 0408; Duncan G. T., 1993, PRIVATE LIVES PUBLIC; Groves R.M., 1998, NONRESPONSE HOUSEHOL; KELLY M, 2000, WASHINGTON POST 0405; MACK A, 2001, SOCIAL RES, V68; MAYER T, 2002, RES REPORT SERIES US; NIE N, TAKING CENSUS ADVERS; PREWITT K, 2003, POLITICS SCI CENSUS, P37; ROSEN J, 2000, UNWANTED GAZE DESTRU; Singer E, 2003, PUBLIC OPIN QUART, V67, P368, DOI 10.1086/377465; *US BUR CENS, US CENS BUR PRIV PRI	12	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1452	1453		10.1126/science.1097727	http://dx.doi.org/10.1126/science.1097727			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178786				2022-12-28	WOS:000221795800026
J	Wardle, DA; Walker, LR; Bardgett, RD				Wardle, DA; Walker, LR; Bardgett, RD			Ecosystem properties and forest decline in contrasting long-term chronosequences	SCIENCE			English	Article							NITROGEN-FIXATION; ISLAND AREA; NEW-ZEALAND; PHOSPHORUS; VEGETATION; LIMITATION; DYNAMICS; DISTRICT; ALASKA; HAWAII	During succession, ecosystem development occurs; but in the long-term absence of catastrophic disturbance, a decline phase eventually follows. We studied six long-term chronosequences, in Australia, Sweden, Alaska, Hawaii, and New Zealand; for each, the decline phase was associated with a reduction in tree basal area and an increase in the substrate nitrogen-to-phosphorus ratio, indicating increasing phosphorus limitation over time. These changes were often associated with reductions in litter decomposition rates, phosphorus release from litter, and biomass and activity of decomposer microbes. Our findings suggest that the maximal biomass phase reached during succession cannot be maintained in the long-term absence of major disturbance, and that similar patterns of decline occur in forested ecosystems spanning the tropical, temperate, and boreal zones.	Swedish Univ Agr Sci, Dept Forest Vegetat Ecol, SE-90183 Umea, Sweden; Landcare Res, Lincoln, New Zealand; Univ Nevada, Dept Biol Sci, Las Vegas, NV 89154 USA; Univ Lancaster, Inst Environm & Nat Sci, Lancaster LA1 4YQ, England	Swedish University of Agricultural Sciences; Landcare Research - New Zealand; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Lancaster University	Wardle, DA (corresponding author), Swedish Univ Agr Sci, Dept Forest Vegetat Ecol, SE-90183 Umea, Sweden.	david.wardle@svek.slu.se	Wardle, David A./F-6031-2011	Wardle, David A./0000-0002-0476-7335				[Anonymous], 2001, PLANT STRATEGIES VEG; Chadwick OA, 1999, NATURE, V397, P491, DOI 10.1038/17276; CHAPIN FS, 1994, ECOL MONOGR, V64, P149, DOI 10.2307/2937039; Clements F.E., 1928, PLANT SUCCESSION IND; COLEMAN DC, 1983, ADV ECOL RES, V13, P1, DOI 10.1016/S0065-2504(08)60107-5; Crews TE, 2000, ECOSYSTEMS, V3, P386, DOI 10.1007/s100210000034; CREWS TE, 1995, ECOLOGY, V76, P1407, DOI 10.2307/1938144; DeLuca TH, 2002, NATURE, V419, P917, DOI 10.1038/nature01051; Elser JJ, 2000, ECOL LETT, V3, P540, DOI 10.1046/j.1461-0248.2000.00185.x; Jenkinson DS, 1981, SOIL BIOCH, V5, P415; MARK AF, 1988, J ROY SOC NEW ZEAL, V18, P29, DOI 10.1080/03036758.1988.10421692; NOBLE MG, 1984, BRYOLOGIST, V87, P119, DOI 10.2307/3243117; ODUM EP, 1969, SCIENCE, V164, P262, DOI 10.1126/science.164.3877.262; REDFIELD AC, 1958, AM SCI, V46, P205; Rees M, 2001, SCIENCE, V293, P650, DOI 10.1126/science.1062586; Richardson SJ, 2004, OECOLOGIA, V139, P267, DOI 10.1007/s00442-004-1501-y; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444; THOMPSON CH, 1981, NATURE, V291, P59, DOI 10.1038/291059a0; Vitousek PM, 1997, BIOGEOCHEMISTRY, V37, P63, DOI 10.1023/A:1005757218475; Walker J, 2001, ECOSYST HEALTH, V7, P7, DOI 10.1046/j.1526-0992.2001.007001007.x; Walker L.R., 2003, PRIMARY SUCCESSION E, DOI 10.1017/cbo9780511615078; WALKER LR, 1987, OIKOS, V50, P131, DOI 10.2307/3565409; WALKER TW, 1976, GEODERMA, V15, P1, DOI 10.1016/0016-7061(76)90066-5; WARD CM, 1988, J ROY SOC NEW ZEAL, V18, P1; Wardle D., 2002, COMMUNITIES ECOSYSTE; Wardle DA, 1995, SOIL BIOL BIOCHEM, V27, P1601, DOI 10.1016/0038-0717(95)00093-T; Wardle DA, 2003, SCIENCE, V300, P972, DOI 10.1126/science.1082709; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; WILLIAMSON WB, UNPUB	29	697	839	21	522	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	2004	305	5683					509	513		10.1126/science.1098778	http://dx.doi.org/10.1126/science.1098778			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840AH	15205475				2022-12-28	WOS:000222828900037
J	Ding, H; Schertzer, M; Wu, XL; Gertsenstein, M; Selig, S; Kammori, M; Pourvali, R; Poon, S; Vulto, I; Chavez, E; Tam, PPL; Nagy, A; Lansdorp, PM				Ding, H; Schertzer, M; Wu, XL; Gertsenstein, M; Selig, S; Kammori, M; Pourvali, R; Poon, S; Vulto, I; Chavez, E; Tam, PPL; Nagy, A; Lansdorp, PM			Regulation of murine telomere length by Rtel: An essential gene encoding a helicase-like protein	CELL			English	Article							HUMAN-CHROMOSOMES; MAMMALIAN TELOMERES; HUMAN FIBROBLASTS; DNA-STRUCTURE; REPLICATION; CELLS; END; YEAST; INSTABILITY; INTERACTS	Little is known about the genes that regulate telomere length diversity between mammalian species. A candidate gene locus was previously mapped to a region on distal mouse Chr 2q. Within this region, we identified a gene similar to the dog-1 DNA helicase-like gene in C. elegans. We cloned this Regulator of telomere length (Rtel) gene and inactivated its expression in mice. Rtel(-/-) mice died between days 10 and 11.5 of gestation with defects in the nervous system, heart, vasculature, and extraembryonic tissues. Rtel(-/-) embryonic stem cells showed telomere loss and displayed many chromosome breaks and fusions upon differentiation in vitro. Crosses of Rtel(+/-) mice with Mus spretus showed that Rtel from the Mus musculus parent is required for telomere elongation of M. spretus chromosomes in F1 cells. We conclude that Rtel is an essential gene that regulates telomere length and prevents genetic instability.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Sydney, Childrens Med Res Inst, Embryol Unit, Westmead, NSW 2145, Australia; Rambam Med Ctr, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 4E3, Canada	British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Children's Medical Research Institute - Australia; University of Sydney; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Toronto; University of British Columbia	Lansdorp, PM (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada.	plansdor@bccrc.ca	Nagy, Andras/G-6465-2013	Nagy, Andras/0000-0003-4311-0413; Lansdorp, Peter/0000-0001-7435-1071				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Baerlocher GM, 2003, CYTOM PART A, V55A, P1, DOI 10.1002/cyto.a.10064; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; Bai YL, 2003, HUM GENET, V113, P337, DOI 10.1007/s00439-003-0972-y; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Choe W, 2002, MOL CELL BIOL, V22, P4202, DOI 10.1128/MCB.22.12.4202-4217.2002; Dahlen M, 2003, MOL CELL BIOL, V23, P3031, DOI 10.1128/MCB.23.9.3031-3042.2003; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gertsenstein M, 2002, Methods Mol Biol, V185, P285; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2003, MOL CELL BIOL, V23, P8450, DOI 10.1128/MCB.23.23.8450-8461.2003; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; Kent OA, 2003, J BIOL CHEM, V278, P50572, DOI 10.1074/jbc.M307976200; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lustig AJ, 2003, NAT REV GENET, V4, P916, DOI 10.1038/nrg1207; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Martens UM, 2000, EXP CELL RES, V256, P291, DOI 10.1006/excr.2000.4823; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Mieczkowski PA, 2003, P NATL ACAD SCI USA, V100, P10854, DOI 10.1073/pnas.1934561100; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; Ray S, 2002, MOL CELL BIOL, V22, P5859, DOI 10.1128/MCB.22.16.5859-5868.2002; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Schmidt KH, 2002, J BIOL CHEM, V277, P45331, DOI 10.1074/jbc.M207263200; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; Schulz VP, 1996, HUM GENET, V97, P750; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Vega LR, 2003, NAT REV MOL CELL BIO, V4, P948, DOI 10.1038/nrm1256; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhu LX, 1998, P NATL ACAD SCI USA, V95, P8648, DOI 10.1073/pnas.95.15.8648; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	54	254	260	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					873	886		10.1016/j.cell.2004.05.026	http://dx.doi.org/10.1016/j.cell.2004.05.026			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210109	Bronze			2022-12-28	WOS:000222300200006
J	Wong, L; Rehm, J				Wong, L; Rehm, J			Radiation injury from a fluoroscopic procedure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Tennessee, Coll Med, Chattanooga, TN 37403 USA	University of Tennessee System; University of Tennessee Health Science Center	Wong, L (corresponding author), Univ Tennessee, Coll Med, Chattanooga, TN 37403 USA.								0	30	30	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					E23	E23		10.1056/NEJMicm030503	http://dx.doi.org/10.1056/NEJMicm030503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201428				2022-12-28	WOS:000222054700012
J	Fox, CS; Parise, H; D'Agostino, RB; Lloyd-Jones, DM; Vasan, RS; Wang, TJ; Levy, D; Wolf, PA; Benjamin, EJ				Fox, CS; Parise, H; D'Agostino, RB; Lloyd-Jones, DM; Vasan, RS; Wang, TJ; Levy, D; Wolf, PA; Benjamin, EJ			Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; FRAMINGHAM; ARRHYTHMIAS; PREVALENCE; IMPACT; ADULTS; STROKE; LOCUS	Context Atrial fibrillation (AF) is the most common cardiac dysrhythmia in the United States. Whereas rare cases of familial AF have been reported, it is unknown if AF among unselected individuals is a heritable condition. Objective To determine whether parental AF increases the risk for the development of offspring AF. Design, Setting, and Participants Prospective cohort study (1983-2002) within the Framingham Heart Study, a population-based epidemiologic study. Participants were 2243 offspring (1165 women, 1078 men) at least 30 years of age and free of AF whose parents had both been evaluated in the original cohort. Main Outcome Measures Development of new-onset AF in the offspring was prospectively examined in association with previously documented parental AF. Results Among 2243 offspring participants, 681 (30%) had at least 1 parent with documented AF; 70 offspring participants (23 women; mean age, 62 [range, 40-81] years) developed AF in follow-up. Compared with no parental AF, AF in at least 1 parent increased the risk of offspring AF (multivariable-adjusted odds ratio [OR], 1.85; 95% confidence interval [Cl], 1.12-3.06; P=.02). These results were stronger when age was limited to younger than 75 years in both parents and offspring (multivariable-adjusted OR, 3.23; 95% Cl, 1.87-5.58; P<.001) and when the sample was further limited to those without antecedent myocardial infarction, heart failure, or valve disease (multivariable-adjusted OR, 3.17; 95% Cl, 1.71-5.86; P<.001). Conclusions Parental AF increases the future risk for offspring AF, an observation supporting a genetic susceptibility to developing this dysrhythmia. Further research into the genetic factors predisposing to AF is warranted.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Boston Univ, Dept Math, Boston, MA 02215 USA; Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Prevent Med Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Boston University; Harvard University; Massachusetts General Hospital; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Fox, CS (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	foxca@nhlbi.nih.gov	Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Lloyd-Jones, Donald M/C-5899-2009; Benjamin, Emelia/E-7103-2011	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Wolf, Philip/0000-0002-3628-301X; Lloyd-Jones, Donald/0000-0003-0847-6110; Parise, Helen/0000-0001-7761-4973	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL074077, K23HL004253, K24HL004334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-25195, K24-HL-04334, K23-HL-074077-01, K23-HL-04253] Funding Source: Medline; NINDS NIH HHS [5R01-NS-17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 2000, SAS STAT US GUID VER; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Broeckel U, 2002, NAT GENET, V30, P210, DOI 10.1038/ng827; Brugada R, 1997, NEW ENGL J MED, V336, P905, DOI 10.1056/NEJM199703273361302; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760; Conway DSG, 2003, STROKE, V34, P413, DOI 10.1161/01.STR.0000051728.85133.32; CUPPLES LA, 1987, NIH PUBLICATION; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Darbar D, 2003, J AM COLL CARDIOL, V41, P2185, DOI 10.1016/S0735-1097(03)00465-0; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Ehm MG, 2000, AM J HUM GENET, V66, P1871, DOI 10.1086/302950; Ellinor PT, 2003, CIRCULATION, V107, P2880, DOI 10.1161/01.CIR.0000077910.80718.49; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; HANSEN BC, 1995, DIABETES CARE, V18, pA2; Heath AC, 2001, BRIT J PSYCHIAT, V178, pS33, DOI 10.1192/bjp.178.40.s33; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; Lai LP, 2002, AM HEART J, V144, P485, DOI 10.1067/mhj.2002.123573; Levy D, 2000, HYPERTENSION, V36, P477, DOI 10.1161/01.HYP.36.4.477; Olgin JE, 2002, CARDIOVASC RES, V54, P280, DOI 10.1016/S0008-6363(02)00225-0; Psaty BM, 1997, CIRCULATION, V96, P2455; SHURTLEFF D, 1973, DHEW PUBLICATION; Stewart S, 2002, AM J MED, V113, P359, DOI 10.1016/S0002-9343(02)01236-6; Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; Wolf PA, 1998, ARCH INTERN MED, V158, P229, DOI 10.1001/archinte.158.3.229	28	448	458	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2851	2855		10.1001/jama.291.23.2851	http://dx.doi.org/10.1001/jama.291.23.2851			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199036	Bronze			2022-12-28	WOS:000221962500031
J	Grabowski, DC; Campbell, CM; Morrisey, MA				Grabowski, DC; Campbell, CM; Morrisey, MA			Elderly licensure laws and motor vehicle fatalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER DRIVERS; RENEWAL POLICIES; VISION; IMPAIRMENT; CRASHES; ADULTS; AGE	Context Little is known about how state-level driver licensure laws, such as in-person renewal, vision tests, road tests, and the frequency of license renewal relate to the older driver traffic fatality rate. Objective To determine whether state driver's license renewal policies are associated with the fatality rate among elderly drivers. Design, Setting, and Population Retrospective, longitudinal study conducted January 1990 through December 2000 of all fatal crashes in the contiguous United States identified in the Fatality Analysis Reporting System, which involved either an older (ages 65-74 years, 75-84 years, and greater than or equal to85 years) or middle-aged (ages 25-64 years) driver. Two regression approaches were used to study the effect of state laws mandating in-person renewal, vision tests, road tests, and frequency of license renewal on driver fatalities, controlling for state-level factors including the number of licensed elderly drivers, primary and secondary seatbelt laws, maximum speed limit laws, blood alcohol level of 0.08, and administrative license revocation drinking and driving laws, per capita income, and unemployment rate. The first regression approach examined only elderly driver fatalities and the second approach examined daytime elderly driver fatalities and used daytime fatalities among middle-aged drivers as a general control for unobserved variation across states and over time. Main Outcome Measures Older driver fatalities and older and middle-aged daytime driver fatalities. Results Among individuals aged 85 years or older, there were a total of 4605 driver fatalities and 4179 daytime driver fatalities during the study period. For this age cohort, after controlling for middle-aged daytime driver deaths, states with in-person license renewal were associated with a lower driver fatality rate (incident rate ratio [RR], 0.83; 95% confidence interval [Cl], 0.72-0.96). This was the only policy related to older drivers that was significantly associated with a lower fatality risk across both regression models. Thus, state-mandated vision tests, road tests, more frequent license renewal, and in-person renewal (for individuals aged 65-74 years and 75-84 years) were not found to be independently associated with the fatality rate among older drivers in the 2 models. Conclusions In-person license renewal was related to a significantly lower fatality rate among the oldest old drivers: More stringent state licensure policies such as vision tests, road tests, and more frequent license renewal cycles were not independently associated with additional benefits.	Univ Alabama, Sch Publ Hlth, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA; Univ Alabama, Sch Publ Hlth, Lister Hill Ctr Hlth Policy, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Grabowski, DC (corresponding author), Univ Alabama, Sch Publ Hlth, Dept Hlth Care Org & Policy, RPHB 330,1665 Univ Blvd, Birmingham, AL 35294 USA.	grabowsk@uab.edu		Morrisey, Michael A/0000-0001-9357-1141; Grabowski, David/0000-0003-2915-5770	ODCDC CDC HHS [R49/CCR403641] Funding Source: Medline	ODCDC CDC HHS		*AM MED ASS COUNC, 2003, OLD DRIV SAF; Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4; *BUR EC AN, 2002, ANN STAT PERS INC; *BUR LAB STAT, 2002, HIST STAT LAB FORC D; *BUR LAB STAT, 2003, CONS PRIC IND URB CO; Dee TS, 2003, ECON LETT, V79, P401, DOI 10.1016/S0165-1765(03)00026-0; Dee TS, 2001, J HUM RESOUR, V36, P823, DOI 10.2307/3069643; Eisenberg D, 2003, J POLICY ANAL MANAG, V22, P249, DOI 10.1002/pam.10116; EVANS WN, 1991, J RISK UNCERTAINTY, V4, P61, DOI 10.1007/BF00057886; EVANS WN, 1991, ALCOHOL DRUGS DRIVIN, V4, P31; Fain MJ, 2003, ARCH INTERN MED, V163, P2126, DOI 10.1001/archinte.163.18.2126; *FED HIGHW ADM, HIGHW STAT 2000; Fitten LJ, 2003, ARCH INTERN MED, V163, P2129, DOI 10.1001/archinte.163.18.2129; Grabowski DC, 2001, MILBANK Q, V79, P517, DOI 10.1111/1468-0009.00220; GRUBER J, 1994, AM ECON REV, V84, P622; *INS I HIGHW SAF, STAT LAWS 2002; LEVY DT, 1995, JAMA-J AM MED ASSOC, V274, P1026, DOI 10.1001/jama.274.13.1026; LEVY DT, 1995, ACCIDENT ANAL PREV, V27, P461, DOI 10.1016/0001-4575(94)00081-V; Lyman S, 2002, INJ PREV, V8, P116, DOI 10.1136/ip.8.2.116; *NAT HIGH SAF ADM, FAT AN REP SYST; *NAT HIGHW SAF ADM, 2000, TRAFF SAF FACTS 1999; NELSON DE, 1992, NEW ENGL J MED, V326, P1784; Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1; Rock SM, 1998, ACCIDENT ANAL PREV, V30, P69, DOI 10.1016/S0001-4575(97)00063-8; Ruhm CJ, 1996, J HEALTH ECON, V15, P435, DOI 10.1016/S0167-6296(96)00490-0; Shipp MD, 1998, OPTOMETRY VISION SCI, V75, P103, DOI 10.1097/00006324-199802000-00014; West CG, 2003, J AM GERIATR SOC, V51, P1348, DOI 10.1046/j.1532-5415.2003.51482.x; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; 2003, US TODAY        0718; 2003, DALLAS MORNING  0728, pA12; 2003, NY TIMES        0727	31	107	107	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2840	2846		10.1001/jama.291.23.2840	http://dx.doi.org/10.1001/jama.291.23.2840			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	828GT	15199034	Bronze			2022-12-28	WOS:000221962500029
J	Koenig, HG				Koenig, HG			Taking a spiritual history	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY PHYSICIANS; ATTITUDES; FAITH; CARE		Duke Univ, Med Ctr, Durham, NC 27710 USA; GRECC VA Med Ctr, Durham, NC USA	Duke University; Geriatric Research Education & Clinical Center	Koenig, HG (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.		Koenig, Harold G/F-7379-2011					BUTLER SM, 2003, HERITAGE LECT, V816; Chibnall JT, 2001, SOUTHERN MED J, V94, P374; Clark Paul Alexander, 2003, Jt Comm J Qual Saf, V29, P659; ELL K O, 1989, Journal of Psychosocial Oncology, V7, P63, DOI 10.1300/J077v07n03_05; Ellis MR, 2002, J FAM PRACTICE, V51, P249; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KING DE, 1992, J FAM PRACTICE, V35, P158; King DE, 2003, SOUTH MED J, V96, P391, DOI 10.1097/01.SMJ.0000054222.15226.4D; Koenig HG, 1998, AM J PSYCHIAT, V155, P536, DOI 10.1176/ajp.155.4.536; Koenig HG, 1998, INT J GERIATR PSYCH, V13, P213, DOI 10.1002/(SICI)1099-1166(199804)13:4<213::AID-GPS755>3.0.CO;2-5; Kristeller JL, 1999, PSYCHO-ONCOLOGY, V8, P451, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<451::AID-PON422>3.3.CO;2-V; Monroe MH, 2003, ARCH INTERN MED, V163, P2751, DOI 10.1001/archinte.163.22.2751; Pargament KI, 2001, ARCH INTERN MED, V161, P1881, DOI 10.1001/archinte.161.15.1881; Silvestri GA, 2003, J CLIN ONCOL, V21, P1379, DOI 10.1200/JCO.2003.08.036	14	36	37	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2881	2881		10.1001/jama.291.23.2881	http://dx.doi.org/10.1001/jama.291.23.2881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	828GT	15199042				2022-12-28	WOS:000221962500037
J	Messaad, D; Sahla, H; Benahmed, S; Godard, P; Bousquet, J; Demoly, P				Messaad, D; Sahla, H; Benahmed, S; Godard, P; Bousquet, J; Demoly, P			Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction	ANNALS OF INTERNAL MEDICINE			English	Article							GENERAL-CONSIDERATIONS; DIAGNOSIS; ASPIRIN; ALLERGY; SKIN	Background: Drug hypersensitivity reactions are common and can be life-threatening. Confirmation of the diagnosis should be rigorous and based on clinical history and a physical examination, possibly followed by skin tests and drug provocation tests. Objective: To describe the outcome of drug provocation tests in evaluating patients with histories suggesting drug allergy. Design: Retrospective analysis of clinic case series. Setting: The department for drug allergy at a university hospital. Patients: 898 consecutive patients with suspected immediate drug allergy referred to the clinic between September 1996 and August 2001. Patients with severe skin reactions and those with positive results on skin tests for beta-lactams were excluded. Intervention: Single-blinded administration of increasing doses of the suspected drug, up to the usual daily dose, under strict hospital surveillance. Results: 1372 drug provocation tests were performed using various drugs, including beta-lactams (30.3%), aspirin (14.5%), other nonsteroidal anti-inflammatory drugs (11.7%), paracetamol (8.9%), macrolides (7.4%), and quinolones (2.4%). There were 241 (17.6%) positive drug provocation test results. Drug provocation reproduced the same symptoms, albeit milder and of a shorter duration, in the following patients: 13 (5.4%) with a history of anaphylactic shock, 17 (7.0%) with a history of anaphylaxis without shock, 10 (4.1%) with a history of laryngeal edema, 19 (7.9%) with a history of bronchospasm, 160 (66.4%) with a history of urticaria, and 22 (9.1%) with a history of maculopapular eruption. All adverse reactions were completely reversed by prednisolone, H-1-antihistamines, and epinephrine as needed. Limitations: Falsely negative results on drug provocation tests may have occurred because of loss of sensitization, rare cofactors not included in the diagnostic procedure, and tolerance induction during provocation. Conclusions: Drug provocation tests in individuals with suspected drug allergy performed in carefully controlled settings can confirm drug hypersensitivity.	CHU Montpellier, Hop Arnaud Villeneuve, INSERM, U454 IFR3, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Demoly, P (corresponding author), CHU Montpellier, Hop Arnaud Villeneuve, INSERM, U454 IFR3, F-34295 Montpellier, France.	demoly@montp.inserm.fr	Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964				Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x; Brockow K, 2002, ALLERGY, V57, P45; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; Demoly P, 2002, ALLERGY, V57, P37, DOI 10.1034/j.1398-9995.57.s72.7.x; DERNOLY P, 2001, CURR OPIN ALLERGY CL, V1, P305; Gruchalla RS, 2000, LANCET, V356, P1505, DOI 10.1016/S0140-6736(00)02885-3; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kvedariene V, 2002, CLIN EXP ALLERGY, V32, P1366, DOI 10.1046/j.1365-2222.2002.01476.x; Primeau MN, 2001, CURR OPIN ALLERGY CL, V1, P337, DOI 10.1097/00130832-200108000-00009; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; STEVENSON DD, 1993, ANN ALLERGY, V71, P417; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x	13	237	248	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					1001	1006		10.7326/0003-4819-140-12-200406150-00009	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NK	15197017				2022-12-28	WOS:000222055500003
J	Williams, JW; Katon, W; Lin, EHB; Noel, PH; Worchel, J; Cornell, J; Harpole, L; Fultz, BA; Hunkeler, E; Mika, VS; Unutzer, J				Williams, JW; Katon, W; Lin, EHB; Noel, PH; Worchel, J; Cornell, J; Harpole, L; Fultz, BA; Hunkeler, E; Mika, VS; Unutzer, J		IMPACT Investigators	The effectiveness of depression care management on diabetes-related outcomes in older patients	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; OF-THE-LITERATURE; MAJOR DEPRESSION; LATE-LIFE; COLLABORATIVE MANAGEMENT; TREATMENT GUIDELINES; IMPROVE TREATMENT; MENTAL-DISORDERS	Background: Depression frequently occurs in combination with diabetes mellitus, adversely affecting the course of illness. Objective: To determine whether enhancing care for depression improves affective and diabetic outcomes in older adults with diabetes and depression. Design: Preplanned subgroup analysis of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) randomized, controlled trial. Setting: 18 primary care clinics from 8 health care organizations in 5 states. Patients: 1801 patients 60 years of age or older with depression; 417 had coexisting diabetes mellitus. Intervention: A care manager offered education, problem-solving treatment, or support for antidepressant management by the patient's primary care physician; diabetes care was not specifically enhanced. Measurements: Assessments at baseline and at 3, 6, and 12 months for depression, functional impairment, and diabetes self-care behaviors. Hemoglobin A(1c) levels were obtained for 293 patients at baseline and at 6 and 12 months. Results: At 12 months, diabetic patients who were assigned to intervention had less severe depression (range, 0 to 4 on a checklist of 20 depression items; between-group difference, -0.43 [95% CI, -0.57 to -0.29]; P < 0.001) and greater improvement in overall functioning (range, 0 [none] to 10 [unable to perform activities]; between-group difference, -0.89 [CI, -1.46 to -0.32]) than did participants who received usual care. In the intervention group, weekly exercise days increased (between-group difference, 0.50 day [CI, 0.12 to 0.89 day]; P= 0.001); other self-care behaviors were not affected. At baseline, mean (+/-SD) hemoglobin A(1c) levels were 7.28% 1.43%; follow-up values were unaffected by the intervention (P > 0.2). Limitations: Because patients had good glycemic control at baseline, power to detect small but clinically important improvements in glycemic control was limited. Conclusions: Collaborative care improves affective and functional status in older patients with depression and diabetes; however, among patients with good glycemic control, such care minimally affects diabetes-specific outcomes.	Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Duke Univ, Sch Med, Durham, NC USA; Univ Washington, Sch Med, Seattle, WA USA; Grp Hlth Cooperat Puget Sound, Seattle, WA USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; S Texas Vet Hlth Care Syst, San Antonio, TX USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Cent Texas Vet Hlth Care Syst, Austin, TX USA; Indiana Univ, Ctr Aging Res, Regenstrief Inst, Indianapolis, IN USA; Univ Calif Los Angeles, Los Angeles, CA USA; Kaiser Permanente No Calif, Oakland, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; University of Washington; University of Washington Seattle; Group Health Cooperative; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; University of California System; University of California Los Angeles; Kaiser Permanente	Williams, JW (corresponding author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St, Durham, NC 27705 USA.		Williams, John W/A-3696-2008; Williams, John/AAM-4572-2020; Unutzer, Jurgen/N-4048-2018	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558; Noel, Polly/0000-0002-1519-7489				Alexopoulos G S, 1992, Clin Geriatr Med, V8, P363; Anderson RJ, 2001, DIABETES CARE, V24, P1069, DOI 10.2337/diacare.24.6.1069; Arean P., 1999, PROBLEM SOLVING THER; Arean P. A., 1999, PROBLEM SOLVING TREA; Barefoot JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3; Callahan CM, 2002, MED CARE, V40, P771, DOI 10.1097/00005650-200209000-00007; Carney C, 1998, Depress Anxiety, V7, P149, DOI 10.1002/(SICI)1520-6394(1998)7:4<149::AID-DA2>3.0.CO;2-5; Cole MG, 1997, AM J GERIAT PSYCHIAT, V5, P4; de Groot M, 2001, PSYCHOSOM MED, V63, P619, DOI 10.1097/00006842-200107000-00015; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; GOLDSTEIN DE, 1987, CLIN CHEM, V33, P2267; HARPOLE L, 1999, MAKING IMPACT IMPROV; Hegel M. T., 2003, PROBLEM SOLVING TREA; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Katon W, 2002, GEN HOSP PSYCHIAT, V24, P20, DOI 10.1016/S0163-8343(01)00171-2; Katon W, 1997, J CLIN PSYCHIAT, V58, P20; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; Klinkman MS, 1997, GEN HOSP PSYCHIAT, V19, P98, DOI 10.1016/S0163-8343(96)00145-4; Krittayaphong R, 1997, PSYCHOSOM MED, V59, P231, DOI 10.1097/00006842-199705000-00004; Kroenke K, 2000, PSYCHOSOMATICS, V41, P39, DOI 10.1016/S0033-3182(00)71172-8; Lamberg L, 1996, JAMA-J AM MED ASSOC, V276, P857, DOI 10.1001/jama.276.11.857; LAVORI PW, 1995, STAT MED, V14, P1913, DOI 10.1002/sim.4780141707; Lin EHB, 2001, J GEN INTERN MED, V16, P614, DOI 10.1046/j.1525-1497.2001.016009614.x; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; LITTLE RJA, 1988, J BUS ECON STAT, V6, P287, DOI 10.2307/1391878; LITTLEFIELD CH, 1992, DIABETES CARE, V15, P90, DOI 10.2337/diacare.15.1.90; Lustman PJ, 1997, PSYCHOSOM MED, V59, P241, DOI 10.1097/00006842-199705000-00007; Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934; LUSTMAN PJ, 1992, DIABETES CARE, V15, P1631, DOI 10.2337/diacare.15.11.1631; Lustman PJ, 2000, DIABETES CARE, V23, P618, DOI 10.2337/diacare.23.5.618; Lustman PJ, 1998, ANN INTERN MED, V129, P613, DOI 10.7326/0003-4819-129-8-199810150-00005; Lyness JM, 1999, J GEN INTERN MED, V14, P249, DOI 10.1046/j.1525-1497.1999.00326.x; MARCUS MD, 1992, DIABETES CARE, V15, P253, DOI 10.2337/diacare.15.2.253; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MEYERS BS, 1997, NAT I MENT HLTH C IM; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Nachtigall D. M., 1999, JGIM, V14, P57; OISHI S, 1999, MAKING IMPACT LATE L; OXMAN TE, 1990, PSYCHOSOMATICS, V31, P174, DOI 10.1016/S0033-3182(90)72191-3; PERKINS AJ, IN PRESS MED CARE; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; Rost K, 1994, Arch Fam Med, V3, P409, DOI 10.1001/archfami.3.5.409; Rost K, 2002, BMJ-BRIT MED J, V325, P934, DOI 10.1136/bmj.325.7370.934; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Saur CD, 2002, J AM PSYCHIAT NURSES, V8, P159; Schulberg HC, 1999, J CLIN PSYCHIAT, V60, P19; Schulberg HC, 1998, INT J PSYCHIAT MED, V28, P421, DOI 10.2190/G23R-NGGN-K1P1-MQ8N; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sullivan MD, 1997, AM J MED, V103, P348, DOI 10.1016/S0002-9343(97)00167-8; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; Toobert DJ, 1994, HDB PSYCHOL DIABETES; Unutzer J, 2002, PSYCHIATR SERV, V53, P671, DOI 10.1176/appi.ps.53.6.671; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Unutzer J, 2000, INT PSYCHOGERIATR, V12, P15, DOI 10.1017/S1041610200006177; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watkins LL, 1999, AM HEART J, V137, P453, DOI 10.1016/S0002-8703(99)70491-6; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Williams JW, 1999, ARCH FAM MED, V8, P58, DOI 10.1001/archfami.8.1.58; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011	65	213	219	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	2004	140	12					1015	1024		10.7326/0003-4819-140-12-200406150-00012	http://dx.doi.org/10.7326/0003-4819-140-12-200406150-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	829NK	15197019				2022-12-28	WOS:000222055500005
J	Fong, DD; Stephenson, GB; Streiffer, SK; Eastman, JA; Auciello, O; Fuoss, PH; Thompson, C				Fong, DD; Stephenson, GB; Streiffer, SK; Eastman, JA; Auciello, O; Fuoss, PH; Thompson, C			Ferroelectricity in ultrathin perovskite films	SCIENCE			English	Article							CHEMICAL-VAPOR-DEPOSITION; X-RAY-SCATTERING; THIN-FILMS; PBTIO3; POLARIZATION; SURFACE; THICKNESS; PARTICLES; LIMIT	Understanding the suppression of ferroelectricity in perovskite thin films is a fundamental issue that has remained unresolved for decades. We report a synchrotron x-ray study of lead titanate as a function of temperature and film thickness for films as thin as a single unit cell. At room temperature, the ferroelectric phase is stable for thicknesses down to 3 unit cells (1.2 nanometers). Our results imply that no thickness limit is imposed on practical devices by an intrinsic ferroelectric size effect.	Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; No Illinois Univ, Dept Phys, De Kalb, IL 60115 USA	United States Department of Energy (DOE); Argonne National Laboratory; Northern Illinois University	Stephenson, GB (corresponding author), Argonne Natl Lab, Div Mat Sci, 9700 S Cass Ave, Argonne, IL 60439 USA.	stephenson@anl.gov	Streiffer, Stephen K/A-1756-2009; Eastman, Jeffrey A/E-4380-2011; Auciello, Orlando/E-2058-2013	Thompson, Carol/0000-0003-3832-4855; Fuoss, Paul/0000-0002-3714-7239; Eastman, Jeffrey/0000-0002-0847-4265				Ahn CH, 2004, SCIENCE, V303, P488, DOI 10.1126/science.1092508; Auciello O, 1998, PHYS TODAY, V51, P22, DOI 10.1063/1.882324; Bune AV, 1998, NATURE, V391, P874, DOI 10.1038/36069; Chu MW, 2004, NAT MATER, V3, P87, DOI 10.1038/nmat1057; Ghosez P, 2000, APPL PHYS LETT, V76, P2767, DOI 10.1063/1.126469; Ishikawa K, 1996, JPN J APPL PHYS 1, V35, P5196, DOI 10.1143/JJAP.35.5196; Jiang B, 2000, J APPL PHYS, V87, P3462, DOI 10.1063/1.372367; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; Kohlstedt H, 2002, MATER RES SOC SYMP P, V688, P161; Kopal A, 1997, FERROELECTRICS, V202, P267, DOI 10.1080/00150199708213485; KRETSCHMER R, 1979, PHYS REV B, V20, P1065, DOI 10.1103/PhysRevB.20.1065; Maruyama T, 1998, APPL PHYS LETT, V73, P3524, DOI 10.1063/1.122824; Meyer B, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.205426; Meyer B, 1999, FARADAY DISCUSS, V114, P395, DOI 10.1039/a903029h; Munkholm A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.016101; Muralt P, 2000, J MICROMECH MICROENG, V10, P136, DOI 10.1088/0960-1317/10/2/307; Murty MVR, 2002, APPL PHYS LETT, V80, P1809, DOI 10.1063/1.1458530; Parker CB, 2002, APPL PHYS LETT, V81, P340, DOI 10.1063/1.1490148; Pertsev NA, 1998, PHYS REV LETT, V80, P1988, DOI 10.1103/PhysRevLett.80.1988; Ramesh R, 2002, SCIENCE, V296, P1975, DOI 10.1126/science.1072855; Roelofs A, 2002, APPL PHYS LETT, V81, P5231, DOI 10.1063/1.1534412; Shaw TM, 2000, ANNU REV MATER SCI, V30, P263, DOI 10.1146/annurev.matsci.30.1.263; Stephenson GB, 2003, PHYSICA B, V336, P81, DOI 10.1016/S0921-4526(03)00273-4; Stephenson GB, 1999, MRS BULL, V24, P21, DOI 10.1557/S088376940005168X; Streiffer SK, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067601; STRUKOV BA, 1998, FERROELECTRIC PHENOM, pCH6; TIMONIN PN, 1996, SOV PHYS JETP, V83, P503; Tybell T, 1999, APPL PHYS LETT, V75, P856, DOI 10.1063/1.124536; Waser R, 2004, NAT MATER, V3, P81, DOI 10.1038/nmat1067; Zembilgotov AG, 2002, J APPL PHYS, V91, P2247, DOI 10.1063/1.1427406	30	1013	1035	27	535	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1650	1653		10.1126/science.1098252	http://dx.doi.org/10.1126/science.1098252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192223				2022-12-28	WOS:000221934300044
J	Ryan, L; Hawton, K				Ryan, L; Hawton, K			Ten-minute consultation - Female dyspareunia	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Warneford Hosp, Oxford OX3 7JX, England; Alec Turnbull Ctr, E Oxford Hlth Ctr, Oxford OX4 1XD, England		Hawton, K (corresponding author), Warneford Hosp, Oxford OX3 7JX, England.	keith.hawton@psychiatry.ox.ac.uk							0	5	5	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1357	1357		10.1136/bmj.328.7452.1357	http://dx.doi.org/10.1136/bmj.328.7452.1357			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178614	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221952700021
J	van den Berg, B; Black, PN; Clemons, WM; Rapoport, TA				van den Berg, B; Black, PN; Clemons, WM; Rapoport, TA			Crystal structure of the long-chain fatty acid transporter FadL	SCIENCE			English	Article							COENZYME-A SYNTHETASE; ACYL-COA SYNTHETASE; ESCHERICHIA-COLI; OUTER-MEMBRANE; TRANSMEMBRANE MOVEMENT; PSEUDOMONAS-PUTIDA; GENE-PRODUCT; PROTEIN; BINDING; IDENTIFICATION	The mechanisms by which hydrophobic molecules, such as long-chain fatty acids, enter cells are poorly understood. In Gram-negative bacteria, the lipopolysaccharide layer in the outer membrane is an efficient barrier for fatty acids and aromatic hydrocarbons destined for biodegradation. We report crystal structures of the long-chain fatty acid transporter FadL from Escherichia coli at 2.6 and 2.8 angstrom resolution. FadL forms a 14-stranded beta barrel that is occluded by a central hatch domain. The structures suggest that hydrophobic compounds bind to multiple sites in FadL and use a transport mechanism that involves spontaneous conformational changes in the hatch.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Ordway Res Inst, Ctr Metab Dis, Albany, NY 12208 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Ordway Research Institute	van den Berg, B (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA.	lvandenberg@hms.harvard.edu	Clemons, William M/D-1026-2009	Clemons, William M/0000-0002-0021-889X; Black, Paul/0000-0002-6272-6881; van den Berg, Bert/0000-0003-1966-8804				Abumrad N, 1998, J LIPID RES, V39, P2309; AZIZAN A, 1994, J BACTERIOL, V176, P6653, DOI 10.1128/JB.176.21.6653-6662.1994; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1995, BIOCHEM J, V310, P389, DOI 10.1042/bj3100389; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLACK PN, UNPUB; Braun V, 2002, CURR OPIN MICROBIOL, V5, P194, DOI 10.1016/S1369-5274(02)00298-9; Brinkmann JFF, 2002, BIOCHEM J, V367, P561, DOI 10.1042/BJ20020747; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; Ferguson AD, 2004, CELL, V116, P15, DOI 10.1016/S0092-8674(03)01030-4; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Kasai Y, 2001, J BACTERIOL, V183, P6662, DOI 10.1128/JB.183.22.6662-6666.2001; KORCHAK HM, 1994, J BIOL CHEM, V269, P30281; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NUNN WD, 1986, J BIOL CHEM, V261, P167; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Reese AJ, 2004, J LIPID RES, V45, P232, DOI 10.1194/jlr.M300113-JLR200; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; van der Vusse GJ, 2000, CARDIOVASC RES, V45, P279, DOI 10.1016/S0008-6363(99)00263-1; WANG Y, 1995, MOL GEN GENET, V246, P570, DOI 10.1007/BF00298963; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	30	163	167	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	2004	304	5676					1506	1509		10.1126/science.1097524	http://dx.doi.org/10.1126/science.1097524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178802				2022-12-28	WOS:000221795800046
J	Koehler, F; Kivelitz, D				Koehler, F; Kivelitz, D			A calcified pelvic mass	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Charite Univ Med Berlin, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Koehler, F (corresponding author), Charite Univ Med Berlin, D-10098 Berlin, Germany.			Koehler, Friedrich/0000-0003-0441-4123					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					E21	E21		10.1056/NEJMicm030463	http://dx.doi.org/10.1056/NEJMicm030463			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175453				2022-12-28	WOS:000221754200011
J	Svensen, H; Planke, S; Malthe-Sorenssen, A; Jamtveit, B; Myklebust, R; Eidem, TR; Rey, SS				Svensen, H; Planke, S; Malthe-Sorenssen, A; Jamtveit, B; Myklebust, R; Eidem, TR; Rey, SS			Release of methane from a volcanic basin as a mechanism for initial Eocene global warming	NATURE			English	Article							VORING BASIN; MARGIN; SILLS; DISSOCIATION; END	A 200,000-yr interval of extreme global warming marked the start of the Eocene epoch about 55 million years ago. Negative carbon-and oxygen-isotope excursions in marine and terrestrial sediments show that this event was linked to a massive and rapid (similar to10,000 yr) input of isotopically depleted carbon(1,2). It has been suggested previously that extensive melting of gas hydrates buried in marine sediments may represent the carbon source(3,4) and has caused the global climate change. Large-scale hydrate melting, however, requires a hitherto unknown triggering mechanism. Here we present evidence for the presence of thousands of hydrothermal vent complexes identified on seismic reflection profiles from the Voring and More basins in the Norwegian Sea. We propose that intrusion of voluminous mantle-derived melts in carbon-rich sedimentary strata in the northeast Atlantic may have caused an explosive release of methane-transported to the ocean or atmosphere through the vent complexes-close to the Palaeocene/Eocene boundary. Similar volcanic and metamorphic processes may explain climate events associated with other large igneous provinces such as the Siberian Traps (similar to250 million years ago) and the Karoo Igneous Province (similar to183 million years ago).	Univ Oslo, N-0316 Oslo, Norway; Volcan Basin Petr Res, N-0349 Oslo, Norway; TGS NOPEC Geophys Co, N-3478 Naersnes, Norway	University of Oslo	Svensen, H (corresponding author), Univ Oslo, POB 1048 Blindern, N-0316 Oslo, Norway.	hsvensen@geo.uio.no; planke@vbpr.no	Malthe-Sørenssen, Anders/C-2015-2015; Planke, Sverre/AAE-1721-2021	Malthe-Sørenssen, Anders/0000-0001-8138-3995; Planke, Sverre/0000-0001-6128-2193; Jamtveit, Bjorn/0000-0001-5700-1803				BERGGREN WA, 1995, SEPM SPEC PUBL, V54, P212; Berndt C, 2000, J GEOPHYS RES-SOL EA, V105, P28443, DOI 10.1029/2000JB900217; Berndt C, 2001, J GEOL SOC LONDON, V158, P413, DOI 10.1144/jgs.158.3.413; Brekke H, 2000, GEOL SOC SPEC PUBL, V167, P327, DOI 10.1144/GSL.SP.2000.167.01.13; Brekke H., 1999, PETROLEUM GEOLOGY NW, P261, DOI DOI 10.1144/0050261; CALDEIRA K, 1991, GEOPHYS RES LETT, V18, P987, DOI 10.1029/91GL01237; Chevallier L, 1999, S AFR J GEOL, V102, P43; Crouch EM, 2001, GEOLOGY, V29, P315, DOI 10.1130/0091-7613(2001)029<0315:GDEAWT>2.0.CO;2; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; ECKHOFF EE, 1999, THESIS U OSLO; ELDHOLM O, 1994, J GEOPHYS RES-SOL EA, V99, P2955, DOI 10.1029/93JB02879; ELDHOLM O, 1993, EARTH PLANET SC LETT, V117, P319, DOI 10.1016/0012-821X(93)90087-P; Galushkin YI, 1997, ORG GEOCHEM, V26, P645, DOI 10.1016/S0146-6380(97)00030-2; HOPPER PR, 1997, AGU GEOPHYS MONOGR, V100, P1; Hunt J.M., 1996, PETROLEUM GEOLOGY GE; IPCC, 2001, ADV CLIM CHANG RES; JAMVEIT B, IN PRESS GEOL SOC LO; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; KJELDSTAD A, 2003, ADV TOPICS COMPUTATI, P611; PLANKE S, IN PRESS PETROL GEOL; Schmitz B, 2003, GEOLOGY, V31, P689, DOI 10.1130/G19527.1; SKOGSEID J, 1992, GEOL SOC SPEC PUBL, P305; Smallwood Jr, 2002, GEOL SOC SPEC PUBL, V197, P271, DOI 10.1144/GSL.SP.2002.197.01.11; Svensen H, 2003, GEO-MAR LETT, V23, P351, DOI 10.1007/s00367-003-0141-2; Trude J, 2003, GEOLOGY, V31, P813, DOI 10.1130/G19559.1; WEINBERG RF, 1994, J GEOPHYS RES-SOL EA, V99, P9543, DOI 10.1029/93JB03461; Wignall PB, 2001, EARTH-SCI REV, V53, P1, DOI 10.1016/S0012-8252(00)00037-4; WOODFORD AC, 2001, HYDROGEOLOGY MAIN KA; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110; Zhang YX, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016658	31	675	705	6	259	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					542	545		10.1038/nature02566	http://dx.doi.org/10.1038/nature02566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175747				2022-12-28	WOS:000221767700034
J	Muggli, ME; LeGresley, EM; Hurt, RD				Muggli, ME; LeGresley, EM; Hurt, RD			Big tobacco is watching: British American Tobacco's surveillance and information concealment at the Guildford depository	LANCET			English	Article							INDUSTRY DOCUMENTS; SCIENCE; SMOKE	The 1998 State of Minnesota legal settlement with the tobacco industry required British American Tobacco (BAT) to provide public access to the 8 million pages housed in its document depository located near Guildford, UK, and to any company documents sent to the Minnesota depository. While the Minnesota depository is managed by an independent third party, BAT's Guildford depository is run by the company itself. Starkly different from the Minnesota depository, at the Guildford depository it is extraordinarily more difficult to access, search, and obtain requested documents. BAT's approach to running the Guildford depository, in our view, amounts to concealing what is supposed to be public information. Newly produced BAT documents from subsequent litigation, dating from 1996 to 2001 disclose the company's efforts to gather intelligence on visitors and their work. We believe that BAT has acted to make access to information more difficult by delaying document production requested by public visitors and refusing to supply requested documents in an electronic format despite, in the company's own words, the establishment of "big time imaging" capabilities at the Guildford depository. During testimony in 2000, then BAT Chairman, Martin Broughton stated to the UK House of Commons Health Select Committee that the scanning and subsequent placement of the Guildford collection online "would be an extreme effort for absolutely no purpose whatsoever", stating that "there is no indication to me that serious researchers are showing any interest in the papers...". New documents show that not only did the company recognise the importance of research undertaken by visitors, but also invested substantial resources and undertook numerous scanning projects during that time. The vulnerability of this important resource is demonstrated by the decreased number of files listed on the electronic database and the inadvertent deletion of an audio tape housed at the depository. With regard to intelligence gathering, BAT's law firm reported to BAT on the daily activities of depository visitors. Despite assurances to the contrary, these depository visitor reports show that BAT apparently tracked the database searches of a visitor. The company also tracked the physical movement of visitors and, in at least one instance, observed and noted the personal mobile phone use of a visitor. These activities raise ethical issues about BAT and/or its solicitors observing the work of lawyers and researchers representing health and government bodies. Given this new evidence, we assert that BAT is incapable of operating its depository in the spirit of the Minnesota settlement and should, therefore, be divorced from its operation. Accordingly, we recommend that the company provide its entire document collection electronically to interested parties thus allowing greater access to the public-health community as has been done in the USA.	Mayo Clin, Nicotine Dependence Ctr, Rochester, MN 55905 USA; Mayo Clin Nicotine Res Program, St Paul, MN 55105 USA	Mayo Clinic; Mayo Clinic	Hurt, RD (corresponding author), Mayo Clin, Nicotine Dependence Ctr, Rochester, MN 55905 USA.	rhurt@mayo.edu			NCI NIH HHS [R01 CA90791] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090791] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTANER D, 2002, BLOOMBERG NEWS  0416; Balbach ED, 2002, TOB CONTROL, V11, P68, DOI 10.1136/tc.11.1.68; BENGER J, 2000, COMMUNICATION   0218; BENGER J, 2000, COMMUNICATION   0302; BENGER J, 2000, COMMUNICATION   0228; BRAMLEY D, 1994, PROJECT DISCOVERY; *BRIT AM TOB, 1996, DISC PROC FLOW CHART; *BRIT AM TOB, CORP SOC RESP; CHALFEN S, 2000, COMMUNICATION   0222; CHALFEN S, 2000, COMMUNICATION   0307; CHARMAN S, 2000, PMG; CHARMAN S, 2000, TCC TIMECHECK; CHARMAN S, 2000, PMG VISIT; CIRESI M, 1998, COMMUNICATION   1203; CONDE M, 1999, COMMUNICATION   0831; CONDE M, 2000, PROJECT GREY SMUGGLI; *DP ADV LTD, 1996, PROP SCANN; GILBEY M, 2003, COMMUNICATION   0501; GILBEY M, 2003, COMMUNICATION   0424; Glantz S.A., 1996, CIGARETTE PAPERS; GRANT R, 2000, COMMUNICATION   0608; GREEN J, 2000, US DOJ VISIT; HECTOR S, 2001, COMMUNICATION    JAN; *INT CONS INV JOUR, 2000, GLOB REACH TOB CO IN; *INT CONS INV JOUR, 2000, MAJ TOB MULT IMPL CI; *INT CONS INV JOUR, 2001, TOB CO LINK CRIM ORG; LEWIS J, REQUIESTED GUILDFORD; LEWIS J, 1999, ISRAEL LATIN AM 0312; LEWIS J, 1999, LWD COPY REQUESTS; LOVELLS DD, 2000, 250 BRIT AM TOB; LOVELLS GD, 1999, 162 BRIT AM TOB; LOVES DAG, 1999, 106 BRIT AM TOB; *LTL, 1998, BR00002 PROJ MAN DRA; MAGUIRE K, 2000, GUARDIAN LONDON 0131, P1; Malone RE, 2000, TOB CONTROL, V9, P334, DOI 10.1136/tc.9.3.334; MARSH F, 1998, M LEG TECHN GUILDF J; MOODY L, 1992, PGL POISTIONING STAT; Muggli ME, 2003, NICOTINE TOB RES, V5, P303, DOI 10.1080/1462220031000094169; Muggli ME, 2003, TOB CONTROL, V12, P104, DOI 10.1136/tc.12.1.104; Muggli ME, 2001, AM J PUBLIC HEALTH, V91, P1419, DOI 10.2105/AJPH.91.9.1419; Ong EK, 2001, AM J PUBLIC HEALTH, V91, P1749, DOI 10.2105/AJPH.91.11.1749; *PA CONS GROUP, 1999, CURR SIT; ROSE E, 1999, CD MOVEMENTS; SCOURFIELD P, 1995, COMMUNICATION   0714; *UK DEP HLTH, UK GOV RESP HLTH SEL; *UK PARL, 2000, UK HOUS COMM HLTH SE; WALBURN R, 2004, COMMUNICATION    FEB; GUILDFORD SITE 2000; 2000, TOBACCO CO STRATEGIE; 1999, GUILDFORD RELATED CO; 1994, HANDWRITTEN MEMO PLA	51	29	29	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1812	1819		10.1016/S0140-6736(04)16309-5	http://dx.doi.org/10.1016/S0140-6736(04)16309-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172782				2022-12-28	WOS:000221705800025
J	Bavinck, JNB; Feltkamp, MCW				Bavinck, JNB; Feltkamp, MCW			Milk of human kindness? HAMLET, human papillomavirus, and warts.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SKIN-CANCER		Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Infect Dis, Dept Med Microbiol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bavinck, JNB (corresponding author), Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands.		Feltkamp, Mariet/A-3788-2010	Feltkamp, Mariet/0000-0001-5993-9846				Feltkamp MCW, 2003, CANCER RES, V63, P2695; Gibbs S, 2002, BMJ-BRIT MED J, V325, P461, DOI 10.1136/bmj.325.7362.461; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Struijk L, 2003, J INVEST DERMATOL, V121, P1531, DOI 10.1046/j.1523-1747.2003.12632.x	5	17	18	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2639	2642		10.1056/NEJMp048086	http://dx.doi.org/10.1056/NEJMp048086			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215478				2022-12-28	WOS:000222199000003
J	Rasa, M; Philipse, AP				Rasa, M; Philipse, AP			Evidence for a macroscopic electric field in the sedimentation profiles of charged colloids	NATURE			English	Article							SILICA SPHERES; ORGANIC-SOLVENT; EQUILIBRIUM; SUSPENSIONS	The determination of molecular masses from barometric sedimentation profiles, a main topic in ultracentrifugal analysis, is thought to be quantitatively correct for non-interacting particles(1,2). Whereas this expectation is justified for uncharged colloids or macromolecules at low volume fractions, early ultracentrifugation studies(3) on charged particles had already indicated that the obtained masses might be much too low. More recently, expanded sedimentation profiles have been observed for charged particles(4,5), sometimes inflated by orders of magnitude(5) relative to the barometric prediction, which highlights a shortcoming in our understanding of centrifugation of even very dilute charged species(5). Theory(6) and simulations(7), anticipated by various authors(4,8,9), now propose that strongly non-barometric sedimentation profiles might be caused by an internal macroscopic electric field that, even for non-interacting particles, significantly decreases the buoyant particle mass. The existence of this field and its intriguing consequences still lack experimental verification. Here we report ultracentrifugation experiments on charged colloidal silica spheres, showing both the existence of such a macroscopic electric field and its drastic effects on the sedimentation profiles of very dilute dispersions at low ionic strength.	Univ Utrecht, Debye Inst, Vant Hoff Lab Phys & Colloid Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University	Philipse, AP (corresponding author), Univ Utrecht, Debye Inst, Vant Hoff Lab Phys & Colloid Chem, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	a.p.philipse@chem.uu.nl	Philipse, Albert P/E-7003-2012					Becker W. M., 2000, WORLD CELL; BIBEN T, 1994, J PHYS-CONDENS MAT, V6, pA345, DOI 10.1088/0953-8984/6/23A/057; HARDING SE, 1993, ANAL ULTRACENTRIFUGA; HUNTER RJ, 1991, FDN COLLOID SCI, V1; Hynninen AP, 2004, EUROPHYS LETT, V65, P719, DOI 10.1209/epl/i2003-10178-y; Lowen H, 1998, J PHYS-CONDENS MAT, V10, pL479, DOI 10.1088/0953-8984/10/28/002; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Philipse AP, 2003, ADV COLLOID INTERFAC, V100, P613, DOI 10.1016/S0001-8686(02)00078-7; PHILIPSE AP, 1988, J CHEM PHYS, V88, P6459, DOI 10.1063/1.454432; PHILIPSE AP, 1989, J COLLOID INTERF SCI, V128, P121, DOI 10.1016/0021-9797(89)90391-3; PHILIPSE AP, UNPUB J PHYS CONDENS; PIAZZA R, 1993, PHYS REV LETT, V71, P4267, DOI 10.1103/PhysRevLett.71.4267; RASA M, IN PRESS J COLLOID I; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Svedberg T, 1940, ULTRAZENTRIFUGE; THIESWEESIE DME, 1995, J COLLOID INTERF SCI, V176, P43, DOI 10.1006/jcis.1995.0006; van Roij R, 2003, J PHYS-CONDENS MAT, V15, pS3569, DOI 10.1088/0953-8984/15/48/016	17	81	81	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					857	860		10.1038/nature02672	http://dx.doi.org/10.1038/nature02672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215860	Green Published			2022-12-28	WOS:000222213000037
J	Belsky, L; Richardson, HS				Belsky, L; Richardson, HS			Medical researchers' ancillary clinical care responsibilities	BRITISH MEDICAL JOURNAL			English	Article									NIH, Dept Clin Bioeth, Bethesda, MD 20898 USA	National Institutes of Health (NIH) - USA	Belsky, L (corresponding author), NIH, Dept Clin Bioeth, 10 Ctr Dr, Bethesda, MD 20898 USA.	lbelsky@mail.cc.nih.gov		Richardson, Henry/0000-0002-4593-4726				Fitzgerald DW, 2003, LANCET, V361, P68, DOI 10.1016/S0140-6736(03)12166-6; Katz Jay, 1993, St Louis Univ Law J, V38, P7; MCINTYRE A, 1994, PHILOS PUBLIC AFF, V23, P157, DOI 10.1111/j.1088-4963.1994.tb00009.x; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; *NUFF COUNC BIOETH, 2002, ETH RES REL HEALTC D, P97; PELLEGRINO ED, 1995, ANN INTERN MED, V122, P337; Richardson HS, 2004, HASTINGS CENT REP, V34, P25, DOI 10.2307/3528248; Scanlon TM, 1998, WHAT WE OWE EACH OTH, P224	8	109	109	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	2004	328	7454					1494	1496		10.1136/bmj.328.7454.1494	http://dx.doi.org/10.1136/bmj.328.7454.1494			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205296	Green Published			2022-12-28	WOS:000222244600025
J	Black, N; Barker, M; Payne, M				Black, N; Barker, M; Payne, M			Cross sectional survey of multicentre clinical databases in the United Kingdom	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To describe the multicentre clinical databases that exist in the United Kingdom, to report on their quality, to explore which organisational and managerial features are associated with high quality, and to make recommendations for improvements. Design Cross sectional survey, with interviews with database custodians and search of electronic bibliographic database (PubMed). Studies reviewed 105 clinical databases across the United Kingdom. Results Clinical databases existed in all areas of health care, but their distribution was uneven-cancer and surgery were better covered than mental health and obstetrics. They varied greatly in age, size, growth rate, and geographical areas covered. Their scope (and thus their potential uses) and the quality of the data collected also varied. The latter was not associated with any organisational characteristics. Despite impressive achievements, many faced substantial financial uncertainty. Considerable scope existed for improvements: greater use of nationally approved codes; more support from relevant professional organisations; greater involvement by nurses, allied health professionals, managers, and laypeople in database management teams; and more attention to data security and ensuring patient confidentiality. With some notable exceptions, the audit and research potential of most databases had not been realised: half the databases had each produced only four or fewer peer reviewed research articles. Conclusions At least one clinical database support unit is needed in the United Kingdom to provide assistance in organisation and management, information technology, epidemiology, and statistics. Without such an initiative, the variable picture of databases reported here is likely to persist and their potential not be realised.	London Sch Hyg & Trop Med, Hlth Serv Res Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Black, N (corresponding author), London Sch Hyg & Trop Med, Hlth Serv Res Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England.	nick.black@lshtm.ac.uk						Black N, 2003, QUAL SAF HEALTH CARE, V12, P348, DOI 10.1136/qhc.12.5.348; Black N, 1999, LANCET, V353, P1205, DOI 10.1016/S0140-6736(99)00108-7; Black N, 2002, BRIT MED J, V324, P1194, DOI 10.1136/bmj.324.7347.1194; Black N, 2003, J HLTH SERVICES R S1, V8, P36, DOI DOI 10.1258/135581903766468873; Cheung WY, 2003, HLTH TECHNOL ASSESS, V7, P1; *DEP HLTH, 2000, COMPR CRIT CAR REV A; HIGGINS J, 2003, J HLTH SERV RES P S1, V8, P8; Lowrance WW, 2002, LEARNING EXPERIENCE; Lundin J, 2003, BRIT MED J, V326, P29, DOI 10.1136/bmj.326.7379.29; MCGLYNN EA, 1998, HLTH INFORMATION SYS; Newton J., 2002, DIS REGISTERS ENGLAN; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; Smith R, 2003, BRIT MED J, V327, P1239, DOI 10.1136/bmj.327.7426.1239; SCOTTISH AUDIT SURG	14	53	53	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1478	1481		10.1136/bmj.328.7454.1478	http://dx.doi.org/10.1136/bmj.328.7454.1478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205292	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-28	WOS:000222244600018
J	Hedley, AA; Ogden, CL; Johnson, CL; Carroll, MD; Curtin, LR; Flegal, KM				Hedley, AA; Ogden, CL; Johnson, CL; Carroll, MD; Curtin, LR; Flegal, KM			Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRENDS	Context The prevalence of overweight and obesity has increased markedly in the last 2 decades in the United States. Objective To update the US prevalence estimates of overweight in children and obesity in adults, using the most recent national data of height and weight measurements. Design, Setting, and Participants As part of the National Health and Nutrition Examination Survey (NHANES), a complex multistage probability sample of the US non institutionalized civilian population, both height and weight measurements were obtained from 4115 adults and 4018 children in 1999-2000 and from 4390 adults and 4258 children in 2001-2002. Main Outcome Measure Prevalence of overweight (body mass index [BMI] greater than or equal to95th percentile of the sex-specific BMI-for-age growth chart) among children and prevalence of overweight (BMI, 25.0-29.9), obesity (BMI greater than or equal to30.0), and extreme obesity (BMI greater than or equal to40.0) among adults by sex, age, and racial/ethnic group. Results Between 1999-2000 and 2001-2002, there were no significant changes among adults in the prevalence of overweight or obesity (64.5% vs 65.7%), obesity (30.5% vs 30.6%), or extreme obesity (4.7% vs 5.1%), or among children aged 6 through 19 years in the prevalence of at risk for overweight or overweight (29.9% vs 31.5%) or overweight (15.0% vs 16.5%). Overall, among adults aged at least 20 years in 19992002, 65.1% were overweight or obese, 30.4% were obese, and 4.9% were extremely obese. Among children aged 6 through 19 years in 1999-2002, 31.0% were at risk for overweight or overweight and 16.0% were overweight. The NHANES results indicate continuing disparities by sex and between racial/ethnic groups in the prevalence of overweight and obesity. Conclusions There is no indication that the prevalence of obesity among adults and overweight among children is decreasing. The high levels of overweight among children and obesity among adults remain a major public health concern.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA; Univ Calif Berkeley, Ctr Weight & Hlth, Berkeley, CA 94720 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	Hedley, AA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4307, Hyattsville, MD 20782 USA.	ahedley@cdc.gov	Kohn, Geoffrey P/A-9056-2009; Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; Hill JO, 1998, PEDIATRICS, V101, P570, DOI 10.1542/peds.101.3.570; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; LUCAS JW, 2004, VITAL HLTH STAT, V10; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; *PHS, 2001, SURG GEN CALL ACT PR; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2	11	3122	3187	5	148	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2847	2850		10.1001/jama.291.23.2847	http://dx.doi.org/10.1001/jama.291.23.2847			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199035	Bronze			2022-12-28	WOS:000221962500030
J	Jarman, B; Aylin, P; Bottle, A				Jarman, B; Aylin, P; Bottle, A			Social class and elective caesareans in the English NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Jarman, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Bottle, Alex/0000-0001-9978-2011; Aylin, Paul/0000-0003-4589-1743					0	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1399	1399		10.1136/bmj.328.7453.1399	http://dx.doi.org/10.1136/bmj.328.7453.1399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15191977	Green Published, Green Submitted			2022-12-28	WOS:000222114400014
J	Phoncharoensri, D; Witoonpanich, R; Tunlayadechanont, S; Laothamatas, J				Phoncharoensri, D; Witoonpanich, R; Tunlayadechanont, S; Laothamatas, J			Confusion and paraparesis	LANCET			English	Editorial Material							JAPANESE ENCEPHALITIS-VIRUS		Mahidol Univ, Fac Med, Dept Med, Div Neurol, Bangkok 10700, Thailand; Mahidol Univ, Fac Med, Dept Radiol, Bangkok 10700, Thailand; Mahidol Univ, Ramathibodi Hosp, Bangkok 10700, Thailand	Mahidol University; Mahidol University; Mahidol University	Witoonpanich, R (corresponding author), Mahidol Univ, Fac Med, Dept Med, Div Neurol, Bangkok 10700, Thailand.	rarwt@mahidol.ac.th						GROSSMAN RA, 1973, AM J EPIDEMIOL, V98, P121, DOI 10.1093/oxfordjournals.aje.a121537; Li J, 2003, ANN NEUROL, V53, P703, DOI 10.1002/ana.10575; Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; Solomon T, 1997, NEUROL INFECT EPIDEM, V2, P191	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1954	1954		10.1016/S0140-6736(04)16410-6	http://dx.doi.org/10.1016/S0140-6736(04)16410-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194256				2022-12-28	WOS:000221962800010
J	Porter, M; Bhattacharya, S				Porter, M; Bhattacharya, S			Preventing unnecessary caesarean sections: marginal benefit of a second opinion	LANCET			English	Editorial Material							PREFERENCE; RATES		Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Porter, M (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen AB25 2ZD, Scotland.	m.a.porter@abdn.ac.uk		Bhattacharya, Siladitya/0000-0002-4588-356X				AlMufti R, 1997, EUR J OBSTET GYN R B, V73, P1, DOI 10.1016/S0301-2115(96)02692-9; [Anonymous], 2002, BMJ, V324; [Anonymous], 1985, LANCET, V2, P436; Behague DP, 2002, BMJ-BRIT MED J, V324, P942, DOI 10.1136/bmj.324.7343.942; Ecker JL, 2004, AM J OBSTET GYNECOL, V190, P314, DOI 10.1016/S0002-9378(03)00869-X; Gamble JA, 2001, BIRTH-ISS PERINAT C, V28, P101, DOI 10.1046/j.1523-536X.2001.00101.x; Leitch CR, 1998, BRIT J OBSTET GYNAEC, V105, P621, DOI 10.1111/j.1471-0528.1998.tb10176.x; Roberts CL, 2000, BRIT MED J, V321, P137, DOI 10.1136/bmj.321.7254.137; Walker R, 2002, BIRTH-ISS PERINAT C, V29, P28, DOI 10.1046/j.1523-536X.2002.00153.x; WILLIAMS B, 1994, SOC SCI MED, V38, P509, DOI 10.1016/0277-9536(94)90247-X	10	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	2004	363	9425					1921	1922		10.1016/S0140-6736(04)16437-4	http://dx.doi.org/10.1016/S0140-6736(04)16437-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194248				2022-12-28	WOS:000221962800003
J	Smith, JE; Guly, HR				Smith, JE; Guly, HR			Lesson of the week - Nalbuphine and slow release morphine	BRITISH MEDICAL JOURNAL			English	Review							INTRAVENOUS NALBUPHINE; ANALGESIA; REQUIREMENTS		Derriford Hosp, Dept Accid & Emergency, Plymouth PL6 8DH, Devon, England	Derriford Hospital	Smith, JE (corresponding author), Derriford Hosp, Dept Accid & Emergency, Plymouth PL6 8DH, Devon, England.	jasonesmith@doctors.org.uk	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421				CHAMBERS JA, 1994, RESUSCITATION, V27, P153, DOI 10.1016/0300-9572(94)90008-6; Houlihan KPG, 1999, J ACCID EMERG MED, V16, P29; JOHNSON GS, 1995, J ACCID EMERG MED, V12, P20; LO MW, 1987, EUR J CLIN PHARMACOL, V33, P297, DOI 10.1007/BF00637566; PRESTON KL, 1989, J PHARMACOL EXP THER, V248, P929; Robinson N, 1999, J ACCID EMERG MED, V16, P392; STENE JK, 1988, AM J EMERG MED, V6, P634, DOI 10.1016/0735-6757(88)90109-X	7	5	5	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1426	1426		10.1136/bmj.328.7453.1426	http://dx.doi.org/10.1136/bmj.328.7453.1426			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15191981	Green Published			2022-12-28	WOS:000222114400027
J	Seymour, B; O'Doherty, JP; Dayan, P; Koltzenburg, M; Jones, AK; Dolan, RJ; Friston, KJ; Frackowiak, RS				Seymour, B; O'Doherty, JP; Dayan, P; Koltzenburg, M; Jones, AK; Dolan, RJ; Friston, KJ; Frackowiak, RS			Temporal difference models describe higher-order learning in humans	NATURE			English	Article							NEURAL SUBSTRATE; HUMAN BRAIN; PREDICTION; DOPAMINE; REWARD; PAIN; EXPECTATION; EVENTS; FEAR	The ability to use environmental stimuli to predict impending harm is critical for survival. Such predictions should be available as early as they are reliable. In pavlovian conditioning, chains of successively earlier predictors are studied in terms of higher-order relationships, and have inspired computational theories such as temporal difference learning(1). However, there is at present no adequate neurobiological account of how this learning occurs. Here, in a functional magnetic resonance imaging ( fMRI) study of higher-order aversive conditioning, we describe a key computational strategy that humans use to learn predictions about pain. We show that neural activity in the ventral striatum and the anterior insula displays a marked correspondence to the signals for sequential learning predicted by temporal difference models. This result reveals a flexible aversive learning process ideally suited to the changing and uncertain nature of real-world environments. Taken with existing data on reward learning(2), our results suggest a critical role for the ventral striatum in integrating complex appetitive and aversive predictions to coordinate behaviour.	Wellcome Dept Imaging Neurosci, London WC1N 3BG, England; Gatsby Computat Neurosci Unit, London WC1N 3AR, England; UCL, Inst Child Hlth, London WC1N 1EH, England; Univ Manchester, Ctr Rheumat Dis, Hope Hosp, Manchester M6 8HD, Lancs, England; Fdn Santa Lucia, I-00179 Rome, Italy	University of London; University College London; University of London; University College London; University of London; University College London; University of Manchester; IRCCS Santa Lucia	Seymour, B (corresponding author), Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3BG, England.	bseymour@fil.ion.ucl.ac.uk	Frackowiak, Richard/H-4383-2011; Friston, Karl/D-9230-2011; Koltzenburg, Martin/C-1349-2008; O'Doherty, John P/F-1204-2013; Frackowiak, Richard S/I-1809-2013	Frackowiak, Richard/0000-0002-3151-822X; Friston, Karl/0000-0001-7984-8909; Koltzenburg, Martin/0000-0001-9181-5966; Jones, Anthony/0000-0001-6944-9365; Seymour, Ben/0000-0003-1724-5832; Dayan, Peter/0000-0003-3476-1839; Dolan, Ray/0000-0001-9356-761X				AZMITIA EC, 1978, J COMP NEUROL, V179, P641, DOI 10.1002/cne.901790311; Barto A.G., 1990, LEARNING COMPUTATION, P539; BARTO AG, 1983, IEEE T SYST MAN CYB, V13, P834, DOI 10.1109/TSMC.1983.6313077; Beiser, 1995, MODELS INFORM PROCES, P215; Brandon SE, 2003, BEHAV PROCESS, V62, P5, DOI 10.1016/S0376-6357(03)00016-0; Buchel C, 1999, J NEUROSCI, V19, P10869; Buchel C, 2000, CURR OPIN NEUROBIOL, V10, P219, DOI 10.1016/S0959-4388(00)00078-7; CHUDLER EH, 1995, PAIN, V60, P3, DOI 10.1016/0304-3959(94)00172-B; Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; Deichmann R, 2003, NEUROIMAGE, V19, P430, DOI 10.1016/S1053-8119(03)00073-9; Dickinson A., 1980, CONT ANIMAL LEARNING; Dickinson A., 1979, MECH LEARNING MOTIVA, P203; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; Horvitz JC, 2002, BEHAV BRAIN RES, V137, P65, DOI 10.1016/S0166-4328(02)00285-1; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Ploghaus A, 2003, TRENDS COGN SCI, V7, P197, DOI 10.1016/S1364-6613(03)00061-5; Ploghaus A, 2000, P NATL ACAD SCI USA, V97, P9281, DOI 10.1073/pnas.160266497; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Suri RE, 2001, NEURAL COMPUT, V13, P841, DOI 10.1162/089976601300014376; Sutton R.S., 1990, LEARNING COMPUTATION, P497; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135	30	439	441	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	2004	429	6992					664	667		10.1038/nature02581	http://dx.doi.org/10.1038/nature02581			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190354	Green Published			2022-12-28	WOS:000221912600042
J	Ma, RCW; Tsang, MW; Ozaki, R; Tong, PC; Cockram, CS				Ma, RCW; Tsang, MW; Ozaki, R; Tong, PC; Cockram, CS			Fever, headache, and a stiff neck	LANCET			English	Editorial Material							PITUITARY APOPLEXY		Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; United Christian Hosp, Dept Med & Geriatr, Kowloon, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; United Christian Hospital	Ma, RCW (corresponding author), Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	rcwma@netvigator.com	Ma, Ronald/C-2788-2009	Ma, Ronald/0000-0002-1227-803X				BJERRE P, 1986, ACTA NEUROL SCAND, V74, P304; CARDOSO ER, 1984, NEUROSURGERY, V14, P363, DOI 10.1227/00006123-198403000-00021; CONOMY JP, 1975, NEUROLOGY, V25, P580, DOI 10.1212/WNL.25.6.580; Randeva HS, 1999, CLIN ENDOCRINOL, V51, P181, DOI 10.1046/j.1365-2265.1999.00754.x	4	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1868	1868		10.1016/S0140-6736(04)16355-1	http://dx.doi.org/10.1016/S0140-6736(04)16355-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183625				2022-12-28	WOS:000221822300011
J	Weir, REP; Whitehead, DEJ; Zaidi, FH; Greaves, BBG				Weir, REP; Whitehead, DEJ; Zaidi, FH; Greaves, BBG			Pupil blown by a puffer	LANCET			English	Editorial Material									UCL, Inst Ophthalmol, Dept Physiol Opt, London EC1V 9EL, England; William Harvey Hosp, Dept Ophthalmol, Ashford, E Kent, England; Canterbury Hosp, Dept Ophthalmol, Canterbury, E Kent, England; Wexham Pk Hosp, Dept Plast Surg, Slough, Berks, England; Univ London Imperial Coll Sci Technol & Med, Dept Ophthalmol, London, England	University of London; University College London; Imperial College London	Weir, REP (corresponding author), UCL, Inst Ophthalmol, Dept Physiol Opt, London EC1V 9EL, England.			Weir, Robert/0000-0002-7432-6375					0	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1853	1853		10.1016/S0140-6736(04)16352-6	http://dx.doi.org/10.1016/S0140-6736(04)16352-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183622	Bronze			2022-12-28	WOS:000221822300008
J	Liu, J; Hong, YL; D'Agostino, RB; Wu, ZS; Wang, W; Sun, JY; Wilson, PWF; Kannel, WB; Zhao, D				Liu, J; Hong, YL; D'Agostino, RB; Wu, ZS; Wang, W; Sun, JY; Wilson, PWF; Kannel, WB; Zhao, D			Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; MONICA PROJECT; PRIMARY PREVENTION; CLINICAL-PRACTICE; TASK-FORCE; MORTALITY; TRENDS; VALIDATION; GUIDELINES	Context The Framingham Heart Study helped to establish tools to assess coronary heart disease (CHD) risk, but the homogeneous nature of the Framingham population prevents simple extrapolation to other populations. Recalibration of Framingham functions could permit various regions of the world to adapt Framingham tools to local populations. Objective To evaluate the performance of the Framingham CHD risk functions, directly and after recalibration, in a large Chinese population, compared with the performance of the functions derived from the Chinese Multi-provincial Cohort Study (CMCS). Design, Setting, and Participants The CMCS cohort included 30121 Chinese adults aged 35 to 64 years at baseline. Participants were recruited from 11 provinces and were followed up for new CHD events from 1992 to 2002. Participants in the Framingham Heart Study were 5251 white US residents of Framingham, Mass, who were 30 to 74 years old at baseline in 1971 to 1974 and followed up for 12 years. Main Outcome Measures "Hard" CHD (coronary death and myocardial infarction) was used as the end point in comparisons of risk factors (age, blood pressure, smoking, diabetes, total cholesterol, and high-density lipoprotein cholesterol [HDL-C]) as evaluated by the CMCS functions, original Framingham functions, and recalibrated Framingham functions. Results The CMCS cohort had 191 hard CHD events and 625 total deaths vs 273 CHD events and 293 deaths, respectively, for Framingham. For most risk factor categories, the relative risks for CHID were similar for Chinese and Framingham participants, with a few exceptions (ie, age, total cholesterol of 200-239 mg/dL [5.18-6.19 mmol/L], and HDL-C less than 35 mg/dL [0.91 mmol/L] in men; smoking in women). The discrimination using the Framingham functions in the CMCS cohort was similar to the CMCS functions: the area under the receiver operating characteristic curve was 0.705 for men and 0.742 for women using the Framingham functions vs 0.736 for men and 0.759 for women using the CMCS functions. However, the original Framingham functions systematically overestimated the absolute CHD risk in the CMCS cohort. For example, in the 10th risk decile in men, the predicted rate of CHD death was 20% Vs an actual rate of 3%. Recalibration of the Framingham functions using the mean values of risk factors and mean CHD incidence rates of the CMCS cohort substantially improved the performance of the Framingham functions in the CMCS cohort. Conclusions The original Framingham functions overestimated the risk of CHD for CMCS participants. Recalibration of the Framingham functions improved the estimates and demonstrated that the Framingham model is useful in the Chinese population. For regions that have no established cohort, recalibration using CHD rates and risk factors may be an effective method to develop CHD risk prediction algorithms suited for local practice.	Beijing Inst Heart Lung & Blood Vessel Dis, Dept Epidemiol, Beijing 100029, Peoples R China; Amer Heart Assoc, Dallas, TX USA; Boston Univ, Boston, MA 02215 USA	Boston University	Liu, J (corresponding author), Beijing Inst Heart Lung & Blood Vessel Dis, Dept Epidemiol, Beijing 100029, Peoples R China.	jingliu0516@yahoo.com.cn	Liu, Jing/AAH-8079-2021; Wilson, Peter W.F./J-2455-2016	Liu, Jing/0000-0002-3311-0818; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073272] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL 073272-01, N01-HC-380380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Chalmers J, 1999, J HYPERTENS, V17, P151; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; DAWBER TR, 1959, AM J PUBLIC HEALTH N, V49, P1349, DOI 10.2105/AJPH.49.10.1349; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 1998, CIRCULATION, V97, P1876, DOI 10.1161/01.CIR.97.18.1876; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hense HW, 2003, EUR HEART J, V24, P937, DOI 10.1016/S0195-668X(03)00081-2; Jackson R, 2000, BMJ-BRIT MED J, V320, P659, DOI 10.1136/bmj.320.7236.659; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KANNEL WB, 1964, ANN INTERN MED, V61, P888, DOI 10.7326/0003-4819-61-5-888; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; Liao YL, 1999, AM HEART J, V137, P837, DOI 10.1016/S0002-8703(99)70407-2; Liu J., 2001, CHIN J CARDIOL, V29, P561; Marrugat J, 2003, J EPIDEMIOL COMMUN H, V57, P634, DOI 10.1136/jech.57.8.634; NAM BH, 2000, DISCRIMINATION CALIB; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; POSNER BM, 1995, J AM DIET ASSOC, V95, P171, DOI 10.1016/S0002-8223(95)00043-7; PYORALA K, 1994, EUR HEART J, V15, P1300; STEWART AW, 1994, INT J EPIDEMIOL, V23, P505; Thomsen TF, 2002, INT J EPIDEMIOL, V31, P817, DOI 10.1093/ije/31.4.817; Tolonen H, 2002, STROKE, V33, P2367, DOI 10.1161/01.STR.0000033131.27936.7F; TUOMILEHTO J, 1989, INT J EPIDEMIOL, V18, pS38; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wood D, 1998, EUR HEART J, V19, P1434; World Health Organization, 1985, WHO TECHN REP SER, V727; [吴桂贤 Wu Guixian], 2003, [中华流行病学杂志, Chinese Journal of Epidemiology], V24, P551; Wu Z., 2001, CHIN J CARDIOL, V29, P246; Wu ZS, 2001, CIRCULATION, V103, P462; WU ZS, 1999, CHIN J CARDIOL, V27, P5; ZHAO D, 1999, CVD PREV, V2, P252; 赵冬, 2001, 中华心血管病杂志, V29, P612	35	477	533	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2591	2599		10.1001/jama.291.21.2591	http://dx.doi.org/10.1001/jama.291.21.2591			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173150	Bronze			2022-12-28	WOS:000221738800022
J	Bravata, DM; McDonald, KM; Smith, WM; Rydzak, C; Szeto, H; Buckeridge, DL; Haberland, C; Owens, DK				Bravata, DM; McDonald, KM; Smith, WM; Rydzak, C; Szeto, H; Buckeridge, DL; Haberland, C; Owens, DK			Systematic review: Surveillance systems for early detection of bioterrorism-related diseases	ANNALS OF INTERNAL MEDICINE			English	Review							MONTE-CARLO TECHNIQUES; HOSPITAL-INFECTION-CONTROL; HEALTH MONITORING-SYSTEM; DECISION-SUPPORT-SYSTEM; EMERGENCY ID NET; INFLUENZA SURVEILLANCE; ANTIMICROBIAL RESISTANCE; COMMUNICABLE DISEASES; PARAMETER SENSITIVITY; ELECTRONIC NETWORK	Background: Given the threat of bioterrorism and the increasing availability of electronic data for surveillance, surveillance systems for the early detection of illnesses and syndromes potentially related to bioterrorism have proliferated. Purpose: To critically evaluate the potential utility of existing surveillance systems for illnesses and syndromes related to bioterrorism. Data Sources: Databases of peer-reviewed articles (for example, MEDLINE for articles published from January 1985 to April 2002) and Web sites of relevant government and nongovernment agencies. Study Selection: Reports that described or evaluated systems for collecting, analyzing, or presenting surveillance data for bioterrorism-related illnesses or syndromes. Data Extraction: From each included article, the authors abstracted information about the type of surveillance data collected; method of collection, analysis, and presentation of surveillance data; and outcomes of evaluations of the system. Data Synthesis: 17 510 article citations and 8088 government and nongovernmental Web sites were reviewed. From these, the authors included 115 systems that collect various surveillance reports, including 9 syndromic surveillance systems, 20 systems collecting bioterrorism detector data, 13 systems collecting influenza-related data, and 23 systems collecting laboratory and antimicrobial resistance data. Only the systems collecting syndromic surveillance data and detection system data were designed, at least in part, for bioterrorism preparedness applications. Syndromic surveillance systems have been deployed for both event-based and continuous bioterrorism surveillance. Few surveillance systems have been comprehensively evaluated. Only 3 systems have had both sensitivity and specificity evaluated. Limitations: Data from some existing surveillance systems (particularly those developed by the military) may not be publicly available. Conclusions: Few surveillance systems have been specifically designed for collecting and analyzing data for the early detection of a bioterrorist event. Because current evaluations of surveillance systems for detecting bioterrorism and emerging infections are insufficient to characterize the timeliness or sensitivity and specificity, clinical and public health decision making based on these systems may be compromised.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Univ Calif San Francisco, Stanford Evidence Practice Ctr, San Francisco, CA USA; Kaiser Permanente, Redwood City, CA USA; Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA	Stanford University; University of California System; University of California San Francisco; Kaiser Permanente; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Bravata, DM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.	bravata@healthpolicy.stanford.edu			PHS HHS [290-97-0013] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altmann M, 1998, MATH BIOSCI, V150, P153, DOI 10.1016/S0025-5564(98)00012-1; [Anonymous], PRINCIPLES PRACTICE; BERNARD KW, 1989, INT J EPIDEMIOL, V18, P220, DOI 10.1093/ije/18.1.220; BIRKHEAD G, 1991, AM J PUBLIC HEALTH, V81, P1313, DOI 10.2105/AJPH.81.10.1313; Blajan L, 1991, Rev Sci Tech, V10, P51; Bouam S, 1999, J AM MED INFORM ASSN, P696; Boussard E, 1996, BMJ-BRIT MED J, V313, P1381, DOI 10.1136/bmj.313.7069.1381; BRAVATA DM, 2002, BIOTERRORISM PREPARE; BRAVATA DM, 2003, J URBAN HEALTH, V80, pI122; Brossette SE, 1998, J AM MED INFORM ASSN, V5, P373, DOI 10.1136/jamia.1998.0050373; Brossette SE, 2000, METHOD INFORM MED, V39, P303; BRUCKNER GK, 1995, OFF INT EP COMPR REP; BURKEN MI, 1990, INFECT CONT HOSP EP, V11, P410; Bush E. J., 1995, Epidemiologie et Sante Animale, P113; Campbell J, 1999, MIL MED, V164, P541, DOI 10.1093/milmed/164.8.541; Canas LC, 2000, MIL MED, V165, P52, DOI 10.1093/milmed/165.suppl_2.52; Carrat F, 1998, J EPIDEMIOL COMMUN H, V52, p32S; *CDCP, 2000, FOODN SURV REP 1999; Chauvin P, 1997, INT J EPIDEMIOL, V26, P166, DOI 10.1093/ije/26.1.166; CORWIN A, 2000, NAVY MED         SEP, P1; COSTAGLIOLA D, 1991, AM J PUBLIC HEALTH, V81, P97, DOI 10.2105/AJPH.81.1.97; CROOK P, 2000, EUROSURVEILLANCE WEE; Darling RG, 2002, EMERG MED CLIN N AM, V20, P273, DOI 10.1016/S0733-8627(02)00005-6; Davis SR, 2000, MIL MED, V165, P35, DOI 10.1093/milmed/165.suppl_2.35; de Neeling AJ, 1998, J ANTIMICROB CHEMOTH, V41, P93, DOI 10.1093/jac/41.1.93; Doyle TJ, 2000, J INFECT DIS, V182, P1503, DOI 10.1086/315876; Effler P, 1999, JAMA-J AM MED ASSOC, V282, P1845, DOI 10.1001/jama.282.19.1845; EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; EVANS RS, 1992, AM J INFECT CONTROL, V20, P4; Flahault A, 1998, JAMA-J AM MED ASSOC, V280, P1330, DOI 10.1001/jama.280.15.1330; FLAHAULT A, 1995, LANCET, V346, P162, DOI 10.1016/S0140-6736(95)91214-2; Fleming DM, 1996, J PUBLIC HEALTH MED, V18, P133, DOI 10.1093/oxfordjournals.pubmed.a024472; FRANK GR, 1988, J AM VET MED ASSOC, V192, P1063; GARNER M, 1995, B ASS ETUDE MALADIES, V27, P143; GARNERIN P, 1992, ANN NY ACAD SCI, V670, P29, DOI 10.1111/j.1749-6632.1992.tb26072.x; GARNERIN P, 1992, COMPUT BIOL MED, V22, P189, DOI 10.1016/0010-4825(92)90015-F; Gilchrist JR, 2000, MIL MED, V165, P28, DOI 10.1093/milmed/165.suppl_2.28; GONZALEZGUZMAN J, 1989, MATH BIOSCI, V96, P33, DOI 10.1016/0025-5564(89)90081-3; GRAITCER PL, 1987, AM J PREV MED, V3, P123; Grant A D, 1993, Commun Dis Rep CDR Rev, V3, pR75; HANNOUN C, 1989, EUR J EPIDEMIOL, V5, P285, DOI 10.1007/BF00144828; HANSEN G, 2001, GUIDE IMPLEMENTATION, P13; Harcourt S E, 2001, Commun Dis Public Health, V4, P178; Heininger A, 1999, INFECT CONT HOSP EP, V20, P444, DOI 10.1086/501652; Heymann DL, 1998, EMERG INFECT DIS, V4, P362, DOI 10.3201/eid0403.980305; Hoban DJ, 2001, CLIN INFECT DIS, V32, pS81, DOI 10.1086/320181; HUESTON WD, 1990, PREV VET MED, V8, P97, DOI 10.1016/0167-5877(90)90003-Z; Hung J, 1998, J AM MED INFORM ASSN, P688; Hutwagner LC, 1997, EMERG INFECT DIS, V3, P395, DOI 10.3201/eid0303.970322; Joch J, 2000, STUD HEALTH TECHNOL, V77, P812; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; Kahn M G, 1995, Medinfo, V8 Pt 2, P1064; Kahn MG, 1996, J AM MED INFORM ASSN, V3, P216, DOI 10.1136/jamia.1996.96310635; Kahn MG, 1996, J AM MED INFORM ASSN, V3, P258, DOI 10.1136/jamia.1996.96413133; KAHN MG, 1993, P ANN S COMP APPL ME, V3, P171; Karras DJ, 2000, ANN EMERG MED, V35, P93; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; KELLO D, 1990, FOOD ADDIT CONTAM, V7, pS5, DOI 10.1080/02652039009373835; King KD, 1999, BIOSENS BIOELECTRON, V14, P163, DOI 10.1016/S0956-5663(98)00108-0; Koplan J, 2001, PUBLIC HEALTH REP, V116, P9, DOI 10.1016/S0033-3549(04)50132-2; KRALOVIC SM, 2001, ANN M INF DIS SOC AM, P127; LANGMUIR AD, 1963, NEW ENGL J MED, V268, P182, DOI 10.1056/NEJM196301242680405; Lazarus R, 2001, BMC PUBLIC HEALTH, V1, DOI 10.1186/1471-2458-1-9; Lober WB, 2002, J AM MED INFORM ASSN, V9, P105, DOI 10.1197/jamia.M1052; Losinger WC, 1998, PREV VET MED, V34, P147, DOI 10.1016/S0167-5877(97)00076-7; MA JZ, 1993, INT J BIOMED COMPUT, V33, P297, DOI 10.1016/0020-7101(93)90043-6; MA JZ, 1993, INT J BIOMED COMPUT, V32, P255, DOI 10.1016/0020-7101(93)90018-2; MA JZ, 1993, INT J BIOMED COMPUT, V32, P237, DOI 10.1016/0020-7101(93)90017-Z; Madsen KM, 1998, INFECT CONT HOSP EP, V19, P175; MAGGINI M, 1991, J CLIN EPIDEMIOL, V44, P1299, DOI 10.1016/0895-4356(91)90091-M; MAQBOOL S, 2001, NEWS            0711; MARTIN SM, 1995, EMERG INFECT DIS, V1, P124, DOI 10.3201/eid0104.950403; Massari V, 1998, EUR J EPIDEMIOL, V14, P765, DOI 10.1023/A:1007596929640; MCCLURE PJ, 1994, INT J FOOD MICROBIOL, V23, P265, DOI 10.1016/0168-1605(94)90156-2; McLaws M L, 2000, J Qual Clin Pract, V20, P6, DOI 10.1046/j.1440-1762.2000.00347.x; McLaws ML, 2000, AM J INFECT CONTROL, V28, P401, DOI 10.1067/mic.2000.111373; Moran GJ, 2002, EMERG MED CLIN N AM, V20, P311, DOI 10.1016/S0733-8627(01)00003-7; O'Brien T F, 1996, Diagn Microbiol Infect Dis, V25, P162; OBRIEN TF, 1995, EMERG INFECT DIS, V1, P66, DOI 10.3201/eid0102.950209; Osaka K, 1999, EPIDEMIOL INFECT, V123, P431, DOI 10.1017/S0950268899003179; Parsons D F, 1996, Telemed J, V2, P273, DOI 10.1089/tmj.1.1996.2.273; PAVLIN JA, 2001, ESSENCE ELECT SURVEI; Powell SC, 1998, J FOOD PROTECT, V61, P1170, DOI 10.4315/0362-028X-61.9.1170; Quenel P, 1998, EUR J EPIDEMIOL, V14, P275, DOI 10.1023/A:1007467814485; Ramphal R, 2000, DIAGN MICR INFEC DIS, V36, P125, DOI 10.1016/S0732-8893(99)00118-2; RASLEY D, 1988, INFECTION, V16, P373, DOI 10.1007/BF01644554; Richet HM, 2001, EMERG INFECT DIS, V7, P319, DOI 10.3201/eid0702.010235; RIVIERE JE, 1986, J FOOD PROTECT, V49, P826, DOI 10.4315/0362-028X-49.10.826; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164; Rundio A Jr, 1994, Health Care Superv, V12, P20; Rypka E W, 1997, Am Clin Lab, V16, P6; Rypka E W, 1997, Am Clin Lab, V16, P14; Sahm DF, 1999, CLIN INFECT DIS, V29, P259, DOI 10.1086/520195; Sahm DF, 2001, ANTIMICROB AGENTS CH, V45, P267, DOI 10.1128/AAC.45.1.267-274.2001; SAMORE M, 1997, P AMIA ANN FALL S, V21, P56; Sanson R., 1994, Surveillance (Wellington), V21, P22; Sanson RL, 1999, REV SCI TECH OIE, V18, P593, DOI 10.20506/rst.18.3.1181; SCHIFMAN RB, 1985, J CLIN MICROBIOL, V21, P493, DOI 10.1128/JCM.21.4.493-495.1985; SCHOUB BD, 1994, S AFR MED J, V84, P674; Schwoebel V, 1999, Med Arh, V53, P9; Sischo WM, 1999, J AM VET MED ASSOC, V214, P344; SMYTH ETM, 1993, J HOSP INFECT, V25, P137, DOI 10.1016/0195-6701(93)90105-9; Smyth ETM, 1997, INFECT CONT HOSP EP, V18, P486; Smyth ETM, 1996, J HOSP INFECT, V34, P87, DOI 10.1016/S0195-6701(96)90133-4; Snacken R, 1998, METHOD INFORM MED, V37, P266; Snacken R, 1995, METHOD INFORM MED, V34, P518; Sosin DM, 2003, J URBAN HEALTH, V80, pI8; SOSIN DM, 2003, DRAFT FRAMEWORK EVAL; SPRENGER MJW, 1992, LANCET, V339, P874, DOI 10.1016/0140-6736(92)90319-X; Stark KDC, 1998, REV SCI TECH OIE, V17, P682, DOI 10.20506/rst.17.3.1130; Stelling JM, 1997, CLIN INFECT DIS, V24, pS157, DOI 10.1093/clinids/24.Supplement_1.S157; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P1337, DOI 10.1001/jama.277.17.1337; Stern L, 1999, EPIDEMIOL INFECT, V122, P103, DOI 10.1017/S0950268898001939; STERN L, 1996, P 1 WORLD C COMP MED, P1395; Swaminathan B, 2001, EMERG INFECT DIS, V7, P382; SZECSENYI J, 1995, J EPIDEMIOL COMMUN H, V49, P9, DOI 10.1136/jech.49.Suppl_1.9; Takahashi T, 2001, JPN J INFECT DIS, V54, P27; Talan DA, 1998, ANN EMERG MED, V32, P703, DOI 10.1016/S0196-0644(98)70071-X; Talan DA, 1999, CLIN INFECT DIS, V28, P401, DOI 10.1086/517199; TALASKA T, 1994, B WORLD HEALTH ORGAN, V72, P69; *US DEP DEF, 2000, CEHM BIOL DEF PROGR; *US DEP DEF, 1999, GLOB EM INF SYST ANN; Valleron A J, 1993, Commun Dis Rep CDR Rev, V3, pR82; VALLERON AJ, 1986, AM J PUBLIC HEALTH, V76, P1289, DOI 10.2105/AJPH.76.11.1289; van Gerwen SJC, 1997, INT J FOOD MICROBIOL, V38, P1, DOI 10.1016/S0168-1605(97)00077-9; van Gerwen SJC, 2000, J APPL MICROBIOL, V88, P938, DOI 10.1046/j.1365-2672.2000.01059.x; VANCASTEREN V, 1992, METHOD INFORM MED, V31, P147; Vatopoulos AC, 1999, B WORLD HEALTH ORGAN, V77, P595; Wallace DJ, 2000, J FOOD PROTECT, V63, P807, DOI 10.4315/0362-028X-63.6.807; Wein LM, 2003, P NATL ACAD SCI USA, V100, P4346, DOI 10.1073/pnas.0636861100; Williams RJ, 1997, MIL MED, V162, P82, DOI 10.1093/milmed/162.2.82; World Health Organization, 2003, OP RESP SARS; Yokoe DS, 1999, EMERG INFECT DIS, V5, P779, DOI 10.3201/eid0506.9906; ZELICOFF A, 2001, RAPID SYNDROME VALID; 2001, MMWR MORB MORTAL WKL, V50, P241; 1999, MMWR MORB MORTAL WKL, V48, P305; 2000, EURO TB INVSKNCV NAT; 1988, MMWR MORB MORTAL W S, V37, P1; 1997, MMWR MORB MORTAL WKL, V46, P258; 1999, CHEM BIOL TERRORISM; 1989, MMWR MORB MORTAL WKL, V38, P855; 1999, EMERG INFECT DIS, V5, P314; 1990, WKLY EPIDEMIOL REC, V65, P103	144	177	180	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					910	922		10.7326/0003-4819-140-11-200406010-00013	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00013			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824IS	15172906				2022-12-28	WOS:000221680600008
J	Iida, K; Proctor, RN				Iida, K; Proctor, RN			Learning from Philip Morris: Japan Tobacco's strategies regarding evidence of tobacco health harms as revealed in internal documents from the American tobacco industry	LANCET			English	Article							MARKET LIBERALIZATION; SMOKING	Japan is in the midst of a rapid increase in tobacco-related disease mortality, following the rapid growth of smoking after WWII. Stomach cancer was the country's leading cause of cancer death for most of the 20th century, until lung cancer took over this position in 1993. Cigarettes are the major cause of lung cancer in Japan, but the country's leading manufacturer, Japan Tobacco, two thirds of which is owned by the Japanese government, continues to question whether tobacco is a major cause of disease and death. Japanese courts do not have the power to subpoena a company's internal records, which has made it difficult to document Japan Tobacco's strategies concerning tobacco and health. Our interpretation of online archives of internal documents from American tobacco companies, however, is that Japan Tobacco has long known about the-potential health risks involved in smoking and has sought to obstruct effective tobacco control. Beginning in the mid-1980s, these efforts were often co-ordinated with American tobacco manufacturers. The documentary evidence shows that cigarette manufacturer Philip Morris in particular assisted with and sometimes also supervised Japan Tobacco's actions and statements on smoking and health. In one instance, data gathered for an article published by the Japan Public Monopoly Corporation (Japan Tobacco's predecessor) were deliberately altered to lower the reported value of a hazard indicator (nicotine concentration in the air). International collaboration has made it easier for companies such as Japan Tobacco to develop effective anti-antismoking strategies. Evidence of such global industry collaborations might grow as lawsuits begin to be filed in other nations.	Stanford Univ, Dept Hist, Stanford, CA 94305 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Proctor, RN (corresponding author), Stanford Univ, Dept Hist, Stanford, CA 94305 USA.	proctor@stanford.edu						Honjo K, 2000, TOB CONTROL, V9, P193, DOI 10.1136/tc.9.2.193; *IARC, 2000, GLOBOCAN; *JAP TOB, FACT BOOK 2003; *MIN HLTH WELF JAP, 1987, KITS TO KENK KITS TO; MINOWA M, 1996, MISEINENSHA NO KITSU; Muggli ME, 2001, AM J PUBLIC HEALTH, V91, P1419, DOI 10.2105/AJPH.91.9.1419; MURAMATSU M, 1984, ENVIRON RES, V35, P218, DOI 10.1016/0013-9351(84)90130-0; *NAT CANC CTR, EST CANC INC YEAR 20; National Cancer Center, CANC STAT JAP; Sato H, 1999, SOC SCI MED, V49, P581, DOI 10.1016/S0277-9536(99)00087-8; Sato H, 2000, ADDICTION, V95, P1079, DOI 10.1046/j.1360-0443.2000.95710799.x; *TOB DIS LAWS SUPP, TAB BYO SOSH; *US CDCP, NAT TOB INF ONL SYST; 2000, KINEN JYANARU, P110; 2003, ASAHI SHIMBUN   0301	15	22	22	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1820	1824		10.1016/S0140-6736(04)16310-1	http://dx.doi.org/10.1016/S0140-6736(04)16310-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824SD	15172783	Green Submitted			2022-12-28	WOS:000221705800026
J	Bietenholz, MF; Bartel, N; Rupen, MP				Bietenholz, MF; Bartel, N; Rupen, MP			Discovery of a compact radio component in the center of supernova 1986J	SCIENCE			English	Article							PULSAR NEBULA; EVOLUTION; DECELERATION; EXPANSION; REMNANTS; EMISSION; 1993J; VLBI	Very-long-baseline interferometry observations have revealed a bright, compact radio component near the center of the expanding shell of supernova 1986J. The component, not present in earlier images, has an inverted radio spectrum different from that of the shell. Such an inversion has not been seen in the spectrum of any other supernova. The new component is likely radio emission associated either with accretion onto a black hole or with the nebula formed around an energetic young neutron star in the center of SN 1986J, which would directly link either a black hole or a neutron star to a modern supernova.	York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada; Natl Radio Astron Observ, Socorro, NM 87801 USA	York University - Canada; National Radio Astronomy Observatory (NRAO)	Bietenholz, MF (corresponding author), York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada.	mbieten@yorku.ca						BANDIERA R, 1983, ASTRON ASTROPHYS, V126, P7; BANDIERA R, 1984, ASTROPHYS J, V285, P134, DOI 10.1086/162484; Bartel N, 2000, SCIENCE, V287, P112, DOI 10.1126/science.287.5450.112; BARTEL N, 1991, NATURE, V350, P212, DOI 10.1038/350212a0; Bietenholz MF, 2001, ASTROPHYS J, V560, P772, DOI 10.1086/323066; Bietenholz MF, 2003, ASTROPHYS J, V597, P374, DOI 10.1086/378265; Bietenholz MF, 2002, ASTROPHYS J, V581, P1132, DOI 10.1086/344251; BIETENHOLZ MF, 1991, ASTROPHYS J, V373, pL59, DOI 10.1086/186051; BIETENHOLZ MF, FUTURE DIRECTIONS HI; CHEVALIER RA, 1987, NATURE, V329, P611, DOI 10.1038/329611a0; CHEVALIER RA, 1992, ASTROPHYS J, V395, P540, DOI 10.1086/171674; Chevalier RA, 1998, ASTROPHYS J, V499, P810, DOI 10.1086/305676; Fryer CL, 1999, ASTROPHYS J, V522, P413, DOI 10.1086/307647; Gvaramadze VV, 2002, ASTR SOC P, V271, P23; Mioduszewski AJ, 2001, ASTROPHYS J, V562, P869, DOI 10.1086/323852; REYNOLDS SP, 1984, ASTROPHYS J, V278, P630, DOI 10.1086/161831; Rohlfs K., 1996, TOOLS RADIO ASTRONOM; RUPEN MP, 1987, ASTRON J, V94, P61, DOI 10.1086/114447; TANANBAUM H, 1999, 7246 IAU; Tonry JL, 2001, ASTROPHYS J, V546, P681, DOI 10.1086/318301; VANGORKOM J, 1986, 4248 IAU; Weiler KW, 2002, ANNU REV ASTRON ASTR, V40, P387, DOI 10.1146/annurev.astro.40.060401.093744; WEILER KW, 1990, ASTROPHYS J, V364, P611, DOI 10.1086/169444; White RL, 1997, ASTROPHYS J, V475, P479, DOI 10.1086/303564	24	34	34	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1947	1949		10.1126/science.1099460	http://dx.doi.org/10.1126/science.1099460			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15192155				2022-12-28	WOS:000222241600040
J	Zou, DJ; Feinstein, P; Rivers, AL; Mathews, GA; Kim, A; Greer, CA; Mombaerts, P; Firestein, S				Zou, DJ; Feinstein, P; Rivers, AL; Mathews, GA; Kim, A; Greer, CA; Mombaerts, P; Firestein, S			Postnatal refinement of peripheral olfactory projections	SCIENCE			English	Article							MICE DEFICIENT; NARIS CLOSURE; BULB; SYSTEM; EPITHELIUM; GLOMERULI; MOUSE; MAP; ORGANIZATION; SPECIFICITY	Axonal projections from the olfactory epithelium to the olfactory bulb are organized into glomeruli according to the expressed odorant receptor. Using gene-targeted mice, we show that glomerular maturation proceeds along different time courses for two similar receptors and requires sensory input during distinct sensitive periods. During early development, some glomeruli are innervated by axons of neurons that do not express the same receptor. These heterogeneous glomeruli normally disappear with age, but they persist in adults deprived of sensory input by unilateral and permanent naris closure. Persistence may be due, in part, to prolonged survival of olfactory sensory neurons.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Rockefeller Univ, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA	Columbia University; Rockefeller University; Yale University; Yale University	Zou, DJ (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	dz98@columbia.edu; sjf24@columbia.edu						Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; BENSON TE, 1984, J NEUROSCI, V4, P638; BRUNJES PC, 1994, BRAIN RES REV, V19, P146; Conzelmann S, 2001, EUR J NEUROSCI, V14, P1623, DOI 10.1046/j.0953-816x.2001.01788.x; Ebrahimi FAW, 2000, CURR BIOL, V10, P219, DOI 10.1016/S0960-9822(00)00342-0; FARBMAN AI, 1988, J NEUROSCI, V8, P3290; HALASZ N, 1993, J COMP NEUROL, V337, P307, DOI 10.1002/cne.903370211; Kasowski HJ, 1999, J COMP NEUROL, V407, P261, DOI 10.1002/(SICI)1096-9861(19990503)407:2<261::AID-CNE7>3.0.CO;2-G; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Klenoff JR, 1998, J COMP NEUROL, V390, P256; Lin DM, 2000, NEURON, V26, P69, DOI 10.1016/S0896-6273(00)81139-3; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nakatani H, 2003, EUR J NEUROSCI, V18, P2425, DOI 10.1046/j.1460-9568.2003.02998.x; Philpot BD, 1997, J NEUROBIOL, V33, P374, DOI 10.1002/(SICI)1097-4695(199710)33:4<374::AID-NEU3>3.0.CO;2-7; Potter SM, 2001, J NEUROSCI, V21, P9713, DOI 10.1523/JNEUROSCI.21-24-09713.2001; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Royal SJ, 1999, J NEUROSCI, V19, P9856; Tenne-Brown J, 1999, J COMP NEUROL, V410, P20, DOI 10.1002/(SICI)1096-9861(19990719)410:1<20::AID-CNE3>3.0.CO;2-T; Treloar HB, 2002, J NEUROSCI, V22, P2469, DOI 10.1523/JNEUROSCI.22-07-02469.2002; Trinh K, 2003, NAT NEUROSCI, V6, P519, DOI 10.1038/nn1039; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Zhao HQ, 2001, CELL, V104, P651, DOI 10.1016/S0092-8674(02)01107-8; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X; ZOU D, UNPUB	26	177	180	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1976	1979		10.1126/science.1093468	http://dx.doi.org/10.1126/science.1093468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15178749				2022-12-28	WOS:000222241600048
J	Fairhurst, RM; Casella, JF				Fairhurst, RM; Casella, JF			Homozygous hemoglobin C disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIAID, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Fairhurst, RM (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.								0	6	6	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					E24	E24		10.1056/NEJMicm030486	http://dx.doi.org/10.1056/NEJMicm030486			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215497				2022-12-28	WOS:000222199000012
J	Atkins, D; Best, D; Briss, PA; Eccles, M; Falck-Ytter, Y; Flottorp, S; Guyatt, GH; Harbour, RT; Haugh, MC; Henry, D; Hill, S; Jaeschke, R; Leng, G; Liberati, A; Magrini, N; Mason, J; Middleton, P; Mrukowicz, J; O'Connell, D; Oxman, AD; Phillips, B; Schunemann, HJ; Edejer, TTT; Varonen, H; Vist, GE; Williams, JW; Zaza, S				Atkins, D; Best, D; Briss, PA; Eccles, M; Falck-Ytter, Y; Flottorp, S; Guyatt, GH; Harbour, RT; Haugh, MC; Henry, D; Hill, S; Jaeschke, R; Leng, G; Liberati, A; Magrini, N; Mason, J; Middleton, P; Mrukowicz, J; O'Connell, D; Oxman, AD; Phillips, B; Schunemann, HJ; Edejer, TTT; Varonen, H; Vist, GE; Williams, JW; Zaza, S		GRADE Working Grp	Grading quality of evidence and strength of recommendations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL RECOMMENDATIONS; RULES; GUIDELINES; MORTALITY		Norwegian Hlth Serv Res Ctr, Informed Choice Res Dept, POB 7004, N-0130 Oslo, Norway		Oxman, AD (corresponding author), Norwegian Hlth Serv Res Ctr, Informed Choice Res Dept, POB 7004, N-0130 Oslo, Norway.	oxman@online.no	Henry, David/AAU-4650-2020; Eccles, Martin P/AAD-4029-2020; Henry, David/AAJ-4332-2020; Falck-Ytter, Yngve/GZH-0993-2022; Yngve Falck-Ytter, AGAF/AAC-5362-2019; Mason, James M/D-9904-2011; Oxman, Andrew/Y-3004-2019	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242; Yngve Falck-Ytter, AGAF/0000-0002-4688-3211; Mason, James M/0000-0001-9210-4082; Oxman, Andrew/0000-0002-5608-5061; Flottorp, Signe/0000-0003-2961-7461; Schunemann, Holger/0000-0003-3211-8479; Edejer, Tessa/0000-0003-1068-332X				Briss PA, 2000, AM J PREV MED, V18, P35, DOI 10.1016/S0749-3797(99)00119-1; BROSS IDJ, 1967, J CHRON DIS, V20, P487, DOI 10.1016/0021-9681(67)90080-X; *CEVEAS, SCHEM GRAD DEVEAS; Clarke M, 2002, COCHRANE LIB; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1992, CHEST, V102, pS305; *CTR HLTH SERV RES, 1997, EV BAS CLIN PRACT GU; Dans A, 2002, USERS GUIDE MED LIT, V369-84; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Greer N, 2000, Jt Comm J Qual Improv, V26, P700; Guyatt G, 2001, CHEST, V119, p3S, DOI 10.1378/chest.119.1_suppl.3S; GUYATT G, 2002, USERS GUIDES MED LIT, P55; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS8; HADORN DC, 1994, JOINT COMM J QUAL IM, V20, P539, DOI 10.1016/S1070-3241(16)30099-2; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Harris RG, 2001, INT J MANAG REV, V3, P21, DOI 10.1111/1468-2370.00052; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Juni P, 2001, SYSTEMATIC REV HLTH, P87; Kleijnen J, 1997, NONRANDOM REFLECTION, P93; Kunz R, 2002, RANDOMISATION PROTEC; LACCHETTI C, 2002, USERS GUIDES MED LIT, P247; MCALISTER F, 2002, USERS GUIDE MED LIT, P415; National Health and Medical Research Council, 2000, US EV ASS APPL SCI E; Phillips B, LEVELS EVIDENCE GRAD; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Roman S H, 2000, Eff Clin Pract, V3, P85; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SACKETT DL, 1986, ARCH INTERN MED, V146, P464; SACKETT DL, 1986, CHEST, V89, pS2, DOI 10.1378/chest.89.2_Supplement.2S; Scottish Intercollegiate Guidelines Network, 2001, SIGN PUBL, V50; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Thompson DC, 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001855, DOI 10.1002/14651858.CD001855]; *US DEP HHS, 1992, AHCPR PUB; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, pR39; WEST S, 2002, SYSTEMS RATE STRENGT, P51; West S, 2002, AHRQ PUBLICATION, P64; Woloshin S, 2000, Eff Clin Pract, V3, P94; Woolf SH, 2001, AM J PREV MED, V20, P13, DOI 10.1016/S0749-3797(01)00262-8; Worster A, 2002, ANN EMERG MED, V40, P280, DOI 10.1067/mem.2002.126170; WORSTER A, 2002, CAN ASSOC RADIOL J, V53, P241; Zaza S, 2000, AM J PREV MED, V18, P44, DOI 10.1016/S0749-3797(99)00122-1; 1979, CAN MED ASS J, V121, P1193	47	3046	3205	2	147	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1490	+						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205295				2022-12-28	WOS:000222244600024
J	Chapple, A; Ziebland, S; McPherson, A				Chapple, A; Ziebland, S; McPherson, A			Stigma, shame, and blame experienced by patients with lung cancer: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING-CESSATION	Objectives To draw on narrative interviews with patients with lung cancer and to explore their perceptions and experience of stigma. Design Qualitative study. Setting United Kingdom. Participants 45 patients with lung cancer recruited through several sources. Results Participants experienced stigma commonly felt by patients with other types of cancer, but, whether they smoked or not, they felt particularly stigmatised because the disease is so strongly associated with smoking. Interaction with family, friends, and doctors was often affected as a result, and many patients, particularly those who had stopped smoking years ago or who had never smoked, felt unjustly blamed for their illness. Those who resisted victim blaming maintained that the real culprits were tobacco companies with unscrupulous policies. Some patients concealed their illness, which sometimes had adverse financial consequences or made it hard for them to gain support from other people. Some indicated that newspaper and television reports may have added to the stigma: television advertisements aim to put young people off tobacco, but they usually portray a dreadful death, which may exacerbate fear and anxiety. A few patients were worried that diagnosis, access to care, and research into lung cancer might be adversely affected by the stigma attached to the disease and those who smoke. Conclusions Patients with lung cancer report stigmatisation with far reaching consequences. Efforts to help people quit smoking are important, but clinical and educational interventions should be presented with care so as not to add to the stigma experienced by patients with lung cancer and other smoking related diseases.	Univ Oxford, DIPEx Res Grp, Dept Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Chapple, A (corresponding author), Univ Oxford, DIPEx Res Grp, Dept Primary Hlth Care, Oxford OX3 7LF, England.	alison.chapple@dphpc.ox.ac.uk		Ziebland, Sue/0000-0002-6496-4859				Ablon J, 2002, EPILEPSY BEHAV, V3, pS2; ALBRECHT GL, 1982, SOC SCI MED, V16, P1319, DOI 10.1016/0277-9536(82)90027-2; BELLABY P, 1990, SOCIOL HEALTH ILL, V12, P47, DOI 10.1111/1467-9566.ep10844878; Chambers J, 1999, BMJ-BRIT MED J, V318, P1; Coyne IT, 1997, J ADV NURS, V26, P623, DOI 10.1046/j.1365-2648.1997.t01-25-00999.x; *DEP HLTH, 1998, CMND3852; Douglas M., 2003, PURITY DANGER ANAL C, DOI 10.4324/9780203361832; Fife BL, 2000, J HEALTH SOC BEHAV, V41, P50, DOI 10.2307/2676360; Fowler G, 2000, EUR J PUBLIC HEALTH, V10, P3; Frank A., 1991, WILL BODY REFLECTION; Frank AW., 2013, WOUNDED STORYTELLER; Goffman E., 1963, STIGMA; MACDONALD L, 1988, LIVING CHRONIC ILLNE; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; MENEC VH, 1995, J AGING HEALTH, V7, P365, DOI 10.1177/089826439500700302; MOORE A, 2003, HLTH SERVICE J   FEB, P12; Morse JM, 1997, QUAL HEALTH RES, V7, P445, DOI 10.1177/104973239700700401; MURRAY E, 2003, BRIT MED J, V326, P368; MUZZIN LJ, 1994, SOC SCI MED, V38, P1201, DOI 10.1016/0277-9536(94)90185-6; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Richards L, 1993, USING COMPUTERS QUAL, P38; Rosman S, 2004, PATIENT EDUC COUNS, V52, P333, DOI 10.1016/S0738-3991(03)00040-5; SCAMBLER G, 1984, EXPERIENCE ILLNESS, P203; Schneider J.W., 1983, HAVING EPILEPSY EXPE; SILVERMAN D, 1994, INTERPRETING QUALITA; Sontag S., 1978, ILLNESS METAPHOR; Tesch R., 1991, QUALITATIVE RES ANAL; THE AM, 2002, PALLIATIVE CARE COMM; Waskul DD, 2002, SYMB INTERACT, V25, P487, DOI 10.1525/si.2002.25.4.487; WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738; White C, 2003, BRIT MED J, V326, P1417, DOI 10.1136/bmj.326.7404.1417-b; WILLIAMS S, 1987, SOCIOLOGICAL THEORY	33	482	492	4	69	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1470	1473		10.1136/bmj.38111.639734.7C	http://dx.doi.org/10.1136/bmj.38111.639734.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	832CK	15194599	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222244600016
J	McCarey, DW; McInnes, LB; Madhok, R; Hampson, R; Scherbakova, O; Ford, I; Capell, HA; Sattar, N				McCarey, DW; McInnes, LB; Madhok, R; Hampson, R; Scherbakova, O; Ford, I; Capell, HA; Sattar, N			Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial	LANCET			English	Article							C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; AORTIC ENDOTHELIAL-CELLS; COA REDUCTASE INHIBITOR; STATINS; METHOTREXATE; SIMVASTATIN; THERAPY; RISK; ARTERIOSCLEROSIS	Background Rheumatoid arthritis is characterised by inflammatory synovitis, articular destruction, and accelerated atherogenesis. HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (statins) mediate clinically significant vascular risk reduction in patients without inflammatory disease and might have immunomodulatory function. We postulated that statins might reduce inflammatory factors in rheumatoid arthritis and modify surrogates for vascular risk. Methods 116 patients with rheumatoid arthritis were randomised in a double-blind placebo-controlled trial to receive 40 mg atorvastatin or placebo as an adjunct to existing disease-modifying antirheumatic drug therapy. Patients were followed up over 6 months and disease activity variables and circulating vascular risk factors were measured. Coprimary outcomes were change in disease activity score (DAS28) and proportion meeting EULAR (European League Against Rheumatism) response criteria. Analysis was by intention to treat. Findings At 6 months, DAS28 improved significantly on atorvastatin (-0.5, 95% Cl -0.75 to -0.25) compared with placebo (0.03, -0.23 to 0.28; difference between groups -0.52. 95% Cl -0.87 to -0.17, p=0.004). DAS28 EULAR response was achieved in 18 of 58 (31%) patients allocated atorvastatin compared with six of 58 (10%) allocated placebo (odds ratio 3.9, 95% Cl 1.42-10.72, p=0.006). C-reactive protein and erythrocyte sedimentation rate declined by 50% and 28%, respectively, relative to placebo (p<0.0001, p=0.005, respectively). Swollen joint count also fell (-2.69 vs -0.53; mean difference -2.16, 95% Cl -3.67 to -0.64, p=0.0058). Adverse events occurred with similar frequency in patients allocated atorvastatin and placebo. Interpretation These data show that statins can mediate modest but clinically apparent anti-inflammatory effects with modification of vascular risk factors in the context of high-grade autoimmune inflammation.	Univ Glasgow, Glasgow Royal Infirm, Ctr Rheumat Dis, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Dept Vasc Biochem, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	McInnes, LB (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Ctr Rheumat Dis, 3rd Floor Queen Elizabeth Bldg, Glasgow G31 2ER, Lanark, Scotland.	i.b.mcinnes@clinmed.gla.ac.uk	Ford, Ian/ABE-6145-2020	McInnes, Iain/0000-0002-6462-4280				Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9; Blake Gavin J, 2000, Curr Control Trials Cardiovasc Med, V1, P161, DOI 10.1186/CVM-1-3-161; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; Choi M, 2003, KIDNEY INT, V63, P96, DOI 10.1046/j.1523-1755.2003.00718.x; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Devaraj S, 2003, CIRCULATION, V107, P398, DOI 10.1161/01.CIR.0000052617.91920.FD; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Hakamada-Taguchi R, 2003, CIRC RES, V93, P948, DOI 10.1161/01.RES.0000101298.76864.14; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; Kobayashi S, 2003, ARTERIOSCL THROM VAS, V23, P1398, DOI 10.1161/01.ATV.0000081637.36475.BC; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524; Marz W, 2003, AM J CARDIOL, V92, P305, DOI 10.1016/S0002-9149(03)00633-7; McCarty MF, 2003, MED HYPOTHESES, V60, P634, DOI 10.1016/S0306-9877(02)00232-3; Packard CJ, 2000, NEW ENGL J MED, V343, P1148, DOI 10.1056/NEJM200010193431603; Palinski W, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018400.39687.8C; Palinski W, 2002, ARTERIOSCL THROM VAS, V22, P1745, DOI 10.1161/01.ATV.0000038754.39483.CD; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Sattar N, 2003, CIRCULATION, V108, P2957, DOI 10.1161/01.CIR.0000099844.31524.05; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shimizu K, 2003, CIRCULATION, V108, P2113, DOI 10.1161/01.CIR.0000092949.67153.74; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; Van Doornum S, 2002, ARTHRITIS RHEUM-US, V46, P862, DOI 10.1002/art.10089; van Gestel AM, 1999, J RHEUMATOL, V26, P705; VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519; Vaudo G, 2004, ANN RHEUM DIS, V63, P31, DOI 10.1136/ard.2003.007740; Venugopal SK, 2002, CIRCULATION, V106, P1439, DOI 10.1161/01.CIR.0000033116.22237.F9; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Yokota N, 2003, AM J NEPHROL, V23, P13, DOI 10.1159/000066301; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zwaka TP, 2001, CIRCULATION, V103, P1194	36	624	680	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	2004	363	9426					2015	2021		10.1016/S0140-6736(04)16449-0	http://dx.doi.org/10.1016/S0140-6736(04)16449-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207950				2022-12-28	WOS:000222159800006
J	Lum, L; Beachy, PA				Lum, L; Beachy, PA			The Hedgehog response network: Sensors, switches, and routers	SCIENCE			English	Review							KINESIN-RELATED PROTEIN; DROSOPHILA CUBITUS INTERRUPTUS; WNT SIGNALING PATHWAYS; SONIC HEDGEHOG; SUBCELLULAR-LOCALIZATION; LIMB DEVELOPMENT; SUPPRESSOR; COSTAL2; TRANSDUCTION; DISTINCT	The Hedgehog (Hh) signaling pathway is intimately linked to cell growth and differentiation, with normal roles in embryonic pattern formation and adult tissue homeostasis and pathological roles in tumor initiation and growth. Recent advances in our understanding of Hh response have resulted from the identification of new pathway components and new mechanisms of action for old pathway components. The most striking new finding is that signal transmission from membrane to cytoplasm proceeds through recruitment, by the seven-transmembrane protein Smoothened, of an atypical kinesin, which routes pathway activation by interaction with other components of a complex that includes the latent zinc finger transcription factor, Ci.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	pbeachy@jhmi.edu						Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bulgakov OV, 2004, DEVELOPMENT, V131, P2149, DOI 10.1242/dev.01122; Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; Caspary T, 2002, CURR BIOL, V12, P1628, DOI 10.1016/S0960-9822(02)01147-8; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Chen C., UNPUB; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Chen Y, 2000, MOL CELL BIOL, V20, P1616, DOI 10.1128/MCB.20.5.1616-1625.2000; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Desbordes SC, 2003, DEVELOPMENT, V130, P6245, DOI 10.1242/dev.00874; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hooper JE, 2003, DEVELOPMENT, V130, P3951, DOI 10.1242/dev.00594; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Jia JH, 2003, GENE DEV, V17, P2709, DOI 10.1101/gad.1136603; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lefers MA, 2001, DEV BIOL, V236, P411, DOI 10.1006/dbio.2001.0345; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; LUM L, UNPUB; Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Mann RK, 2004, ANNU REV BIOCHEM, V73, P891, DOI 10.1146/annurev.biochem.73.011303.073933; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Methot N, 2000, DEVELOPMENT, V127, P4001; Methot N, 2001, DEVELOPMENT, V128, P733; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Park HL, 2000, DEVELOPMENT, V127, P1593; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; PREAT T, 1992, GENETICS, V132, P725; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Wang GL, 2004, DEV BIOL, V268, P493, DOI 10.1016/j.ydbio.2004.01.008; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wang QT, 1999, DEVELOPMENT, V126, P5097; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wolff C, 2003, CURR BIOL, V13, P1169, DOI 10.1016/S0960-9822(03)00461-5; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099; Zhu AJ, 2003, GENE DEV, V17, P1240, DOI 10.1101/gad.1080803	66	653	710	1	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1755	1759		10.1126/science.1098020	http://dx.doi.org/10.1126/science.1098020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205520				2022-12-28	WOS:000222089500031
J	McPherson, JP; Lemmers, B; Chahwan, R; Pamidi, A; Migon, E; Matysiak-Zablocki, E; Moynahan, ME; Essers, J; Hanada, K; Poonepalli, A; Sanchez-Sweatman, O; Khokha, R; Kanaar, R; Jasin, M; Hande, MP; Hakem, R				McPherson, JP; Lemmers, B; Chahwan, R; Pamidi, A; Migon, E; Matysiak-Zablocki, E; Moynahan, ME; Essers, J; Hanada, K; Poonepalli, A; Sanchez-Sweatman, O; Khokha, R; Kanaar, R; Jasin, M; Hande, MP; Hakem, R			Involvement of mammalian Mus81 in genome integrity and tumor suppression	SCIENCE			English	Article							HOLLIDAY JUNCTIONS; SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; ENDONUCLEASE; RESOLUTION; CELLS; REPLICATION; MECHANISM; STABILITY	Mus81-Eme1 endonuclease has been implicated in the rescue of stalled replication forks and the resolution of meiotic recombination intermediates in yeast. We used gene targeting to study the physiological requirements of Mus81 in mammals. Mus81(-/-) mice are viable and fertile, which indicates that mammalian Mus81 is not essential for recombination processes associated with meiosis. Mus81-deficient mice and cells were hypersensitive to the DNA cross-linking agent mitomycin C but not to gamma-irradiation. Remarkably, both homozygous Mus81(-/-) and heterozygous Mus81(-/-) mice exhibited a similar susceptibility to spontaneous chromosomal damage and a profound and equivalent predisposition to lymphomas and other cancers. These studies demonstrate a critical role for the proper biallelic expression of the mammalian Mus81 in the maintenance of genomic integrity and tumor suppression.	Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Univ Med Ctr, Erasmus MC, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Univ Med Ctr, Erasmus MC, Dept Radiat Oncol, NL-3000 DR Rotterdam, Netherlands; Natl Univ Singapore, Dept Physiol, Fac Med, Singapore 117597, Singapore; Natl Univ Singapore, Oncol Res Inst, Fac Med, Singapore 117597, Singapore	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Memorial Sloan Kettering Cancer Center; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; National University of Singapore; National University of Singapore	Hakem, R (corresponding author), Ontario Canc Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.	rhakem@uhnres.utoronto.ca	Hande, M. Prakash/B-1645-2008; Pinheiro, Maísa/E-7424-2012; Chahwan, Richard/AAQ-9381-2021	Hande, M. Prakash/0000-0002-4511-6256; Chahwan, Richard/0000-0002-8672-7790; Khokha, Rama/0000-0002-6028-1524; Hakem, Razqallah/0000-0001-5948-7931; Moynahan, Mary Ellen/0000-0002-0167-1020; Hanada, Katsuhiro/0000-0003-0429-1899				Abraham J, 2003, EMBO J, V22, P6137, DOI 10.1093/emboj/cdg580; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Ciccia A, 2003, J BIOL CHEM, V278, P25172, DOI 10.1074/jbc.M302882200; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gaillard PHL, 2003, MOL CELL, V12, P747, DOI 10.1016/S1097-2765(03)00342-3; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; Heyer WD, 2003, TRENDS BIOCHEM SCI, V28, P548, DOI 10.1016/j.tibs.2003.08.011; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lilley DMJ, 2001, NAT REV MOL CELL BIO, V2, P433, DOI 10.1038/35073057x; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; MCPHERSON J, UNPUB; Mullen JR, 2001, GENETICS, V157, P103; Ogrunc M, 2003, J BIOL CHEM, V278, P21715, DOI 10.1074/jbc.M302484200; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049	28	149	157	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1822	1826		10.1126/science.1094557	http://dx.doi.org/10.1126/science.1094557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205536				2022-12-28	WOS:000222089500051
J	Shav-Tal, Y; Darzacq, X; Shenoy, SM; Fusco, D; Janicki, SM; Spector, DL; Singer, RH				Shav-Tal, Y; Darzacq, X; Shenoy, SM; Fusco, D; Janicki, SM; Spector, DL; Singer, RH			Dynamics of single mRNPs in nuclei of living cells	SCIENCE			English	Article							MESSENGER-RNA; MOVEMENT; DIFFUSION; MOBILITY; VISUALIZATION; PROTEINS; BINDING	Understanding gene expression requires the ability to follow the fate of individual molecules. Here we use a cellular system for monitoring messenger RNA (mRNA) expression to characterize the movement in real time of single mRNA-protein complexes (mRNPs) in the nucleus of living mammalian cells. This mobility was not directed but was governed by simple diffusion. Some mRNPs were partially corralled throughout the nonhomogenous nuclear environment, but no accumulation at subnuclear domains was observed. Following energy deprivation, energy-independent motion of mRNPs was observed in a highly ATP-dependent nuclear environment; movements were constrained to chromatin-poor domains and excluded by newly formed chromatin barriers. This observation resolves a controversy, showing that the energetic requirements of nuclear mRNP trafficking are consistent with a diffusional model.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cold Spring Harbor Laboratory	Singer, RH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rhsinger@aecom.yu.edu	Darzacq, Xavier/A-7546-2008; shenoy, shailesh/AAD-4962-2020	Shav-Tal, Yaron/0000-0002-8017-948X; Shenoy, Shailesh/0000-0002-5132-7236; Darzacq, Xavier/0000-0003-2537-8395	NIBIB NIH HHS [R01 EB002060, EB2060] Funding Source: Medline; NIGMS NIH HHS [GM42694, R01 GM042694] Funding Source: Medline; PHS HHS [DOE63056] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Calapez A, 2002, J CELL BIOL, V159, P795, DOI 10.1083/jcb.200203046; Carmo-Fonseca M, 2002, TRENDS CELL BIOL, V12, P491, DOI 10.1016/S0962-8924(02)02387-5; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Fusco D, 2003, CURR BIOL, V13, P161, DOI 10.1016/S0960-9822(02)01436-7; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; Molenaar C, 2004, J CELL BIOL, V165, P191, DOI 10.1083/jcb.200310139; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Politz JC, 2000, J STRUCT BIOL, V129, P252, DOI 10.1006/jsbi.2000.4227; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Saxton MJ, 1996, BIOPHYS J, V70, P1250, DOI 10.1016/S0006-3495(96)79682-0; Singh OP, 1999, EXP CELL RES, V251, P135, DOI 10.1006/excr.1999.4490; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729	18	372	382	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	2004	304	5678					1797	1800		10.1126/science.1099754	http://dx.doi.org/10.1126/science.1099754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205532	Green Accepted			2022-12-28	WOS:000222089500044
J	Harrison-Woolrych, M; Clark, DWJ				Harrison-Woolrych, M; Clark, DWJ			Nose bleeds associated with use of risperidone	BRITISH MEDICAL JOURNAL			English	Article									Univ Otago, Dept Prevent & Social Med, New Zealand Pharmacovigilance Ctr, Intens Med Monitoring Programme, Dunedin, New Zealand	University of Otago	Harrison-Woolrych, M (corresponding author), POB 913, Dunedin, New Zealand.	Mira.harrison-woolrych@stonebow.otago.ac.nz						Assion HJ, 1996, PHARMACOPSYCHIATRY, V29, P227, DOI 10.1055/s-2007-979577; *MED EC, 2000, PHYS DESK REF, P1456; Satomura K, 2002, CLIN CARDIOL, V25, P28, DOI 10.1002/clc.4950250108	3	21	22	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1416	1416		10.1136/bmj.328.7453.1416	http://dx.doi.org/10.1136/bmj.328.7453.1416			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15191978	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222114400023
J	Fingerman, IM; Briggs, SD				Fingerman, IM; Briggs, SD			p53-mediated transcriptional activation: From test tube to cell	CELL			English	Editorial Material							METHYLATION; CBP	Posttranslational modifications of histones have been strongly correlated with transcriptional regulation. In this issue of Cell, An et al. (2004) comprehensively examined the nature of arginine methyltransferases and histone modifications in p53-mediated transcription.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Fingerman, IM (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ St, W Lafayette, IN 47907 USA.			Briggs, Scott D/0000-0003-2852-3594				Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	7	15	16	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	2004	117	6					690	691		10.1016/j.cell.2004.05.021	http://dx.doi.org/10.1016/j.cell.2004.05.021			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186770	Bronze			2022-12-28	WOS:000222048400002
J	Kalir, S; Alon, U				Kalir, S; Alon, U			Using a quantitative blueprint to reprogram the dynamics of the flagella gene network	CELL			English	Article							ESCHERICHIA-COLI; EXPRESSION; PROMOTERS; OPERONS	Detailed understanding and control of biological networks will require a level of description similar to that of electronic engineering blueprints. Currently, however, even the best-studied systems are usually described using qualitative arrow diagrams. A quantitative blueprint requires in vivo measurements of (1) the relative strength of the interactions (numbers on the arrows) and (2) the functions that integrate multiple inputs. Here, we address this using a well-studied system, the flagella biosynthesis transcription network in Escherichia coli. We use theory and high-resolution experiments to obtain a quantitative blueprint with (1) numbers on the arrows, finding different hierarchies of activation coefficients for the two regulators, FlhDC and FliA; and (2) cis-regulatory input functions, which summate the input from the two regulators (SUM gates). We then demonstrate experimentally how this blueprint can be used to reprogram temporal expression patterns in this system, using controlled expression of the regulators or point mutations in their binding sites. The present approach can be used to define blueprints of other gene networks and to quantitatively reprogram their dynamics.	Hebrew Univ Jerusalem, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Alon, U (corresponding author), Hebrew Univ Jerusalem, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il						Aldridge P, 2002, CURR OPIN MICROBIOL, V5, P160, DOI 10.1016/S1369-5274(02)00302-8; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; Bolouri H, 2002, BIOESSAYS, V24, P1118, DOI 10.1002/bies.10189; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Buchler NE, 2003, P NATL ACAD SCI USA, V100, P5136, DOI 10.1073/pnas.0930314100; Claret L, 2002, J MOL BIOL, V321, P185, DOI 10.1016/S0022-2836(02)00600-9; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ikebe T, 1999, MICROBIOL-SGM, V145, P1389, DOI 10.1099/13500872-145-6-1389; Ikebe T, 1999, GENES GENET SYST, V74, P179, DOI 10.1266/ggs.74.179; Kalir S, 2001, SCIENCE, V292, P2080, DOI 10.1126/science.1058758; KASHTAN N, 2004, IN PRESS PHYS REV E; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; Laub MT, 2000, SCIENCE, V290, P2144, DOI 10.1126/science.290.5499.2144; Lazebnik Y, 2002, CANCER CELL, V2, P179, DOI 10.1016/S1535-6108(02)00133-2; Lee E, 2004, PLOS BIOL, V2, P405, DOI 10.1371/journal.pbio.0020089; Liao JC, 2003, P NATL ACAD SCI USA, V100, P15522, DOI 10.1073/pnas.2136632100; Liu XY, 1996, MOL MICROBIOL, V21, P613, DOI 10.1111/j.1365-2958.1996.tb02569.x; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Macnab RM, 1999, J BACTERIOL, V181, P7149, DOI 10.1128/JB.181.23.7149-7153.1999; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Setty Y, 2003, P NATL ACAD SCI USA, V100, P7702, DOI 10.1073/pnas.1230759100; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Staropoli JF, 2000, BIOPHYS J, V78, P513, DOI 10.1016/S0006-3495(00)76613-6; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Wolf Denise M., 2002, OMICS A Journal of Integrative Biology, V6, P91, DOI 10.1089/15362310252780852; Zaslaver A, 2004, NAT GENET, V36, P486, DOI 10.1038/ng1348	38	98	100	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					713	720		10.1016/j.cell.2004.05.010	http://dx.doi.org/10.1016/j.cell.2004.05.010			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186773	Bronze			2022-12-28	WOS:000222048400005
J	Qi, MH; Lidorikis, E; Rakich, PT; Johnson, SG; Joannopoulos, JD; Ippen, EP; Smith, HI				Qi, MH; Lidorikis, E; Rakich, PT; Johnson, SG; Joannopoulos, JD; Ippen, EP; Smith, HI			A three-dimensional optical photonic crystal with designed point defects	NATURE			English	Article							BANDGAP CRYSTALS; FABRICATION; LITHOGRAPHY; WAVELENGTHS; SCALE; GAP	Photonic crystals(1-3) offer unprecedented opportunities for miniaturization and integration of optical devices. They also exhibit a variety of new physical phenomena, including suppression or enhancement of spontaneous emission, low-threshold lasing, and quantum information processing(4). Various techniques for the fabrication of three-dimensional (3D) photonic crystals-such as silicon micromachining(5), wafer fusion bonding(6), holographic lithography(7), self-assembly(8,9), angled-etching(10), micromanipulation(11), glancing-angle deposition(12) and autocloning(13,14)-have been proposed and demonstrated with different levels of success. However, a critical step towards the fabrication of functional 3D devices, that is, the incorporation of microcavities or waveguides in a controllable way, has not been achieved at optical wavelengths. Here we present the fabrication of 3D photonic crystals that are particularly suited for optical device integration using a lithographic layer-by-layer approach(15). Point-defect microcavities are introduced during the fabrication process and optical measurements show they have resonant signatures around telecommunications wavelengths (1.3-1.5 mum). Measurements of reflectance and transmittance at near-infrared are in good agreement with numerical simulations.	MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Qi, MH (corresponding author), MIT, Ctr Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	mqi@alum.mit.edu	Joannopoulos, John D/E-6401-2013	Rakich, Peter/0000-0002-6081-1249; Johnson, Steven/0000-0001-7327-4967; Lidorikis, Elefterios/0000-0002-9552-9366				Aoki K, 2002, APPL PHYS LETT, V81, P3122, DOI 10.1063/1.1515117; Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; BOEGLI V, 1990, J VAC SCI TECHNOL B, V8, P1994, DOI 10.1116/1.584890; Campbell M, 2000, NATURE, V404, P53, DOI 10.1038/35003523; Cheng CC, 1995, J VAC SCI TECHNOL B, V13, P2696, DOI 10.1116/1.588051; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Fleming JG, 1999, OPT LETT, V24, P49, DOI 10.1364/OL.24.000049; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Johnson SG, 2000, APPL PHYS LETT, V77, P3490, DOI 10.1063/1.1328369; Johnson SG, 2001, OPT EXPRESS, V8, P173, DOI 10.1364/OE.8.000173; Kennedy SR, 2002, NANO LETT, V2, P59, DOI 10.1021/nl015635q; Kunz K. S., 1993, FINITE DIFFERENCE TI; Kuramochi E, 2002, OPT QUANT ELECTRON, V34, P53, DOI 10.1023/A:1013326610166; Lidorikis E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.023902; Nicholson JW, 2003, OPT LETT, V28, P643, DOI 10.1364/OL.28.000643; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Povinelli ML, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.075313; Qi MH, 2002, J VAC SCI TECHNOL B, V20, P2991, DOI 10.1116/1.1523021; Sato T, 2002, OPT QUANT ELECTRON, V34, P63, DOI 10.1023/A:1013382711983; Savas TA, 1996, J VAC SCI TECHNOL B, V14, P4167, DOI 10.1116/1.588613; STING DW, 1987, Patent No. 4653880; Vlasov YA, 2001, NATURE, V414, P289, DOI 10.1038/35104529; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	25	415	439	6	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					538	542		10.1038/nature02575	http://dx.doi.org/10.1038/nature02575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175746				2022-12-28	WOS:000221767700033
J	Lindblade, KA; Eisele, TP; Gimnig, JE; Alaii, JA; Odhiambo, F; ter Kuile, FO; Hawley, WA; Wannemuehler, KA; Phillips-Howard, PA; Rosen, DH; Nahlen, BL; Terlouw, DJ; Adazu, K; Vulule, JM; Slutsker, L				Lindblade, KA; Eisele, TP; Gimnig, JE; Alaii, JA; Odhiambo, F; ter Kuile, FO; Hawley, WA; Wannemuehler, KA; Phillips-Howard, PA; Rosen, DH; Nahlen, BL; Terlouw, DJ; Adazu, K; Vulule, JM; Slutsker, L			Sustainability of reductions in malaria transmission and infant mortality in Western Kenya with use of insecticide-treated bednets - 4 to 6 years of follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BED NETS; CHILD-MORTALITY; YOUNG-CHILDREN; FALCIPARUM TRANSMISSION; MOSQUITO NETS; AREA; MORBIDITY; RESPONSES; EFFICACY; IMPACT	Context Insecticide-treated bednets reduce malaria transmission and child morbidity and mortality in short-term trials, but this impact may not be sustainable. Previous, investigators have suggested that bednet use might paradoxically increase mortality in older children through delayed acquisition of immunity to malaria. Objectives To determine whether adherence to and public health benefits of insecticide-treated bednets can be sustained over time and whether bednet use during infancy increases all-cause mortality rates in older children in an area of intense perennial malaria transmission. Design and Setting A community randomized controlled trial in western Kenya (phase 1: January 1997 to February 2000) followed by continued surveillance of adherence, entomologic parameters, morbidity indicators, and all-cause mortality (phase 2: April 1999 to February 2002), and extended demographic monitoring (January to December 2002). Participants A total of 130000 residents of 221 villages in Asembo and Gem were randomized to receive insecticide-treated bednets at the start of phase 1 (111 villages) or phase 2 (110 villages). Main Outcome Measures Proportion of children younger than 5 years using insecticide-treated bednets, mean number of Anopheles mosquitoes per house, and all-cause mortality rates. Results Adherence to bednet use in children younger than 5 years increased from 65.9% in phase 1 to 82.5% in phase 2 (P<.001). After 3 to 4 years of bednet use, the mean number of Anopheles mosquitoes per house in the study area was 77% lower than in a neighboring area without bed nets (risk ratio, 0:23; 95% confidence interval [CI], 0.15-0.35). All-cause mortality rates in infants aged 1 to 11 months were significantly reduced in intervention villages during phase 1 (hazard ratio [HR], 0.78; 95% CI, 0.67-0.90); low rates were maintained during phase 2. Mortality rates did not differ during 2002 (after up to 6 years of bednet use) between children from former intervention and former control households born during phase 1 (HR, 1.01; 95% CI, 0.86-1.19). Conclusions The public health benefits of insecticide-treated bednets were sustained for up to 6 years. There is no evidence that bednet use from birth increases all-cause mortality in older children in an area of intense perennial transmission of malaria.	Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA; Tulane Sch Publ Hlth & Trop Med, Dept Int Hlth & Dev, New Orleans, LA USA; Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya; CDC, Nairobi, Kenya; Kenya Govt Med Res Ctr, Nairobi, Kenya	Centers for Disease Control & Prevention - USA; Tulane University; Kenya Medical Research Institute; Kenya Medical Research Institute	Lindblade, KA (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, 4770 Buford Hwy,MS F-22, Atlanta, GA 30333 USA.	klindblade@kisian.mimcom.net	Nahlen, Bernard/AAH-2051-2021; Kuile, Feiko ter/ABD-6681-2020; Eisele, Thom/AAE-8958-2020	Kuile, Feiko ter/0000-0003-3663-5617; Wannemuehler, Kathleen/0000-0001-9535-6277; Phillips-Howard, Penelope A/0000-0003-1018-116X; Terlouw, Anja/0000-0001-5327-8995; Lindblade, Kim/0000-0002-5593-0470				Alaii JA, 2003, AM J TROP MED HYG, V68, P137, DOI 10.4269/ajtmh.2003.68.137; [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; BEIER JC, 1990, J MED ENTOMOL, V27, P570, DOI 10.1093/jmedent/27.4.570; Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4; Bloland PB, 1999, AM J TROP MED HYG, V60, P641, DOI 10.4269/ajtmh.1999.60.641; *CENTR BUR STAT MI, 1999, 1999 POP HOUS CENS; Curtis C, 2003, LANCET INFECT DIS, V3, P304, DOI 10.1016/S1473-3099(03)00612-1; Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85; Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205; Gimnig JE, 2003, AM J TROP MED HYG, V68, P16, DOI 10.4269/ajtmh.2003.68.16; GRABOWSKY M, 2002, AM SOC TROP MED HYG; Guillet P, 2001, B WORLD HEALTH ORGAN, V79, P998; Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560; Kariuki SK, 2003, AM J TROP MED HYG, V68, P108, DOI 10.4269/ajtmh.2003.68.108; King CL, 2002, J IMMUNOL, V168, P356, DOI 10.4049/jimmunol.168.1.356; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; Molineaux L, 1997, ANN TROP MED PARASIT, V91, P811, DOI 10.1080/00034989760572; Murray DM, 1998, DESIGN ANAL GROUP RA; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23, DOI 10.4269/ajtmh.2003.68.23; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P10, DOI 10.4269/ajtmh.2003.68.10; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P3, DOI 10.4269/ajtmh.2003.68.3; Riley EM, 2001, PARASITE IMMUNOL, V23, P51, DOI 10.1046/j.1365-3024.2001.00364.x; Schellenberg JRMA, 1999, T ROY SOC TROP MED H, V93, P225, DOI 10.1016/S0035-9203(99)90001-9; Service M., 1976, MOSQUITO ECOLOGY FIE, V3; SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P100, DOI 10.4269/ajtmh.2003.68.100; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50, DOI 10.4269/ajtmh.2003.68.50; Therneau TM, 2000, MODELING SURVIVAL DA; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; *WHO, 2002, WHO PUBL, P43; *WHO, 2003, WHO PUBL; WIRTZ RA, 1987, B WORLD HEALTH ORGAN, V65, P39; Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6	35	122	124	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2571	2580		10.1001/jama.291.21.2571	http://dx.doi.org/10.1001/jama.291.21.2571			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173148	Bronze			2022-12-28	WOS:000221738800020
J	Lennmarken, C; Sandin, R				Lennmarken, C; Sandin, R			Neuromonitoring for awareness during surgery	LANCET			English	Editorial Material							GENERAL-ANESTHESIA		Linkoping Univ Hosp, Dept Anaesthesia & Intens Care, S-58185 Linkoping, Sweden; Cty Hosp, Dept Anaesthesia & Intens Care, Kalmar, Sweden; Karolinska Inst, Stockholm, Sweden	Linkoping University; Karolinska Institutet	Lennmarken, C (corresponding author), Linkoping Univ Hosp, Dept Anaesthesia & Intens Care, S-58185 Linkoping, Sweden.	Claes.Lennmarken@lio.se						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Domino KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; EVANS JM, 1987, PATIENTS EXPERIENCES, P184; HUTCHINSON R, 1960, BRIT J ANAESTH, V33, P463; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; Lennmarken C, 2002, ACTA ANAESTH SCAND, V46, P229, DOI 10.1034/j.1399-6576.2002.t01-1-460301.x; MOERMAN N, 1993, ANESTHESIOLOGY, V79, P454, DOI 10.1097/00000542-199309000-00007; Myles PS, 2000, BRIT J ANAESTH, V84, P6, DOI 10.1093/oxfordjournals.bja.a013383; O'Connor MF, 2001, ANESTHESIOLOGY, V94, P520, DOI 10.1097/00000542-200103000-00025; PRYSROBERTS C, 1987, BRIT J ANAESTH, V59, P1341, DOI 10.1093/bja/59.11.1341; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; Schwender D, 1998, BRIT J ANAESTH, V80, P133, DOI 10.1093/bja/80.2.133; Vandam LD, 2000, ANESTHESIA, P2	14	14	16	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1747	1748		10.1016/S0140-6736(04)16335-6	http://dx.doi.org/10.1016/S0140-6736(04)16335-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172768				2022-12-28	WOS:000221705800003
J	Milliner, DS				Milliner, DS			Pediatric renal-replacement therapy - Coming of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Div Pediat Nephrol, Rochester, MN 55905 USA	Mayo Clinic	Milliner, DS (corresponding author), Mayo Clin, Div Pediat Nephrol, Rochester, MN 55905 USA.							*N AM PED REN TRAN, 2003 ANN REP; *US ORG PROC TRANS, 2003 ANN REP; *US REN DAT SYST, 2003 ANN DAT REP ATL	3	10	10	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2637	2639		10.1056/NEJMp048125	http://dx.doi.org/10.1056/NEJMp048125			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215477				2022-12-28	WOS:000222199000002
J	Schuelke, M; Wagner, KR; Stolz, LE; Hubner, C; Riebel, T; Komen, W; Braun, T; Tobin, JF; Lee, SJ				Schuelke, M; Wagner, KR; Stolz, LE; Hubner, C; Riebel, T; Komen, W; Braun, T; Tobin, JF; Lee, SJ			Brief report - Myostatin mutation associated with gross muscle hypertrophy in a child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA SUPERFAMILY MEMBER; RNA SPLICE JUNCTIONS; MUSCULAR-DYSTROPHY; SATELLITE CELL; GENE CAUSES; MICE; CATTLE; DELETION; GROWTH; MASS		Univ Med Ctr Berlin, Charite, Dept Neuropediat, D-13353 Berlin, Germany; Univ Med Ctr Berlin, Charite, Dept Pediat Radiol, D-13353 Berlin, Germany; Univ Med Ctr Berlin, Charite, Dept Neonatol, D-13353 Berlin, Germany; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Wyeth Res, Dept Cardiovasc & Metab Dis, Cambridge, MA USA; Univ Halle Wittenberg, Inst Physiol Chem, Halle Saale, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johns Hopkins University; Johns Hopkins University; Pfizer; Martin Luther University Halle Wittenberg	Schuelke, M (corresponding author), Univ Med Ctr Berlin, Charite, Dept Neuropediat, Augustenburger Pl 1, D-13353 Berlin, Germany.	markus.schuelke@charite.de	Braun, Thomas/B-2310-2008	Schuelke, Markus/0000-0003-2824-3891; Braun, Thomas/0000-0002-6165-4804	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035887] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA088866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002212] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA88866] Funding Source: Medline; NICHD NIH HHS [R01HD35887] Funding Source: Medline; NIGMS NIH HHS [01GM0302] Funding Source: Medline; NINDS NIH HHS [K08NS02212] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amthor H, 2002, DEV BIOL, V251, P241, DOI 10.1006/dbio.2002.0812; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; CHELLY J, 1991, J CLIN INVEST, V88, P1161, DOI 10.1172/JCI115417; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Grobet L, 1998, MAMM GENOME, V9, P210, DOI 10.1007/s003359900727; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lin J, 2002, BIOCHEM BIOPH RES CO, V291, P701, DOI 10.1006/bbrc.2002.6500; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Szabo G, 1998, MAMM GENOME, V9, P671, DOI 10.1007/s003359900843; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	23	982	1160	2	72	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2682	2688		10.1056/NEJMoa040933	http://dx.doi.org/10.1056/NEJMoa040933			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215484				2022-12-28	WOS:000222199000009
J	Burns, RB				Burns, RB			A 54-year-old man with obstructive sleep apnea	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Kuna ST, 2002, JAMA-J AM MED ASSOC, V288, P2032, DOI 10.1001/jama.288.16.2032	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					3004	3004		10.1001/jama.291.24.3004	http://dx.doi.org/10.1001/jama.291.24.3004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213213				2022-12-28	WOS:000222184600031
J	Farmer, JJ; Gangarosa, RE; Gangarosa, EJ				Farmer, JJ; Gangarosa, RE; Gangarosa, EJ			Does Laribacter hongkongensis cause diarrhoea, or does diarrhoea "cause" L hongkongensis?	LANCET			English	Editorial Material									Ctr Dis Control & Prevent, Foodborne & diarrheal Dis Lab Sect, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis,Ctr Infect Dis, Atlanta, GA 30333 USA; EJG Associates, Stone Mt, GA USA	Centers for Disease Control & Prevention - USA	Farmer, JJ (corresponding author), Ctr Dis Control & Prevent, Foodborne & diarrheal Dis Lab Sect, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis,Ctr Infect Dis, Atlanta, GA 30333 USA.	jimfarmer812@earthlink.net						BARR JM, 2004, GREAT INFLUENZA EPIC; Blaser MJ, 2002, INFECT GASTROINTESTI; Gilman R H, 1971, Southeast Asian J Trop Med Public Health, V2, P186; HOLMBERG SD, 1984, REV INFECT DIS, V6, P633; JANDA JM, 2002, AEROMONAS PLESIOMONA, P785; Reiss E., 2002, MANUAL CLIN LAB IMMU, P559; Shiga K, 1898, ZENTRALBL BAKTERIOL, V24, P817; WARREN JR, 1983, LANCET, V1, P1273; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983; WILSON GS, 1955, TOPLEY WILSONS PRINC	10	10	10	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	2004	363	9425					1923	1924		10.1016/S0140-6736(04)16439-8	http://dx.doi.org/10.1016/S0140-6736(04)16439-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194250				2022-12-28	WOS:000221962800005
J	Deschamps, J				Deschamps, J			Hox genes in the limb: A play in two acts	SCIENCE			English	Editorial Material							POLARIZING ACTIVITY; NUMBER; REGION		Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Deschamps, J (corresponding author), Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	jacqueli@niob.knaw.nl						Charite J, 2000, DEVELOPMENT, V127, P2461; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Tickle C, 2002, INT J DEV BIOL, V46, P847; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695; Zakany J, 2004, SCIENCE, V304, P1669, DOI 10.1126/science.1096049	10	20	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1610	1611		10.1126/science.1099162	http://dx.doi.org/10.1126/science.1099162			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192209				2022-12-28	WOS:000221934300029
J	Augustin, L; Barbante, C; Barnes, PRF; Barnola, JM; Bigler, M; Castellano, E; Cattani, O; Chappellaz, J; DahlJensen, D; Delmonte, B; Dreyfus, G; Durand, G; Falourd, S; Fischer, H; Fluckiger, J; Hansson, ME; Huybrechts, P; Jugie, R; Johnsen, SJ; Jouzel, J; Kaufmann, P; Kipfstuhl, J; Lambert, F; Lipenkov, VY; Littot, GVC; Longinelli, A; Lorrain, R; Maggi, V; Masson-Delmotte, V; Miller, H; Mulvaney, R; Oerlemans, J; Oerter, H; Orombelli, G; Parrenin, F; Peel, DA; Petit, JR; Raynaud, D; Ritz, C; Ruth, U; Schwander, J; Siegenthaler, U; Souchez, R; Stauffer, B; Steffensen, JP; Stenni, B; Stocker, TF; Tabacco, IE; Udisti, R; van de Wal, RSW; van den Broeke, M; Weiss, J; Wilhelms, F; Winther, JG; Wolff, EW; Zucchelli, M				Augustin, L; Barbante, C; Barnes, PRF; Barnola, JM; Bigler, M; Castellano, E; Cattani, O; Chappellaz, J; DahlJensen, D; Delmonte, B; Dreyfus, G; Durand, G; Falourd, S; Fischer, H; Fluckiger, J; Hansson, ME; Huybrechts, P; Jugie, R; Johnsen, SJ; Jouzel, J; Kaufmann, P; Kipfstuhl, J; Lambert, F; Lipenkov, VY; Littot, GVC; Longinelli, A; Lorrain, R; Maggi, V; Masson-Delmotte, V; Miller, H; Mulvaney, R; Oerlemans, J; Oerter, H; Orombelli, G; Parrenin, F; Peel, DA; Petit, JR; Raynaud, D; Ritz, C; Ruth, U; Schwander, J; Siegenthaler, U; Souchez, R; Stauffer, B; Steffensen, JP; Stenni, B; Stocker, TF; Tabacco, IE; Udisti, R; van de Wal, RSW; van den Broeke, M; Weiss, J; Wilhelms, F; Winther, JG; Wolff, EW; Zucchelli, M		EPICA Community Members	Eight glacial cycles from an Antarctic ice core	NATURE			English	Article							DOME CONCORDIA; EAST ANTARCTICA; ATMOSPHERIC CO2; CLIMATE; VOSTOK; RECORD; MICROSTRUCTURE; ISOTOPE	The Antarctic Vostok ice core provided compelling evidence of the nature of climate, and of climate feedbacks, over the past 420,000 years. Marine records suggest that the amplitude of climate variability was smaller before that time, but such records are often poorly resolved. Moreover, it is not possible to infer the abundance of greenhouse gases in the atmosphere from marine records. Here we report the recovery of a deep ice core from Dome C, Antarctica, that provides a climate record for the past 740,000 years. For the four most recent glacial cycles, the data agree well with the record from Vostok. The earlier period, between 740,000 and 430,000 years ago, was characterized by less pronounced warmth in interglacial periods in Antarctica, but a higher proportion of each cycle was spent in the warm mode. The transition from glacial to interglacial conditions about 430,000 years ago ( Termination V) resembles the transition into the present interglacial period in terms of the magnitude of change in temperatures and greenhouse gases, but there are significant differences in the patterns of change. The interglacial stage following Termination V was exceptionally long - 28,000 years compared to, for example, the 12,000 years recorded so far in the present interglacial period. Given the similarities between this earlier warm period and today, our results may imply that without human intervention, a climate similar to the present one would extend well into the future.	CNRS, Lab Glaciol & Geophys Environm, F-38042 St Martin Dheres, France; Univ Venice, Dept Environm Sci, I-30123 Venice, Italy; British Antarctic Survey, Cambridge CB3 0ET, England; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Univ Florence, Dept Chem, Analyt Chem Sect, I-50019 Florence, Italy; CE Saclay, Inst Pierre Simon Laplace, Lab Sci Climat & Environm, UMR 1572,CEA,CNRS, F-91191 Gif Sur Yvette, France; Univ Copenhagen, Niels Bohr Inst Astron Phys & Geophys, DK-2100 Copenhagen, Denmark; Univ Milano Bicocca, Dept Sci Ambiente & Terr, I-20126 Milan, Italy; Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany; Stockholm Univ, Dept Phys Geog & Quaternary Geol, S-10691 Stockholm, Sweden; Inst Polar Francais Paul Amile Victor IPEV, F-29280 Plouzane, France; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia; Univ Parma, Dept Earth Sci, I-43100 Parma, Italy; Free Univ Brussels, Dept Sci Terre & Environm, Fac Sci, B-1050 Brussels, Belgium; Inst Marine & Atmospher Res Utrecht, NL-3584 CC Utrecht, Netherlands; Univ Trieste, Dept Geol Environm & Marine Sci, I-34127 Trieste, Italy; Univ Milan, Dept Earth Sci, I-20129 Milan, Italy; Norwegian Polar Res Inst, N-9296 Tromso, Norway; CRE Casaccia, ENEA, I-00060 Santa Maria Di Galeria, RM, Italy	Centre National de la Recherche Scientifique (CNRS); Universita Ca Foscari Venezia; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University of Bern; University of Florence; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); University of Copenhagen; Niels Bohr Institute; University of Milano-Bicocca; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Stockholm University; Arctic & Antarctic Research Institute; University of Parma; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Utrecht University; University of Trieste; University of Milan; Norwegian Polar Institute; Italian National Agency New Technical Energy & Sustainable Economics Development	Augustin, L (corresponding author), CNRS, Lab Glaciol & Geophys Environm, BP 96, F-38042 St Martin Dheres, France.		Parrenin, Frédéric/H-3054-2014; Stocker, Thomas/B-1273-2013; Dahl-Jensen, Dorthe/AAO-6951-2020; Lambert, Fabrice/M-2003-2014; Udisti, Roberto/M-7966-2015; van de wal, roderik/D-1705-2011; Raynaud, Dominique/H-9626-2016; raynaud, dominique/ABG-4718-2020; Barbante, Carlo/B-3195-2011; Maggi, Valter/E-1878-2014; Masson-Delmotte, Valerie L/G-1995-2011; Mulvaney, Robert/K-3929-2012; Delmonte, Barbara/L-2555-2015; Oerlemans, Johannes/G-3802-2011; Lipenkov, Vladimir Y/Q-8262-2016; Van den Broeke, Michiel R./F-7867-2011; Maggi, Valter/AAX-5728-2020; Fluckiger, Jacqueline/G-3457-2011; Fischer, Hubertus/A-1211-2014; Chappellaz, Jérôme A./A-4872-2011; Dahl-Jensen, Dorthe/N-4401-2016; Wolff, Eric W/D-7925-2014; Barnes, Piers R. F./F-1558-2010; Wolff, Eric/AAB-1097-2021; Huybrechts, Philippe/J-5278-2013	Parrenin, Frédéric/0000-0002-9489-3991; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Lambert, Fabrice/0000-0002-2192-024X; Udisti, Roberto/0000-0003-4440-8238; van de wal, roderik/0000-0003-2543-3892; Masson-Delmotte, Valerie L/0000-0001-8296-381X; Mulvaney, Robert/0000-0002-5372-8148; Lipenkov, Vladimir Y/0000-0003-4221-5440; Van den Broeke, Michiel R./0000-0003-4662-7565; Maggi, Valter/0000-0001-6287-1213; Fischer, Hubertus/0000-0002-2787-4221; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Wolff, Eric W/0000-0002-5914-8531; Barnes, Piers R. F./0000-0002-7537-8759; Wolff, Eric/0000-0002-5914-8531; Wilhelms, Frank/0000-0001-7688-3135; Barbante, Carlo/0000-0003-4177-2288; Delmonte, Barbara/0000-0002-9074-2061; Stenni, Barbara/0000-0003-4950-3664; Huybrechts, Philippe/0000-0003-1406-0525; Becagli, Silvia/0000-0003-3633-4849; Steffensen, Jorgen Peder/0000-0002-5516-1093; Ritz, Catherine/0000-0003-0785-8571; Miller, Heinrich/0000-0003-1015-2828; Durand, Gael/0000-0001-8979-2355				BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; Becquey S, 2002, PALAEOGEOGR PALAEOCL, V182, P221, DOI 10.1016/S0031-0182(01)00497-7; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Berger A., 2003, GEOPHYS MONOGR SER, P17, DOI DOI 10.1029/137GM02); Berger W.H., 2003, GEOPHYS MONOGRAPH SE, V137, P41, DOI [10.1029/137GM04, DOI 10.1029/137GM04]; Blunier T, 2004, EARTH PLANET SC LETT, V218, P379, DOI 10.1016/S0012-821X(03)00672-1; Delmonte B, 2002, CLIM DYNAM, V18, P647, DOI 10.1007/s00382-001-0193-9; Droxler A. W., 2003, GEOPHYS MONOGR SER, V137, P1, DOI DOI 10.1029/137GM01; Fischer H, 1999, SCIENCE, V283, P1712, DOI 10.1126/science.283.5408.1712; Gay M, 1999, J GLACIOL, V45, P547, DOI 10.3189/S0022143000001416; Goujon C, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003319; Hearty PJ, 1999, GEOLOGY, V27, P375, DOI 10.1130/0091-7613(1999)027<0375:AMMPSL>2.3.CO;2; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; IPCC, 2001, IPCC 3 ASS REP CLIM; Johnsen SJ, 2001, J QUATERNARY SCI, V16, P299, DOI 10.1002/jqs.622; Jouzel J, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002677; Jouzel J, 2001, GEOPHYS RES LETT, V28, P3199, DOI 10.1029/2000GL012243; Landais A, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003147; Lea D.W., 2003, EARTHS CLIMATE ORBIT, V137, P147; Littot GC, 2002, ANN GLACIOL-SER, V35, P299, DOI 10.3189/172756402781817022; LORIUS C, 1979, NATURE, V280, P644, DOI 10.1038/280644a0; MARTINERIE P, 1992, EARTH PLANET SC LETT, V112, P1, DOI 10.1016/0012-821X(92)90002-D; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; Parrenin F, 2001, J GEOPHYS RES-ATMOS, V106, P31837, DOI 10.1029/2001JD900245; Pepin L, 2001, J GEOPHYS RES-ATMOS, V106, P31885, DOI 10.1029/2001JD900117; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; RAYNAUD D, 2003, GEOPHYS MONOGR SER, V137, P27; Ritz C, 2001, J GEOPHYS RES-ATMOS, V106, P31943, DOI 10.1029/2001JD900232; RITZ C, 1992, THESIS U J FOURIER; Rothlisberger R, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003604; Rothlisberger R, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015186; Rothlisberger R, 2000, ENVIRON SCI TECHNOL, V34, P338, DOI 10.1021/es9907055; Schwander J, 2001, GEOPHYS RES LETT, V28, P4243, DOI 10.1029/2000GL011981; STAUFFER B, IN PRESS ANN GLACIOL; Stenni B, 2001, SCIENCE, V293, P2074, DOI 10.1126/science.1059702; Stocker TF, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000920; Watanabe O, 2003, NATURE, V422, P509, DOI 10.1038/nature01525; Weiss J, 2002, ANN GLACIOL-SER, V35, P552, DOI 10.3189/172756402781816573; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; Wolff E, 1999, ANN GLACIOL, V29, P89, DOI 10.3189/172756499781820888; 2002, EOS T, V83, P509	41	1377	1446	9	520	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					623	628		10.1038/nature02599	http://dx.doi.org/10.1038/nature02599			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190344	Bronze, Green Published			2022-12-28	WOS:000221912600031
J	Bertet, C; Sulak, L; Lecuit, T				Bertet, C; Sulak, L; Lecuit, T			Myosin-dependent junction remodelling controls planar cell intercalation and axis elongation	NATURE			English	Article							POLARIZED MEMBRANE GROWTH; HEAVY-CHAIN FUNCTION; NONMUSCLE MYOSIN; EPITHELIAL-CELLS; LIGHT CHAIN; DROSOPHILA; MORPHOGENESIS; CYTOKINESIS; OOGENESIS; MIGRATION	Shaping a developing organ or embryo relies on the spatial regulation of cell division and shape. However, morphogenesis also occurs through changes in cell-neighbourhood relationships produced by intercalation(1,2). Intercalation poses a special problem in epithelia because of the adherens junctions, which maintain the integrity of the tissue. Here we address the mechanism by which an ordered process of cell intercalation directs polarized epithelial morphogenesis during germ-band elongation, the developmental elongation of the Drosophila embryo. Intercalation progresses because junctions are spatially reorganized in the plane of the epithelium following an ordered pattern of disassembly and reassembly. The planar remodelling of junctions is not driven by external forces at the tissue boundaries but depends on local forces at cell boundaries. Myosin II is specifically enriched in disassembling junctions, and its planar polarized localization and activity are required for planar junction remodelling and cell intercalation. This simple cellular mechanism provides a general model for polarized morphogenesis in epithelial organs.	Univ Mediterranee, Lab Genet & Physiol Dev, Inst Biol Dev Marseille, CNRS,INSERM, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Lecuit, T (corresponding author), Univ Mediterranee, Lab Genet & Physiol Dev, Inst Biol Dev Marseille, CNRS,INSERM, Campus Luminy,Case 907, F-13288 Marseille 9, France.	lecuit@ibdm.univ-mrs.fr	Ladoux, Benoit/A-9879-2013					Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hutson MS, 2003, SCIENCE, V300, P145, DOI 10.1126/science.1079552; IRVINE KD, 1994, DEVELOPMENT, V120, P827; Jazwinska A, 2003, NAT CELL BIOL, V5, P895, DOI 10.1038/ncb1049; Johansen KA, 2003, DEVELOPMENT, V130, P135, DOI 10.1242/dev.00202; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Lecuit T, 2002, TRAFFIC, V3, P92, DOI 10.1034/j.1600-0854.2002.030202.x; Lecuit T, 2002, DEV CELL, V2, P425, DOI 10.1016/S1534-5807(02)00141-7; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Oda H, 2001, J CELL SCI, V114, P493; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; Royou A, 2002, J CELL BIOL, V158, P127, DOI 10.1083/jcb.200203148; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; Stein JA, 2002, DEVELOPMENT, V129, P3925; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; WHEATLEY S, 1995, DEVELOPMENT, V121, P1937; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wolf WA, 1999, CELL MOL LIFE SCI, V55, P108, DOI 10.1007/s000180050274; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	29	648	658	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					667	671		10.1038/nature02590	http://dx.doi.org/10.1038/nature02590			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190355				2022-12-28	WOS:000221912600043
J	Johansson, JE; Andren, O; Andersson, SO; Dickman, PW; Holmberg, L; Magnuson, A; Adami, HO				Johansson, JE; Andren, O; Andersson, SO; Dickman, PW; Holmberg, L; Magnuson, A; Adami, HO			Natural history of early, localized prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVAL; QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; FOLLOW-UP; POPULATION; MEN; METASTASIS; MANAGEMENT; CARCINOMA; TUMORS	Context Among men with early prostate cancer, the natural history without initial therapy determines the potential for survival benefit following radical local treatment. However, little is known about disease progression and mortality beyond 10 to 15 years of watchful waiting. Objective To examine the long-term natural history of untreated, early stage prostatic cancer. Design Population-based, cohort study with a mean observation period of 21 years. Setting Regionally well-defined catchment area in central Sweden (recruitment March 1977 through February 1984). Patients A consecutive sample of 223 patients (98% of all eligible) with early-stage (T0-T2 NX MO classification), initially untreated prostatic cancer. Patients with tumor progression were hormonally treated (either by orchiectomy or estrogens) if they had symptoms. Main Outcome Measures Progression-free, cause-specific, and overall survival. Results After complete follow-up, 39 (17%) of all patients experienced generalized disease. Most cancers had an indolent course during the first 10 to 15 years. However, further follow-up from 15 (when 49 patients were still alive) to 20 years, revealed a substantial decrease in cumulative progression-free survival (from 45.0% to 36.0%), survival without metastases (from 76.9% to 51.2%), and prostate cancer-specific survival (from 78.7% to 54.4%). The prostate cancer mortality rate increased from 15 per 1000 person-years (95% confidence interval, 10-21) during the first 15 years to 44 per 1000 person-years (95% confidence interval, 22-88) beyond 15 years of follow-up (P=.01). Conclusion Although most prostate cancers diagnosed at an early stage have an indolent course, local tumor progression and aggressive metastatic disease may develop in the long term. These findings would support early radical treatment, notably among patients with an estimated life expectancy exceeding 15 years.	Orebro Univ Hosp, Dept Urol, SE-70185 Orebro, Sweden; Orebro Univ Hosp, Dept Clin Med, SE-70185 Orebro, Sweden; Orebro Univ Hosp, Clin Res Ctr, Stat Unit, SE-70185 Orebro, Sweden; Ctr Assessment Med Technol, Orebro, Sweden; Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; Univ Uppsala Hosp, Reg Oncol Ctr, Uppsala, Sweden; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Harvard Ctr Canc Prevent, Boston, MA 02115 USA	Orebro University; Orebro University; Orebro University; Karolinska Institutet; Uppsala University; Uppsala University Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Johansson, JE (corresponding author), Orebro Univ Hosp, Dept Urol, SE-70185 Orebro, Sweden.	jan-erik.johansson@orebroll.se	Dickman, Paul W/B-4572-2013	Dickman, Paul W/0000-0002-5788-3380				Adolfsson J, 2000, PROSTATE CANCER P D, V3, P37, DOI 10.1038/sj.pcan.4500395; Adolfsson J, 1997, UROLOGY, V50, P722, DOI 10.1016/S0090-4295(97)00320-8; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bishoff JT, 1998, J UROLOGY, V160, P454, DOI 10.1016/S0022-5347(01)62924-0; Blasko JC, 2000, RADIOTHER ONCOL, V57, P273, DOI 10.1016/S0167-8140(00)00288-7; Borre M, 1997, CANCER, V80, P917; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; Hanks GE, 2000, INT J RADIAT ONCOL, V46, P823, DOI 10.1016/S0360-3016(99)00498-8; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; Hills, 1993, STAT MODELS EPIDEMIO; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; *INT UN CANC, 1978, TNM CLASS MAL TUM; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; Oliver SE, 2003, BJU INT, V91, P331, DOI 10.1046/j.1464-410X.2003.04083.x; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; WALSH PC, 1987, CANCER, V60, P526, DOI 10.1002/1097-0142(19870801)60:3+<526::AID-CNCR2820601515>3.0.CO;2-9; *WHO, 1980, INT HIST CLASS TUM, V22	26	492	520	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2713	2719		10.1001/jama.291.22.2713	http://dx.doi.org/10.1001/jama.291.22.2713			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826XH	15187052	Bronze			2022-12-28	WOS:000221862300025
J	de Gruchy, J; Fish, J				de Gruchy, J; Fish, J			Doctors' involvement in human rights abuses of men who have sex with men in Egypt	LANCET			English	Editorial Material									Nottingham City Primary Care Trust, Hlth Equal Directorate, Nottingham NG1 6GN, England; De Montfort Univ, Sch Life & Hlth Sci, Leicester LE1 9BH, Leics, England	De Montfort University	de Gruchy, J (corresponding author), Nottingham City Primary Care Trust, Hlth Equal Directorate, Stand Court,Pk Row, Nottingham NG1 6GN, England.	jeanelle.degruchy@ntlworld.com						Human Rights Watch, 2004, TIM TORT ASS JUST EG; International Dual Loyalty Working Group, 2002, DUAL LOYALT HUM RIGH; Lewin S, 2001, LANCET, V358, P1899, DOI 10.1016/S0140-6736(01)06894-5; Miller AM, 2001, AM J PUBLIC HEALTH, V91, P861, DOI 10.2105/AJPH.91.6.861	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1903	1903		10.1016/S0140-6736(04)16362-9	http://dx.doi.org/10.1016/S0140-6736(04)16362-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15185707				2022-12-28	WOS:000221822300026
J	Samii, A; Nutt, JG; Ransom, BR				Samii, A; Nutt, JG; Ransom, BR			Parkinson's disease	LANCET			English	Review							DEEP-BRAIN-STIMULATION; MULTIPLE SYSTEM ATROPHY; PROGRESSIVE SUPRANUCLEAR PALSY; LEVODOPA-INDUCED DYSKINESIAS; ALPHA-SYNUCLEIN; SUBTHALAMIC NUCLEUS; LEWY BODIES; DOPAMINE TRANSPORTER; MOVEMENT-DISORDERS; CLINICAL-FEATURES	Parkinson's disease is the most common serious movement disorder in the world, affecting about 1% of adults older than 60 years. The disease is attributed to selective loss of neurons in the substantia nigra, and its cause is enigmatic in most individuals. Symptoms of Parkinson's disease respond in varying degrees to drugs, and surgery offers hope for patients no longer adequately controlled in this manner. The high prevalence of the disease, and important advances in its management, mean that generalists need to have a working knowledge of this disorder. This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis.	VA Puget Sound Hlth Care Syst, NW Parkinson Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Portland VA Med Ctr, NW Parkinson Dis Res Educ & Clin Ctr, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Samii, A (corresponding author), VA Puget Sound Hlth Care Syst, NW Parkinson Dis Res Educ & Clin Ctr, Mailstop 127,1660 S Columbian Way, Seattle, WA 98108 USA.	asamii@u.washington.edu	Ransom, Bruce/ABE-4606-2021; Schapira, Anthony/A-1245-2010	Schapira, Anthony/0000-0002-3018-3966; Ransom, Bruce R./0000-0002-9658-0294				Aarsland D, 2002, J NEUROL NEUROSUR PS, V72, P708, DOI 10.1136/jnnp.72.6.708; Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Adler CH, 2003, MOVEMENT DISORD, V18, P287, DOI 10.1002/mds.10390; Arenas E, 2002, BRAIN RES BULL, V57, P795, DOI 10.1016/S0361-9230(01)00772-9; Assal F, 1998, LANCET, V352, P958, DOI 10.1016/S0140-6736(05)61511-5; Baldereschi M, 2000, NEUROLOGY, V55, P1358, DOI 10.1212/WNL.55.9.1358; Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Beric A, 2001, STEREOT FUNCT NEUROS, V77, P73, DOI 10.1159/000064600; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bostantjopoulou S, 2001, MOVEMENT DISORD, V16, P1007, DOI 10.1002/mds.1221; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BURCHIEL KJ, 1995, NEUROSURG CLIN N AM, V6, P55; Burn DJ, 2003, MOVEMENT DISORD, V18, pS72, DOI 10.1002/mds.10567; BURN DJ, 1992, NEUROLOGY, V42, P1894, DOI 10.1212/WNL.42.10.1894; CALNE DB, 1991, ANN NEUROL, V30, P206, DOI 10.1002/ana.410300213; CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721; CALNE S, 1987, CAN J NEUROL SCI, V14, P303, DOI 10.1017/S0317167100026664; Casals J, 1998, J NEURAL TRANSM, V105, P645, DOI 10.1007/s007020050086; Cedarbaum J M, 1987, Adv Neurol, V45, P469; Chase Thomas N., 1998, Neurology, V50, pS17; Clarke CE, 2002, LANCET, V360, P1767, DOI 10.1016/S0140-6736(02)11668-0; CORDES M, 1994, ANN NEUROL, V36, P667, DOI 10.1002/ana.410360420; CURRAN T, 1994, MOVEMENT DISORD, V9, P508, DOI 10.1002/mds.870090503; de Rijk MC, 2000, NEUROLOGY, V54, pS21; Demirkiran M, 2001, ACTA NEUROL SCAND, V104, P63, DOI 10.1034/j.1600-0404.2001.104002063.x; EIDELBERG D, 1993, J CEREBR BLOOD F MET, V13, P881, DOI 10.1038/jcbfm.1993.110; Emre M, 2003, LANCET NEUROL, V2, P229, DOI 10.1016/S1474-4422(03)00351-X; Etminan M, 2003, DRUG SAFETY, V26, P439, DOI 10.2165/00002018-200326060-00005; Etminan M, 2001, DRUG SAFETY, V24, P863, DOI 10.2165/00002018-200124110-00007; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Fernandez HH, 2003, DRUG SAFETY, V26, P643, DOI 10.2165/00002018-200326090-00004; Foltynie T, 2002, NEUROEPIDEMIOLOGY, V21, P1, DOI 10.1159/000048607; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; Friedman J, 1999, NEW ENGL J MED, V340, P757; Furukawa Y, 1999, MOVEMENT DISORD, V14, P709, DOI 10.1002/1531-8257(199909)14:5<709::AID-MDS1001>3.0.CO;2-T; GAMBOA ET, 1974, ARCH NEUROL-CHICAGO, V31, P228, DOI 10.1001/archneur.1974.00490400042003; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gasser T, 2003, ADV NEUROL, V91, P143; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Ghika J, 1999, J NEUROSURG, V91, P313, DOI 10.3171/jns.1999.91.2.0313; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Gilman S, 1999, J NEUROL SCI, V163, P94, DOI 10.1016/S0022-510X(98)00304-9; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goetz CG, 2003, ADV NEUROL, V91, P213; GOLBE LI, 1991, NEUROLOGY, V41, P168, DOI 10.1212/WNL.41.2_Part_1.168; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Guridi J, 1997, NEUROSURGERY, V41, P1169, DOI 10.1097/00006123-199711000-00029; Guttman M, 2001, NEUROLOGY, V56, P1559, DOI 10.1212/WNL.56.11.1559; Halliwell B, 1998, LANCET, V351, P1510, DOI 10.1016/S0140-6736(05)78898-X; HELY MA, 1994, J NEUROL NEUROSUR PS, V57, P903, DOI 10.1136/jnnp.57.8.903; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Homann CN, 2003, ADV NEUROL, V91, P335; Hughes AJ, 2002, BRAIN, V125, P861, DOI 10.1093/brain/awf080; Hussain IF, 2001, J NEUROL NEUROSUR PS, V71, P371, DOI 10.1136/jnnp.71.3.371; Inzelberg R, 2002, AM J MED GENET, V111, P459, DOI 10.1002/ajmg.10586; JANKOVIC J, 1989, ANN NEUROL, V25, P211, DOI 10.1002/ana.410250226; Jankovic J, 2000, NEUROLOGY, V54, pS21; JimenezJimenez FJ, 1997, DRUG SAFETY, V16, P180, DOI 10.2165/00002018-199716030-00004; Jost WH, 2003, J NEUROL, V250, P28, DOI 10.1007/s00415-003-1105-z; KISH SJ, 1992, J NEUROCHEM, V58, P642, DOI 10.1111/j.1471-4159.1992.tb09766.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koller WC, 1999, NEUROLOGY, V53, P1012, DOI 10.1212/WNL.53.5.1012; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krack P, 1998, BRAIN, V121, P451, DOI 10.1093/brain/121.3.451; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lai BCL, 2003, PARKINSONISM RELAT D, V9, P233, DOI 10.1016/S1353-8020(02)00093-7; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lee CS, 2000, ANN NEUROL, V47, P493, DOI 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Lozano AM, 2003, ADV NEUROL, V91, P303; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; LUQUIN MR, 1992, MOVEMENT DISORD, V7, P117, DOI 10.1002/mds.870070204; Marek K, 2002, EUR J NEUROL, V9, P15, DOI 10.1046/j.1468-1331.9.s3.2.x; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; Mark MH, 2001, NEUROL CLIN, V19, P607, DOI 10.1016/S0733-8619(05)70037-2; Marshall V, 2003, MOVEMENT DISORD, V18, P1415, DOI 10.1002/mds.10592; MARTINEZMARTIN P, 1994, MOVEMENT DISORD, V9, P76, DOI 10.1002/mds.870090112; MARTTILA RJ, 1988, NEUROLOGY, V38, P1217, DOI 10.1212/WNL.38.8.1217; MAYEUX R, 1995, AM J EPIDEMIOL, V142, P820, DOI 10.1093/oxfordjournals.aje.a117721; McCall S, 2001, J NEUROPATH EXP NEUR, V60, P696, DOI 10.1093/jnen/60.7.696; McDonald WA, 2003, BIOL PSYCHIAT, V54, P363, DOI 10.1016/S0006-3223(03)00530-4; MCGEER PL, 1977, ARCH NEUROL-CHICAGO, V34, P33, DOI 10.1001/archneur.1977.00500130053010; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; McKeith IG, 2000, ANN NY ACAD SCI, V920, P1; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; Moro E, 1999, NEUROLOGY, V53, P85, DOI 10.1212/WNL.53.1.85; MUTHANE UB, 1994, MOVEMENT DISORD, V9, P539, DOI 10.1002/mds.870090506; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Nutt JG, 2001, PARKINSONISM RELAT D, V8, P101, DOI 10.1016/S1353-8020(01)00024-4; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Oh MY, 2002, NEUROSURGERY, V50, P1268; Olanow CW, 2000, ANN NEUROL, V47, pS167; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Olanow CW, 2000, NEUROLOGY, V55, pS72; Olson EJ, 2000, BRAIN, V123, P331, DOI 10.1093/brain/123.2.331; Parkinson Study Group, 2000, JAMA, V284, P1931; PAYAMI H, 1994, ANN NEUROL, V36, P659, DOI 10.1002/ana.410360417; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pradhan S, 1999, NEUROLOGY, V53, P1781, DOI 10.1212/WNL.53.8.1781; Pritchett AM, 2002, MAYO CLIN PROC, V77, P1280, DOI 10.4065/77.12.1280; Priyadarshi A, 2001, ENVIRON RES, V86, P122, DOI 10.1006/enrs.2001.4264; QUINN NP, 1986, LANCET, V1, P1366; Rajput A, 2001, DRUG AGING, V18, P913, DOI 10.2165/00002512-200118120-00003; RAJPUT AH, 1992, CAN J NEUROL SCI, V19, P103, DOI 10.1017/S0317167100041457; RANSOM BR, 1987, NEUROSCI LETT, V75, P323, DOI 10.1016/0304-3940(87)90543-X; Rascol O, 2003, ADV NEUROL, V91, P203; Rascol O, 2002, LANCET, V359, P1589, DOI 10.1016/S0140-6736(02)08520-3; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Rasmussen A, 2000, NEUROPEDIATRICS, V31, P190, DOI 10.1055/s-2000-7461; RINNE JO, 1994, BRAIN, V117, P1183, DOI 10.1093/brain/117.5.1183; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Saint-Cyr JA, 2000, BRAIN, V123, P2091, DOI 10.1093/brain/123.10.2091; Samii A, 1999, PARKINSON'S DISEASE: THE TREATMENT OPTIONS, P229; Samii A, 1999, BRAIN, V122, P417, DOI 10.1093/brain/122.3.417; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Schapira AHV, 2004, JAMA-J AM MED ASSOC, V291, P358, DOI 10.1001/jama.291.3.358; Schapira AHV, 2000, NEUROLOGY, V55, pS65; Schrag A, 1998, MOVEMENT DISORD, V13, P885, DOI 10.1002/mds.870130605; SCHULZER M, 1992, ANN NEUROL, V32, P795, DOI 10.1002/ana.410320614; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Shoulson I, 2002, ANN NEUROL, V51, P604, DOI 10.1002/ana.10191; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stacy M, 2002, DRUG AGING, V19, P733, DOI 10.2165/00002512-200219100-00002; Steece-Collier K, 2002, P NATL ACAD SCI USA, V99, P13972, DOI 10.1073/pnas.242594999; Stoessl AJ, 1999, CAN J NEUROL SCI, V26, pS1, DOI 10.1017/S0317167100000020; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Thase ME, 1998, J CLIN PSYCHIAT, V59, P502, DOI 10.4088/JCP.v59n1002; Tsui JKC, 1999, CAN J PUBLIC HEALTH, V90, P334, DOI 10.1007/BF03404523; Umemura A, 2003, J NEUROSURG, V98, P779, DOI 10.3171/jns.2003.98.4.0779; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; van Dyck CH, 2002, AM J GERIAT PSYCHIAT, V10, P36, DOI 10.1176/appi.ajgp.10.1.36; VINGERHOETS FJG, 1994, ANN NEUROL, V36, P759, DOI 10.1002/ana.410360512; Volkmann J, 1998, ANN NEUROL, V44, P953, DOI 10.1002/ana.410440615; Wakabayashi K, 1997, EUR NEUROL, V38, P2, DOI 10.1159/000113469; WARD CD, 1990, ADV NEUROL, V53, P245; WARD CD, 1983, NEUROLOGY, V33, P815, DOI 10.1212/WNL.33.7.815; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Whone AL, 2003, ANN NEUROL, V54, P93, DOI 10.1002/ana.10609; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; Winogrodzka A, 2001, J NEURAL TRANSM, V108, P1011, DOI 10.1007/s007020170019; Yamada T, 1996, Parkinsonism Relat Disord, V2, P187, DOI 10.1016/S1353-8020(96)00024-7	156	850	897	2	148	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2004	363	9423					1783	1793		10.1016/S0140-6736(04)16305-8	http://dx.doi.org/10.1016/S0140-6736(04)16305-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172778				2022-12-28	WOS:000221705800021
J	Wong, TY; Shankar, A; Klein, R; Klein, BEK; Hubbard, LD				Wong, TY; Shankar, A; Klein, R; Klein, BEK; Hubbard, LD			Prospective cohort study of retinal vessel diameters and risk of hypertension	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ATHEROSCLEROSIS RISK; VISUAL-ACUITY; ABNORMALITIES; POPULATION	Objective To examine the relation between diameters of the retinal artcrioles and 10 year incidence of hypertension. Design Population based prospective cohort study. Setting Beaver Dam eye study. Participants 2451 normotensive people aged 43 to 84 years. Main outcome measures Diameters of retinal arterioles and venules measured from digitised photographs of the retina taken at baseline. Measurements summarised as the arteriole:venule ratio, with a lower ratio indicating smaller arteriolar diameters. Incident hypertension, defined as systolic blood pressure greater than or equal to 140 mm Hg, diastolic blood pressure greater than or equal to 90 mm Hg, or use of antihypertensive drugs during follow tip. Results 72 1 participants developed hypertension over a 10 year period. Those with lower arteriole:venule ratios had a higher cumulative incidence of hypertension (incidences of 17.4%, 24.1%, 31.0%, and 45.1%, respectively, for decreasing quarters of distribution of arteriole:venule ratio). After adjustment for age and sex, participants with arteriole:venule ratios in the lowest quarter had a threefold higher risk of hypertension (odds ratio 2.95, 95% confidence interval 2.77 to 3.88) than those with ratios in the highest quarter. This association remained significant after further adjustment for baseline systolic and diastolic blood pressure and other risk factors (1.82, 1.39 to 2.40, for lowest versus highest ratio quarters). Conclusions Narrowed retinal arterioles are associated with long term risk of hypertension, suggesting that structural alterations of the microvasculature may be linked to the development of hypertension.	Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia; Univ Wisconsin, Dept Ophthalmol, Madison, WI 53726 USA; Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA	Centre for Eye Research Australia; University of Melbourne; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Wong, TY (corresponding author), Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.	twong@unimelb.edu.au	Wong, Tien Yin/AAC-9724-2020	Wong, Tien Yin/0000-0002-8448-1264	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066018] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beevers G, 2001, BRIT MED J, V322, P912, DOI 10.1136/bmj.322.7291.912; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0; Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; KLEIN R, PB91149823 NTIS; KLEIN R, 1991, PB91149823 NTIS; KLEIN R, 2000, ARTERIOSCLER THROMB, V20, P44; Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049; Levy BI, 2001, CIRCULATION, V104, P735, DOI 10.1161/hc3101.091158; Mulrow CD, 2001, BMJ-BRIT MED J, V322, P1107, DOI 10.1136/bmj.322.7294.1107; Mulvany MJ, 1996, HYPERTENSION, V28, P505; MULVANY MJ, 1991, HYPERTENSION, V18, P52, DOI 10.1161/01.HYP.18.3_Suppl.I52; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; NORRELUND H, 1994, HYPERTENSION, V24, P301, DOI 10.1161/01.HYP.24.3.301; Pries AR, 1999, HYPERTENSION, V33, P153, DOI 10.1161/01.HYP.33.1.153; Rizzoni D, 2003, CIRCULATION, V108, P2230, DOI 10.1161/01.CIR.0000095031.51492.C5; RIZZONI D, 1994, AM J HYPERTENS, V7, P193, DOI 10.1093/ajh/7.2.193; The hypertension detection and follow-up program. Hypertension detetection and follow-up program cooperative group, 1976, PREV MED, V5, P207; THYBO NK, 1995, HYPERTENSION, V25, P474, DOI 10.1161/01.HYP.25.4.474; TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132; Wong TY, 2004, ANN INTERN MED, V140, P248, DOI 10.7326/0003-4819-140-4-200402170-00006; Wong TY, 2003, INVEST OPHTH VIS SCI, V44, P4644, DOI 10.1167/iovs.03-0079	26	190	196	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					79	82A		10.1136/bmj.38124.682523.55	http://dx.doi.org/10.1136/bmj.38124.682523.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15175230	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222645000017
J	Irigoien, X; Huisman, J; Harris, RP				Irigoien, X; Huisman, J; Harris, RP			Global biodiversity patterns of marine phytoplankton and zooplankton	NATURE			English	Article							PRODUCTIVITY; DIVERSITY; COMPETITION; RESOURCES; GROWTH	Although the oceans cover 70% of the Earth's surface, our knowledge of biodiversity patterns in marine phytoplankton and zooplankton is very limited compared to that of the biodiversity of plants and herbivores in the terrestrial world. Here, we present biodiversity data for marine plankton assemblages from different areas of the world ocean. Similar to terrestrial vegetation(1-3), marine phytoplankton diversity is a unimodal function of phytoplankton biomass, with maximum diversity at intermediate levels of phytoplankton biomass and minimum diversity during massive blooms. Contrary to expectation, we did not find a relation between phytoplankton diversity and zooplankton diversity. Zooplankton diversity is a unimodal function of zooplankton biomass. Most strikingly, these marine biodiversity patterns show a worldwide consistency, despite obvious differences in environmental conditions of the various oceanographic regions. These findings may serve as a new benchmark in the search for global biodiversity patterns of plants and herbivores.	AZTI, Arrantza Elikaigintzarako Inst Teknol, Harrera Kaia Portualdea, Pasaia 20110, Spain; Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, NL-1018 WS Amsterdam, Netherlands; Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England	AZTI; University of Amsterdam; Plymouth Marine Laboratory	Irigoien, X (corresponding author), AZTI, Arrantza Elikaigintzarako Inst Teknol, Harrera Kaia Portualdea, Pasaia 20110, Spain.	xirigoien@pas.azti.es	Huisman, Jef/A-1089-2013; Irigoien, Xabier/B-8171-2009	Huisman, Jef/0000-0001-9598-3211; Irigoien, Xabier/0000-0002-5411-6741	Natural Environment Research Council [NER/O/S/2001/00680] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Agawin NSR, 2000, LIMNOL OCEANOGR, V45, P591, DOI 10.4319/lo.2000.45.3.0591; Calbet A, 2004, LIMNOL OCEANOGR, V49, P51, DOI 10.4319/lo.2004.49.1.0051; Chase JM, 2002, NATURE, V416, P427, DOI 10.1038/416427a; Collins SL, 1998, SCIENCE, V280, P745, DOI 10.1126/science.280.5364.745; Dodson SI, 2000, ECOLOGY, V81, P2662, DOI 10.1890/0012-9658(2000)081[2662:TRILCB]2.0.CO;2; Fukami T, 2003, NATURE, V424, P423, DOI 10.1038/nature01785; GRIME JP, 1973, NATURE, V242, P344, DOI 10.1038/242344a0; Hamm CE, 2003, NATURE, V421, P841, DOI 10.1038/nature01416; Hillebrand H, 2003, OIKOS, V100, P592, DOI 10.1034/j.1600-0706.2003.12045.x; HOLLIGAN PM, 1977, J MAR BIOL ASSOC UK, V57, P1075, DOI 10.1017/S002531540002614X; Huisman J, 1999, AM NAT, V154, P46, DOI 10.1086/303220; Huisman J, 1999, ECOLOGY, V80, P211, DOI 10.1890/0012-9658(1999)080[0211:CFLBPS]2.0.CO;2; Interlandi SJ, 2001, ECOLOGY, V82, P1270, DOI 10.2307/2679988; Joint I, 2000, J EXP MAR BIOL ECOL, V250, P233, DOI 10.1016/S0022-0981(00)00199-4; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; Kirk J., 1983, LIGHT PHOTOSYNTHESIS; Li WKW, 2002, NATURE, V419, P154, DOI 10.1038/nature00994; Longhurst, 2006, ECOLOGICAL GEOGRAPHY; MARGALEF R, 1978, OCEANOL ACTA, V1, P493; Mauchline J, 1998, BIOL CALANOID COPEPO; Mittelbach GG, 2001, ECOLOGY, V82, P2381, DOI 10.1890/0012-9658(2001)082[2381:WITORB]2.0.CO;2; OHMAN MD, 1994, LIMNOL OCEANOGR, V39, P21, DOI 10.4319/lo.1994.39.1.0021; Raven JA, 1998, FUNCT ECOL, V12, P503, DOI 10.1046/j.1365-2435.1998.00233.x; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; STRATHMANN RR, 1967, LIMNOL OCEANOGR, V12, P411, DOI 10.4319/lo.1967.12.3.0411; Strom S, 2003, LIMNOL OCEANOGR, V48, P217, DOI 10.4319/lo.2003.48.1.0217; Tilman D., 1982, Monographs in Population Biology, pi; Waide RB, 1999, ANNU REV ECOL SYST, V30, P257, DOI 10.1146/annurev.ecolsys.30.1.257; WILLIAMS LG, 1964, ECOLOGY, V45, P809, DOI 10.2307/1934927; Worm B, 2002, NATURE, V417, P848, DOI 10.1038/nature00830	30	294	306	12	204	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					863	867		10.1038/nature02593	http://dx.doi.org/10.1038/nature02593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215862				2022-12-28	WOS:000222213000039
J	Karlson, RH; Cornell, HV; Hughes, TP				Karlson, RH; Cornell, HV; Hughes, TP			Coral communities are regionally enriched along an oceanic biodiversity gradient	NATURE			English	Article							SPECIES RICHNESS; DIVERSITY; PATTERNS; SCALE; REEFS	Ecological communities are influenced by processes operating at multiple scales(1-5). Thus, a better understanding of how broad- as well as local-scale processes affect species diversity and richness is increasingly becoming a central focus in modern community ecology(6-9). Here, in a study of unprecedented geographical scope, we show significant regional and local variation in the species richness of coral assemblages across an oceanic biodiversity gradient. The gradient that we sampled extends 10,000 km eastwards from the world's richest coral biodiversity hotspot in the central Indo-Pacific(10). Local richness and the size of regional species pools decline significantly across 15 islands spanning the gradient. In addition, richness declines across three adjacent habitats ( reef slopes, crests and flats). In each habitat, a highly consistent linear relationship between local and regional species richness indicates strong regional enrichment. Thus, even on the most diverse coral reefs in the world, local coral assemblages are profoundly affected by regional-scale processes. Understanding these historical and biogeographical influences is essential for the effective management and preservation of these endangered communities.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; James Cook Univ N Queensland, Dept Marine Biol, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia	University of Delaware; James Cook University	Karlson, RH (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.	rkarlson@udel.edu	Hughes, Terry P/L-4721-2013	Hughes, Terry P/0000-0002-5257-5063				[Anonymous], 1982, AUSTR I MARINE SCI M; Caley MJ, 1997, ECOLOGY, V78, P70; Caswell Hal, 1993, P99; COLWELL RK, 1994, PHILOS T R SOC B, V345, P101, DOI 10.1098/rstb.1994.0091; Cornell HV, 1996, J ANIM ECOL, V65, P233, DOI 10.2307/5726; CORNELL HV, 1992, J ANIM ECOL, V61, P1, DOI 10.2307/5503; Elton C.S., 1933, ECOLOGY ANIMALS; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Hayek L.C., 1997, SURVEYING NATURAL PO; Holt Robert D., 1997, P149, DOI 10.1016/B978-012323445-2/50010-9; Holt Robert D., 1993, P77; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Hughes TP, 2002, ECOL LETT, V5, P775, DOI 10.1046/j.1461-0248.2002.00383.x; Hughes TP, 1999, NATURE, V397, P59, DOI 10.1038/16237; Karlson RH, 1998, ECOL MONOGR, V68, P259, DOI 10.1890/0012-9615(1998)068[0259:SDVILV]2.0.CO;2; Karlson RH, 2002, ECOLOGY, V83, P452, DOI 10.2307/2680027; LEVIN SA, 1992, ECOLOGY, V73, P1943, DOI 10.2307/1941447; Loreau M, 1999, AM NAT, V154, P427, DOI 10.1086/303252; MACARTHUR RH, 1965, BIOL REV, V40, P510, DOI 10.1111/j.1469-185X.1965.tb00815.x; PACALA SW, 1990, ECOL MONOGR, V60, P113, DOI 10.2307/1943028; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; RICKLEFS RE, 1987, SCIENCE, V235, P167, DOI 10.1126/science.235.4785.167; Roughgarden J, 1989, PERSPECTIVES ECOLOGI; Shurin JB, 2001, AM NAT, V158, P624, DOI 10.1086/323589; Stoll P, 2001, ECOLOGY, V82, P319, DOI 10.1890/0012-9658(2001)082[0319:IAACII]2.0.CO;2; Tilman D, 1997, SPATIAL ECOLOGY ROLE; Veron J.E.N., 2000, CORALS WORLD, V1-3; VERON JEN, AUSTR I MARINE SCI M, P77; Wallace C.C., 1999, STAGHORN CORALS WORL, DOI 10.1071/9780643101388; Yodzis P., 1989, INTRO THEORETICAL EC	30	111	116	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	2004	429	6994					867	870		10.1038/nature02685	http://dx.doi.org/10.1038/nature02685			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15201847				2022-12-28	WOS:000222213000040
J	Espeland, MA; Rapp, SR; Shumaker, SA; Brunner, R; Manson, JE; Sherwin, BB; Hsia, J; Margolis, KL; Hogan, PE; Wallace, R; Dailey, M; Freeman, R; Hays, J				Espeland, MA; Rapp, SR; Shumaker, SA; Brunner, R; Manson, JE; Sherwin, BB; Hsia, J; Margolis, KL; Hogan, PE; Wallace, R; Dailey, M; Freeman, R; Hays, J		Womens Hlth Initiative Memory Stud	Conjugated equine estrogens and global cognitive function in postmenopausal women - Women's Health Initiative Memory Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENTAL-STATE-EXAMINATION; HORMONE REPLACEMENT THERAPY; PLUS PROGESTIN; DEMENTIA; IMPAIRMENT; 3MS; PREVALENCE; COHORT; RISK; MMSE	Context The Women's Health Initiative Memory Study (WHIMS) previously reported that estrogen plus progestin therapy does not protect cognition among women aged 65 years or older. The effect of estrogen-alone therapy, also evaluated in WHIMS, on cognition has not been established for this population. Objectives To determine whether conjugated equine estrogen (CEE) alters global cognitive function in older women and to compare its effect with CEE plus medroxyprogesterone acetate (CEE plus MPA). Design, Setting, and Participants A randomized, double-blind, placebo-controlled ancillary study of the Women's Health Initiative (WHI), WHIMS evaluated the effect of CEE on incidence of probable dementia among community-dwelling women aged 65 to 79 years with prior hysterectomy from 39 US academic centers that started in June 1995. Of 3200 eligible women free of probable dementia enrolled in the WHI, 2947 (92.1%) were enrolled in WHIMS. Analyses were conducted on the 2808 women (95.3%) with a baseline and at least 1 follow-up measure of global cognitive function before the trial's termination on February 29, 2004. Interventions Participants received 1 daily tablet containing either 0.625 mg of CEE (n = 1387) or matching placebo (n = 142 1). Main Outcome Measure Global cognitive function measured annually with the Modified Mini-Mental State Examination (3MSE). Results During a mean follow-up of 5.4 years, mean (SE) 3MSE scores were 0.26 (0.13) units lower than among women assigned to CEE compared with placebo (P=.04). For pooled hormone therapy (CEE combined with CEE plus MPA), the mean (SE) decrease was 0.21 (0.08; P=.006). Removing women with dementia, mild cognitive impairment, or stroke from the analyses lessened these differences. The adverse effect of hormone therapy was more pronounced among women with lower cognitive function at baseline (all P<.01). For women assigned to CEE compared with placebo, the relative risk of having a 10-unit decrease in 3MSE scores (>2 SDs) was estimated to be 1.47 (95% confidence interval, 1.04-2.07). Conclusion For women aged 65 years or older, hormone therapy had an adverse effect on cognition, which was greater among women with lower cognitive function at initiation of treatment.	Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; Univ Nevada, Sch Med, Womens Hlth Ctr, Reno, NV 89557 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA; McGill Univ, Dept Psychol, Montreal, PQ, Canada; McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3A 2T5, Canada; George Washington Univ, Dept Med, Washington, DC USA; Hennepin Cty Med Ctr, Div Clin Epidemiol, Minneapolis, MN 55415 USA; Univ Iowa, Coll Med, Dept Epidemiol, Iowa City, IA USA; Montefiore Med Ctr, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA; Baylor Coll Med, Ctr Womens Hlth, Houston, TX 77030 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Nevada System of Higher Education (NSHE); University of Nevada Reno; Harvard University; Brigham & Women's Hospital; Harvard Medical School; McGill University; McGill University; George Washington University; Hennepin County Medical Center; University of Iowa; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine	Espeland, MA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mespelan@wfubmc.edu		Margolis, Karen/0000-0003-1862-7402; Hays-Grudo, Jennifer/0000-0002-8107-1243				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; BARKER A, 1995, BRIT J PSYCHIAT, V167, P642, DOI 10.1192/bjp.167.5.642; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bravo G, 1997, NEUROEPIDEMIOLOGY, V16, P141; CORIA F, 1993, J NEUROL NEUROSUR PS, V56, P973, DOI 10.1136/jnnp.56.9.973; Foy MR, 2000, CURR DIR PSYCHOL SCI, V9, P148, DOI 10.1111/1467-8721.00081; GALEN BJ, 2004, J AM GERIATR SOC, V52, P182; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Hogervorst E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003122; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Linzmayer L, 2001, ARZNEIMITTEL-FORSCH, V51, P238; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; Mitchell JL, 2003, ARCH INTERN MED, V163, P2485, DOI 10.1001/archinte.163.20.2485; NADLER JD, 1995, J GERIATR PSYCH NEUR, V8, P177, DOI 10.1177/089198879500800307; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Smith YR, 2001, J CLIN ENDOCR METAB, V86, P679, DOI 10.1210/jc.86.2.679; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TENG EL, 1990, PSYCHOGERIATRICS BIO, P189; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	40	591	609	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2959	2968		10.1001/jama.291.24.2959	http://dx.doi.org/10.1001/jama.291.24.2959			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213207	Bronze			2022-12-28	WOS:000222184600025
J	Kyrle, PA; Minar, E; Bialonczyk, C; Hirschl, M; Weltermann, A; Eichinger, S				Kyrle, PA; Minar, E; Bialonczyk, C; Hirschl, M; Weltermann, A; Eichinger, S			The risk of recurrent venous thromboembolism in men and women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; EPISODE	Background: Whether a patient's sex is associated with the risk of recurrent venous thromboembolism is unknown. Methods: We studied 826 patients for an average of 36 months after a first episode of spontaneous venous thromboembolism and the withdrawal of oral anticoagulants. We excluded pregnant patients and patients with a deficiency of antithrombin, protein C, or protein S; the lupus anticoagulant; cancer; or a requirement for potentially long-term antithrombotic treatment. The end point was objective evidence of a recurrence of symptomatic venous thromboembolism. Results: Venous thromboembolism recurred in 74 of the 373 men, as compared with 28 of the 453 women (20 percent vs. 6 percent; relative risk of recurrence, 3.6; 95 percent confidence interval, 2.3 to 5.5; P<0.001). The risk remained unchanged after adjustment for age, the duration of anticoagulation, and the presence or absence of a first symptomatic pulmonary embolism, factor V Leiden, factor II G20210A, or an elevated level of factor VIII or IX. At five years, the likelihood of recurrence was 30.7 percent among men, as compared with 8.5 percent among women (P<0.001). The relative risk of recurrence was similar among women who had had their first thrombosis during oral-contraceptive use or hormone-replacement therapy and women in the same age group in whom the first event was idiopathic. Conclusions: The risk of recurrent venous thromboembolism is higher among men than women.	Ludwig Boltzmann Inst Thromboseforsch, Dept Internal Med 1, Div Hematol & Hemostasis, A-1090 Vienna, Austria; Med Univ Vienna, Dept Internal Med 2, Div Angiol, Vienna, Austria; Wilhelminenspital Stadt Wien, Vienna, Austria; Hanusch Hosp, Vienna, Austria	Ludwig Boltzmann Institute; Medical University of Vienna; Wilhelminenspital; WGKK - Hanusch Hospital	Kyrle, PA (corresponding author), Ludwig Boltzmann Inst Thromboseforsch, Dept Internal Med 1, Div Hematol & Hemostasis, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	paul.kyrle@meduniwien.ac.at						ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; Berkowitz DE, 2003, CIRCULATION, V108, P2000, DOI 10.1161/01.CIR.0000092948.04444.C7; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; Eichinger S, 2004, ARCH INTERN MED, V164, P92, DOI 10.1001/archinte.164.1.92; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V341, P298; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; O'Brien J, 2000, LANCET, V355, P1295; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Rosendaal FR, 2003, J THROMB HAEMOST, V1, P1371, DOI 10.1046/j.1538-7836.2003.00264.x; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; vandenBelt AGM, 1997, ARCH INTERN MED, V157, P2227, DOI 10.1001/archinte.157.19.2227; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Weltermann A, 2003, J THROMB HAEMOST, V1, P28, DOI 10.1046/j.1538-7836.2003.00038.x	25	347	361	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2558	2563		10.1056/NEJMoa032959	http://dx.doi.org/10.1056/NEJMoa032959			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201412				2022-12-28	WOS:000222054700006
J	Haga, SB; Burke, W				Haga, SB; Burke, W			Using pharmacogenetics to improve drug safety and efficacy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THIOPURINE S-METHYLTRANSFERASE; HOSPITALIZED-PATIENTS; THERAPY; EVENTS; OPTIMIZATION; POLYMORPHISM; COSTS; CARE		Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA; Ctr Advancement Gen, Rockville, MD USA	University of Washington; University of Washington Seattle	Burke, W (corresponding author), Univ Washington, Dept Med Hist & Eth, Box 357120,1959 NE Pacific,Room A204, Seattle, WA 98195 USA.	wburke@u.washington.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01HGO2263] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], PRESCRIBING INFORMAT; Balis FM, 1999, J NATL CANCER I, V91, P1983, DOI 10.1093/jnci/91.23.1983; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Chasman DI, 2004, JAMA-J AM MED ASSOC, V291, P2821, DOI 10.1001/jama.291.23.2821; *CHILDR ONC GROUP, CHILDR ONC GROUP WEB; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Fry RN, 2003, VALUE HEALTH, V6, P505, DOI 10.1046/j.1524-4733.2003.65327.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Khoury MJ, 2004, GENET MED, V6, P38, DOI 10.1097/01.GIM.0000105751.71430.79; Krynetski EY, 1999, PHARM RES-DORDR, V16, P342, DOI 10.1023/A:1011909315614; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lennard L, 1996, THER DRUG MONIT, V18, P328, DOI 10.1097/00007691-199608000-00003; Lindpaintner K, 2003, CLIN CHEM LAB MED, V41, P398, DOI 10.1515/CCLM.2003.063; Mackenzie IS, 2002, CLIN MED, V2, P465, DOI 10.7861/clinmedicine.2-5-465; *NAT I GEN MED SCI, PHARM RES NETW; *NIH, NIH ROADM ACC MED DI; Oscarson M, 2003, CLIN CHEM LAB MED, V41, P573, DOI 10.1515/CCLM.2003.087; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Regalado A, 1999, AM J HEALTH-SYST PH, V56, P40, DOI 10.1093/ajhp/56.1.40; Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; US Department Health and Human Services Food and Drug Administration, 2005, GUID IND PHARM DAT S; Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601; COMPUTER RETRIEVAL I	28	36	38	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2869	2871		10.1001/jama.291.23.2869	http://dx.doi.org/10.1001/jama.291.23.2869			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199039				2022-12-28	WOS:000221962500034
J	Alonso, A; Sasin, J; Bottini, N; Friedberg, I; Friedberg, I; Osterman, A; Godzik, A; Hunter, T; Dixon, J; Mustelin, T				Alonso, A; Sasin, J; Bottini, N; Friedberg, I; Friedberg, I; Osterman, A; Godzik, A; Hunter, T; Dixon, J; Mustelin, T			Protein tyrosine phosphatases in the human genome	CELL			English	Review							CRYSTAL-STRUCTURE; MYOTUBULAR MYOPATHY; GERMLINE MUTATIONS; MOLECULAR-CLONING; BINDING DOMAIN; GENE STRUCTURE; EYES ABSENT; SPECIFICITY; DISEASE; KINASE	Tyrosine phosphorylation is catalyzed by protein tyrosine kinases, which are represented by 90 genes in the human genome. Here, we present the set of 107 genes in the human genome that encode members of the four protein tyrosine phosphatase (PTP) families. The four families of PTPases, their substrates, structure, function, regulation, and the role of these enzymes in human disease will be discussed.	Burnham Inst, Program Signal Transduct, La Jolla, CA 92037 USA; Burnham Inst, Program Bioinformat, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Salk Institute; University of California System; University of California San Diego	Mustelin, T (corresponding author), Burnham Inst, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Godzik, Adam/AAW-1467-2020; Alonso, Andrés/L-7523-2014; Friedberg, Iddo/S-4793-2019; Godzik, Adam/A-7279-2009; Ingegnoli, Francesca/B-6226-2017	Godzik, Adam/0000-0002-2425-852X; Alonso, Andrés/0000-0001-8674-9378; Friedberg, Iddo/0000-0002-1789-8000; Godzik, Adam/0000-0002-2425-852X; Mustelin, Tomas/0000-0001-5912-8840; Ingegnoli, Francesca/0000-0002-6727-1273				Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; ALONSO A, 2004, IN PRESS J BIOL CHEM; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Azzedine H, 2003, AM J HUM GENET, V72, P1141, DOI 10.1086/375034; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; Bottini N, 2002, ARCH IMMUNOL THER EX, V50, P95; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; BRYSON GLM, 1995, GENOMICS, V30, P133; Bult A, 1997, EUR J CELL BIOL, V72, P337; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CZEMILOFSKY AP, 1980, NATURE, V287, P198; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; EICHEBLY M, 1999, SCIENCE, V283, P1544; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Huynh H, 2003, J IMMUNOL, V171, P6661, DOI 10.4049/jimmunol.171.12.6661; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Kashio N, 1998, J BIOL CHEM, V273, P33856, DOI 10.1074/jbc.273.50.33856; Kawasaki E, 1996, BIOCHEM BIOPH RES CO, V227, P440, DOI 10.1006/bbrc.1996.1526; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kung C, 2000, NAT MED, V6, P343; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Mustelin GS, 2002, FRONT BIOSCI, V7, P85; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD918, DOI 10.2741/musteli1; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; MUSTELIN T, 2002, M MITOSIS CELL CYCLE; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Satow R, 2002, BIOCHEM BIOPH RES CO, V295, P85, DOI 10.1016/S0006-291X(02)00641-1; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Seroude L, 2002, AGING CELL, V1, P47, DOI 10.1046/j.1474-9728.2002.00007.x; Siniossoglou S, 2000, J BIOL CHEM, V275, P19352, DOI 10.1074/jbc.M001314200; Siniossoglou S, 1998, EMBO J, V17, P6449, DOI 10.1093/emboj/17.22.6449; Smith M, 2000, AM J MED GENET, V96, P765, DOI 10.1002/1096-8628(20001204)96:6<765::AID-AJMG13>3.0.CO;2-L; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tailor P, 1999, EUR J BIOCHEM, V262, P277, DOI 10.1046/j.1432-1327.1999.00353.x; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; WISHART MJ, 1995, J BIOL CHEM, V270, P26782, DOI 10.1074/jbc.270.45.26782; Yamaguchi S, 1999, EUR J BIOCHEM, V259, P946, DOI 10.1046/j.1432-1327.1999.00143.x; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	77	1444	1508	8	157	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	2004	117	6					699	711		10.1016/j.cell.2004.05.018	http://dx.doi.org/10.1016/j.cell.2004.05.018			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186772	Bronze			2022-12-28	WOS:000222048400004
J	Carter, RM; Gammon, P				Carter, RM; Gammon, P			New Zealand maritime glaciation: Millennial-scale southern climate change since 3.9 Ma	SCIENCE			English	Article							ICE CORE; CIRCULATION; ANTARCTICA; GREENLAND; ATLANTIC; NORTH; ALPS	Ocean Drilling Program Site 1119 is ideally located to intercept discharges of sediment from the mid-latitude glaciers of the New Zealand Southern Alps. The natural gamma ray signal from the site's sediment core contains a history of the South Island mountain ice cap since 3.9 million years ago (Ma). The younger record, to 0.37 Ma, resembles the climatic history of Antarctica as manifested by the Vostok ice core. Beyond, and back to the late Pliocene, the record may serve as a proxy for both mid-latitude and Antarctic polar plateau air temperature. The gamma ray signal, which is atmospheric, also resembles the ocean climate history represented by oxygen isotope time series.	Univ Adelaide, Sch Earth & Environm Sci, Adelaide, SA 5005, Australia	University of Adelaide	Carter, RM (corresponding author), Univ Adelaide, Sch Earth & Environm Sci, Adelaide, SA 5005, Australia.	bob.carter@jcu.edu.au						Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Carter RM, 2004, MAR GEOL, V205, P29, DOI 10.1016/S0025-3227(04)00017-9; CARTER RM, 1999, P ODP INIT REP, V181; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; Clare GR, 2002, INT J CLIMATOL, V22, P107, DOI 10.1002/joc.722; Dansgaard W., 1971, LATE CENOZOIC GLACIA, P37; DENTON GH, 1994, SCIENCE, V264, P1434, DOI 10.1126/science.264.5164.1434; Haine TWN, 1998, J GEOPHYS RES-OCEANS, V103, P27637, DOI 10.1029/98JC02476; NELSON CS, 1993, PALEOCEANOGRAPHY, V8, P435, DOI 10.1029/93PA01162; Newnham RM, 2000, GEOLOGY, V28, P759, DOI 10.1130/0091-7613(2000)028<0759:FRPROL>2.3.CO;2; OERLEMANS J, 1992, SCIENCE, V258, P115, DOI 10.1126/science.258.5079.115; Pahnke K, 2003, SCIENCE, V301, P948, DOI 10.1126/science.1084451; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; RAYMO ME, 1992, NATO ASI SER, V1, P207; Seager R, 2002, Q J ROY METEOR SOC, V128, P2563, DOI 10.1256/qj.01.128; Singer C, 1998, SCIENCE, V281, P812, DOI 10.1126/science.281.5378.812; Turney CSM, 2003, GEOLOGY, V31, P223, DOI 10.1130/0091-7613(2003)031<0223:ACCBNZ>2.0.CO;2; Vidal L, 1999, CLIM DYNAM, V15, P909, DOI 10.1007/s003820050321; Watanabe O, 2003, NATURE, V422, P509, DOI 10.1038/nature01525; Wunsch C, 2003, QUATERNARY SCI REV, V22, P1631, DOI 10.1016/S0277-3791(03)00152-5	21	41	45	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1659	1662		10.1126/science.1093726	http://dx.doi.org/10.1126/science.1093726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192226				2022-12-28	WOS:000221934300047
J	Loewen, CJR; Gaspar, ML; Jesch, SA; Delon, C; Ktistakis, NT; Henry, SA; Levine, TP				Loewen, CJR; Gaspar, ML; Jesch, SA; Delon, C; Ktistakis, NT; Henry, SA; Levine, TP			Phospholipid metabolism regulated by a transcription factor sensing phosphatidic acid	SCIENCE			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATOR; GENETIC-REGULATION; BINDING DOMAIN; YEAST; MEMBRANE; PROTEIN; BIOSYNTHESIS; EXPRESSION	Cells regulate the biophysical properties of their membranes by coordinated synthesis of different classes of lipids. Here, we identified a highly dynamic feedback mechanism by which the budding yeast Saccharomyces cerevisiae can regulate phospholipid biosynthesis. Phosphatidic acid on the endoplasmic reticulum directly bound to the soluble transcriptional repressor Opi1p to maintain it as inactive outside the nucleus. After the addition of the lipid precursor inositol, this phosphatidic acid was rapidly consumed, releasing Opi1p from the endoplasmic reticulum and allowing its nuclear translocation and repression of target genes. Thus, phosphatidic acid appears to be both an essential ubiquitous metabolic intermediate and a signaling lipid.	Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England	University of London; University College London; Cornell University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Levine, TP (corresponding author), Inst Ophthalmol, Div Cell Biol, Bath St, London EC1V 9EL, England.	tim.levine@ucl.ac.uk	Henry, Susan/K-5464-2014	Levine, Timothy/0000-0002-7231-0775; Delon, Christine/0000-0001-5163-1716	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BBS/E/B/0000F969] Funding Source: Medline; NIGMS NIH HHS [GM-19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baillie GS, 2002, J BIOL CHEM, V277, P28298, DOI 10.1074/jbc.M108353200; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Ghosh S, 2003, J BIOL CHEM, V278, P45690, DOI 10.1074/jbc.M302933200; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Kagiwada S, 2003, J BIOCHEM, V133, P515, DOI 10.1093/jb/mvg068; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; Manifava M, 2001, J BIOL CHEM, V276, P8987, DOI 10.1074/jbc.M010308200; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Sakamoto T, 2002, CURR OPIN MICROBIOL, V5, P206, DOI 10.1016/S1369-5274(02)00306-5; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; WHITE MJ, 1991, J BIOL CHEM, V266, P863	28	351	363	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	2004	304	5677					1644	1647		10.1126/science.1096083	http://dx.doi.org/10.1126/science.1096083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827WL	15192221				2022-12-28	WOS:000221934300042
J	Abazov, VM; Abbott, B; Abdesselam, A; Abolins, M; Abramov, V; Acharya, BS; Adams, DL; Adams, M; Ahmed, SN; Alexeev, GD; Alton, A; Alves, GA; Arnoud, Y; Avila, C; Babintsev, VV; Babukhadia, L; Bacon, TC; Baden, A; Baffioni, S; Baldin, B; Balm, PW; Banerjee, S; Barberis, E; Baringer, P; Barreto, J; Bartlett, JF; Bassler, U; Bauer, D; Bean, A; Beaudette, F; Begel, M; Belyaev, A; Beri, SB; Bernardi, G; Bertram, I; Besson, A; Beuselinck, R; Bezzubov, VA; Bhat, PC; Bhatnagar, V; Bhattacharjee, M; Blazey, G; Blekman, F; Blessing, S; Boehnlein, A; Bojko, NI; Bolton, TA; Borcherding, F; Bos, K; Bose, T; Brandt, A; Briskin, G; Brock, R; Brooijmans, G; Bross, A; Buchholz, D; Buehler, M; Buescher, V; Burtovoi, VS; Butler, JM; Canelli, F; Carvalho, W; Casey, D; Castilla-Valdez, H; Chakraborty, D; Chan, KM; Chekulaev, SV; Cho, DK; Choi, S; Chopra, S; Claes, D; Clark, AR; Connolly, B; Cooper, WE; Coppage, D; Crepe-Renaudin, S; Cummings, MAC; Cutts, D; da Motta, H; Davis, GA; De, K; de Jong, SJ; Demarteau, M; Demina, R; Demine, P; Denisov, D; Denisov, SP; Desai, S; Diehl, HT; Diesburg, M; Doulas, S; Dudko, LV; Duflot, L; Dugad, SR; Duperrin, A; Dyshkant, A; Edmunds, D; Ellison, J; Eltzroth, JT; Elvira, VD; Engelmann, R; Eno, S; Eppley, G; Ermolov, P; Eroshin, OV; Estrada, J; Evans, H; Evdokimov, VN; Ferbel, T; Filthaut, F; Fisk, HE; Fortner, M; Fox, H; Fu, S; Fuess, S; Gallas, E; Galyaev, AN; Gao, M; Gavrilov, V; Genik, RJ; Genser, K; Gerber, CE; Gershtein, Y; Ginther, G; Gomez, B; Goncharov, PI; Gounder, K; Goussiou, A; Grannis, PD; Greenlee, H; Greenwood, ZD; Grinstein, S; Groer, L; Grunendahl, S; Grunewald, MW; Gurzhiev, SN; Gutierrez, G; Gutierrez, P; Hadley, NJ; Haggerty, H; Hagopian, S; Hagopian, V; Hall, RE; Han, C; Hansen, S; Hauptman, JM; Hebert, C; Hedin, D; Heinmiller, JM; Heinson, AP; Heintz, U; Hildreth, MD; Hirosky, R; Hobbs, JD; Hoeneisen, B; Huang, J; Huang, Y; Iashvili, I; Illingworth, R; Ito, AS; Jaffre, M; Jain, S; Jesik, R; Johns, K; Johnson, M; Jonckheere, A; Jostlein, H; Juste, A; Kahl, W; Kahn, S; Kajfasz, E; Kalinin, AM; Karmanov, D; Karmgard, D; Kehoe, R; Kesisoglou, S; Khanov, A; Kharchilava, A; Klima, B; Kohli, JM; Kostritskiy, AV; Kotcher, J; Kothari, B; Kozelov, AV; Kozlovsky, EA; Krane, J; Krishnaswamy, MR; Krivkova, P; Krzywdzinski, S; Kubantsev, M; Kuleshov, S; Kulik, Y; Kunori, S; Kupco, A; Kuznetsov, VE; Landsberg, G; Lee, WM; Leflat, A; Lehner, F; Leonidopoulos, C; Li, J; Li, QZ; Lima, JGR; Lincoln, D; Linn, SL; Linnemann, J; Lipton, R; Lucotte, A; Lueking, L; Lundstedt, C; Luo, C; Maciel, AKA; Madaras, RJ; Malyshev, VL; Manankov, V; Mao, HS; Marshall, T; Martin, MI; Mattingly, SEK; Mayorov, AA; McCarthy, R; McMahon, T; Melanson, HL; Melnitchouk, A; Merkin, A; Merritt, KW; Miao, C; Miettinen, H; Mihalcea, D; Mokhov, N; Mondal, NK; Montgomery, HE; Moore, RW; Mutaf, YD; Nagy, E; Narain, M; Narasimham, VS; Naumann, NA; Neal, HA; Negret, JP; Nelson, S; Nomerotski, A; Nunnemann, T; O'Neil, D; Oguri, V; Oshima, N; Padley, P; Papageorgiou, K; Parashar, N; Partridge, R; Parua, N; Patwa, A; Peters, O; Petroff, P; Piegaia, R; Pope, BG; Prosper, HB; Protopopescu, S; Przybycien, MB; Qian, J; Rajagopalan, S; Rapidis, PA; Reay, NW; Reucroft, S; Ridel, M; Rijssenbeek, M; Rizatdinova, F; Rockwell, T; Royon, C; Rubinov, P; Ruchti, R; Sabirov, BM; Sajot, G; Santoro, A; Sawyer, L; Schamberger, RD; Schellman, H; Schwartzman, A; Shabalina, E; Shivpuri, RK; Shpakov, D; Shupe, M; Sidwell, RA; Simak, V; Sirotenko, V; Slattery, P; Smith, RP; Snow, GR; Snow, J; Snyder, S; Solomon, J; Song, Y; Sorin, V; Sosebee, M; Sotnikova, N; Soustruznik, K; Souza, M; Stanton, NR; Steinbruck, G; Stoker, D; Stolin, V; Stone, A; Stoyanova, DA; Strang, MA; Strauss, M; Strovink, M; Stutte, L; Sznajder, A; Talby, M; Taylor, W; Tentindo-Repond, S; Trippe, TG; Turcot, AS; Tuts, PM; Van Kooten, R; Vaniev, V; Varelas, N; Villeneuve-Seguier, F; Volkov, AA; Vorobiev, AP; Wahl, HD; Wang, ZM; Warchol, J; Watts, G; Wayne, M; Weerts, H; White, A; Whiteson, D; Wijngaarden, DA; Willis, S; Wimpenny, SJ; Womersley, J; Wood, DR; Xu, Q; Yamada, R; Yasuda, T; Yatsunenko, YA; Yip, K; Yu, J; Zanabria, M; Zhang, X; Zhou, B; Zhou, Z; Zielinski, M; Zieminska, D; Zieminski, A; Zutshi, V; Zverev, EG; Zylberstejn, A				Abazov, VM; Abbott, B; Abdesselam, A; Abolins, M; Abramov, V; Acharya, BS; Adams, DL; Adams, M; Ahmed, SN; Alexeev, GD; Alton, A; Alves, GA; Arnoud, Y; Avila, C; Babintsev, VV; Babukhadia, L; Bacon, TC; Baden, A; Baffioni, S; Baldin, B; Balm, PW; Banerjee, S; Barberis, E; Baringer, P; Barreto, J; Bartlett, JF; Bassler, U; Bauer, D; Bean, A; Beaudette, F; Begel, M; Belyaev, A; Beri, SB; Bernardi, G; Bertram, I; Besson, A; Beuselinck, R; Bezzubov, VA; Bhat, PC; Bhatnagar, V; Bhattacharjee, M; Blazey, G; Blekman, F; Blessing, S; Boehnlein, A; Bojko, NI; Bolton, TA; Borcherding, F; Bos, K; Bose, T; Brandt, A; Briskin, G; Brock, R; Brooijmans, G; Bross, A; Buchholz, D; Buehler, M; Buescher, V; Burtovoi, VS; Butler, JM; Canelli, F; Carvalho, W; Casey, D; Castilla-Valdez, H; Chakraborty, D; Chan, KM; Chekulaev, SV; Cho, DK; Choi, S; Chopra, S; Claes, D; Clark, AR; Connolly, B; Cooper, WE; Coppage, D; Crepe-Renaudin, S; Cummings, MAC; Cutts, D; da Motta, H; Davis, GA; De, K; de Jong, SJ; Demarteau, M; Demina, R; Demine, P; Denisov, D; Denisov, SP; Desai, S; Diehl, HT; Diesburg, M; Doulas, S; Dudko, LV; Duflot, L; Dugad, SR; Duperrin, A; Dyshkant, A; Edmunds, D; Ellison, J; Eltzroth, JT; Elvira, VD; Engelmann, R; Eno, S; Eppley, G; Ermolov, P; Eroshin, OV; Estrada, J; Evans, H; Evdokimov, VN; Ferbel, T; Filthaut, F; Fisk, HE; Fortner, M; Fox, H; Fu, S; Fuess, S; Gallas, E; Galyaev, AN; Gao, M; Gavrilov, V; Genik, RJ; Genser, K; Gerber, CE; Gershtein, Y; Ginther, G; Gomez, B; Goncharov, PI; Gounder, K; Goussiou, A; Grannis, PD; Greenlee, H; Greenwood, ZD; Grinstein, S; Groer, L; Grunendahl, S; Grunewald, MW; Gurzhiev, SN; Gutierrez, G; Gutierrez, P; Hadley, NJ; Haggerty, H; Hagopian, S; Hagopian, V; Hall, RE; Han, C; Hansen, S; Hauptman, JM; Hebert, C; Hedin, D; Heinmiller, JM; Heinson, AP; Heintz, U; Hildreth, MD; Hirosky, R; Hobbs, JD; Hoeneisen, B; Huang, J; Huang, Y; Iashvili, I; Illingworth, R; Ito, AS; Jaffre, M; Jain, S; Jesik, R; Johns, K; Johnson, M; Jonckheere, A; Jostlein, H; Juste, A; Kahl, W; Kahn, S; Kajfasz, E; Kalinin, AM; Karmanov, D; Karmgard, D; Kehoe, R; Kesisoglou, S; Khanov, A; Kharchilava, A; Klima, B; Kohli, JM; Kostritskiy, AV; Kotcher, J; Kothari, B; Kozelov, AV; Kozlovsky, EA; Krane, J; Krishnaswamy, MR; Krivkova, P; Krzywdzinski, S; Kubantsev, M; Kuleshov, S; Kulik, Y; Kunori, S; Kupco, A; Kuznetsov, VE; Landsberg, G; Lee, WM; Leflat, A; Lehner, F; Leonidopoulos, C; Li, J; Li, QZ; Lima, JGR; Lincoln, D; Linn, SL; Linnemann, J; Lipton, R; Lucotte, A; Lueking, L; Lundstedt, C; Luo, C; Maciel, AKA; Madaras, RJ; Malyshev, VL; Manankov, V; Mao, HS; Marshall, T; Martin, MI; Mattingly, SEK; Mayorov, AA; McCarthy, R; McMahon, T; Melanson, HL; Melnitchouk, A; Merkin, A; Merritt, KW; Miao, C; Miettinen, H; Mihalcea, D; Mokhov, N; Mondal, NK; Montgomery, HE; Moore, RW; Mutaf, YD; Nagy, E; Narain, M; Narasimham, VS; Naumann, NA; Neal, HA; Negret, JP; Nelson, S; Nomerotski, A; Nunnemann, T; O'Neil, D; Oguri, V; Oshima, N; Padley, P; Papageorgiou, K; Parashar, N; Partridge, R; Parua, N; Patwa, A; Peters, O; Petroff, P; Piegaia, R; Pope, BG; Prosper, HB; Protopopescu, S; Przybycien, MB; Qian, J; Rajagopalan, S; Rapidis, PA; Reay, NW; Reucroft, S; Ridel, M; Rijssenbeek, M; Rizatdinova, F; Rockwell, T; Royon, C; Rubinov, P; Ruchti, R; Sabirov, BM; Sajot, G; Santoro, A; Sawyer, L; Schamberger, RD; Schellman, H; Schwartzman, A; Shabalina, E; Shivpuri, RK; Shpakov, D; Shupe, M; Sidwell, RA; Simak, V; Sirotenko, V; Slattery, P; Smith, RP; Snow, GR; Snow, J; Snyder, S; Solomon, J; Song, Y; Sorin, V; Sosebee, M; Sotnikova, N; Soustruznik, K; Souza, M; Stanton, NR; Steinbruck, G; Stoker, D; Stolin, V; Stone, A; Stoyanova, DA; Strang, MA; Strauss, M; Strovink, M; Stutte, L; Sznajder, A; Talby, M; Taylor, W; Tentindo-Repond, S; Trippe, TG; Turcot, AS; Tuts, PM; Van Kooten, R; Vaniev, V; Varelas, N; Villeneuve-Seguier, F; Volkov, AA; Vorobiev, AP; Wahl, HD; Wang, ZM; Warchol, J; Watts, G; Wayne, M; Weerts, H; White, A; Whiteson, D; Wijngaarden, DA; Willis, S; Wimpenny, SJ; Womersley, J; Wood, DR; Xu, Q; Yamada, R; Yasuda, T; Yatsunenko, YA; Yip, K; Yu, J; Zanabria, M; Zhang, X; Zhou, B; Zhou, Z; Zielinski, M; Zieminska, D; Zieminski, A; Zutshi, V; Zverev, EG; Zylberstejn, A		DO Collaboration	A precision measurement of the mass of the top quark	NATURE			English	Article							PAIR PRODUCTION; DETECTOR; EVENT	The standard model of particle physics contains parameters such as particle masses - whose origins are still unknown and which cannot be predicted, but whose values are constrained through their interactions. In particular, the masses of the top quark (M-t) and W boson (M-W)(1) constrain the mass of the long-hypothesized, but thus far not observed, Higgs boson. A precise measurement of Mt can therefore indicate where to look for the Higgs, and indeed whether the hypothesis of a standard model Higgs is consistent with experimental data. As top quarks are produced in pairs and decay in only about 10(-24) s into various final states, reconstructing their masses from their decay products is very challenging. Here we report a technique that extracts more information from each top-quark event and yields a greatly improved precision (of +/- 5.3 GeV/c(2)) when compared to previous measurements(2). When our new result is combined with our published measurement in a complementary decay mode(3) and with the only other measurements available(2), the new world average for M-t becomes(4) 178.0 +/- 4.3 GeV/c(2). As a result, the most likely Higgs mass increases from the experimentally excluded(5) value(6) of 96 to 117GeV/c(2), which is beyond current experimental sensitivity. The upper limit on the Higgs mass at the 95% confidence level is raised from 219 to 251 GeV/c(2).	Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA; Joint Inst Nucl Res, Dubna 141980, Russia; Univ Oklahoma, Dept Phys & Astron, Norman, OK 73019 USA; Lab Accelerateur Lineaire, CNRS, IN2P3, F-91898 Orsay, France; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Inst High Energy Phys, Protvino 142284, Russia; Tata Inst Fundamental Res, Sch Nat Sci, Bombay 400005, Maharashtra, India; Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Univ Illinois, Dept Phys, Chicago, IL 60607 USA; Univ Nijmegen, NIKHEF, NL-6500 GL Nijmegen, Netherlands; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; Ctr Brasileiro Pesquisas Fis, LAFEX, BR-22290180 Rio De Janeiro, Brazil; Univ Grenoble 1, Lab Phys Subatom & Cosmol, CNRS, IN2P3, F-38026 Grenoble, France; Univ Los Andes, Dept Fis, HEP Grp, Bogota, Colombia; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA; Univ London Imperial Coll Sci Technol & Med, Dept Phys, London SW7 2BW, England; Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Univ Mediterranee, CPPM, CNRS, IN2P3, F-13288 Marseille, France; Fermilab Natl Accelerator Lab, Batavia, IL 60510 USA; FOM, Inst NIKHEF, NL-1009 DB Amsterdam, Netherlands; Univ Amsterdam, NIKHEF, NL-1009 DB Amsterdam, Netherlands; Northeastern Univ, Dept Phys, Boston, MA 02115 USA; Univ Kansas, Dept Phys & Astron, Lawrence, KS 66045 USA; Univ Paris 06, LPNHE, CNRS, IN2P3, F-75252 Paris, France; Univ Paris 07, LPNHE, CNRS, IN2P3, F-75252 Paris, France; Indiana Univ, Dept Phys, Bloomington, IN 47405 USA; Florida State Univ, Dept Phys 4350, Tallahassee, FL 32306 USA; Panjab Univ, Dept Phys, Chandigarh 160014, India; Univ Lancaster, Dept Phys, Lancaster LA1 4YB, England; No Illinois Univ, Dept Phys, De Kalb, IL 60115 USA; Kansas State Univ, Dept Phys, Manhattan, KS 66506 USA; Columbia Univ, Dept Phys, New York, NY 10027 USA; Univ Texas, Dept Phys, Arlington, TX 76019 USA; Brown Univ, Dept Phys, Providence, RI 02912 USA; Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA; Univ Freiburg, Inst Phys, D-79104 Freiburg, Germany; Boston Univ, Dept Phys, Boston, MA 02215 USA; Univ Estado Rio de Janeiro, Inst Fis, BR-20559900 Rio De Janeiro, Brazil; CINVESTAV, Dept Fis, Mexico City 07000, DF, Mexico; Univ Calif Riverside, Dept Phys, Riverside, CA 92521 USA; Univ Nebraska, Dept Phys & Astron, Lincoln, NE 68588 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; CEA Saclay, Serv Phys Particules, DAPNIA, F-91191 Gif Sur Yvette, France; Moscow MV Lomonosov State Univ, Dept Phys, Moscow 119899, Russia; Rice Univ, Bonner Nucl Lab, Houston, TX 77005 USA; Inst Theoret & Expt Phys, Moscow 117259, Russia; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Louisiana Tech Univ, Dept Phys, Ruston, LA 71272 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis, RA-1428 Buenos Aires, DF, Argentina; Natl Univ Ireland Univ Coll Dublin, Fac Sci, Dept Expt Phys, Dublin 4, Ireland; Calif State Univ Fresno, Dept Phys, Fresno, CA 93740 USA; Iowa State Univ, Dept Phys, High Energy Phys Grp, Ames, IA 50011 USA; Univ Virginia, Dept Phys, Charlottesville, VA 22901 USA; Univ San Francisco Quito, Quito, Ecuador; Univ Arizona, Dept Phys, Tucson, AZ 85721 USA; Charles Univ Prague, Fac Math & Phys, Ctr Particle Phys, Inst Nucl & Particle Phys, CZ-18000 Prague 8, Czech Republic; Acad Sci Czech Republ, Inst Phys, Ctr Particle Phys, CZ-18221 Prague 8, Czech Republic; Inst High Energy Phys, Beijing 100039, Peoples R China; Langston Univ, Dept Math, Langston, OK 73050 USA; Univ Delhi, Dept Phys & Astrophys, Delhi 110007, India; Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; Univ Washington, Dept Phys, Seattle, WA 98195 USA	University of Rochester; Joint Institute for Nuclear Research - Russia; University of Oklahoma System; University of Oklahoma - Norman; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universite Paris Saclay; Michigan State University; National Research Centre - Kurchatov Institute; Institute of High Energy Physics - IHEP; Tata Institute of Fundamental Research (TIFR); United States Department of Energy (DOE); Brookhaven National Laboratory; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; FOM National Institute for Subatomic Physics; Radboud University Nijmegen; University of Michigan System; University of Michigan; Centro Brasileiro de Pesquisas Fisicas; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Universidad de los Andes (Colombia); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Imperial College London; University System of Maryland; University of Maryland College Park; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Aix-Marseille Universite; United States Department of Energy (DOE); University of Chicago; Fermi National Accelerator Laboratory; FOM National Institute for Subatomic Physics; University of Amsterdam; Northeastern University; University of Kansas; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Indiana University System; Indiana University Bloomington; State University System of Florida; Florida State University; Panjab University; Lancaster University; Northern Illinois University; Kansas State University; Columbia University; University of Texas System; University of Texas Arlington; Brown University; Northwestern University; University of Freiburg; Boston University; Universidade do Estado do Rio de Janeiro; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; University of California System; University of California Riverside; University of Nebraska System; University of Nebraska Lincoln; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; CEA; UDICE-French Research Universities; Universite Paris Saclay; Lomonosov Moscow State University; Rice University; National Research Centre - Kurchatov Institute; Alikhanov Institute for Theoretical & Experimental Physics; University of Notre Dame; University of Louisiana System; Louisiana Technical University; University of Buenos Aires; University College Dublin; California State University System; California State University Fresno; Iowa State University; University of Virginia; University of Arizona; Charles University Prague; Czech Academy of Sciences; Institute of Physics of the Czech Academy of Sciences; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Langston University; University of Delhi; University of California System; University of California Irvine; University of Washington; University of Washington Seattle	Estrada, J (corresponding author), Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA.	estrada@fnal.gov	Sznajder, Andre/L-1621-2016; Kuleshov, Sergey V/D-9940-2013; Belyaev, Alexander/F-6637-2015; Canelli, Florencia/O-9693-2016; Oguri, Vitor/B-5403-2013; Soustruznik, Karel/Q-7662-2017; BARRILLON, Stephanie/ABA-6873-2021; Sirotenko, Vladimir/H-3489-2013; Wimpenny, Stephen J/K-8848-2013; Nomerotski, Andrei/A-5169-2010; Grinstein, Sebastian/ABE-1880-2020; Leflat, Alexander K/D-7284-2012; De, Kaushik/N-1953-2013; Alves, Gilvan A/C-4007-2013; da Motta, Helio/H-4589-2018; Chekulaev, Sergey V/O-1145-2015; de Paula Carvalho, Wagner/V-3343-2019; Dudko, Lev/D-7127-2012; Gutierrez, Phillip/C-1161-2011; Shivpuri, R K/A-5848-2010; Blekman, Freya/ABD-7916-2020; Santoro, Alberto F.S./E-7932-2014; Canelli, Florencia/AAI-1616-2021; Yip, Kin/D-6860-2013; Juste, Aurelio/I-2531-2015	Sznajder, Andre/0000-0001-6998-1108; Kuleshov, Sergey V/0000-0002-3065-326X; Belyaev, Alexander/0000-0002-1733-4408; Canelli, Florencia/0000-0001-6361-2117; Soustruznik, Karel/0000-0003-1264-9109; BARRILLON, Stephanie/0000-0002-7075-1673; Wimpenny, Stephen J/0000-0003-0505-4908; Grinstein, Sebastian/0000-0002-6460-8694; De, Kaushik/0000-0002-5647-4489; da Motta, Helio/0000-0002-9577-1953; de Paula Carvalho, Wagner/0000-0003-0738-6615; Dudko, Lev/0000-0002-4462-3192; Gutierrez, Phillip/0000-0003-2326-3877; Blekman, Freya/0000-0002-7366-7098; Santoro, Alberto F.S./0000-0002-0568-665X; Canelli, Florencia/0000-0001-6361-2117; Yip, Kin/0000-0002-8576-4311; Begel, Michael/0000-0002-1634-4399; Evans, Harold/0000-0003-2183-3127; Filthaut, Frank/0000-0003-3338-2247; Leonidopoulos, Christos/0000-0002-7241-2114; Grunewald, Martin/0000-0002-5754-0388; Bauer, Daniela/0000-0001-9412-4562; Heinson, Ann/0000-0003-4209-6146; Hoeneisen, Bruce/0000-0002-6059-4256; Diehl, Herman/0000-0002-8357-7467; snyder, scott/0000-0001-8610-8423; Duperrin, Arnaud/0000-0002-5789-9825; Sawyer, Lee/0000-0001-8295-0605; Moore, Roger/0000-0003-4160-4700; Beaudette, Florian/0000-0002-1194-8556; Lima, Jose Guilherme/0000-0003-4585-0546; Brandt, Andrew/0000-0002-6290-4940; Juste, Aurelio/0000-0002-1558-3291; GOUSSIOU, ANNA/0000-0001-6211-7122; Strovink, Mark/0000-0001-7020-7769; Fox, Harald/0000-0003-3089-6090; Hedin, David/0000-0001-9984-215X; Naumann, Axel/0000-0002-4725-0766; Alves, Gilvan/0000-0002-8369-1446; Wahl, Horst/0000-0002-1345-0401; Qian, Jianming/0000-0003-4813-8167; Gershtein, Yuri/0000-0002-4871-5449; Taylor, Wendy/0000-0002-6596-9125; Bassler, Ursula/0000-0002-9041-3057; grannis, paul/0000-0003-4692-2142; Melnychuk, Oleksandr/0000-0002-2089-8685; Blessing, Susan/0000-0002-4455-7279; Landsberg, Greg/0000-0002-4184-9380; Prosper, Harrison Bertrand/0000-0002-4077-2713; Blazey, Gerald Charles/0000-0002-7435-5758; Beuselinck, Raymond/0000-0003-2613-7446; Madaras, Ronald/0000-0001-7399-2993; Lucotte, Arnaud/0000-0002-5992-0640; KAJFASZ, Eric/0000-0002-8575-405X; Shabalina, Elizaveta/0000-0003-4849-556X; de Jong, Sijbrand/0000-0002-3120-3367				ABACHI S, 1995, PHYS REV LETT, V74, P2632, DOI 10.1103/PhysRevLett.74.2632; ABACHI S, 1994, NUCL INSTRUM METH A, V338, P185, DOI 10.1016/0168-9002(94)91312-9; Abazov VM, 2003, PHYS REV D, V67, DOI 10.1103/PhysRevD.67.012004; Abbaneo D, 2003, PHYS LETT B, V565, P61, DOI 10.1016/S0370-2693(03)00614-2; Abbott B, 1998, PHYS REV D, V58, DOI 10.1103/PhysRevD.58.052001; Abbott B, 1999, PHYS REV D, V60, DOI 10.1103/PhysRevD.60.012001; ABE F, 1995, PHYS REV LETT, V74, P2626, DOI 10.1103/PhysRevLett.74.2638; Abreu P, 1998, EUR PHYS J C, V2, P581, DOI 10.1007/s100520050163; Affolder T, 2001, PHYS REV D, V63, DOI 10.1103/PhysRevD.63.032003; Berends FA, 1998, PHYS LETT B, V417, P385, DOI 10.1016/S0370-2693(97)01374-9; CANELLI F, 2003, THESIS U ROCHESTER, P1; *CDF COLL DO COLL, COMB CDF DO RES TOP; Chanowitz MS, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.073002; Dalitz R. H., 1999, Proceedings of the Royal Society of London, Series A (Mathematical, Physical and Engineering Sciences), V455, P2803, DOI 10.1098/rspa.1999.0428; Degrassi G, 2003, EUR PHYS J C, V28, P133, DOI 10.1140/epjc/s2003-01152-2; ELLIS J, 2002, COMMENTS NUCL PART A, V2, P89; ESTRADA J, 2001, THESIS U ROCHESTER, P1; Hagiwara K, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.010001; JUSTE A, 1998, THESIS U AUTONOMA BA, P1; KONDO K, 1993, J PHYS SOC JPN, V62, P1177, DOI 10.1143/JPSJ.62.1177; LAI HL, 1995, PHYS REV D, V51, P4763, DOI 10.1103/PhysRevD.51.4763; *LEP COLL ALEPH DE, 2003, COMB PREL EL MEAS CO; *LEP COLL ALEPH DE, 2001, SEARCH NEUTR HIGGS B; Mahlon G, 1996, PHYS REV D, V53, P4886, DOI 10.1103/PhysRevD.53.4886; Mahlon G, 1997, PHYS LETT B, V411, P173, DOI 10.1016/S0370-2693(97)00987-8	26	229	230	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					638	642		10.1038/nature02589	http://dx.doi.org/10.1038/nature02589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190311	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000221912600034
J	Gatfield, D; Izaurralde, E				Gatfield, D; Izaurralde, E			Nonsense-mediated messenger RNA decay is initiated by endonucleolytic cleavage in Drosophila	NATURE			English	Article							GENE-EXPRESSION; DEGRADATION; CODON; PATHWAY; YEAST; CELLS; ENDORIBONUCLEASE; IDENTIFICATION; DEADENYLATION; SURVEILLANCE	In eukaryotic cells, messenger RNAs harbouring premature termination codons (PTCs) are rapidly degraded by a conserved post-transcriptional mechanism referred to as nonsense-mediated mRNA decay (NMD)(1,2), which prevents the synthesis of truncated proteins that could be deleterious for the cell(1,2). Studies in yeast and mammals indicate that degradation by means of this pathway can occur from both the 5' end of the message (involving decapping and 5'-to-3' exonucleolytic digestion by XRN1) or the 3' end (through accelerated deadenylation and exosome-mediated 3'-to-5' decay)(3-9). Here we show that, contrary to expectation, degradation of PTC-containing messages in Drosophila is initiated by endonucleolytic cleavage(s) in the vicinity of the nonsense codon. The resulting 5' fragment is rapidly degraded by exonucleolytic digestion by the exosome, whereas the 3' fragment is degraded by XRN1. This decay route is shown for several PTC-containing reporters, as well as an endogenous mRNA that is naturally regulated by NMD. We conclude that, despite conservation in the NMD machinery, PTC-containing transcripts are degraded in Drosophila by a mechanism that differs considerably from those described in yeast and mammals(3,6,7).	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Izaurralde, E (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	izaurralde@embl-heidelberg.de	Gatfield, David/C-2354-2011; Izaurralde, Elisa/G-3239-2012	Gatfield, David/0000-0001-5114-2824; Izaurralde, Elisa/0000-0001-7365-2649				BINDER R, 1989, J BIOL CHEM, V264, P16910; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Cao D, 2003, CELL, V113, P533, DOI 10.1016/S0092-8674(03)00353-2; Chen CYA, 2003, MOL CELL BIOL, V23, P4805, DOI 10.1128/MCB.23.14.4805-4813.2003; Chernokalskaya E, 1998, RNA, V4, P1537, DOI 10.1017/S1355838298980451; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; He F, 2001, MOL CELL BIOL, V21, P1515, DOI 10.1128/MCB.21.5.1515-1530.2001; Ivanov IP, 1998, MOL CELL BIOL, V18, P1553, DOI 10.1128/MCB.18.3.1553; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Lejeune F, 2003, MOL CELL, V12, P675, DOI 10.1016/S1097-2765(03)00349-6; LIM SK, 1992, EMBO J, V11, P3271, DOI 10.1002/j.1460-2075.1992.tb05405.x; Mitchell P, 2003, MOL CELL, V11, P1405, DOI 10.1016/S1097-2765(03)00190-4; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Muhlrad D, 1999, RNA, V5, P1299, DOI 10.1017/S1355838299990829; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; REMER KA, 2003, RNA, V9, P1157; SCHEPER W, 1995, MOL CELL BIOL, V15, P235, DOI 10.1128/MCB.15.1.235; Stevens A, 2002, P NATL ACAD SCI USA, V99, P12741, DOI 10.1073/pnas.192442399; Sunohara T, 2004, RNA, V10, P378, DOI 10.1261/rna.5169404; Van Dijk EL, 1998, RNA, V4, P1623, DOI 10.1017/S1355838298981316; Wagner E, 2002, J CELL SCI, V115, P3033; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	30	177	185	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					575	578		10.1038/nature02559	http://dx.doi.org/10.1038/nature02559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175755				2022-12-28	WOS:000221767700043
J	Hurwitz, H; Fehrenbacher, L; Novotny, W; Cartwright, T; Hainsworth, J; Heim, W; Berlin, J; Baron, A; Griffing, S; Holmgren, E; Ferrara, N; Fyfe, G; Rogers, B; Ross, R; Kabbinavar, F				Hurwitz, H; Fehrenbacher, L; Novotny, W; Cartwright, T; Hainsworth, J; Heim, W; Berlin, J; Baron, A; Griffing, S; Holmgren, E; Ferrara, N; Fyfe, G; Rogers, B; Ross, R; Kabbinavar, F			Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED-TRIAL; SOLID TUMORS; ANTIBODY; THERAPY; PHASE; VEGF	Background: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. Methods: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. Results: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. Conclusions: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.	Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Durham, NC 27710 USA; Kaiser Permanente, Vallejo, CA USA; Genentech Inc, San Francisco, CA 94080 USA; Ocala Oncol, Ocala, FL USA; Sarah Cannon Canc Ctr, Nashville, TN USA; Hematol & Oncol Associates NE Penn, Scranton, PA USA; Vanderbilt Univ, Nashville, TN USA; Calif Pacific Med Ctr, San Francisco, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA	Duke University; Kaiser Permanente; Roche Holding; Genentech; Sarah Cannon Research Institute; Vanderbilt University; California Pacific Medical Center; University of California System; University of California Los Angeles	Hurwitz, H (corresponding author), Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Rm 3802,Red Zone,Duke S Clin,Box 3052, Durham, NC 27710 USA.	hurwi004@mc.duke.edu			NATIONAL CANCER INSTITUTE [K23CA085582] Funding Source: NIH RePORTER; NCI NIH HHS [K23 CA085582-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON AB, 2003, P AN M AM SOC CLIN, V22, P243; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; HURWITZ H, 2002, P AN M AM SOC CLIN, V21, P82; HURWITZ H, 2003, 94 AACR ANN M WASH D; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Nissen NN, 1998, AM J PATHOL, V152, P1445; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; *PHARM UPJ, 2002, CPT 11 CAMPT; Presta LG, 1997, CANCER RES, V57, P4593; Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; *SAN SYNTH, 2004, OX EL; Tebbutt NC, 2003, GUT, V52, P568, DOI 10.1136/gut.52.4.568; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	19	8074	8481	12	755	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2335	2342		10.1056/NEJMoa032691	http://dx.doi.org/10.1056/NEJMoa032691			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175435				2022-12-28	WOS:000221754200004
J	Martens, JA; Laprade, L; Winston, F				Martens, JA; Laprade, L; Winston, F			Intergenic transcription is required to repress the Saccharomyces cerevisiae SER3 gene	NATURE			English	Article							RNA-POLYMERASE-II; PROMOTER; INTERFERENCE; YEAST; TERMINATION; COMPONENTS; BINDING; SWI/SNF; FORMS	Transcription by RNA polymerase II in Saccharomyces cerevisiae and in humans is widespread, even in genomic regions that do not encode proteins(1-6). The purpose of such intergenic transcription is largely unknown, although it can be regulatory(7,8). We have discovered a role for one case of intergenic transcription by studying the S. cerevisiae SER3 gene. Our previous results demonstrated that transcription of SER3 is tightly repressed during growth in rich medium(9). We now show that the regulatory region of this gene is highly transcribed under these conditions and produces a non-protein-coding RNA (SRG1). Expression of the SRG1 RNA is required for repression of SER3. Additional experiments have demonstrated that repression occurs by a transcription-interference mechanism in which SRG1 transcription across the SER3 promoter interferes with the binding of activators. This work identifies a previously unknown class of transcriptional regulatory genes.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Winston, F (corresponding author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	winston@genetics.med.harvard.edu						ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; Albers E, 2003, J BIOL CHEM, V278, P10264, DOI 10.1074/jbc.M211692200; Andersen AA, 2003, CURR OPIN CELL BIOL, V15, P281, DOI 10.1016/S0955-0674(03)00041-3; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; Dudley AM, 1999, GENETICS, V151, P1365; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Duina AA, 2004, MOL CELL BIOL, V24, P561, DOI 10.1128/MCB.24.2.561-572.2004; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; Gottesman S, 2002, GENE DEV, V16, P2829, DOI 10.1101/gad.1030302; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; HAUSLER B, 1979, J MOL BIOL, V127, P353, DOI 10.1016/0022-2836(79)90335-8; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HIRSCHMAN JE, 1988, MOL CELL BIOL, V8, P4608, DOI 10.1128/MCB.8.11.4608; Hurowitz EH, 2004, GENOME BIOL, V5; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Valerius O, 2002, J BIOL CHEM, V277, P21440, DOI 10.1074/jbc.M201841200; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000	30	459	479	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					571	574		10.1038/nature02538	http://dx.doi.org/10.1038/nature02538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175754				2022-12-28	WOS:000221767700042
J	Lilley, BN; Ploegh, HL				Lilley, BN; Ploegh, HL			A membrane protein required for dislocation of misfolded proteins from the ER	NATURE			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; TO-CYTOSOL DISLOCATION; I HEAVY-CHAINS; QUALITY-CONTROL; RETRO-TRANSLOCATION; SIGNAL PEPTIDE; PROTEASOME; TRANSPORT; REVEALS; YEAST	After insertion into the endoplasmic reticulum ( ER), proteins that fail to fold there are destroyed. Through a process termed dislocation such misfolded proteins arrive in the cytosol, where ubiquitination, deglycosylation and finally proteasomal proteolysis dispense with the unwanted polypeptides. The machinery involved in the extraction of misfolded proteins from the ER is poorly defined. The human cytomegalovirus-encoded glycoproteins US2 and US11 catalyse the dislocation of class I major histocompatibility complex (MHC) products, resulting in their rapid degradation. Here we show that US11 uses its transmembrane domain to recruit class I MHC products to a human homologue of yeast Der1p, a protein essential for the degradation of a subset of misfolded ER proteins. We show that this protein, Derlin-1, is essential for the degradation of class I MHC molecules catalysed by US11, but not by US2. We conclude that Derlin-1 is an important factor for the extraction of certain aberrantly folded proteins from the mammalian ER.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	ploegh@hms.harvard.edu						Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fiebiger E, 2002, EMBO J, V21, P1041, DOI 10.1093/emboj/21.5.1041; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; Gewurz BE, 2002, J BIOL CHEM, V277, P11306, DOI 10.1074/jbc.M107904200; GREEN N, 1998, CURRENT PROTOCOLS CE; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lilley BN, 2003, MOL BIOL CELL, V14, P3690, DOI 10.1091/mbc.E03-03-0192; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; PLOEGH HL, 1995, CURRENT PROTOCOLS SC; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; SAWIN KE, 1992, J CELL SCI, V101, P303; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Tirosh B, 2003, J BIOL CHEM, V278, P6664, DOI 10.1074/jbc.M210158200; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsukahara M, 2001, DEV GROWTH DIFFER, V43, P285; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YE Y, NATURE; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ying H, 2001, BIOCHEM BIOPH RES CO, V286, P394, DOI 10.1006/bbrc.2001.5390	48	543	556	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	2004	429	6994					834	840		10.1038/nature02592	http://dx.doi.org/10.1038/nature02592			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215855				2022-12-28	WOS:000222213000032
J	Phillips, GN; Evans, KA				Phillips, GN; Evans, KA			Role of CO2 in the formation of gold deposits	NATURE			English	Article							PARTIAL MOLAL PROPERTIES; WITWATERSRAND BASIN; HIGH-PRESSURES; FLUID; MINERALIZATION; TRANSPORT; TEMPERATURES; IONS	Much of global gold production has come from deposits with uneconomic concentrations of base metals, such as copper, lead and zinc(1). These 'gold-only' deposits are thought to have formed from hot, aqueous fluids rich in carbon dioxide(2), but only minor significance has been attached to the role of the CO2 in the process of gold transport. This is because chemical bonding between gold ions and CO2 species is not strong(3), and so it is unlikely that CO2 has a direct role in gold transport. An alternative indirect role for CO2 as a weak acid that buffers pH has also appeared unlikely, because previously inferred pH values for such gold-bearing fluids are variable(2,4,5,6). Here we show that such calculated pH values are unlikely to record conditions of gold transport, and propose that CO2 may play a critical role during gold transport by buffering the fluid in a pH range where elevated gold concentration can be maintained by complexation with reduced sulphur. Our conclusions, which are supported by geochemical modelling, may provide a platform for new gold exploration methods.	Monash Univ, CSIRO, Sch Geosci, Div Explorat & Min, Clayton, Vic 3800, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Monash University		neil.phillips@csiro.au	Evans, Katy A/G-5748-2011	Evans, Katy A/0000-0001-5144-4507				AHRLAND S, 1958, Q REV CHEM SOC, V12, P265, DOI 10.1039/qr9581200265; Barnicoat AC, 1997, NATURE, V386, P820, DOI 10.1038/386820a0; Benning LG, 1996, GEOCHIM COSMOCHIM AC, V60, P1849, DOI 10.1016/0016-7037(96)00061-0; BOHLKE JK, 1989, ECON GEOL, V84, P291, DOI 10.2113/gsecongeo.84.2.291; EASTOE CJ, 1978, ECON GEOL, V73, P721, DOI 10.2113/gsecongeo.73.5.721; GIBERT F, 1992, CONTRIB MINERAL PETR, V112, P371, DOI 10.1007/BF00310467; GOELLNICHT NM, 1989, EC GEOL MONOGR, V6, P151; HELGESON HC, 1981, AM J SCI, V281, P1259; KESTIN J, 1984, J PHYS CHEM REF DATA, V13, P175, DOI 10.1063/1.555707; KUEHN CA, 1995, ECON GEOL BULL SOC, V90, P17, DOI 10.2113/gsecongeo.90.1.17; Morrison G.W., 1991, ORE GEOL REV, V6, P333, DOI DOI 10.1016/0169-1368(91)90009-V; NEALL FB, 1987, ECON GEOL, V82, P1679, DOI 10.2113/gsecongeo.82.7.1679; OELKERS EH, 1990, GEOCHIM COSMOCHIM AC, V54, P727, DOI 10.1016/0016-7037(90)90368-U; Phillips G. N., 2003, CSIRO EXPLORES, V1, P1; PHILLIPS GN, 1983, J GEOL SOC AUST, V30, P25, DOI 10.1080/00167618308729234; PHILLIPS GN, 1993, ECON GEOL BULL SOC, V88, P1084, DOI 10.2113/gsecongeo.88.5.1084; PHILLIPS GN, 1988, MEM GEOL SOC INDIA, V11, P59; Phillips GN., 2000, REV EC GEOL, V13, P439; Puddephatt R.J., 1978, CHEM GOLD; ROBB LJ, 1991, ECON GEOL BULL SOC, V86, P396, DOI 10.2113/gsecongeo.86.2.396; SEWARD TM, 1973, GEOCHIM COSMOCHIM AC, V37, P379, DOI 10.1016/0016-7037(73)90207-X; SHOCK EL, 1992, J CHEM SOC FARADAY T, V88, P803, DOI 10.1039/ft9928800803; Shvarov Y. V., 1999, 25 AUSTR GEOL SURV O; SMITH TJ, 1984, ECON GEOL, V79, P1265, DOI 10.2113/gsecongeo.79.6.1265; TANGER JC, 1988, AM J SCI, V288, P19, DOI 10.2475/ajs.288.1.19; [No title captured]; [No title captured]	27	245	324	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	2004	429	6994					860	863		10.1038/nature02644	http://dx.doi.org/10.1038/nature02644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215861				2022-12-28	WOS:000222213000038
J	Balague, F				Balague, F			Do not dismiss intense pain	LANCET			English	Editorial Material									Hop Cantonal Fribourg, Dept Rheumatol Phys Med & Rehabil, CH-1708 Fribourg, Switzerland		Balague, F (corresponding author), Hop Cantonal Fribourg, Dept Rheumatol Phys Med & Rehabil, CH-1708 Fribourg, Switzerland.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2021	2021		10.1016/S0140-6736(04)16450-7	http://dx.doi.org/10.1016/S0140-6736(04)16450-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15207951				2022-12-28	WOS:000222159800007
J	Jordan, MB; Mills, DM; Kappler, J; Marrack, P; Cambier, JC				Jordan, MB; Mills, DM; Kappler, J; Marrack, P; Cambier, JC			Promotion of B cell immune responses via an alum-induced myeloid cell population	SCIENCE			English	Article							CLASS-II MOLECULES; ACTIVATION; IL-4; PROLIFERATION; LYMPHOCYTES; RECEPTOR	Exposure of naive B cells to the cytokine interleukin-4 (IL-4) and/or antigen leads to a state of "priming," in which subsequent aggregation of major histocompatibility complex class II molecules induces the mobilization of calcium ions and cell proliferation. However, it is not clear how critical this priming is for immune responses or how it is normally induced in vivo. Injection of mice with the commonly used adjuvant alum led to priming of splenic B cells and to the accumulation in the spleen of a previously unknown population of IL-4-producing, Gr1(+) cells. These cells and IL-4 were both required for in vivo priming and expansion of antigen-specific B cells, as well as for optimal production of antibody. These studies reveal a key role for a previously unknown accessory myeloid cell population in the generation of humoral immune responses.	Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Howard Hughes Med Inst, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cambier, JC (corresponding author), Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	cambierj@njc.org	Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687; Cambier, John/0000-0002-7803-242X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018785, P01AI022295, R56AI018785, K08AI050802, R01AI017134, R01AI020519, R01AI052225, R56AI017134, R37AI017134, R37AI018785] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20519, AI-17134, AI-18785, AI-52225, AI-50802, AI-22295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bishop GA, 2001, CURR OPIN IMMUNOL, V13, P278, DOI 10.1016/S0952-7915(00)00216-8; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Jordan M.D., UNPUB; LANE PJL, 1990, J IMMUNOL, V144, P3684; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; Lansford R, 1998, INT IMMUNOL, V10, P325, DOI 10.1093/intimm/10.3.325; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; STPIERRE Y, 1991, J IMMUNOL, V147, P2875	14	184	195	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	2004	304	5678					1808	1810		10.1126/science.1089926	http://dx.doi.org/10.1126/science.1089926			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829YU	15205534				2022-12-28	WOS:000222089500047
J	Bowman, GD; O'Donnell, M; Kuriyan, J				Bowman, GD; O'Donnell, M; Kuriyan, J			Structural analysis of a eukaryotic sliding DNA clamp-clamp loader complex	NATURE			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; CRYSTAL-STRUCTURE; HELICASE-PRIMASE; GAMMA COMPLEX; DELTA-SUBUNIT; POLYMERASE; MECHANISM; DOMAIN; PROTEINS	Sliding clamps are ring-shaped proteins that encircle DNA and confer high processivity on DNA polymerases. Here we report the crystal structure of the five-protein clamp loader complex ( replication factor-C, RFC) of the yeast Saccharomyces cerevisiae, bound to the sliding clamp ( proliferating cell nuclear antigen, PCNA). Tight interfacial coordination of the ATP analogue ATP-gamma S by RFC results in a spiral arrangement of the ATPase domains of the clamp loader above the PCNA ring. Placement of a model for primed DNA within the central hole of PCNA reveals a striking correspondence between the RFC spiral and the grooves of the DNA double helix. This model, in which the clamp loader complex locks onto primed DNA in a screw-cap-like arrangement, provides a simple explanation for the process by which the engagement of primer-template junctions by the RFC: PCNA complex results in ATP hydrolysis and release of the sliding clamp on DNA.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Howard Hughes Medical Institute; Rockefeller University	Kuriyan, J (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	kuriyan@berkeley.edu			NIGMS NIH HHS [F32 GM066586, F32 GM066586-01, F32 GM066586-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2003, J BIOL CHEM, V278, P10033, DOI 10.1074/jbc.M211741200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Goedken ER, 2004, J MOL BIOL, V336, P1047, DOI 10.1016/j.jmb.2003.12.074; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gonzalez A, 2003, ACTA CRYSTALLOGR D, V59, P1935, DOI 10.1107/S0907444903017700; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Heras B, 2003, STRUCTURE, V11, P139, DOI 10.1016/S0969-2126(03)00005-4; Hortnagel K, 1999, J MOL BIOL, V286, P1097, DOI 10.1006/jmbi.1998.2515; HUANG CC, 1981, J BIOL CHEM, V256, P4087; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAFORTELLE ED, 1997, METHOD ENZYMOL, V276, P476; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; LEE SH, 1991, J BIOL CHEM, V266, P594; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Mirshad JK, 2003, BIOCHEMISTRY-US, V42, P5945, DOI 10.1021/bi027233i; MIYATA T, IN PRESS NATURE STRU; Neuwald AF, 1999, GENOME RES, V9, P27; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Saenger W., 1984, PRINCIPLES NUCL ACID; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Xiong Y, 2000, NUCLEIC ACIDS RES, V28, P2171, DOI 10.1093/nar/28.10.2171; Yang W, 2003, P NATL ACAD SCI USA, V100, P874, DOI 10.1073/pnas.0337432100; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	49	333	345	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					724	730		10.1038/nature02585	http://dx.doi.org/10.1038/nature02585			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201901				2022-12-28	WOS:000222059900029
J	He, DZZ; Jia, SP; Dallos, P				He, DZZ; Jia, SP; Dallos, P			Mechanoelectrical transduction of adult outer hair cells studied in a gerbil hemicochlea	NATURE			English	Article							GUINEA-PIG COCHLEA; INTRACELLULAR-RECORDINGS; MECHANICAL RESPONSES; MOTOR PROTEIN; MOUSE COCHLEA; PRESTIN; CURRENTS; CONDUCTANCE; ADAPTATION; MEMBRANE	Sensory receptor cells of the mammalian cochlea are morphologically and functionally dichotomized. Inner hair cells transmit auditory information to the brain, whereas outer hair cells (OHC) amplify the mechanical signal, which is then transduced by inner hair cells(1). Amplification by OHCs is probably mediated by their somatic motility(2,3) in a mechanical feedback process. OHC motility in vivo is thought to be driven by the cell's receptor potential. The first steps towards the generation of the receptor potential are the deflection of the stereociliary bundle(4), and the subsequent flow of transducer current through the mechanosensitive transducer channels located at their tips(5). Quantitative relations between transducer currents and basilar membrane displacements are lacking, as well as their variation along the cochlear length. To address this, we simultaneously recorded OHC transducer currents (or receptor potentials) and basilar membrane motion in an excised and bisected cochlea, the hemicochlea(6). This preparation permits recordings from adult OHCs at various cochlear locations while the basilar membrane is mechanically stimulated. Furthermore, the stereocilia are deflected by the same means of stimulation as in vivo. Here we show that asymmetrical transducer currents and receptor potentials are significantly larger than previously thought, they possess a highly restricted dynamic range and strongly depend on cochlear location.	Creighton Univ, Dept Biomed Sci, Hair Cell Biophys Lab, Omaha, NE 68175 USA; Boys Town Natl Res Hosp, Omaha, NE 68131 USA; Northwestern Univ, Dept Neurobiol & Physiol, Hugh Knowles Ctr, Auditory Lab, Evanston, IL 60208 USA; Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60208 USA	Creighton University; Boys Town National Research Hospital; Northwestern University; Northwestern University	He, DZZ (corresponding author), Creighton Univ, Dept Biomed Sci, Hair Cell Biophys Lab, Omaha, NE 68175 USA.	hed@creighton.edu	Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591; He (he zhi zhou), Zhi-Zhou/0000-0001-8383-9634	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004696] Funding Source: NIH RePORTER; NIDCD NIH HHS [R21 DC006039, R01 DC004696] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ASHMORE JF, 1993, BIOPHYSICS HAIR CELL, P151; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CHEATHAM MA, 2004, ASS RES OT ABSTR, V1248; Cooper NP, 1997, J NEUROPHYSIOL, V78, P261, DOI 10.1152/jn.1997.78.1.261; COREY DP, 1979, NATURE, V281, P675, DOI 10.1038/281675a0; CRAWFORD AC, 1991, J PHYSIOL-LONDON, V434, P369, DOI 10.1113/jphysiol.1991.sp018475; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; DALLOS P, 1982, SCIENCE, V218, P582, DOI 10.1126/science.7123260; DALLOS P, 1986, HEARING RES, V22, P185, DOI 10.1016/0378-5955(86)90095-X; DALLOS P, 1985, J NEUROSCI, V5, P1591; Dallos P, 2003, JARO-J ASSOC RES OTO, V4, P416, DOI 10.1007/s10162-002-3049-z; DALLOS P, 1992, J NEUROSCI, V12, P4575; Denk W, 1995, NEURON, V15, P1311, DOI 10.1016/0896-6273(95)90010-1; GALE JE, 1994, P ROY SOC B-BIOL SCI, V255, P243, DOI 10.1098/rspb.1994.0035; Geleoc GSG, 1997, P ROY SOC B-BIOL SCI, V264, P611, DOI 10.1098/rspb.1997.0087; He DZZ, 2003, J NEUROSCI, V23, P9089; Holt JR, 2002, CELL, V108, P371, DOI 10.1016/S0092-8674(02)00629-3; HOUSLEY GD, 1992, J PHYSIOL-LONDON, V448, P73, DOI 10.1113/jphysiol.1992.sp019030; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; Kennedy HJ, 2003, NAT NEUROSCI, V6, P832, DOI 10.1038/nn1089; KROS CJ, 1992, P ROY SOC B-BIOL SCI, V249, P185, DOI 10.1098/rspb.1992.0102; Liberman MC, 2002, NATURE, V419, P300, DOI 10.1038/nature01059; Mammano F, 1996, J PHYSIOL-LONDON, V496, P639, DOI 10.1113/jphysiol.1996.sp021715; Muller M, 1996, HEARING RES, V94, P148, DOI 10.1016/0378-5955(95)00230-8; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Ricci AJ, 2003, NEURON, V40, P983, DOI 10.1016/S0896-6273(03)00721-9; Richter CP, 1998, J NEUROPHYSIOL, V79, P2255, DOI 10.1152/jn.1998.79.5.2255; RUSSELL IJ, 1986, HEARING RES, V22, P199, DOI 10.1016/0378-5955(86)90096-1; RUSSELL IJ, 1983, J PHYSIOL-LONDON, V338, P179, DOI 10.1113/jphysiol.1983.sp014668; RUSSELL IJ, 1986, NATURE, V321, P517, DOI 10.1038/321517a0; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	31	102	107	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	2004	429	6993					766	770		10.1038/nature02591	http://dx.doi.org/10.1038/nature02591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201911				2022-12-28	WOS:000222059900040
J	O'Dell, JR				O'Dell, JR			Drug therapy - Therapeutic strategies for rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANTITUMOR NECROSIS FACTOR; LOW-DOSE METHOTREXATE; DOUBLE-BLIND; LONG-TERM; COMBINATION THERAPY; MONOCLONAL-ANTIBODY; JOINT DESTRUCTION; GASTROINTESTINAL TOXICITY; PULSE METHOTREXATE; 2ND-LINE DRUGS		Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Omaha Vet Affairs Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	O'Dell, JR (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, 983025 Nebraska Med Ctr, Omaha, NE 68198 USA.	jrodell@unmc.edu						ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489; [Anonymous], 1959, ANN RHEUM DIS, V18, P173; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bathon JM, 2001, NEW ENGL J MED, V344, P240; Bingham SJ, 2004, RHEUMATOLOGY, V43, P364, DOI 10.1093/rheumatology/keh057; Blake Gavin J, 2000, Curr Control Trials Cardiovasc Med, V1, P161, DOI 10.1186/CVM-1-3-161; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Boers M, 1998, LANCET, V351, P220; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BROOKS PJ, 1990, ARTHRITIS RHEUM, V33, P91, DOI 10.1002/art.1780330112; Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496; Calguneri M, 1999, CLIN EXP RHEUMATOL, V17, P699; Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907; Choi HK, 2002, J RHEUMATOL, V29, P1156; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141; Crofford LJ, 2000, ARTHRITIS RHEUM, V43, P1891, DOI 10.1002/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R; Da Silva E, 2003, ARTHRIT RHEUM-ARTHR, V49, P216, DOI 10.1002/art.10998; del Rincon I, 2003, ARTHRITIS RHEUM, V48, P1833, DOI 10.1002/art.11078; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2294, DOI 10.1002/art.10529; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Edwards JCW, 2002, ARTHRITIS RHEUM-US, V46, pS197; EGSMOSE C, 1995, J RHEUMATOL, V22, P2208; Ellerin T, 2003, ARTHRITIS RHEUM-US, V48, P3013, DOI 10.1002/art.11301; *FDA, ARTHR ADV COMM OP PA; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FURST DE, 1989, J RHEUMATOL, V16, P313; Gabriel SE, 1999, J RHEUMATOL, V26, P2529; Gabriel SE, 2001, RHEUM DIS CLIN N AM, V27, P269, DOI 10.1016/S0889-857X(05)70201-5; Genovese M, 2000, ARTHRITIS RHEUM, V43, pS382; Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P236, DOI 10.1186/ar93; GOLUB LM, 1994, ANN NY ACAD SCI, V732, P96, DOI 10.1111/j.1749-6632.1994.tb24728.x; HALLGREN R, 1983, ACTA MED SCAND, V213, P351; Haugeberg G, 2002, ARTHRITIS RHEUM-US, V46, P1720, DOI 10.1002/art.10408; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; HERMAN RA, 1989, J PHARM SCI, V78, P165, DOI 10.1002/jps.2600780219; Hickling P, 1998, BRIT J RHEUMATOL, V37, P930; Jansen ALMA, 2002, J RHEUMATOL, V29, P2074; Janssen NM, 2000, ARCH INTERN MED, V160, P610, DOI 10.1001/archinte.160.5.610; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; KOOPMAN WJ, 2001, ARTHRITIS ALLIED CON, V1, P1153; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P1829, DOI 10.1002/art.1780401016; Kremer JM, 2002, ANN INTERN MED, V137, P726, DOI 10.7326/0003-4819-137-9-200211050-00007; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kremer JM, 2002, J RHEUMATOL, V29, P1590; Krishnan E, 2003, AM J MED, V115, P371, DOI 10.1016/S0002-9343(03)00397-8; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Landewe RBM, 2002, ARTHRITIS RHEUM-US, V46, P347, DOI 10.1002/art.10083; Lard LR, 2001, AM J MED, V111, P446, DOI 10.1016/S0002-9343(01)00872-5; Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5; Mattey DL, 2002, ARTHRITIS RHEUM, V46, P640, DOI 10.1002/art.10174; MCDOUGALL R, 1994, J RHEUMATOL, V21, P1207; McInnes IB, 2001, RHEUM DIS CLIN N AM, V27, P373, DOI 10.1016/S0889-857X(05)70207-6; *MED RES COUNC NUF, 1960, ANN RHEUM DIS, V19, P331; MICHEL BA, 1991, J RHEUMATOL, V18, P804; Mikuls TR, 2000, ARTHRITIS RHEUM, V43, P464, DOI 10.1002/1529-0131(200002)43:2<464::AID-ANR30>3.0.CO;2-U; Mikuls TR, 2001, RHEUM DIS CLIN N AM, V27, P283, DOI 10.1016/S0889-857X(05)70202-7; Moreland LW, 2002, ARTHRITIS RHEUM-US, V46, P2553, DOI 10.1002/art.10567; MORGAN SL, 1994, ANN INTERN MED, V121, P833, DOI 10.7326/0003-4819-121-11-199412010-00002; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; Nelson JL, 1997, RHEUM DIS CLIN N AM, V23, P195, DOI 10.1016/S0889-857X(05)70323-9; Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P380, DOI 10.1002/art.20018; O'Dell JR, 2002, ARTHRITIS RHEUM, V46, P283, DOI 10.1002/art.10092; O'Dell JR, 1998, ANN RHEUM DIS, V57, P209, DOI 10.1136/ard.57.4.209; O'Dell JR, 2001, ARTHRITIS RHEUM-US, V44, P2235, DOI 10.1002/1529-0131(200110)44:10&lt;2235::AID-ART385&gt;3.0.CO;2-A; O'Dell JR, 2002, ARTHRITIS RHEUM, V46, P1164, DOI 10.1002/art.10228; Oʼdell J R, 1996, J Clin Rheumatol, V2, P59, DOI 10.1097/00124743-199604000-00001; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; ODell JR, 1997, ARTHRITIS RHEUM, V40, P842, DOI 10.1002/art.1780400510; ODell JR, 1997, RHEUM DIS CLIN N AM, V23, P779, DOI 10.1016/S0889-857X(05)70360-4; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; Ortendahl M, 2002, J RHEUMATOL, V29, P2084; Panayi GS, 2001, RHEUM DIS CLIN N AM, V27, P317, DOI 10.1016/S0889-857X(05)70204-0; PINCUS T, 1993, BRIT J RHEUMATOL, V32, P28; PINCUS T, 1992, J RHEUMATOL, V19, P1885; Quinn MA, 2001, RHEUMATOLOGY, V40, P1211, DOI 10.1093/rheumatology/40.11.1211; Rau R, 1997, BRIT J RHEUMATOL, V36, P345; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Ritchlin CT, 2000, ARTHRITIS RHEUM, V43, pS345; Saag KG, 1996, ARTHRITIS RHEUM-US, V39, P1818, DOI 10.1002/art.1780391107; SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002-9343(94)90131-7; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; SCOTT DL, 1987, LANCET, V1, P1108; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Simms RW, 1996, ARTHRITIS RHEUM-US, V39, P723; Singh Gurkirpal, 1998, American Journal of Medicine, V105, p31S, DOI 10.1016/S0002-9343(98)00072-2; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Sokka T, 2003, ARTHRITIS RHEUM-US, V48, P313, DOI 10.1002/art.10817; SPITZER WO, 1976, J RHEUMATOL, V3, P88; Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542; Strand V, 2002, ARTHRIT RHEUM-ARTHR, V47, P349, DOI 10.1002/art.10560; Svartz N, 1942, ACTA MED SCAND, V110, P577; SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735; THOMPSON RN, 1984, J RHEUMATOL, V11, P760; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001; Tsakonas E, 2000, J RHEUMATOL, V27, P623; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; Van Doornum S, 2002, ARTHRITIS RHEUM-US, V46, P862, DOI 10.1002/art.10089; van Ede AE, 2001, ARTHRITIS RHEUM-US, V44, P1515, DOI 10.1002/1529-0131(200107)44:7&lt;1515::AID-ART273&gt;3.0.CO;2-7; van Everdingen AA, 2002, ANN INTERN MED, V136, P1, DOI 10.7326/0003-4819-136-1-200201010-00006; VanderHeijde DMFM, 1995, BRIT J RHEUMATOL, V34, P74; Weinblatt M, 2002, ARTHRITIS RHEUM-US, V46, pS204; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Whelton A, 2000, Am J Ther, V7, P159, DOI 10.1097/00045391-200007030-00004; WHELTON A, 2000, AM J THER, V7, P341; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; WOLFE F, 1990, J RHEUMATOL, V17, P994; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Yocum DE, 1998, ARTHRITIS RHEUM, V41, pS364; Zhang ZX, 2001, RHEUM DIS CLIN N AM, V27, P335, DOI 10.1016/S0889-857X(05)70205-2	124	376	433	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2591	2602		10.1056/NEJMra040226	http://dx.doi.org/10.1056/NEJMra040226			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201416				2022-12-28	WOS:000222054700010
J	Snell, WJ; Pan, JM; Wang, Q				Snell, WJ; Pan, JM; Wang, Q			Cilia and flagella revealed: From flagellar assembly in Chlamydomonas to human obesity disorders	CELL			English	Editorial Material							INTRAFLAGELLAR TRANSPORT IFT; DISEASE GENE; KINESIN-II; BODY; FERTILIZATION; PARTICLES; TURNOVER; PROTEINS; CARGO; CYCLE	The recent identification in Chlamydomonas of the intraflagellar transport machinery that assembles cilia and flagella has triggered a renaissance of interest in these organelles that transcends studies on their well-characterized ability to move. New studies on several fronts have revealed that the machinery for flagellar assembly/disassembly is regulated by homologs of mitotic proteins, that cilia play essential roles in sensory transduction, and that mutations in cilia/basal body proteins are responsible for cilia-related human disorders from polycystic kidney disease to a syndrome associated with obesity, hypertension, and diabetes.	Univ Texas, SW Med Sch, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Snell, WJ (corresponding author), Univ Texas, SW Med Sch, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	william.snell@utsouthwestern.edu	Pan, Junmin/H-2673-2014		NIGMS NIH HHS [R01 GM025661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025661] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; Berman SA, 2003, CURR BIOL, V13, P1145, DOI 10.1016/S0960-9822(03)00415-9; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Iomini C, 2001, J CELL BIOL, V153, P13, DOI 10.1083/jcb.153.1.13; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Marshall WF, 2001, J CELL BIOL, V155, P405, DOI 10.1083/jcb.200106141; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Pan JM, 2004, DEV CELL, V6, P445, DOI 10.1016/S1534-5807(04)00064-4; Pan JM, 2002, MOL BIOL CELL, V13, P1417, DOI 10.1091/mbc.01-11-0531; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pedersen LB, 2003, CURR BIOL, V13, P1969, DOI 10.1016/j.cub.2003.10.058; Qin HM, 2004, J CELL BIOL, V164, P255, DOI 10.1083/jcb.200308132; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Wang Q, 2003, J BIOL CHEM, V278, P32936, DOI 10.1074/jbc.M303261200	20	117	117	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	2004	117	6					693	697		10.1016/j.cell.2004.05.019	http://dx.doi.org/10.1016/j.cell.2004.05.019			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829KY	15186771	Bronze			2022-12-28	WOS:000222048400003
J	Oh, P; Li, Y; Yu, JY; Durr, E; Krasinska, KM; Carver, LA; Testa, JE; Schnitzer, JE				Oh, P; Li, Y; Yu, JY; Durr, E; Krasinska, KM; Carver, LA; Testa, JE; Schnitzer, JE			Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy	NATURE			English	Article							IN-VIVO; MONOCLONAL-ANTIBODIES; CANCER-THERAPY; IMMUNOHISTOCHEMICAL LOCALIZATION; DIFFERENTIAL EXPRESSION; DRUG DISCOVERY; PHAGE DISPLAY; GENE DELIVERY; ANNEXIN-I; CELLS	The molecular complexity of tissues and the inaccessibility of most cells within a tissue limit the discovery of key targets for tissue-specific delivery of therapeutic and imaging agents in vivo. Here, we describe a hypothesis-driven, systems biology approach to identifying a small subset of proteins induced at the tissue - blood interface that are inherently accessible to antibodies injected intravenously. We use subcellular fractionation, subtractive proteomics and bioinformatics to identify endothelial cell surface proteins exhibiting restricted tissue distribution and apparent tissue modulation. Expression profiling and gamma-scintigraphic imaging with antibodies establishes two of these proteins, aminopeptidase- P and annexin A1, as selective in vivo targets for antibodies in lungs and solid tumours, respectively. Radio-immunotherapy to annexin A1 destroys tumours and increases animal survival. This analytical strategy can map tissue- and disease-specific expression of endothelial cell surface proteins to uncover novel accessible targets useful for imaging and therapy.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA		Schnitzer, JE (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	jschnitzer@skcc.org						Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; Anzick SL, 2002, ONCOLOGY-NY, V16, P7; AUERBACH R, 1987, CANCER RES, V47, P1492; Bredow S, 2000, EUR J CANCER, V36, P675, DOI 10.1016/S0959-8049(99)00335-4; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cavenee WK, 2002, CARCINOGENESIS, V23, P683, DOI 10.1093/carcin/23.5.683; Dreier R, 1998, HISTOCHEM CELL BIOL, V110, P137, DOI 10.1007/s004180050275; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; EBERHARD DA, 1994, AM J PATHOL, V145, P640; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; Farah RA, 1998, CRIT REV EUKAR GENE, V8, P321, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.50; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; HENNIKER AJ, 1990, DIS MARKERS, V8, P179; Herschman HR, 2003, SCIENCE, V302, P605, DOI 10.1126/science.1090585; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hu ZW, 2001, P NATL ACAD SCI USA, V98, P12180, DOI 10.1073/pnas.201420298; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Huber LA, 2003, NAT REV MOL CELL BIO, V4, P74, DOI 10.1038/nrm1007; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lindsay MA, 2003, NAT REV DRUG DISCOV, V2, P831, DOI 10.1038/nrd1202; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398; McKanna JA, 1997, J HISTOCHEM CYTOCHEM, V45, P527, DOI 10.1177/002215549704500405; Oh P, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P34; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; Schnitzer JE, 1998, NEW ENGL J MED, V339, P472, DOI 10.1056/NEJM199808133390711; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; St Croix B, 2000, SCIENCE, V289, P1197; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; von Mehren M, 2003, ANNU REV MED, V54, P343, DOI 10.1146/annurev.med.54.101601.152442; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Workman P, 2001, CURR CANCER DRUG TAR, V1, P33, DOI 10.2174/1568009013334269	46	388	446	0	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	2004	429	6992					629	635		10.1038/nature02580	http://dx.doi.org/10.1038/nature02580			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	827PJ	15190345				2022-12-28	WOS:000221912600032
J	Goff, BA; Mandel, LS; Melancon, CH; Muntz, HG				Goff, BA; Mandel, LS; Melancon, CH; Muntz, HG			Frequency of symptoms of ovarian cancer in women presenting to primary care clinics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS; STAGE; DELAY; RISK	Context Women with ovarian cancer frequently report symptoms prior to diagnosis, but distinguishing these symptoms from those that normally occur in women remains problematic. Objective To compare the frequency, severity, and duration of symptoms between women with ovarian cancer and women presenting to primary care clinics. Design, Setting, and Patients A prospective case-control study of women who visited 2 primary care clinics (N = 1709) and completed an anonymous survey of symptoms experienced over the past year (July 2001-January 2002). Severity of symptoms was rated on a 5-point scale, duration was recorded, and frequency was indicated as number of episodes per month. An identical survey was administered preoperatively to 128 women with a pelvic mass (84 benign and 44 malignant). Main Outcome Measures Comparison of self-reported symptoms between ovarian cancer patients and women seeking care in primary care clinics. Results In the clinic population, 72% of women had recurring symptoms with a median number of 2 symptoms. The most common were back pain (45%), fatigue (34%), bloating (27%), constipation (24%), abdominal pain (22%), and urinary symptoms (16%). Comparing ovarian cancer cases to clinic controls resulted in an odds ratio: of 7.4 (95% confidence interval [CI], 3.8-14.2) for increased abdominal size; 3.6 (95% Cl, 1.8-7.0) for bloating; 2.5 (95% Cl, 1.3-4.8) for urinary urgency; and 2.2 (95% Cl, 1.2-3.9) for pelvic pain. Women with malignant masses typically experienced symptoms 20 to 30 times per month and had significantly more symptoms of higher severity and more recent onset than women with benign masses or controls. The combination of bloating, increased abdominal size, and urinary symptoms was found in 43% of those with cancer but in only 8% of those presenting to primary care clinics. Conclusions Symptoms that are more severe or frequent than expected and of recent onset warrant further diagnostic investigation because they are more likely to be associated with both benign and-malignant ovarian masses.	Univ Washington, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Conversations, Amarillo, TX USA; Virginia Mason Med Ctr, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; Virginia Mason Medical Center	Goff, BA (corresponding author), Univ Washington, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA.	bgoff@u.washington.edu		Goff, Barbara/0000-0003-0153-5544				*ACOG, 1998, ACOG ED B, V250, P665; [Anonymous], 1994, Gynecol Oncol, V55, pS4; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; Clement KD, 1998, FAMILY MED PRINCIPLE, P916; Eltabbakh GH, 1999, GYNECOL ONCOL, V75, P476, DOI 10.1006/gyno.1999.5621; FLAM F, 1988, EUR J OBSTET GYN R B, V27, P53, DOI 10.1016/S0028-2243(88)80010-8; Goff BA, 2000, CANCER, V89, P2068, DOI 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z; Igoe B A, 1997, Nurse Pract, V22, P127; IHDE DC, 1998, HARRISONS PRINCIPLES, P360; Liede A, 2002, J CLIN ONCOL, V20, P1570, DOI 10.1200/JCO.20.6.1570; Olson SH, 2001, OBSTET GYNECOL, V98, P212, DOI 10.1016/S0029-7844(01)01457-0; Ozols RF, 2000, PRINCIPLES PRACTICE, P981; Paley PJ, 2001, AM J OBSTET GYNECOL, V184, P1021, DOI 10.1067/mob.2001.111714; Petignat P, 1997, SCHWEIZ MED WSCHR, V127, P1993; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; SMITH EM, 1985, CANCER-AM CANCER SOC, V56, P2727, DOI 10.1002/1097-0142(19851201)56:11<2727::AID-CNCR2820561138>3.0.CO;2-8; van Nagell JR, 2000, GYNECOL ONCOL, V77, P350, DOI 10.1006/gyno.2000.5816; Vine MF, 2001, GYNECOL ONCOL, V83, P466, DOI 10.1006/gyno.2001.6411; Wikborn C, 1996, INT J GYNECOL OBSTET, V52, P263, DOI 10.1016/0020-7292(95)02588-X; WIKBORN C, 1993, INT J GYNECOL OBSTET, V42, P261, DOI 10.1016/0020-7292(93)90222-I; YOUNG RC, 1998, HARRISONS PRINCIPLES, P605	21	281	288	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2004	291	22					2705	2712		10.1001/jama.291.22.2705	http://dx.doi.org/10.1001/jama.291.22.2705			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826XH	15187051	Bronze			2022-12-28	WOS:000221862300024
J	Hettiaratchy, S; Dziewulski, P				Hettiaratchy, S; Dziewulski, P			ABC of burns - Introduction	BRITISH MEDICAL JOURNAL			English	Review									Pan Thames Training Scheme, London, England; Broomfield Hosp, St Andrews Ctr Plast Surg & Burns, Chelmsford, Essex, England	Mid Essex Hospital Services NHS Trust; Broomfield Hospital	Hettiaratchy, S (corresponding author), Pan Thames Training Scheme, London, England.							Herndon DN, 2018, TOTAL BURN CARE; Liao CC, 2000, BURNS, V26, P422, DOI 10.1016/S0305-4179(00)00026-7; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; Wilkinson E, 1998, BURNS, V24, P139, DOI 10.1016/S0305-4179(98)80001-6	4	64	66	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 5	2004	328	7452					1366	1368		10.1136/bmj.328.7452.1366	http://dx.doi.org/10.1136/bmj.328.7452.1366			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15178618	Green Published			2022-12-28	WOS:000221952700025
J	Lobb, E; Meiser, B				Lobb, E; Meiser, B			Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer	LANCET			English	Editorial Material							INCREASED RISK; MASTECTOMY; COMMUNICATION; CONSULTATIONS; OOPHORECTOMY; CARRIERS; IMPACT; BRCA2		Edith Cowan Univ, WA Ctr Canc & Palliat Care, Perth, WA 6018, Australia; Prince Wales Hosp, Hereditary Canc Clin, Randwick, NSW 2031, Australia	Edith Cowan University	Lobb, E (corresponding author), Edith Cowan Univ, WA Ctr Canc & Palliat Care, Perth, WA 6018, Australia.	e.lobb@ecu.edu.au	Meiser, Bettina/AAG-5480-2021					Armstrong K, 2004, J CLIN ONCOL, V22, P1045, DOI 10.1200/JCO.2004.06.090; Hallowell N., 1999, HEALTH RISK SOC, V1, P267, DOI DOI 10.1080/13698579908406316; Hartmann LC, 2004, J CLIN ONCOL, V22, P981, DOI 10.1200/JCO.2004.01.925; Hatcher MB, 2001, BRIT MED J, V322, P76, DOI 10.1136/bmj.322.7278.76; Lobb EA, 2004, BRIT J CANCER, V90, P321, DOI 10.1038/sj.bjc.6601502; Lobb EA, 2002, BRIT J CANCER, V87, P502, DOI 10.1038/sj.bjc.6600484; Meiser B, 2000, J CLIN ONCOL, V18, P2250, DOI 10.1200/JCO.2000.18.11.2250; Mild Y, 1994, SCIENCE, V266, P66; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Tiller K, 2002, GYNECOL ONCOL, V86, P212, DOI 10.1006/gyno.2002.6737; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	11	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	2004	363	9424					1841	1842		10.1016/S0140-6736(04)16393-9	http://dx.doi.org/10.1016/S0140-6736(04)16393-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183619				2022-12-28	WOS:000221822300005
J	Hays, GC; Houghton, JDR; Myers, AE				Hays, GC; Houghton, JDR; Myers, AE			Endanqered species - Pan-Atlantic leatherback turtle movements	NATURE			English	Editorial Material							DERMOCHELYS-CORIACEA		Univ Coll Swansea, Sch Biol Sci, Inst Environm Sustainabil, Swansea SA2 8PP, W Glam, Wales	Swansea University	Hays, GC (corresponding author), Univ Coll Swansea, Sch Biol Sci, Inst Environm Sustainabil, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	g.hays@swan.ac.uk		Hays, Graeme/0000-0002-3314-8189				Brongersma L.D., 1972, Zoologische Verh Leiden, VNo. 121, P1; ECKERT SA, 1986, HERPETOLOGICA, V42, P381; ECKERT SA, 1998, NOAA TECHNICAL MEMOR, V415, P46; Lewison RL, 2004, ECOL LETT, V7, P221, DOI 10.1111/j.1461-0248.2004.00573.x; Luschi P, 2003, P ROY SOC B-BIOL SCI, V270, pS129, DOI 10.1098/rsbl.2003.0036; Morreale SJ, 1996, NATURE, V384, P319, DOI 10.1038/384319a0; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; *NOAA, 2001, NOAA NE DIST FISH EX; Polovina JJ, 2004, FISH OCEANOGR, V13, P36, DOI 10.1046/j.1365-2419.2003.00270.x; Spotila JR, 2000, NATURE, V405, P529, DOI 10.1038/35014729; YOKAWA K, 2003, COL VOL SCI PAP ICCA, V55, P475	11	131	145	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					522	522		10.1038/429522a	http://dx.doi.org/10.1038/429522a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175742				2022-12-28	WOS:000221767700029
J	Tranquada, JM; Woo, H; Perring, TG; Goka, H; Gu, GD; Xu, G; Fujita, M; Yamada, K				Tranquada, JM; Woo, H; Perring, TG; Goka, H; Gu, GD; Xu, G; Fujita, M; Yamada, K			Quantum magnetic excitations from stripes in copper oxide superconductors	NATURE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; SPIN; FLUCTUATIONS; LADDER; LA2-XSRXCUO4; YBA2CU3O6.6; SPECTRUM; WAVES	In the copper oxide parent compounds of the high-transition-temperature superconductors(1) the valence electrons are localized-one per copper site-by strong intra-atomic Coulomb repulsion. A symptom of this localization is antiferromagnetism(2), where the spins of localized electrons alternate between up and down. Superconductivity appears when mobile 'holes' are doped into this insulating state, and it coexists with antiferromagnetic fluctuations(3). In one approach to describing the coexistence, the holes are believed to self-organize into 'stripes' that alternate with antiferromagnetic (insulating) regions within copper oxide planes(4), which would necessitate an unconventional mechanism of superconductivity(5). There is an apparent problem with this picture, however: measurements of magnetic excitations in superconducting YBa2Cu3O6+x near optimum doping(6) are incompatible with the naive expectations(7,8) for a material with stripes. Here we report neutron scattering measurements on stripe-ordered La1.875Ba0.125CuO4. We show that the measured excitations are, surprisingly, quite similar to those in YBa2Cu3O6+x (refs 9, 10) ( that is, the predicted spectrum of magnetic excitations(7,8) is wrong). We find instead that the observed spectrum can be understood within a stripe model by taking account of quantum excitations. Our results support the concept that stripe correlations are essential to high-transition-temperature superconductivity(11).	Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Rutherford Appleton Lab, ISIS Facil, Didcot OX11 0QX, Oxon, England; Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan	United States Department of Energy (DOE); Brookhaven National Laboratory; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; Tohoku University	Tranquada, JM (corresponding author), Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA.	jtran@bnl.gov	Tranquada, John M./A-9832-2009; Xu, Guangyong/A-8707-2010; spectrometer, MAPS/AAA-5554-2020; Yamada, Kazuyoshi/C-2728-2009; Fujita, Masaki/D-8430-2013	Tranquada, John M./0000-0003-4984-8857; Xu, Guangyong/0000-0003-1441-8275; 				ANDERSON PW, 1959, PHYS REV, V115, P2, DOI 10.1103/PhysRev.115.2; ARRIGONI E, 2003, MECH HIGH TEMPERATUR; BARNES T, 1994, PHYS REV B, V50, P6817, DOI 10.1103/PhysRevB.50.6817; BATISTA CD, 2001, PHYS REV B, V64; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; Boothroyd AT, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.100407; Bourges P, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.147202; Bourges P, 2000, SCIENCE, V288, P1234, DOI 10.1126/science.288.5469.1234; CARLSON EW, IN PRESS PHYS SUPERC, V2; CARLSON EW, 2002, PREPRINT; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; Coldea R, 2001, PHYS REV LETT, V86, P5377, DOI 10.1103/PhysRevLett.86.5377; Dagotto E, 1996, SCIENCE, V271, P618, DOI 10.1126/science.271.5249.618; Eccleston RS, 1998, PHYS REV LETT, V81, P1702, DOI 10.1103/PhysRevLett.81.1702; FUJITA M, 2004, STRIPE ORDER DEPINNI; Hayden SM, 2004, NATURE, V429, P531, DOI 10.1038/nature02576; Hayden SM, 1996, PHYS REV LETT, V76, P1344, DOI 10.1103/PhysRevLett.76.1344; Ito M, 2003, J PHYS SOC JPN, V72, P1627, DOI 10.1143/JPSJ.72.1627; Kaneshita E, 2001, J PHYS SOC JPN, V70, P866, DOI 10.1143/JPSJ.70.866; Kao YJ, 2000, PHYS REV B, V61, P11898, DOI 10.1103/PhysRevB.61.R11898; Kastner MA, 1998, REV MOD PHYS, V70, P897, DOI 10.1103/RevModPhys.70.897; MOODENBAUGH AR, 1988, PHYS REV B, V38, P4596, DOI 10.1103/PhysRevB.38.4596; Mook HA, 2000, NATURE, V404, P729, DOI 10.1038/35008005; Norman MR, 2000, PHYS REV B, V61, P14751, DOI 10.1103/PhysRevB.61.14751; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; REZNIK D, 2003, DISPERSION MAGNETIC; SACHDEV S, 1991, INT J MOD PHYS B, V5, P219, DOI 10.1142/S0217979291000158; SHAMOTO S, 1993, PHYS REV B, V48, P13817, DOI 10.1103/PhysRevB.48.13817; White SR, 1998, PHYS REV LETT, V80, P1272, DOI 10.1103/PhysRevLett.80.1272; Zaanen J, 2001, PHILOS MAG B, V81, P1485, DOI 10.1080/13642810110051791	31	503	507	1	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	2004	429	6991					534	538		10.1038/nature02574	http://dx.doi.org/10.1038/nature02574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825OL	15175745	Green Submitted			2022-12-28	WOS:000221767700032
J	de Onis, M; Blossner, M; Borghi, E; Frongillo, EA; Morris, R				de Onis, M; Blossner, M; Borghi, E; Frongillo, EA; Morris, R			Estimates of global prevalence of childhood underweight in 1990 and 2015	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCHOOL-CHILDREN; MALNUTRITION; GROWTH; SURVIVAL; OBESITY; TRENDS	Context One key target of the United Nations Millennium Development goals is to reduce the prevalence of underweight among children younger than 5 years by half between 1990 and 2015. Objective To estimate trends in childhood underweight by geographic regions of the world. Design, Setting, and Participants Time series study of prevalence of underweight, defined as weight 2 SDs below the mean weight for age of the National Center for Health Statistics and World Health Organization (WHO) reference population. National prevalence rates derived from the WHO Global Database on Child Growth and Malnutrition, which includes data on approximately 31 million children younger than 5 years who participated in 419 national nutritional surveys in 139 countries from 1965 through 2002. Main Outcome Measures Linear mixed-effects modeling was used to estimate prevalence rates and numbers of underweight children by region in 1990 and 2015 and to calculate the changes (ie, increase or decrease) to these values between 1990 and 2015. Results Worldwide, underweight prevalence was projected to decline from 26.5% in 1990 to 17.6% in 2015, a change of -34% (95% confidence interval [CI], -43% to -23%). In developed countries, the prevalence was estimated to decrease from 1.6% to 0.9%, a change of -41% (95% CI, -92% to 343%). In developing regions, the prevalence was forecasted to decline from 30.2% to 19.3%, a change of -36% (95% CI, -45% to -26%). In Africa, the prevalence of underweight was forecasted to increase from 24.0% to 26.8%, a change of 12% (95% CI, 8%-16%). In Asia, the prevalence was estimated to decrease from 35.1% to 18.5%, a change of -47% (95% CI, -58% to -34%). Worldwide, the number of underweight children was projected to decline from 163.8 million in 1990 to 113.4 million in 2015, a change of -31% (95% CI, -40% to -20%). Numbers are projected to decrease in all subregions except the subregions of sub-Saharan, Eastern, Middle, and Western Africa, which are expected to experience substantial increases in the number of underweight children. Conclusions An overall improvement in the global situation is anticipated; however, neither the world as a whole, nor the developing regions, are expected to achieve the Millennium Development goals. This is largely due to the deteriorating situation in Africa where all subregions, except Northern Africa, are expected to fail to meet the goal.	WHO, Dept Nutr, CH-1211 Geneva 27, Switzerland; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England	World Health Organization; Cornell University; University of London; University College London; UCL Medical School	de Onis, M (corresponding author), WHO, Dept Nutr, CH-1211 Geneva 27, Switzerland.	deonism@who.int		Morris, Richard/0000-0001-7240-4563				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; CAULFIELD LE, IN PRESS AM J CLIN N; Chang SM, 2002, J CHILD PSYCHOL PSYC, V43, P775, DOI 10.1111/1469-7610.00088; de Onis M, 2000, AM J CLIN NUTR, V72, P1032; de Onis M, 2000, B WORLD HEALTH ORGAN, V78, P1222; de Onis M, 2003, INT J EPIDEMIOL, V32, P518, DOI 10.1093/ije/dyg099; *DEP EC SOC AFF UN, 2001, WORLD POP PROSP SEX; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Hop LT, 2003, J NUTR, V133, p4006S, DOI 10.1093/jn/133.11.4006S; Luo J, 2002, INT J OBESITY, V26, P553, DOI 10.1038/sj.ijo.0801944; Martorell R, 1992, HUMAN GROWTH BASIC C, P143; Pelletier DL, 2003, J NUTR, V133, P107, DOI 10.1093/jn/133.1.107; Sakamoto N, 2001, INT J OBESITY, V25, P389, DOI 10.1038/sj.ijo.0801477; Shrimpton R, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e75; UN, MILL DEV GOALS; UNICEF, 2004, STAT WORLDS CHILDR 2; Verbeke G, 2000, LINEAR MIXED MODELS; Walker N, 2002, LANCET, V360, P284, DOI 10.1016/S0140-6736(02)09550-8; Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227; *WHO EXP COMM REP, 1995, WHO TECHN REP SER, V854	22	156	162	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2600	2606		10.1001/jama.291.21.2600	http://dx.doi.org/10.1001/jama.291.21.2600			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173151	Bronze			2022-12-28	WOS:000221738800023
J	Zhang, P; Engelgau, MM; Norris, SL; Gregg, EW; Narayan, V				Zhang, P; Engelgau, MM; Norris, SL; Gregg, EW; Narayan, V			Application of economic analysis to diabetes and diabetes care	ANNALS OF INTERNAL MEDICINE			English	Article							COST-UTILITY ANALYSIS; PREVENTION; GUIDELINES; MELLITUS; HEALTH; INTERVENTIONS; BENEFITS; NIDDM; MODEL	Facing limited resources and increases in demand from competing programs, policymakers and health care providers seek guidance from economic studies on how to use health care resources wisely. Previous economic studies mainly focused on estimating the cost of diabetes and cost-effectiveness of different interventions. These studies found that diabetes is costly and that its cost will continue to increase; thus, more resources should be devoted to research aimed at finding effective means to prevent the disease and its complications. In addition, the cost-effectiveness of interventions varies greatly in terms of quality-adjusted life-years gained; therefore, efficient uses of resources should be an important consideration when interventions are prioritized. The need for economic studies will continue to grow because of increasing demand for limited resources from the growing number of interventions available. Future studies should be of better quality and broadened in areas of research.	CDCP, Div Diabet Translat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Zhang, P (corresponding author), CDCP, Div Diabet Translat, Mailstop K-10,4770 Buford Highway NE, Atlanta, GA 30341 USA.	paz2@cdc.gov		Gregg, Edward/0000-0003-2381-6822				Bagust A, 2001, DIABETES, V50, pA2; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Earnshaw SR, 2002, MED DECIS MAKING, V22, pS80, DOI 10.1177/027298902237704; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Engelgau MM, 1998, JAMA-J AM MED ASSOC, V280, P1757; Ettaro L, 2004, PHARMACOECONOMICS, V22, P149, DOI 10.2165/00019053-200422030-00002; EVANS RG, 1995, ANN INTERN MED, V123, P59, DOI 10.7326/0003-4819-123-1-199507010-00010; Golan L, 1999, ANN INTERN MED, V131, P660, DOI 10.7326/0003-4819-131-9-199911020-00005; Gold MR, 1996, COST EFFECTIVENESS H; Haddix AC, 2003, PREVENTION EFFECTIVE; Herman WH, 2003, DIABETES CARE, V26, P36; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; Jonsson B, 2002, DIABETOLOGIA, V45, pS5, DOI 10.1007/s00125-002-0858-x; JOSEPHINE M, 2003, PHARMACOECONOMICS, V21, P991; Klonoff DC, 2000, DIABETES CARE, V23, P390, DOI 10.2337/diacare.23.3.390; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; Ollendorf DA, 1998, DIABETES CARE, V21, P1240, DOI 10.2337/diacare.21.8.1240; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Petersen M, 2003, DIABETES CARE, V26, P917; Siegel JE, 1997, PHARMACOECONOMICS, V11, P159, DOI 10.2165/00019053-199711020-00005; SONGER TJ, DIABETES HLTH EC BIB; Tennvall GR, 2001, DIABETOLOGIA, V44, P2077; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Vijan S, 2000, JAMA-J AM MED ASSOC, V283, P889, DOI 10.1001/jama.283.7.889	27	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					972	977		10.7326/0003-4819-140-11-200406010-00039	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00039			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824IS	15172923				2022-12-28	WOS:000221680600029
J	Ebers, GC; Sadovnick, AD; Dyment, DA; Yee, IML; Willer, CJ; Risch, N				Ebers, GC; Sadovnick, AD; Dyment, DA; Yee, IML; Willer, CJ; Risch, N			Parent-of-origin effect in multiple sclerosis: observations in half-siblings	LANCET			English	Article								Multiple sclerosis is a complex trait in which occurrence rates in offspring are 20-50-fold greater than in the general population. Parent-of-origin effects have been difficult to screen for, since most cases are sporadic. We have compared recurrence risks in half-siblings with respect to their parent in common. Of the 1567 index cases with half-siblings in multiple sclerosis clinics across Canada, we recorded 3436 half-siblings and 2706 full-siblings. Age-adjusted full-sibling risk was 3.11%. By contrast, half-sibling risk in the same families was significantly lower at 1.89% (chi(2) test, p=0.006), but higher than expected if familial risk was simply polygenic. For maternal half-siblings, the risk was 2.35% (34 affected siblings of 1859), and 1.31% for paternal half-siblings (15 of 1577), (p=0.048). The difference in risk suggests a maternal parent-of-origin effect in multiple sclerosis susceptibility.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC, Canada; Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA	University of Oxford; Wellcome Centre for Human Genetics; Radcliffe Infirmary; University of Oxford; University of British Columbia; University of British Columbia; Stanford University	Ebers, GC (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.	george.ebers@clinical-neurology.oxford.ac.uk		Sadovnick, Dessa/0000-0003-2987-2008; Willer, Cristen/0000-0001-5645-4966; Ebers, George/0000-0003-4771-4177				DAVIE AM, 1979, ANN HUM GENET, V42, P507, DOI 10.1111/j.1469-1809.1979.tb00683.x; RISCH N, 1983, BIOMETRICS, V39, P929, DOI 10.2307/2531328; Sadovnick AD, 1998, CAN J NEUROL SCI, V25, P216, DOI 10.1017/S0317167100034041; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; Willer CJ, 2003, P NATL ACAD SCI USA, V100, P12877, DOI 10.1073/pnas.1932604100	5	193	196	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	2004	363	9423					1773	1774		10.1016/S0140-6736(04)16304-6	http://dx.doi.org/10.1016/S0140-6736(04)16304-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824SD	15172777				2022-12-28	WOS:000221705800012
J	Lee, PE; Gill, SS; Freedman, M; Bronskill, SE; Hillmer, MP; Rochon, PA				Lee, PE; Gill, SS; Freedman, M; Bronskill, SE; Hillmer, MP; Rochon, PA			Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; ALZHEIMERS-DISEASE; RANDOMIZED-TRIAL; RISPERIDONE; PLACEBO; CARE; HALOPERIDOL; OLANZAPINE; QUALITY; AGITATION	Objective To review the role of oral atypical antipsychotic drugs in the management of the behavioural and psychological symptoms of dementia (BPSD). Data sources Medline, Embase, and the Cochrane Library. Reference lists were reviewed and experts were contacted to identify additional trials. Study selection Double blind randomised controlled trials that evaluated the four oral atypical antipsychotic therapies for BPSD. Review methods Two reviewers assessed trial validity independently. Data extraction Demographics of patients, study duration, dose of antipsychotic, primary end points, adverse events. Results 77 abstracts were reviewed. Five randomised trials (1570 patients) evaluating risperidone and olanzapine were identified. The quality of trials was generally good. Most participants were in an institution (> 96%), elderly (weighted mean 82.3 years), and had Alzheimer's disease (76.3%). Trials lasted 6-12 weeks. Treatment with atypical antipsychotic drugs was superior to placebo for the primary end point in three of the five trials. Two trials comparing risperidone with haloperidol did not find any differences in the primary measures of efficacy. Adverse events were common and included extrapyramidal symptoms, somnolence, and abnormal gait. Conclusions Although atypical antipsychotic drugs are being used with increasing frequency, few randomised trials have evaluated their use for BPSD. Limited evidence supports the perception of improved efficacy and adverse event profiles compared with typical antipsychotic drugs.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5G 2C4, Canada; Baycrest Ctr Geriatr Care, KLARU, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Baycrest	Lee, PE (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	pelee@providencehealth.bc.ca	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; Ballard CG, 2001, J CLIN PSYCHIAT, V62, P631, DOI 10.4088/JCP.v62n0810; *BRIT MED ASS ROYA, 2004, BRIT NAT FORM, P179; Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; BRONSKILL SE, 2004, IN PRESS J AM GERIAT; Buse JB, 2002, J CLIN PSYCHIAT, V63, P37; *CAN PHARM ASS, 2003, COMP PHARM SPEC, P1505; Chan WC, 2001, INT J GERIATR PSYCH, V16, P1156, DOI 10.1002/gps.504; CHOUINARD G, 1980, CAN J NEUROL SCI, V7, P233; COHEN CA, 1993, GERONTOLOGIST, V33, P714, DOI 10.1093/geront/33.6.714; Cohen-Mansfield J, 1998, J AM GERIATR SOC, V36, P7; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Davidson M, 2001, J CLIN PSYCHIAT, V62, P26; De Deyn PP, 2001, J CLIN PSYCHIAT, V62, P19; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; DUFF G, ATYPICAL ANTIPSYCHOT; Fabbrini G, 2001, INT J GERIATR PSYCH, V16, pS19, DOI 10.1002/1099-1166(200112)16:1+<::AID-GPS563>3.0.CO;2-0; *FDA, 2003, SAF AL RISP RISP; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Guy W, 1976, ECDEU ASSESSMENT MAN, DOI DOI 10.1037/E591322011-001; Hall E, 2001, AM BOOK REV, V22, P12; Hughes CM, 1999, BRIT MED J, V319, P1060, DOI 10.1136/bmj.319.7216.1060; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jeste DV, 1999, J AM GERIATR SOC, V47, P716, DOI 10.1111/j.1532-5415.1999.tb01595.x; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Koss E, 1997, ALZ DIS ASSOC DIS, V11, pS45; Lindenmayer JP, 2003, AM J PSYCHIAT, V160, P290, DOI 10.1176/appi.ajp.160.2.290; Meehan KM, 2002, NEUROPSYCHOPHARMACOL, V26, P494, DOI 10.1016/S0893-133X(01)00365-7; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PWEE KH, 2003, 36 CAN COORD OFF HLT; REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9; Schneider LS, 2001, AM J GERIAT PSYCHIAT, V9, P346, DOI 10.1176/appi.ajgp.9.4.346; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; SCHNEIDER LS, ALZHEIMER DIS ASS DI; SEMLA TP, 1994, J AM GERIATR SOC, V42, P648, DOI 10.1111/j.1532-5415.1994.tb06865.x; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358; SIMPSON GM, 1970, ACTA PSYCHIAT SCAND, P11; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Street JS, 2001, INT J GERIATR PSYCH, V16, pS62, DOI 10.1002/1099-1166(200112)16:1+<::AID-GPS569>3.0.CO;2-J; van Reekum R, 2002, INT PSYCHOGERIATR, V14, P197, DOI 10.1017/S1041610202008396; Wirshing WC, 2001, J CLIN PSYCHIAT, V62, P15; 2004, PHYS DES REFERENCE; [No title captured]	45	146	149	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					75	78A		10.1136/bmj.38125.465579.55	http://dx.doi.org/10.1136/bmj.38125.465579.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	837ON	15194601	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222645000016
J	Straus, SE; Wilson, K; Rambaldini, G; Rath, D; Lin, Y; Gold, WL; Kapral, MK				Straus, SE; Wilson, K; Rambaldini, G; Rath, D; Lin, Y; Gold, WL; Kapral, MK			Severe acute respiratory syndrome and its impact on professionalism: qualitative study of physicians' behaviour during an emerging healthcare crisis	BRITISH MEDICAL JOURNAL			English	Article							RISK; AIDS; OBLIGATIONS; MEDICINE	Objective To explore issues of medical professionalism in the context of severe acute respiratory syndrome (SARS), a new emerging health threat. Design Qualitative interviews analysed with grounded theory methodology. Setting University hospitals in Toronto, Canada, during the SARS outbreak in 2003. Participants 14 staff physicians from divisions of infectious diseases, general internal medicine, and critical care medicine. Results Of 14 attending physicians, four became ill during die outbreak. Participants described their experiences during the outbreak and highlighted several themes about values inherent to medical professionalism that arose during this crisis including the balance between care of patients and accepted personal risk, confidentiality, appropriate interactions between physicians and patients, ethical research conduct, and role modelling of professionalism for junior doctors. Conclusion Despite concerns raised by professional societies about the erosion of professionalism, participants in this study amply demonstrated the necessary qualities during the recent healthcare crisis. However, there were several examples of strained professional behaviour witnessed by the participants and these examples highlight aspects of medical professionalism that medical educators and professional organisations should address in the future, including the balance between personal safety and duty of care.	Univ Hlth Network, Div Gen Internal Med, Toronto, ON M5G 2C4, Canada; Univ British Columbia, Dept Haematol, Vancouver, BC V5Z 4E3, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of British Columbia	Straus, SE (corresponding author), Univ Hlth Network, Div Gen Internal Med, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	sharon.straus@utoronto.ca	Lin, Yulia/G-1254-2014					Barondess JA, 2003, ARCH INTERN MED, V163, P145, DOI 10.1001/archinte.163.2.145; Brownell AKW, 2001, ACAD MED, V76, P734, DOI 10.1097/00001888-200107000-00019; Cohn J A, 1991, Md Med J, V40, P185; Cruess SR, 1997, BRIT MED J, V315, P1674, DOI 10.1136/bmj.315.7123.1674; Cruess SR, 2002, MED J AUSTRALIA, V177, P208, DOI 10.5694/j.1326-5377.2002.tb04735.x; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; Gray GM, 2002, HEALTH AFFAIR, V21, P106, DOI 10.1377/hlthaff.21.6.106; Ha K G, 1991, Tex Med, V87, P76; HARSH ES, 1991, MED CARE, V29, P1051; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; LOEWY EH, 1986, SOC SCI MED, V22, P1363, DOI 10.1016/0277-9536(86)90100-0; Maunder R, 2003, CAN MED ASSOC J, V168, P1245; Mays N., 1999, QUALITATIVE RES HLTH; Misch DA, 2002, ACAD MED, V77, P489, DOI 10.1097/00001888-200206000-00004; REYNOLDS PP, 1994, ANN INTERN MED, V120, P609, DOI 10.7326/0003-4819-120-7-199404010-00013; RODERICK P, 1990, AIDS CARE, V2, P126; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924	19	58	58	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	2004	329	7457					83	85		10.1136/bmj.38127.444838.63	http://dx.doi.org/10.1136/bmj.38127.444838.63			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	837ON	15175231	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222645000018
J	Adams, PL; Stahley, MR; Kosek, AB; Wang, JM; Strobel, SA				Adams, PL; Stahley, MR; Kosek, AB; Wang, JM; Strobel, SA			Crystal structure of a self-splicing group I intron with both exons	NATURE			English	Article							METAL-ION INTERACTION; TETRAHYMENA RIBOZYME; ACTIVE-SITE; RNA; BINDING; GUANOSINE; IDENTIFICATION; MECHANISM; CATALYSIS; CLEAVAGE	The discovery of the RNA self-splicing group I intron provided the first demonstration that not all enzymes are proteins. Here we report the X-ray crystal structure (3.1-Angstrom resolution) of a complete group I bacterial intron in complex with both the 50'-and the 3'-exons. This complex corresponds to the splicing intermediate before the exon ligation step. It reveals how the intron uses structurally unprecedented RNA motifs to select the 5'-and 3'-splice sites. The 5'-exon's 3'-OH is positioned for inline nucleophilic attack on the conformationally constrained scissile phosphate at the intron-3'-exon junction. Six phosphates from three disparate RNA strands converge to coordinate two metal ions that are asymmetrically positioned on opposing sides of the reactive phosphate. This structure represents the first splicing complex to include a complete intron, both exons and an organized active site occupied with metal ions.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Wang, JM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 260 Whitney Ave, New Haven, CT 06520 USA.	wang@csb.yale.edu; strobel@csb.yale.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; Basu S, 1998, NAT STRUCT BIOL, V5, P986, DOI 10.1038/2960; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; Cech TR, 1999, RNA WORLD, P321; DAMBERGER SH, 1994, NUCLEIC ACIDS RES, V22, P3508, DOI 10.1093/nar/22.17.3508; Duarte CM, 2003, NUCLEIC ACIDS RES, V31, P4755, DOI 10.1093/nar/gkg682; Ferre-D'Amare AR, 2000, J MOL BIOL, V295, P541, DOI 10.1006/jmbi.1999.3398; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knitt DS, 1996, BIOCHEMISTRY-US, V35, P1560, DOI 10.1021/bi9521147; Kuo LY, 1999, BBA-GENE STRUCT EXPR, V1489, P281, DOI 10.1016/S0167-4781(99)00200-6; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MORAN S, 1993, BIOCHEMISTRY-US, V32, P5247, DOI 10.1021/bi00070a037; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; Rangan P, 2003, J MOL BIOL, V329, P229, DOI 10.1016/S0022-2836(03)00430-3; Rangan P, 2003, P NATL ACAD SCI USA, V100, P1574, DOI 10.1073/pnas.0337743100; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Shan S, 2001, BIOCHEMISTRY-US, V40, P5161, DOI 10.1021/bi002887h; Shan SO, 1999, BIOCHEMISTRY-US, V38, P10958, DOI 10.1021/bi990388e; Shan SO, 1999, P NATL ACAD SCI USA, V96, P12299, DOI 10.1073/pnas.96.22.12299; Sigel RKO, 2000, NAT STRUCT BIOL, V7, P1111; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; Sontheimer EJ, 1997, NATURE, V388, P801, DOI 10.1038/42068; Soukup JK, 2002, BIOCHEMISTRY-US, V41, P10426, DOI 10.1021/bi020265l; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Strauss-Soukup JK, 2000, J MOL BIOL, V302, P339, DOI 10.1006/jmbi.2000.4056; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; Strobel SA, 1999, CHEM BIOL, V6, P153, DOI 10.1016/S1074-5521(99)89007-3; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; Szewczak AA, 2002, BIOCHEMISTRY-US, V41, P2516, DOI 10.1021/bi011973u; Tanner MA, 1996, RNA, V2, P74; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yoshida A, 1999, NAT STRUCT BIOL, V6, P318	50	350	371	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					45	50		10.1038/nature02642	http://dx.doi.org/10.1038/nature02642			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15175762				2022-12-28	WOS:000222356800037
J	Wang, ZR; Singhvi, A; Kong, P; Scott, K				Wang, ZR; Singhvi, A; Kong, P; Scott, K			Taste representations in the Drosophila brain	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; OLFACTORY SENSORY MAP; C-ELEGANS; CHEMOSENSORY NEURONS; MAMMALIAN SWEET; GENE-EXPRESSION; ANTENNAL LOBE; BITTER TASTE; FLY BRAIN; MELANOGASTER	Drosophila taste compounds with gustatory neurons on many parts of the body, suggesting that a fly detects both the location and quality of a food source. For example, activation of taste neurons on the legs causes proboscis extension or retraction, whereas activation of proboscis taste neurons causes food ingestion or rejection. We examined whether the features of taste location and taste quality are mapped in the fly brain using molecular, genetic, and behavioral approaches. We find that projections are segregated by the category of tastes that they recognize: neurons that recognize sugars project to a region different from those recognizing noxious substances. Transgenic axon labeling experiments also demonstrate that gustatory projections are segregated based on their location in the periphery. These studies reveal the gustatory map in the first relay of the fly brain and demonstrate that taste quality and position are represented in anatomical projection patterns.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Scott, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	kscott@berkeley.edu			NIDCD NIH HHS [R01 DC006252, 1R01DC006252-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006252] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BELLEN HJ, 1992, DEVELOPMENT, V114, P787; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chyb S, 2003, P NATL ACAD SCI USA, V100, P14526, DOI 10.1073/pnas.2135339100; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; Dahanukar A, 2001, NAT NEUROSCI, V4, P1182, DOI 10.1038/nn765; Del Punta K, 2002, NEURON, V35, P1057, DOI 10.1016/S0896-6273(02)00904-2; Dethier VG, 1976, HUNGRY FLY; Dunipace L, 2001, CURR BIOL, V11, P822, DOI 10.1016/S0960-9822(01)00258-5; FALK R, 1976, J MORPHOL, V150, P327, DOI 10.1002/jmor.1051500206; FUJISHIRO N, 1984, J INSECT PHYSIOL, V30, P317, DOI 10.1016/0022-1910(84)90133-1; Gao Q, 2000, NAT NEUROSCI, V3, P780, DOI 10.1038/77680; Glover JC, 2000, PHYSIOL REV, V80, P615, DOI 10.1152/physrev.2000.80.2.615; Halfon MS, 2002, GENESIS, V34, P135, DOI 10.1002/gene.10136; Han DD, 2000, DEVELOPMENT, V127, P573; Hiroi M, 2002, ZOOL SCI, V19, P1009, DOI 10.2108/zsj.19.1009; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Kunes Samuel, 1993, Current Opinion in Neurobiology, V3, P53, DOI 10.1016/0959-4388(93)90035-W; Laissue PP, 1999, J COMP NEUROL, V405, P543; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Martini S, 2001, J NEUROSCI, V21, P843, DOI 10.1523/JNEUROSCI.21-03-00843.2001; Meunier N, 2003, J NEUROBIOL, V56, P139, DOI 10.1002/neu.10235; Meunier N, 2000, CURR BIOL, V10, P1583, DOI 10.1016/S0960-9822(00)00860-5; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; POWER ME, 1948, J COMP NEUROL, V88, P347, DOI 10.1002/cne.900880303; RAJASHEKHAR KP, 1994, J COMP NEUROL, V349, P633, DOI 10.1002/cne.903490410; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RICE MJ, 1977, NATURE, V268, P747, DOI 10.1038/268747a0; Robertson HM, 2003, P NATL ACAD SCI USA, V100, P14537, DOI 10.1073/pnas.2335847100; RUBIN GM, 1985, TRENDS NEUROSCI, V8, P231, DOI 10.1016/0166-2236(85)90094-3; Scott K, 2001, CELL, V104, P661, DOI 10.1016/S0092-8674(01)00263-X; Singh RN, 1997, MICROSC RES TECHNIQ, V39, P547, DOI 10.1002/(SICI)1097-0029(19971215)39:6<547::AID-JEMT7>3.0.CO;2-A; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; STOCKER RF, 1981, CELL TISSUE RES, V216, P513; TAYLOR BJ, 1989, J NEUROGENET, V5, P193, DOI 10.3109/01677068909066208; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; TRUMAN JW, 1993, FORMATION ADULT NERV, V2, P1245; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; Ueno K, 2001, CURR BIOL, V11, P1451, DOI 10.1016/S0960-9822(01)00450-X; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Wes PD, 2001, NATURE, V410, P698, DOI 10.1038/35070581; Wong AM, 2002, CELL, V109, P229, DOI 10.1016/S0092-8674(02)00707-9; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	56	324	334	2	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	2004	117	7					981	991		10.1016/j.cell.2004.06.011	http://dx.doi.org/10.1016/j.cell.2004.06.011			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	832XE	15210117	Bronze			2022-12-28	WOS:000222300200014
J	Barnes, PJ				Barnes, PJ			Small airways in COPD	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE		Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.			Barnes, Peter/0000-0002-5122-4018				Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218	5	83	90	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2635	2637		10.1056/NEJMp048102	http://dx.doi.org/10.1056/NEJMp048102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215476				2022-12-28	WOS:000222199000001
J	Nee, S				Nee, S			More than meets the eye - Earth's real biodiversity is invisible, whether we like it or not	NATURE			English	Editorial Material									Univ Edinburgh, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Nee, S (corresponding author), Univ Edinburgh, Ashworth Labs, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	sean.nee@ed.ac.uk						Edwards KJ, 2000, SCIENCE, V287, P1796, DOI 10.1126/science.287.5459.1796; FENCHEL T, 1995, ECOLOGY EVOLUTION AN; MAY RM, 1990, PHILOS T R SOC B, V330, P293, DOI 10.1098/rstb.1990.0200; Strous M, 1999, NATURE, V400, P446, DOI 10.1038/22749; Surridge AK, 1999, NATURE, V400, P726, DOI 10.1038/23393	5	45	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	2004	429	6994					804	805		10.1038/429804a	http://dx.doi.org/10.1038/429804a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	831RE	15215837				2022-12-28	WOS:000222213000017
J	Guthrie, RD				Guthrie, RD			Radiocarbon evidence of mid-Holocene mammoths stranded on an Alaskan Bering Sea island	NATURE			English	Article							EXTINCTION	Island colonization and subsequent dwarfing of Pleistocene proboscideans is one of the more dramatic evolutionary and ecological occurrences(1-3), especially in situations where island populations survived end-Pleistocene extinctions whereas those on the nearby mainland did not(4). For example, Holocene mammoths have been dated from Wrangel Island in northern Russia(4). In most of these cases, few details are available about the dynamics of how island colonization and extinction occurred. As part of a large radiocarbon dating project of Alaskan mammoth fossils, I addressed this question by including mammoth specimens from Bering Sea islands known to have formed during the end-Pleistocene sea transgression(5). One date of 7,908 +/- 6 100 yr BP (radiocarbon years before present) established the presence of Holocene mammoths on St Paul Island, a first Holocene island record for the Americas. Four lines of evidence 265 accelerator mass spectrometer (AMS) radiocarbon dates from Alaskan mainland mammoths(6), 13 new dates from Alaskan island mammoths, recent reconstructions of bathymetric plots(5) and sea transgression rates from the Bering Sea(5)-made it possible to reconstruct how mammoths became stranded in the Pribilofs and why this apparently did not happen on other Alaskan Bering Sea islands.	Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA	University of Alaska System; University of Alaska Fairbanks	Guthrie, RD (corresponding author), Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA.	ffrdg@uaf.edu						Agenbroad Larry D., 2003, Deinsea, V9, P1; AGENBROAD LD, 2002, AM QUAT ASS 17 AMQUA; AGER TA, 2003, QUATERNARY RES, V60, P17; COLINVAUX P, 1981, QUATERNARY RES, V16, P18, DOI 10.1016/0033-5894(81)90125-3; CROSSEN KJ, 2003, ANN GEOL SOC AM C NW, P424; Falconer D. S., 1989, Introduction to quantitative genetics.; FITZHUGH WW, 1997, ANTHR NEWS NATL MUS, V9, P1; FLADMARK KR, 1977, AM ANTIQUITY, V4, P55; Frankham R, 1998, CONSERV BIOL, V12, P665, DOI 10.1046/j.1523-1739.1998.96456.x; GERASIMOV D, 2002, NEW MAT INTERPRETATI, P379; Guthrie R.D., 1984, P259; Guthrie R.D., 1990, FROZEN FAUNA MAMMOTH; Guthrie RD, 2003, NATURE, V426, P169, DOI 10.1038/nature02098; HOPKINS DM, 1966, SCIENCE, V152, P343, DOI 10.1126/science.152.3720.343; Laws R.M., 1975, ELEPHANTS THEIR HABI; LISTER AM, 1999, ANN NAT HIST MUS ROT, V6, P79; MANLEY WF, INSTAAR2002; Martin P. S., 1984, QUATERNARY EXTINCTIO, P345; PALOMBO MR, 2001, WORLD ELEPHANTS, P486; Scheffer VB, 1951, SCI MON, V73, P356; Sondaar P.Y., 1977, MAJOR PATTERNS VERTE, P671, DOI DOI 10.1007/978-1-4684-8851-7; Sulerzhitsky LD, 1999, AMBIO, V28, P251; VARTANYAN SL, 1993, NATURE, V362, P336, DOI DOI 10.1038/362337A0	23	101	109	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	2004	429	6993					746	749		10.1038/nature02612	http://dx.doi.org/10.1038/nature02612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	829OS	15201907				2022-12-28	WOS:000222059900035
J	Orringer, JS; Kang, SW; Hamilton, T; Schumacher, W; Cho, SY; Hammerberg, C; Fisher, GJ; Karimipour, DJ; Johnson, TM; Voorhees, JJ				Orringer, JS; Kang, SW; Hamilton, T; Schumacher, W; Cho, SY; Hammerberg, C; Fisher, GJ; Karimipour, DJ; Johnson, TM; Voorhees, JJ			Treatment of acne vulgaris with a pulsed dye laser - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY; NM; SYSTEM; LIGHT	Context The high prevalence of acne vulgaris and its significant morbidity underscore the need for convenient, low-risk, and efficacious therapy. Treatment with various lasers has been reported to improve acne. Objective To evaluate the clinical efficacy of pulsed dye laser therapy in the treatment of acne. Design, Setting, and Patients Randomized, single-blind, controlled, split-face clinical trial of a volunteer sample of 40 patients aged 13 years or older with facial acne conducted at an academic referral center from August 2002 to September 2003. Intervention One or 2 nonpurpuric pulsed dye laser treatments to half of the face (fluence of 3 J/cm(2)), serial blinded clinical assessments (lesion counts), and grading of acne severity using standardized bilateral serial photographs. Main Outcome Measures Comparison of the changes in lesion counts from baseline to 12 weeks between treated and untreated sides of the face and changes in photographic evidence of acne severity as graded by a panel of dermatologists blinded to treatment assignment. Results After 12 weeks, using intent-to-treat analysis with last observation carried forward, there were no significant differences between laser-treated and untreated skin for changes in mean papule counts (-4.2 vs -2.2; P=.08), mean pustule counts (0 vs -1.0; P=.12), or mean comedone counts (2.9 vs 1.6; P=.63). Grading of serial photographs confirmed the clinical assessments, showing no significant mean (SE) differences in Leeds scores (range, 1-12) for treated skin (3.98 [0.32] at baseline and 3.94 [0.27] at week 12) compared with untreated skin (3.83 [0.32] at baseline and 3.79 [0.28] at week 12) (P>.99). Conclusions In this study, the nonpurpuric pulsed dye laser therapy did not result in significant improvement of facial acne. More research is needed before this laser therapy may be recommended as an acne treatment.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Orringer, JS (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, 1910 Taubman Ctr, Ann Arbor, MI 48109 USA.	jorringe@umich.edu	Cho, Soyun/B-7359-2013; Voorhees, John/AAM-9966-2020; Cho, Soyun/J-5666-2012	Voorhees, John/0000-0003-1856-785X; Cho, Soyun/0000-0003-2468-485X	NIAMS NIH HHS [1 K24 AR02159-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR002159] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bjerring P, 2000, J Cutan Laser Ther, V2, P9, DOI 10.1080/14628830050516542; CUNLIFFE WJ, 1986, BRIT J DERMATOL, V115, P386, DOI 10.1111/j.1365-2133.1986.tb05757.x; EADEN E, 1993, BRIT MED J, V306, P555; ELGAMMAL C, 1995, NONINVASIVE METHODS, P517; Ellis CN, 2001, J AM ACAD DERMATOL, V45, pS150, DOI 10.1067/mjd.2001.113717; Gough A, 1996, BRIT MED J, V312, P169; Hirsch RJ, 2003, CUTIS, V71, P353; Hongcharu W, 2000, J INVEST DERMATOL, V115, P183, DOI 10.1046/j.1523-1747.2000.00046.x; Jacob CI, 2001, J AM ACAD DERMATOL, V45, P109, DOI 10.1067/mjd.2001.113451; LAYTON A, 1998, J CUTAN MED SURG S3, V2, P14; Leyden JJ, 2001, J EUR ACAD DERMATOL, V15, P51, DOI 10.1046/j.0926-9959.2001.00013.x; LEYDEN JJ, 1986, J AM ACAD DERMATOL, V15, P907, DOI 10.1016/S0190-9622(86)70250-8; Lloyd JR, 2002, LASER SURG MED, V31, P115, DOI 10.1002/lsm.10080; O'Brien SC, 1998, J DERMATOL TREAT, V9, P215, DOI 10.3109/09546639809160698; Paithankar DY, 2002, LASER SURG MED, V31, P106, DOI 10.1002/lsm.10086; Papageorgiou P, 2000, BRIT J DERMATOL, V142, P973, DOI 10.1046/j.1365-2133.2000.03481.x; Patel N, 2002, DERMATOL SURG, V28, P942, DOI 10.1046/j.1524-4725.2002.02062.x; Seaton ED, 2003, LANCET, V362, P1347, DOI 10.1016/S0140-6736(03)14629-6; STILLMAN S, 2000, J EUR ACAD DERMAT S1, V14, P47; Till AE, 2000, BRIT J DERMATOL, V142, P885, DOI 10.1046/j.1365-2133.2000.03467.x; Webster GF, 2002, BMJ-BRIT MED J, V325, P475, DOI 10.1136/bmj.325.7362.475	21	104	104	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2834	2839		10.1001/jama.291.23.2834	http://dx.doi.org/10.1001/jama.291.23.2834			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199033	Bronze			2022-12-28	WOS:000221962500028
J	Hettiaratchy, S; Dziewulski, P				Hettiaratchy, S; Dziewulski, P			ABC of burns - Pathophysiology and types of burns	BRITISH MEDICAL JOURNAL			English	Review									Pan Thames Training Scheme, London, England; Broomfield Hosp, St Andrews Ctr Plast Surg & Burns, Chelmsford, Essex, England	Mid Essex Hospital Services NHS Trust; Broomfield Hospital	Hettiaratchy, S (corresponding author), Pan Thames Training Scheme, London, England.							Andronicus M, 1998, BURNS, V24, P552, DOI 10.1016/S0305-4179(98)00062-X; Herndon DN, 2018, TOTAL BURN CARE; Kao CC, 2000, PLAST RECONSTR SURG, V105, P2482, DOI 10.1097/00006534-200006000-00028; KIRKPATRICK JJR, 1995, BURNS, V21, P483, DOI 10.1016/0305-4179(95)93254-H; Luce EA, 2000, CLIN PLAST SURG, V27, P133	5	157	169	1	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 12	2004	328	7453					1427	1429		10.1136/bmj.328.7453.1427	http://dx.doi.org/10.1136/bmj.328.7453.1427			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15191982	Green Published			2022-12-28	WOS:000222114400028
J	Lonser, RR; Kim, J; Butman, JA; Vortmeyer, AO; Choo, DI; Oldfield, EH				Lonser, RR; Kim, J; Butman, JA; Vortmeyer, AO; Choo, DI; Oldfield, EH			Tumors of the endolymphatic sac in von Hippel-Lindau disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPRESSOR GENE; HEMANGIOBLASTOMAS; ADENOCARCINOMA		Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, Neurootol Branch, NIH, Bethesda, MD USA; NIH, Dept Diagnost Radiol, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Otolaryngol, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Lonser, RR (corresponding author), Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bldg 10,Rm 5D37, Bethesda, MD 20892 USA.	lonserr@ninds.nih.gov	Butman, John/J-2780-2013; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991, Z01NS002855] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brandt R, 1921, ALBRECHT VONGRAEFES, V106, P127; Choo D, 2004, J NEUROSURG, V100, P480, DOI 10.3171/jns.2004.100.3.0480; Gaeta M, 1999, NEURORADIOLOGY, V41, P799, DOI 10.1007/s002340050845; HEFFNER DK, 1989, CANCER, V64, P2292, DOI 10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lindau, 1926, ACTA PATH MICROBIO S, V1, P1; Lonser RR, 2003, J NEUROSURG, V98, P106, DOI 10.3171/jns.2003.98.1.0106; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Manski TJ, 1997, JAMA-J AM MED ASSOC, V277, P1461, DOI 10.1001/jama.277.18.1461; Megerian CA, 2002, OTOL NEUROTOL, V23, P378, DOI 10.1097/00129492-200205000-00026; MEGERIAN CA, 1995, LARYNGOSCOPE, V105, P801, DOI 10.1288/00005537-199508000-00006; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; PACK SD, 2001, COLORECTAL CANC METH, P35; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Vortmeyer AO, 1997, JNCI-J NATL CANCER I, V89, P970, DOI 10.1093/jnci/89.13.970-a; Wanebo JE, 2003, J NEUROSURG, V98, P82, DOI 10.3171/jns.2003.98.1.0082	17	87	91	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2481	2486		10.1056/NEJMoa040666	http://dx.doi.org/10.1056/NEJMoa040666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190140				2022-12-28	WOS:000221887200007
J	Falini, B; Tiacci, E; Liso, A; Basso, K; Sabattini, E; Pacini, R; Foa, R; Pulsoni, A; Dalla Favera, R; Pileri, S				Falini, B; Tiacci, E; Liso, A; Basso, K; Sabattini, E; Pacini, R; Foa, R; Pulsoni, A; Dalla Favera, R; Pileri, S			Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)	LANCET			English	Article								A marker capable of distinguishing with certainty between hairy cell leukaemia and other B-cell malignant disease would be of great diagnostic value. Through gene expression profiling, annexin A1 (ANXA1) has been identified as a gene that is upregulated in hairy cell leukaemia. We did immunostaining of 500 B-cell tumours with a specific anti-ANXA1 monoclonal antibody and showed that ANXA1 protein expression is specific to hairy cell leukaemia. Immunocytochemical detection of ANXA1 represents a simple, inexpensive, highly sensitive and specific (100%) assay for diagnosis of hairy cell leukaemia. This assay will be especially useful in distinguishing hairy cell leukaemia from splenic lymphoma with villous lymphocytes and variant hairy cell leukaemia, both of which usually respond poorly to treatments that are effective in hairy cell leukaemia.	Univ Perugia, Monteluce Policlin, Inst Haematol, I-06100 Perugia, Italy; Univ Foggia, Inst Haematol, Foggia, Italy; Columbia Univ, Inst Canc Genet, New York, NY USA; Columbia Univ, Dept Pathol, New York, NY USA; Columbia Univ, Dept Genet & Dev, New York, NY USA; Univ Roma La Sapienza, Inst Haematol, Rome, Italy; Univ Bologna, Inst Haematol, I-40126 Bologna, Italy	University of Perugia; University of Foggia; Columbia University; Columbia University; Columbia University; Sapienza University Rome; University of Bologna	Falini, B (corresponding author), Univ Perugia, Monteluce Policlin, Inst Haematol, I-06100 Perugia, Italy.	faliniem@unipg.it	Sabattini, Elena/K-6720-2016	Sabattini, Elena/0000-0002-4136-3591; FALINI, Brunangelo/0000-0002-7198-5965; Liso, Arcangelo/0000-0001-5638-227X				Basso K, 2004, J EXP MED, V199, P59, DOI 10.1084/jem.20031175; FOUCAR K, 2001, WHO CLASSIFICATION T, P138; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; MATUTES E, 1994, LEUKEMIA LYMPHOMA, V14, P57; TALLMAN MS, 2000, HEMATOLOGY BASIC PRI, P1363	5	165	176	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	2004	363	9424					1869	1871		10.1016/S0140-6736(04)16356-3	http://dx.doi.org/10.1016/S0140-6736(04)16356-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826IH	15183626				2022-12-28	WOS:000221822300012
J	Roos, CF; Riebe, M; Haffner, H; Hansel, W; Benhelm, J; Lancaster, GPT; Becher, C; Schmidt-Kaler, F; Blatt, R				Roos, CF; Riebe, M; Haffner, H; Hansel, W; Benhelm, J; Lancaster, GPT; Becher, C; Schmidt-Kaler, F; Blatt, R			Control and measurement of three-qubit entangled states	SCIENCE			English	Article							QUANTUM; DECOHERENCE	We report the deterministic creation of maximally entangled three-qubit states - specifically the Greenberger- Horne- Zeilinger (GHZ) state and the W state - with a trapped-ion quantum computer. We read out one of the qubits selectively and show how GHZ and W states are affected by this local measurement. Additionally, we demonstrate conditional operations controlled by the results from reading out one qubit. Tripartite entanglement is deterministically transformed into bipartite entanglement by local operations only. These operations are the measurement of one qubit of a GHZ state in a rotated basis and, conditioned on this measurement result, the application of single-qubit rotations.	Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Quantenopt & Quanteninformat, A-6020 Innsbruck, Austria	University of Innsbruck; Austrian Academy of Sciences	Schmidt-Kaler, F (corresponding author), Univ Innsbruck, Inst Expt Phys, Technikerstr 25, A-6020 Innsbruck, Austria.	ferdinand.schmidt-kaler@uibk.ac.at	Haeffner, Hartmut/D-8046-2012; Roos, Christian F/D-8475-2011; Becker, Jonas/GZG-4234-2022; Becher, Christoph/AAE-8756-2020; Schmidt-Kaler, Ferdinand/E-2151-2017; Blatt, Rainer/H-9527-2014	Haeffner, Hartmut/0000-0002-5113-9622; Roos, Christian F/0000-0001-7121-8259; Becher, Christoph/0000-0003-4645-6882; Schmidt-Kaler, Ferdinand/0000-0002-5697-2568				BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Dur W, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.062314; Eibl M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.077901; Garisto R, 1999, PHYS REV A, V60, P827, DOI 10.1103/PhysRevA.60.827; Greenberger DM, 1989, BELLS THEOREM QUANTU, P73; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; Kielpinski D, 2001, SCIENCE, V291, P1013, DOI 10.1126/science.1057357; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pan JW, 2001, PHYS REV LETT, V86, P4435, DOI 10.1103/PhysRevLett.86.4435; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; ROOS CF, 2003, IN PRESS PHYS REV LE; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Schmidt-Kaler F, 2003, APPL PHYS B-LASERS O, V77, P789, DOI 10.1007/s00340-003-1346-9; Schmidt-Kaler F, 2003, NATURE, V422, P408, DOI 10.1038/nature01494; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; Steane AM, 1999, NATURE, V399, P124, DOI 10.1038/20127; Steane AM, 1996, PHYS REV LETT, V77, P793, DOI 10.1103/PhysRevLett.77.793; Teklemariam G, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.012309; Zeilinger A., 1997, NASA C PUBL, V3135	22	307	316	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1478	1480		10.1126/science.1097522	http://dx.doi.org/10.1126/science.1097522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178795				2022-12-28	WOS:000221795800036
J	Woods, CG				Woods, CG			Neuroscience - Crossing the midline	SCIENCE			English	Editorial Material							SLIT		Univ Leeds, Sch Med, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	University of Leeds	Woods, CG (corresponding author), Univ Leeds, Sch Med, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England.	msjcgw@leeds.ac.uk	woods, christopher g/A-1361-2010					Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Camurri L, 2004, GENE EXPR PATTERNS, V4, P99, DOI 10.1016/S1567-133X(03)00142-X; Jen JC, 2004, SCIENCE, V304, P1509, DOI 10.1126/science.1096437; Sabatier C, 2004, CELL, V117, P157, DOI 10.1016/S0092-8674(04)00303-4; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X	7	8	8	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	2004	304	5676					1455	1456		10.1126/science.1099534	http://dx.doi.org/10.1126/science.1099534			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825YR	15178787				2022-12-28	WOS:000221795800027
J	Jha, AK; Shojania, KG; Saint, S				Jha, AK; Shojania, KG; Saint, S			Forgotten but not gone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILIARY TUBERCULOSIS; SEPTIC SHOCK; ADRENAL INSUFFICIENCY; DIAGNOSIS		Brigham & Womens Hosp, Div Gen Med, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Michigan, Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Jha, AK (corresponding author), Brigham & Womens Hosp, Div Gen Med, 1620 Tremont St, Boston, MA 02120 USA.	ajha@hsph.harvard.edu	Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AHUJA SS, 1992, CRIT CARE MED, V20, P901, DOI 10.1097/00003246-199206000-00031; *CDCP, 2002, REP TUB US 2001; DYER RA, 1985, CRIT CARE MED, V13, P12, DOI 10.1097/00003246-198501000-00004; George S, 1996, CLIN INFECT DIS, V22, P188, DOI 10.1093/clinids/22.1.188; Gurley RJ, 1996, NEW ENGL J MED, V334, P1710, DOI 10.1056/NEJM199606273342606; HEFFNER JE, 1988, ARCH INTERN MED, V148, P1103, DOI 10.1001/archinte.148.5.1103; KIM JH, 1990, REV INFECT DIS, V12, P583; Kwong JS, 1996, CHEST, V110, P339, DOI 10.1378/chest.110.2.339; MAARTENS G, 1990, AM J MED, V89, P291, DOI 10.1016/0002-9343(90)90340-J; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; *WHO, 2002, 104 WHO	13	2	2	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2399	2404		10.1056/NEJMcps032575	http://dx.doi.org/10.1056/NEJMcps032575			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175442				2022-12-28	WOS:000221754200012
J	Luby, SP; Agboatwalla, M; Painter, J; Altaf, A; Billhimer, WL; Hoekstra, RM				Luby, SP; Agboatwalla, M; Painter, J; Altaf, A; Billhimer, WL; Hoekstra, RM			Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERSISTENT DIARRHEA; MORTALITY; BANGLADESH; CHILDREN; SOAP; DEATHS; IMPACT; HANDS	Context Washing hands with soap prevents diarrhea, but children at the highest risk of death from diarrhea are younger than 1 year, too young to wash their own hands. Previous studies lacked sufficient power to assess the impact of household handwashing on diarrhea in infants. Objective To evaluate the effect of promoting household handwashing with, soap among children at the highest risk of death from diarrhea. Design, Setting, and Participants A cluster randomized controlled trial of 36 low-income neighborhoods in urban squatter settlements in Karachi, Pakistan. Field workers visited participating households at least weekly from April 15, 2002, to April 5, 2003. Eligible households located in the study area had at least 2 children younger than 15 years, at least 1 of whom was younger than 5 years. Interventions Weekly visits in 25 neighborhoods to promote handwashing with soap after defecation and before preparing food, eating, and feeding a child. Within intervention neighborhoods, 300 households (1523 children) received a regular supply of antibacterial soap and 300 households (1640 children) received plain soap. Eleven neighborhoods (306 households and 1528 children) comprised the control group. Main Outcome Measure Incidence density of diarrhea among children, defined as the number of diarrheal episodes per 100 person-weeks of observation. Results Children younger than 15 years living in households that received handwashing promotion and plain soap had a 53% lower incidence of diarrhea (95% confidence interval [CI], -65% to -41%) compared with children living in control neighborhoods. Infants living in households that received handwashing promotion and plain soap had 39% fewer days with diarrhea (95% CI, -61% to -16%) vs infants living in control neighborhoods. Severely malnourished children (weight forage z score, <-3.0) younger than 5 years living in households that received handwashing promotion and plain soap had 42% fewer days with diarrhea (95% CI, -69% to -16%) vs severely malnourished children in the control group. Similar reductions in diarrhea were observed among children living in households receiving antibacterial soap. Conclusion In a setting in which diarrhea is a leading cause of child death, improvement in handwashing in the household reduced the incidence of diarrhea among children at high risk of death from diarrhea.	CDCP, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Aga Khan Univ, Karachi, Pakistan; Procter & Gamble Co, Cincinnati, OH USA	Centers for Disease Control & Prevention - USA; Aga Khan University; Procter & Gamble	Luby, SP (corresponding author), CDCP, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd,Mailstop A-38, Atlanta, GA 30333 USA.	sluby@cdc.gov		Hoekstra, Robert Michael/0000-0002-0340-8015; Luby, Stephen/0000-0001-5385-899X				Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; BHANDARI N, 1992, ACTA PAEDIATR, V81, P3, DOI 10.1111/j.1651-2227.1992.tb12363.x; BLUM D, 1983, INT J EPIDEMIOL, V12, P357, DOI 10.1093/ije/12.3.357; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; DONNER K, 2000, RANDOMIZATION TRIALS; Fikree FF, 2002, B WORLD HEALTH ORGAN, V80, P271; HEINZE JE, 1988, EPIDEMIOL INFECT, V101, P135, DOI 10.1017/S0950268800029290; KALTENTHALER E, 1991, J TROP MED HYG, V94, P358; LIMA AAM, 1992, ACTA PAEDIATR, V81, P39, DOI 10.1111/j.1651-2227.1992.tb12370.x; LOWBURY EJL, 1964, BMJ-BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5403.230; Luby S, 2001, Int J Infect Dis, V5, P144, DOI 10.1016/S1201-9712(01)90089-X; Marsh D, 1995, HEALTH POLICY PLANN, V10, P395, DOI 10.1093/heapol/10.4.395; Morris SS, 1996, AM J EPIDEMIOL, V144, P582, DOI 10.1093/oxfordjournals.aje.a008968; *PLANN DEV CORP PA, 1990, KAR DEV PLAN 2000, P20; SACHDEV HPS, 1991, J PEDIATR GASTR NUTR, V12, P76, DOI 10.1097/00005176-199101000-00016; Serfling R. J, 1980, APPROXIMATION THEORE; Shahid NS, 1996, J DIARRHOEAL DIS RES, V14, P85; SHAMEBO D, 1991, J TROP PEDIATRICS, V37, P254, DOI 10.1093/tropej/37.5.254; STANTON BF, 1987, AM J EPIDEMIOL, V125, P292, DOI 10.1093/oxfordjournals.aje.a114529; Teka T, 1996, ACTA PAEDIATR, V85, P1070, DOI 10.1111/j.1651-2227.1996.tb14219.x; Walsh SE, 2003, J APPL MICROBIOL, V94, P240, DOI 10.1046/j.1365-2672.2003.01825.x; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yassin KM, 2000, SOC SCI MED, V51, P185, DOI 10.1016/S0277-9536(99)00459-1; Yoon PW, 1997, AM J CLIN NUTR, V65, P1070, DOI 10.1093/ajcn/65.4.1070	24	172	172	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2547	2554		10.1001/jama.291.21.2547	http://dx.doi.org/10.1001/jama.291.21.2547			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173145	Bronze			2022-12-28	WOS:000221738800017
J	Kobayashi, J; Mori, Y; Okamoto, K; Akiyama, R; Ueno, M; Kitamori, T; Kobayashi, S				Kobayashi, J; Mori, Y; Okamoto, K; Akiyama, R; Ueno, M; Kitamori, T; Kobayashi, S			A microfluidic device for conducting gas-liquid-solid hydrogenation reactions	SCIENCE			English	Article							CATALYTIC ASYMMETRIC DIHYDROXYLATION; PALLADIUM CATALYSTS; POLYMER; FLOW; MICROREACTOR; REACTORS; DESIGN; SYSTEM	We have developed an efficient system for triphase reactions using a micro-channel reactor. Using this system, we conducted hydrogenation reactions that proceeded smoothly to afford the desired products quantitatively within 2 minutes for a variety of substrates. The system could also be applied to deprotection reactions. We could achieve an effective interaction between hydrogen, substrates, and a palladium catalyst using extremely large interfacial areas and the short path required for molecular diffusion in the very narrow channel space. This concept could be extended to other multiphase reactions that use gas-phase reagents such as oxygen and carbon dioxide.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Engn, Dept Appl Chem, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo; University of Tokyo	Kobayashi, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	skobayas@mol.f.u-tokyo.ac.jp	Kobayashi, Shu/E-9214-2012; UENO, Masaharu/M-1609-2013	UENO, Masaharu/0000-0001-5253-0968; Kitamori, Takehiko/0000-0003-2969-6550				Akiyama R, 2003, J AM CHEM SOC, V125, P3412, DOI 10.1021/ja029146j; Akiyama R, 2002, ANGEW CHEM INT EDIT, V41, P2602, DOI 10.1002/1521-3773(20020715)41:14<2602::AID-ANIE2602>3.0.CO;2-3; Akiyama R, 2001, ANGEW CHEM INT EDIT, V40, P3469, DOI 10.1002/1521-3773(20010917)40:18<3469::AID-ANIE3469>3.0.CO;2-T; ARNOLD MR, 1956, IND ENG CHEM, V48, P1629, DOI 10.1021/ie51401a008; Besser RS, 2003, CHEM ENG SCI, V58, P19, DOI 10.1016/S0009-2509(02)00398-6; Chambers RD, 1999, CHEM COMMUN, P883, DOI 10.1039/a901473j; de Bellefon C, 2000, ANGEW CHEM INT EDIT, V39, P3442, DOI 10.1002/1521-3773(20001002)39:19<3442::AID-ANIE3442>3.0.CO;2-Q; Ehrfeld W., 2000, MICROREACTORS; Fletcher PDI, 2002, TETRAHEDRON, V58, P4735, DOI 10.1016/S0040-4020(02)00432-5; Fukuyama T, 2002, ORG LETT, V4, P1691, DOI 10.1021/ol0257732; Greenway GM, 2000, SENSOR ACTUAT B-CHEM, V63, P153, DOI 10.1016/S0925-4005(00)00352-X; Hisamoto H, 2003, ANAL CHEM, V75, P350, DOI 10.1021/ac025794+; Hisamoto H, 2001, CHEM COMMUN, P2662, DOI 10.1039/b106494k; Jahnisch K, 2004, ANGEW CHEM INT EDIT, V43, P406, DOI 10.1002/anie.200300577; Jahnisch K, 2000, J FLUORINE CHEM, V105, P117, DOI 10.1016/S0022-1139(00)00300-6; Kobayashi S, 1999, J AM CHEM SOC, V121, P11229, DOI 10.1021/ja993099m; Kobayashi S, 2001, ORG LETT, V3, P2649, DOI 10.1021/ol0161965; Kobayashi S, 1998, J AM CHEM SOC, V120, P2985, DOI 10.1021/ja9739289; Losey MW, 2001, IND ENG CHEM RES, V40, P2555, DOI 10.1021/ie000523f; Losey MW, 2002, J MICROELECTROMECH S, V11, P709, DOI 10.1109/JMEMS.2002.803416; Mills PL, 1997, CATAL TODAY, V37, P367, DOI 10.1016/S0920-5861(97)00028-X; Nagayama S, 1998, J ORG CHEM, V63, P6094, DOI 10.1021/jo981127y; Negishi E.-I., 2002, HDB ORGANOPALLADIUM; OKAMOTO K, UNPUB; Ouyang X, 2003, CATAL TODAY, V84, P33, DOI 10.1016/S0920-5861(03)00298-0; Poli G, 2000, TETRAHEDRON, V56, P5959, DOI 10.1016/S0040-4020(00)00438-5; Serizawa A, 2002, EXP THERM FLUID SCI, V26, P703, DOI 10.1016/S0894-1777(02)00175-9; Tokeshi M, 2002, ANAL CHEM, V74, P1565, DOI 10.1021/ac011111z; Trost BM, 1996, CHEM REV, V96, P395, DOI 10.1021/cr9409804; Tsuji J., 1995, PALLADIUM REAGENTS C; Ueno M, 2003, CHEM COMMUN, P936, DOI 10.1039/b301638b; Wiessmeier G, 1996, IND ENG CHEM RES, V35, P4412; Yoshida J, 2002, CHEM-EUR J, V8, P2651; YOSHIDA JI, 2000, MICROREACTOR EPOCH M	34	484	522	13	315	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1305	1308		10.1126/science.1096956	http://dx.doi.org/10.1126/science.1096956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166375				2022-12-28	WOS:000221669600049
J	Hill, J				Hill, J			Physical activity and obesity	LANCET			English	Editorial Material									Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hill, J (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, 4200 E 9th Ave, Denver, CO 80262 USA.	james.hill@uchsc.edu						Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Peters J C, 2002, Obes Rev, V3, P69, DOI 10.1046/j.1467-789X.2002.00059.x; Saris W H M, 2003, Obes Rev, V4, P101, DOI 10.1046/j.1467-789X.2003.00101.x; AM MOVE	4	30	31	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	2004	363	9404					182	182		10.1016/S0140-6736(03)15368-8	http://dx.doi.org/10.1016/S0140-6736(03)15368-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765AG	15194273				2022-12-28	WOS:000188243900004
